Glycan structure dictionary: Difference between revisions

Latest revision as of 18:21, 13 April 2023

Glycan Structure Dictionary (GSD) contains terms commonly used to describe glycan structural features in publications. The glycan structure terms are primarily sourced via automatic and manual literature mining as well as from other bioinformatics databases. The Glycan Structure Dictionary is a work in progress and the terms are updated regularly to include the new term(s) and annotations. On this Wiki page the Glycan Structure Dictionary terms are listed by term name (alphabetically) and also by glycan dictionary accessions. To submit new terms go to section Glycan Structure Dictionary#Submit new terms. Contact https://www.glygen.org/contact-us/ to report any issues.

Please cite use of Glycan Structure Dictionary with: Vora J, Navelkar R, Vijay-Shanker K, Edwards N, Martinez K, Ding X, Wang T, Su P, Ross K, Lisacek F, Hayes C, Kahsay R, Ranzinger R, Tiemeyer M, Mazumder R. The glycan structure dictionary-a dictionary describing commonly used glycan structure terms. Glycobiology. 2023 Feb 17:cwad014. doi: 10.1093/glycob/cwad014. PMID: 36799723.

Terms (by Term Name)

2,6-Branched O-mannose

term (main_entry) : 2,6-Branched O-mannose 

glycan_dictionary_accession : GSD000001 

glytoucan_accession  : G06953DR 

term_in_sentence : Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6-branched structure in the brain O-mannosyl glycan.[PMID:14617637] 

publication : 14617637|10469154 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-[[(2R,3S,4S,5S,6S)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:157265] 

term_xref : CHEBI:157265|GlycoMotif:GGM.000056|GTC:G06953DR 

synonyms : 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→2)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→6)]-alpha-D-manno-hexopyranose|NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)]a-Man 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

2,6-sialyl-Sulfo-LN

term (main_entry) : 2,6-sialyl-Sulfo-LN 

glycan_dictionary_accession : GSD000002 

glytoucan_accession  : G41145LF 

term_in_sentence : The alpha2-6-sialylated 6-sulfo-LacNAc determinant defined by the antibody was significantly expressed on a majority of normal human peripheral B-lymphocytes as well as follicular B-lymphocytes in peripheral lymph nodes.[PMID:17728258] 

publication : 17728258 

definition :  

term_xref : GlycoMotif:GGM.000026|GTC:G41145LF  

synonyms : 6-sialyl-6-sulfo LN 

function : B-cell interaction with blood vessels and trafficking[PMID: 17728258] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

2-Fucosyl-GD1b

term (main_entry) : 2-Fucosyl-GD1b 

glycan_dictionary_accession : GSD000003 

glytoucan_accession  : G67383AR 

term_in_sentence : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:3654655] 

publication : 3654655 

definition : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] 

term_xref : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR  

synonyms : 6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose|Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-8)NeuAc(a2-3)]Gal(b1-4)Glc 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

2-Fucosyl-GM1

term (main_entry) : 2-Fucosyl-GM1 

glycan_dictionary_accession : GSD000004 

glytoucan_accession  : G56526JU 

term_in_sentence : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:3654655] 

publication : 3654655 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] 

term_xref : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101|GTC:G56526JU

synonyms : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

3-Sialyl-LN (type 2)

term (main_entry) : 3-Sialyl-LN (type 2) 

glycan_dictionary_accession : GSD000005 

glytoucan_accession  : G10203DW 

term_in_sentence : Using new crystal structures, we also provide the atomic resolution basis for the differential recognition of 3′ and 6′SiaLacNAc1–4 (with the Galβ1–4 linkage known as Type 2 backbone16; Scheme 1) by TgMIC1-MARR, and make comparisons with the Type 1 chain isomer of 3′SiaLacNAc1–4 (designated 3′SiaLacNAc1–3).[PMID:19593815] 

publication : 19593815|15659615|2414279|8586620|2111348|23747419 

definition : A linear amino trisaccharide consisting of α-neuraminyl, β-D-galactosyl and N-acetyl-D-glucosamine residues linked in a (2→3) and (1→4) sequence.[CHEBI:52472] 

term_xref : GTC:G10203DW|KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 

synonyms :  

function :  

disease_associations : Chronic gastritis[SugarBind_Ligand:109]|Toxoplasmosis[SugarBind_Ligand:109]|Peptic ulcers[SugarBind_Ligand:109]|Gastric cancer[SugarBind_Ligand:109] 

wikipedia :  

essentials_of_glycobiology :

3'-Sulfo-Lewis a

term (main_entry) : 3'-Sulfo-Lewis a 

glycan_dictionary_accession : GSD000006 

glytoucan_accession  : G78706CK 

term_in_sentence : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:11504739] 

publication : 11504739|17499486|17691854|12944557|19394320|7534477|11604107|28025252|9061363|9878545|11918697|24239607|28628803|25339106|21400496|17998215|12626387|11425799|12219077|10955596|9453593 

definition : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] 

term_xref : GTC:G78706CK|GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 

synonyms : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a 

function : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

3'-Sulfo-Lewis x

term (main_entry) : 3'-Sulfo-Lewis x 

glycan_dictionary_accession : GSD000007 

glytoucan_accession  : G12295TB 

term_in_sentence : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:11504739] 

publication : 11504739|20695481|8688428|10536036|12770775|11352731|9784103|9022803 

definition : An amino trisaccharide that consists of N-acetyl-β-D-glucosamine having an α-L-fucosyl residue attached at position 3 and a 3-sulfated β-D-galactosyl residue attached at position 4; β-D-Galp3S-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the configuration at the anomeric centre of the reducing-end residue is β. [CHEBI:65171] 

term_xref : GTC:G12295TB|GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029 

synonyms : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

6,6'-bisSulfo-Lewis x

term (main_entry) : 6,6'-bisSulfo-Lewis x 

glycan_dictionary_accession : GSD000008 

glytoucan_accession  : G00659GQ 

term_in_sentence : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best  candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:9556613] 

publication : 19756298|14593101|15175329|14568956|12163379|11919403|11520459|10728707|10200296|10528213|9712885|9556613|9456330|9556613|9257857|9164959|9015359|8958810|7560094|7485559|7538131|8161542|7684905

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] 

term_xref : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ 

synonyms : 6,6'-DiSulfo Sialyl Lewis x|6,6-bisSulfo-Lewis x (6,60-bissulfo Lewis x )|6,6'- Disulfo Sialyl Lewis x|6,6'-bisSulfo-Lewis x|6,6'-bissulfo Lex|6,6'-Disulfo Sialyl Lewis x|6,6'-bissulfo Le^x 

function : lymphocyte homing[GlycoEpitope:EP0016] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

6-Sialyl-GalNAc

term (main_entry) : 6-Sialyl-GalNAc

 glycan_dictionary_accession : GSD000009 

glytoucan_accession  : G08371CD 

term_in_sentence : mmunohistochemical distributions of carbohydrate antigens based on the type 2 chain in normal as well as fetal and neoplastic tissues of human gastrointestinal tract were investigated with a monoclonal antibody (MAb) H11 (specific for type 2 chain) alone and in combination with the two MAbs MSG15 (for alpha 2----6 sialylated type 2 chain) and IB9 (for the alpha 2----6 sialylated type 2 chain and glycoproteins having NeuAc alpha 2----6Gal-NAc), and 188C1 (for short- and long-chain Lex antigens) and FH2 (for the long-chain Lex antigen). [PMID: 1618643] 

publication : 1618643|6194157 

definition : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] 

term_xref : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035|GTC:G08371CD 

synonyms : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

6-Sulfo LacNac

term (main_entry) : 6-Sulfo LacNac 

glycan_dictionary_accession : GSD000010 

glytoucan_accession  : G13157WZ 

term_in_sentence : In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan).[PMID:31572354] 

publication : 31572354|31191513|29977237|29900053|30984181|28732748|26510404|28769928|31154896|27541644|25262889|26155414|28499587|27086951|27315572|26162403|26391152|31730025|12354382|27318477|23879812|25340085|24682513|21377044|21098395|18942710|23559493|23890755|22643330|23460612|23402811|22890025|19589615|32939325|20210806|17616642|22907335|16782032|22188261|21283706|29875315|32413173|19546436|19384158|1429720|30519676 

definition : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] 

term_xref : GlycoEpitope:EP0141|GTC:G13157WZ|CID:10322152|CHEBI:148005 

synonyms : 6-Sulfo LacNAc 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

6-Sulfo Sialyl Lewis x

term (main_entry) : 6-Sulfo Sialyl Lewis x 

glycan_dictionary_accession : GSD000188

glytoucan_accession  : G80722US 

term_in_sentence : The cognate ligands for L-selectin possess the unusual sulfated tetrasaccharide epitope 6-sulfo sialyl Lewis x (Siaalpha2-->3Galbeta1-->4[Fucalpha1-->3][SO(3)-->6]GlcNAc).[PMID:11331001] 

publication : 11331001|2288521|26137907|9400621|9556613|15972893|9015359|22691873|18652681|9722682|10435581|19359410|15228275|18250165|10536036|17944600|10460836|27993973|19149511|19150806|17172261|17142960|27956273|7578028|22260995|24519996|21596021|21982762|21775439|17334369|9710564|14593101|16227985|11895802|22750968|15157883|19067429 

definition : 

term_xref : GlycoMotif:GGM.000027|GlycoEpitope:EP0015|CID:70698321|CHEBI:71628

synonyms : 6-sulfo SLex|6-Sulfo-sialyl Lewis x|6-sulfo SLe^x 

function : lymphocyte homing[GlycoEpitope:EP0015]

disease_associations : 

wikipedia :  

essentials_of_glycobiology : Chapter 34|Chapter 35

6'-Sulfo Sialyl Lewis x

term (main_entry) : 6'-Sulfo Sialyl Lewis x 

glycan_dictionary_accession : GSD000011 

glytoucan_accession  : G00672PE 

term_in_sentence : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:2288521] 

publication : 2288521|26137907|9400621|32744401|9556613|15972893|9015359|22691873|18652681|9722682|10435581|19458105|19359410|15228275|18250165|10536036|17944600|10460836|27993973|19149511|19150806|17172261|17142960|27956273|7578028|22260995|24519996|21596021|21982762|21775439|17334369|9710564|14593101|16227985|11895802|22750968|15157883|19067429 

definition : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] 

term_xref : GlycoMotif:GGM.000025|GTC:G00672PE|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128

synonyms : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x 

function : lymphocyte homing[GlycoEpitope:EP0014] 

disease_associations : Influenza[SugarBind_Ligand:128] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

9-O-Acetyl GD3

term (main_entry) : 9-O-Acetyl GD3 

glycan_dictionary_accession : GSD000012 

glytoucan_accession  : G74121RX 

term_in_sentence : To determine whether 9-O-acetyl GD3 (acGD3) has a general antiapoptotic potential, the apoptosis-sensitive Jurkat cell line and an apoptosis-sensitive variant of the cell line Molt-4 were preincubated with micromolar concentrations of acGD3 and then treated with inducers of apoptosis.[PMID:16432837] 

publication : 16432837|21507905|17512674|21930212|18194438|20739294|3216430|14724245|31373393|7558412|11273644|17385751|30694652|22894715|12973826|7859075|9749956|9874495|12486096|1989525|25330147|23478187|21807667|8486686|11465673|9511990|29270199|9268945|25045067|21618115|16434401|12493756|2302705|2198284|2685488|9328574|4055789|10096568|1644805|2582447 

definition :  

term_xref : GTC:G74121RX|GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 

synonyms : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b 

function :  

disease_associations : pancreas cancer[GlycoEpitope:EP0064] 

wikipedia :  

essentials_of_glycobiology :

9-O-Acetyl sialic acid

term (main_entry) : 9-O-Acetyl sialic acid 

glycan_dictionary_accession : GSD000013 

glytoucan_accession  : G47325QT 

term_in_sentence : Levels of 9-O-acetyl sialic acid provide a distinct way to define progenitors and thus facilitate the study of hematopoietic differentiation.[PMID:31411667] 

publication : 31411667|27936566|2509478|10049046|1826463 

definition : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] 

term_xref : GTC:G47325QT|GlycoEpitope:EP0065|CID:13991612|CHEBI:84941 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 15

Alpha-gal antigen

term (main_entry) : Alpha-gal antigen 

glycan_dictionary_accession : GSD000016 

glytoucan_accession  : G24432YB 

term_in_sentence : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:31267683] 

publication : 31267683|29319188|29481481|26140655|30337555|29235434|22909134|28280265|7532618|23390540|22808845|29898796|22262104|31267683|25430953|22993330|23578170|21043478|28294277|27696820|15814276|17991149|25577211|30578545|19895316|28068870|18546155|32907757|26485996|9771839|12042247|27567275|12131678|23114154|19184002|29577591|29806570|15638815|21118731 

definition : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] 

term_xref : GTC:G24432YB|GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330 

synonyms : a-Gal antigen 

function : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

Alpha-galactosylceramide

term (main_entry) : Alpha-galactosylceramide 

glycan_dictionary_accession : GSD000017 

glytoucan_accession  :  

term_in_sentence : From 24 weeks of age, NZB/NZW F1 mice were injected with alpha-galactosylceramide (α-GalCer) or vehicle once a week for four weeks.[PMID:29844470] 

publication : 29844470|30421497|31575643|30745361|30953000|30556652|29617191|31689579|28872688|30195979|29940370|27004737|27198610|28743554|31649670|31484693|25752588|21383248|25527277|30821985|28947140|31244823|29311431|30803854|29576533|26101952|31213291|22412194|28067024|31199716|27354638|24465013|25445911|28120096|15630427|27803187|21392534|31075434|22683545|26191196|26811064|23935988|28623127|24913977|25434827|23420533|21839133|25314062|27325450|23874157 

definition :  

term_xref :  

synonyms : alpha-GalCer|alpha-GalCers|α-GalCer 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Asialo-biantennary

term (main_entry) : Asialo-biantennary 

glycan_dictionary_accession : GSD000018 

glytoucan_accession  :  

term_in_sentence : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:30990348] 

publication : 30990348|17645671|20959391|18615430|16945378|2065054|3084472|2386787|22911097|24692304|17013932|7513972|6626573|10835250|9684342 

definition :  

term_xref :  

synonyms : asialo diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Asialo-GM1

term (main_entry) : Asialo-GM1 

glycan_dictionary_accession : GSD000019 

glytoucan_accession  : G21856LC 

term_in_sentence : We compared the lateral structure of giant unilamellar vesicles (GUVs) composed of three pseudo binary mixtures of different glycosphingolipid (GSL), i.e. sulfatide, asialo-GM1 or GM1, with POPC.[PMID:29106974] 

publication : 29106974|3418980|26975993|8613364|9288228|26710925|24922516|6839313|1828259|2581667|8210226|25062498|9671150|10377092|6171919|3093429|6652964|3124753|8905612|18788941|1467432|8225593|2083955|6171918|7806377|1802483|7927723|9209156|21174147|2584393|12137200|6175621|2936802|8610366|21490162|1548508|3486908|26453755|7910939|3756909|1639356|3259967|2443562|3112077|2572647|25137483|2168971|6950172 

definition :  

term_xref : GlycoMotif:GGM.000099|GTC:G21856LC|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216  

synonyms : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a|ganglio-N-tetraosylceramide 

function :  

disease_associations : Pleuropneumonia[SugarBind_Ligand:2]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:2]|Actinomycosis[SugarBind_Ligand:2]|Lazy leukocyte syndrome[SugarBind_Ligand:2]|Pertussis[SugarBind_Ligand:2]|Cutaneous lesions[SugarBind_Ligand:2]|Melioidosis[SugarBind_Ligand:2]|Candidiasis[SugarBind_Ligand:2]|Taiwan acute respiratory agent[SugarBind_Ligand:2]|Trachoma[SugarBind_Ligand:2]|Cystitis[SugarBind_Ligand:2]|Chronic gastritis[SugarBind_Ligand:2]|Peptic ulcers[SugarBind_Ligand:2]|Gastric cancer[SugarBind_Ligand:2]|Klebsiella pneumonia infection[SugarBind_Ligand:2]|Pneumonia[SugarBind_Ligand:2]|Legionnaires' disease[SugarBind_Ligand:2]|Gonorrhea[SugarBind_Ligand:2]|Gastroenteritis[SugarBind_Ligand:2]|Toxoplasmosis[SugarBind_Ligand:2]|Plague[SugarBind_Ligand:2]|Diarrhea[SugarBind_Ligand:2] 

wikipedia :  

essentials_of_glycobiology :

B-GD1B

term (main_entry) : B-GD1B 

glycan_dictionary_accession : GSD000020 

glytoucan_accession  : G72557NR 

term_in_sentence : The Molecular Modelling and 10 ns MD simulation of Botulinum Neuro Toxin/B-GD1A and BoNT/B-GD1B complex revealed that this toxin can interact with GD1A in the single binding mode and with GD1B in two binding modes.[PMID:22929125] 

publication : 27956354|22929125 

definition :  

term_xref : GlycoMotif:GGM.000104|GTC:G72557NR|CID:91847819|KEGG:G01803|CHEBI:153361 

synonyms : B-GD1b 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

B-GM1

term (main_entry) : B-GM1 

glycan_dictionary_accession : GSD000021 

glytoucan_accession  : G11485ID 

term_in_sentence : The contribution of GM3 and GD3, which accounted for 95% of the ganglioside sialic acid at birth, decreased during the first 3 weeks of life. GM1, fucosyl-GM1, and B-GM1 were not detected at birth. [PMID: 3680254] 

publication : 3680254 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] 

term_xref : GlycoMotif:GGM.000102|GTC:G11485ID|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 

synonyms :  

function :  

disease_associations : Cholera[SugarBind_Ligand:181] 

wikipedia :  

essentials_of_glycobiology : Chapter 37

Biantennary

term (main_entry) : Biantennary 

glycan_dictionary_accession : GSD000022 

glytoucan_accession  :  

term_in_sentence : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID:29249147] 

publication : 29249147|24991291|29409839|30325416|18083109|26926155|16715395|12634321|24211369|23115267|31907993|23360551|20861009|33142198|11442281|18687680|15680603|31888963|14686925|15819890|22530754|22098756|9346821|19341309|18529007|20580347|11784152|7773775|10913832|8547276|10463590|9404657|30525457|15316280|8068637|3881425|6425277|8576139|29956878|1576211|11129583|30421263|8069634|30973186|16704415|21612260|29806066|29443078 

definition : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary] 

term_xref :  

synonyms : diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

Biantennary complex

term (main_entry) : Biantennary complex 

glycan_dictionary_accession : GSD000023 

glytoucan_accession  :  

term_in_sentence : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:16704415] 

publication : 16704415|3731182|26747427|32597008|6626573|29249147|28597152|25045879|30325416|12634321|31888963|26926155|23360551|33142198|9404657|29956878|14686925|18687680|11784152|7773775|22530754|20580347|22098756|21612260|6425277|7691595|26780731|16285669|15819890|3924097|30448401|8547276|17049014|29408873 

definition : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] 

term_xref : CHEBI:156251 

synonyms : diantennary complex type 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Bisecting GlcNac

term (main_entry) : Bisecting GlcNac 

glycan_dictionary_accession : GSD000024 

glytoucan_accession  :  

term_in_sentence : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:1374031] 

publication : 1374031|29909448|29274553|32719771|22476631|31375533|26467158|27429195|20816221|26109616|30542567|30144245|25727145|29593568|32612952|9006930|19508951|16000695|32597008|19053837|22530754|30405631|19940114|32719549|9560299|29655002|10589784|29959030|20661133|9061364|31065629|20395209|29549127|30305426|29632412|24108122|24282611|27821068|14686925|10816579|25032906|30025558|9661906|8542600|31585439|29699572|27443163|30315103|23808883|18812317|19776078 

definition : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: 22476631] 

term_xref : SID:163312364|KEGG:G13066 

synonyms :  

function : The bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression through modulating N-glycan/galectin interactions.[PMID: 22476631]Inhibits growth factor signaling and retards mammary tumor progression[PMID: 20395209]Integrin-mediated cell adhesion [PMID: 20816221]Important in fertilization and fetal development, neuritogenesis, immune tolerance, immunoglobulin G (IgG)[PMID: 32719771] 

disease_associations : mammary tumor.[PMID: 20395209] 

wikipedia :  

essentials_of_glycobiology : Chapter 9

Bisialo-biantennary

term (main_entry) : Bisialo-biantennary 

glycan_dictionary_accession : GSD000025 

glytoucan_accession  :  

term_in_sentence : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. 

publication : 2386787|2065054 

definition : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. 

term_xref :  

synonyms : disialo biantennary|disialo diantennary|disialylated biantennary|disialylated diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Bisialo-biantennary complex-type

term (main_entry) : Bisialo-biantennary complex-type 

glycan_dictionary_accession : GSD000026 

glytoucan_accession  :  

term_in_sentence : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID:2386787] 

publication : 2386787|26966183 

definition : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae.  

term_xref :  

synonyms : Fully sialylated biantennary N-glycan 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 25

Blood group A trisaccharide

term (main_entry) : Blood group A trisaccharide 

glycan_dictionary_accession : GSD000029 

glytoucan_accession  : G00066MO 

term_in_sentence : A readily detectable carbohydrate in the urine of two siblings with neuronal ceroid lipofuscinosis was found to be the blood group A trisaccharide.[PMID:7249368] 

publication : 19582848|7249368|8774717|2749874|28771597|30619340|2122121|11886841|2991755|12588002|3149698|7048329|7015594|10359132|8724140|1418679|1446307 

definition : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] 

term_xref : GlycoEpitope:EP0255|GTC:G00066MO|CID:49852448|KEGG:G10638|CHEBI:61012 

synonyms : blood group A trisaccharide|blood group A type 1 trisaccharide 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Blood group A (Type 1)

term (main_entry) : Blood group A (Type 1) 

glycan_dictionary_accession : GSD000030 

glytoucan_accession  : G66163TI 

term_in_sentence : he basis of blood group A(1) and A(2) phenotypes has been debated for many decades, and still the chemical basis is unresolved. [PMID:19121199] 

publication : 10942408|19121199 

definition : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] 

term_xref : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 

synonyms : Blood group A(1)|blood group A antigen type 1 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Blood group A (Type 1) - Lewis b

term (main_entry) : Blood group A (Type 1) - Lewis b

glycan_dictionary_accession : GSD000190

glytoucan_accession  : G97501MA 

term_in_sentence :  Ten monoclonal antibodies and one lectin were used to study the localization and distribution of Blood Group ABH, type 1 chain (Lewis a, Lewis b) and type 2 chain (H-2, Y) antigens in 22 cases of normal uterine cervix, with known ABO and Lewis phenotype and secretor status.[PMID:2247887]

publication :  2247887|19756298|4041428|5686860

definition :  A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 4 of the glucosamine. Corresponds to a partial structure of blood group A type 1 oligosaccharide.[CHEBI:62988]

term_xref : GlycoMotif:GGM.000047|CID:53477630|CHEBI:62988|GlycoEpitope:EP0260

synonyms :  Blood Group A Type 1 (difucosyl)|ALe^b|A-Leb|A-Le^b|A Lewis b

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Blood group A (Type 2)

term (main_entry) : Blood group A (Type 2) 

glycan_dictionary_accession : GSD000014 

glytoucan_accession  : G74353FF 

term_in_sentence : One hybridoma antibody (AH16), obtained on immunization with human gastric cancer cell MKN45, was directed to the blood group A determinant carried by both type 1 and type 2 chains. [PMID:6583282] 

publication : 27196314|6583282|8340255|18701592|21901093|2413709|8036794|1615929|3285099 

definition : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] 

term_xref : GTC:G74353FF|CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 

synonyms : A Type 2|Blood group A type 2 chain

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

Blood group A (Type 2) - Lewis y

term (main_entry) : Blood group A (Type 2) - Lewis y 

glycan_dictionary_accession : GSD000027 

glytoucan_accession  : G54826OZ 

term_in_sentence : Monoclonal antibodies defining blood group A variants with difucosyl type 1 chain (ALeb) and difucosyl type 2 chain (ALey).[PMID:2417620] 

publication : 2417620 

definition : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] 

term_xref : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039 

synonyms : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Blood group A (Type 3)

term (main_entry) : Blood group A (Type 3)

glycan_dictionary_accession : GSD000187

glytoucan_accession  : G99315PE

term_in_sentence : 

publication : 7800218|17998569|19756298|3191504

definition : 

term_xref : GlycoMotif:GGM.000011|GTC:G99315PE

synonyms :  A type 3 antigen|blood group A type 3|A antigen (type 3)

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :  Chapter 14

Blood group A (Type 4)

term (main_entry) : Blood group A (Type 4) 

glycan_dictionary_accession : GSD000028 

glytoucan_accession  : G37830TX 

term_in_sentence : Moreover, we have found that αGal, but not αGalNAc, is a weak binder itself for DC-SIGN, which could endow an additional binding mode for the blood group B antigen, but not for blood group A.[PMID:31283166] 

publication : 7800218|7521740|2458640|31283166 

definition :  

term_xref : GlycoMotif:GGM.000088|GTC:G37830TX|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48 

synonyms :  

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:48]|Acute cystitis[SugarBind_Ligand:48] 

wikipedia :  

essentials_of_glycobiology :

Blood group A1 (Type 3)

term (main_entry) : Blood group A1 (Type3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                glycan_dictionary_accession : GSD000031 

glytoucan_accession  : G44060QH 

term_in_sentence : The structure is essentially a repetitive A epitope attached to type 2 chain and is hereby called type 3 chain A. [PMID:2579390] 

publication : 2579390|19756298 

definition : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665] 

term_xref : GTC:G44060QH|CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040 

synonyms : Blood group A1 (type 3)|Blood Group A1 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Blood group A2 (A-associated H type 3)

term (main_entry) : Blood group A2 (A-associated H type 3) 

glycan_dictionary_accession : GSD000032

glytoucan_accession  : G62735WZ 

term_in_sentence : The H NMR spectrum of the associated H antigen (type 3 chain H) was characterized by the unusual presence of three n-anomeric resonances ('CJ'.~ = 3-4 Hz) in addition to five resonances from @-anomeric protons ("J1:2 = 7-9 Hz).[PMID: 3944091]

publication : 3944091|29000000|28658771

definition : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543] 

term_xref : CHEBI:152543|CID:91852328|GlycoMotif:GGM.000041|GTC:G62735WZ

synonyms : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Blood group B (Type 1)

term (main_entry) : Blood group B (Type 1) 

glycan_dictionary_accession : GSD000033 

glytoucan_accession  : G31734OS 

term_in_sentence : The minimal binding epitope was identified as the blood group H type 1 determinant (Fucα2Galβ3GlcNAc), while an optimal binding epitope was created by addition of the terminal α3-linked galactose or N-acetylgalactosamine of the blood group B type 1 determinant (Galα3(Fucα2)Galβ3GlcNAc) and the blood group A type 1 determinant (GalNAcα3(Fucα2)-Galβ3GlcNAc). [PMID: 19208633] 

publication : 18701592|24749871|19387828|19208633|29562255 

definition : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242] 

term_xref : GlycoMotif:GGM.000043|GTC:G31734OS|CID:56927779|CHEBI:63242 

synonyms : blood group B type 1 tetrasaccharide 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Blood group B (Type 1) - Lewis b

term (main_entry) : Blood group B (Type 1) - Lewis b

glycan_dictionary_accession : GSD000189

glytoucan_accession  : G89208KM 

term_in_sentence :  Ten monoclonal antibodies and one lectin were used to study the localization and distribution of Blood Group ABH, type 1 chain (Lewis a, Lewis b) and type 2 chain (H-2, Y) antigens in 22 cases of normal uterine cervix, with known ABO and Lewis phenotype and secretor status. [PMID:2247887]

publication :  2247887|19756298|30831115

definition :  

term_xref : GlycoMotif:GGM.000046

synonyms :  Blood Group B, type 1 chain (Lewis b)|B-Leb|B-Le^b

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Blood group B (Type 2)

term (main_entry) : Blood group B (Type 2) 

glycan_dictionary_accession : GSD000034 

glytoucan_accession  : G34881WK 

term_in_sentence : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID:2432062] 

publication : 2432062|27196314|18701592 

definition :  

term_xref : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262 

synonyms : blood group B type 2 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Blood group B (Type 4)

term (main_entry) : Blood group B (Type 4) 

glycan_dictionary_accession : GSD000035 

glytoucan_accession  : G25216QA 

term_in_sentence : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:1390942] 

publication : 1390942|1841684 

definition :  

term_xref : GlycoMotif:GGM.000087|GTC:G25216QA 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Blood group H (Type 1)

term (main_entry) : Blood group H (Type 1) 

glycan_dictionary_accession : GSD000036 

glytoucan_accession  : G00294TN 

term_in_sentence : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:7718581] 

publication : 7718581|6309836|19208633|27431816|2432062|24219248|6352465|8499478|3348768|3718924 

definition :  

term_xref : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153 

synonyms : H type 1 

function :  

disease_associations : Gastroenteritis[SugarBind_Ligand:153] 

wikipedia :  

essentials_of_glycobiology :

Blood group H (Type 2)

term (main_entry) : Blood group H (Type 2) 

glycan_dictionary_accession : GSD000037 

glytoucan_accession  : G70519XK 

term_in_sentence : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID:9405495] 

publication : 9405495|8082855|6177241|3944092|21406562|2410664|8731502|6203846|2238560| 

definition :  

term_xref : GTC:G70519XK|GlycoMotif:GGM.000036 

synonyms : Blood group H (type 2)|H type 2|H type 2 chain|H type 2 antigen|type 2 chain H|blood group H type II 

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

Blood group H (Type 2) - Lewis y

term (main_entry) : Blood group H (Type 2) - Lewis y 

glycan_dictionary_accession : GSD000038 

glytoucan_accession  : G00052MO 

term_in_sentence : The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes.[PMID: 11479278] 

publication : 11479278 

definition : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] 

term_xref : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045 

synonyms : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y 

function : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] 

disease_associations : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

Blood group H (Type 3)

term (main_entry) : Blood group H (Type 3) 

glycan_dictionary_accession : GSD000105 

glytoucan_accession  :  G94435QH

term_in_sentence : One particular lambody, VLRB.aGPA.23, was shown by glycan array analysis to be selective for the blood group H type 3 trisaccharide (BG-H3, Fucα1-2Galβ1-3GalNAcα), aGPA, and TFα (Galβ1-3GalNAcα), with affinity constants of 0.2, 1, and 8 nM, respectively.[PMID:23030719] 

publication : 23030719|20466654|1563908|3944092|11218748|11101633|18842005|27550195|2469783|2433836|23118206|8445257|2664192|3063304 

definition :  

term_xref :  GlycoMotif:GGM.000010|GTC:G94435QH

synonyms : H type 3|H antigen (type 3)|Type 3 chain H 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11

Blood group H (Type 4)

term (main_entry) : Blood group H (Type 4) 

glycan_dictionary_accession : GSD000039 

glytoucan_accession  : G98465JN 

term_in_sentence : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID:1841684] 

publication : 11261842|1841684|11101633|9405495 

definition : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245] 

term_xref : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245  

synonyms :  

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:61] 

wikipedia :  

essentials_of_glycobiology :

C2-O-sLex

term (main_entry) : C2-O-sLex 

glycan_dictionary_accession : GSD000040 

glytoucan_accession  : G97345NY 

term_in_sentence : PSGL-1 lacks 6-sulfo-sLex but contains sulfated tyrosine residues (Tyr-SO3)at positions 46, 48, and 51 and sLex in a core 2-based O-glycan (C2-O-sLex) on Thr at position 57.[PMID:12736247] 

publication : 12736247|19267921|21283832|15596301|17072011 

definition : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192] 

term_xref : GlycoMotif:GGM.000053|GTC:G97345NY|CID:91860725|KEGG:G10899|CHEBI:155160 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Ceramide dihexosyl sulfate

term (main_entry) : Ceramide dihexosyl sulfate 

glycan_dictionary_accession : GSD000041 

glytoucan_accession  : G04416BG 

term_in_sentence : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:818074] 

publication : 818074 

definition : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides. [http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/] 

term_xref : GTC:G04416BG|GlycoMotif:GGM.000065 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Chondroitin sulfate

term (main_entry) : Chondroitin sulfate 

glycan_dictionary_accession : GSD000043 

glytoucan_accession  :  

term_in_sentence : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: 31013685] 

publication : 31013685|27526113|27194526|26980567|28847361|24413804|29891297|29600622|25129732|31317901|29181550|31250530|22265655|25756648|29402610|17928217|20236040|28091940|30824935|26572336|31207331|21110089|30599999|20399897|27226567|19388612|23186102|31494830|28982096|30241863|30295666|25366475|20521042|29456007|31304829|18661362|28576008|29494632|30016441|26906924|24861964|23774590|31887904|31339761|12512856|26957048|29625000 

definition : Any of a class of 10‚Äî60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397] 

term_xref : CHEBI:37397|CID:24766 

synonyms : chondroitin polysulfate|chondroitin sulfate|chondroitin sulfates|chondroitin sulfuric acid|chondroitin sulphate|Chondroitinsulfate 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Chondroitin sulfate/dermatan sulfate

term (main_entry) : Chondroitin sulfate/dermatan sulfate

glycan_dictionary_accession : GSD000184

glytoucan_accession  : 

term_in_sentence : Heparan sulfate (HS) and chondroitin sulfate/dermatan sulfate (CS/DS) proteoglycans are heavily glycosylated proteins, crucial for animal development and homeostasis. [PMID:35192612]

publication : 35192612|35425970

definition : 

term_xref :

synonyms :  CS/DS|chondroitin/dermatan sulfate

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

cisGM1

term (main_entry) : cisGM1 

glycan_dictionary_accession : GSD000044 

glytoucan_accession  : G03277YI 

term_in_sentence : Macrophage ganglioside patterns dramatically increase in complexity when murine peritoneal macrophages are stimulated in vivo with the appearance of the sialidase-sensitive monosialoganglioside GM1b (cisGM1) as a major component.[PMID: 9455923] 

publication : 9455923 

definition : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580] 

term_xref : GlycoMotif:GGM.000100|GTC:G03277YI|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 

synonyms : GM1b 

function :  

disease_associations : Influenza[SugarBind_Ligand:92] 

wikipedia :  

essentials_of_glycobiology : Chapter 23

Complex-type N-glycans

term (main_entry) : Complex-type N-glycans 

glycan_dictionary_accession : GSD000045 

glytoucan_accession  :  

term_in_sentence : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:10988252] 

publication : 29902282|29212795|29343819|27705835|26745022|18399796|16825488|21964725|15864431|22890903|12417032|28039392|19426135|30253927|16794314|19806620|22975979|25931033|15201278|1912963419129628|24032650|22530754|31021709|30973186|28091941|23115339|20829342|27304954|29090617|21802690|29725121|30471292|16581187|26098720|31080188|1930135|31888963|30844485|24014058|11129583 

definition : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  

term_xref :  

synonyms :  

function : Involved in protein stability.[PMID:12417032] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 17

Core 1

term (main_entry) : Core 1

glycan_dictionary_accession : GSD000186

glytoucan_accession  : G00031MO

term_in_sentence : O-glycans are initiated by the addition of GalNAc to serine or threonine (via the ppGalNAcT family of glycosyltransferases), forming the Tn antigen (GalNAcα-O-Ser/Thr), which is used to generate the core 1 structure (Galβ1,3GalNAcα-O-Ser/Thr) on which most complex and branched O-glycans are derived. [PMID:31645367]

publication : 31645367|32297877

definition : 

term_xref : GTC:G00031MO|GlycoMotif:GGM.001005 

synonyms :  C1G

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

Core 2

term (main_entry) : Core 2 

glycan_dictionary_accession : GSD000046 

glytoucan_accession  : G00033MO 

term_in_sentence : To investigate the biological roles of core 2 O-glycans, we produced and characterized mice deficient in one or more of the three known glycosyltransferases that generate core 2 O-glycans (C2GnT1, C2GnT2, and C2GnT3).[PMID: 19349303]

publication : 19349303|30315106|23640779|26677400 

definition : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158] 

term_xref : GTC:G00033MO|CID:52921656|CHEBI:62158 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Core 3

term (main_entry) : Core 3 

glycan_dictionary_accession : GSD000047 

glytoucan_accession  : G00035MO 

term_in_sentence : Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells.[PMID: 28745318] 

publication : 28745318|27259834|27143302| 

definition : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344] 

term_xref : GTC:G00035MO|CID:25061208|CHEBI:71344 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

Core 4

term (main_entry) : Core 4 

glycan_dictionary_accession : GSD000048 

glytoucan_accession  : G00037MO 

term_in_sentence : The results confirm the predicted existence of a beta1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation.[PMID: 9988682] 

publication : 9988682|10747980| 

definition : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341] 

term_xref : GTC:G00037MO| CID:25229562|CHEBI:71341 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 8

Core-fucosylated

term (main_entry) : Core-fucosylated 

glycan_dictionary_accession : GSD000049 

glytoucan_accession  : G78059CC 

term_in_sentence : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:27678371] 

publication : 27678371|26514868|15538974|24914453|17049014|32078267|31268672|28674882|29956878|27798819|32044029|30962950|31548313|30907281|29090617|29571940|28800497|27629418|29733746|31623829|28768188|26897254|31451706|26514868|29427759|28982386|26587313|30940702|15538974|31249452|27282921|31229844|30445455|31325506|24732908|29209018|26965517|28609658|24914453|25573275|17049014|19218400|27012207|27139574|32078267|25861849|32561391|21374780|31669139|25732060|29408166|31268672|30472795|30614075|19003000|25664929 

definition : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006]. 

term_xref : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 

synonyms : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc 

function : Required for signaling through TCR [PMID: 29434598]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:17132494]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:29062024] 

disease_associations : Emphysema|systemic lupus erythematosuslung cancer|autoimmunity|tumor metastasis 

wikipedia :  

essentials_of_glycobiology : Chapter 8

Core-fucosylated biantennary

term (main_entry) : Core-fucosylated biantennary 

glycan_dictionary_accession : GSD000050 

glytoucan_accession  : G78059CC 

term_in_sentence : The IFN-alpha14c N-glycans were shown to exhibit core-fucosylated biantennary glycans , with about 10% carrying an additional alpha1,3-linked fucose unit at the antennae.[PMID:9654101] 

publication : 9654101|15819890|28263871|26763099|22256781|23681398|25855029|10529240|26544759|8206921|33149259|8547276 

definition : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. 

term_xref : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 

synonyms : core-fucosylated diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 8

Core-fucosylated biantennary complex-type

term (main_entry) : Core-fucosylated biantennary complex-type 

glycan_dictionary_accession : GSD000051 

glytoucan_accession  : G78059CC 

term_in_sentence : The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.[PMID:10731668] 

publication : 10731668 

definition : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. 

term_xref : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 

synonyms : core fucosylated diantennary complex-type 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Cyclic sialyl 6-sulfo Lewis x

term (main_entry) : Cyclic sialyl 6-sulfo Lewis x 

glycan_dictionary_accession : GSD000052 

glytoucan_accession  :  G11148DZ

term_in_sentence : Stimulation of the sialyl 6-sulfo Lewis X-positive colon cancer cell line with a calcium ionophore ionomycin markedly reduced sialyl 6-sulfo Lewis X and induced cyclic sialyl 6-sulfo Lewis X expression.[PMID:10728707] 

publication : 10728707|31222115|9990070|23088960 

definition :  

term_xref :  GlycoEpitope:EP0017|CID:91858084|CHEBI:147484

synonyms :  

function : The accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Cytolipin R

term (main_entry) : Cytolipin R 

glycan_dictionary_accession : GSD000053 

glytoucan_accession  : G57710SU 

term_in_sentence : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:4110375] 

publication : 893368|4375678|51702|186204|4110375|5068000|24174198|6072378|389925|7054174 

definition : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:5068000] 

term_xref : GlycoMotif:GGM.000083|GTC:G57710SU|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17 

synonyms :  

function :  

disease_associations : Actinomycosis[SugarBind_Ligand:17] 

wikipedia :  

essentials_of_glycobiology :

Dermatan sulfate

term (main_entry) : Dermatan sulfate 

glycan_dictionary_accession : GSD000054 

glytoucan_accession  :  

term_in_sentence : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:29111696] 

publication : 27526113|29111696|29891297|26164146|30869126|7789716|8597249|12512856|31250530|17928217|12213784|27226567|31455633|28091940|19075609|31071403|15078125|18661328|20581662|17239765|15749837|2777747|20632047|8930750|7762784|31006321|26876822|1522290|131009|26986023|8161353|15315969|12543559|30637950|2525357|18156656|9692613|9200333|19661164|2299256|16075147|1126924|9774430|8537360|15563459|21077227|23275130|17137817|6447930|6209270 

definition : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.[CHEBI:18376] 

term_xref : CHEBI:18376|CID:32756 

synonyms : beta-Heparin|Chondroitin sulfate B|Dermatan L-iduronate 

function : Wound healing[Essentials of Glycobiology:Chapter 7]|maintain the structure of the dermis.[Essentials of Glycobiology:Chapter 41]

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Desialylated

term (main_entry) : Desialylated 

glycan_dictionary_accession : GSD000055 

glytoucan_accession  :  

term_in_sentence : Furthermore, we found no evidence for "desialylated" apoB100 glycans in any of the samples analyzed.[PMID:11588155] 

publication : 30015642|26168491|29492899|31774586|32321401|23780974|7600681|18045697|1450583|4137057|28911304|27562992|29950245|31978220|2408573|8612720|10910970|27195066|1434544|22175031|24517196|29794068|30101537|18972200|1478792|4440781|21229239|30844664|31351722|31330845|1872910 

definition : A glycan from which sialyl groups have been removed. [https://en.wiktionary.org/wiki/desialylated] 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Desialylated tetrasaccharide

term (main_entry) : Desialylated tetrasaccharide 

glycan_dictionary_accession : GSD000056 

glytoucan_accession  :  

term_in_sentence : The structures of a desialylated tetrasaccharide , two monosialylated trisaccharides , and five other minor products were defined.[PMID:8384526] 

publication : 8384526 

definition : A tetrasachharide (four branches) glycan from which sialyl groups have been removed.  

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 17

Difucosylated tetra-antennary N-glycans

term (main_entry) : Difucosylated tetra-antennary N-glycans 

glycan_dictionary_accession : GSD000057 

glytoucan_accession  :  

term_in_sentence : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID:18214858] 

publication : 18214858 

definition : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added. 

term_xref :  

synonyms :  

function :  

disease_associations : pancreatic cancer[PMID:18214858] 

wikipedia :  

essentials_of_glycobiology :

Dimeric Lewis x

term (main_entry) : Dimeric Lewis x 

glycan_dictionary_accession : GSD000058 

glytoucan_accession  : G79535HZ 

term_in_sentence : The carbohydrate antigen dimeric Lewis X (DimLex), which accumulates in colonic and liver adenocarcinomas, is a valuable target to develop anti-cancer therapeutics.[PMID:32957489] 

publication : 32957489|31276881|12062524|15488731|1979361|8737237|17939723|7683631|11384108|11133015|17388629|15483381|12662048|3233598|18618154|21892456 

definition : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325] 

term_xref : GTC:G79535HZ|GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031 

synonyms : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx 

function : cancer-associated antigen[GlycoEpitope:EP0093] 

disease_associations : colonic cancer[GlycoEpitope:EP0093]|liver cancer[GlycoEpitope:EP0093] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

Diphosphorylated Man6

term (main_entry) : Diphosphorylated Man6 

glycan_dictionary_accession : GSD000059 

glytoucan_accession  : G54792LL 

term_in_sentence : Here we report that the single-chain variable domain (scFv) M6P-1 is a unique antibody fragment with specificity for Man6P monosaccharide that, through an array-screening approach against a number of phosphorylated N-glycans, is shown to bind mono- and diphosphorylated Man6 and Man7 glycans that contain terminal αMan6P(1 → 2)αMan(1 → 3)αMan.[PMID:26503547] 

publication : 26503547 

definition :  

term_xref : GTC:G54792LL|GlycoMotif:GGM.000054  

synonyms : Diphosphorylated Man_6 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Disialosyl globopentaosylceramide

term (main_entry) : Disialosyl globopentaosylceramide 

glycan_dictionary_accession : GSD000060 

glytoucan_accession  : G97932OH 

term_in_sentence : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID:31339142] 

publication : 31339142|24637536|25864532|27344728|12084983|32567311|28205070|20663960|18214042 

definition : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:28205070] 

term_xref : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID:91860287|KEGG:G00181|SugarBind_Ligand:57 

synonyms : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside 

function : promotes metastasis[PMID:28205070] 

disease_associations : prostate cancer[PMID:24637536]|renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] 

wikipedia :  

essentials_of_glycobiology :

Disialyl Gb5

term (main_entry) : Disialyl Gb5 

glycan_dictionary_accession : GSD000061 

glytoucan_accession  : G97932OH 

term_in_sentence : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: 12084983] 

publication : 12084983 

definition :  

term_xref : GlycoEpitope:EP0098|GTC:G97932OH|CID:91860287|SugarBind_Ligand:57|KEGG:G00181 

synonyms :  

function :  

disease_associations : renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] 

wikipedia :  

essentials_of_glycobiology :

Disialyl I

term (main_entry) : Disialyl I 

glycan_dictionary_accession : GSD000062 

glytoucan_accession  : G54937EM 

term_in_sentence : Here we present an example of promotion of binding of soluble-form FN from placenta or from hepatoma cells, having a specific carbohydrate epitope termed "disialyl-I," to K562 or VA13 cell surface in the presence of glycosphingolipid Gg3, which interacts specifically with disialyl-I[PMID:10640401] 

publication : 10640401 

definition :  

term_xref : GlycoEpitope:EP0095|GTC:G54937EM|CID:91849523 

synonyms : disialyl-I 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Disialyl Lewis a

term (main_entry) : Disialyl Lewis a 

glycan_dictionary_accession : GSD000063 

glytoucan_accession  : G93400AK 

term_in_sentence : Biosynthesis of disialyl Lewis a (Lea) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides.[PMID:12668675] 

publication : 12668675|17760270|15231659|12668106|30716533|32050430|22467657 

definition : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:15231659] 

term_xref : GTC:G93400AK |GlycoEpitope:EP0040|CID:91854138|CHEBI:155549 

synonyms : disialyl Lea 

function : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040] 

disease_associations : Mucin antigen carrying 2-3 sialylated Le a antigen or 2-3, 2-6 disialylated Lc4 antigen in cancer patients had the lowest carbohydrate/protein ratio. Thus, the carbohydrate/protein ratio in the type 1 chain mucin antigens in sera of normal subjects is higher than that in sera of cancer patients.[GlycoEpitope:EP0040] 

wikipedia :  

essentials_of_glycobiology :

Disialyl T antigen

term (main_entry) : Disialyl T antigen 

glycan_dictionary_accession : GSD000064 

glytoucan_accession  : G01614ZM 

term_in_sentence : The most potent glycoside was disialyl T antigen (NeuAcalpha2-3Galbeta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides.[PMID: 15701648] 

publication : 29113555|17974963|33242079|12645620|15701648|26598643 

definition : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602] 

term_xref : GlycoMotif:GGM.000014|GTC:G01614ZM|CID:70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027 

synonyms : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen 

function : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Disialylated biantennary

term (main_entry) : Disialylated biantennary 

glycan_dictionary_accession : GSD000065 

glytoucan_accession  :  

term_in_sentence : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:8486673 

publication : 22426998|17171781|25022802|24812685|24780636|26582205|9499382|22978794|22594947|8486673|20356825|1634621|9244386|12966096|1472054|24243045|19579232|27943633 

definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. 

term_xref :  

synonyms : disialylated diantennary 

function : appears in human transferrin[PMID: 24243045]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] 

disease_associations : galactosemia.[PMID:9499382] 

wikipedia :  

essentials_of_glycobiology :

Disialylated biantennary complex-type

term (main_entry) : Disialylated biantennary complex-type 

glycan_dictionary_accession : GSD000066 

glytoucan_accession  :  

term_in_sentence : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:11738084] 

publication : 11738084|9499382|9244386|24243045|12966096|25124522|19371135 

definition : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. 

term_xref :  

synonyms :  

function : appears in human transferrin[PMID:24243045]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] 

disease_associations : galactosemia.[PMID:9499382] 

wikipedia :  

essentials_of_glycobiology :

Disialylated fucosylated

term (main_entry) : Disialylated fucosylated 

glycan_dictionary_accession : GSD000067 

glytoucan_accession  :  

term_in_sentence : Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.[PMID:17591618] 

publication : 17591618 

definition : A fucosylated glycan with two sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 45

Forssman antigen

term (main_entry) : Forssman antigen 

glycan_dictionary_accession : GSD000068 

glytoucan_accession  : G80062GG 

term_in_sentence : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution.[PMID:28510705] 

publication : 28510705|31933576|28134301|7021748|1802714|7512587|7747818|23325748|268649|31816281|22015168|4147161|2857159|6267170|7293775|13367419|20636540|10460829|23255552|2675268|18955372|7020692|31784953|4114942|31273262|6257673|7696847|1916901|11169215|48262|26022515|6175621|31404475|6983878|8381954|10431785|3257757|6792413|25039359 

definition : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789] 

term_xref : GTC:G80062GG |GlycoEpitope:EP0037|CID91825690|CHEBI:85789  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 45

Forssman glycolipid

term (main_entry) : Forssman glycolipid 

glycan_dictionary_accession : GSD000069 

glytoucan_accession  : G80062GG 

term_in_sentence : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:3040119] 

publication : 3040119|268649|23240079|28134301|3495590|1138893|10460829|10506200|8855242|1955453|1933935|3355161|6773959|14573676|29898878|10431785|1747956|11214737|7423202|389939|3871816|6187373|16133832|469271|3753492|2695680|7037611|25703376|23798992|414913|1868069|7960243 

definition : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789] 

term_xref : GlycoMotif:GGM.000084|GTC:G80062GG|CID:91825690|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86  

synonyms : Forssman antigen|Globopentosylceramide 

function : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:3495590] 

disease_associations : Pyelonephritis[SugarBind_Ligand:86]|Acute cystitis[SugarBind_Ligand:86] 

wikipedia :  

essentials_of_glycobiology : Chapter 45

Fucose-containing tetraantennary

term (main_entry) : Fucose-containing tetraantennary 

glycan_dictionary_accession : GSD000070 

glytoucan_accession  :  

term_in_sentence : The two major N-linked oligosaccharides of Namalwa EPO were fucose-containing tetraantennary and fucose-containing triantennary structures.[PMID:2550193] 

publication : 2550193 

definition : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of fucose. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia : https://en.wikipedia.org/wiki/Forssman_antigen 

essentials_of_glycobiology : Chapter 14

Fucosyl GM1

term (main_entry) : Fucosyl GM1 

glycan_dictionary_accession : GSD000071 

glytoucan_accession  : G91532KA 

term_in_sentence : Unique localization of fucosyl GM1 implicates its possible role in cell adhesion and recognition in the nervous system.[PMID:8068725] 

publication : 6619101|16880505|9089399|29789847|8068725|19556222|1660040|2420639|9076515|15926079|19555091|2541996|16211870|1336587|21174147|14967068|18923900|30021910|16941490|27070150|8305235|10602885|2645049|7993838|10537341|3002616|8336147|15447995|8905401|11714535|9260862|32228455|3315641|8076384|2317201|3680254|6403518 

definition : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686] 

term_xref : GTC:G91532KA |GlycoEpitope:EP0049|CID:53356699|CHEBI:62686 

synonyms :  

function :  

disease_associations : small-cell lung cancer(SCLC)[GlycoEpitope:EP0049]|hepatoma[GlycoEpitope:EP0049] 

wikipedia :  

essentials_of_glycobiology :

Fucosylated asialo-biantennary

term (main_entry) : Fucosylated asialo-biantennary 

glycan_dictionary_accession : GSD000072 

glytoucan_accession  :  

term_in_sentence : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:2065054] 

publication : 2065054|17013932 

definition : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose. 

term_xref :  

synonyms : fucosylated asialo-diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Fucosylated biantennary

term (main_entry) : Fucosylated biantennary 

glycan_dictionary_accession : GSD000073 

glytoucan_accession  :  

term_in_sentence : The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class.[PMID:17956937] 

publication : 17956937|30525457|1933856 

definition : a biantennary glycan with two GlcNAc branches linked to the core and the addition of fucose. 

term_xref :  

synonyms : fucosylated bisialo-diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Fucosylated bisialo-biantennary

term (main_entry) : Fucosylated bisialo-biantennary 

glycan_dictionary_accession : GSD000074 

glytoucan_accession  :  

term_in_sentence : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:2065054] 

publication : 2065054 

definition : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added. 

term_xref :  

synonyms : Fucosylated biantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Fucosylated LDN

term (main_entry) : Fucosylated LDN 

glycan_dictionary_accession : GSD000075 

glytoucan_accession  : G02240AO 

term_in_sentence : To date, oligomeric LDN and oligomeric fucosylated LDN (LDNF) have been found only on N-glycans from mammalian cells engineered to express Caenorhabditis elegansbeta4-GalNAc transferase and human alpha3-fucosyltransferase IX [Z. S. Kawar et al. (2005) J Biol Chem280, 12810-12819]. [PMID:16403022] 

publication : 16403022|28151933|19545571|22448293 

definition : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864] 

term_xref : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID:52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594 

synonyms : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Fucosylated N-glycans

term (main_entry) : Fucosylated N-glycans 

glycan_dictionary_accession : GSD000076 

glytoucan_accession  :  

term_in_sentence : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:18214858] 

publication : 18214858|31141660|26869352|29790113|31931062 

definition : The fucose from GDP-fucose is transferred to N-linked glycans. 

term_xref :  

synonyms :  

function :  

disease_associations : pancreatic cancer.[PMID: 26869352] 

wikipedia :  

essentials_of_glycobiology :

Fucosylated triantennary

term (main_entry) : Fucosylated triantennary 

glycan_dictionary_accession : GSD000077 

glytoucan_accession  :  

term_in_sentence : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:2513186 

publication : 2513186|29642865|7679920|31110965|2551687|15051952|12943224 

definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose. 

term_xref :  

synonyms :  

function : appears in human alpha-fetoprotein (AFP).[PMID: 7679920] 

disease_associations : neoplastic diseases of the liver[PMID: 7679920 ]|hepatocellular carcinoma[PMID: 7679920]. 

wikipedia :  

essentials_of_glycobiology : Chapter 43

Galabiosylceramide

term (main_entry) : Galabiosylceramide 

glycan_dictionary_accession : GSD000078 

glytoucan_accession  : G67988RO 

term_in_sentence : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:33360824] 

publication : 33360824|29099167|25582508|2824515|4027258|32854306|32868283|31319156|29530250|27367163|2564247|27727434|10216186|10460829|24992926|23590301|15702404|1854798|14761135|3600200|8603914|8601603|1965141|17400502|3840690|15959771|7930586|7721812|17095952|2500499|3815386|8842706|10746023|3928791|3782065|6440894 

definition : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314] 

term_xref : GlycoEpitope:EP0113|GTC:G67988RO|CID:5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314 

synonyms :  

function :  

disease_associations : tumor/lung[GlycoEpitope:EP0113]|tumor/gallbladder[GlycoEpitope:EP0113]|tumor/kidney[GlycoEpitope:EP0113]|tumor/pancreas[GlycoEpitope:EP0113] 

wikipedia :  

essentials_of_glycobiology :

Galactosylceramide

term (main_entry) : Galactosylceramide 

glycan_dictionary_accession : GSD000079 

glytoucan_accession  : G65889KE 

term_in_sentence : Galactosylceramide improved behavioral, neuropathological, and biochemical parameters in Cln3 Cln3 Δex7/8 mice, paving the way for effective therapy for CLN3 disease and use of serum ceramide as a potential biomarker to track impact of therapies.[PMID:31393621] 

publication : 31393621|19941861|9883654|33006978|26735924|22032265|18035062|25129050|2802541|1761517|28660574|475780|2302222 

definition :  

term_xref : GTC:G65889KE|GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061 

synonyms : GalCer|Galactocerebroside|LC 

function :  

disease_associations : Pleuropneumonia[SugarBind_Ligand:1]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:1]|Lyme disease[SugarBind_Ligand:1]|Plague[SugarBind_Ligand:1]|Acquired immune deficiency syndrome[SugarBind_Ligand:1] 

wikipedia :  

essentials_of_glycobiology :

Galnac disialyl Lc4 (Hexasaccharide)

term (main_entry) : Galnac disialyl Lc4 (Hexasaccharide) 

glycan_dictionary_accession : GSD000080 

glytoucan_accession  : G33532XU 

term_in_sentence : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: 12084983] 

publication : 15704108|11278988|12084983|7509790 

definition : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID:91857945] 

term_xref : GlycoEpitope:EP0097|GTC:G33532XU|CID:91857945|CHEBI:149360 

synonyms :  

function :  

disease_associations : prostate cancer[GlycoEpitope:EP0097]|renal cell carcinoma/RCC[GlycoEpitope:EP0097] 

wikipedia :  

essentials_of_glycobiology :

Gb5

term (main_entry) : Gb5 

glycan_dictionary_accession : GSD000081 

glytoucan_accession  : G99053DY 

term_in_sentence : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:25839135] 

publication : 12401210|25839135|31540393|31140679|3028540|3674263|31339142|30026902|10721708|30671362|26176557|25039255|24044869|32567311|27857717|21491978|24910250|29077212|8014006|27107335|32679486|1747956|8679447|28352526|11341836|10837462|7960243|16158941|3297853|2431136|21734356|8625206|30732055|12716912|20128040|2582447|14659673 

definition : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842] 

term_xref : GlycoMotif:GGM.000076|GTC:G99053DY|CID:53239691|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12 

synonyms : Globopentaosylceramide 

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:12]|Actinomycosis[SugarBind_Ligand:12|Influenza[SugarBind_Ligand:12] 

wikipedia :  

essentials_of_glycobiology : Chapter 11

GD1

G81983KG

term (main_entry) : GD1 

glycan_dictionary_accession : GSD000082 

glytoucan_accession  : G81983KG 

term_in_sentence : Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1.[PMID:31791361] 

publication : 5652802|25345088|31791361|29361370|31234327|30264864|25250137|7528216|31669751|20684311|16306603|10420586|7766692|31614613|26384672|31613991|19210136|8926633|29696051|32300455|7513313|26674302|20336376|24259734|31704237|21067946|30516933|27979707|26345314|30516941|31849452|27789132|30218706|29388611|20177787 

definition :  

term_xref : GlycoMotif:GGM.000105|GTC:G81983KG|CID:91859783|KEGG:G00126  

synonyms : GD1c 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GD1a

term (main_entry) : GD1a 

glycan_dictionary_accession : GSD000083 

glytoucan_accession  : G46677TE | G45714BQ

term_in_sentence : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: 28899916] 

publication : 28899916|26860251|21930390|32906699|26054879|29951721|11745410|17653976|26119566|21554929|18435913|15342262|26865725|21151139|15716397|21492147|16942752|26973195|24449473|14999485|22735313|20589721|10521808|22929125|7827024|16897174|25062498|17227759 

definition : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209] 

term_xref : GlycoMotif:GGM.000106|GlycoMotif:GGM.000107|GTC:G46677TE|GTC:G45714BQ|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111  

synonyms : GD1alpha 

function :  

disease_associations : Gastroenteritis[SugarBind_Ligand:22]|Actinomycosis[SugarBind_Ligand:22]|Lazy leukocyte syndrome[SugarBind_Ligand:22]|Toxoplasmosis[SugarBind_Ligand:22]|Lyme disease[SugarBind_Ligand:22]|Botulism[SugarBind_Ligand:22]|Keratoconjunctivitis[SugarBind_Ligand:22]|Influenza[SugarBind_Ligand:22] 

wikipedia :  

essentials_of_glycobiology :

GD1b

term (main_entry) : GD1b 

glycan_dictionary_accession : GSD000084 

glytoucan_accession  : G37184KW 

term_in_sentence : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: 27144558] 

publication : 27144558|24859332|18625966|7945223|32518172|26710925|31837178|20594196|30985655|11511306|1742806|11123278|7685064|2709011|33279873|22929125|9179156|17964572|8821498|32726962|26560950|2611779|10072058|20030259|16415013|10797556|11342695|8619520|21519903|16199892|23777091|30246056|10481046 

definition : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222] 

term_xref : GlycoMotif:GGM.000108|GTC:G37184KW|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 47

GD2

term (main_entry) : GD2 

glycan_dictionary_accession : GSD000085 

glytoucan_accession  : G02657AK 

term_in_sentence : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: 25440605] 

publication : 28154831|32002293|32733795|28145567|31500597|31903906|29180536|28415563|25440605|30617136|25604432|30198960|31075227|31721713|30955398|32195035|27304202|31015228|31653037|31016728|30670592|30613134|29221154|30027525|29442009|31762628|30485077|25642322|29436609|29151270|24773917|30612272|27654028|26298772 

definition : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218] 

term_xref : GlycoMotif:GGM.000094|GTC:G02657AK|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88  

synonyms :  

function :  

disease_associations : breast cancer[PMID:28415563] 

wikipedia :  

essentials_of_glycobiology : Chapter 11|Chatper 35

GD3

term (main_entry) : GD3 

glycan_dictionary_accession : GSD000086 

glytoucan_accession  : G98544DH 

term_in_sentence : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: 12531552] 

publication : 30245960|27591028|12531552|29069780|12470841|29436609|28295752|27304202|31138648|27288875|30446565|8721669|3903474|16081368|32743804|24372645|26792897|20890432|25330147|20581115|11174200|16040804|23783008|17368571|11023989|12901230|21807667|7061953|2231782|19423750|22632091|18202973|6392333|15896784|8261439|20052288|12847141|12486096|12118012|19912988|22795094|18655184|17043769|21395555|2472199|19776077 

definition : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210] 

term_xref : GlycoMotif:GGM.000091|GTC:G98544DH|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062 

synonyms :  

function :  

disease_associations : Cholera[SugarBind_Ligand:89]|Influenza[SugarBind_Ligand:89] 

wikipedia :  

essentials_of_glycobiology : Chapter 11

Globoside

term (main_entry) : Globoside 

glycan_dictionary_accession : GSD000087 

glytoucan_accession  : G00061MO 

term_in_sentence : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:10993897] 

publication : 10993897 

definition :  

term_xref : GlycoMotif:GGM.000070|GTC:G00061MO 

synonyms : Cytolipin K|Gb4|Globoside I|Globotetraosylceramide|P antigen 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 47

Globotetraosylceramide

term (main_entry) : Globotetraosylceramide 

glycan_dictionary_accession : GSD000088 

glytoucan_accession  : G00061MO 

term_in_sentence : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:28392398] 

publication : 28392398|25787850|23471986|2559078|32455599|2663859|32796033|3517161|20082214|30853699|15279935|26104834|20732996|30224239|31142708|30338271|25033755|30413389|7104376|29866658|24983355|6794884|31361021|21740983|33168837|31752441|28123520|29068380|24841197|27932383|28535204|31691795|27916888|27558838|10227680|26464281|22348006|22279060|25156739|32314902|22718629|23701631|23906628|8613382|23555772|20059899|7868240 

definition : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] 

term_xref : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID:5288889|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032

synonyms : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K 

function :  

disease_associations : Actinomycosis[SugarBind_Ligand:18]|Pyelonephritis[SugarBind_Ligand:18]|Acute cystitis[SugarBind_Ligand:18]|Shigellosis[SugarBind_Ligand:18]|Lazy leukocyte syndrome[SugarBind_Ligand:18]|Influenza[SugarBind_Ligand:18] 

wikipedia :  

essentials_of_glycobiology : Chapter 11

Globotriaosylceramide

term (main_entry) : Globotriaosylceramide 

glycan_dictionary_accession : GSD000089 

glytoucan_accession  : G00059MO 

term_in_sentence : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:32127409] 

publication : 32127409|28674962|30875019|30413389|31778662|31101366|24335674|31241709|24158513|28947349|31566927|28672034|31939530|29530250|27851774|26426881|25031264|29982630|24496231|29983334|28756410|27190352|29274327|29099167|28402705|23680766|28625968|26960552|26797827|22742555|27756537|31630715|3827883|28384397|29523338|31010832|27195818|26661087|23093409|30879639|27081853|17409683|29921669|25575293|26291612|23146289|25857295|26070511 

definition : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] 

term_xref : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID:5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27 

synonyms : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide 

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:27]|Acute cystitis[SugarBind_Ligand:27]|Shigellosis[SugarBind_Ligand:27]|Lyme disease[SugarBind_Ligand:27]|Cutaneous lesions[SugarBind_Ligand:27]|Diarrhea[SugarBind_Ligand:27] 

wikipedia :  

essentials_of_glycobiology :

Glucosylceramide

term (main_entry) : Glucosylceramide 

glycan_dictionary_accession : GSD000090 

glytoucan_accession  : G71142DF 

term_in_sentence : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321] 

publication : 31265321|29290548|29627573|20919653|28427052|30550553|24415933|31914593|31051284|23073611|30146946|31619618|26840726|29750412|8065509|27412675|27840079|30611744|31353719|25661072|28686011|25803043|28865794|28154347|31466334|30242129|12531551|30639288|30864417|27711049|22764777|27905603|29077010|28744000|23555901|24115322|12803919|29204666|23628459|28851512|26136173|23563543|30110701|26572681|2193825|29926415|31727994|27479571 

definition : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963] 

term_xref : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF  

synonyms : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH 

function : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:30611744]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321] 

disease_associations : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] 

wikipedia :  

essentials_of_glycobiology : Chapter 31

GM1

term (main_entry) : GM1 

glycan_dictionary_accession : GSD000091 

glytoucan_accession  : G48558GR 

term_in_sentence : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238] 

publication : 18524657|31761138|36180805|29920238|33859490|31937438|25762012|25931034|31776384|32013258|30776097|31048748|31447771|30292198|28796418|27806275|21076871|27552916|17986147|26960162|27815022|25851126|32916822|11462671|28236574|15911874|28577204|28497346|1794005|31934908|30267299|16902585|29439846|32325905|29747823|27576485|26338710|27858734|24501414|26818965|26629687|26958633|1854596|32134593|32198666|6619101 

definition : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] 

term_xref : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 

synonyms :  GM1 ganglioside|GM1-ganglioside

function :  The branched pentasaccharide chain of ganglioside GM1 is a prominent cell surface ligand, for example, for cholera toxin or tumor growth-regulatory homodimeric galectins.[PMID:16267866]

disease_associations : GM1 gangliosidosis (GM1) [PMID: 33859490]|Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13] 

wikipedia : https://en.wikipedia.org/wiki/GM1 

essentials_of_glycobiology :  Chapter 11| Chapter 14

GM2

term (main_entry) : GM2 

glycan_dictionary_accession : GSD000092 

glytoucan_accession  : G79389NT 

term_in_sentence : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: 27491214] 

publication : 29618308|27491214|32867370|30030044|27499644|31097363|29100724|27402091|31852956|30389374|30988135|8786814|14533808|23370522|28192816|32692591|29106755|28833537|11339652|9728335|27270764|9714704|26175473|27018595|28615102|28974375|32951593|11462672|28955902|17192692|26538065|25421609|9572057|11596983|15264019|23236285|11596984|31261761|30113798|24391178|24309906|22224667|7980537|18272501|9006924| 

definition : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] 

term_xref : GlycoMotif:GGM.000095|GTC:G79389NT|CID:45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351 

synonyms :  

function :  

disease_associations : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]|Gastroenteritis[SugarBind_Ligand:39]|Cholera[SugarBind_Ligand:39]|Clostridial myonecrosis[SugarBind_Ligand:39]|Tetanus[SugarBind_Ligand:39] 

wikipedia : https://en.wikipedia.org/wiki/GM1_gangliosidoses 

essentials_of_glycobiology : Chapter 11

GM3

term (main_entry) : GM3 

glycan_dictionary_accession : GSD000093 

glytoucan_accession  : G91237TK 

term_in_sentence : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: 29747813] 

publication : 29376491|29747813|25613425|30318083|31526872|31004109|28019668|26434718|27313500|27539856|30111401|28544772|29407985|19364317|30190430|31297734|30091781|26043887|32183071|30665141|27873002|25801320|30209782|32378734|23050851|22768242|14993837|24934090|17638075|21518140|26102277|19759399|24502144|25303960|23564406|16636105|16491123|11259118|15102521|12724312|24985965|8496625|25403557|15690123|15939439|25893133|23591593|20634908|2004380|739008| 

definition : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] 

term_xref : GlycoMotif:GGM.000090|GTC:G91237TK|CID:5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 

synonyms :  

function : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844] 

disease_associations : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35]|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35] 

wikipedia :  

essentials_of_glycobiology : Chapter 37

GM4

term (main_entry) : GM4 

glycan_dictionary_accession : GSD000094 

glytoucan_accession  : G30207PZ 

term_in_sentence : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:23999868] 

publication : 23999868|2332419|12091485|19542236|8407875|23320941|28808804|3621237|23203271|7057115|26362868|6170387|18034482|7076644|2391348|25464080|3701369|11217952|6201236|30744426|9388026|27177620|30246056|15979459|7586078|6779816|29402905|7335153|3306476|17499534|7074082|9668345|3701884|26862430|6831238|27311552|26831445|24417799|7097284|4169231|16854400|26483798 

definition : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position
[CHEBI:63155] 

term_xref : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 

synonyms :  Sialylated GalCer

function :  

disease_associations : Chronic gastritis[SugarBind_Ligand:110]|Peptic ulcers[SugarBind_Ligand:110]|Gastric cancer[SugarBind_Ligand:110] 

wikipedia :  

essentials_of_glycobiology : Chapter 11|Chapter 15|Chapter 44|Appendix 45A

GP1c

term (main_entry) : GP1c 

glycan_dictionary_accession : GSD000095 

glytoucan_accession  : G93805MV 

term_in_sentence : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:19053458] 

publication : 1606358]|19053458|1695858|4091974|10775425|2468656|2299350|3064875|11432974|9613831|11831845|1879553|10699494|8969459|8474578| 12031286|1304332|9153001| 10564776 

definition :  

term_xref : GlycoMotif:GGM.000118|GTC:G93805MV 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11|Chapter 14|Chapter 27|Chapter 35|Chapter 45 |Chapter 47|Chapter 49

GQ1b

term (main_entry) : GQ1b 

glycan_dictionary_accession : GSD000096 

glytoucan_accession  : G18625KA 

term_in_sentence : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:31186474] 

publication : 30798387|31186474|26704905|23677659|26984947|24184316| 23804237|9819299|18514410|22189683|24859332 

definition : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] 

term_xref : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11

GQ1ba

term (main_entry) : GQ1ba 

glycan_dictionary_accession : GSD000097 

glytoucan_accession  : G54733XO 

term_in_sentence : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:25024341] 

publication : 25024341|23717411|17870542|10702226|21137678|26748510|8662799|21274438|24649890|16580208|28124591|20095613|17507233|23565921|14505645|20930939|9201997 

definition :  

term_xref : GlycoMotif:GGM.000116|GTC:G54733XO 

synonyms : GQ1balpha 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GQ1c

term (main_entry) : GQ1c 

glycan_dictionary_accession : GSD000098 

glytoucan_accession  : G99524KA 

term_in_sentence : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: 6640289] 

publication : 6640289|1695858|7798936|1729139|2468656|20368669| 2723647|1814411|3064875|6085330|1613492|17883393|11831845|10775425|8219015|8804704|1384262|7066685|2299192|9613831|10350354|1304337|9153001|11959025| 8474578|2299350|10564776|10699494|3942818|12031286| 7361620 

definition : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID:91860352] 

term_xref : GlycoMotif:GGM.000117|GTC:G99524KA|CID:91860352|CHEBI:145645|KEGG:G00121 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 46

GT1a

term (main_entry) : GT1a 

glycan_dictionary_accession : GSD000099 

glytoucan_accession  : G68110IF 

term_in_sentence : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:26197476] 

publication : 12023422|32623212|26197476|9585812|29747820|23804237|11993188|31683059|19631994|9742882|29709941|8971119|8706663|893404|31829433|8910600|30600291|29319803|26176883|29063860|6766128|31602715|29808463|30711390|29847988|30116054|28187751 

definition : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] 

term_xref : CID:45266863|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GT1a alpha

term (main_entry) : GT1a alpha 

glycan_dictionary_accession : GSD000100 

glytoucan_accession  : G02149VR 

term_in_sentence : A new class of gangliosides, GT1a alpha and GQ1b alpha, were initially identified as cholinergic neuron-specific antigens in bovine brain. [PMID:8082783] 

publication : 7710562|8082783|10972137|9468624|9143254|8221098|9679279|11368158|11878808 

definition :  

term_xref : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID:91851751|CHEBI:156678|KEGG:G00128  

synonyms : GT1aa 

function : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GT1b

term (main_entry) : GT1b 

glycan_dictionary_accession : GSD000101 

glytoucan_accession  : G40183QN 

term_in_sentence : GT1b ganglioside is axonally transported to the spinal cord dorsal horn and contributes to characteristics of neuropathic pain such as mechanical and thermal hypersensitivity.[PMID: 32030804] 

publication : 32030804|26370787|32046393|9712688|7636307|9931455|25520869|19605473|17188834|10233751|22735313|20540782|22746533|1861141|19490186|9521848|11921200|10731661|31431523|15274627|32726962|12573517|18277613|11370834|11234774|11123278|18704164|16291967|11411041|27549393|25253868|22720883|10686582|11511306|29904724|31472390|19156870 

definition : A branched amino heptasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries an N-acetyl-α-neuraminyl-(2→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl trisaccharide unit and an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide unit through (2→4) and (2→3) linkages respectively. It corresponds to the carbohydrate portion of ganglioside GT1b.[CHEBI:59225] 

term_xref : GlycoMotif:GGM.000112|GTC:G40183QN|GlycoEpitopeEP0067|CID:45266781|CHEBI:59225| GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116

synonyms :  

function :  

disease_associations : Toxoplasmosis[SugarBind_Ligand:26]|Lyme disease[SugarBind_Ligand:26]|Cholera[SugarBind_Ligand:26]|Botulism[SugarBind_Ligand:26]|Tetanus[SugarBind_Ligand:26]|Influenza[SugarBind_Ligand:26] 

wikipedia :  

essentials_of_glycobiology :

GT1c

term (main_entry) : GT1c 

glycan_dictionary_accession : GSD000102 

glytoucan_accession  : G78818SP 

term_in_sentence : We show here that VVH associates with ganglioside GM1a, Fucosyl-GM1, GD1a, GT1c, and GD1b by glycan array.[PMID: 32228455] 

publication : 28088450|30085356|32228455|2468656|19841910|23877172|1695858|10564776|1613492|8474578|7798936|11180643|2723647|7066685|9613831|7361620|10699494 

definition : A branched amino heptasaccharide consisting of a linear tetrasaccharide of β-D-galactose, N-acetyl-β-D-galactosamine, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→4) and (1→4), to the galactose residue proximal to the reducing end is also linked (2→3) an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl trisaccharide side-chain. The carbohydrate moiety of ganglioside GT1c.[CHEBI:90509] 

term_xref : GlycoMotif:GGM.000113|GTC:G78818SP|CID:91846734|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GT2

term (main_entry) : GT2 

glycan_dictionary_accession : GSD000103 

glytoucan_accession  : G36476BA 

term_in_sentence : Biosynthesis of the c-series gangliosides GT3, GT2 and GP1c was studied in Golgi derived from rat liver.[PMID: 1606358] 

publication : 1606358|15498585|16005859|27540730|31533196|31201844 

definition : A branched amino hexasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-galactosaminyl residue. The carbohydrate moiety of ganglioside GT2.[CHEBI:72446] 

term_xref : GlycoMotif:GGM.000109|GTC:G36476BA|CID:70788971|CHEBI:72446|KEGG:G00119 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11

GT3

term (main_entry) : GT3 

glycan_dictionary_accession : GSD000104 

glytoucan_accession  : G93899SO 

term_in_sentence : The purpose of this study was two-fold: (1) to formulate γ-tocotrienol (GT3) in a nanoemulsion formulation as a prophylactic orally administered radioprotective agent; and (2) to optimize the storage conditions to preserve the structural integrity of both the formulation and the compound.[PMID: 28029115] 

publication : 28029115|31355968|30987413|27869747|27216753|8631981|29672891|10385047|29642403|10412028|27193023|30068561|23415908|8858920|2303428|27153057|27128741|2654294|26930378|7561885|25860286|30845647|24712339|30070965|8910600|1606358|27356050|8514740|18509108|23000517|29769046|29566611 

definition : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444] 

term_xref : GlycoEpitope:EP0070|KEGG:G00118|CID:70788970|GlycoMotif:GGM.000092|GTC:G93899SO|CHEBI:72444 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11

Heparan sulfate

term (main_entry) : Heparan sulfate 

glycan_dictionary_accession : GSD000106 

glytoucan_accession  :  

term_in_sentence : In Niemann-Pick C-1 fibroblasts, where deaminative degradation of heparan sulfate is defective, carbonylated proteins were abundant.[PMID: 17540770] 

publication : 32266657|29554552|29032302|30003471|25197032|28538085|26236728|16917509|22899865|17080204|23042481|28982096|24146040|25081076|15719168|17453622|25325954|21110089|29797526|21967329|23313092|11212344|28465034|11746174|12512855|8836040|28394734|24182748|28264929|28745308|26555370|14718374|16767693|25246018|19584012|8274190|25034023|8370471|26571620|29920400|31731076|20816205|16880267|31547957|11457867|27241222|28718936|21204109|31016560|11166215|11457866 

definition : A linear polysaccharide in which the backbone consists of a variably sulfated repeating disaccharide unit.[CHEBI:28815] 

term_xref : CHEBI:28815|CID: 53477715|GlycoEpitope: EP0086 

synonyms : Heparan N-sulfate|Heparan sulfate|Heparan sulphate|Heparatan sulfate|Heparin monosulfate| Heparin sulfate|Heparitin monosulfate|Heparitin sulfate|N-Acetylheparan sulfate 

function : Heparan sulfate proteoglycans (HSPGs) play crucial roles regulating key developmental signaling pathways, such as the Wnt, Hedgehog, transforming growth factor-beta, and fibroblast growth factor pathways.[GlycoEpitope: EP0086] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

Heparin

term (main_entry) : Heparin 

glycan_dictionary_accession : GSD000107 

glytoucan_accession  :  

term_in_sentence : Two cellulose-based membranes, containing 5 and 20% N, N-diethyl-aminoethyl cellulose (DEAE) respectively, were investigated for ionic attachment of heparin and heparin release.[PMID:6416324] 

publication : 27100512|22566218|27264866|30094590|31077659|26975675|2083874|25088334|3333067|2191809|28118750|28224913|22495506|29385025|10332503|22393937|19947315|27655335|14529394|2419035|22048616|23849978|10204652|28958760|12627673|9042555|15639107|28880550|27238483|1964668|16716101|10796377|25981976|24680753|2191118|21166465|30582884|1322434|15330727|9752370|6416324|14996629|20452241|1340407|29050610|345399|6916469|6565376|26714061 

definition : A highly sulfated linear glycosaminoglycan comprising complex patterns of uronic acid-(1→4)-D-glucosamine repeating subunits. Used as an injectable anticoagulant, it has the highest negative charge density of any known biological molecule.[CHEBI:28304] 

term_xref : CID:772|CHEBI:28304 

synonyms : bemiparin|bemiparin|certoparin|Cy 222|enoxaparin|fluxum|Heparin|Heparinic acid|parnaparin|reviparin|sandoparin 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Heparan sulfate/heparin

term (main_entry) : Heparan sulfate/heparin

glycan_dictionary_accession : GSD000185

glytoucan_accession  : 

term_in_sentence : Heparan sulfate (HS)/heparin is a structurally complex class of glycosaminoglycans (GAGs) that have been implicated in a wide range of biological activities. [PMID:31016560]

publication : 23313092|31016560|23152789

definition : 

term_xref : 

synonyms :  HS/heparin|heparan sufate (HS)/heparin|H/HS

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

High mannose

term (main_entry) : High mannose 

glycan_dictionary_accession : GSD000108 

glytoucan_accession  : G55220VL 

term_in_sentence : Each glycoform contained a number of peaks differing by 162 Da indicating heterogeneity and suggesting the presence of high-mannose sugars.[PMID:11258925] 

publication : 11258925|17956937|2059624|2065054|26791533|4077844|7780197|9136890|30659065|30075362|21421994|31076349|29738673|29508223|26747427|30634645|23007868|29051951|24549150|12417032|26724786|26956389|26493153|31102532|29673624|8348230|25586968|24975601|29803109|28465212|25776945|30151520|21097542|24326091|27995699|26003537|6722291|2925680|25565276|21460211|25196214|27387600|22373601|3729933|16423983|24174266|30605318|32371950

definition : An N-linked oligosaccharide that possesses between five and nine mannose residues attached to the chitobiose [(GlcNAc)2] core. [CHEBI:5717] None of the Man residues are substituted with any monosaccharide other than Man . 

term_xref : GTC:G55220VL|CID:70698382|CHEBI:71514

synonyms : oligomannose, high-mannose, oligomannose-type 

function : Involved in promotion of protein folding in ER. [PMID:12417032].|High Man glycans are enriched at cell surface during apoptosis.[PMID: 17516205] 

disease_associations : Relative abundance changes in multiple CDGs [PMID: 30770376[PMID: 28484880 

wikipedia :  

essentials_of_glycobiology : Chapter 17

HNK-1

term (main_entry) : HNK-1 

glycan_dictionary_accession : GSD000109 

glytoucan_accession  : G54406UD 

term_in_sentence : The human natural killer-1 (HNK-1) carbohydrate, a unique trisaccharide possessing sulfated glucuronic acid in a non-reducing terminus (HSO3-3GlcAß1-3Galß1-4GlcNAc-), is highly expressed in the nervous system and its spatiotemporal expression is strictly regulated.[PMID:28709864] 

publication : 28709864|31738061|26738850|30306736|11070366|20855890|18024472|22669261|19729452|19796667|26850637|11769463|18263654|15843379|26659409|9003039|22087768|21771787|15173636|9210489|15258996|17924534|26382082|16171882|18802400|9800516|7504418|11891229|15232286|9013478|21621858|11677051|18668221|11414798|19265195|8982638|8798480|28403522|17935701|1691305|10998116|9364602|7528651|12472892|21176892|28416698|19389918|28427937|25450311 

definition : An amino trisaccharide consisting of a 3-O-sulfo-β-D-glucuronic acid residue, a D-galactosyl residue and an N-acetyl-D-glucosamine residue (at the reducing end) in a linear sequence.[CHEBI:60322] 

term_xref : GTC:G54406UD|GlycoEpitope:EP0001|CID:46906103|CHEBI:60322|GlycoMotif:GGM.000058 

synonyms : HNK-1 carbohydrate epitope| CD57|HNK-1 antigen 

function : learning and memory[GlycoEpitope:EP0001]|neural crest cell migration[GlycoEpitope:EP0001]|neurite extension[GlycoEpitope:EP0001]|neuron-astrocyte adhesion[GlycoEpitope:EP0001] 

disease_associations : schizophrenia-like psychosis[GlycoEpitope:EP0001]|neuropathy[GlycoEpitope:EP0001]|exfoliation syndrome[GlycoEpitope:EP0001]|secondary cataract[GlycoEpitope:EP0001] 

wikipedia : https://en.wikipedia.org/wiki/N-linked_glycosylation 

essentials_of_glycobiology : Chapter 17

Hybrid

term (main_entry) : Hybrid 

glycan_dictionary_accession : GSD000110 

glytoucan_accession  : G16828VN 

term_in_sentence : A hybrid-type N-glycan was accessed by total synthesis, converted to an oxazoline, and used as a donor substrate with both wild type Endo M and an N175Q glycosynthase Endo M mutant allowing the convergent synthesis of a glycosylated amino acid bearing a hybrid N-glycan structure. [PMID:27058295] 

publication : 27058295|15044398|28714086|29578688|26999365 

definition : An N-linked glycan in which the Manα1-6 arm of the trimannosyl core Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1–4GlcNAcβ1–Asn-X-Ser/Thr is substituted by one or more additional Man residues and the Manα1-3 arm is substituted by a GlcNAc residue added by GlcNAcT1. The GlcNAc linked to the a3 Man can be extended in the same manner as any complex glycan antenna. The trimannosyl core can also be core fucosylated and/or bisected by the addition of a GlcNAc to the 3 position of the α-linked Man residue.[Essentials of Glycobiology:Chapter 9] 

term_xref : GTC:G16828VN|CID:91847108|CHEBI:147471 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

Hyaluronan

term (main_entry) : Hyaluronan

glycan_dictionary_accession : GSD000183

glytoucan_accession  : G29086KO

term_in_sentence : Hyaluronan (HA) comprises a major component of the extracellular matrix (ECM) in vertebrate connective tissues and is abundant in the cartilage, skin, brain, vitreous body, umbilical cord, and synovial fluid. [PMID:33171800]

publication : 33171800|34209222

definition : 

term_xref : GTC:G29086KO

synonyms :  HA

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

i antigen

G46055MA

term (main_entry) : i antigen 

glycan_dictionary_accession : GSD000111 

glytoucan_accession  : G00058MO|G46055MA 

term_in_sentence : Inasmuch as the hybridoma was established by hybridization of lymphocytes derived from regional lymph nodes of lung cancer, and the antigen was found in the patient's lung cancer tissue, the i antigen in lung cancer is probably recognized as a tumor-associated antigen by the host's immune cell system.[PMID:2422274] 

publication : 2422274|15679458| 21912254|12468428|28508465|6203982|30728302|8449405|9122902|10360315|6159787|6183759|518539|6715951|21933024 

definition :  

term_xref : GlycoMotif:GGM.000004|GlycoMotif:GGM.000002|GTC:G46055MA|GTC:G00058MO 

synonyms : Type 2 LN2 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

I antigen

term (main_entry) : I antigen 

glycan_dictionary_accession : GSD000112 

glytoucan_accession  : G56045WU 

term_in_sentence : The I antigen is formed by the action of an enzyme (a glycosyltransferase), which adds branches onto the i antigen.[PMID:15679458] 

publication : 15679458|21912254|30705292|33403394|6715951| 12468428|6088627| 6159787 

definition : N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S,6R)-4-[(2R,3R,4R,5S,6R)-3-Acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[[(2R,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide (CHEBI:151390) is a amino sugar.[CHEBI:151390] 

term_xref : GlycoMotif:GGM.000003|GlycoEpitope:EP0138|GTC:G56045WU|CID:91852915|CHEBI:151390

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

Isoglobotetraosylceramide

term (main_entry) : Isoglobotetraosylceramide 

glycan_dictionary_accession : GSD000113 

glytoucan_accession  : G57710SU 

term_in_sentence : Furthermore, isoglobotetraosylceramide seems to play a direct role in the metastatic process since the blocking of exposed antigen with monoclonal antibodies, or their Fab fragments, results in a highly significant decrease in lung colony formation.[PMID:8504431] 

publication : 1396705|8504431|2713378|3489485|18997175|7053385|3379797|2465279|3743633|11479210 

definition :  

term_xref : GlycoMotif:GGM.000071|GTC:G57710SU|CID: 91849719|KEGG:G03211|CHEBI:148232|SugarBind_Ligand:17 

synonyms :  

function : a marker for highly metastatic cells in rat mammary adenocarcinomas[PMID:8504431] 

disease_associations : Actinomycosis[SugarBind_Ligand:17] 

wikipedia : https://en.wikipedia.org/wiki/Ii_antigen_system 

essentials_of_glycobiology :

Keratan sulfate

term (main_entry) : Keratan sulfate 

glycan_dictionary_accession : GSD000114 

glytoucan_accession  :  G82109MW 

term_in_sentence : Compared to the other classes of glycosaminoglycans (GAGs), that is, chondroitin/dermatan sulfate, heparin/heparan sulfate and hyaluronan, keratan sulfate (KS), have the least known of its interactive properties.[PMID: 30578672] 

publication : 29340594|30578672|12512857|29625490|25325967|30025865|29924315|9549787|11030741|28078490|8298243|29096187|30059256|26958998|26773479|22840010|15597951|28110685|28535934|2942429|18234072|8641829|8940154|2027120|30849116|41589|6238957|1907283|7722002|29275050|24274541|2527236|1731862|8991509|24291704|10517185|6451953|7688312|8663590|139406 |25770829|25036480|9275006|25179279|32627425|26903438|27941632|12807022|32266652|21624346 

definition : A sulfated glycosaminoglycan, a linear polymer that consists of the repeating disaccharide [3)-β-Gal-(1→4)-β-GlcNAc-(1→] and containing sulfo groups located at random positions.[CHEBI:60924] 

term_xref : CHEBI:60924|CID:446715|GlycoEpitope: EP0085|GTC: G82109MW 

synonyms : keratan| Kerato sulphate|Kerato sulfate|Keratan sulphate|kerato 6'-sulfate|keratan 6'-sulfate|Kerato 6'-sulphate|Keratan 6'-sulphate 

function : Tissue hydration.[PMID: 11030741] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

LacdiNac

term (main_entry) : LacdiNac 

glycan_dictionary_accession : GSD000115 

glytoucan_accession  : G31736BK 

term_in_sentence : We previously showed that the expression level of the LacdiNAc group in N-glycans decreases dramatically during the progression of human breast cancer.[PMID:25003135] 

publication : 25003135|31711843|31145522|27601469|30669833|25210040|24633693|24755437|22653491|30898876|7758724|22474328|21305673|31558607|31271862|28549117|26213980|9134425|25561735|31756927|31170332|16282603|15265923|32267274|23015818|32676595|16728562|10814702|9591048|22245701|29751628|22997242|15535969|31911241|30622255|29888905|30236114| 30298790|29373511|22298779|19179461|31606752|15653684|16403022|11162373|32005658|30529570 

definition : An amino disaccharide consisting of N-acetylglucosamine having an N-acetylgalactosaminyl resiude attached at the 4-position via a β-linkage.[CHEBI:61190] 

term_xref : GTC:G31736BK|GlycoEpitope:P0150|CID:25257164 25257164|CHEBI:61190|GlycoMotif:GGM.000016  

synonyms : LDN 

function : Has a role of epitope.[CHEBI:61190] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Lactosylceramide

term (main_entry) : Lactosylceramide 

glycan_dictionary_accession : GSD000116 

glytoucan_accession  : G84224TW 

term_in_sentence : In the 1970s, a neutral glycosphingolipid lactosylceramide (LacCer) was found to bind specifically to several kinds of microorganisms.[PMID:30175814] 

publication : 30175814|26900161|30502090|29624959|28444900|25408340|31801289|29099167|25595946|32592089|27729551|24658420|25216636|25638276|9499377|17986153|8143857|23801329|18077097|32708181|15346887|19015977|18393821|25279740|21057870|11915327|25212460|23882130|11915329|8195125|8808768|3396945|22128256|6733104|24968752|32518749|30688114|7666005|8200356|24718572|6193809|25781947|12383912|26086247|30606995|12419803 

definition : Glycosphingolipids which contain as their polar head group a lactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in lactosylceramide beta-galactosidase, is the cause of lactosylceramidosis.[MeSH:D007790] 

term_xref : GTC:G84224TW|MeSH:D007790|GlycoMotif:GGM.000064|GlycoEpitope:EP0078|SugarBind_Ligand:3 

synonyms : LacCer|Lc2|CDH 

function : mammalian cell receptors for Neisseria gonorrhoeae recognized by Helicobacter pylori[GlycoEpitope:EP0078] 

disease_associations : chronic gastritis[GlycoEpitope:EP0078,SugarBind_Ligand:3]|duodenal ulcers[GlycoEpitope:EP0078]|gastric adenocarcinoma[GlycoEpitope:EP0078,SugarBind_Ligand:3]|gastric ulcers[GlycoEpitope:EP0078]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Actinomycosis[SugarBind_Ligand:3]|Pertussis[SugarBind_Ligand:3]|Candidiasis[SugarBind_Ligand:3]|Cryptococcosis[SugarBind_Ligand:3]|Hemorrhagic colitis[SugarBind_Ligand:3]|Peptic ulcers[SugarBind_Ligand:3]|Histoplasmosis[SugarBind_Ligand:3]|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Gonorrhea[SugarBind_Ligand:3]|Sporotrichosis[SugarBind_Ligand:3]|Plague[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] 

wikipedia :  

essentials_of_glycobiology : Chapter 17

Lactotriaosylceramide

term (main_entry) : Lactotriaosylceramide 

glycan_dictionary_accession : GSD000117 

glytoucan_accession  : G06239NA 

term_in_sentence : The results showed that AML patients had higher expression of the GSL lactotriaosylceramide (Lc3), GM3 and neolactotetraosylceramide (nLc4) in their bone marrow than did the healthy donors (P < 0.05), especially the M1 subtype of AML.[PMID:22411838] 

publication : 22411838|20693232|26104834|27435676|26405105|32340400|25241919|23404501|32452379|2960671|272643|27711049|33202844|4060695|27638607|20547865|2277039|6238026|8448388|8489255|9363437|11836161|6892925|1551117|6811267|8059935|7861954|11283017|8514762|1291049|3805024|10816509|12393713|6417117|11054095|8781973|1692829 

definition : A linear amino trisaccharide consisting of β-D-glucose at the reducing end having an N-acetyl-β-D-glucosaminyl-(1→3)-β-D-galactosyl group attached at the 4-position.[CHEBI:61758] 

term_xref : GTC:G06239NA|GlycoMotif:GGM.000067|MeSH:C025575|CID:10230777|CHEBI:61758|SugarBind_Ligand:20 

synonyms : Lc3|Lc(3)Cer|Lc_3 

function : acute myeloid leukemia-associated glycosphingolipids lactotriaosylceramide, GM3 and neolactotetraosylceramide are possibly involved in initiation and differentiation of acute myeloid leukemia.[PMID:22411838] 

disease_associations : Pharyngitis[SugarBind_Ligand:20]|Tracheobronchitis[SugarBind_Ligand:20]|Gonorrhea[SugarBind_Ligand:20]|Actinomycosis[SugarBind_Ligand:20]|Diarrhea[SugarBind_Ligand:20] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

LcGg4

term (main_entry) : LcGg4 

glycan_dictionary_accession : GSD000118 

glytoucan_accession  : G62554JH 

term_in_sentence : Murine leukemia cells (M1), in their undifferentiated state, have been characterized by the presence of cancer-associated lactoganglio-series glycolipids, one of which was identified as lactogangliotetraosylceramide (LcGg4) having a novel branching at the II-Gal of lactosylceramide through GlcNAc beta 1----3 and GalNAc beta 1----4 linkage, as shown below (Kannagi, R., Levery, S.B., and Hakomori, S. (1984) J. Biol. Chem., 259, 8444-8451): GalNAc beta 1----4 Gal beta 1----4Glc beta 1----1Cer GlcNac beta 1----3 [PMID: 3805024] 

publication : 3805024|33395290 

definition : N-[(2S,3R,4R,5R,6R)-2-[(2R,3S,4R,5R,6S)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide is an oligosaccharide.[CHEBI:152521] 

term_xref : GlycoMotif:GGM.000075|GTC:G62554JH|CID:91850076|CHEBI:152521|GlycoEpitope:EP0035 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

Lewis a

term (main_entry) : Lewis a 

glycan_dictionary_accession : GSD000119 

glytoucan_accession  : G00047MO 

term_in_sentence : Regardless of the vaccine administered, significantly fewer of the children with Lewis A phenotype (0/14) seroconverted after receiving the first vaccine dose compared to 26% (45/175) of those with the Lewis B phenotype and 32% (15/47) of the Lewis negative individuals (P < 0.01). [PMID:29367698] 

publication : 29367698|27187324|30562693| 27646625|26911286|30225822|28600306|32527016| 2385097|11064310|23809433|30050155|1615929| 29527514| 9207264|1675497| 3677023|27705835|7593252| 2579997|17630273|9350993|9098001 

definition : A lewis blood group antigen with structure beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an alpha-linkage and a galactosyl residue attached at the 3-position via a beta-linkage. It has a role as an epitope and an antigen. It is an amino trisaccharide and a glucosamine oligosaccharide.[CHEBI:62265] 

term_xref : GTC:G00047MO|CID:22806751|CHEBI:62265|GlycoMotif:GGM.000020|SugarBind_Ligand:155 

synonyms : Le(a)|Lea-3|Lea|Le^a 

function :  

disease_associations : Gastroenteritis[SugarBind_Ligand:155] 

wikipedia : https://www.wikidata.org/wiki/Q50687009] 

essentials_of_glycobiology :

Lewis b

term (main_entry) : Lewis b 

glycan_dictionary_accession : GSD000120 

glytoucan_accession  : G39211DH 

term_in_sentence : Human mannose-binding lectin preferentially binds to human colon adenocarcinoma cell lines expressing high amount of Lewis A and Lewis B antigens.[PMID:10328552] 

publication : 10328552|23408949|31927399|26601230|28279343|32527016|30831115|27318698|9207264|23828675| 29527514|1615929|2385097|2579997|25516619|3677023|8509439|19832116|15270746|3166398|30909206|7718581|18400963| 29751628|8982241|30284922|24576035|30974776| 9098001|31768613|1651804|25428879|15946883|30298790|30544260|29197783|8632739|7679772|18666312|20231766|29922666|95124|2247887|21519121|25153235|28751211 

definition :  

term_xref : GlycoMotif:GGM.000021|SugarBind_Ligand:146|GTC:G39211DH|CID: 45480568|CHEBI:59440 

synonyms : Le(b)|Lewis(b)|Le^b 

function : possible receptor for Helicobacter pylori[https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/blood-group-lewis-system] 

disease_associations : Gastroenteritis[SugarBind_Ligand:146] 

wikipedia :  

essentials_of_glycobiology :

Lewis x

term (main_entry) : Lewis x 

glycan_dictionary_accession : GSD000121 

glytoucan_accession  : G00051MO 

term_in_sentence : In particular, the observation of oxonium ions at m/z 512.2 and 803.2 is useful for probing outer non-reducing terminal fucosylation, which represented carbohydrate structures consisting of Hex Hex , dHex Hex , and HexNAc , and NeuNAc , Hex Hex , dHex Hex , and HexNAc , respectively, from which the Lewis X structure (Galbeta1-4(Fucalpha1-3)GlcNAc) was readily deduced.[PMID:15536627] 

publication : 15536627|31666308|29019053|28296340|29593094|17607374|16581086|20858014|19962782|7912739|25121780|24059473|29210428|31276881|9015359|7628844|7499837|16850248|28425129|28869691|19576189|10223649|22593503|15632313|27198630|26582608|11500392|31256373|23399157|21984435|26244810|26162743|17335083|15388363|9556613|10760152|11267844|20876654|12131290 

definition : A Lewis blood group antigen with structure α-L-Fucp-(1→3)-[β-D-Galp-(1→4)]-D-GlcpNAc where the glucosamine at the reducing end has β-configuration at its anomeric centre. Commonly known as Lewis x trisaccharide or Lex.[CHEBI:59294] 

term_xref : GTC:G00051MO |GlycoEpitope:EP0011|CID:44611539|CHEBI:59294|GlycoMotif:GGM.000018  

synonyms : Lex|Galbeta1-4(Fucalpha1-3)GlcNAc|Lewis x trisaccharide|Le(X)|Le^x|SSEA-1 

function : Involved in carbohydrate-carbohydrate interaction[Glycoepitope:EP0011].|Also implicated in apoptosis.[Glycoepitope:EP0011]|influence antigenic presentation and interfere with pathogen transfer in breastfed infants.[Glycoepitope:EP0011] 

disease_associations : acute leukemia[GlycoEpitope:EP0011]|lymphoma[GlycoEpitope:EP0011] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

Lewis y

term (main_entry) : Lewis y 

glycan_dictionary_accession : GSD000122 

glytoucan_accession  : G00052MO 

term_in_sentence : In conclusion, Lewis y antigen and CD147 were significantly upregulated in ovarian tumors, and the altered expression of Lewis y may cause changes in CD147.[PMID:30816446] 

publication : 30816446]|20003467| 24692145| 24998328|25726913|29299130|30816446| 20003467|24692145| 24998328|20127027|22138668|23894390| 25726913|25416440|27646625|23725446|21294926|22312289|25973320|23242548|30328452|21119363|29130097|23443083|23708102|28671040|19715603|23468946|27723168|21747684|19771739 

definition : A Lewis blood group antigen which is a branched amino tetrasaccharide with structure alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc, consisting of consisting of N-acetyl-beta-D-glucosamine at the reducing end having an alpha-L-fucosyl residue attached at the 3-position and an alpha-L-fucosyl-(1→2)-beta-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure. It has a role as an antigen and an epitope. [CHEBI:59045] 

term_xref : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000019 

synonyms : LeY|Le(y)|Ley|Le^y 

function : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] 

disease_associations : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

Monosialylated

term (main_entry) : Monosialylated 

glycan_dictionary_accession : GSD000123 

glytoucan_accession  :  

term_in_sentence : The structures of the asparagine-linked sugar chains of U- CD59 were biantennary complex type , only 4.2% of which are monosialylated.[PMID:7514386] 

publication : 7514386|8477709|8942648|29752599|31669586|29747818|16425369|12089170|31390883|1632647|29733234|31110965|31566965|30555678|28263871|29652662|25915761|16381065|29247593|28370937|23896595|26633899|32155999|25261856|2737211|26945091|27065039|26784838|26582205 

definition : A glycan that have the addition of one sialic acid residues. 

term_xref :  

synonyms :  

function : appears in bovine brain gangliosides.[PMID: 29752599] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Monosialyl-biantennary

term (main_entry) : Monosialyl-biantennary 

glycan_dictionary_accession : GSD000124 

glytoucan_accession  :  

term_in_sentence : In contrast, the sugar chain structure of HCC highly specific AFP isoform was found to comprise a monosialyl-biantennary sugar chain with additional fucosylation of the proximal N-acetylglucosamine.[PMID:7686446] 

publication : 7686446|1374031|9648261|10460833|19524219|10207016|15797573|15218190 

definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of one sialic acid residues. 

term_xref :  

synonyms : monosialyl biantennary|sialylated diantennary|sialylated biantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Monosialyl-Gb5

G32254QI

term (main_entry) : Monosialyl-Gb5 

glycan_dictionary_accession : GSD000125 

glytoucan_accession  : G32254QI 

term_in_sentence : Thus, malignancy of MCF-7 is highly dependent on monosialyl-Gb5, and its activation of cSrc and FAK in GEM.[PMID:12401210] 

publication : 12401210|16995838|27318475 

definition : alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp is a linear amino hexasaccharide comprising β-D-glucose at the reducing end with at the 4-position a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety, α(2→3)-sialylated at the terminal galactosyl residue.[CHEBI:62313] 

term_xref : GTC:G32254QI|GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID:73427363|CHEBI:62313 

synonyms : GL-7 globoseries ganglioside (SSEA-4)|Monosialyl Gb5|Sialosyl galactosyl globoside|GL-7 globoseries ganglioside|SSEA-4 

function :  

disease_associations : renal cell carcinoma/RCC[GlycoEpitope:EP0099] 

wikipedia :  

essentials_of_glycobiology :

Mono-sulfated globopentaosylceramide

term (main_entry) : Mono-sulfated globopentaosylceramide 

glycan_dictionary_accession : GSD000126 

glytoucan_accession  : G80193TN 

term_in_sentence : Mono-sulfated globopentaosylceramide from human kidney.[PMID:2777788] 

publication : 2777788 

definition :  

term_xref : GlycoMotif:GGM.000072|GTC:G80193TN 

synonyms : Monosulfated globopentaosylceramide 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Mono-sulfated globotetraosylceramide

term (main_entry) : Mono-sulfated globotetraosylceramide 

glycan_dictionary_accession : GSD000127 

glytoucan_accession  : G05297EK 

term_in_sentence : Mono-sulfated globotetraosylceramide from human kidney.[PMID:2559078] 

publication : 2559078 

definition :  

term_xref : GlycoMotif:GGM.000073|GTC:G05297EK

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

N-acetyl GM2

term (main_entry) : N-acetyl GM2 

glycan_dictionary_accession : GSD000128 

glytoucan_accession  : G79389NT 

term_in_sentence : The appearance of the N-acetyl GM2 antigen correlated well with the degree of differentiation of the cancer cells in patients with squamous cell carcinoma and adenocarcinoma of the lung.[PMID:3167861] 

publication :3167861|2153431| 25673107 

definition : beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp is a branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] 

term_xref : GTC:G79389NT|GlycoEpitope:EP0051|CID: 45266845|CHEBI:59220 

synonyms :  

function : The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.[CHEBI:59220] 

disease_associations : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051] 

wikipedia :  

essentials_of_glycobiology :

N-acetyllactosamine (Type 1)

term (main_entry) : N-acetyllactosamine (Type 1)

glycan_dictionary_accession : GSD000181

glytoucan_accession  : G00056MO

term_in_sentence : The N-acetyllactosamine type 1 (LacNAc type 1, Galβ1,3GlcNAc) is a well-known precursor of several important blood group epitopes, such as Lewis A, Lewis B, or sialyl Lewis A [1], which are involved in many biological processes, e.g., fertilization [2] and pathogen adhesion [3]. [PMID:28796164]

publication :  28796164|28167527

definition : 

term_xref : GTC:G00056MO|GlycoMotif:GGM.000005

synonyms : LacNAc type 1|Type 1 LN|Type-1 lactosamine

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

N-acetyllactosamine (Type 2)

term (main_entry) : N-acetyllactosamine (Type 2)

glycan_dictionary_accession : GSD000129 

glytoucan_accession  : G00055MO 

term_in_sentence : Utilising a fast and sensitive screening method based on imidazolium-tagged probes, we report unprecedented reversible activity of bacterial beta1,4-galactosyltransferases to catalyse the transgalactosylation from lactose to N-acetylglucosamine to form N-acetyllactosamine in the presence of UDP.[PMID:31165848] 

publication : 31165848|31126011|28796164|6236210|9751793|29740087|9151975|10567443|21472942|26477523|6548353|28167527|20056550|7737204|22052010|10223649|11323440|10420596|7766648|25257940|17977857|15556936|26541999|23650594|9692202|29429899|21062783|25034434|8985145|28503789|8720464/ 

definition : N-acetyllactosamine is a beta-D-galactopyranosyl-(1→4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. It is also known as galb1-4glcnacb or lacnac, belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group. N-Acetyllactosamine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Acetyllactosamine exists in all living organisms, ranging from bacteria to humans.[CHEBI:16153,HMDB0001542] 

term_xref : GTC:G00055MO|CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001 

synonyms : LacNAc|Type 2 LN 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

N-Glycolyl-GM2

term (main_entry) : N-Glycolyl-GM2 

glycan_dictionary_accession : GSD000130 

glytoucan_accession  : G56478LD 

term_in_sentence : The monoclonal antibodies MK2-34 and MK1-16 (both IgM), which specifically detect N-glycolyl GM2 and N-acetyl GM2, respectively, were generated by immunizing mice with liposomes containing monophosphoryl lipid A, trehalose dimycolate, and the antigenic ganglioside.[PMID:3167861] 

publication : [3167861|11861662|17980710|3731079| 25673107] 

definition : (2S,4S,5R,6R)-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of carbohydrates and carbohydrate derivatives.[CHEBI:151464] 

term_xref : GTC:G56478LD |GlycoEpitope:EP0052|CID:91845742|CHEBI:151464|GlycoEpitope:GGM.000096  

synonyms :  

function :  

disease_associations : choriocarcinoma[GlycoEpitope:EP0052]|teratocarcinoma|[GlycoEpitope:EP0052]yolk sac tumor[GlycoEpitope:EP0052] 

wikipedia :  

essentials_of_glycobiology :

N-linked glycans

term (main_entry) : N-linked glycans 

glycan_dictionary_accession : GSD000131 

glytoucan_accession  : G78059CC 

term_in_sentence : Our study identifies extracellular N-linked glycans-and the glycoprotein neurexin 1β specifically-as key modulators of neuronal uptake of αSacetyl, drawing attention to the potential therapeutic value of αSacetyl-glycan interactions.[PMID:31211781] 

publication : 31211781|28384382|30305477|31364612|26899268|29945790|29652253|29723274|30962676|29778448|25325701|31100702|28898525|22944671|19277537|24473128|17957771|27554083|15189166|11269317|19577919|24303005|12042249|22191536|28324664|25965797|25434632|30484244|28110657| 29865036|20129637|27346875|30280442|26911286|22491358|26582281|26398792|31548313|31066275|28331984|25482090| 28518173|30733536|22326428|30063825|30315103|21558494|31676555|31256374 

definition : The carbohydrate portion of a glycoprotein that has a glycan linked through the nitrogen of an asparagine side-chain.[CHEBI:59520] 

term_xref : GTC:G78059CC|CID: 70679232|CHEBI:70967 

synonyms :  

function : N-glycans modulate the function of several cell surface proteins which involved in migration, adhesion and which are responsible for regulating myelination.[PMID: 25151374]|Affect transportation of the glycosylated proteins in the Golgi.[PMID: 25151374]|Affects cell-cell interaction, adhesion, expression, proper folding.[PMID: 25151374]|extracellular N-glycans act as key modulators of neuronal uptake of αacetyl [PMID: 31211781]. 

disease_associations : Rheumatoid arthritis[PMID:17392038]|Type 1 Diabetes[PMID:29146600]|Lung Cancer[PMID: 23766031] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

Nonfucosylated

term (main_entry) : Nonfucosylated 

glycan_dictionary_accession : GSD000132 

glytoucan_accession  :  

term_in_sentence : In the carbohydrate moiety , alpha-subunit from normal pregnancy hCG contained nonfucosylated , mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).[PMID:9449027] 

publication : 9449027 |30258536|23554380|16675584|26747427|22457527|24362443|19657637|8811881|19218011|20022111|17363544|17368483|20564614|27054024|28397880|31490688|31860772|17012310|29633346|9442021|30350565|30296068|31800250|30021910|31133022| 29224385|28630087|26444434|31697975|30991260 

definition : glycans without a fucose component/monosaccharide residue. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Nonfucosylated biantennary

term (main_entry) : Nonfucosylated biantennary 

glycan_dictionary_accession : GSD000133 

glytoucan_accession  :  

term_in_sentence : Structural analysis combining methylation-mass spectrometry and 400 MHz 1H-n.m.r. spectrometry of oligosaccharide alditols released from human leucocyte lactotransferrin shows the presence of two disialylated and non-fucosylated biantennary glycans of the N-acetyl-lactosaminic type.[PMID: 2390069] 

publication :  2390069| 9449027 |1375510|9101715|2332109 

definition : A biantennary glycan with two GlcNAc branches linked to the core and no fucose appears. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

Nonfucosylated biantennary N-Linked structures

term (main_entry) : Nonfucosylated biantennary N-Linked structures 

glycan_dictionary_accession : GSD000134 

glytoucan_accession  :  

term_in_sentence : The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).[PMID:9449027] 

publication : 9449027 

definition : A biantennary N-linked glycan with two GlcNAc branches linked to the core and no fucose appears. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Nonfucosylated triantennary

term (main_entry) : Nonfucosylated triantennary 

glycan_dictionary_accession : GSD000135 

glytoucan_accession  :  

term_in_sentence : Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans.[PMID:7679920] 

publication : 7679920|23274891 

definition : A triantennary N-linked glycan with three GlcNAc branches linked to the core and no fucose appears. 

term_xref :  

synonyms :  

function : Appears in human alpha-fetoprotein (AFP).[PMID:7679920] 

disease_associations : hepatocellular carcinoma[PMID:7679920]. 

wikipedia :  

essentials_of_glycobiology :

Nonsialylated

term (main_entry) : Nonsialylated 

glycan_dictionary_accession : GSD000136 

glytoucan_accession  :  

term_in_sentence : The pattern of nonsialylated oligosaccharides was used for interpretation of the fully sialylated species using bioinformatics tools. From pooled human plasma, we find 90, 101, and 64 different glycan compositions for genetic variants ORM1*F1, ORM1*S, and ORM2, respectively. Glycan structures carry dominantly between 15 and 16 sialic acids indicating an almost complete termination of all antenae with sialic acid.[PMID:30295034] 

publication : 14533820|1377689|9705949|30788437|28090561|12498371|26839900| 31490688|2656426|30295034|31545048|12381155|25730103|26787879|25646460| 29224385|26063435|26954852|32889432|2825412|27504786|22431161 

definition : A glycan which is not sialylated. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

O-fucose glycans

term (main_entry) : O-fucose glycans 

glycan_dictionary_accession : GSD000137 

glytoucan_accession  : G39294YF 

term_in_sentence : Recently, a number of laboratories have shown that O-fucose glycans on the epidermal growth factor (EGF)-like repeats of the Notch extracellular domain modulate Notch signaling.[PMID:12417415] 

publication : 19594638|30690220| 18952191|22415200|12417415|16400812|18948267|21464368|20816394|30207383|20301232|27129198|17132502|22492969|30030822|30214079|26175457|25378397|18272537|28729422|11524432|31722217|23045360|24803430|28876865|25700513|32518939|30523691|18227520|20816217|24909690|17964136|12036964|27268051|15653671|19948734|31590629|32201074|15189151|17263732|32913123|12909620|28785176|17132500|22949680|25053492|28939751 

definition : Form of glycosylation where the protein is modified by a fucose residue and can be extended futher to form a tetrasaccharide in certain cases. alpha-linked o-fucose have a consensus motif of C2X4(s/T)C3 where C2 and C3 are conserved cysteines number 2 and 3 respectively of the EGFR like repeats. [Essentials of Glycobiology:Chapter13] 

term_xref : GTC:G39294YF|GlycoEpitope:EP0005

synonyms :  

function : modification of Notch signaling.[GlycoEpitope:EP0005] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

O-GlcNAc

term (main_entry) : O-GlcNAc 

glycan_dictionary_accession : GSD000138 

glytoucan_accession  : G49108TO 

term_in_sentence : A better understanding of the mechanisms of OGT/OGA action would enable us to derive therapeutic benefits of resetting cellular O-GlcNAc levels within an optimal range.[PMID:30464755] 

publication : 30464755|29049853|29594839|31654859|29404877|30105004|30669087|29790000|28408483|26862193|30523150|30037904|28408480|29352075|29456783|29577901|29223644|28638491|30221662|29904918|32155042|30298013|31630803|31847126|29784830|30181664|28768194|30134155|25336654|30356792|30199580|32329777|28408494|29774032|29044951|23836420|20301273|29772801|28922739|30100348|30793403|30657688|31237748|29756380|29954943|30018219|32207184|25566193|30626734|24759912| 

definition : Form of glycosylation which exclusively occurs in the mitochondrial, cytoplasmic or nuclear compartments of the cell where the protein is modified by a GlcNAc monosaccharide on the serine or threonine residues and is generally not modified or elongated further to form more complex structures. [Essentials of Glycobiology:Chapter19] 

term_xref : GTC:G49108TO|GlycoEpitope:EP0004|CID:24139|HMDB:HMDB0000803  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

O-linked glycans

term (main_entry) : O-linked glycans 

glycan_dictionary_accession : GSD000139 

glytoucan_accession  :  

term_in_sentence : Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.[PMID:29865036] 

publication : 29865036|30952424|31611643|19577919|32019882|19139197|26184710|11159917|21536259|25186198|19277556|22261557|24115046|18725413|15966855|24256304|25477510|10359703|24406064|22259135|29279989| 15966855|30619255|9673446| 31676555|28745859|28196325|27975143|30591584| 28518173|17522109| 26328495|32178593|27529638|24663386|22474328|28096352|27496768| 18952191|11135308|24917611|11532966|22786570|11891229|18332077|26867212|26925665|16769205|23475718|16005634|28785176 

definition : The carbohydrate portion of a glycoprotein that has a glycan linked through the hydroxyl oxygen of serine, threonine, hydroxylysine or hydroxyproline side-chains.[CHEBI:59521] 

term_xref : CHEBI:59521 

synonyms :  

function : Affects several important activities like protein stability, modulation of signaling molecules and enzyme activity.[PMID:9673446] 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

O-linked mannose

term (main_entry) : O-linked mannose 

glycan_dictionary_accession : GSD000140 

glytoucan_accession  : G59126YU 

term_in_sentence : Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2) catalyzes the first step toward the functional matriglycan structure on alpha-dystroglycan that is responsible for binding extracellular matrix proteins and certain arenaviruses.[PMID: 27932460] 

publication : 27932460|24526361|25381909|26644575|23851827|28810660|19054127|23929950|21684258|22608994|28973932|24733390|31851597|29884773|28711406|14577328|21089343|14617637|9838223|17072003| 26328495|11181560|31949166|31988979|20362685|27733679|27493216|20044576|30643095|29732660|10580142|14568618|28079948|15467391|27812179|23761899|25737452|32930586|25381372|23434682|16857188|21452199|19429925|25361541|24297939|30322079|23428289|28427937|22746206|27533452|17502374|20816174|27496765 

definition : O-linked glycans that are initiated by the addtion of a Man residue to Ser or Thr. Subsequent extension of the Man defines the O-Man core type, either M1, M2, or M3. The M1 type is initated by addition of a GlcNAc in β-linkage to the 2 position of the Man residue. M2 is initiated by addition of another GlcNAc to the 6 position of the M1 core. M3 is initiated by the addition of a GlcNAc in β-linkage to the 4 position of the Man residue. M1 and M2 type core glycans can be extended and branched with Gal, Fuc, Sialic Acid, and GlcA. The M3 core is uniquely extended by a multienzyme system to generate the matriglycan polysaccharide, a protein-specific modification found only on alpha-dystroglycan. [CHEBI:87761] 

term_xref : GlycoMotif:GGM.000055|GTC:G59126YU|CHEBI:87761|GlycoEpitope:EP0002|CID: 91859038

synonyms : O-mannosyl glycan 

function :  

disease_associations : MEB/muscle-eye-brain disease[GlycoEpitope:EP0002]|WWS/walker-warburg syndrome |muscular dystrophy[GlycoEpitope:EP0002]|neuronal migration disorder[GlycoEpitope:EP0002]|Muscle-Eye-Brain disease (MEB) and Walker-Warburg Syndrome (WWS) have mutations in genes encoding glycosyltransferases needed for O -mannosyl oligosaccharide synthesis[GlycoEpitope:EP0002]|Muscular dystrophy and neuronal migration disorder are caused by mutations in a glycosyltransferase, POMGnT1.[GlycoEpitope:EP0002] 

wikipedia :  

essentials_of_glycobiology :

P1 antigen

term (main_entry) : P1 antigen 

glycan_dictionary_accession : GSD000141 

glytoucan_accession  : G12460DL 

term_in_sentence : The P1 antigen was disovered in 1927 by Landsteiner and Levine, and Pk and NOR were described in 1951 and 1982, respectively.[PMID: 24046920] 

publication : 29622537|26773500|24046920|6207232|8550516|6609976|6375319|817855|2428855|3312011|15364312|1937801|7729906 

definition : An amino pentasaccharide consisting of α-D-galactose, β-D-galactose N-acetyl-α-D-glucosamine, β-D-galactose, and β-D-glucose residues joined in sequence with ((1→4)-, (1→4)-, (1→3)- and (1→4)-linkages, respectively.[CHEBI:68484] 

term_xref : GlycoMotif:GGM.000069|GTC:G12460DL|CID:71296137|CHEBI:68484|SugarBind_Ligand:160  

synonyms :  

function :  

disease_associations : Shigellosis[SugarBind_Ligand:160] 

wikipedia :  

essentials_of_glycobiology : Chapter 23

Para-Forssman glycolipid

term (main_entry) : Para-Forssman glycolipid 

glycan_dictionary_accession : GSD000142 

glytoucan_accession  : G51699SI 

term_in_sentence : A novel pentaglycosyl ceramide containing di-beta-N-acetylgalactos-aminyl residue (Para-Forssman glycolipid) isolated from human erythrocyte membrane. [PMID:6814203] 

publication : 6814203 

definition : GalNAcβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1Cer [https://doi.org/10.1016/S0040-4039(01)93814-6] 

term_xref : GlycoMotif:GGM.000085|GTC:G51699SI|CID:56836111|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565 

synonyms :  

function :  

disease_associations : Actinomycosis[SugarBind_Ligand:19] 

wikipedia : https://en.wikipedia.org/wiki/P1PK_blood_group_system 

essentials_of_glycobiology :

Paragloboside

term (main_entry) : Paragloboside 

glycan_dictionary_accession : GSD000143 

glytoucan_accession  : G58896AZ 

term_in_sentence : Galactosyltransferase activities in sera of cancer patients were determined by assaying the formation of paragloboside from UDP-galactose and lactotriaosylceramide immobilized on microtiter plates by means of the enzyme-linked immunosorbent assay using a monoclonal antibody, H-11, directed to paragloboside. [PMID: 1551117] 

publication : 3345524|850070|10569746|30624951|29438961|6816790|1551117|6865961|25039255 

definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is α.[CHEBI:65257] 

term_xref : GlycoMotif:GGM.000077|GTC:G58896AZ|CID: 21670519|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15  

synonyms :  

function :  

disease_associations : Pharyngitis[SugarBind_Ligand:15]|Tracheobronchitis[SugarBind_Ligand:15]|Gonorrhea[SugarBind_Ligand:15]|Actinomycosis[SugarBind_Ligand:15]|Diarrhea[SugarBind_Ligand:15]|Hemorrhagic colitis[SugarBind_Ligand:15]|Chronic gastritis[SugarBind_Ligand:15]|Peptic ulcers[SugarBind_Ligand:15]|Gastric cancer[SugarBind_Ligand:15]|Influenza[SugarBind_Ligand:15] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

Paucimannose

term (main_entry) : Paucimannose 

glycan_dictionary_accession : GSD000144 

glytoucan_accession  :  

term_in_sentence : The galactosylation of core fucose (GalFuc epitope) in paucimannose and complex-type N-glycans is characteristic of protostome organisms, including flatworms (planarians).[PMID:29475940] 

publication : 29475940|29803109|12603202|31817246|31719144|21057214|31932305|17132514|30382146|27731363|31325506|25746926|26513758|16522637|21169367|25190359|27928741|22496646|27384337|16897177|15228383|27379103|27189951|23475714|24907509|20558211|28060516|20441997|27720757|28817611|24550396|19494052|19515361|28630087|31320997|30651366|30253927|25922361|31655162|18056652|24467287|32367383 

definition : Any N-linked glycan derivative with composition Man1-4Fuc0-1 GlcNAc2, in which the chitobiose core (GlcNAc2) is intact. Found in relatively large amounts in invertebrates and plants, they are formed by removal of the non-reducing terminal GlcNAc (\added by GlcNAcT1) from GlcNAcMan3-5GlcNAc2 by a Golgi hexosaminidase and subsequent removal of Man residues by Golgi mannosidases. Pauscimannose glycans have also been detected in vertebrates.[CHEBI:144386] 

term_xref : CHEBI:144386 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Polysialic acid

term (main_entry) : Polysialic acid

glycan_dictionary_accession : GSD000182

glytoucan_accession  : 

term_in_sentence : Polysialic acid (PSA) is a carbohydrate composed of a linear polymer of α2,8-linked sialic acids, primarily attached to the Neural Cell Adhesion Molecule (NCAM). [PMID:36076963]

publication : 36076963|35222358

definition : 

term_xref : GlycoMotif:GGM.000252

synonyms :  polySia|PSA

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Sd(A)/Cad

term (main_entry) : Sd(A)/Cad 

glycan_dictionary_accession : GSD000145 

glytoucan_accession  : G41052GC 

term_in_sentence : The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2.[PMID:24112972] 

publication : 24112972|11577689|30067891|15361072 

definition : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, β-D-galactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the galactose residue of which is also linked (1→4) an N-acetyl-β-L-galactosamine residue.
[CHEBI:71561] 

term_xref : GlycoMotif:GGM.000051|GTC:G41052GC|CID:70698375|CHEBI:71561 

synonyms : Sd^a /Cad 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

SDlex

term (main_entry) : SDlex 

glycan_dictionary_accession : GSD000146 

glytoucan_accession  : G19619KS 

term_in_sentence : Hepatic expression of sialylated difucosyl Lex antigen (SDLex, NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-) was studied with monoclonal antibody FH6, which defines this structure.[PMID: 3341453] 

publication : 30226570|3341453|12725333 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:148203] 

term_xref : GlycoMotif:GGM.000032|GTC:G19619KS|CID:91856705|CHEBI:148203  

synonyms : Sdlex|SDLe^x|SDLex 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

Seminolipid

term (main_entry) : Seminolipid 

glycan_dictionary_accession : GSD000147 

glytoucan_accession  : G72548RZ 

term_in_sentence : A concise total synthesis of seminolipid, a sulfoglycolipid, has been achieved; key features include regioselective, tin-free sulfation of allyl β-d-galactopyranoside using 2,6-bis(trifluoromethyl)phenylboronic acid as protective reagent, stereoselective epoxidation, and site-selective acylation. [PMID: 31353379] 

publication : 31353379|31736776|12810822|19582571|19542524|20670037|15659616|20817833|870059|10801776|21965315|8095813|1280685|4690236|34199863|4207869|2373957|845131 

definition :  

term_xref : GlycoMotif:GGM.000062|GTC:G72548RZ

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

Sialopentaosylceramide

term (main_entry) : Sialopentaosylceramide 

glycan_dictionary_accession : GSD000148 

glytoucan_accession  : G13224CR 

term_in_sentence : Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosap[PMID: 2139874] 

publication : 2139874 

definition : A ganglioside in which the oligosaccharide portion is composed of a pentasaccharide containing one or more sialic acid residues.[CHEBI:36542] 

term_xref : GlycoMotif:GGM.000097|GTC:G13224CR|CID: 91859576|CHEBI:148045|KEGG:G00883|CHEBI:36542 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Sialosyl paragloboside

G50123ZO

term (main_entry) : Sialosyl paragloboside 

glycan_dictionary_accession : GSD000149 

glytoucan_accession  : G50123ZO 

term_in_sentence : Unlike CNS myelin, human peripheral nerve myelin has the acidic glycosphingolipids sialosyl paragloboside (SPG), sialosyl lactosaminyl paragloboside (SLPG), and sulfated glucuronyl paragloboside (SGPG).[PMID:8862128] 

publication : 8862128|7236652|2370108|3133978|2905604|1749114|1573418 

definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-D-GlcpNAc with β configuration at the anomeric position of the reducing-end N-acetyl-D-glucosamine residue.[CHEBI:71612] 

term_xref : GlycoMotif:GGM.000081|GTC:G50123ZO|CID:91845504|KEGG:G01429|CHEBI:151914  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Sialyl Lewis a

term (main_entry) : Sialyl Lewis a 

glycan_dictionary_accession : GSD000150 

glytoucan_accession  : G00053MO 

term_in_sentence : By comparing the serum O-glycan profiles from healthy controls with those of cancer patients, we identified a marker candidate, core 1 sialyl Lewis A (NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal) (abbreviated C1SLA), whose concentration appeared to be weakly correlated with CA19-9 values.[PMID:26641888] 

publication :  26641888|31424423|26530370|17760270|18343410|16033091|8829184|11907351|20592391|26641888|24128856|30249386|10773785|16149606|10996727|10436809|10667238|7720892|7630017|10612415|9836451|12511721|22623153 

definition : A sialyated version of Lewis A with a branched structure of amino tetrasaccharide consisting of a sialyl residue, linked (2→3) to a galactosyl residue that in turn is linked (1→3) to a glucosaminyl residue at the reducing end, which is also carrying a fucosyl residue at the 4-position.[CHEBI:62681] 

term_xref : GTC:G00053MO|GlycoEpitope:EP0008|CID:53356732|CHEBI:62681|GlycoMotif:GGM.000024

synonyms : SLea|CA19-9|CA19-9 antigen|SLe^a|Slea 

function : The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0008] 

disease_associations : pancreatic adenocarcinoma[GlycoEpitope:EP0008]|hepatocellular cancer[GlycoEpitope:EP0008]|cholangiocellular cancer[GlycoEpitope:EP0008]|gastric cancer|[GlycoEpitope:EP0008]colorectal cancer[GlycoEpitope:EP0008]|ovarian cancer[GlycoEpitope:EP0008]|lung cancer[GlycoEpitope:EP0008]|breast cancer[GlycoEpitope:EP0008]|uterine cancer[GlycoEpitope:EP0008] 

wikipedia :  

essentials_of_glycobiology :

Sialyl Lewis x

term (main_entry) : Sialyl Lewis x 

glycan_dictionary_accession : GSD000151 

glytoucan_accession  : G00054MO 

term_in_sentence : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:12828079] 

publication : 12828079|8940172|10075923|19054801|9642161|31054033|15229399|29061785|16033070|10728707|9556613|8940172|9298692|18607721|22593503|25944902| 9642161|15780091|20401888 

definition : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH:2030970],CHEI:71622 

term_xref : GTC:G00054MO |GlycoEpitope:EP0012|CID: 44456859|CHEBI:71622|MESH:2030970|GlycoMotif:GGM.000022 

synonyms : SLe(x)|SLe^x|SLex|Slex 

function : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012] 

disease_associations : colon cancer[GlycoEpitope:EP0012]|colorectal cancer[GlycoEpitope:EP0012] 

wikipedia :  

essentials_of_glycobiology :

Sialyl Lewis x-i

term (main_entry) : Sialyl Lewis x-i 

glycan_dictionary_accession : GSD000152 

glytoucan_accession  : G06597DS 

term_in_sentence : Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001).[PMID:9815711] 

publication : 9815711|9730796|11867833|9713476|2819663|9372327|9615762|1352835|2575680|9330526|8753037|2210805|12680155|11974864|10453898|2565704|17144590 

definition :  

term_xref : GTC:G06597DS|GlycoEpitope:EP0043|CID: 91855346|CHEBI:147019 

synonyms :  

function : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043] 

disease_associations : lung cancer[GlycoEpitope:EP0043]|ovarian cancer[GlycoEpitope:EP0043]|pancreatic adenocarcinoma[GlycoEpitope:EP0043] 

wikipedia :  

essentials_of_glycobiology :

Sialyl T antigen

term (main_entry) : Sialyl T antigen 

glycan_dictionary_accession : GSD000153 

glytoucan_accession  : G65562ZE 

term_in_sentence : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:32583304] 

publication : 32583304|31897478|31719620| 10365852|25727149|11523928|20407596|25464017|30864133|26391208|19811634|29796594|23725156|8905873|11192238|18275089|27037304|11949946|15604091|24118321 

definition : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257] 

term_xref : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:44611726|CHEBI:65257  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Sialylated biantennary

term (main_entry) : Sialylated biantennary 

glycan_dictionary_accession : GSD000154 

glytoucan_accession  :  

term_in_sentence : Simbucus nigra agglutinin or an antibody specific to sialylated lactosamine with a preference for Neu5Acalpha2-6Gal rather than Neu5Acalpha2-3Gal reduced sperm binding to oviduct isthmic cells, as did occupying putative receptors on sperm with sialylated biantennary glycans.[PMID:23115267] 

publication : 23115267|31510952|29265394|31589880|3979568|26045275|29029079|30252064 

definition : A binantennary glycan with one or two sialic acid residues as non-reducing terminal residues on one or both antennae. [RN] 

term_xref :  

synonyms : sialyl biantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Sialylated complex-type

term (main_entry) : Sialylated complex-type 

glycan_dictionary_accession : GSD000155 

glytoucan_accession  :  

term_in_sentence : By using 1H-NMR spectroscopy we were able to establish that our product contains a single N-linked biantennary , fully sialylated complex-type oligosaccharide , typical of human hepatomas.[PMID:1694115] 

publication : 1694115|15201278|30471292|30969765|11058758|28342150 

definition : Complex N-linked glycan that have added GlcNAc residues at both the α-3 and α-6 mannose sites and do not contain mannose residues apart from the core structure but with sialic acid residues. 

term_xref :  

synonyms : sialo-complex type 

function : enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes [PMID: 15201278] Appears in IgG-Fc.[PMID:20647032 ] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 10

Sialylated LacdiNAc

term (main_entry) : Sialylated LacdiNAc

glycan_dictionary_accession : GSD000192

glytoucan_accession  : G55583HW 

term_in_sentence :  The major non-reducing epitopes in the complex-type glycans are: Gal beta 1-4GlcNAc (lacNAc), GalNAc beta 1-4GlcNAc (lacdiNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacdiNAc), Gal beta 1-4(Fuc alpha 1-3)GlcNAc (Lewisx), and GalNAc beta 1-4(Fuc alpha 1-3)GlcNAc (lacdiNAc analogue of Lewisx).[PMID:7592613]

publication :  7592613|34192302|19756298|16286643

definition :  

term_xref : GlycoMotif:GGM.000050

synonyms :  sialylated-LacdiNAc|Sialylated LDN

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Sialylated tetraantennary

term (main_entry) : Sialylated tetraantennary 

glycan_dictionary_accession : GSD000156 

glytoucan_accession  :  

term_in_sentence : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:16321355] 

publication : 16321355|1940447|27501865 

definition : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Sialyl-Tn antigen

term (main_entry) : Sialyl-Tn antigen 

glycan_dictionary_accession : GSD000157 

glytoucan_accession  : G36123IU 

term_in_sentence : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:23035012] 

publication : 23035012|29273237|15770530|31595388|26617889|1720922|15466199|10971172|14652017|8616877|1543361|16965854|21566901|9269833|9834267|24970145|22367369|10778170|30018351|28628803|16149605|32134186|28632300|11308020| 10365852|17195456|23567325|11014575|2342728|8575847|1851822|11735169|20960853|7846011 

definition : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818] 

term_xref : GTC:G36123IU|GlycoEpitope:EP0022|CID:51351800|CHEBI:61818 

synonyms :  

function : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022] 

disease_associations : anaplastic meningioma[GlycoEpitope:EP0022]|Barrett's esophagus[GlycoEpitope:EP0022]|bladder cancer[GlycoEpitope:EP0022]|breast cancer[GlycoEpitope:EP0022]|colon cancer[GlycoEpitope:EP0022]|colorectal cancer[GlycoEpitope:EP0022]|erythroblastic leukemia[GlycoEpitope:EP0022]|esophageal cancer[GlycoEpitope:EP0022]|gastric cancer[GlycoEpitope:EP0022]|helicobacter pylori chronic gastritis(HpCG)[GlycoEpitope:EP0022]|liver cancer[GlycoEpitope:EP0022]|iterome cancer[GlycoEpitope:EP0022]|ovary tumor[GlycoEpitope:EP0022]|pancreas cancer[GlycoEpitope:EP0022] 

wikipedia :  

essentials_of_glycobiology : Chapter 56

SLex Core 2 O-glycan

term (main_entry) : SLex Core 2 O-glycan 

glycan_dictionary_accession : GSD000158 

glytoucan_accession  : G97345NY 

term_in_sentence : In particular, the sLeX-modified core 2 O-glycan structure C2-O-sLeX has been directly demonstrated to confer significantly higher affinity selectin binding than sLeX.[PMID:15596301] 

publication : 15596301 

definition :  

term_xref : GlycoMotif:GGM.000053|GTC:G97345NY 

synonyms : SLe^x Core 2 O-glycan 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

SSEA-1

term (main_entry) : SSEA-1 

glycan_dictionary_accession : GSD000159 

glytoucan_accession  : G85497PI 

term_in_sentence : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:27550342] 

publication : 27550342|25564944|30987116|10778174|19427293|24923741|28092949|16499901|10470652|18787210|2885312|16149609|17003364|27363517|15505339|27990704|2568298|20491542|23572256|1977666|9553168|20458727|2566639|14577357|20960856|15547746|9096265|30639212|1357195|1359630|20181261|20508065|2907526|22624699|22988836|17183690|27188587|7908065|10400391|6137429|1979260|2898921|14736812|30919971 

definition :  

term_xref : GTC:G85497PI |GlycoEpitope:EP0042|CID:91851144|CHEBI:154343  

synonyms :  

function : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 10

SSEA-3

term (main_entry) : SSEA-3 

glycan_dictionary_accession : GSD000160 

glytoucan_accession  : G25129BT 

term_in_sentence : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID: 31817926] 

publication : 31817926|30271856|32684574|26677875|23175153|32525407| 29227830| 18773292|25561682|10837462|2412924|21149348| 17008424| 2874662|25171543|31304790|31642560|30484221|30525067|21161592|27325407|28170296|29637816| 27318475|31346146|7648586|24236059|21964054|27456773|30558911|21559451|29312455|27549315|30599359|6141938|28883415|30733757|26041528|16643871 

definition : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071] 

term_xref : GTC:G25129BT|GlycoEpitope:EP0039|CID:91855781|CHEBI:149071|GlycoMotif:GGM.000079 

synonyms :  

function :  

disease_associations : embryonal carcinoma[GlycoEpitope:EP0039]|teratocarcinoma[GlycoEpitope:EP0039]|yolk sac carcinoma[GlycoEpitope:EP0039] 

wikipedia :  

essentials_of_glycobiology :

SSEA-4

term (main_entry) : SSEA-4 

glycan_dictionary_accession : GSD000161 

glytoucan_accession  : G84263XI 

term_in_sentence : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:31817926] 

publication : 27845370|31817926|26295543| 25171543|25978997|30296654|25853231|24862940|31243630|28736232|22895512|24578244|29478902|23574147|23768762|27797400|29227830| 18773292|25123923|22924692|22665977|23330736|31831622|31916611| 2412924|16033656|24866102| 20458727| 21149348|26940129| 17008424| 2874662|23301556|27836003|19118716|24550271|32988880|22743677|20683402|17062733|23570331|30310530|31545316|23509763|24364909|18273440|28985528|22266579 

definition :  

term_xref : GTC:G84263XI|GlycoEpitope:EP0044|CID: 91845478|CHEBI:154843 

synonyms :  

function :  

disease_associations : teratocarcinoma[GlycoEpitope:EP0044] 

wikipedia :  

essentials_of_glycobiology : Chapter 47

Sulfated LacdiNAc

term (main_entry) : Sulfated LacdiNAc

glycan_dictionary_accession : GSD000191

glytoucan_accession  : G18464VS 

term_in_sentence :  The mRNA expression of the enzymes related to the formation of sulfated LacdiNAc:β(1,4)-N-acetylgalactosaminyltransferases 3 (B4GALNT3) and 4 (B4GALNT4), carbohydrate sulfotransferases 8 (CHST8) and 9 (CHST9); and β(1,4)-galactosyltransferase 1 (B4GALT1) in these cells was confirmed by RT-PCR (Fig. S4).[PMID:31558607]

publication :  31558607|27318476|19756298|11279168|26688390

definition :  

term_xref : GlycoMotif:GGM.000049

synonyms :  4'-O-sulfated LacdiNAc|4'-sulfated LDN|sulfated LDN

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Sulfatide

term (main_entry) : Sulfatide 

glycan_dictionary_accession : GSD000162 

glytoucan_accession  : G72548RZ 

term_in_sentence : In a previous study we found that sulfatide was efficient in lowering HIV-1 viral loads in SCID mice engrafted with human fetal liver/thymus tissues (SCID-hu).[PMID:23550344] 

publication : 23550344|18465098|26542149|15158666|10434709|22619219|29676479|30196830|16143863|1052451|30400820|29887538|26981544|17986152|31739035|19941861|24578319|30531843|25645724|31197846|22821828|27861899|31037952|23593400|23604989|17855742|25966258|25989600|9657940|29497057|12838515|25170267|9878314|20554435|1410493|26585924|17257892|17044925|21089387|11445552|22977233|21437360|17179664|6273571|8370675 

definition :  

term_xref : GlycoMotif:GGM.000063|GTC:G72548RZ 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 47

T antigen

term (main_entry) : T antigen 

glycan_dictionary_accession : GSD000163 

glytoucan_accession  : G00031MO 

term_in_sentence : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] 

publication :723127|19505650|31527246|28113048|25868857|26731525|22994493|3849428|25589241|12709866|26615524|26136575|19671663|18551603|11160729|22261839|30758913|25681708|29113555|24998850|1654819|28039910|29206210|32404521|10555041|26517398|2446015|2998768|3026642|18812503|6092664|2153691|8709258|3009889|15109748| 12709866|31787742|27433780|26017382|24048785|26735515|9224657|26061652|29343574| 25681708|23805194|26751495|22023388|15381338|8249277|3023660|25866902 

definition : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] 

term_xref : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009

synonyms : TF antigen 

function : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] 

disease_associations : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020] 

wikipedia :  

essentials_of_glycobiology : Chapter 47

Tetraantennary

term (main_entry) : Tetraantennary 

glycan_dictionary_accession : GSD000164 

glytoucan_accession  :  

term_in_sentence : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:24308486] 

publication : 24308486|17951374|28880909|9177699|9760189|12322961|20129637|2492275|3402460|2361735|6525453|27730440|2551687|25365149|9751793|29875690|29479898|9134426|30943309|3546284|29888905|30624066|30537828|31110965|29311294|12852965|3015940|1907570|29137999|29359131|29858715|30295034|31829566|8381405|26929217|20662591|30612270|3089784|28186213|3427034|26763099|27354006|24991291|7496138|1940447|11114588|29031301|9448855|3979385|27722599|31126011|28002670|28991403|24032650| 15316281|25154914|22490318|22430811|1463783|18803208|7881173|7697655|7240157|1768292 

definition : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:Glossary] 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia : https://www.wikidata.org/wiki/Q27104888 

essentials_of_glycobiology :

Tetraantennary complex-type

term (main_entry) : Tetraantennary complex-type 

glycan_dictionary_accession : GSD000165 

glytoucan_accession  :  

term_in_sentence : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID: 1899031] 

publication : 1899031|8251489|8274017|1899031| 6317691|23668542| 6088518|21495009|1457971|1783599|10988252|11425798|7522229|2574992|3730425|10200178|2939068|21584695| 7524670|7682847|2930192|1726466|9881746|11068879|6704968|2302846| 24032650|15316281|11051207|10220588|2813359|2174368|21755550|3571208|1929437|3681300|6581225|3364983|2902877|2297756|1315684|6830758|1998670 

definition : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:Glossary]  

term_xref : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 10

Tetrasialylated diantennary

term (main_entry) : Tetrasialylated diantennary 

glycan_dictionary_accession : GSD000166 

glytoucan_accession  :  

term_in_sentence : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:1997323] 

publication : 1997323 

definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Tn antigen

term (main_entry) : Tn antigen 

glycan_dictionary_accession : GSD000167 

glytoucan_accession  : G57321FI 

term_in_sentence : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] 

publication : 27679419|31938254|30637914|24643043|31225574|21259410|31742337|28514044|33014816|28708980|27432485|33050853|26045765|27542280|24411673|27760846|30115016|1410473|29802864|29669308|29251002|32541028|31019509|1582597|2981150|10842187|29638123|22367369|10778170|1510031|19372570|20641477|16149605|15770530|27856425|23814067|28068458|32134186|8174100|10571017|27453399|1727666|23740330 

definition : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212] 

term_xref : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008 

synonyms :  

function : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] 

disease_associations : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021]. 

wikipedia :  

essentials_of_glycobiology :

Triantennary

term (main_entry) : Triantennary 

glycan_dictionary_accession : GSD000168 

glytoucan_accession  :  

term_in_sentence : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] 

publication : 24992960|27025342|29642865|29456020|26914862|26926155|26299345|28981809|18395704|2211710|23461434|18327885|15264862|22954207|9061362|16581187|26537865|3979568|28129130|7679920|8068017|7783116|3857231|20540518|1706936|2430615|8078981|2211711|6767476|3814128|2597120|7451505|8204583|20619452|10460831|1924399|6643471|31809011|30042045|2477056|7882496|2430614|2551687|2426141|2065052|28988716|31144994| 26966183|29809215 

definition : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary] 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Triantennary complex

term (main_entry) : Triantennary complex 

glycan_dictionary_accession : GSD000169 

glytoucan_accession  :  

term_in_sentence : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998] 

publication : 9118998|9061362|18395704|3814128|7451505|10460831|26926155|26966183|16581187|16973123|8204583|29809215|11114588|31322324|15044389|16372382|8251489|8299583|1555586|7509658|1569060|16261636 

definition : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252]  Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  

term_xref : CHEBI:156252 

synonyms : Triantennary complex-type 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 10

Triantennary N-glycans

term (main_entry) : Triantennary N-glycans 

glycan_dictionary_accession : GSD000170 

glytoucan_accession  :  

term_in_sentence : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163] 

publication : 29399163|22325877|18439991|24873509|11454001 

definition : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:Glossary]  

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Triantennary sialylated

term (main_entry) : Triantennary sialylated 

glycan_dictionary_accession : GSD000171 

glytoucan_accession  :  

term_in_sentence : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:18642129] 

publication : 18642129|31964828|3979568|27936604|23681398|21538882|7579793|7613477|2223825|3539023|3674882 

definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. 

term_xref :  

synonyms :  

function : Appears in human serotransferrin.[PMID: 3979568] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Triantennary trisialylated fucosylated

term (main_entry) : Triantennary trisialylated fucosylated 

glycan_dictionary_accession : GSD000172 

glytoucan_accession  :  

term_in_sentence : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:17591618] 

publication : 17591618 

definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Trifucosyl Lewis b antigen

term (main_entry) : Trifucosyl Lewis b antigen 

glycan_dictionary_accession : GSD000173 

glytoucan_accession  : G74578MX 

term_in_sentence : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:1735443] 

publication : 1735443 

definition : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] 

term_xref : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783 

synonyms : trifucosyl-Leb antigen 

function : cancer-associated antigen[GlycoEpitope: EP0092] 

disease_associations : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092] 

wikipedia :  

essentials_of_glycobiology :

Trifucosyl lewis y

term (main_entry) : Trifucosyl lewis y 

glycan_dictionary_accession : GSD000174 

glytoucan_accession  : G74917JX 

term_in_sentence : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:3733752] 

publication : 3733752|2426269

definition : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] 

term_xref : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332  

synonyms : trifucosyl Ley 

function :  

disease_associations : colonic adenocarcinomia[GlycoEpitope: EP0094] 

wikipedia :  

essentials_of_glycobiology :

Trimannosyl core

term (main_entry) : Trimannosyl core 

glycan_dictionary_accession : GSD000175 

glytoucan_accession  :  

term_in_sentence : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:18320567] 

publication : 18320567|27629418|26514868|26821880|2477227|6213618|31747570|29273674|31064325|1291063|28353332|1421754|29666272|11421342|15648688|28179475|28903882|27189951|9455915|22768188|9254048|8721739|2249985|22933239|25629585|24489949|2981047|11067815|1729985|1710649|16672288|2719668|19003000|23025485|22500028|10409642|1325461|23136055|23085445|21656680|22448293|22132163|1425696|20696712|18056652|15084511|18633282|15814299 

definition : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Trisialylated

term (main_entry) : Trisialylated 

glycan_dictionary_accession : GSD000176 

glytoucan_accession  :  

term_in_sentence : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:8477709] 

publication : 6469957|18818422|18332077|21138277|9136890|10782293|19841910|20067809|14751029|8797382|16877748|19131698|20578731|24669823|22426998|27501865|2121479|24663386|32209427|32737218|33245334|26927318|30962676|28370937|30194503|26321095|30463578|31455764|31566965|31266306|29782424|31247951|30487799|2049094| 1997323|10913832 

definition : A glycan with three sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Trisialylated complex-type oligosaccharide-alditols

term (main_entry) : Trisialylated complex-type oligosaccharide-alditols 

glycan_dictionary_accession : GSD000177 

glytoucan_accession  :  

term_in_sentence : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:3571205] 

publication : 3571205 

definition :  

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Trisialylated diantennary

term (main_entry) : Trisialylated diantennary 

glycan_dictionary_accession : GSD000178 

glytoucan_accession  :  

term_in_sentence : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:1997323] 

publication : 1997323 

definition : A diantennary/biantennary glycans with three sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Trisialylated triantennary

term (main_entry) : Trisialylated triantennary 

glycan_dictionary_accession : GSD000179 

glytoucan_accession  :  

term_in_sentence : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] 

publication : 30194503|27501865|10998266|20578731|17591618|14751029|18818422|8942648|8900952 

definition : A triantennry glycan with three sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

essentials_of_glycobiology :

VIM-2

term (main_entry) : VIM-2 

glycan_dictionary_accession : GSD000180 

glytoucan_accession  : G22418PV 

term_in_sentence : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:1690317] 

publication : 27834790|31523406|29978304|29575185|27326514|29029114|32450200|29432937|31906402|28739428|29298123|30976429|29091730|27770796|31330771|31138570|27154587|31542553|30519059|30590504|25880997|27490501|29981456|28559273|28193652|26638216|25897818|26238337|19553129|29644540|26242685|28487556|32622213|30248413|24762211|11451678|33169865|11897589|31479607 

definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] 

term_xref : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033  

synonyms :  

function : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] 

disease_associations : chronic myelogenous leukemia.[GlycoEpitope:EP0019] 

wikipedia :  

essentials_of_glycobiology :

Terms (by Glycan Dictionary Accessions)

GSD000001

term (main_entry) : 2,6-Branched O-mannose 

glycan_dictionary_accession : GSD000001 

glytoucan_accession  : G06953DR 

term_in_sentence : Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6-branched structure in the brain O-mannosyl glycan.[PMID:14617637] 

publication : 14617637|10469154 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-[[(2R,3S,4S,5S,6S)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:157265] 

term_xref : CHEBI:157265|GlycoMotif:GGM.000056|GTC:G06953DR  

synonyms : 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→2)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→6)]-alpha-D-manno-hexopyranose|NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)]a-Man 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000002

term (main_entry) : 2,6-sialyl-Sulfo-LN 

glycan_dictionary_accession : GSD000002 

glytoucan_accession  : G41145LF 

term_in_sentence : The alpha2-6-sialylated 6-sulfo-LacNAc determinant defined by the antibody was significantly expressed on a majority of normal human peripheral B-lymphocytes as well as follicular B-lymphocytes in peripheral lymph nodes.[PMID:17728258] 

publication : 17728258 

definition :  

term_xref : GlycoMotif:GGM.000026|GTC:G41145LF 

synonyms : 6-sialyl-6-sulfo LN 

function : B-cell interaction with blood vessels and trafficking[PMID: 17728258] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000003

term (main_entry) : 2-Fucosyl-GD1b 

glycan_dictionary_accession : GSD000003 

glytoucan_accession  : G67383AR 

term_in_sentence : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:3654655] 

publication :  3654655 

definition : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] 

term_xref : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR

synonyms : 6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose|Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-8)NeuAc(a2-3)]Gal(b1-4)Glc 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000004

term (main_entry) : 2-Fucosyl-GM1 

glycan_dictionary_accession : GSD000004 

glytoucan_accession  : G56526JU 

term_in_sentence : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:3654655] 

publication :  3654655 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] 

term_xref : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101|GTC:G56526JU  

synonyms : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000005

term (main_entry) : 3-Sialyl-LN (type 2) 

glycan_dictionary_accession : GSD000005 

glytoucan_accession  : G10203DW 

term_in_sentence : Using new crystal structures, we also provide the atomic resolution basis for the differential recognition of 3′ and 6′SiaLacNAc1–4 (with the Galβ1–4 linkage known as Type 2 backbone16; Scheme 1) by TgMIC1-MARR, and make comparisons with the Type 1 chain isomer of 3′SiaLacNAc1–4 (designated 3′SiaLacNAc1–3).[PMID:19593815] 

publication : 19593815|15659615|2414279|8586620|2111348|23747419 

definition : A linear amino trisaccharide consisting of α-neuraminyl, β-D-galactosyl and N-acetyl-D-glucosamine residues linked in a (2→3) and (1→4) sequence.[CHEBI:52472] 

term_xref : GTC:G10203DW|KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 

synonyms : 

function :  

disease_associations : Chronic gastritis[SugarBind_Ligand:109]|Toxoplasmosis[SugarBind_Ligand:109]|Peptic ulcers[SugarBind_Ligand:109]|Gastric cancer[SugarBind_Ligand:109] 

wikipedia :  

essentials_of_glycobiology :

GSD000006

term (main_entry) : 3'-Sulfo-Lewis a 

glycan_dictionary_accession : GSD000006 

glytoucan_accession  : G78706CK 

term_in_sentence : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:11504739] 

publication : 11504739|17499486|17691854|12944557|19394320|7534477|11604107|28025252|9061363|9878545|11918697|24239607|28628803|25339106|21400496|17998215|12626387|11425799|12219077|10955596|9453593 

definition : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] 

term_xref : GTC:G78706CK|GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 

synonyms : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a 

function : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000007

term (main_entry) : 3'-Sulfo-Lewis x 

glycan_dictionary_accession : GSD000007 

glytoucan_accession  : G12295TB 

term_in_sentence : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:11504739] 

publication : 11504739|20695481|8688428|10536036|12770775|11352731|9784103|9022803 

definition : An amino trisaccharide that consists of N-acetyl-β-D-glucosamine having an α-L-fucosyl residue attached at position 3 and a 3-sulfated β-D-galactosyl residue attached at position 4; β-D-Galp3S-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the configuration at the anomeric centre of the reducing-end residue is β. [CHEBI:65171] 

term_xref : GTC:G12295TB|GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029  

synonyms : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000008

term (main_entry) : 6,6'-bisSulfo-Lewis x 

glycan_dictionary_accession : GSD000008 

glytoucan_accession  : G00659GQ 

term_in_sentence : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:9556613] 

publication : 19756298|14593101|15175329|14568956|12163379|11919403|11520459|10728707|10200296|10528213|9712885| 9556613|9257857|9164959|9015359|8958810|7560094|7485559|7538131|8161542|7684905 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] 

term_xref : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ  

synonyms : 6,6'-DiSulfo Sialyl Lewis x|6,6-bisSulfo-Lewis x (6,60-bissulfo Lewis x )|6,6'- Disulfo Sialyl Lewis x|6,6'-bisSulfo-Lewis x|6,6'-bissulfo Lex|6,6'-Disulfo Sialyl Lewis x|6,6'-bissulfo Le^x 

function : lymphocyte homing[GlycoEpitope:EP0016] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000009

term (main_entry) : 6-Sialyl-GalNAc 

glycan_dictionary_accession : GSD000009 

glytoucan_accession  : G08371CD 

term_in_sentence : mmunohistochemical distributions of carbohydrate antigens based on the type 2 chain in normal as well as fetal and neoplastic tissues of human gastrointestinal tract were investigated with a monoclonal antibody (MAb) H11 (specific for type 2 chain) alone and in combination with the two MAbs MSG15 (for alpha 2----6 sialylated type 2 chain) and IB9 (for the alpha 2----6 sialylated type 2 chain and glycoproteins having NeuAc alpha 2----6Gal-NAc), and 188C1 (for short- and long-chain Lex antigens) and FH2 (for the long-chain Lex antigen). [PMID: 1618643] 

publication : 1618643|6194157 

definition : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] 

term_xref : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035|GTC:G08371CD 

synonyms : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000010

term (main_entry) : 6-Sulfo LacNac 

glycan_dictionary_accession : GSD000010 

glytoucan_accession  : G13157WZ 

term_in_sentence : In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan).[PMID:31572354] 

publication : 31572354|31191513|29977237|29900053|30984181|28732748|26510404|28769928|31154896|27541644|25262889|26155414|28499587|27086951|27315572|26162403|26391152|31730025|12354382|27318477|23879812|25340085|24682513|21377044|21098395|18942710|23559493|23890755|22643330|23460612|23402811|22890025|19589615|32939325|20210806|17616642|22907335|16782032|22188261|21283706|29875315|32413173|19546436|19384158|1429720|30519676 

definition : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] 

term_xref : GlycoEpitope:EP0141|GTC:G13157WZ|CID:10322152|CHEBI:148005

synonyms : 6-Sulfo LacNAc 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000011

term (main_entry) : 6'-Sulfo Sialyl Lewis x 

glycan_dictionary_accession : GSD000011 

glytoucan_accession  : G00672PE 

term_in_sentence : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:2288521] 

publication : 2288521|26137907|9400621|32744401|9556613|15972893|9015359|22691873|18652681|9722682|10435581|19458105|19359410|15228275|18250165|10536036|17944600|10460836|27993973|19149511|19150806|17172261|17142960|27956273|7578028|22260995|24519996|21596021|21982762|21775439|17334369|9710564|14593101|16227985|11895802|22750968|15157883|19067429 

definition : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] 

term_xref : GlycoMotif:GGM.000025|GTC:G00672PE|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128  

synonyms : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x 

function : lymphocyte homing[GlycoEpitope:EP0014] 

disease_associations : Influenza[SugarBind_Ligand:128] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000012

term (main_entry) : 9-O-Acetyl GD3 

glycan_dictionary_accession : GSD000012 

glytoucan_accession  : G74121RX 

term_in_sentence : To determine whether 9-O-acetyl GD3 (acGD3) has a general antiapoptotic potential, the apoptosis-sensitive Jurkat cell line and an apoptosis-sensitive variant of the cell line Molt-4 were preincubated with micromolar concentrations of acGD3 and then treated with inducers of apoptosis.[PMID:16432837] 

publication : 16432837|21507905|17512674|21930212|18194438|20739294|3216430|14724245|31373393|7558412|11273644|17385751|30694652|22894715|12973826|7859075|9749956|9874495|12486096|1989525|25330147|23478187|21807667|8486686|11465673|9511990|29270199|9268945|25045067|21618115|16434401|12493756|2302705|2198284|2685488|9328574|4055789|10096568|1644805|2582447 

definition :  

term_xref : GTC:G74121RX|GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 

synonyms : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b 

function :  

disease_associations : pancreas cancer[GlycoEpitope:EP0064] 

wikipedia :  

essentials_of_glycobiology :

GSD000013

term (main_entry) : 9-O-Acetyl sialic acid 

glycan_dictionary_accession : GSD000013 

glytoucan_accession  : G47325QT 

term_in_sentence : Levels of 9-O-acetyl sialic acid provide a distinct way to define progenitors and thus facilitate the study of hematopoietic differentiation.[PMID:31411667] 

publication : 31411667|27936566|2509478|10049046|1826463 

definition : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] 

term_xref : GTC:G47325QT|GlycoEpitope:EP0065|CID:13991612|CHEBI:84941  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 15

GSD000014

term (main_entry) : Blood group A (Type 2) 

glycan_dictionary_accession : GSD000014 

glytoucan_accession  : G74353FF 

term_in_sentence : One hybridoma antibody (AH16), obtained on immunization with human gastric cancer cell MKN45, was directed to the blood group A determinant carried by both type 1 and type 2 chains. [PMID:6583282] 

publication : 27196314|6583282|8340255|18701592|21901093|2413709|8036794|1615929|3285099 

definition : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] 

term_xref : GTC:G74353FF|CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 

synonyms : A Type 2|Blood group A type 2 chain

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000016

term (main_entry) : Alpha-gal antigen 

glycan_dictionary_accession : GSD000016 

glytoucan_accession  : G24432YB 

term_in_sentence : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:31267683] 

publication : 31267683|29319188|29481481|26140655|30337555|29235434|22909134|28280265|7532618|23390540|22808845|29898796|22262104| 31267683|25430953|22993330|23578170|21043478|28294277|27696820|15814276|17991149|25577211|30578545|19895316|28068870|18546155|32907757|26485996|9771839|12042247|27567275|12131678|23114154|19184002|29577591|29806570|15638815|21118731 

definition : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] 

term_xref : GTC:G24432YB|GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330  

synonyms : a-Gal antigen 

function : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000017

term (main_entry) : Alpha-galactosylceramide 

glycan_dictionary_accession : GSD000017 

glytoucan_accession  :  

term_in_sentence : From 24 weeks of age, NZB/NZW F1 mice were injected with alpha-galactosylceramide (α-GalCer) or vehicle once a week for four weeks.[PMID:29844470] 

publication : 29844470|30421497|31575643|30745361|30953000|30556652|29617191|31689579|28872688|30195979|29940370|27004737|27198610|28743554|31649670|31484693|25752588|21383248|25527277|30821985|28947140|31244823|29311431|30803854|29576533|26101952|31213291|22412194|28067024|31199716|27354638|24465013|25445911|28120096|15630427|27803187|21392534|31075434|22683545|26191196|26811064|23935988|28623127|24913977|25434827|23420533|21839133|25314062|27325450|23874157 

definition :  

term_xref :  

synonyms : alpha-GalCer|alpha-GalCers|α-GalCer 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000018

term (main_entry) : Asialo-biantennary 

glycan_dictionary_accession : GSD000018 

glytoucan_accession  :  

term_in_sentence : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:30990348] 

publication : 30990348|17645671|20959391|18615430|16945378|2065054|3084472|2386787 |22911097|24692304|17013932|7513972| 6626573|10835250|9684342 

definition :  

term_xref :  

synonyms : asialo diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000019

term (main_entry) : Asialo-GM1 

glycan_dictionary_accession : GSD000019 

glytoucan_accession  : G21856LC 

term_in_sentence : We compared the lateral structure of giant unilamellar vesicles (GUVs) composed of three pseudo binary mixtures of different glycosphingolipid (GSL), i.e. sulfatide, asialo-GM1 or GM1, with POPC.[PMID:29106974] 

publication : 29106974|3418980|26975993|8613364|9288228|26710925|24922516|6839313|1828259|2581667|8210226|25062498|9671150|10377092|6171919|3093429|6652964|3124753|8905612|18788941|1467432|8225593|2083955|6171918|7806377|1802483|7927723|9209156|21174147|2584393|12137200|6175621|2936802|8610366|21490162|1548508|3486908|26453755|7910939|3756909|1639356|3259967|2443562|3112077|2572647|25137483|2168971|6950172 

definition :  

term_xref : GlycoMotif:GGM.000099|GTC:G21856LC|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216  

synonyms : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a|ganglio-N-tetraosylceramide 

function :  

disease_associations : Pleuropneumonia[SugarBind_Ligand:2]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:2]|Actinomycosis[SugarBind_Ligand:2]|Lazy leukocyte syndrome[SugarBind_Ligand:2]|Pertussis[SugarBind_Ligand:2]|Cutaneous lesions[SugarBind_Ligand:2]|Melioidosis[SugarBind_Ligand:2]|Candidiasis[SugarBind_Ligand:2]|Taiwan acute respiratory agent[SugarBind_Ligand:2]|Trachoma[SugarBind_Ligand:2]|Cystitis[SugarBind_Ligand:2]|Chronic gastritis[SugarBind_Ligand:2]|Peptic ulcers[SugarBind_Ligand:2]|Gastric cancer[SugarBind_Ligand:2]|Klebsiella pneumonia infection[SugarBind_Ligand:2]|Pneumonia[SugarBind_Ligand:2]|Legionnaires' disease[SugarBind_Ligand:2]|Gonorrhea[SugarBind_Ligand:2]|Gastroenteritis[SugarBind_Ligand:2]|Toxoplasmosis[SugarBind_Ligand:2]|Plague[SugarBind_Ligand:2]|Diarrhea[SugarBind_Ligand:2] 

wikipedia :  

essentials_of_glycobiology :

GSD000020

term (main_entry) : B-GD1B 

glycan_dictionary_accession : GSD000020 

glytoucan_accession  : G72557NR 

term_in_sentence : The Molecular Modelling and 10 ns MD simulation of Botulinum Neuro Toxin/B-GD1A and BoNT/B-GD1B complex revealed that this toxin can interact with GD1A in the single binding mode and with GD1B in two binding modes.[PMID:22929125] 

publication : 27956354|22929125 

definition :  

term_xref : GlycoMotif:GGM.000104|GTC:G72557NR|CID: 91847819|KEGG:G01803|CHEBI:153361 

synonyms : B-GD1b 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000021

term (main_entry) : B-GM1 

glycan_dictionary_accession : GSD000021 

glytoucan_accession  : G11485ID 

term_in_sentence : The contribution of GM3 and GD3, which accounted for 95% of the ganglioside sialic acid at birth, decreased during the first 3 weeks of life. GM1, fucosyl-GM1, and B-GM1 were not detected at birth. [PMID: 3680254] 

publication : 3680254 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] 

term_xref : GlycoMotif:GGM.000102|GTC:G11485ID|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 

synonyms :  

function :  

disease_associations : Cholera[SugarBind_Ligand:181] 

wikipedia :  

essentials_of_glycobiology : Chapter 37

GSD000022

term (main_entry) : Biantennary 

glycan_dictionary_accession : GSD000022 

glytoucan_accession  :  

term_in_sentence : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID: 29249147] 

publication :  29249147| 24991291|29409839| 30325416|18083109|26926155|16715395| 12634321|24211369|23115267|31907993| 23360551|20861009| 33142198|11442281|18687680|15680603|31888963| 14686925 [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]| 15819890| 22530754 |22098756|9346821|19341309|18529007| 20580347|11784152|7773775|10913832|8547276|10463590|9404657|30525457|15316280|8068637|3881425| 6425277|8576139|29956878|1576211|11129583|30421263|8069634|30973186| 16704415| 21612260|29806066|29443078 

definition : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary] 

term_xref :  

synonyms : diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

GSD000023

term (main_entry) : Biantennary complex 

glycan_dictionary_accession : GSD000023 

glytoucan_accession  :  

term_in_sentence : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:16704415] 

publication : 16704415|3731182|26747427| 32597008|6626573|29249147|28597152|25045879|30325416|12634321|31888963|26926155|23360551|33142198|9404657|29956878| 14686925|18687680|11784152|7773775| 22530754|20580347|22098756|21612260|6425277|7691595|26780731|16285669|15819890|3924097|30448401|8547276|17049014|29408873 

definition : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] 

term_xref : CHEBI:156251 

synonyms : diantennary complex type 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000024

term (main_entry) : Bisecting GlcNac 

glycan_dictionary_accession : GSD000024 

glytoucan_accession  :  

term_in_sentence : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:1374031] 

publication : 1374031|29909448|29274553|32719771|22476631|31375533|26467158|27429195|20816221|26109616|30542567|30144245|25727145|29593568|32612952|9006930|19508951|16000695|32597008|19053837|22530754|30405631|19940114|32719549|9560299|29655002|10589784|29959030|20661133|9061364|31065629|20395209|29549127|30305426|29632412|24108122|24282611|27821068|14686925|10816579|25032906|30025558|9661906|8542600|31585439|29699572|27443163|30315103|23808883|18812317|19776078 

definition : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: 22476631] 

term_xref : SID:163312364|KEGG:G13066

synonyms :  

function : The bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression through modulating N-glycan/galectin interactions.[PMID: 22476631]Inhibits growth factor signaling and retards mammary tumor progression[PMID: 20395209]Integrin-mediated cell adhesion [PMID: 20816221]Important in fertilization and fetal development, neuritogenesis, immune tolerance, immunoglobulin G (IgG)[PMID: 32719771] 

disease_associations : mammary tumor.[PMID: 20395209] 

wikipedia :  

essentials_of_glycobiology : Chapter 9

GSD000025

term (main_entry) : Bisialo-biantennary 

glycan_dictionary_accession : GSD000025 

glytoucan_accession  :  

term_in_sentence : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. 

publication : 2386787|2065054 

definition : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. 

term_xref :  

synonyms : disialo biantennary|disialo diantennary|disialylated biantennary|disialylated diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000026

term (main_entry) : Bisialo-biantennary complex-type 

glycan_dictionary_accession : GSD000026 

glytoucan_accession  :  

term_in_sentence : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID: 2386787] 

publication : 2386787|26966183 

definition : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae.  

term_xref :  

synonyms : Fully sialylated biantennary N-glycan 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 25

GSD000027

term (main_entry) : Blood group A (Type 2) - Lewis y 

glycan_dictionary_accession : GSD000027 

glytoucan_accession  : G54826OZ 

term_in_sentence : Monoclonal antibodies defining blood group A variants with difucosyl type 1 chain (ALeb) and difucosyl type 2 chain (ALey).[PMID:2417620] 

publication : 2417620 

definition : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] 

term_xref : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039  

synonyms : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000028

term (main_entry) : Blood group A (Type 4) 

glycan_dictionary_accession : GSD000028 

glytoucan_accession  : G37830TX 

term_in_sentence : Moreover, we have found that αGal, but not αGalNAc, is a weak binder itself for DC-SIGN, which could endow an additional binding mode for the blood group B antigen, but not for blood group A.[PMID:31283166] 

publication : 7800218|7521740|2458640|31283166 

definition :  

term_xref : GlycoMotif:GGM.000088|GTC:G37830TX|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48  

synonyms :  

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:48]|Acute cystitis[SugarBind_Ligand:48] 

wikipedia :  

essentials_of_glycobiology :

GSD000029

term (main_entry) : Blood group A trisaccharide 

glycan_dictionary_accession : GSD000029 

glytoucan_accession  : G00066MO 

term_in_sentence : A readily detectable carbohydrate in the urine of two siblings with neuronal ceroid lipofuscinosis was found to be the blood group A trisaccharide.[PMID:7249368] 

publication : 19582848|7249368|8774717|2749874|28771597|30619340|2122121|11886841|2991755|12588002|3149698|7048329|7015594|10359132|8724140|1418679|1446307 

definition : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] 

term_xref : GlycoEpitope:EP0255|GTC:G00066MO|CID:49852448|KEGG:G10638|CHEBI:61012  

synonyms : blood group A trisaccharide|blood group A type 1 trisaccharide 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000030

term (main_entry) : Blood group A (Type 1) 

glycan_dictionary_accession : GSD000030 

glytoucan_accession  : G66163TI 

term_in_sentence : he basis of blood group A(1) and A(2) phenotypes has been debated for many decades, and still the chemical basis is unresolved. [PMID:19121199] 

publication : 10942408|19121199 

definition : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] 

term_xref : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 

synonyms : Blood group A(1)|blood group A antigen type 1 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000031

term (main_entry) : Blood group A1 (Type 3) 

glycan_dictionary_accession : GSD000031 

glytoucan_accession  : G44060QH 

term_in_sentence : The structure is essentially a repetitive A epitope attached to type 2 chain and is hereby called type 3 chain A. [PMID:2579390] 

publication : 2579390|19756298 

definition : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665] 

term_xref : GTC:G44060QH|CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040  

synonyms : Blood group A1 (type 3)|Blood Group A1 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000032

term (main_entry) : Blood group A2 (A-associated H type 3) 

glycan_dictionary_accession : GSD000032 

glytoucan_accession  : G62735WZ 

term_in_sentence : The H NMR spectrum of the associated H antigen (type 3 chain H) was characterized by the unusual presence of three n-anomeric resonances ('CJ'.~ = 3-4 Hz) in addition to five resonances from @-anomeric protons ("J1:2 = 7-9 Hz).[PMID: 3944091]
publication : 3944091|29000000|28658771 

definition : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543] 

term_xref : CHEBI:152543|CID: 91852328|GlycoMotif:GGM.000041|GTC:G62735WZ 

synonyms : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000033

term (main_entry) : Blood group B (Type 1) 

glycan_dictionary_accession : GSD000033 

glytoucan_accession  : G31734OS 

term_in_sentence : The minimal binding epitope was identified as the blood group H type 1 determinant (Fucα2Galβ3GlcNAc), while an optimal binding epitope was created by addition of the terminal α3-linked galactose or N-acetylgalactosamine of the blood group B type 1 determinant (Galα3(Fucα2)Galβ3GlcNAc) and the blood group A type 1 determinant (GalNAcα3(Fucα2)-Galβ3GlcNAc). [PMID: 19208633] 

publication : 18701592|24749871|19387828|19208633|29562255 

definition : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242] 

term_xref : GlycoMotif:GGM.000043|GTC:G31734OS|CID:56927779|CHEBI:63242 

synonyms : blood group B type 1 tetrasaccharide 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000034

term (main_entry) : Blood group B (Type 2) 

glycan_dictionary_accession : GSD000034 

glytoucan_accession  : G34881WK 

term_in_sentence : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID: 2432062] 

publication : 2432062|27196314|18701592 

definition :  

term_xref : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262  

synonyms : blood group B type 2 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000035

term (main_entry) : Blood group B (Type 4) 

glycan_dictionary_accession : GSD000035 

glytoucan_accession  : G25216QA 

term_in_sentence : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:1390942] 

publication : 1390942|1841684 

definition :  

term_xref : GlycoMotif:GGM.000087|GTC:G25216QA  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000036

term (main_entry) : Blood group H (Type 1) 

glycan_dictionary_accession : GSD000036 

glytoucan_accession  : G00294TN 

term_in_sentence : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:7718581] 

publication : 7718581|6309836|19208633|27431816| 2432062|24219248|6352465|8499478|3348768|3718924 

definition :  

term_xref : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153  

synonyms : H type 1 

function :  

disease_associations : Gastroenteritis[SugarBind_Ligand:153] 

wikipedia :  

essentials_of_glycobiology :

GSD000037

term (main_entry) : Blood group H (Type 2) 

glycan_dictionary_accession : GSD000037 

glytoucan_accession  : G70519XK 

term_in_sentence : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID: 9405495] 

publication : 9405495|8082855|6177241|3944092|21406562|2410664|8731502|6203846|2238560| 

definition :  

term_xref : GTC:G70519XK|GlycoMotif:GGM.000036  

synonyms : Blood group H (type 2)|H type 2|H type 2 chain|H type 2 antigen|type 2 chain H|blood group H type II 

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

GSD000038

term (main_entry) : Blood group H (Type 2) - Lewis y 

glycan_dictionary_accession : GSD000038 

glytoucan_accession  : G00052MO 

term_in_sentence : The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes.[PMID: 11479278] 

publication : 11479278 

definition : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] 

term_xref : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045  

synonyms : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y 

function : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] 

disease_associations : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000039

term (main_entry) : Blood group H (Type 4) 

glycan_dictionary_accession : GSD000039 

glytoucan_accession  : G98465JN 

term_in_sentence : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID:1841684] 

publication : 11261842| 1841684|11101633|9405495 

definition : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245] 

term_xref : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245

synonyms :  

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:61] 

wikipedia :  

essentials_of_glycobiology :

GSD000040

term (main_entry) : C2-O-sLex 

glycan_dictionary_accession : GSD000040 

glytoucan_accession  : G97345NY 

term_in_sentence : PSGL-1 lacks 6-sulfo-sLex but contains sulfated tyrosine residues (Tyr-SO3)at positions 46, 48, and 51 and sLex in a core 2-based O-glycan (C2-O-sLex) on Thr at position 57.[PMID:12736247] 

publication : 12736247|19267921|21283832|15596301|17072011 

definition : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192] 

term_xref : GlycoMotif:GGM.000053|GTC:G97345NY|CID:91860725|KEGG:G10899|CHEBI:155160  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000041

term (main_entry) : Ceramide dihexosyl sulfate 

glycan_dictionary_accession : GSD000041 

glytoucan_accession  : G04416BG 

term_in_sentence : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:818074] 

publication : 818074 

definition : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides. [http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/] 

term_xref : GTC:G04416BG|GlycoMotif:GGM.000065 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000043

term (main_entry) : Chondroitin sulfate 

glycan_dictionary_accession : GSD000043 

glytoucan_accession  :  

term_in_sentence : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: 31013685] 

publication : 31013685|27526113|27194526|26980567|28847361|24413804|29891297|29600622|25129732|31317901|29181550|31250530|22265655|25756648|29402610|17928217|20236040|28091940|30824935|26572336|31207331|21110089|30599999|20399897|27226567|19388612|23186102|31494830|28982096|30241863|30295666|25366475|20521042|29456007|31304829|18661362|28576008|29494632|30016441|26906924|24861964|23774590|31887904|31339761| 12512856|26957048|29625000 

definition : Any of a class of 10‚Äî60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397] 

term_xref : CHEBI:37397|CID:24766 

synonyms : chondroitin polysulfate|chondroitin sulfate|chondroitin sulfates|chondroitin sulfuric acid|chondroitin sulphate|Chondroitinsulfate 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000044

term (main_entry) : cisGM1 

glycan_dictionary_accession : GSD000044 

glytoucan_accession  : G03277YI 

term_in_sentence : Macrophage ganglioside patterns dramatically increase in complexity when murine peritoneal macrophages are stimulated in vivo with the appearance of the sialidase-sensitive monosialoganglioside GM1b (cisGM1) as a major component.[PMID: 9455923] 

publication : 9455923 

definition : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580] 

term_xref : GlycoMotif:GGM.000100|GTC:G03277YI|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 

synonyms : GM1b 

function :  

disease_associations : Influenza[SugarBind_Ligand:92] 

wikipedia :  

essentials_of_glycobiology : Chapter 23

GSD000045

term (main_entry) : Complex-type N-glycans 

glycan_dictionary_accession : GSD000045 

glytoucan_accession  :  

term_in_sentence : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:10988252 

publication : 29902282|29212795|29343819|27705835|26745022|18399796|16825488|21964725|15864431|22890903|12417032|28039392|19426135|30253927|16794314|19806620|22975979|25931033|15201278|19129634|19129628|24032650|22530754|31021709|30973186|28091941|23115339|20829342|27304954|29090617|21802690|29725121|30471292|16581187|26098720|31080188|1930135|31888963|30844485|24014058|11129583 

definition : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  

term_xref :  

synonyms :  

function : Involved in protein stability.[PMID:12417032] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 17

GSD000046

term (main_entry) : Core 2 

glycan_dictionary_accession : GSD000046 

glytoucan_accession  : G00033MO 

term_in_sentence : To investigate the biological roles of core 2 O-glycans, we produced and characterized mice deficient in one or more of the three known glycosyltransferases that generate core 2 O-glycans (C2GnT1, C2GnT2, and C2GnT3).[PMID: 19349303] 

publication : 19349303|30315106|23640779|26677400 

definition : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158] 

term_xref : GTC:G00033MO|CID: 52921656|CHEBI:62158  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000047

term (main_entry) : Core 3 

glycan_dictionary_accession : GSD000047 

glytoucan_accession  : G00035MO 

term_in_sentence : Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells.[PMID: 28745318] 

publication : 28745318|27259834|27143302| 

definition : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344] 

term_xref : GTC:G00035MO|CID:25061208|CHEBI:71344  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

GSD000048

term (main_entry) : Core 4 

glycan_dictionary_accession : GSD000048 

glytoucan_accession  : G00037MO 

term_in_sentence : The results confirm the predicted existence of a beta1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation.[PMID: 9988682] 

publication : 9988682|10747980| 

definition : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341] 

term_xref : GTC:G00037MO| CID:25229562|CHEBI:71341 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 8

GSD000049

term (main_entry) : Core-fucosylated 

glycan_dictionary_accession : GSD000049 

glytoucan_accession  : G78059CC 

term_in_sentence : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:27678371] 

publication : 27678371|26514868|15538974|24914453| 17049014|32078267|31268672|28674882|29956878|27798819|32044029|30962950|31548313|30907281|29090617|29571940|28800497|27629418|29733746|31623829|28768188|26897254|31451706|26514868]|29427759|28982386|26587313|30940702| 15538974|31249452|27282921|31229844|30445455|31325506|24732908|29209018|26965517|28609658| 24914453|25573275|17049014|19218400|27012207|27139574| 32078267|25861849|32561391|21374780|31669139|25732060|29408166|31268672|30472795|30614075|19003000|25664929 

definition : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006]. 

term_xref : GTC:G78059CC|CID: 70679232|CHEBI:70967|CHEBI:156499 

synonyms : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc 

function : Required for signaling through TCR [PMID: 29434598]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:17132494]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:29062024] 

disease_associations : Emphysema|systemic lupus erythematosuslung cancer|autoimmunity|tumor metastasis 

wikipedia :  

essentials_of_glycobiology : Chapter 8

GSD000050

term (main_entry) : Core-fucosylated biantennary 

glycan_dictionary_accession : GSD000050 

glytoucan_accession  : G78059CC 

term_in_sentence : The IFN-alpha14c N-glycans were shown to exhibit core-fucosylated biantennary glycans , with about 10% carrying an additional alpha1,3-linked fucose unit at the antennae.[PMID:9654101] 

publication : 9654101|15819890|28263871|26763099|22256781|23681398|25855029|10529240|26544759|8206921|33149259|8547276 

definition : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. 

term_xref : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 

synonyms : core-fucosylated diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 8

GSD000051

term (main_entry) : Core-fucosylated biantennary complex-type 

glycan_dictionary_accession : GSD000051 

glytoucan_accession  : G78059CC 

term_in_sentence : The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.[PMID:10731668] 

publication : 10731668 

definition : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. 

term_xref : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499  

synonyms : core fucosylated diantennary complex-type 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000052

term (main_entry) : Cyclic sialyl 6-sulfo Lewis x 

glycan_dictionary_accession : GSD000052 

glytoucan_accession  :  G11148DZ

term_in_sentence : Stimulation of the sialyl 6-sulfo Lewis X-positive colon cancer cell line with a calcium ionophore ionomycin markedly reduced sialyl 6-sulfo Lewis X and induced cyclic sialyl 6-sulfo Lewis X expression.[PMID:10728707] 

publication : 10728707|31222115|9990070|23088960 

definition :  

term_xref :  GlycoEpitope:EP0017|CID: 91858084|CHEBI:147484

synonyms :  

function : The accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000053

term (main_entry) : Cytolipin R 

glycan_dictionary_accession : GSD000053 

glytoucan_accession  : G57710SU 

term_in_sentence : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:4110375] 

publication : 893368|4375678|51702|186204|4110375|5068000|24174198|6072378|389925|7054174 

definition : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:5068000] 

term_xref : GlycoMotif:GGM.000083|GTC:G57710SU|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17  

synonyms :  

function :  

disease_associations : Actinomycosis[SugarBind_Ligand:17] 

wikipedia :  

essentials_of_glycobiology :

GSD000054

term (main_entry) : Dermatan sulfate 

glycan_dictionary_accession : GSD000054 

glytoucan_accession  :  

term_in_sentence : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:29111696] 

publication : 27526113|29111696|29891297|26164146|30869126|7789716|8597249|12512856| 31250530| 17928217|12213784|27226567|31455633|28091940|19075609|31071403|15078125|18661328|20581662|17239765|15749837|2777747|20632047|8930750|7762784|31006321|26876822|1522290|131009|26986023|8161353|15315969|12543559|30637950|2525357|18156656|9692613|9200333|19661164|2299256|16075147|1126924|9774430|8537360|15563459|21077227|23275130|17137817|6447930|6209270 

definition : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.[CHEBI:18376] 

term_xref : CHEBI:18376|CID:32756 

synonyms : beta-Heparin|Chondroitin sulfate B|Dermatan L-iduronate 

function : Wound healing[Essentials of Glycobiology:Chapter 7]|maintain the structure of the dermis.[Essentials of Glycobiology:Chapter 41] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000055

term (main_entry) : Desialylated 

glycan_dictionary_accession : GSD000055 

glytoucan_accession  :  

term_in_sentence : Furthermore, we found no evidence for "desialylated" apoB100 glycans in any of the samples analyzed.[PMID:11588155] 

publication : 30015642|26168491|29492899|31774586|32321401|23780974|7600681|18045697|1450583|4137057|28911304|27562992|29950245|31978220|2408573|8612720|10910970|27195066|1434544|22175031|24517196|29794068|30101537|18972200|1478792|4440781|21229239|30844664|31351722|31330845|1872910 

definition : A glycan from which sialyl groups have been removed. [https://en.wiktionary.org/wiki/desialylated] 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000056

term (main_entry) : Desialylated tetrasaccharide 

glycan_dictionary_accession : GSD000056 

glytoucan_accession  :  

term_in_sentence : The structures of a desialylated tetrasaccharide , two monosialylated trisaccharides , and five other minor products were defined.[PMID:8384526] 

publication : 8384526 

definition : A tetrasachharide (four branches) glycan from which sialyl groups have been removed.  

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 17

GSD000057

term (main_entry) : Difucosylated tetra-antennary N-glycans 

glycan_dictionary_accession : GSD000057 

glytoucan_accession  :  

term_in_sentence : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID: 18214858] 

publication : 18214858 

definition : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added. 

term_xref :  

synonyms :  

function :  

disease_associations : pancreatic cancer[PMID:18214858] 

wikipedia :  

essentials_of_glycobiology :

GSD000058

term (main_entry) : Dimeric Lewis x 

glycan_dictionary_accession : GSD000058 

glytoucan_accession  : G79535HZ 

term_in_sentence : The carbohydrate antigen dimeric Lewis X (DimLex), which accumulates in colonic and liver adenocarcinomas, is a valuable target to develop anti-cancer therapeutics.[PMID:32957489] 

publication : 32957489|31276881|12062524|15488731|1979361|8737237|17939723|7683631|11384108|11133015|17388629|15483381|12662048|3233598|18618154|21892456 

definition : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325] 

term_xref : GTC:G79535HZ|GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031 

synonyms : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx 

function : cancer-associated antigen[GlycoEpitope:EP0093] 

disease_associations : colonic cancer[GlycoEpitope:EP0093]|liver cancer[GlycoEpitope:EP0093] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000059

term (main_entry) : Diphosphorylated Man6 

glycan_dictionary_accession : GSD000059 

glytoucan_accession  : G54792LL 

term_in_sentence : Here we report that the single-chain variable domain (scFv) M6P-1 is a unique antibody fragment with specificity for Man6P monosaccharide that, through an array-screening approach against a number of phosphorylated N-glycans, is shown to bind mono- and diphosphorylated Man6 and Man7 glycans that contain terminal αMan6P(1 → 2)αMan(1 → 3)αMan.[PMID:26503547] 

publication : 26503547 

definition :  

term_xref : GTC:G54792LL|GlycoMotif:GGM.000054

synonyms : Diphosphorylated Man_6 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000060

term (main_entry) : Disialosyl globopentaosylceramide 

glycan_dictionary_accession : GSD000060 

glytoucan_accession  : G97932OH 

term_in_sentence : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID:31339142] 

publication : 31339142|24637536|25864532|27344728| 12084983 12084983| 32567311|28205070|20663960|18214042 

definition : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:28205070] 

term_xref : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID:91860287|KEGG:G00181|SugarBind_Ligand:57  

synonyms : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside 

function : promotes metastasis[PMID:28205070] 

disease_associations : prostate cancer[PMID:24637536]|renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] 

wikipedia :  

essentials_of_glycobiology :

GSD000061

term (main_entry) : Disialyl Gb5 

glycan_dictionary_accession : GSD000061 

glytoucan_accession  : G97932OH 

term_in_sentence : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: 12084983] 

publication : 12084983  

definition :  

term_xref : GlycoEpitope:EP0098|GTC:G97932OH|CID:  91860287|SugarBind_Ligand:57|KEGG:G00181  

synonyms :  

function :  

disease_associations : renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] 

wikipedia :  

essentials_of_glycobiology :

GSD000062

term (main_entry) : Disialyl I 

glycan_dictionary_accession : GSD000062 

glytoucan_accession  : G54937EM 

term_in_sentence : Here we present an example of promotion of binding of soluble-form FN from placenta or from hepatoma cells, having a specific carbohydrate epitope termed "disialyl-I," to K562 or VA13 cell surface in the presence of glycosphingolipid Gg3, which interacts specifically with disialyl-I[PMID:10640401] 

publication : 10640401 

definition :  

term_xref : GlycoEpitope:EP0095|GTC:G54937EM|CID:91849523  

synonyms : disialyl-I 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000063

term (main_entry) : Disialyl Lewis a 

glycan_dictionary_accession : GSD000063 

glytoucan_accession  : G93400AK 

term_in_sentence : Biosynthesis of disialyl Lewis a (Lea) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides.[PMID:12668675] 

publication : 12668675|17760270|15231659|12668106|30716533|32050430|22467657 

definition : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:15231659] 

term_xref : GTC:G93400AK |GlycoEpitope:EP0040|CID:91854138|CHEBI:155549 

synonyms : disialyl Lea 

function : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040] 

disease_associations : Mucin antigen carrying 2-3 sialylated Le a antigen or 2-3, 2-6 disialylated Lc4 antigen in cancer patients had the lowest carbohydrate/protein ratio. Thus, the carbohydrate/protein ratio in the type 1 chain mucin antigens in sera of normal subjects is higher than that in sera of cancer patients.[GlycoEpitope:EP0040] 

wikipedia :  

essentials_of_glycobiology :

GSD000064

term (main_entry) : Disialyl T antigen 

glycan_dictionary_accession : GSD000064 

glytoucan_accession  : G01614ZM 

term_in_sentence : The most potent glycoside was disialyl T antigen (NeuAcalpha2-3Galbeta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides.[PMID: 15701648] 

publication : 29113555|17974963|33242079|12645620|15701648|26598643 

definition : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602] 

term_xref : GlycoMotif:GGM.000014|GTC:G01614ZM|CID: 70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027  

synonyms : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen 

function : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000065

term (main_entry) : Disialylated biantennary 

glycan_dictionary_accession : GSD000065 

glytoucan_accession  :  

term_in_sentence : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:8486673] 

publication : 22426998|17171781|25022802|24812685|24780636|26582205|9499382|22978794|22594947|8486673|20356825|1634621|9244386|12966096|1472054| 24243045|19579232|27943633 

definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. 

term_xref :  

synonyms : disialylated diantennary 

function : appears in human transferrin[PMID:  24243045]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] 

disease_associations : galactosemia.[PMID: 9499382] 

wikipedia :  

essentials_of_glycobiology :

GSD000066

term (main_entry) : Disialylated biantennary complex-type 

glycan_dictionary_accession : GSD000066 

glytoucan_accession  :  

term_in_sentence : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:11738084] 

publication : 11738084|9499382|9244386|24243045|12966096|25124522|19371135 

definition : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. 

term_xref :  

synonyms :  

function : appears in human transferrin[PMID:24243045]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] 

disease_associations : galactosemia.[PMID:9499382] 

wikipedia :  

essentials_of_glycobiology :

GSD000067

term (main_entry) : Disialylated fucosylated 

glycan_dictionary_accession : GSD000067 

glytoucan_accession  :  

term_in_sentence : Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.[PMID:17591618] 

publication : 17591618 

definition : A fucosylated glycan with two sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 45

GSD000068

term (main_entry) : Forssman antigen 

glycan_dictionary_accession : GSD000068 

glytoucan_accession  : G80062GG 

term_in_sentence : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution).[PMID:28510705] 

publication : 28510705|31933576| 28134301|7021748|1802714|7512587|7747818|23325748|268649|31816281|22015168|4147161|2857159|6267170|7293775|13367419|20636540| 10460829  10460829|23255552|2675268|18955372|7020692|31784953|4114942|31273262|6257673|7696847|1916901|11169215|48262|26022515|6175621|31404475|6983878|8381954| 10431785|3257757|6792413|25039359 

definition : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789 

term_xref : GTC:G80062GG |GlycoEpitope:EP0037|CID 91825690|CHEBI:85789 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 45

GSD000069

term (main_entry) : Forssman glycolipid 

glycan_dictionary_accession : GSD000069 

glytoucan_accession  : G80062GG 

term_in_sentence : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:3040119] 

publication : 3040119|268649|23240079|28134301|3495590|1138893| 10460829|10506200|8855242|1955453|1933935|3355161|6773959|14573676|29898878|10431785|1747956|11214737|7423202|389939|3871816|6187373|16133832|469271|3753492|2695680|7037611|25703376|23798992|414913|1868069| 7960243 

definition : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789] 

term_xref : GlycoMotif:GGM.000084|GTC:G80062GG|CID:91825690|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86 

synonyms : Forssman antigen|Globopentosylceramide 

function : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:3495590] 

disease_associations : Pyelonephritis[SugarBind_Ligand:86]|Acute cystitis[SugarBind_Ligand:86] 

wikipedia :  

essentials_of_glycobiology : Chapter 45

GSD000070

term (main_entry) : Fucose-containing tetraantennary 

glycan_dictionary_accession : GSD000070 

glytoucan_accession  :  

term_in_sentence : The two major N-linked oligosaccharides of Namalwa EPO were fucose-containing tetraantennary and fucose-containing triantennary structures.[PMID:2550193] 

publication : 2550193 

definition : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of fucose. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia : https://en.wikipedia.org/wiki/Forssman_antigen 

essentials_of_glycobiology : Chapter 14

GSD000071

term (main_entry) : Fucosyl GM1 

glycan_dictionary_accession : GSD000071 

glytoucan_accession  : G91532KA 

term_in_sentence : Unique localization of fucosyl GM1 implicates its possible role in cell adhesion and recognition in the nervous system.[PMID:8068725] 

publication : 6619101|16880505|9089399|29789847|8068725|19556222|1660040|2420639|9076515|15926079|19555091|2541996|16211870|1336587|21174147|14967068|18923900|30021910|16941490|27070150|8305235|10602885|2645049|7993838|10537341|3002616|8336147|15447995|8905401|11714535|9260862|32228455|3315641|8076384|2317201|3680254|6403518 

definition : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686] 

term_xref : GTC:G91532KA |GlycoEpitope:EP0049|CID: 53356699|CHEBI:62686 

synonyms :  

function :  

disease_associations : small-cell lung cancer(SCLC)[GlycoEpitope:EP0049]|hepatoma[GlycoEpitope:EP0049] 

wikipedia :  

essentials_of_glycobiology :

GSD000072

term (main_entry) : Fucosylated asialo-biantennary 

glycan_dictionary_accession : GSD000072 

glytoucan_accession  :  

term_in_sentence : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:2065054] 

publication : 2065054|17013932 

definition : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose. 

term_xref :  

synonyms : fucosylated asialo-diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000073

term (main_entry) : Fucosylated biantennary 

glycan_dictionary_accession : GSD000073 

glytoucan_accession  :  

term_in_sentence : The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class.[PMID:17956937] 

publication : 17956937|30525457|1933856 

definition : a biantennary glycan with two GlcNAc branches linked to the core and the addition of fucose. 

term_xref :  

synonyms : fucosylated bisialo-diantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000074

term (main_entry) : Fucosylated bisialo-biantennary 

glycan_dictionary_accession : GSD000074 

glytoucan_accession  :  

term_in_sentence : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:2065054] 

publication : 2065054 

definition : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added. 

term_xref :  

synonyms : Fucosylated biantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000075

term (main_entry) : Fucosylated LDN 

glycan_dictionary_accession : GSD000075 

glytoucan_accession  : G02240AO 

term_in_sentence : To date, oligomeric LDN and oligomeric fucosylated LDN (LDNF) have been found only on N-glycans from mammalian cells engineered to express Caenorhabditis elegansbeta4-GalNAc transferase and human alpha3-fucosyltransferase IX [Z. S. Kawar et al. (2005) J Biol Chem280, 12810-12819]. [PMID:16403022] 

publication : 16403022|28151933|19545571|22448293 

definition : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864] 

term_xref : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID: 52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594 

synonyms : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000076

term (main_entry) : Fucosylated N-glycans 

glycan_dictionary_accession : GSD000076 

glytoucan_accession  :  

term_in_sentence : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858 18214858]] 

publication : 18214858|31141660|26869352|29790113|31931062 

definition : The fucose from GDP-fucose is transferred to N-linked glycans. 

term_xref :  

synonyms :  

function :  

disease_associations : pancreatic cancer.[PMID: 26869352] 

wikipedia :  

essentials_of_glycobiology :

GSD000077

term (main_entry) : Fucosylated triantennary 

glycan_dictionary_accession : GSD000077 

glytoucan_accession  :  

term_in_sentence : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:2513186] 

publication : 2513186|29642865|7679920|31110965|2551687|15051952|12943224 

definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose. 

term_xref :  

synonyms :  

function : appears in human alpha-fetoprotein (AFP).[PMID: 7679920] 

disease_associations : neoplastic diseases of the liver[PMID: 7679920] |hepatocellular carcinoma[PMID:  7679920]. 

wikipedia :  

essentials_of_glycobiology : Chapter 43

GSD000078

term (main_entry) : Galabiosylceramide 

glycan_dictionary_accession : GSD000078 

glytoucan_accession  : G67988RO 

term_in_sentence : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:33360824] 

publication : 33360824|29099167|25582508|2824515|4027258|32854306|32868283|31319156|29530250|27367163|2564247|27727434|10216186| 10460829|24992926|23590301|15702404|1854798|14761135|3600200|8603914|8601603|1965141|17400502|3840690|15959771|7930586|7721812|17095952|2500499|3815386|8842706|10746023|3928791|3782065|6440894 

definition : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314] 

term_xref : GlycoEpitope:EP0113|GTC:G67988RO|CID: 5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314 

synonyms :  

function :  

disease_associations : tumor/lung[GlycoEpitope:EP0113]|tumor/gallbladder[GlycoEpitope:EP0113]|tumor/kidney[GlycoEpitope:EP0113]|tumor/pancreas[GlycoEpitope:EP0113] 

wikipedia :  

essentials_of_glycobiology :

GSD000079

term (main_entry) : Galactosylceramide 

glycan_dictionary_accession : GSD000079 

glytoucan_accession  : G65889KE 

term_in_sentence : Galactosylceramide improved behavioral, neuropathological, and biochemical parameters in Cln3 Cln3 Δex7/8 mice, paving the way for effective therapy for CLN3 disease and use of serum ceramide as a potential biomarker to track impact of therapies.[PMID:31393621] 

publication : 31393621|19941861|9883654|33006978|26735924|22032265|18035062|25129050|2802541|1761517|28660574|475780|2302222 

definition :  

term_xref : GTC:G65889KE|GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061

synonyms : GalCer|Galactocerebroside|LC 

function :  

disease_associations : Pleuropneumonia[SugarBind_Ligand:1]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:1]|Lyme disease[SugarBind_Ligand:1]|Plague[SugarBind_Ligand:1]|Acquired immune deficiency syndrome[SugarBind_Ligand:1] 

wikipedia :  

essentials_of_glycobiology :

GSD000080

term (main_entry) : Galnac disialyl Lc4 (Hexasaccharide) 

glycan_dictionary_accession : GSD000080 

glytoucan_accession  : G33532XU 

term_in_sentence : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: 12084983] 

publication : 15704108|11278988|12084983|7509790 

definition : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID: 91857945] 

term_xref : GlycoEpitope:EP0097|GTC:G33532XU|CID: 91857945|CHEBI:149360 

synonyms :  

function :  

disease_associations : prostate cancer[GlycoEpitope:EP0097]|renal cell carcinoma/RCC[GlycoEpitope:EP0097] 

wikipedia :  

essentials_of_glycobiology :

GSD000081

term (main_entry) : Gb5 

glycan_dictionary_accession : GSD000081 

glytoucan_accession  : G99053DY 

term_in_sentence : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:25839135] 

publication : 12401210|25839135|31540393|31140679|3028540|3674263|31339142|30026902|10721708|30671362|26176557|25039255|24044869|32567311|27857717|21491978|24910250|29077212|8014006|27107335|32679486|1747956|8679447|28352526|11341836|10837462| 7960243|16158941|3297853|2431136|21734356|8625206|30732055|12716912|20128040|2582447|14659673 

definition : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842] 

term_xref : GlycoMotif:GGM.000076|GTC:G99053DY|CID:53239691|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12

synonyms : Globopentaosylceramide 

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:12]|Actinomycosis[SugarBind_Ligand:12|Influenza[SugarBind_Ligand:12] 

wikipedia :  

essentials_of_glycobiology : Chapter 11

GSD000082

term (main_entry) : GD1 

glycan_dictionary_accession : GSD000082 

glytoucan_accession  : G81983KG 

term_in_sentence : Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1.[PMID:31791361] 

publication : 5652802|25345088|31791361|29361370|31234327|30264864|25250137|7528216|31669751|20684311|16306603|10420586|7766692|31614613|26384672|31613991|19210136|8926633|29696051|32300455|7513313|26674302|20336376|24259734|31704237|21067946|30516933|27979707|26345314|30516941|31849452|27789132|30218706|29388611|20177787 

definition :  

term_xref : GlycoMotif:GGM.000105|GTC:G81983KG|CID: 91859783|KEGG:G00126  

synonyms : GD1c 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000083

term (main_entry) : GD1a 

glycan_dictionary_accession : GSD000083 

glytoucan_accession  : G46677TE | G45714BQ

term_in_sentence : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: 28899916] 

publication : 28899916|26860251|21930390|32906699|26054879|29951721|11745410|17653976|26119566|21554929|18435913|15342262|26865725|21151139|15716397|21492147|16942752|26973195|24449473|14999485|22735313|20589721|10521808|22929125|7827024|16897174|25062498|17227759 

definition : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209] 

term_xref : GlycoMotif:GGM.000106|GlycoMotif:GGM.000107|GTC:G46677TE|GTC:G45714BQ|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111  

synonyms : GD1alpha 

function :  

disease_associations : Gastroenteritis[SugarBind_Ligand:22]|Actinomycosis[SugarBind_Ligand:22]|Lazy leukocyte syndrome[SugarBind_Ligand:22]|Toxoplasmosis[SugarBind_Ligand:22]|Lyme disease[SugarBind_Ligand:22]|Botulism[SugarBind_Ligand:22]|Keratoconjunctivitis[SugarBind_Ligand:22]|Influenza[SugarBind_Ligand:22] 

wikipedia :  

essentials_of_glycobiology :

GSD000084

term (main_entry) : GD1b 

glycan_dictionary_accession : GSD000084 

glytoucan_accession  : G37184KW 

term_in_sentence : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: 27144558] 

publication : 27144558|24859332|18625966|7945223|32518172|26710925|31837178|20594196|30985655|11511306|1742806|11123278|7685064|2709011|33279873|22929125|9179156|17964572|8821498|32726962|26560950|2611779|10072058|20030259|16415013|10797556|11342695|8619520|21519903|16199892|23777091|30246056|10481046 

definition : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222] 

term_xref : GlycoMotif:GGM.000108|GTC:G37184KW|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 47

GSD000085

term (main_entry) : GD2 

glycan_dictionary_accession : GSD000085 

glytoucan_accession  : G02657AK 

term_in_sentence : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: 25440605] 

publication : 28154831|32002293|32733795|28145567|31500597|31903906|29180536|28415563|25440605|30617136|25604432|30198960|31075227|31721713|30955398|32195035|27304202|31015228|31653037|31016728|30670592|30613134|29221154|30027525|29442009|31762628|30485077|25642322| 29436609|29151270|24773917|30612272|27654028|26298772 

definition : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218] 

term_xref : GlycoMotif:GGM.000094|GTC:G02657AK|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88  

synonyms :  

function :  

disease_associations : breast cancer[PMID:28415563] 

wikipedia :  

essentials_of_glycobiology : Chapter 11|Chatper 35

GSD000086

term (main_entry) : GD3 

glycan_dictionary_accession : GSD000086 

glytoucan_accession  : G98544DH 

term_in_sentence : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: 12531552] 

publication : 30245960|27591028|12531552|29069780|12470841|29436609|28295752|27304202]|31138648|27288875|30446565|8721669|3903474|16081368|32743804|24372645|26792897|20890432|25330147|20581115|11174200|16040804|23783008|17368571|11023989|12901230|21807667|7061953|2231782|19423750|22632091|18202973|6392333|15896784|8261439|20052288|12847141|12486096|12118012|19912988|22795094|18655184|17043769|21395555|2472199|19776077 

definition : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210] 

term_xref : GlycoMotif:GGM.000091|GTC:G98544DH|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062  

synonyms :  

function :  

disease_associations : Cholera[SugarBind_Ligand:89]|Influenza[SugarBind_Ligand:89] 

wikipedia :  

essentials_of_glycobiology : Chapter 11

GSD000087

term (main_entry) : Globoside 

glycan_dictionary_accession : GSD000087 

glytoucan_accession  : G00061MO 

term_in_sentence : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:10993897] 

publication : 10993897 

definition :  

term_xref : GlycoMotif:GGM.000070|GTC:G00061MO  

synonyms : Cytolipin K|Gb4|Globoside I|Globotetraosylceramide|P antigen 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 47

GSD000088

term (main_entry) : Globotetraosylceramide 

glycan_dictionary_accession : GSD000088 

glytoucan_accession  : G00061MO 

term_in_sentence : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:28392398] 

publication : 28392398|25787850|23471986|2559078|32455599|2663859|32796033|3517161|20082214|30853699|15279935|26104834|20732996|30224239|31142708|30338271|25033755|30413389|7104376|29866658|24983355|6794884|31361021|21740983|33168837|31752441|28123520|29068380|24841197|27932383|28535204|31691795|27916888|27558838|10227680|26464281|22348006|22279060|25156739|32314902|22718629|23701631|23906628|8613382|23555772|20059899|7868240 

definition : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] 

term_xref : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID: 5288889|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032

synonyms : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K 

function :  

disease_associations : Actinomycosis[SugarBind_Ligand:18]|Pyelonephritis[SugarBind_Ligand:18]|Acute cystitis[SugarBind_Ligand:18]|Shigellosis[SugarBind_Ligand:18]|Lazy leukocyte syndrome[SugarBind_Ligand:18]|Influenza[SugarBind_Ligand:18] 

wikipedia :  

essentials_of_glycobiology :  Chapter 11

GSD000089

term (main_entry) : Globotriaosylceramide 

glycan_dictionary_accession : GSD000089 

glytoucan_accession  : G00059MO 

term_in_sentence : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:32127409] 

publication : 32127409|28674962|30875019|30413389|31778662|31101366|24335674|31241709|24158513|28947349|31566927|28672034|31939530|29530250|27851774|26426881|25031264|29982630|24496231|29983334|28756410|27190352|29274327|29099167|28402705|23680766|28625968|26960552|26797827|22742555|27756537|31630715|3827883|28384397|29523338|31010832|27195818|26661087|23093409|30879639|27081853|17409683|29921669|25575293|26291612|23146289|25857295|26070511 

definition : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] 

term_xref : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID: 5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27  

synonyms : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide 

function :  

disease_associations : Pyelonephritis[SugarBind_Ligand:27]|Acute cystitis[SugarBind_Ligand:27]|Shigellosis[SugarBind_Ligand:27]|Lyme disease[SugarBind_Ligand:27]|Cutaneous lesions[SugarBind_Ligand:27]|Diarrhea[SugarBind_Ligand:27] 

wikipedia :  

essentials_of_glycobiology :

GSD000090

term (main_entry) : Glucosylceramide 

glycan_dictionary_accession : GSD000090 

glytoucan_accession  : G71142DF 

term_in_sentence : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321] 

publication : 31265321|29290548|29627573|20919653|28427052|30550553|24415933|31914593|31051284|23073611|30146946|31619618|26840726|29750412|8065509|27412675|27840079|30611744|31353719|25661072|28686011|25803043|28865794|28154347|31466334|30242129|12531551|30639288|30864417|27711049|22764777|27905603|29077010|28744000|23555901|24115322|12803919|29204666|23628459|28851512|26136173|23563543|30110701|26572681|2193825|29926415|31727994|27479571 

definition : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963] 

term_xref : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF

synonyms : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH 

function : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:30611744]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321] 

disease_associations : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] 

wikipedia :  

essentials_of_glycobiology : Chapter 31

GSD000091

term (main_entry) : GM1 

glycan_dictionary_accession : GSD000091 

glytoucan_accession  : G48558GR 

term_in_sentence : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238] 

publication : 18524657|31761138|36180805|29920238|33859490|31937438|25762012|25931034|31776384|32013258|30776097|31048748|31447771|30292198|28796418|27806275|21076871|27552916|17986147|26960162|27815022|25851126|32916822|11462671|28236574|15911874|28577204|28497346|1794005|31934908|30267299|16902585|29439846|32325905|29747823|27576485|26338710|27858734|24501414|26818965|26629687|26958633|1854596|32134593|32198666|6619101 

definition : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] 

term_xref : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 

synonyms :  GM1 ganglioside|GM1-ganglioside

function :  The branched pentasaccharide chain of ganglioside GM1 is a prominent cell surface ligand, for example, for cholera toxin or tumor growth-regulatory homodimeric galectins.[PMID:16267866]

disease_associations : GM1 gangliosidosis (GM1) [PMID: 33859490]|Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13] 

wikipedia : https://en.wikipedia.org/wiki/GM1 

essentials_of_glycobiology :  Chapter 11| Chapter 14

GSD000092

term (main_entry) : GM2 

glycan_dictionary_accession : GSD000092 

glytoucan_accession  : G79389NT 

term_in_sentence : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: 27491214] 

publication : 29618308|27491214|32867370|30030044|27499644|31097363|29100724|27402091|31852956|30389374|30988135|8786814|14533808|23370522|28192816|32692591|29106755|28833537|11339652|9728335|27270764|9714704|26175473|27018595|28615102|28974375|32951593|11462672|28955902|17192692|26538065|25421609|9572057|11596983|15264019|23236285|11596984|31261761|30113798|24391178|24309906|22224667|7980537|18272501|9006924| 

definition : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] 

term_xref : GlycoMotif:GGM.000095|GTC:G79389NT|CID: 45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351  

synonyms :  

function :  

disease_associations : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]|Gastroenteritis[SugarBind_Ligand:39]|Cholera[SugarBind_Ligand:39]|Clostridial myonecrosis[SugarBind_Ligand:39]|Tetanus[SugarBind_Ligand:39] 

wikipedia : https://en.wikipedia.org/wiki/GM1_gangliosidoses 

essentials_of_glycobiology : Chapter 11

GSD000093

term (main_entry) : GM3 

glycan_dictionary_accession : GSD000093 

glytoucan_accession  : G91237TK 

term_in_sentence : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: 29747813] 

publication : 29376491|29747813|25613425|30318083|31526872|31004109|28019668|26434718|27313500|27539856|30111401|28544772|29407985|19364317|30190430|31297734|30091781|26043887|32183071|30665141|27873002|25801320|30209782|32378734|23050851|22768242|14993837|24934090|17638075|21518140|26102277|19759399|24502144|25303960|23564406|16636105|16491123|11259118|15102521|12724312|24985965|8496625|25403557|15690123|15939439|25893133|23591593|20634908|2004380|739008| 

definition : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] 

term_xref : GlycoMotif:GGM.000090|GTC:G91237TK|CID: 5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 

synonyms :  

function : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844] 

disease_associations : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35] 

wikipedia :  

essentials_of_glycobiology : Chapter 37

GSD000094

term (main_entry) : GM4 

glycan_dictionary_accession : GSD000094 

glytoucan_accession  : G30207PZ 

term_in_sentence : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:23999868] 

publication : 23999868|2332419|12091485|19542236|8407875|23320941|28808804|3621237|23203271|7057115|26362868|6170387|18034482|7076644|2391348|25464080|3701369|11217952|6201236|30744426|9388026|27177620|30246056|15979459|7586078|6779816|29402905|7335153|3306476|17499534|7074082|9668345|3701884|26862430|6831238|27311552|26831445|24417799|7097284|4169231|16854400|26483798 

definition : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position
[CHEBI:63155] 

term_xref : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 

synonyms :  Sialylated GalCer

function :  

disease_associations : Chronic gastritis[SugarBind_Ligand:110]|Peptic ulcers[SugarBind_Ligand:110]|Gastric cancer[SugarBind_Ligand:110] 

wikipedia :  

essentials_of_glycobiology : Chapter 11|Chapter 15|Chapter 44|Appendix 45A

GSD000095

term (main_entry) : GP1c 

glycan_dictionary_accession : GSD000095 

glytoucan_accession  : G93805MV 

term_in_sentence : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:19053458] 

publication : 1606358|19053458|1695858|4091974|10775425|2468656|2299350|3064875|11432974| 9613831|11831845|1879553| 10699494|8969459|8474578|12031286|1304332|9153001|10564776 

definition :  

term_xref : GlycoMotif:GGM.000118|GTC:G93805MV

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11|Chapter 14|Chapter 27|Chapter 35|Chapter 45 |Chapter 47|Chapter 49

GSD000096

term (main_entry) : GQ1b 

glycan_dictionary_accession : GSD000096 

glytoucan_accession  : G18625KA 

term_in_sentence : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:31186474] 

publication : 30798387|31186474|26704905|23677659|26984947|24184316|23804237|9819299|18514410|22189683|24859332 

definition : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] 

term_xref : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11

GSD000097

term (main_entry) : GQ1ba 

glycan_dictionary_accession : GSD000097 

glytoucan_accession  : G54733XO 

term_in_sentence : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:25024341] 

publication : 25024341|23717411|17870542|10702226|21137678|26748510|8662799|21274438|24649890|16580208|28124591|20095613|17507233|23565921|14505645|20930939|9201997 

definition :  

term_xref : GlycoMotif:GGM.000116|GTC:G54733XO  

synonyms : GQ1balpha 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000098

term (main_entry) : GQ1c 

glycan_dictionary_accession : GSD000098 

glytoucan_accession  : G99524KA 

term_in_sentence : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: 6640289] 

publication : 6640289| 1695858|7798936|1729139|2468656|20368669|2723647|1814411| 3064875|6085330|1613492|17883393|11831845| 10775425|8219015|8804704|1384262|7066685|2299192|9613831|10350354|1304337|9153001|11959025|8474578|2299350| 10564776|10699494|3942818|12031286|7361620 

definition : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID: 91860352] 

term_xref : GlycoMotif:GGM.000117|GTC:G99524KA|CID: 91860352|CHEBI:145645|KEGG:G00121 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 46

GSD000099

term (main_entry) : GT1a 

glycan_dictionary_accession : GSD000099 

glytoucan_accession  : G68110IF 

term_in_sentence : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:26197476] 

publication : 12023422|32623212|26197476|9585812|29747820|23804237|11993188|31683059|19631994|9742882|29709941|8971119|8706663|893404|31829433|8910600|30600291|29319803|26176883|29063860|6766128|31602715|29808463|30711390|29847988|30116054|28187751 

definition : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] 

term_xref : CID:45266863|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000100

term (main_entry) : GT1a alpha 

glycan_dictionary_accession : GSD000100 

glytoucan_accession  : G02149VR 

term_in_sentence : A new class of gangliosides, GT1a alpha and GQ1b alpha, were initially identified as cholinergic neuron-specific antigens in bovine brain. [PMID:8082783] 

publication : 7710562|8082783|10972137|9468624|9143254|8221098|9679279|11368158|11878808 

definition :  

term_xref : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID: 91851751|CHEBI:156678|KEGG:G00128  

synonyms : GT1aa 

function : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000101

term (main_entry) : GT1b 

glycan_dictionary_accession : GSD000101 

glytoucan_accession  : G40183QN 

term_in_sentence : GT1b ganglioside is axonally transported to the spinal cord dorsal horn and contributes to characteristics of neuropathic pain such as mechanical and thermal hypersensitivity.[PMID: 32030804] 

publication : 32030804|26370787|32046393|9712688|7636307|9931455|25520869|19605473|17188834|10233751|22735313|20540782|22746533|1861141|19490186|9521848|11921200|10731661|31431523|15274627|32726962|12573517|18277613|11370834|11234774|11123278|18704164|16291967|11411041|27549393|25253868|22720883|10686582|11511306|29904724|31472390|19156870 

definition : A branched amino heptasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries an N-acetyl-α-neuraminyl-(2→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl trisaccharide unit and an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide unit through (2→4) and (2→3) linkages respectively. It corresponds to the carbohydrate portion of ganglioside GT1b.[CHEBI:59225] 

term_xref : GlycoMotif:GGM.000112|GTC:G40183QN|GlycoEpitopeEP0067|CID:45266781|CHEBI:59225| GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116  

synonyms :  

function :  

disease_associations : Toxoplasmosis[SugarBind_Ligand:26]|Lyme disease[SugarBind_Ligand:26]|Cholera[SugarBind_Ligand:26]|Botulism[SugarBind_Ligand:26]|Tetanus[SugarBind_Ligand:26]|Influenza[SugarBind_Ligand:26] 

wikipedia :  

essentials_of_glycobiology :

GSD000102

term (main_entry) : GT1c 

glycan_dictionary_accession : GSD000102 

glytoucan_accession  : G78818SP 

term_in_sentence : We show here that VVH associates with ganglioside GM1a, Fucosyl-GM1, GD1a, GT1c, and GD1b by glycan array.[PMID: 32228455] 

publication : 28088450|30085356|32228455|2468656|19841910|23877172|1695858|10564776|1613492|8474578|7798936|11180643|2723647|7066685|9613831|7361620|10699494 

definition : A branched amino heptasaccharide consisting of a linear tetrasaccharide of β-D-galactose, N-acetyl-β-D-galactosamine, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→4) and (1→4), to the galactose residue proximal to the reducing end is also linked (2→3) an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl trisaccharide side-chain. The carbohydrate moiety of ganglioside GT1c.[CHEBI:90509] 

term_xref : GlycoMotif:GGM.000113|GTC:G78818SP|CID:91846734|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000103

term (main_entry) : GT2 

glycan_dictionary_accession : GSD000103 

glytoucan_accession  : G36476BA 

term_in_sentence : Biosynthesis of the c-series gangliosides GT3, GT2 and GP1c was studied in Golgi derived from rat liver.[PMID:1606358] 

publication : 1606358|15498585|16005859|27540730|31533196|31201844 

definition : A branched amino hexasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-galactosaminyl residue. The carbohydrate moiety of ganglioside GT2.[CHEBI:72446] 

term_xref : GlycoMotif:GGM.000109|GTC:G36476BA|CID: 70788971|CHEBI:72446|KEGG:G00119  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11

GSD000104

term (main_entry) : GT3 

glycan_dictionary_accession : GSD000104 

glytoucan_accession  : G93899SO 

term_in_sentence : The purpose of this study was two-fold: (1) to formulate γ-tocotrienol (GT3) in a nanoemulsion formulation as a prophylactic orally administered radioprotective agent; and (2) to optimize the storage conditions to preserve the structural integrity of both the formulation and the compound.[PMID: 28029115] 

publication : 28029115|31355968|30987413|27869747|27216753|8631981|29672891|10385047|29642403|10412028|27193023|30068561|23415908|8858920|2303428|27153057|27128741|2654294|26930378|7561885|25860286|30845647|24712339|30070965|8910600|1606358|27356050|8514740|18509108|23000517|29769046|29566611 

definition : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444] 

term_xref : GlycoEpitope:EP0070|KEGG:G00118|CID:70788970|GlycoMotif:GGM.000092|GTC:G93899SO|CHEBI:72444  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11

GSD000105

term (main_entry) : Blood group H (Type 3) 

glycan_dictionary_accession : GSD000105 

glytoucan_accession  :  G94435QH

term_in_sentence : One particular lambody, VLRB.aGPA.23, was shown by glycan array analysis to be selective for the blood group H type 3 trisaccharide (BG-H3, Fucα1-2Galβ1-3GalNAcα), aGPA, and TFα (Galβ1-3GalNAcα), with affinity constants of 0.2, 1, and 8 nM, respectively.[PMID:23030719] 

publication : 23030719|20466654|1563908|3944092|11218748|11101633|18842005|27550195|2469783|2433836|23118206|8445257|2664192|3063304 

definition :  

term_xref :  GlycoMotif:GGM.000010|GTC:G94435QH

synonyms : H type 3|H antigen (type 3)|Type 3 chain H 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 11

GSD000106

term (main_entry) : Heparan sulfate 

glycan_dictionary_accession : GSD000106 

glytoucan_accession  :  

term_in_sentence : In Niemann-Pick C-1 fibroblasts, where deaminative degradation of heparan sulfate is defective, carbonylated proteins were abundant.[PMID: 17540770] 

publication : 32266657|29554552|29032302|30003471|25197032|28538085|26236728|16917509|22899865|17080204|23042481|28982096|24146040|25081076|15719168|17453622|25325954|21110089|29797526|21967329|23313092|11212344|28465034|11746174|12512855|8836040|28394734|24182748|28264929|28745308|26555370|14718374|16767693|25246018|19584012|8274190|25034023|8370471|26571620|29920400|31731076|20816205|16880267|31547957|11457867|27241222|28718936|21204109|31016560|11166215|11457866 

definition : A linear polysaccharide in which the backbone consists of a variably sulfated repeating disaccharide unit.[CHEBI:28815] 

term_xref : CHEBI:28815|CID: 53477715|GlycoEpitope: EP0086 

synonyms : Heparan N-sulfate|Heparan sulfate|Heparan sulphate|Heparatan sulfate|Heparin monosulfate| Heparin sulfate|Heparitin monosulfate|Heparitin sulfate|N-Acetylheparan sulfate 

function : Heparan sulfate proteoglycans (HSPGs) play crucial roles regulating key developmental signaling pathways, such as the Wnt, Hedgehog, transforming growth factor-beta, and fibroblast growth factor pathways.[GlycoEpitope: EP0086] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000107

term (main_entry) : Heparin 

glycan_dictionary_accession : GSD000107 

glytoucan_accession  :  

term_in_sentence : Two cellulose-based membranes, containing 5 and 20% N, N-diethyl-aminoethyl cellulose (DEAE) respectively, were investigated for ionic attachment of heparin and heparin release.[PMID:6416324] 

publication : 27100512|22566218|27264866|30094590|31077659|26975675|2083874|25088334|3333067|2191809|28118750|28224913|22495506|29385025|10332503|22393937|19947315|27655335|14529394|2419035|22048616|23849978|10204652|28958760|12627673|9042555|15639107|28880550|27238483|1964668|16716101|10796377|25981976|24680753|2191118|21166465|30582884|1322434|15330727|9752370|6416324|14996629|20452241|1340407|29050610|345399|6916469|6565376|26714061 

definition : A highly sulfated linear glycosaminoglycan comprising complex patterns of uronic acid-(1→4)-D-glucosamine repeating subunits. Used as an injectable anticoagulant, it has the highest negative charge density of any known biological molecule.[CHEBI:28304] 

term_xref : CID:772|CHEBI:28304  

synonyms : bemiparin|bemiparin|certoparin|Cy 222|enoxaparin|fluxum|Heparin|Heparinic acid|parnaparin|reviparin|sandoparin 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000108

term (main_entry) : High mannose 

glycan_dictionary_accession : GSD000108 

glytoucan_accession  : G55220VL 

term_in_sentence : Each glycoform contained a number of peaks differing by 162 Da indicating heterogeneity and suggesting the presence of high-mannose sugars.[PMID:11258925] 

publication : 11258925|17956937|2059624|2065054|26791533|4077844|7780197|9136890|30659065|30075362|21421994|31076349|29738673|29508223| 26747427|30634645|23007868|29051951|24549150|12417032|26724786|26956389|26493153|31102532|29673624|8348230|25586968|24975601| 29803109|28465212|25776945|30151520|21097542|24326091|27995699|26003537|6722291|2925680|25565276|21460211|25196214|27387600|22373601|3729933|16423983|24174266|30605318 

definition : An N-linked oligosaccharide that possesses between five and nine mannose residues attached to the chitobiose [(GlcNAc)2] core. [CHEBI:5717] None of the Man residues are substituted with any monosaccharide other than Man . 

term_xref : GTC:G55220VL|CID:70698382|CHEBI:71514  

synonyms : oligomannose 

function : Involved in promotion of protein folding in ER. [PMID:12417032].|High Man glycans are enriched at cell surface during apoptosis.[PMID: 17516205] 

disease_associations : Relative abundance changes in multiple CDGs [PMID: 30770376][PMID: 28484880] 

wikipedia :  

essentials_of_glycobiology : Chapter 17

GSD000109

term (main_entry) : HNK-1 

glycan_dictionary_accession : GSD000109 

glytoucan_accession  : G54406UD 

term_in_sentence : The human natural killer-1 (HNK-1) carbohydrate, a unique trisaccharide possessing sulfated glucuronic acid in a non-reducing terminus (HSO3-3GlcAß1-3Galß1-4GlcNAc-), is highly expressed in the nervous system and its spatiotemporal expression is strictly regulated.[PMID:28709864] 

publication : 28709864|31738061|26738850|30306736|11070366|20855890|18024472|22669261|19729452|19796667|26850637|11769463|18263654|15843379|26659409|9003039|22087768|21771787|15173636|9210489|15258996|17924534|26382082|16171882|18802400|9800516|7504418| 11891229|15232286|9013478|21621858|11677051|18668221|11414798|19265195|8982638|8798480|28403522|17935701|1691305|10998116|9364602|7528651|12472892|21176892|28416698|19389918| 28427937|25450311 

definition : An amino trisaccharide consisting of a 3-O-sulfo-β-D-glucuronic acid residue, a D-galactosyl residue and an N-acetyl-D-glucosamine residue (at the reducing end) in a linear sequence.[CHEBI:60322] 

term_xref : GTC:G54406UD|GlycoEpitope:EP0001|CID: 46906103|CHEBI:60322|GlycoMotif:GGM.000058 

synonyms : HNK-1 carbohydrate epitope| CD57|HNK-1 antigen 

function : learning and memory[GlycoEpitope:EP0001]|neural crest cell migration[GlycoEpitope:EP0001]|neurite extension[GlycoEpitope:EP0001]|neuron-astrocyte adhesion[GlycoEpitope:EP0001] 

disease_associations : schizophrenia-like psychosis[GlycoEpitope:EP0001]|neuropathy[GlycoEpitope:EP0001]|exfoliation syndrome[GlycoEpitope:EP0001]|secondary cataract[GlycoEpitope:EP0001] 

wikipedia : https://en.wikipedia.org/wiki/N-linked_glycosylation 

essentials_of_glycobiology : Chapter 17

GSD000110

term (main_entry) : Hybrid 

glycan_dictionary_accession : GSD000110 

glytoucan_accession  : G16828VN 

term_in_sentence : A hybrid-type N-glycan was accessed by total synthesis, converted to an oxazoline, and used as a donor substrate with both wild type Endo M and an N175Q glycosynthase Endo M mutant allowing the convergent synthesis of a glycosylated amino acid bearing a hybrid N-glycan structure. [PMID:27058295] 

publication : 27058295|15044398|28714086|29578688|26999365 

definition : An N-linked glycan in which the Manα1-6 arm of the trimannosyl core Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1–4GlcNAcβ1–Asn-X-Ser/Thr is substituted by one or more additional Man residues and the Manα1-3 arm is substituted by a GlcNAc residue added by GlcNAcT1. The GlcNAc linked to the a3 Man can be extended in the same manner as any complex glycan antenna. The trimannosyl core can also be core fucosylated and/or bisected by the addition of a GlcNAc to the 3 position of the α-linked Man residue.[Essentials of Glycobiology:Chapter 9] 

term_xref : GTC:G16828VN|CID:91847108|CHEBI:147471 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

GSD000111

term (main_entry) : i antigen 

glycan_dictionary_accession : GSD000111 

glytoucan_accession  : G00058MO|G46055MA 

term_in_sentence : Inasmuch as the hybridoma was established by hybridization of lymphocytes derived from regional lymph nodes of lung cancer, and the antigen was found in the patient's lung cancer tissue, the i antigen in lung cancer is probably recognized as a tumor-associated antigen by the host's immune cell system.[PMID:2422274] 

publication : 2422274|15679458|21912254|12468428|28508465|6203982|30728302|8449405|9122902|10360315|6159787|6183759|518539| 6715951|21933024 

definition :  

term_xref : GlycoMotif:GGM.000004|GlycoMotif:GGM.000002|GTC:G46055MA|GTC:G00058MO 

synonyms : Type 2 LN2 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000112

term (main_entry) : I antigen 

glycan_dictionary_accession : GSD000112 

glytoucan_accession  : G56045WU 

term_in_sentence : The I antigen is formed by the action of an enzyme (a glycosyltransferase), which adds branches onto the i antigen.[PMID: 15679458] 

publication : 15679458|21912254|30705292|33403394|6715951|12468428|6088627|6159787 

definition : N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S,6R)-4-[(2R,3R,4R,5S,6R)-3-Acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[[(2R,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide (CHEBI:151390) is a amino sugar.[CHEBI:151390] 

term_xref : GlycoMotif:GGM.000003|GlycoEpitope:EP0138|GTC:G56045WU|CID: 91852915|CHEBI:151390 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

GSD000113

term (main_entry) : Isoglobotetraosylceramide 

glycan_dictionary_accession : GSD000113 

glytoucan_accession  : G57710SU 

term_in_sentence : Furthermore, isoglobotetraosylceramide seems to play a direct role in the metastatic process since the blocking of exposed antigen with monoclonal antibodies, or their Fab fragments, results in a highly significant decrease in lung colony formation.[PMID:8504431] 

publication : 1396705|8504431|2713378|3489485|18997175|7053385|3379797|2465279|3743633|11479210 

definition :  

term_xref : GlycoMotif:GGM.000071|GTC:G57710SU|CID:91849719|KEGG:G03211|CHEBI:148232|SugarBind_Ligand:17  

synonyms :  

function : a marker for highly metastatic cells in rat mammary adenocarcinomas[PMID:8504431] 

disease_associations : Actinomycosis[SugarBind_Ligand:17] 

wikipedia : https://en.wikipedia.org/wiki/Ii_antigen_system 

essentials_of_glycobiology :

GSD000114

term (main_entry) : Keratan sulfate 

glycan_dictionary_accession : GSD000114 

glytoucan_accession  :  G82109MW 

term_in_sentence : Compared to the other classes of glycosaminoglycans (GAGs), that is, chondroitin/dermatan sulfate, heparin/heparan sulfate and hyaluronan, keratan sulfate (KS), have the least known of its interactive properties.[PMID: 30578672] 

publication : 29340594|30578672|12512857|29625490|25325967|30025865|29924315|9549787|11030741|28078490|8298243|29096187|30059256|26958998|26773479|22840010|15597951|28110685|28535934|2942429|18234072|8641829|8940154|2027120|30849116|41589|6238957|1907283|7722002|29275050|24274541|2527236|1731862|8991509|24291704|10517185|6451953|7688312|8663590|139406|25770829|25036480|9275006|25179279|32627425|26903438|27941632|12807022|32266652|21624346 

definition : A sulfated glycosaminoglycan, a linear polymer that consists of the repeating disaccharide [3)-β-Gal-(1→4)-β-GlcNAc-(1→] and containing sulfo groups located at random positions.[CHEBI:60924] 

term_xref : CHEBI:60924|CID:446715|GlycoEpitope: EP0085|GTC: G82109MW  

synonyms : keratan| Kerato sulphate|Kerato sulfate|Keratan sulphate|kerato 6'-sulfate|keratan 6'-sulfate|Kerato 6'-sulphate|Keratan 6'-sulphate 

function : Tissue hydration.[PMID: 11030741] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000115

term (main_entry) : LacdiNac 

glycan_dictionary_accession : GSD000115 

glytoucan_accession  : G31736BK 

term_in_sentence : We previously showed that the expression level of the LacdiNAc group in N-glycans decreases dramatically during the progression of human breast cancer.[PMID:25003135] 

publication : 25003135|31711843|31145522|27601469|30669833|25210040|24633693|24755437|22653491|30898876|7758724| 22474328|21305673|31558607|31271862|28549117|26213980|9134425|25561735|31756927|31170332|16282603|15265923|32267274|23015818|32676595|16728562|10814702|9591048|22245701| 29751628|22997242|15535969|31911241|30622255|29888905|30236114| 30298790|29373511|22298779|19179461|31606752|15653684|16403022|11162373|32005658|30529570 

definition : An amino disaccharide consisting of N-acetylglucosamine having an N-acetylgalactosaminyl resiude attached at the 4-position via a β-linkage.[CHEBI:61190] 

term_xref : GTC:G31736BK|GlycoEpitope:P0150|CID:25257164|CHEBI:61190|GlycoMotif:GGM.000016 

synonyms : LDN 

function : Has a role of epitope.[CHEBI:61190] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000116

term (main_entry) : Lactosylceramide 

glycan_dictionary_accession : GSD000116 

glytoucan_accession  : G84224TW 

term_in_sentence : In the 1970s, a neutral glycosphingolipid lactosylceramide (LacCer) was found to bind specifically to several kinds of microorganisms.[PMID:30175814] 

publication : 30175814|26900161|30502090|29624959|28444900|25408340|31801289|29099167|25595946|32592089|27729551|24658420|25216636|25638276|9499377|17986153|8143857|23801329|18077097|32708181|15346887|19015977|18393821|25279740|21057870|11915327|25212460|23882130|11915329|8195125|8808768|3396945|22128256|6733104|24968752|32518749|30688114|7666005|8200356|24718572|6193809|25781947|12383912|26086247|30606995|12419803 

definition : Glycosphingolipids which contain as their polar head group a lactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in lactosylceramide beta-galactosidase, is the cause of lactosylceramidosis.[MeSH:D007790] 

term_xref : GTC:G84224TW|MeSH:D007790|GlycoMotif:GGM.000064|GlycoEpitope:EP0078|SugarBind_Ligand:3 

synonyms : LacCer|Lc2|CDH 

function : mammalian cell receptors for Neisseria gonorrhoeae recognized by Helicobacter pylori[GlycoEpitope:EP0078] 

disease_associations : chronic gastritis[GlycoEpitope:EP0078,SugarBind_Ligand:3]|duodenal ulcers[GlycoEpitope:EP0078]|gastric adenocarcinoma[GlycoEpitope:EP0078,SugarBind_Ligand:3]|gastric ulcers[GlycoEpitope:EP0078]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Actinomycosis[SugarBind_Ligand:3]|Pertussis[SugarBind_Ligand:3]|Candidiasis[SugarBind_Ligand:3]|Cryptococcosis[SugarBind_Ligand:3]|Hemorrhagic colitis[SugarBind_Ligand:3]|Peptic ulcers[SugarBind_Ligand:3]|Histoplasmosis[SugarBind_Ligand:3]|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Gonorrhea[SugarBind_Ligand:3]|Sporotrichosis[SugarBind_Ligand:3]|Plague[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] 

wikipedia :  

essentials_of_glycobiology : Chapter 17

GSD000117

term (main_entry) : Lactotriaosylceramide 

glycan_dictionary_accession : GSD000117 

glytoucan_accession  : G06239NA 

term_in_sentence : The results showed that AML patients had higher expression of the GSL lactotriaosylceramide (Lc3), GM3 and neolactotetraosylceramide (nLc4) in their bone marrow than did the healthy donors (P < 0.05), especially the M1 subtype of AML.[PMID:22411838] 

publication : 22411838|20693232|26104834|27435676|26405105|32340400|25241919|23404501|32452379|2960671|272643|27711049|33202844|4060695|27638607|20547865|2277039|6238026|8448388|8489255|9363437|11836161|6892925|1551117|6811267|8059935|7861954|11283017|8514762|1291049|3805024|10816509|12393713|6417117|11054095|8781973|1692829 

definition : A linear amino trisaccharide consisting of β-D-glucose at the reducing end having an N-acetyl-β-D-glucosaminyl-(1→3)-β-D-galactosyl group attached at the 4-position.[CHEBI:61758] 

term_xref : GTC:G06239NA|GlycoMotif:GGM.000067|MeSH:C025575|CID: 10230777|CHEBI:61758|SugarBind_Ligand:20

synonyms : Lc3|Lc(3)Cer|Lc_3 

function : acute myeloid leukemia-associated glycosphingolipids lactotriaosylceramide, GM3 and neolactotetraosylceramide are possibly involved in initiation and differentiation of acute myeloid leukemia.[PMID:22411838] 

disease_associations : Pharyngitis[SugarBind_Ligand:20]|Tracheobronchitis[SugarBind_Ligand:20]|Gonorrhea[SugarBind_Ligand:20]|Actinomycosis[SugarBind_Ligand:20]|Diarrhea[SugarBind_Ligand:20] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000118

term (main_entry) : LcGg4 

glycan_dictionary_accession : GSD000118 

glytoucan_accession  : G62554JH 

term_in_sentence : Murine leukemia cells (M1), in their undifferentiated state, have been characterized by the presence of cancer-associated lactoganglio-series glycolipids, one of which was identified as lactogangliotetraosylceramide (LcGg4) having a novel branching at the II-Gal of lactosylceramide through GlcNAc beta 1----3 and GalNAc beta 1----4 linkage, as shown below (Kannagi, R., Levery, S.B., and Hakomori, S. (1984) J. Biol. Chem., 259, 8444-8451): GalNAc beta 1----4 Gal beta 1----4Glc beta 1----1Cer GlcNac beta 1----3 [PMID: 3805024] 

publication : 3805024|33395290 

definition : N-[(2S,3R,4R,5R,6R)-2-[(2R,3S,4R,5R,6S)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide is an oligosaccharide.[CHEBI:152521] 

term_xref : GlycoMotif:GGM.000075|GTC:G62554JH|CID:91850076|CHEBI:152521|GlycoEpitope:EP0035  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000119

term (main_entry) : Lewis a 

glycan_dictionary_accession : GSD000119 

glytoucan_accession  : G00047MO 

term_in_sentence : Regardless of the vaccine administered, significantly fewer of the children with Lewis A phenotype (0/14) seroconverted after receiving the first vaccine dose compared to 26% (45/175) of those with the Lewis B phenotype and 32% (15/47) of the Lewis negative individuals (P < 0.01). [PMID:29367698] 

publication : 29367698|27187324|30562693|27646625| 26911286|30225822|28600306|32527016| 2385097|11064310|23809433|30050155|1615929| 29527514| 9207264|1675497| 3677023|27705835|7593252| 2579997|17630273|9350993| 9098001 

definition : A lewis blood group antigen with structure beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an alpha-linkage and a galactosyl residue attached at the 3-position via a beta-linkage. It has a role as an epitope and an antigen. It is an amino trisaccharide and a glucosamine oligosaccharide.[CHEBI:62265] 

term_xref : GTC:G00047MO|CID: 22806751|CHEBI:62265|GlycoMotif:GGM.000020|SugarBind_Ligand:155  

synonyms : Le(a)|Lea-3|Lea|Le^a 

function :  

disease_associations : Gastroenteritis[SugarBind_Ligand:155] 

wikipedia : https://www.wikidata.org/wiki/Q50687009 

essentials_of_glycobiology :

GSD000120

term (main_entry) : Lewis b 

glycan_dictionary_accession : GSD000120 

glytoucan_accession  : G39211DH 

term_in_sentence : Human mannose-binding lectin preferentially binds to human colon adenocarcinoma cell lines expressing high amount of Lewis A and Lewis B antigens.[PMID:10328552] 

publication : 10328552|23408949|31927399|26601230|28279343|32527016|30831115|27318698|9207264|23828675|29527514|1615929| 2385097|2579997|25516619| 3677023|8509439|19832116|15270746|3166398|30909206|7718581|18400963| 29751628|8982241|30284922|24576035|30974776| 9098001|31768613|1651804|25428879|15946883| 30298790|30544260|29197783|8632739|7679772|18666312|20231766|29922666|95124|2247887|21519121|25153235|28751211 

definition :  

term_xref : GlycoMotif:GGM.000021|SugarBind_Ligand:146|GTC:G39211DH|CID:45480568|CHEBI:59440 

synonyms : Le(b)|Lewis(b)|Le^b 

function : possible receptor for Helicobacter pylori[https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/blood-group-lewis-system] 

disease_associations : Gastroenteritis[SugarBind_Ligand:146] 

wikipedia :  

essentials_of_glycobiology :

GSD000121

term (main_entry) : Lewis x 

glycan_dictionary_accession : GSD000121 

glytoucan_accession  : G00051MO 

term_in_sentence : In particular, the observation of oxonium ions at m/z 512.2 and 803.2 is useful for probing outer non-reducing terminal fucosylation, which represented carbohydrate structures consisting of Hex Hex , dHex Hex , and HexNAc , and NeuNAc , Hex Hex , dHex Hex , and HexNAc , respectively, from which the Lewis X structure (Galbeta1-4(Fucalpha1-3)GlcNAc) was readily deduced.[PMID:15536627] 

publication : 15536627|31666308|29019053|28296340|29593094|17607374|16581086|20858014|19962782|7912739|25121780|24059473|29210428|31276881|9015359|7628844|7499837|16850248|28425129|28869691|19576189| 10223649|22593503|15632313|27198630|26582608|11500392|31256373|23399157|21984435|26244810|26162743|17335083|15388363|9556613|10760152|11267844|20876654|12131290 

definition : A Lewis blood group antigen with structure α-L-Fucp-(1→3)-[β-D-Galp-(1→4)]-D-GlcpNAc where the glucosamine at the reducing end has β-configuration at its anomeric centre. Commonly known as Lewis x trisaccharide or Lex.[CHEBI:59294] 

term_xref : GTC:G00051MO |GlycoEpitope:EP0011|CID:44611539|CHEBI:59294|GlycoMotif:GGM.000018 

synonyms : Lex|Galbeta1-4(Fucalpha1-3)GlcNAc|Lewis x trisaccharide|Le(X)|Le^x|SSEA-1 

function : Involved in carbohydrate-carbohydrate interaction[Glycoepitope:EP0011].|Also implicated in apoptosis.[Glycoepitope:EP0011]|influence antigenic presentation and interfere with pathogen transfer in breastfed infants.[Glycoepitope:EP0011] 

disease_associations : acute leukemia[GlycoEpitope:EP0011]|lymphoma[GlycoEpitope:EP0011] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000122

term (main_entry) : Lewis y 

glycan_dictionary_accession : GSD000122 

glytoucan_accession  : G00052MO 

term_in_sentence : In conclusion, Lewis y antigen and CD147 were significantly upregulated in ovarian tumors, and the altered expression of Lewis y may cause changes in CD147.[PMID:30816446] 

publication : 30816446|20003467|24692145| 24998328| 25726913|29299130|30816446|20003467| 24692145| 24998328|20127027|22138668|23894390|25726913|25416440|27646625|23725446|21294926|22312289|25973320|23242548|30328452|21119363|29130097|23443083|23708102|28671040|19715603|23468946|27723168|21747684|19771739 

definition : A Lewis blood group antigen which is a branched amino tetrasaccharide with structure alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc, consisting of consisting of N-acetyl-beta-D-glucosamine at the reducing end having an alpha-L-fucosyl residue attached at the 3-position and an alpha-L-fucosyl-(1→2)-beta-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure. It has a role as an antigen and an epitope. [CHEBI:59045] 

term_xref : GTC:G00052MO|GlycoEpitope:EP0018|CID: 45266908|CHEBI:59045|GlycoMotif:GGM.000019  

synonyms : LeY|Le(y)|Ley|Le^y 

function : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] 

disease_associations : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000123

term (main_entry) : Monosialylated 

glycan_dictionary_accession : GSD000123 

glytoucan_accession  :  

term_in_sentence : The structures of the asparagine-linked sugar chains of U- CD59 were biantennary complex type , only 4.2% of which are monosialylated.[PMID:7514386] 

publication : 7514386|8477709|8942648|29752599|31669586|29747818|16425369|12089170|31390883|1632647|29733234|31110965|31566965|30555678|28263871|29652662|25915761|16381065|29247593|28370937|23896595|26633899|32155999|25261856|2737211|26945091|27065039|26784838|26582205 

definition : A glycan that have the addition of one sialic acid residues. 

term_xref :  

synonyms :  

function : appears in bovine brain gangliosides.[PMID: 29752599] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000124

term (main_entry) : Monosialyl-biantennary 

glycan_dictionary_accession : GSD000124 

glytoucan_accession  :  

term_in_sentence : In contrast, the sugar chain structure of HCC highly specific AFP isoform was found to comprise a monosialyl-biantennary sugar chain with additional fucosylation of the proximal N-acetylglucosamine.[PMID:7686446] 

publication : 7686446|1374031|9648261|10460833|19524219|10207016|15797573|15218190 

definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of one sialic acid residues. 

term_xref :  

synonyms : monosialyl biantennary|sialylated diantennary|sialylated biantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000125

term (main_entry) : Monosialyl-Gb5 

glycan_dictionary_accession : GSD000125 

glytoucan_accession  : G32254QI 

term_in_sentence : Thus, malignancy of MCF-7 is highly dependent on monosialyl-Gb5, and its activation of cSrc and FAK in GEM.[PMID:12401210] 

publication : 12401210|16995838|27318475 

definition : alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp is a linear amino hexasaccharide comprising β-D-glucose at the reducing end with at the 4-position a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety, α(2→3)-sialylated at the terminal galactosyl residue.[CHEBI:62313] 

term_xref : GTC:G32254QI|GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID: 73427363|CHEBI:62313  

synonyms : GL-7 globoseries ganglioside (SSEA-4)|Monosialyl Gb5|Sialosyl galactosyl globoside|GL-7 globoseries ganglioside|SSEA-4 

function :  

disease_associations : renal cell carcinoma/RCC[GlycoEpitope:EP0099] 

wikipedia :  

essentials_of_glycobiology :

GSD000126

term (main_entry) : Mono-sulfated globopentaosylceramide 

glycan_dictionary_accession : GSD000126 

glytoucan_accession  : G80193TN 

term_in_sentence : Mono-sulfated globopentaosylceramide from human kidney.[PMID:2777788] 

publication : 2777788 

definition :  

term_xref : GlycoMotif:GGM.000072|GTC:G80193TN 

synonyms : Monosulfated globopentaosylceramide 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000127

term (main_entry) : Mono-sulfated globotetraosylceramide 

glycan_dictionary_accession : GSD000127 

glytoucan_accession  : G05297EK 

term_in_sentence : Mono-sulfated globotetraosylceramide from human kidney.[PMID:2559078] 

publication : 2559078 

definition :  

term_xref : GlycoMotif:GGM.000073|GTC:G05297EK

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000128

term (main_entry) : N-acetyl GM2 

glycan_dictionary_accession : GSD000128 

glytoucan_accession  : G79389NT 

term_in_sentence : The appearance of the N-acetyl GM2 antigen correlated well with the degree of differentiation of the cancer cells in patients with squamous cell carcinoma and adenocarcinoma of the lung.[PMID:3167861] 

publication : 3167861|2153431| 25673107 

definition : beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp is a branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] 

term_xref : GTC:G79389NT|GlycoEpitope:EP0051|CID: 45266845|CHEBI:59220 

synonyms :  

function : The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.[CHEBI:59220] 

disease_associations : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051] 

wikipedia :  

essentials_of_glycobiology :

GSD000129

term (main_entry) : N-acetyllactosamine (Type 2)

glycan_dictionary_accession : GSD000129 

glytoucan_accession  : G00055MO 

term_in_sentence : Utilising a fast and sensitive screening method based on imidazolium-tagged probes, we report unprecedented reversible activity of bacterial beta1,4-galactosyltransferases to catalyse the transgalactosylation from lactose to N-acetylglucosamine to form N-acetyllactosamine in the presence of UDP.[PMID:31165848] 

publication : 31165848|31126011|28796164|6236210|9751793|29740087|9151975|10567443|21472942|26477523|6548353|28167527|20056550|7737204|22052010| 10223649|11323440|10420596|7766648|25257940|17977857|15556936|26541999|23650594|9692202|29429899|21062783|25034434|8985145|28503789|8720464/ 

definition : N-acetyllactosamine is a beta-D-galactopyranosyl-(1→4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. It is also known as galb1-4glcnacb or lacnac, belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group. N-Acetyllactosamine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Acetyllactosamine exists in all living organisms, ranging from bacteria to humans.[CHEBI:16153,HMDB0001542] 

term_xref : GTC:G00055MO|CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001  

synonyms : LacNAc|Type 2 LN 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000130

term (main_entry) : N-Glycolyl-GM2 

glycan_dictionary_accession : GSD000130 

glytoucan_accession  : G56478LD 

term_in_sentence : The monoclonal antibodies MK2-34 and MK1-16 (both IgM), which specifically detect N-glycolyl GM2 and N-acetyl GM2, respectively, were generated by immunizing mice with liposomes containing monophosphoryl lipid A, trehalose dimycolate, and the antigenic ganglioside.[PMID:3167861] 

publication : 3167861|11861662|17980710|3731079|25673107 

definition : (2S,4S,5R,6R)-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of carbohydrates and carbohydrate derivatives.[CHEBI:151464] 

term_xref : GTC:G56478LD |GlycoEpitope:EP0052|CID: 91845742|CHEBI:151464|GlycoEpitope:GGM.000096  

synonyms :  

function :  

disease_associations : choriocarcinoma[GlycoEpitope:EP0052]|teratocarcinoma|[GlycoEpitope:EP0052]yolk sac tumor[GlycoEpitope:EP0052] 

wikipedia :  

essentials_of_glycobiology :

GSD000131

term (main_entry) : N-linked glycans 

glycan_dictionary_accession : GSD000131 

glytoucan_accession  : G78059CC 

term_in_sentence : Our study identifies extracellular N-linked glycans-and the glycoprotein neurexin 1β specifically-as key modulators of neuronal uptake of αSacetyl, drawing attention to the potential therapeutic value of αSacetyl-glycan interactions.[PMID:31211781] 

publication : 31211781|28384382|30305477|31364612|26899268|29945790|29652253|29723274|30962676|29778448|25325701|31100702|28898525|22944671|19277537|24473128|17957771|27554083|15189166|11269317|19577919|24303005|12042249|22191536|28324664|25965797|25434632|30484244|28110657|29865036|20129637|27346875|30280442|26911286|22491358|26582281|26398792|31548313|31066275|28331984|25482090|28518173|30733536|22326428|30063825|30315103|21558494|31676555|31256374 

definition : The carbohydrate portion of a glycoprotein that has a glycan linked through the nitrogen of an asparagine side-chain.[CHEBI:59520] 

term_xref : GTC:G78059CC|CID:70679232|CHEBI:70967 

synonyms :  

function : N-glycans modulate the function of several cell surface proteins which involved in migration, adhesion and which are responsible for regulating myelination.[PMID: 25151374]|Affect transportation of the glycosylated proteins in the Golgi.[PMID: 25151374]|Affects cell-cell interaction, adhesion, expression, proper folding.[PMID: 25151374]|extracellular N-glycans act as key modulators of neuronal uptake of αacetyl [PMID: 31211781]. 

disease_associations : Rheumatoid arthritis[PMID:17392038]|Type 1 Diabetes[PMID:29146600]|Lung Cancer[PMID: 23766031] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000132

term (main_entry) : Nonfucosylated 

glycan_dictionary_accession : GSD000132 

glytoucan_accession  :  

term_in_sentence : In the carbohydrate moiety , alpha-subunit from normal pregnancy hCG contained nonfucosylated , mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).[PMID: 9449027] 

publication :  9449027|30258536|23554380|16675584|26747427|22457527|24362443|19657637|8811881|19218011|20022111|17363544|17368483|20564614|27054024|28397880|31490688|31860772|17012310|29633346|9442021|30350565|30296068|31800250|30021910|31133022|29224385|28630087|26444434|31697975|30991260 

definition : glycans without a fucose component/monosaccharide residue. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000133

term (main_entry) : Nonfucosylated biantennary 

glycan_dictionary_accession : GSD000133 

glytoucan_accession  :  

term_in_sentence : Structural analysis combining methylation-mass spectrometry and 400 MHz 1H-n.m.r. spectrometry of oligosaccharide alditols released from human leucocyte lactotransferrin shows the presence of two disialylated and non-fucosylated biantennary glycans of the N-acetyl-lactosaminic type.[PMID:2390069] 

publication :  2390069| 9449027|1375510|9101715|2390069|2332109 

definition : A biantennary glycan with two GlcNAc branches linked to the core and no fucose appears. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

GSD000134

term (main_entry) : Nonfucosylated biantennary N-Linked structures 

glycan_dictionary_accession : GSD000134 

glytoucan_accession  :  

term_in_sentence : The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).[PMID:9449027] 

publication : 9449027 

definition : A biantennary N-linked glycan with two GlcNAc branches linked to the core and no fucose appears. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000135

term (main_entry) : Nonfucosylated triantennary 

glycan_dictionary_accession : GSD000135 

glytoucan_accession  :  

term_in_sentence : Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans.[PMID:7679920] 

publication : 7679920|23274891 

definition : A triantennary N-linked glycan with three GlcNAc branches linked to the core and no fucose appears. 

term_xref :  

synonyms :  

function : Appears in human alpha-fetoprotein (AFP).[PMID:7679920] 

disease_associations : hepatocellular carcinoma[PMID:7679920]. 

wikipedia :  

essentials_of_glycobiology :

GSD000136

term (main_entry) : Nonsialylated 

glycan_dictionary_accession : GSD000136 

glytoucan_accession  :  

term_in_sentence : The pattern of nonsialylated oligosaccharides was used for interpretation of the fully sialylated species using bioinformatics tools. From pooled human plasma, we find 90, 101, and 64 different glycan compositions for genetic variants ORM1*F1, ORM1*S, and ORM2, respectively. Glycan structures carry dominantly between 15 and 16 sialic acids indicating an almost complete termination of all antenae with sialic acid.[PMID:30295034] 

publication : 14533820|1377689|9705949|30788437|28090561|12498371|26839900|31490688|2656426|30295034|31545048|12381155|25730103|26787879|25646460| 29224385|26063435|26954852|32889432|2825412|27504786|22431161 

definition : A glycan which is not sialylated. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000137

term (main_entry) : O-fucose glycans 

glycan_dictionary_accession : GSD000137 

glytoucan_accession  : G39294YF 

term_in_sentence : Recently, a number of laboratories have shown that O-fucose glycans on the epidermal growth factor (EGF)-like repeats of the Notch extracellular domain modulate Notch signaling.[PMID:12417415] 

publication : 19594638|30690220|18952191|22415200|12417415|16400812|18948267|21464368|20816394|30207383|20301232|27129198|17132502|22492969|30030822|30214079|26175457|25378397|18272537|28729422|11524432|31722217|23045360|24803430|28876865|25700513|32518939|30523691|18227520|20816217|24909690|17964136|12036964|27268051|15653671|19948734|31590629|32201074|15189151|17263732|32913123|12909620|28785176|17132500|22949680|25053492|28939751 

definition : Form of glycosylation where the protein is modified by a fucose residue and can be extended futher to form a tetrasaccharide in certain cases. alpha-linked o-fucose have a consensus motif of C2X4(s/T)C3 where C2 and C3 are conserved cysteines number 2 and 3 respectively of the EGFR like repeats. [Essentials of Glycobiology:Chapter13]

term_xref : GTC:G39294YF|GlycoEpitope:EP0005  

synonyms :  

function : modification of Notch signaling.[GlycoEpitope:EP0005] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000138

term (main_entry) : O-GlcNAc 

glycan_dictionary_accession : GSD000138 

glytoucan_accession  : G49108TO 

term_in_sentence : A better understanding of the mechanisms of OGT/OGA action would enable us to derive therapeutic benefits of resetting cellular O-GlcNAc levels within an optimal range.[PMID:30464755] 

publication : 30464755|29049853|29594839|31654859|29404877|30105004|30669087|29790000|28408483|26862193|30523150|30037904|28408480|29352075|29456783|29577901|29223644|28638491|30221662|29904918|32155042|30298013|31630803|31847126|29784830|30181664|28768194|30134155|25336654|30356792|30199580|32329777|28408494|29774032|29044951|23836420|20301273|29772801|28922739|30100348|30793403|30657688|31237748|29756380|29954943|30018219|32207184|25566193|30626734|24759912| 

definition : Form of glycosylation which exclusively occurs in the mitochondrial, cytoplasmic or nuclear compartments of the cell where the protein is modified by a GlcNAc monosaccharide on the serine or threonine residues and is generally not modified or elongated further to form more complex structures. [Essentials of Glycobiology:Chapter19] 

term_xref : GTC:G49108TO|GlycoEpitope:EP0004|CID:24139|HMDB:HMDB0000803 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000139

term (main_entry) : O-linked glycans 

glycan_dictionary_accession : GSD000139 

glytoucan_accession  :  

term_in_sentence : Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.[PMID:29865036] 

publication : 29865036|30952424|31611643|19577919|32019882|19139197|26184710|11159917|21536259|25186198|19277556|22261557|24115046|18725413| 15966855|24256304|25477510|10359703|24406064|22259135|29279989| 15966855|30619255|9673446| 31676555|28745859|28196325|27975143|30591584| 28518173|17522109| 26328495|32178593|27529638|24663386|22474328|28096352|27496768| 18952191|11135308|24917611|11532966|22786570| 11891229|18332077|26867212|26925665|16769205|23475718|16005634|28785176 

definition : The carbohydrate portion of a glycoprotein that has a glycan linked through the hydroxyl oxygen of serine, threonine, hydroxylysine or hydroxyproline side-chains.[CHEBI:59521] 

term_xref : CHEBI:59521 

synonyms :  

function : Affects several important activities like protein stability, modulation of signaling molecules and enzyme activity.[PMID:9673446] 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

GSD000140

term (main_entry) : O-linked mannose 

glycan_dictionary_accession : GSD000140 

glytoucan_accession  : G59126YU 

term_in_sentence : Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2) catalyzes the first step toward the functional matriglycan structure on alpha-dystroglycan that is responsible for binding extracellular matrix proteins and certain arenaviruses.[PMID: 27932460] 

publication : 27932460|24526361|25381909|26644575|23851827|28810660|19054127|23929950|21684258|22608994|28973932|24733390|31851597|29884773|28711406|14577328|21089343|14617637|9838223|17072003| 26328495|11181560|31949166|31988979|20362685|27733679|27493216|20044576|30643095|29732660|10580142|14568618|28079948|15467391|27812179|23761899|25737452|32930586|25381372|23434682|16857188|21452199|19429925|25361541|24297939|30322079|23428289| 28427937|22746206|27533452|17502374|20816174|27496765 

definition : O-linked glycans that are initiated by the addtion of a Man residue to Ser or Thr. Subsequent extension of the Man defines the O-Man core type, either M1, M2, or M3. The M1 type is initated by addition of a GlcNAc in β-linkage to the 2 position of the Man residue. M2 is initiated by addition of another GlcNAc to the 6 position of the M1 core. M3 is initiated by the addition of a GlcNAc in β-linkage to the 4 position of the Man residue. M1 and M2 type core glycans can be extended and branched with Gal, Fuc, Sialic Acid, and GlcA. The M3 core is uniquely extended by a multienzyme system to generate the matriglycan polysaccharide, a protein-specific modification found only on alpha-dystroglycan. [CHEBI:87761] 

term_xref : GlycoMotif:GGM.000055|GTC:G59126YU|CHEBI:87761|GlycoEpitope:EP0002|CID: 91859038 

synonyms : O-mannosyl glycan 

function :  

disease_associations : MEB/muscle-eye-brain disease[GlycoEpitope:EP0002]|WWS/walker-warburg syndrome |muscular dystrophy[GlycoEpitope:EP0002]|neuronal migration disorder[GlycoEpitope:EP0002]|Muscle-Eye-Brain disease (MEB) and Walker-Warburg Syndrome (WWS) have mutations in genes encoding glycosyltransferases needed for O -mannosyl oligosaccharide synthesis[GlycoEpitope:EP0002]|Muscular dystrophy and neuronal migration disorder are caused by mutations in a glycosyltransferase, POMGnT1.[GlycoEpitope:EP0002] 

wikipedia :  

essentials_of_glycobiology :

GSD000141

term (main_entry) : P1 antigen 

glycan_dictionary_accession : GSD000141 

glytoucan_accession  : G12460DL 

term_in_sentence : The P1 antigen was disovered in 1927 by Landsteiner and Levine, and Pk and NOR were described in 1951 and 1982, respectively.[PMID: 24046920] 

publication : 29622537|26773500|24046920|6207232|8550516|6609976|6375319|817855|2428855|3312011|15364312|1937801|7729906 

definition : An amino pentasaccharide consisting of α-D-galactose, β-D-galactose N-acetyl-α-D-glucosamine, β-D-galactose, and β-D-glucose residues joined in sequence with ((1→4)-, (1→4)-, (1→3)- and (1→4)-linkages, respectively.[CHEBI:68484] 

term_xref : GlycoMotif:GGM.000069|GTC:G12460DL|CID:71296137|CHEBI:68484|SugarBind_Ligand:160  

synonyms :  

function :  

disease_associations : Shigellosis[SugarBind_Ligand:160] 

wikipedia :  

essentials_of_glycobiology : Chapter 23

GSD000142

term (main_entry) : Para-Forssman glycolipid 

glycan_dictionary_accession : GSD000142 

glytoucan_accession  : G51699SI 

term_in_sentence : A novel pentaglycosyl ceramide containing di-beta-N-acetylgalactos-aminyl residue (Para-Forssman glycolipid) isolated from human erythrocyte membrane. [PMID:6814203] 

publication : 6814203 

definition : GalNAcβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1Cer [https://doi.org/10.1016/S0040-4039(01)93814-6] 

term_xref : GlycoMotif:GGM.000085|GTC:G51699SI|CID:56836111|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565 

synonyms :  

function :  

disease_associations : Actinomycosis[SugarBind_Ligand:19] 

wikipedia : https://en.wikipedia.org/wiki/P1PK_blood_group_system 

essentials_of_glycobiology :

GSD000143

term (main_entry) : Paragloboside 

glycan_dictionary_accession : GSD000143 

glytoucan_accession  : G58896AZ 

term_in_sentence : Galactosyltransferase activities in sera of cancer patients were determined by assaying the formation of paragloboside from UDP-galactose and lactotriaosylceramide immobilized on microtiter plates by means of the enzyme-linked immunosorbent assay using a monoclonal antibody, H-11, directed to paragloboside. [PMID:  1551117] 

publication : 3345524|850070|10569746|30624951|29438961|6816790| 1551117|6865961|25039255 

definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is α.[CHEBI:65257] 

term_xref : GlycoMotif:GGM.000077|GTC:G58896AZ|CID: 21670519|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15 

synonyms :  

function :  

disease_associations : Pharyngitis[SugarBind_Ligand:15]|Tracheobronchitis[SugarBind_Ligand:15]|Gonorrhea[SugarBind_Ligand:15]|Actinomycosis[SugarBind_Ligand:15]|Diarrhea[SugarBind_Ligand:15]|Hemorrhagic colitis[SugarBind_Ligand:15]|Chronic gastritis[SugarBind_Ligand:15]|Peptic ulcers[SugarBind_Ligand:15]|Gastric cancer[SugarBind_Ligand:15]|Influenza[SugarBind_Ligand:15] 

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000144

term (main_entry) : Paucimannose 

glycan_dictionary_accession : GSD000144 

glytoucan_accession  :  

term_in_sentence : The galactosylation of core fucose (GalFuc epitope) in paucimannose and complex-type N-glycans is characteristic of protostome organisms, including flatworms (planarians).[PMID:29475940] 

publication : 29475940| 29803109|12603202|31817246|31719144|21057214|31932305|17132514|30382146|27731363|31325506|25746926|26513758|16522637|21169367|25190359|27928741|22496646|27384337|16897177|15228383|27379103|27189951|23475714|24907509|20558211|28060516|20441997|27720757|28817611|24550396|19494052|19515361| 28630087|31320997|30651366|30253927|25922361|31655162|18056652|24467287|32367383 

definition : Any N-linked glycan derivative with composition Man1-4Fuc0-1 GlcNAc2, in which the chitobiose core (GlcNAc2) is intact. Found in relatively large amounts in invertebrates and plants, they are formed by removal of the non-reducing terminal GlcNAc (\added by GlcNAcT1) from GlcNAcMan3-5GlcNAc2 by a Golgi hexosaminidase and subsequent removal of Man residues by Golgi mannosidases. Pauscimannose glycans have also been detected in vertebrates.[CHEBI:144386] 

term_xref : CHEBI:144386 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000145

term (main_entry) : Sd(A)/Cad 

glycan_dictionary_accession : GSD000145 

glytoucan_accession  : G41052GC 

term_in_sentence : The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2.[PMID:24112972] 

publication : 24112972|11577689|30067891|15361072 

definition : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, β-D-galactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the galactose residue of which is also linked (1→4) an N-acetyl-β-L-galactosamine residue.
[CHEBI:71561] 

term_xref : GlycoMotif:GGM.000051|GTC:G41052GC|CID:70698375|CHEBI:71561  

synonyms : Sd^a /Cad 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 9

GSD000146

term (main_entry) : SDlex 

glycan_dictionary_accession : GSD000146 

glytoucan_accession  : G19619KS 

term_in_sentence : Hepatic expression of sialylated difucosyl Lex antigen (SDLex, NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-) was studied with monoclonal antibody FH6, which defines this structure.[PMID: 3341453] 

publication : 30226570|3341453|12725333 

definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:148203] 

term_xref : GlycoMotif:GGM.000032|GTC:G19619KS|CID:91856705|CHEBI:148203  

synonyms : Sdlex|SDLe^x|SDLex 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000147

term (main_entry) : Seminolipid 

glycan_dictionary_accession : GSD000147 

glytoucan_accession  : G72548RZ 

term_in_sentence : A concise total synthesis of seminolipid, a sulfoglycolipid, has been achieved; key features include regioselective, tin-free sulfation of allyl β-d-galactopyranoside using 2,6-bis(trifluoromethyl)phenylboronic acid as protective reagent, stereoselective epoxidation, and site-selective acylation. [PMID: 31353379] 

publication : 31353379|31736776|12810822|19582571|19542524|20670037|15659616|20817833|870059|10801776|21965315|8095813|1280685|4690236|34199863|4207869|2373957|845131

definition :  

term_xref : GlycoMotif:GGM.000062|GTC:G72548RZ  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 14

GSD000148

term (main_entry) : Sialopentaosylceramide 

glycan_dictionary_accession : GSD000148 

glytoucan_accession  : G13224CR 

term_in_sentence : Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosap[PMID: 2139874] 

publication : 2139874 

definition : A ganglioside in which the oligosaccharide portion is composed of a pentasaccharide containing one or more sialic acid residues.[CHEBI:36542] 

term_xref : GlycoMotif:GGM.000097|GTC:G13224CR|CID:91859576|CHEBI:148045|KEGG:G00883|CHEBI:36542 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000149

term (main_entry) : Sialosyl paragloboside 

glycan_dictionary_accession : GSD000149 

glytoucan_accession  : G50123ZO 

term_in_sentence : Unlike CNS myelin, human peripheral nerve myelin has the acidic glycosphingolipids sialosyl paragloboside (SPG), sialosyl lactosaminyl paragloboside (SLPG), and sulfated glucuronyl paragloboside (SGPG).[PMID:8862128] 

publication : 8862128|7236652|2370108|3133978|2905604|1749114|1573418 

definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-D-GlcpNAc with β configuration at the anomeric position of the reducing-end N-acetyl-D-glucosamine residue.[CHEBI:71612] 

term_xref : GlycoMotif:GGM.000081|GTC:G50123ZO|CID:91845504|KEGG:G01429|CHEBI:151914  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000150

term (main_entry) : Sialyl Lewis a 

glycan_dictionary_accession : GSD000150 

glytoucan_accession  : G00053MO 

term_in_sentence : By comparing the serum O-glycan profiles from healthy controls with those of cancer patients, we identified a marker candidate, core 1 sialyl Lewis A (NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal) (abbreviated C1SLA), whose concentration appeared to be weakly correlated with CA19-9 values.[PMID: 26641888] 

publication : 26641888|31424423|26530370|17760270|18343410|16033091|8829184|11907351|20592391|26641888|24128856|30249386|10773785|16149606|10996727|10436809|10667238|7720892|7630017|10612415|9836451|12511721|22623153 

definition : A sialyated version of Lewis A with a branched structure of amino tetrasaccharide consisting of a sialyl residue, linked (2→3) to a galactosyl residue that in turn is linked (1→3) to a glucosaminyl residue at the reducing end, which is also carrying a fucosyl residue at the 4-position.[CHEBI:62681] 

term_xref : GTC:G00053MO|GlycoEpitope:EP0008|CID:53356732|CHEBI:62681|GlycoMotif:GGM.000024 

synonyms : SLea|CA19-9|CA19-9 antigen|SLe^a|Slea 

function : The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0008] 

disease_associations : pancreatic adenocarcinoma[GlycoEpitope:EP0008]|hepatocellular cancer[GlycoEpitope:EP0008]|cholangiocellular cancer[GlycoEpitope:EP0008]|gastric cancer|[GlycoEpitope:EP0008]colorectal cancer[GlycoEpitope:EP0008]|ovarian cancer[GlycoEpitope:EP0008]|lung cancer[GlycoEpitope:EP0008]|breast cancer[GlycoEpitope:EP0008]|uterine cancer[GlycoEpitope:EP0008] 

wikipedia :  

essentials_of_glycobiology :

GSD000151

term (main_entry) : Sialyl Lewis x 

glycan_dictionary_accession : GSD000151 

glytoucan_accession  : G00054MO 

term_in_sentence : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:12828079] 

publication : 12828079|8940172|10075923|19054801|9642161|31054033|15229399|29061785|16033070|10728707|9556613| 8940172|9298692|18607721|22593503|25944902| 9642161|15780091|20401888 

definition : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH: 2030970],CHEI:71622 

term_xref : GTC:G00054MO |GlycoEpitope:EP0012|CID: 44456859|CHEBI:71622|MESH: 2030970|GlycoMotif:GGM.000022  

synonyms : SLe(x)|SLe^x|SLex|Slex 

function : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012] 

disease_associations : colon cancer[GlycoEpitope:EP0012]|colorectal cancer[GlycoEpitope:EP0012] 

wikipedia :  

essentials_of_glycobiology :

GSD000152

term (main_entry) : Sialyl Lewis x-i 

glycan_dictionary_accession : GSD000152 

glytoucan_accession  : G06597DS 

term_in_sentence : Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001).[PMID:9815711] 

publication : 9815711|9730796|11867833|9713476|2819663|9372327|9615762|1352835|2575680|9330526|8753037|2210805|12680155|11974864|10453898|2565704|17144590 

definition :  

term_xref : GTC:G06597DS|GlycoEpitope:EP0043|CID: 91855346|CHEBI:147019 

synonyms :  

function : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043] 

disease_associations : lung cancer[GlycoEpitope:EP0043]|ovarian cancer[GlycoEpitope:EP0043]|pancreatic adenocarcinoma[GlycoEpitope:EP0043] 

wikipedia :  

essentials_of_glycobiology :

GSD000153

term (main_entry) : Sialyl T antigen 

glycan_dictionary_accession : GSD000153 

glytoucan_accession  : G65562ZE 

term_in_sentence : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:32583304] 

publication : 32583304|31897478|31719620|10365852|25727149|11523928|20407596|25464017|30864133|26391208|19811634|29796594|23725156|8905873|11192238|18275089|27037304|11949946|15604091|24118321 

definition : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257] 

term_xref : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:44611726|CHEBI:65257

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000154

term (main_entry) : Sialylated biantennary 

glycan_dictionary_accession : GSD000154 

glytoucan_accession  :  

term_in_sentence : Simbucus nigra agglutinin or an antibody specific to sialylated lactosamine with a preference for Neu5Acalpha2-6Gal rather than Neu5Acalpha2-3Gal reduced sperm binding to oviduct isthmic cells, as did occupying putative receptors on sperm with sialylated biantennary glycans.[PMID:23115267] 

publication : 23115267|31510952|29265394|31589880|3979568|26045275|29029079|30252064 

definition : A binantennary glycan with one or two sialic acid residues as non-reducing terminal residues on one or both antennae. [RN] 

term_xref :  

synonyms : sialyl biantennary 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000155

term (main_entry) : Sialylated complex-type 

glycan_dictionary_accession : GSD000155 

glytoucan_accession  :  

term_in_sentence : By using 1H-NMR spectroscopy we were able to establish that our product contains a single N-linked biantennary , fully sialylated complex-type oligosaccharide , typical of human hepatomas.[PMID:1694115] 

publication : 1694115|15201278|30471292|30969765|11058758|28342150 

definition : Complex N-linked glycan that have added GlcNAc residues at both the α-3 and α-6 mannose sites and do not contain mannose residues apart from the core structure but with sialic acid residues. 

term_xref :  

synonyms : sialo-complex type 

function : enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes [PMID: 15201278] Appears in IgG-Fc.[PMID:20647032 ] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 10

GSD000156

term (main_entry) : Sialylated tetraantennary 

glycan_dictionary_accession : GSD000156 

glytoucan_accession  :  

term_in_sentence : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:16321355] 

publication : 16321355| 1940447| 27501865 

definition : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000157

term (main_entry) : Sialyl-Tn antigen 

glycan_dictionary_accession : GSD000157 

glytoucan_accession  : G36123IU 

term_in_sentence : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:23035012] 

publication : 23035012|29273237|15770530|31595388|26617889|1720922|15466199|10971172|14652017|8616877|1543361|16965854|21566901|9269833|9834267|24970145| 22367369| 10778170|30018351|28628803| 16149605|32134186|28632300|11308020| 10365852|17195456|23567325|11014575|2342728|8575847|1851822|11735169|20960853|7846011 

definition : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818] 

term_xref : GTC:G36123IU|GlycoEpitope:EP0022|CID: 51351800|CHEBI:61818  

synonyms :  

function : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022] 

disease_associations : anaplastic meningioma[GlycoEpitope:EP0022]|Barrett's esophagus[GlycoEpitope:EP0022]|bladder cancer[GlycoEpitope:EP0022]|breast cancer[GlycoEpitope:EP0022]|colon cancer[GlycoEpitope:EP0022]|colorectal cancer[GlycoEpitope:EP0022]|erythroblastic leukemia[GlycoEpitope:EP0022]|esophageal cancer[GlycoEpitope:EP0022]|gastric cancer[GlycoEpitope:EP0022]|helicobacter pylori chronic gastritis(HpCG)[GlycoEpitope:EP0022]|liver cancer[GlycoEpitope:EP0022]|iterome cancer[GlycoEpitope:EP0022]|ovary tumor[GlycoEpitope:EP0022]|pancreas cancer[GlycoEpitope:EP0022] 

wikipedia :  

essentials_of_glycobiology : Chapter 56

GSD000158

term (main_entry) : SLex Core 2 O-glycan 

glycan_dictionary_accession : GSD000158 

glytoucan_accession  : G97345NY 

term_in_sentence : In particular, the sLeX-modified core 2 O-glycan structure C2-O-sLeX has been directly demonstrated to confer significantly higher affinity selectin binding than sLeX.[PMID:15596301] 

publication : 15596301 

definition :  

term_xref : GlycoMotif:GGM.000053|GTC:G97345NY  

synonyms : SLe^x Core 2 O-glycan 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000159

term (main_entry) : SSEA-1 

glycan_dictionary_accession : GSD000159 

glytoucan_accession  : G85497PI 

term_in_sentence : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:27550342] 

publication : 27550342|25564944|30987116|10778174|19427293|24923741|28092949|16499901|10470652|18787210|2885312|16149609|17003364|27363517|15505339|27990704|2568298|20491542|23572256|1977666|9553168| 20458727|2566639|14577357|20960856|15547746|9096265|30639212|1357195|1359630|20181261|20508065|2907526|22624699|22988836|17183690|27188587|7908065|10400391|6137429|1979260|2898921|14736812|30919971 

definition :  

term_xref : GTC:G85497PI |GlycoEpitope:EP0042|CID:91851144|CHEBI:154343  

synonyms :  

function : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 10

GSD000160

term (main_entry) : SSEA-3 

glycan_dictionary_accession : GSD000160 

glytoucan_accession  : G25129BT 

term_in_sentence : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:31817926] 

publication : 31817926|30271856|32684574|26677875|23175153|32525407|29227830|18773292|25561682|10837462| 2412924|21149348|17008424| 2874662|25171543|31304790|31642560|30484221|30525067|21161592|27325407|28170296|29637816|27318475|31346146|7648586|24236059|21964054|27456773|30558911|21559451|29312455|27549315|30599359|6141938|28883415|30733757|26041528|16643871 

definition : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071] 

term_xref : GTC:G25129BT|GlycoEpitope:EP0039|CID: 91855781|CHEBI:149071|GlycoMotif:GGM.000079  

synonyms :  

function :  

disease_associations : embryonal carcinoma[GlycoEpitope:EP0039]|teratocarcinoma[GlycoEpitope:EP0039]|yolk sac carcinoma[GlycoEpitope:EP0039] 

wikipedia :  

essentials_of_glycobiology :

GSD000161

term (main_entry) : SSEA-4 

glycan_dictionary_accession : GSD000161 

glytoucan_accession  : G84263XI 

term_in_sentence : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:31817926] 

publication : 27845370|31817926|26295543|25171543|25978997|30296654|25853231|24862940|31243630|28736232|22895512|24578244|29478902|23574147|23768762|27797400| 29227830|18773292|25123923|22924692|22665977|23330736|31831622|31916611| 2412924|16033656|24866102| 20458727| 21149348|26940129| 17008424|2874662|23301556|27836003|19118716|24550271|32988880|22743677|20683402|17062733|23570331|30310530|31545316|23509763|24364909|18273440|28985528|22266579 

definition :  

term_xref : GTC:G84263XI|GlycoEpitope:EP0044|CID:91845478|CHEBI:154843  

synonyms :  

function :  

disease_associations : teratocarcinoma[GlycoEpitope:EP0044] 

wikipedia :  

essentials_of_glycobiology : Chapter 47

GSD000162

term (main_entry) : Sulfatide 

glycan_dictionary_accession : GSD000162 

glytoucan_accession  : G72548RZ 

term_in_sentence : In a previous study we found that sulfatide was efficient in lowering HIV-1 viral loads in SCID mice engrafted with human fetal liver/thymus tissues (SCID-hu).[PMID:23550344] 

publication : 23550344|18465098|26542149|15158666|10434709|22619219|29676479|30196830|16143863|1052451|30400820|29887538|26981544|17986152|31739035|19941861|24578319|30531843|25645724|31197846|22821828|27861899|31037952|23593400|23604989|17855742|25966258|25989600|9657940|29497057|12838515|25170267|9878314|20554435|1410493|26585924|17257892|17044925|21089387|11445552|22977233|21437360|17179664|6273571|8370675 

definition :  

term_xref : GlycoMotif:GGM.000063|GTC:G72548RZ  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 47

GSD000163

term (main_entry) : T antigen 

glycan_dictionary_accession : GSD000163 

glytoucan_accession  : G00031MO 

term_in_sentence : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] 

publication : 723127|19505650|31527246|28113048|25868857|26731525|22994493|3849428|25589241|12709866|26615524|26136575|19671663|18551603|11160729|22261839|30758913|25681708|29113555|24998850|1654819|28039910|29206210|32404521|10555041|26517398|2446015|2998768|3026642|18812503|6092664|2153691|8709258|3009889|15109748| 12709866|31787742|27433780|26017382|24048785|26735515|9224657|26061652|29343574| 25681708|23805194|26751495|22023388|15381338|8249277|3023660|25866902 

definition : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] 

term_xref : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009 

synonyms : TF antigen 

function : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] 

disease_associations : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020] 

wikipedia :  

essentials_of_glycobiology : Chapter 47

GSD000164

term (main_entry) : Tetraantennary
glycan_dictionary_accession : GSD000164
glytoucan_accession :
term_in_sentence : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:24308486]
publication : 24308486|17951374|28880909|9177699|9760189|12322961|20129637|2492275|3402460|2361735|6525453|27730440|2551687|25365149|9751793|29875690|29479898|9134426|30943309|3546284|29888905|30624066|30537828|31110965|29311294|12852965|3015940|1907570|29137999|29359131|29858715|30295034|31829566|8381405|26929217|20662591|30612270|3089784|28186213|3427034|26763099|27354006|24991291|7496138|1940447|11114588|29031301|9448855|3979385|27722599|31126011|28002670|28991403|24032650|15316281|25154914|22490318|22430811|1463783|18803208|7881173|7697655|7240157|1768292
definition : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary]
term_xref :
synonyms :
function :
disease_associations :
wikipedia : https://www.wikidata.org/wiki/Q 27104888
essentials_of_glycobiology :

GSD000165

term (main_entry) : Tetraantennary complex-type 

glycan_dictionary_accession : GSD000165 

glytoucan_accession  :  

term_in_sentence : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID:1899031] 

publication : 1899031|8251489|8274017| 1899031| 6317691|23668542| 6088518|21495009|1457971|1783599|10988252|11425798|7522229|2574992|3730425|10200178|2939068|21584695| 7524670|7682847|2930192|1726466|9881746|11068879|6704968|2302846| 24032650| 15316281|11051207|10220588|2813359|2174368|21755550|3571208|1929437|3681300|6581225|3364983|2902877|2297756|1315684|6830758|1998670 

definition : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:Glossary]  

term_xref : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 10

GSD000166

term (main_entry) : Tetrasialylated diantennary 

glycan_dictionary_accession : GSD000166 

glytoucan_accession  :  

term_in_sentence : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:1997323] 

publication :  1997323 

definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000167

term (main_entry) : Tn antigen 

glycan_dictionary_accession : GSD000167 

glytoucan_accession  : G57321FI 

term_in_sentence : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] 

publication : 27679419|31938254|30637914|24643043|31225574|21259410|31742337|28514044|33014816|28708980|27432485|33050853|26045765|27542280|24411673|27760846|30115016|1410473|29802864|29669308|29251002|32541028|31019509|1582597|2981150|10842187|29638123| 22367369|10778170|1510031|19372570|20641477| 16149605|15770530|27856425|23814067|28068458| 32134186|8174100|10571017|27453399|1727666|23740330 

definition : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212] 

term_xref : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008  

synonyms :  

function : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] 

disease_associations : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021]. 

wikipedia :  

essentials_of_glycobiology :

GSD000168

term (main_entry) : Triantennary 

glycan_dictionary_accession : GSD000168 

glytoucan_accession  :  

term_in_sentence : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] 

publication : 24992960|27025342|29642865|29456020|26914862|26926155|26299345|28981809|18395704|2211710|23461434|18327885|15264862|22954207|9061362|16581187|26537865|3979568|28129130|7679920|8068017|7783116|3857231|20540518|1706936|2430615|8078981|2211711|6767476|3814128|2597120|7451505|8204583|20619452|10460831|1924399|6643471|31809011|30042045|2477056|7882496|2430614| 2551687|2426141|2065052|28988716|31144994|26966183|29809215 

definition : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary] 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000169

term (main_entry) : Triantennary complex 

glycan_dictionary_accession : GSD000169 

glytoucan_accession  :  

term_in_sentence : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998] 

publication : 9118998|9061362|18395704|3814128|7451505|10460831|26926155|26966183|16581187|16973123|8204583|29809215|11114588|31322324|15044389|16372382| 8251489|8299583|1555586|7509658|1569060|16261636 

definition : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252]  Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  

term_xref : CHEBI:156252 

synonyms : Triantennary complex-type 

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology : Chapter 10

GSD000170

term (main_entry) : Triantennary N-glycans 

glycan_dictionary_accession : GSD000170 

glytoucan_accession  :  

term_in_sentence : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163] 

publication : 29399163|22325877|18439991|24873509|11454001 

definition : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:Glossary]  

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000171

term (main_entry) : Triantennary sialylated 

glycan_dictionary_accession : GSD000171 

glytoucan_accession  :  

term_in_sentence : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:18642129] 

publication : 18642129|31964828|3979568|27936604|23681398|21538882|7579793|7613477|2223825|3539023|3674882 

definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. 

term_xref :  

synonyms :  

function : Appears in human serotransferrin.[PMID: 3979568] 

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000172

term (main_entry) : Triantennary trisialylated fucosylated 

glycan_dictionary_accession : GSD000172 

glytoucan_accession  :  

term_in_sentence : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:17591618] 

publication : 17591618 

definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000173

term (main_entry) : Trifucosyl Lewis b antigen 

glycan_dictionary_accession : GSD000173 

glytoucan_accession  : G74578MX 

term_in_sentence : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:1735443] 

publication : 1735443 

definition : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] 

term_xref : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783 

synonyms : trifucosyl-Leb antigen 

function : cancer-associated antigen[GlycoEpitope: EP0092] 

disease_associations : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092] 

wikipedia :  

essentials_of_glycobiology :

GSD000174

term (main_entry) : Trifucosyl lewis y 

glycan_dictionary_accession : GSD000174 

glytoucan_accession  : G74917JX 

term_in_sentence : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:3733752] 

publication : 3733752|2426269 

definition : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] 

term_xref : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332  

synonyms : trifucosyl Ley 

function :  

disease_associations : colonic adenocarcinomia[GlycoEpitope: EP0094] 

wikipedia :  

essentials_of_glycobiology :

GSD000175

term (main_entry) : Trimannosyl core 

glycan_dictionary_accession : GSD000175 

glytoucan_accession  :  

term_in_sentence : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:18320567] 

publication : 18320567|27629418|26514868|26821880|2477227|6213618|31747570|29273674|31064325|1291063|28353332|1421754|29666272|11421342|15648688|28179475|28903882|27189951|9455915|22768188|9254048|8721739|2249985|22933239|25629585|24489949|2981047|11067815|1729985|1710649|16672288|2719668|19003000|23025485|22500028|10409642|1325461|23136055|23085445|21656680|22448293|22132163|1425696|20696712|18056652|15084511|18633282|15814299 

definition : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000176

term (main_entry) : Trisialylated 

glycan_dictionary_accession : GSD000176 

glytoucan_accession  :  

term_in_sentence : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:8477709] 

publication : 6469957|18818422|18332077|21138277|9136890|10782293|19841910|20067809|14751029|8797382|16877748|19131698|20578731|24669823|22426998|27501865|2121479|24663386|32209427|32737218|33245334|26927318|30962676|28370937|30194503|26321095|30463578|31455764|31566965|31266306|29782424|31247951|30487799|2049094|1997323|10913832 

definition : A glycan with three sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000177

term (main_entry) : Trisialylated complex-type oligosaccharide-alditols 

glycan_dictionary_accession : GSD000177 

glytoucan_accession  :  

term_in_sentence : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:3571205] 

publication : 3571205 

definition :  

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000178

term (main_entry) : Trisialylated diantennary 

glycan_dictionary_accession : GSD000178 

glytoucan_accession  :  

term_in_sentence : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:1997323] 

publication : 1997323 

definition : A diantennary/biantennary glycans with three sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000179

term (main_entry) : Trisialylated triantennary 

glycan_dictionary_accession : GSD000179 

glytoucan_accession  :  

term_in_sentence : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] 

publication : 30194503| 27501865 |10998266|20578731|17591618|14751029|18818422|8942648|8900952 

definition : A triantennry glycan with three sialic acid components. 

term_xref :  

synonyms :  

function :  

disease_associations :  

essentials_of_glycobiology :

GSD000180

term (main_entry) : VIM-2 

glycan_dictionary_accession : GSD000180 

glytoucan_accession  : G22418PV 

term_in_sentence : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:1690317] 

publication : 27834790|31523406|29978304|29575185|27326514|29029114|32450200|29432937|31906402|28739428|29298123|30976429|29091730|27770796|31330771|31138570|27154587|31542553|30519059|30590504|25880997|27490501|29981456|28559273|28193652|26638216|25897818|26238337|19553129|29644540|26242685|28487556|32622213|30248413|24762211|11451678|33169865|11897589|31479607 

definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] 

term_xref : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033 

synonyms :  

function : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] 

disease_associations : chronic myelogenous leukemia.[GlycoEpitope:EP0019] 

wikipedia :  

essentials_of_glycobiology :

GSD000181

term (main_entry) : N-acetyllactosamine (Type 1)

glycan_dictionary_accession : GSD000181

glytoucan_accession  : G00056MO

term_in_sentence : The N-acetyllactosamine type 1 (LacNAc type 1, Galβ1,3GlcNAc) is a well-known precursor of several important blood group epitopes, such as Lewis A, Lewis B, or sialyl Lewis A [1], which are involved in many biological processes, e.g., fertilization [2] and pathogen adhesion [3]. [PMID:28796164]

publication : 28796164|28167527

definition : 

term_xref : GTC:G00056MO|GlycoMotif:GGM.000005

synonyms :  LacNAc type 1|Type 1 LN|Type-1 lactosamine

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

GSD000182

term (main_entry) : Polysialic acid

glycan_dictionary_accession : GSD000182

glytoucan_accession  : 

term_in_sentence : Polysialic acid (PSA) is a carbohydrate composed of a linear polymer of α2,8-linked sialic acids, primarily attached to the Neural Cell Adhesion Molecule (NCAM). [PMID:36076963]

publication : 36076963|35222358

definition : 

term_xref : GlycoMotif:GGM.000252 

synonyms :  polySia|PSA

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

GSD000183

term (main_entry) : Hyaluronan

glycan_dictionary_accession : GSD000183

glytoucan_accession  : G29086KO

term_in_sentence : Hyaluronan (HA) comprises a major component of the extracellular matrix (ECM) in vertebrate connective tissues and is abundant in the cartilage, skin, brain, vitreous body, umbilical cord, and synovial fluid. [PMID:33171800]

publication : 33171800|34209222

definition : 

term_xref : GTC:G29086KO

synonyms :  HA

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

GSD000184

term (main_entry) : Chondroitin sulfate/dermatan sulfate

glycan_dictionary_accession : GSD000184

glytoucan_accession  : 

term_in_sentence : Heparan sulfate (HS) and chondroitin sulfate/dermatan sulfate (CS/DS) proteoglycans are heavily glycosylated proteins, crucial for animal development and homeostasis. [PMID:35192612]

publication : 35192612|35425970

definition : 

term_xref : 

synonyms :  CS/DS|chondroitin/dermatan sulfate

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

GSD000185

term (main_entry) : Heparan sulfate/heparin

glycan_dictionary_accession : GSD000185

glytoucan_accession  : 

term_in_sentence : Heparan sulfate (HS)/heparin is a structurally complex class of glycosaminoglycans (GAGs) that have been implicated in a wide range of biological activities. [PMID:31016560]

publication : 23313092|31016560|23152789

definition : 

term_xref :  

synonyms :  HS/heparin|heparan sufate (HS)/heparin|H/HS

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

GSD000186

term (main_entry) : Core 1

glycan_dictionary_accession : GSD000186

glytoucan_accession  : G00031MO

term_in_sentence : O-glycans are initiated by the addition of GalNAc to serine or threonine (via the ppGalNAcT family of glycosyltransferases), forming the Tn antigen (GalNAcα-O-Ser/Thr), which is used to generate the core 1 structure (Galβ1,3GalNAcα-O-Ser/Thr) on which most complex and branched O-glycans are derived. [PMID:31645367]

publication : 31645367|32297877

definition : 

term_xref : GTC:G00031MO|GlycoMotif:GGM.001005 

synonyms :  C1G

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :

GSD000187

term (main_entry) : Blood group A (Type 3)

glycan_dictionary_accession : GSD000187

glytoucan_accession  : G99315PE

term_in_sentence : 

publication : 7800218|17998569|19756298|3191504

definition : 

term_xref : GlycoMotif:GGM.000011|GTC:G99315PE

synonyms :  A type 3 antigen|blood group A type 3|A antigen (type 3)

function : 

disease_associations : 

wikipedia :  

essentials_of_glycobiology :  Chapter 14

GSD000188

term (main_entry) : 6-Sulfo Sialyl Lewis x 

glycan_dictionary_accession : GSD000188

glytoucan_accession  : G80722US 

term_in_sentence : The cognate ligands for L-selectin possess the unusual sulfated tetrasaccharide epitope 6-sulfo sialyl Lewis x (Siaalpha2-->3Galbeta1-->4[Fucalpha1-->3][SO(3)-->6]GlcNAc).[PMID:11331001] 

publication : 11331001|2288521|26137907|9400621| 9556613|15972893|9015359|22691873|18652681|9722682|10435581|19359410|15228275|18250165|10536036|17944600|10460836|27993973|19149511|19150806|17172261|17142960|27956273|7578028|22260995|24519996|21596021|21982762|21775439|17334369|9710564|14593101|16227985|11895802|22750968|15157883|19067429 

definition : 

term_xref : GlycoMotif:GGM.000027|GlycoEpitope:EP0015|CID:70698321|CHEBI:71628

synonyms : 6-sulfo SLex|6-Sulfo-sialyl Lewis x|6-sulfo SLe^x 

function : lymphocyte homing[GlycoEpitope:EP0015]

disease_associations : 

wikipedia :  

essentials_of_glycobiology : Chapter 34|Chapter 35

GSD000189

term (main_entry) : Blood group B (Type 1) - Lewis b

glycan_dictionary_accession : GSD000189

glytoucan_accession  : G89208KM 

term_in_sentence :  Ten monoclonal antibodies and one lectin were used to study the localization and distribution of Blood Group ABH, type 1 chain (Lewis a, Lewis b) and type 2 chain (H-2, Y) antigens in 22 cases of normal uterine cervix, with known ABO and Lewis phenotype and secretor status. [PMID:2247887]

publication :  2247887|19756298|30831115

definition :  

term_xref : GlycoMotif:GGM.000046

synonyms :  Blood Group B, type 1 chain (Lewis b)|B-Leb|B-Le^b

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000190

term (main_entry) : Blood group A (Type 1) - Lewis b

glycan_dictionary_accession : GSD000190

glytoucan_accession  : G97501MA 

term_in_sentence :  Ten monoclonal antibodies and one lectin were used to study the localization and distribution of Blood Group ABH, type 1 chain (Lewis a, Lewis b) and type 2 chain (H-2, Y) antigens in 22 cases of normal uterine cervix, with known ABO and Lewis phenotype and secretor status.[PMID:2247887]

publication :  2247887|19756298|4041428|5686860

definition :  A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 4 of the glucosamine. Corresponds to a partial structure of blood group A type 1 oligosaccharide.[CHEBI:62988]

term_xref : GlycoMotif:GGM.000047|CID:53477630|CHEBI:62988|GlycoEpitope:EP0260

synonyms :  Blood Group A Type 1 (difucosyl)|ALe^b|A-Leb|A-Le^b|A Lewis b

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000191

term (main_entry) : Sulfated LacdiNAc

glycan_dictionary_accession : GSD000191

glytoucan_accession  : G18464VS 

term_in_sentence :  The mRNA expression of the enzymes related to the formation of sulfated LacdiNAc:β(1,4)-N-acetylgalactosaminyltransferases 3 (B4GALNT3) and 4 (B4GALNT4), carbohydrate sulfotransferases 8 (CHST8) and 9 (CHST9); and β(1,4)-galactosyltransferase 1 (B4GALT1) in these cells was confirmed by RT-PCR (Fig. S4).[PMID:31558607]

publication :  31558607|27318476|19756298|11279168|26688390

definition :  

term_xref : GlycoMotif:GGM.000049

synonyms :  4'-O-sulfated LacdiNAc|4'-sulfated LDN|sulfated LDN

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

GSD000192

term (main_entry) : Sialylated LacdiNAc

glycan_dictionary_accession : GSD000192

glytoucan_accession  : G55583HW 

term_in_sentence :  The major non-reducing epitopes in the complex-type glycans are: Gal beta 1-4GlcNAc (lacNAc), GalNAc beta 1-4GlcNAc (lacdiNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacdiNAc), Gal beta 1-4(Fuc alpha 1-3)GlcNAc (Lewisx), and GalNAc beta 1-4(Fuc alpha 1-3)GlcNAc (lacdiNAc analogue of Lewisx).[PMID:7592613]

publication :  7592613|34192302|19756298|16286643

definition :  

term_xref : GlycoMotif:GGM.000050

synonyms :  sialylated-LacdiNAc|Sialylated LDN

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :

Retired Terms (by Term Name)

A2

term (main_entry) : A2 

glycan_dictionary_accession : GSD000015 

glytoucan_accession  : G62735WZ 

term_in_sentence : Landsteiner ABO system of blood groups is most important for transfusion medicine and has subtypes of A Antigen, A1 and A2, upon which further groups of A and AB have been classified.[PMID:28658771] 

publication : 29000000|28658771 

definition :  

term_xref : GlycoMotif:GGM.000041|GTC:G62735WZ|CID:91852328 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :  

date retired : 01/27/2023 

reason for retirement : Duplicated entry. See GSD000032.

Chitin

term (main_entry) : Chitin (This term has been retired.)

glycan_dictionary_accession : GSD000042 

glytoucan_accession  :  

term_in_sentence : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241] 

publication : 25738328|31102247|26982439|31685194|29197571|29182521|25725011| 27787767|21736263|25300540|30840869|25081074|28250359| 29763421|29910219|20161969|32019265| 30879650| 12587986|29773374|31376451| 10906950|26096004|25595947| 21673932|29452181|24083454|10856926|22732132| 18657571|29175166|28842199|27592817| 27302593| 27339323| 12705640|31635752| 31063786|31151236|25940531|26093316|28962761|28093332| 30875044|27723949|28119189|30600008|25081085|21673932 

definition : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029] 

term_xref : CHEBI:17029

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :  Chapter 26

date retired : 01/27/2023 

reason for retirement : Not including linear polysaccharides to glycan structure dictionary.

Retired Terms (by Glycan Dictionary Accessions)

GSD000015

term (main_entry) : A2 

glycan_dictionary_accession : GSD000015 

glytoucan_accession  : G62735WZ 

term_in_sentence : Landsteiner ABO system of blood groups is most important for transfusion medicine and has subtypes of A Antigen, A1 and A2, upon which further groups of A and AB have been classified.[PMID:28658771] 

publication : 29000000|28658771 

definition :  

term_xref : GlycoMotif:GGM.000041|GTC:G62735WZ|CID:91852328 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :  

date retired : 01/27/2023 

reason for retirement : Duplicated entry. See GSD000032.

GSD000042

term (main_entry) : Chitin 

glycan_dictionary_accession : GSD000042 

glytoucan_accession  :  

term_in_sentence : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241] 

publication : 25738328|31102247|26982439|31685194|29197571|29182521|25725011|27787767|21736263|25300540|30840869|25081074|28250359| 29763421|29910219|20161969|32019265|30879650|12587986|29773374|31376451| 10906950| 26096004|25595947|21673932|29452181| 24083454|10856926|22732132|18657571|29175166|28842199| 27592817|27302593|27339323|12705640| 31635752| 31063786|31151236|25940531|26093316|28962761|28093332|30875044|27723949|28119189|30600008|25081085| 21673932

definition : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029] 

term_xref : CHEBI:17029 

synonyms :  

function :  

disease_associations :  

wikipedia :  

essentials_of_glycobiology :  Chapter 26

date retired : 01/27/2023 

reason for retirement : Not including linear polysaccharides to glycan structure dictionary.

Submit new terms

If you feel that a term is missing, you can submit a single term using the online form found at https://data.glygen.org/gsd/ . To submit multiple terms you can use GlyGen file upload https://data.glygen.org/uploads. Template for submitting terms can be found here. Contact https://www.glygen.org/contact-us/ for any questions.

@@ Line 1: / Line 1: @@
 {{DISPLAYTITLE:Glycan Structure Dictionary}}
-Glycan Structure Dictionary (GSD) host terms commonly used to describe glycan structural features in publications. The terms are primarily sourced via automatic and manual literature mining as well as from other bioinformatics databases. The terms are updated regularly to include the new term(s) and are listed by term name (alphabetically) and also by glycan dictionary accessions. To submit new terms go to section [[Glycan structure dictionary#Submit new terms|Glycan Structure Dictionary#Submit new terms]]. Please note that the Glycan Structure Dictionary is a work in progress. Contact https://www.glygen.org/contact-us/ to report any issues.
+Glycan Structure Dictionary (GSD) contains terms commonly used to describe glycan structural features in publications. The glycan structure terms are primarily sourced via automatic and manual literature mining as well as from other bioinformatics databases. The Glycan Structure Dictionary is a work in progress and the terms are updated regularly to include the new term(s) and annotations. On this Wiki page the Glycan Structure Dictionary terms are listed by term name (alphabetically) and also by glycan dictionary accessions. To submit new terms go to section [[Glycan structure dictionary#Submit new terms|Glycan Structure Dictionary#Submit new terms]]. Contact https://www.glygen.org/contact-us/ to report any issues.
+Please cite use of Glycan Structure Dictionary with: Vora J, Navelkar R, Vijay-Shanker K, Edwards N, Martinez K, Ding X, Wang T, Su P, Ross K, Lisacek F, Hayes C, Kahsay R, Ranzinger R, Tiemeyer M, Mazumder R. The glycan structure dictionary-a dictionary describing commonly used glycan structure terms. Glycobiology. 2023 Feb 17:cwad014. doi: 10.1093/glycob/cwad014. PMID: 36799723.
 ==Terms (by Term Name)==
 ===2,6-Branched O-mannose===
-'''term (main_entry)''' : 2,6-Branched O-mannose <br>
+[[File:G06953DR.png|thumb|G06953DR]]
-'''glycan_dictionary_accession''' : GD000001 <br>
+ '''term (main_entry)''' : 2,6-Branched O-mannose <br>
-'''glytoucan_accession ''' : G06953DR <br>
+ '''glycan_dictionary_accession''' : GSD000001 <br>
-'''term_in_sentence''' : Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6-branched structure in the brain O-mannosyl glycan.[PMID:14617637] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G06953DR G06953DR] <br>
-'''publication''' : 14617637|10469154 <br>
+ '''term_in_sentence''' : Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6-branched structure in the brain O-mannosyl glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]] <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-[[(2R,3S,4S,5S,6S)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:157265] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]|[https://pubmed.ncbi.nlm.nih.gov/10469154 10469154] <br>
-'''term_xref''' : CHEBI:157265|GlycoMotif:GGM.000056 <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-[[(2R,3S,4S,5S,6S)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:157265] <br>
-'''best_match''' : CHEBI:157265|GlycoMotif:GGM.000056|GTC:G06953DR <br>
+ '''term_xref''' : CHEBI:157265|GlycoMotif:GGM.000056|GTC:G06953DR <br>
-'''synonymns''' : 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→2)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→6)]-alpha-D-manno-hexopyranose|NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)]a-Man <br>
+ '''synonyms''' : 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→2)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→6)]-alpha-D-manno-hexopyranose|NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)]a-Man <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===2,6-sialyl-Sulfo-LN===
-'''term (main_entry)''' : 2,6-sialyl-Sulfo-LN <br>
+[[File:G41145LF.png|thumb|G41145LF]]
-'''glycan_dictionary_accession''' : GD000002 <br>
+ '''term (main_entry)''' : 2,6-sialyl-Sulfo-LN <br>
-'''glytoucan_accession ''' : G41145LF <br>
+ '''glycan_dictionary_accession''' : GSD000002 <br>
-'''term_in_sentence''' : The alpha2-6-sialylated 6-sulfo-LacNAc determinant defined by the antibody was significantly expressed on a majority of normal human peripheral B-lymphocytes as well as follicular B-lymphocytes in peripheral lymph nodes.[PMID:17728258] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G41145LF G41145LF] <br>
-'''publication''' : 17728258 <br>
+ '''term_in_sentence''' : The alpha2-6-sialylated 6-sulfo-LacNAc determinant defined by the antibody was significantly expressed on a majority of normal human peripheral B-lymphocytes as well as follicular B-lymphocytes in peripheral lymph nodes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17728258 17728258]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17728258 17728258] <br>
-'''term_xref''' : GlycoMotif:GGM.000026 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000026|GTC:G41145LF <br>
+ '''term_xref''' : GlycoMotif:GGM.000026|GTC:G41145LF  <br>
-'''synonymns''' : 6-sialyl-6-sulfo LN <br>
+ '''synonyms''' : 6-sialyl-6-sulfo LN <br>
-'''function''' : B-cell interaction with blood vessels and trafficking[PMID: 17728258] <br>
+ '''function''' : B-cell interaction with blood vessels and trafficking[PMID: [https://pubmed.ncbi.nlm.nih.gov/17728258 17728258]] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===2-Fucosyl-GD1b===
-'''term (main_entry)''' : 2-Fucosyl-GD1b <br>
+[[File:G67383AR.png|thumb|G67383AR]]
-'''glycan_dictionary_accession''' : GD000003 <br>
+ '''term (main_entry)''' : 2-Fucosyl-GD1b <br>
-'''glytoucan_accession ''' : G67383AR <br>
+ '''glycan_dictionary_accession''' : GSD000003 <br>
-'''term_in_sentence''' : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:3654655] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67383AR G67383AR] <br>
-'''publication''' : 3654655 <br>
+ '''term_in_sentence''' : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]] <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] <br>
-'''term_xref''' : CHEBI:156680|GlycoMotif:GGM.000103 <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] <br>
-'''best_match''' : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR <br>
+ '''term_xref''' : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR  <br>
-'''synonymns''' : 6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose|Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-8)NeuAc(a2-3)]Gal(b1-4)Glc <br>
+ '''synonyms''' : 6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose|Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-8)NeuAc(a2-3)]Gal(b1-4)Glc <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===2-Fucosyl-GM1===
-'''term (main_entry)''' : 2-Fucosyl-GM1 <br>
+[[File:G56526JU.png|thumb|G56526JU]]
-'''glycan_dictionary_accession''' : GD000004 <br>
+ '''term (main_entry)''' : 2-Fucosyl-GM1 <br>
-'''glytoucan_accession ''' : G56526JU <br>
+ '''glycan_dictionary_accession''' : GSD000004 <br>
-'''term_in_sentence''' : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:3654655] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56526JU G56526JU] <br>
-'''publication''' : 3654655 <br>
+ '''term_in_sentence''' : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]] <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] <br>
-'''term_xref''' : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101 <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] <br>
-'''best_match''' : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101|GTC:G56526JU <br>
+ '''term_xref''' : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101|GTC:G56526JU<br>
-'''synonymns''' : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose <br>
+ '''synonyms''' : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===3-Sialyl-LN (type 2)===
-'''term (main_entry)''' : 3-Sialyl-LN (type 2) <br>
+[[File:G10203DW.png|thumb|G10203DW]]
-'''glycan_dictionary_accession''' : GD000005 <br>
+ '''term (main_entry)''' : 3-Sialyl-LN (type 2) <br>
-'''glytoucan_accession ''' : G10203DW <br>
+ '''glycan_dictionary_accession''' : GSD000005 <br>
-'''term_in_sentence''' : Using new crystal structures, we also provide the atomic resolution basis for the differential recognition of 3′ and 6′SiaLacNAc1–4 (with the Galβ1–4 linkage known as Type 2 backbone16; Scheme 1) by TgMIC1-MARR, and make comparisons with the Type 1 chain isomer of 3′SiaLacNAc1–4 (designated 3′SiaLacNAc1–3).[PMID:19593815] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G10203DW G10203DW] <br>
-'''publication''' : 19593815|15659615|2414279|8586620|2111348|23747419 <br>
+ '''term_in_sentence''' : Using new crystal structures, we also provide the atomic resolution basis for the differential recognition of 3′ and 6′SiaLacNAc1–4 (with the Galβ1–4 linkage known as Type 2 backbone16; Scheme 1) by TgMIC1-MARR, and make comparisons with the Type 1 chain isomer of 3′SiaLacNAc1–4 (designated 3′SiaLacNAc1–3).[PMID:[https://pubmed.ncbi.nlm.nih.gov/19593815 19593815]] <br>
-'''definition''' : A linear amino trisaccharide consisting of α-neuraminyl, β-D-galactosyl and N-acetyl-D-glucosamine residues linked in a (2→3) and (1→4) sequence.[CHEBI:52472] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19593815 19593815]|[https://pubmed.ncbi.nlm.nih.gov/15659615 15659615]|[https://pubmed.ncbi.nlm.nih.gov/2414279 2414279]|[https://pubmed.ncbi.nlm.nih.gov/8586620 8586620]|[https://pubmed.ncbi.nlm.nih.gov/2111348 2111348]|[https://pubmed.ncbi.nlm.nih.gov/23747419 23747419] <br>
-'''term_xref''' : KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 <br>
+ '''definition''' : A linear amino trisaccharide consisting of α-neuraminyl, β-D-galactosyl and N-acetyl-D-glucosamine residues linked in a (2→3) and (1→4) sequence.[CHEBI:52472] <br>
-'''best_match''' : GTC:G10203DW|KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 <br>
+ '''term_xref''' : GTC:G10203DW|KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 <br>
-'''synonymns''' : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444] <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Chronic gastritis[SugarBind_Ligand:109]|Toxoplasmosis[SugarBind_Ligand:109]|Peptic ulcers[SugarBind_Ligand:109]|Gastric cancer[SugarBind_Ligand:109] <br>
+ '''disease_associations''' : Chronic gastritis[SugarBind_Ligand:109]|Toxoplasmosis[SugarBind_Ligand:109]|Peptic ulcers[SugarBind_Ligand:109]|Gastric cancer[SugarBind_Ligand:109] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===3'-Sulfo-Lewis a===
-'''term (main_entry)''' : 3'-Sulfo-Lewis a <br>
+[[File:G78706CK.png|thumb|G78706CK]]
-'''glycan_dictionary_accession''' : GD000006 <br>
+ '''term (main_entry)''' : 3'-Sulfo-Lewis a <br>
-'''glytoucan_accession ''' : G78706CK <br>
+ '''glycan_dictionary_accession''' : GSD000006 <br>
-'''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:11504739] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78706CK G78706CK] <br>
-'''publication''' : 11504739|17499486|17691854|12944557|19394320|7534477|11604107|28025252|9061363|9878545|11918697|24239607|28628803|25339106|21400496|17998215|12626387|11425799|12219077|10955596|9453593 <br>
+ '''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]] <br>
-'''definition''' : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]|[https://pubmed.ncbi.nlm.nih.gov/17499486 17499486]|[https://pubmed.ncbi.nlm.nih.gov/17691854 17691854]|[https://pubmed.ncbi.nlm.nih.gov/12944557 12944557]|[https://pubmed.ncbi.nlm.nih.gov/19394320 19394320]|[https://pubmed.ncbi.nlm.nih.gov/7534477 7534477]|[https://pubmed.ncbi.nlm.nih.gov/11604107 11604107]|[https://pubmed.ncbi.nlm.nih.gov/28025252 28025252]|[https://pubmed.ncbi.nlm.nih.gov/9061363 9061363]|[https://pubmed.ncbi.nlm.nih.gov/9878545 9878545]|[https://pubmed.ncbi.nlm.nih.gov/11918697 11918697]|[https://pubmed.ncbi.nlm.nih.gov/24239607 24239607]|[https://pubmed.ncbi.nlm.nih.gov/28628803 28628803]|[https://pubmed.ncbi.nlm.nih.gov/25339106 25339106]|[https://pubmed.ncbi.nlm.nih.gov/21400496 21400496]|[https://pubmed.ncbi.nlm.nih.gov/17998215 17998215]|[https://pubmed.ncbi.nlm.nih.gov/12626387 12626387]|[https://pubmed.ncbi.nlm.nih.gov/11425799 11425799]|[https://pubmed.ncbi.nlm.nih.gov/12219077 12219077]|[https://pubmed.ncbi.nlm.nih.gov/10955596 10955596]|[https://pubmed.ncbi.nlm.nih.gov/9453593 9453593] <br>
-'''term_xref''' : GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 <br>
+ '''definition''' : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] <br>
-'''best_match''' : GTC:G78706CK|GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 <br>
+ '''term_xref''' : GTC:G78706CK|GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 <br>
-'''synonymns''' : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a <br>
+ '''synonyms''' : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a <br>
-'''function''' : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] <br>
+ '''function''' : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===3'-Sulfo-Lewis x===
-'''term (main_entry)''' : 3'-Sulfo-Lewis x <br>
+[[File:G12295TB.png|thumb|G12295TB]]
-'''glycan_dictionary_accession''' : GD000007 <br>
+ '''term (main_entry)''' : 3'-Sulfo-Lewis x <br>
-'''glytoucan_accession ''' : G12295TB <br>
+ '''glycan_dictionary_accession''' : GSD000007 <br>
-'''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:11504739] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G12295TB G12295TB] <br>
-'''publication''' : 11504739|20695481|8688428|10536036|12770775|11352731|9784103|9022803 <br>
+ '''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]] <br>
-'''definition''' : A sulphated version of lewis X antigen which is a amino trisaccharide with structure β-D-Galp3S-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc that consists of N-acetyl-beta-D-glucosamine having an alpha-L-fucosyl residue attached at position 3 and a 3-sulfated beta-D-galactosyl residue attached at position 4; beta-D-Galp3S-(1→4)-[alpha-L-Fucp-(1→3)]-D-GlcpNAc in which the configuration at the anomeric centre of the reducing-end residue is beta. [CHEBI:65171] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]|[https://pubmed.ncbi.nlm.nih.gov/20695481 20695481]|[https://pubmed.ncbi.nlm.nih.gov/8688428 8688428]|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]|[https://pubmed.ncbi.nlm.nih.gov/12770775 12770775]|[https://pubmed.ncbi.nlm.nih.gov/11352731 11352731]|[https://pubmed.ncbi.nlm.nih.gov/9784103 9784103]|[https://pubmed.ncbi.nlm.nih.gov/9022803 9022803] <br>
-'''term_xref''' : GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029 <br>
+ '''definition''' : An amino trisaccharide that consists of ''N''-acetyl-β-<small>D</small>-glucosamine having an α-<small>L</small>-fucosyl residue attached at position 3 and a 3-sulfated β-<small>D</small>-galactosyl residue attached at position 4; β-<small>D</small>-Gal''p''3S-(1→4)-[α-<small>L</small>-Fuc''p''-(1→3)]-<small>D</small>-Glc''p''NAc in which the configuration at the anomeric centre of the reducing-end residue is β. [CHEBI:65171] <br>
-'''best_match''' : GTC:G12295TB|GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029 <br>
+ '''term_xref''' : GTC:G12295TB|GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029 <br>
-'''synonymns''' : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex <br>
+ '''synonyms''' : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===6,6'-bisSulfo-Lewis x===
-'''term (main_entry)''' : 6,6'-bisSulfo-Lewis x <br>
+[[File:G00659GQ.png|thumb|G00659GQ]]
-'''glycan_dictionary_accession''' : GD000008 <br>
+ '''term (main_entry)''' : 6,6'-bisSulfo-Lewis x <br>
-'''glytoucan_accession ''' : G00659GQ <br>
+ '''glycan_dictionary_accession''' : GSD000008 <br>
-'''term_in_sentence''' : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:9556613] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00659GQ G00659GQ] <br>
-'''publication''' : 19756298|14593101|15175329|14568956|12163379|11919403|11520459|10728707|10200296|10528213|9712885|9556613|9456330|9556613|9257857|9164959|9015359|8958810|7560094|7485559|7538131|8161542|7684905 <br>
+ '''term_in_sentence''' : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best  candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]] <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/15175329 15175329]|[https://pubmed.ncbi.nlm.nih.gov/14568956 14568956]|[https://pubmed.ncbi.nlm.nih.gov/12163379 12163379]|[https://pubmed.ncbi.nlm.nih.gov/11919403 11919403]|[https://pubmed.ncbi.nlm.nih.gov/11520459 11520459]|[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/10200296 10200296]|[https://pubmed.ncbi.nlm.nih.gov/10528213 10528213]|[https://pubmed.ncbi.nlm.nih.gov/9712885 9712885]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/9456330 9456330]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/9257857 9257857]|[https://pubmed.ncbi.nlm.nih.gov/9164959 9164959]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/8958810 8958810]|[https://pubmed.ncbi.nlm.nih.gov/7560094 7560094]|[https://pubmed.ncbi.nlm.nih.gov/7485559 7485559]|[https://pubmed.ncbi.nlm.nih.gov/7538131 7538131]|[https://pubmed.ncbi.nlm.nih.gov/8161542 8161542]|[https://pubmed.ncbi.nlm.nih.gov/7684905 7684905]<br>
-'''term_xref''' : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028 <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] <br>
-'''best_match''' : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ <br>
+ '''term_xref''' : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ <br>
-'''synonymns''' : 6,6'-DiSulfo Sialyl Lewis x|6,6-bisSulfo-Lewis x (6,60-bissulfo Lewis x )|6,6'- Disulfo Sialyl Lewis x|6,6'-bisSulfo-Lewis x|6,6'-bissulfo Lex|6,6'-Disulfo Sialyl Lewis x|6,6'-bissulfo Le^x <br>
+ '''synonyms''' : 6,6'-DiSulfo Sialyl Lewis x|6,6-bisSulfo-Lewis x (6,60-bissulfo Lewis x )|6,6'- Disulfo Sialyl Lewis x|6,6'-bisSulfo-Lewis x|6,6'-bissulfo Lex|6,6'-Disulfo Sialyl Lewis x|6,6'-bissulfo Le^x <br>
-'''function''' : lymphocyte homing[GlycoEpitope:EP0016] <br>
+ '''function''' : lymphocyte homing[GlycoEpitope:EP0016] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===6-Sialyl-GalNAc===
-'''term (main_entry)''' : 6-Sialyl-GalNAc <br>
+[[File:G08371CD.png|thumb|G08371CD]]
-'''glycan_dictionary_accession''' : GD000009 <br>
+ '''term (main_entry)''' : 6-Sialyl-GalNAc<br>
-'''glytoucan_accession ''' : G08371CD <br>
+  '''glycan_dictionary_accession''' : GSD000009 <br>
-'''term_in_sentence''' : mmunohistochemical distributions of carbohydrate antigens based on the type 2 chain in normal as well as fetal and neoplastic tissues of human gastrointestinal tract were investigated with a monoclonal antibody (MAb) H11 (specific for type 2 chain) alone and in combination with the two MAbs MSG15 (for alpha 2----6 sialylated type 2 chain) and IB9 (for the alpha 2----6 sialylated type 2 chain and glycoproteins having NeuAc alpha 2----6Gal-NAc), and 188C1 (for short- and long-chain Lex antigens) and FH2 (for the long-chain Lex antigen). [PMID: 1618643] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G08371CD G08371CD] <br>
-'''publication''' : 1618643|6194157 <br>
+ '''term_in_sentence''' : mmunohistochemical distributions of carbohydrate antigens based on the type 2 chain in normal as well as fetal and neoplastic tissues of human gastrointestinal tract were investigated with a monoclonal antibody (MAb) H11 (specific for type 2 chain) alone and in combination with the two MAbs MSG15 (for alpha 2----6 sialylated type 2 chain) and IB9 (for the alpha 2----6 sialylated type 2 chain and glycoproteins having NeuAc alpha 2----6Gal-NAc), and 188C1 (for short- and long-chain Lex antigens) and FH2 (for the long-chain Lex antigen). [PMID: [https://pubmed.ncbi.nlm.nih.gov/1618643 1618643]] <br>
-'''definition''' : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1618643 1618643]|[https://pubmed.ncbi.nlm.nih.gov/6194157 6194157] <br>
-'''term_xref''' : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035 <br>
+ '''definition''' : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] <br>
-'''best_match''' : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035|GTC:G08371CD <br>
+ '''term_xref''' : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035|GTC:G08371CD <br>
-'''synonymns''' : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) <br>
+ '''synonyms''' : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===6-Sulfo LacNac===
-'''term (main_entry)''' : 6-Sulfo LacNac <br>
+[[File:G62735WZ.png|thumb|G62735WZ]]
-'''glycan_dictionary_accession''' : GD000010 <br>
+ '''term (main_entry)''' : 6-Sulfo LacNac <br>
-'''glytoucan_accession ''' : G13157WZ <br>
+ '''glycan_dictionary_accession''' : GSD000010 <br>
-'''term_in_sentence''' : In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan).[PMID:31572354] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G13157WZ G13157WZ] <br>
-'''publication''' : 31572354|31191513|29977237|29900053|30984181|28732748|26510404|28769928|31154896|27541644|25262889|26155414|28499587|27086951|27315572|26162403|26391152|31730025|12354382|27318477|23879812|25340085|24682513|21377044|21098395|18942710|23559493|23890755|22643330|23460612|23402811|22890025|19589615|32939325|20210806|17616642|22907335|16782032|22188261|21283706|29875315|32413173|19546436|19384158|1429720|30519676 <br>
+ '''term_in_sentence''' : In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31572354 31572354]] <br>
-'''definition''' : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31572354 31572354]|[https://pubmed.ncbi.nlm.nih.gov/31191513 31191513]|[https://pubmed.ncbi.nlm.nih.gov/29977237 29977237]|[https://pubmed.ncbi.nlm.nih.gov/29900053 29900053]|[https://pubmed.ncbi.nlm.nih.gov/30984181 30984181]|[https://pubmed.ncbi.nlm.nih.gov/28732748 28732748]|[https://pubmed.ncbi.nlm.nih.gov/26510404 26510404]|[https://pubmed.ncbi.nlm.nih.gov/28769928 28769928]|[https://pubmed.ncbi.nlm.nih.gov/31154896 31154896]|[https://pubmed.ncbi.nlm.nih.gov/27541644 27541644]|[https://pubmed.ncbi.nlm.nih.gov/25262889 25262889]|[https://pubmed.ncbi.nlm.nih.gov/26155414 26155414]|[https://pubmed.ncbi.nlm.nih.gov/28499587 28499587]|[https://pubmed.ncbi.nlm.nih.gov/27086951 27086951]|[https://pubmed.ncbi.nlm.nih.gov/27315572 27315572]|[https://pubmed.ncbi.nlm.nih.gov/26162403 26162403]|[https://pubmed.ncbi.nlm.nih.gov/26391152 26391152]|[https://pubmed.ncbi.nlm.nih.gov/31730025 31730025]|[https://pubmed.ncbi.nlm.nih.gov/12354382 12354382]|[https://pubmed.ncbi.nlm.nih.gov/27318477 27318477]|[https://pubmed.ncbi.nlm.nih.gov/23879812 23879812]|[https://pubmed.ncbi.nlm.nih.gov/25340085 25340085]|[https://pubmed.ncbi.nlm.nih.gov/24682513 24682513]|[https://pubmed.ncbi.nlm.nih.gov/21377044 21377044]|[https://pubmed.ncbi.nlm.nih.gov/21098395 21098395]|[https://pubmed.ncbi.nlm.nih.gov/18942710 18942710]|[https://pubmed.ncbi.nlm.nih.gov/23559493 23559493]|[https://pubmed.ncbi.nlm.nih.gov/23890755 23890755]|[https://pubmed.ncbi.nlm.nih.gov/22643330 22643330]|[https://pubmed.ncbi.nlm.nih.gov/23460612 23460612]|[https://pubmed.ncbi.nlm.nih.gov/23402811 23402811]|[https://pubmed.ncbi.nlm.nih.gov/22890025 22890025]|[https://pubmed.ncbi.nlm.nih.gov/19589615 19589615]|[https://pubmed.ncbi.nlm.nih.gov/32939325 32939325]|[https://pubmed.ncbi.nlm.nih.gov/20210806 20210806]|[https://pubmed.ncbi.nlm.nih.gov/17616642 17616642]|[https://pubmed.ncbi.nlm.nih.gov/22907335 22907335]|[https://pubmed.ncbi.nlm.nih.gov/16782032 16782032]|[https://pubmed.ncbi.nlm.nih.gov/22188261 22188261]|[https://pubmed.ncbi.nlm.nih.gov/21283706 21283706]|[https://pubmed.ncbi.nlm.nih.gov/29875315 29875315]|[https://pubmed.ncbi.nlm.nih.gov/32413173 32413173]|[https://pubmed.ncbi.nlm.nih.gov/19546436 19546436]|[https://pubmed.ncbi.nlm.nih.gov/19384158 19384158]|[https://pubmed.ncbi.nlm.nih.gov/1429720 1429720]|[https://pubmed.ncbi.nlm.nih.gov/30519676 30519676] <br>
-'''term_xref''' : GlycoEpitope:EP0141|CID:10322152|CHEBI:148005 <br>
+ '''definition''' : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] <br>
-'''best_match''' : GlycoEpitope:EP0141|GTC:G13157WZ|CID:10322152|CHEBI:148005 <br>
+ '''term_xref''' : GlycoEpitope:EP0141|GTC:G13157WZ|CID:10322152|CHEBI:148005 <br>
-'''synonymns''' : 6-Sulfo LacNAc <br>
+ '''synonyms''' : 6-Sulfo LacNAc <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===6-Sulfo Sialyl Lewis x===
+[[File:G80722US.png|thumb|G80722US]]
+ '''term (main_entry)''' : 6-Sulfo Sialyl Lewis x <br>
+ '''glycan_dictionary_accession''' : GSD000188<br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80722US G80722US] <br>
+ '''term_in_sentence''' : The cognate ligands for L-selectin possess the unusual sulfated tetrasaccharide epitope 6-sulfo sialyl Lewis x (Siaalpha2-->3Galbeta1-->4[Fucalpha1-->3][SO(3)-->6]GlcNAc).[PMID:[https://pubmed.ncbi.nlm.nih.gov/11331001 11331001]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11331001 11331001]|[https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]|[https://pubmed.ncbi.nlm.nih.gov/26137907 26137907]|[https://pubmed.ncbi.nlm.nih.gov/9400621 9400621]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/15972893 15972893]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/22691873 22691873]|[https://pubmed.ncbi.nlm.nih.gov/18652681 18652681]|[https://pubmed.ncbi.nlm.nih.gov/9722682 9722682]|[https://pubmed.ncbi.nlm.nih.gov/10435581 10435581]|[https://pubmed.ncbi.nlm.nih.gov/19359410 19359410]|[https://pubmed.ncbi.nlm.nih.gov/15228275 15228275]|[https://pubmed.ncbi.nlm.nih.gov/18250165 18250165]|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]|[https://pubmed.ncbi.nlm.nih.gov/17944600 17944600]|[https://pubmed.ncbi.nlm.nih.gov/10460836 10460836]|[https://pubmed.ncbi.nlm.nih.gov/27993973 27993973]|[https://pubmed.ncbi.nlm.nih.gov/19149511 19149511]|[https://pubmed.ncbi.nlm.nih.gov/19150806 19150806]|[https://pubmed.ncbi.nlm.nih.gov/17172261 17172261]|[https://pubmed.ncbi.nlm.nih.gov/17142960 17142960]|[https://pubmed.ncbi.nlm.nih.gov/27956273 27956273]|[https://pubmed.ncbi.nlm.nih.gov/7578028 7578028]|[https://pubmed.ncbi.nlm.nih.gov/22260995 22260995]|[https://pubmed.ncbi.nlm.nih.gov/24519996 24519996]|[https://pubmed.ncbi.nlm.nih.gov/21596021 21596021]|[https://pubmed.ncbi.nlm.nih.gov/21982762 21982762]|[https://pubmed.ncbi.nlm.nih.gov/21775439 21775439]|[https://pubmed.ncbi.nlm.nih.gov/17334369 17334369]|[https://pubmed.ncbi.nlm.nih.gov/9710564 9710564]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/16227985 16227985]|[https://pubmed.ncbi.nlm.nih.gov/11895802 11895802]|[https://pubmed.ncbi.nlm.nih.gov/22750968 22750968]|[https://pubmed.ncbi.nlm.nih.gov/15157883 15157883]|[https://pubmed.ncbi.nlm.nih.gov/19067429 19067429] <br>
+ '''definition''' : <br>
+ '''term_xref''' : GlycoMotif:GGM.000027|GlycoEpitope:EP0015|CID:70698321|CHEBI:71628<br>
+ '''synonyms''' : 6-sulfo SLex|6-Sulfo-sialyl Lewis x|6-sulfo SLe^x <br>
+ '''function''' : lymphocyte homing[GlycoEpitope:EP0015]<br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK579916/ Chapter 34]|[https://www.ncbi.nlm.nih.gov/books/NBK579966/ Chapter 35]<br>
 ===6'-Sulfo Sialyl Lewis x===
-'''term (main_entry)''' : 6'-Sulfo Sialyl Lewis x <br>
+[[File:G00672PE.png|thumb|G00672PE]]
-'''glycan_dictionary_accession''' : GD000011 <br>
+ '''term (main_entry)''' : 6'-Sulfo Sialyl Lewis x <br>
-'''glytoucan_accession ''' : G00672PE <br>
+ '''glycan_dictionary_accession''' : GSD000011 <br>
-'''term_in_sentence''' : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:2288521] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00672PE G00672PE] <br>
-'''publication''' : 2288521|26137907|9400621|32744401|9556613|15972893|9015359|22691873|18652681|9722682|10435581|19458105|19359410|15228275|18250165|10536036|17944600|10460836|27993973|19149511|19150806|17172261|17142960|27956273|7578028|22260995|24519996|21596021|21982762|21775439|17334369|9710564|14593101|16227985|11895802|22750968|15157883|19067429 <br>
+ '''term_in_sentence''' : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]] <br>
-'''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]|[https://pubmed.ncbi.nlm.nih.gov/26137907 26137907]|[https://pubmed.ncbi.nlm.nih.gov/9400621 9400621]|[https://pubmed.ncbi.nlm.nih.gov/32744401 32744401]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/15972893 15972893]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/22691873 22691873]|[https://pubmed.ncbi.nlm.nih.gov/18652681 18652681]|[https://pubmed.ncbi.nlm.nih.gov/9722682 9722682]|[https://pubmed.ncbi.nlm.nih.gov/10435581 10435581]|[https://pubmed.ncbi.nlm.nih.gov/19458105 19458105]|[https://pubmed.ncbi.nlm.nih.gov/19359410 19359410]|[https://pubmed.ncbi.nlm.nih.gov/15228275 15228275]|[https://pubmed.ncbi.nlm.nih.gov/18250165 18250165]|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]|[https://pubmed.ncbi.nlm.nih.gov/17944600 17944600]|[https://pubmed.ncbi.nlm.nih.gov/10460836 10460836]|[https://pubmed.ncbi.nlm.nih.gov/27993973 27993973]|[https://pubmed.ncbi.nlm.nih.gov/19149511 19149511]|[https://pubmed.ncbi.nlm.nih.gov/19150806 19150806]|[https://pubmed.ncbi.nlm.nih.gov/17172261 17172261]|[https://pubmed.ncbi.nlm.nih.gov/17142960 17142960]|[https://pubmed.ncbi.nlm.nih.gov/27956273 27956273]|[https://pubmed.ncbi.nlm.nih.gov/7578028 7578028]|[https://pubmed.ncbi.nlm.nih.gov/22260995 22260995]|[https://pubmed.ncbi.nlm.nih.gov/24519996 24519996]|[https://pubmed.ncbi.nlm.nih.gov/21596021 21596021]|[https://pubmed.ncbi.nlm.nih.gov/21982762 21982762]|[https://pubmed.ncbi.nlm.nih.gov/21775439 21775439]|[https://pubmed.ncbi.nlm.nih.gov/17334369 17334369]|[https://pubmed.ncbi.nlm.nih.gov/9710564 9710564]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/16227985 16227985]|[https://pubmed.ncbi.nlm.nih.gov/11895802 11895802]|[https://pubmed.ncbi.nlm.nih.gov/22750968 22750968]|[https://pubmed.ncbi.nlm.nih.gov/15157883 15157883]|[https://pubmed.ncbi.nlm.nih.gov/19067429 19067429] <br>
-'''term_xref''' : GlycoMotif:GGM.000025|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128 <br>
+ '''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] <br>
-'''best_match''' : GlycoMotif:GGM.000025|GTC:G00672PE|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128 <br>
+ '''term_xref''' : GlycoMotif:GGM.000025|GTC:G00672PE|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128<br>
-'''synonymns''' : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x <br>
+ '''synonyms''' : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x <br>
-'''function''' : lymphocyte homing[GlycoEpitope:EP0014] <br>
+ '''function''' : lymphocyte homing[GlycoEpitope:EP0014] <br>
-'''disease_associations''' : Influenza[SugarBind_Ligand:128] <br>
+ '''disease_associations''' : Influenza[SugarBind_Ligand:128] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
 ===9-O-Acetyl GD3===
-'''term (main_entry)''' : 9-O-Acetyl GD3 <br>
+[[File:G74121RX.png|thumb|G74121RX]]
-'''glycan_dictionary_accession''' : GD000012 <br>
+ '''term (main_entry)''' : 9-O-Acetyl GD3 <br>
-'''glytoucan_accession ''' : G74121RX <br>
+ '''glycan_dictionary_accession''' : GSD000012 <br>
-'''term_in_sentence''' : To determine whether 9-O-acetyl GD3 (acGD3) has a general antiapoptotic potential, the apoptosis-sensitive Jurkat cell line and an apoptosis-sensitive variant of the cell line Molt-4 were preincubated with micromolar concentrations of acGD3 and then treated with inducers of apoptosis.[PMID:16432837] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74121RX G74121RX] <br>
-'''publication''' : 16432837|21507905|17512674|21930212|18194438|20739294|3216430|14724245|31373393|7558412|11273644|17385751|30694652|22894715|12973826|7859075|9749956|9874495|12486096|1989525|25330147|23478187|21807667|8486686|11465673|9511990|29270199|9268945|25045067|21618115|16434401|12493756|2302705|2198284|2685488|9328574|4055789|10096568|1644805|2582447 <br>
+ '''term_in_sentence''' : To determine whether 9-O-acetyl GD3 (acGD3) has a general antiapoptotic potential, the apoptosis-sensitive Jurkat cell line and an apoptosis-sensitive variant of the cell line Molt-4 were preincubated with micromolar concentrations of acGD3 and then treated with inducers of apoptosis.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16432837 16432837]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16432837 16432837]|[https://pubmed.ncbi.nlm.nih.gov/21507905 21507905]|[https://pubmed.ncbi.nlm.nih.gov/17512674 17512674]|[https://pubmed.ncbi.nlm.nih.gov/21930212 21930212]|[https://pubmed.ncbi.nlm.nih.gov/18194438 18194438]|[https://pubmed.ncbi.nlm.nih.gov/20739294 20739294]|[https://pubmed.ncbi.nlm.nih.gov/3216430 3216430]|[https://pubmed.ncbi.nlm.nih.gov/14724245 14724245]|[https://pubmed.ncbi.nlm.nih.gov/31373393 31373393]|[https://pubmed.ncbi.nlm.nih.gov/7558412 7558412]|[https://pubmed.ncbi.nlm.nih.gov/11273644 11273644]|[https://pubmed.ncbi.nlm.nih.gov/17385751 17385751]|[https://pubmed.ncbi.nlm.nih.gov/30694652 30694652]|[https://pubmed.ncbi.nlm.nih.gov/22894715 22894715]|[https://pubmed.ncbi.nlm.nih.gov/12973826 12973826]|[https://pubmed.ncbi.nlm.nih.gov/7859075 7859075]|[https://pubmed.ncbi.nlm.nih.gov/9749956 9749956]|[https://pubmed.ncbi.nlm.nih.gov/9874495 9874495]|[https://pubmed.ncbi.nlm.nih.gov/12486096 12486096]|[https://pubmed.ncbi.nlm.nih.gov/1989525 1989525]|[https://pubmed.ncbi.nlm.nih.gov/25330147 25330147]|[https://pubmed.ncbi.nlm.nih.gov/23478187 23478187]|[https://pubmed.ncbi.nlm.nih.gov/21807667 21807667]|[https://pubmed.ncbi.nlm.nih.gov/8486686 8486686]|[https://pubmed.ncbi.nlm.nih.gov/11465673 11465673]|[https://pubmed.ncbi.nlm.nih.gov/9511990 9511990]|[https://pubmed.ncbi.nlm.nih.gov/29270199 29270199]|[https://pubmed.ncbi.nlm.nih.gov/9268945 9268945]|[https://pubmed.ncbi.nlm.nih.gov/25045067 25045067]|[https://pubmed.ncbi.nlm.nih.gov/21618115 21618115]|[https://pubmed.ncbi.nlm.nih.gov/16434401 16434401]|[https://pubmed.ncbi.nlm.nih.gov/12493756 12493756]|[https://pubmed.ncbi.nlm.nih.gov/2302705 2302705]|[https://pubmed.ncbi.nlm.nih.gov/2198284 2198284]|[https://pubmed.ncbi.nlm.nih.gov/2685488 2685488]|[https://pubmed.ncbi.nlm.nih.gov/9328574 9328574]|[https://pubmed.ncbi.nlm.nih.gov/4055789 4055789]|[https://pubmed.ncbi.nlm.nih.gov/10096568 10096568]|[https://pubmed.ncbi.nlm.nih.gov/1644805 1644805]|[https://pubmed.ncbi.nlm.nih.gov/2582447 2582447] <br>
-'''term_xref''' : GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 <br>
+ '''definition''' :  <br>
-'''best_match''' : GTC:G74121RX|GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 <br>
+ '''term_xref''' : GTC:G74121RX|GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 <br>
-'''synonymns''' : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b <br>
+ '''synonyms''' : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : pancreas cancer[GlycoEpitope:EP0064] <br>
+ '''disease_associations''' : pancreas cancer[GlycoEpitope:EP0064] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===9-O-Acetyl sialic acid===
-'''term (main_entry)''' : 9-O-Acetyl sialic acid <br>
+[[File:G47325QT.png|thumb|G47325QT]]
-'''glycan_dictionary_accession''' : GD000013 <br>
+ '''term (main_entry)''' : 9-O-Acetyl sialic acid <br>
-'''glytoucan_accession ''' : G47325QT <br>
+ '''glycan_dictionary_accession''' : GSD000013 <br>
-'''term_in_sentence''' : Levels of 9-O-acetyl sialic acid provide a distinct way to define progenitors and thus facilitate the study of hematopoietic differentiation.[PMID:31411667] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G47325QT G47325QT] <br>
-'''publication''' : 31411667|27936566|2509478|10049046|1826463 <br>
+ '''term_in_sentence''' : Levels of 9-O-acetyl sialic acid provide a distinct way to define progenitors and thus facilitate the study of hematopoietic differentiation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31411667 31411667]] <br>
-'''definition''' : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31411667 31411667]|[https://pubmed.ncbi.nlm.nih.gov/27936566 27936566]|[https://pubmed.ncbi.nlm.nih.gov/2509478 2509478]|[https://pubmed.ncbi.nlm.nih.gov/10049046 10049046]|[https://pubmed.ncbi.nlm.nih.gov/1826463 1826463] <br>
-'''term_xref''' : GlycoEpitope:EP0065|CID:13991612|CHEBI:84941 <br>
+ '''definition''' : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] <br>
-'''best_match''' : GTC:G47325QT|GlycoEpitope:EP0065|CID:13991612|CHEBI:84941 <br>
+ '''term_xref''' : GTC:G47325QT|GlycoEpitope:EP0065|CID:13991612|CHEBI:84941 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453082-Chapter 77 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453082/ Chapter 15]<br>
-===A Type 2===
-'''term (main_entry)''' : A Type 2 <br>
-'''glycan_dictionary_accession''' : GD000014 <br>
-'''glytoucan_accession ''' : G74353FF <br>
-'''term_in_sentence''' : Herein we report the synthesis of 3-aminopropyl glycosides of A (type 2) and B (type 2) tetrasaccharides via [3 + 1] block scheme.[PMID:27196314] <br>
-'''publication''' : 27196314|6583282|8340255|18701592|21901093|2413709|8036794|1615929|3285099 <br>
-'''definition''' : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] <br>
-'''term_xref''' : CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 <br>
-'''best_match''' : GTC:G74353FF|CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 <br>
-'''synonymns''' : Blood group A (type 2) <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
-===A2===
-'''term (main_entry)''' : A2 <br>
-'''glycan_dictionary_accession''' : GD000015 <br>
-'''glytoucan_accession ''' : G62735WZ <br>
-'''term_in_sentence''' : Landsteiner ABO system of blood groups is most important for transfusion medicine and has subtypes of A Antigen, A1 and A2, upon which further groups of A and AB have been classified.[PMID:28658771] <br>
-'''publication''' : 29000000|28658771 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000041|CID:91852328 <br>
-'''best_match''' : GlycoMotif:GGM.000041|GTC:G62735WZ|CID:91852328 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Alpha-gal antigen===
-'''term (main_entry)''' : Alpha-gal antigen <br>
+[[File:G24432YB.png|thumb|G24432YB]]
-'''glycan_dictionary_accession''' : GD000016 <br>
+ '''term (main_entry)''' : Alpha-gal antigen <br>
-'''glytoucan_accession ''' : G24432YB <br>
+ '''glycan_dictionary_accession''' : GSD000016 <br>
-'''term_in_sentence''' : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:31267683] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G24432YB G24432YB] <br>
-'''publication''' : 31267683|29319188|29481481|26140655|30337555|29235434|22909134|28280265|7532618|23390540|22808845|29898796|22262104|31267683|25430953|22993330|23578170|21043478|28294277|27696820|15814276|17991149|25577211|30578545|19895316|28068870|18546155|32907757|26485996|9771839|12042247|27567275|12131678|23114154|19184002|29577591|29806570|15638815|21118731 <br>
+ '''term_in_sentence''' : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]] <br>
-'''definition''' : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]|[https://pubmed.ncbi.nlm.nih.gov/29319188 29319188]|[https://pubmed.ncbi.nlm.nih.gov/29481481 29481481]|[https://pubmed.ncbi.nlm.nih.gov/26140655 26140655]|[https://pubmed.ncbi.nlm.nih.gov/30337555 30337555]|[https://pubmed.ncbi.nlm.nih.gov/29235434 29235434]|[https://pubmed.ncbi.nlm.nih.gov/22909134 22909134]|[https://pubmed.ncbi.nlm.nih.gov/28280265 28280265]|[https://pubmed.ncbi.nlm.nih.gov/7532618 7532618]|[https://pubmed.ncbi.nlm.nih.gov/23390540 23390540]|[https://pubmed.ncbi.nlm.nih.gov/22808845 22808845]|[https://pubmed.ncbi.nlm.nih.gov/29898796 29898796]|[https://pubmed.ncbi.nlm.nih.gov/22262104 22262104]|[https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]|[https://pubmed.ncbi.nlm.nih.gov/25430953 25430953]|[https://pubmed.ncbi.nlm.nih.gov/22993330 22993330]|[https://pubmed.ncbi.nlm.nih.gov/23578170 23578170]|[https://pubmed.ncbi.nlm.nih.gov/21043478 21043478]|[https://pubmed.ncbi.nlm.nih.gov/28294277 28294277]|[https://pubmed.ncbi.nlm.nih.gov/27696820 27696820]|[https://pubmed.ncbi.nlm.nih.gov/15814276 15814276]|[https://pubmed.ncbi.nlm.nih.gov/17991149 17991149]|[https://pubmed.ncbi.nlm.nih.gov/25577211 25577211]|[https://pubmed.ncbi.nlm.nih.gov/30578545 30578545]|[https://pubmed.ncbi.nlm.nih.gov/19895316 19895316]|[https://pubmed.ncbi.nlm.nih.gov/28068870 28068870]|[https://pubmed.ncbi.nlm.nih.gov/18546155 18546155]|[https://pubmed.ncbi.nlm.nih.gov/32907757 32907757]|[https://pubmed.ncbi.nlm.nih.gov/26485996 26485996]|[https://pubmed.ncbi.nlm.nih.gov/9771839 9771839]|[https://pubmed.ncbi.nlm.nih.gov/12042247 12042247]|[https://pubmed.ncbi.nlm.nih.gov/27567275 27567275]|[https://pubmed.ncbi.nlm.nih.gov/12131678 12131678]|[https://pubmed.ncbi.nlm.nih.gov/23114154 23114154]|[https://pubmed.ncbi.nlm.nih.gov/19184002 19184002]|[https://pubmed.ncbi.nlm.nih.gov/29577591 29577591]|[https://pubmed.ncbi.nlm.nih.gov/29806570 29806570]|[https://pubmed.ncbi.nlm.nih.gov/15638815 15638815]|[https://pubmed.ncbi.nlm.nih.gov/21118731 21118731] <br>
-'''term_xref''' : GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330 <br>
+ '''definition''' : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] <br>
-'''best_match''' : GTC:G24432YB|GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330 <br>
+ '''term_xref''' : GTC:G24432YB|GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330 <br>
-'''synonymns''' : a-Gal antigen <br>
+ '''synonyms''' : a-Gal antigen <br>
-'''function''' : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] <br>
+ '''function''' : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
 ===Alpha-galactosylceramide===
-'''term (main_entry)''' : Alpha-galactosylceramide <br>
+ '''term (main_entry)''' : Alpha-galactosylceramide <br>
-'''glycan_dictionary_accession''' : GD000017 <br>
+ '''glycan_dictionary_accession''' : GSD000017 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : From 24 weeks of age, NZB/NZW F1 mice were injected with alpha-galactosylceramide (α-GalCer) or vehicle once a week for four weeks.[PMID:29844470] <br>
+ '''term_in_sentence''' : From 24 weeks of age, NZB/NZW F1 mice were injected with alpha-galactosylceramide (α-GalCer) or vehicle once a week for four weeks.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29844470 29844470]] <br>
-'''publication''' : 29844470|30421497|31575643|30745361|30953000|30556652|29617191|31689579|28872688|30195979|29940370|27004737|27198610|28743554|31649670|31484693|25752588|21383248|25527277|30821985|28947140|31244823|29311431|30803854|29576533|26101952|31213291|22412194|28067024|31199716|27354638|24465013|25445911|28120096|15630427|27803187|21392534|31075434|22683545|26191196|26811064|23935988|28623127|24913977|25434827|23420533|21839133|25314062|27325450|23874157 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29844470 29844470]|[https://pubmed.ncbi.nlm.nih.gov/30421497 30421497]|[https://pubmed.ncbi.nlm.nih.gov/31575643 31575643]|[https://pubmed.ncbi.nlm.nih.gov/30745361 30745361]|[https://pubmed.ncbi.nlm.nih.gov/30953000 30953000]|[https://pubmed.ncbi.nlm.nih.gov/30556652 30556652]|[https://pubmed.ncbi.nlm.nih.gov/29617191 29617191]|[https://pubmed.ncbi.nlm.nih.gov/31689579 31689579]|[https://pubmed.ncbi.nlm.nih.gov/28872688 28872688]|[https://pubmed.ncbi.nlm.nih.gov/30195979 30195979]|[https://pubmed.ncbi.nlm.nih.gov/29940370 29940370]|[https://pubmed.ncbi.nlm.nih.gov/27004737 27004737]|[https://pubmed.ncbi.nlm.nih.gov/27198610 27198610]|[https://pubmed.ncbi.nlm.nih.gov/28743554 28743554]|[https://pubmed.ncbi.nlm.nih.gov/31649670 31649670]|[https://pubmed.ncbi.nlm.nih.gov/31484693 31484693]|[https://pubmed.ncbi.nlm.nih.gov/25752588 25752588]|[https://pubmed.ncbi.nlm.nih.gov/21383248 21383248]|[https://pubmed.ncbi.nlm.nih.gov/25527277 25527277]|[https://pubmed.ncbi.nlm.nih.gov/30821985 30821985]|[https://pubmed.ncbi.nlm.nih.gov/28947140 28947140]|[https://pubmed.ncbi.nlm.nih.gov/31244823 31244823]|[https://pubmed.ncbi.nlm.nih.gov/29311431 29311431]|[https://pubmed.ncbi.nlm.nih.gov/30803854 30803854]|[https://pubmed.ncbi.nlm.nih.gov/29576533 29576533]|[https://pubmed.ncbi.nlm.nih.gov/26101952 26101952]|[https://pubmed.ncbi.nlm.nih.gov/31213291 31213291]|[https://pubmed.ncbi.nlm.nih.gov/22412194 22412194]|[https://pubmed.ncbi.nlm.nih.gov/28067024 28067024]|[https://pubmed.ncbi.nlm.nih.gov/31199716 31199716]|[https://pubmed.ncbi.nlm.nih.gov/27354638 27354638]|[https://pubmed.ncbi.nlm.nih.gov/24465013 24465013]|[https://pubmed.ncbi.nlm.nih.gov/25445911 25445911]|[https://pubmed.ncbi.nlm.nih.gov/28120096 28120096]|[https://pubmed.ncbi.nlm.nih.gov/15630427 15630427]|[https://pubmed.ncbi.nlm.nih.gov/27803187 27803187]|[https://pubmed.ncbi.nlm.nih.gov/21392534 21392534]|[https://pubmed.ncbi.nlm.nih.gov/31075434 31075434]|[https://pubmed.ncbi.nlm.nih.gov/22683545 22683545]|[https://pubmed.ncbi.nlm.nih.gov/26191196 26191196]|[https://pubmed.ncbi.nlm.nih.gov/26811064 26811064]|[https://pubmed.ncbi.nlm.nih.gov/23935988 23935988]|[https://pubmed.ncbi.nlm.nih.gov/28623127 28623127]|[https://pubmed.ncbi.nlm.nih.gov/24913977 24913977]|[https://pubmed.ncbi.nlm.nih.gov/25434827 25434827]|[https://pubmed.ncbi.nlm.nih.gov/23420533 23420533]|[https://pubmed.ncbi.nlm.nih.gov/21839133 21839133]|[https://pubmed.ncbi.nlm.nih.gov/25314062 25314062]|[https://pubmed.ncbi.nlm.nih.gov/27325450 27325450]|[https://pubmed.ncbi.nlm.nih.gov/23874157 23874157] <br>
-'''definition''' :  <br>
+ '''definition''' :  <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+  '''synonyms''' : alpha-GalCer|alpha-GalCers|α-GalCer <br>
-'''synonymns''' : alpha-GalCer|alpha-GalCers|α-GalCer <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Asialo-biantennary===
-'''term (main_entry)''' : Asialo-biantennary <br>
+ '''term (main_entry)''' : Asialo-biantennary <br>
-'''glycan_dictionary_accession''' : GD000018 <br>
+ '''glycan_dictionary_accession''' : GSD000018 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:30990348] <br>
+ '''term_in_sentence''' : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:[https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]] <br>
-'''publication''' : 30990348|17645671|20959391|18615430|16945378|2065054|3084472|2386787|22911097|24692304|17013932|7513972|6626573|10835250|9684342 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]|[https://pubmed.ncbi.nlm.nih.gov/17645671 17645671]|[https://pubmed.ncbi.nlm.nih.gov/20959391 20959391]|[https://pubmed.ncbi.nlm.nih.gov/18615430 18615430]|[https://pubmed.ncbi.nlm.nih.gov/16945378 16945378]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]|[https://pubmed.ncbi.nlm.nih.gov/3084472 3084472]|[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]|[https://pubmed.ncbi.nlm.nih.gov/22911097 22911097]|[https://pubmed.ncbi.nlm.nih.gov/24692304 24692304]|[https://pubmed.ncbi.nlm.nih.gov/17013932 17013932]|[https://pubmed.ncbi.nlm.nih.gov/7513972 7513972]|[https://pubmed.ncbi.nlm.nih.gov/6626573 6626573]|[https://pubmed.ncbi.nlm.nih.gov/10835250 10835250]|[https://pubmed.ncbi.nlm.nih.gov/9684342 9684342] <br>
-'''definition''' : A binantennary glycan lacking sialic acid as non-reducing terminal residues on either antennae [https://en.wiktionary.org/wiki/asialobiantennary] <br>
+ '''definition''' :  <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' : asialo diantennary <br>
-'''synonymns''' : asialo diantennary <br>
+ '''function''' :  <br>
-'''function''' : Used as an adjuvant for experimental vaccines [https://www.sciencedirect.com/topics/neuroscience/alpha-galactosylceramide] <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Asialo-GM1===
-'''term (main_entry)''' : Asialo-GM1 <br>
+[[File:G21856LC.png|thumb|G21856LC]]
-'''glycan_dictionary_accession''' : GD000019 <br>
+ '''term (main_entry)''' : Asialo-GM1 <br>
-'''glytoucan_accession ''' : G21856LC <br>
+ '''glycan_dictionary_accession''' : GSD000019 <br>
-'''term_in_sentence''' : We compared the lateral structure of giant unilamellar vesicles (GUVs) composed of three pseudo binary mixtures of different glycosphingolipid (GSL), i.e. sulfatide, asialo-GM1 or GM1, with POPC.[PMID:29106974] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G21856LC G21856LC] <br>
-'''publication''' : 29106974|3418980|26975993|8613364|9288228|26710925|24922516|6839313|1828259|2581667|8210226|25062498|9671150|10377092|6171919|3093429|6652964|3124753|8905612|18788941|1467432|8225593|2083955|6171918|7806377|1802483|7927723|9209156|21174147|2584393|12137200|6175621|2936802|8610366|21490162|1548508|3486908|26453755|7910939|3756909|1639356|3259967|2443562|3112077|2572647|25137483|2168971 <br>
+ '''term_in_sentence''' : We compared the lateral structure of giant unilamellar vesicles (GUVs) composed of three pseudo binary mixtures of different glycosphingolipid (GSL), i.e. sulfatide, asialo-GM1 or GM1, with POPC.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29106974 29106974]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29106974 29106974]|[https://pubmed.ncbi.nlm.nih.gov/3418980 3418980]|[https://pubmed.ncbi.nlm.nih.gov/26975993 26975993]|[https://pubmed.ncbi.nlm.nih.gov/8613364 8613364]|[https://pubmed.ncbi.nlm.nih.gov/9288228 9288228]|[https://pubmed.ncbi.nlm.nih.gov/26710925 26710925]|[https://pubmed.ncbi.nlm.nih.gov/24922516 24922516]|[https://pubmed.ncbi.nlm.nih.gov/6839313 6839313]|[https://pubmed.ncbi.nlm.nih.gov/1828259 1828259]|[https://pubmed.ncbi.nlm.nih.gov/2581667 2581667]|[https://pubmed.ncbi.nlm.nih.gov/8210226 8210226]|[https://pubmed.ncbi.nlm.nih.gov/25062498 25062498]|[https://pubmed.ncbi.nlm.nih.gov/9671150 9671150]|[https://pubmed.ncbi.nlm.nih.gov/10377092 10377092]|[https://pubmed.ncbi.nlm.nih.gov/6171919 6171919]|[https://pubmed.ncbi.nlm.nih.gov/3093429 3093429]|[https://pubmed.ncbi.nlm.nih.gov/6652964 6652964]|[https://pubmed.ncbi.nlm.nih.gov/3124753 3124753]|[https://pubmed.ncbi.nlm.nih.gov/8905612 8905612]|[https://pubmed.ncbi.nlm.nih.gov/18788941 18788941]|[https://pubmed.ncbi.nlm.nih.gov/1467432 1467432]|[https://pubmed.ncbi.nlm.nih.gov/8225593 8225593]|[https://pubmed.ncbi.nlm.nih.gov/2083955 2083955]|[https://pubmed.ncbi.nlm.nih.gov/6171918 6171918]|[https://pubmed.ncbi.nlm.nih.gov/7806377 7806377]|[https://pubmed.ncbi.nlm.nih.gov/1802483 1802483]|[https://pubmed.ncbi.nlm.nih.gov/7927723 7927723]|[https://pubmed.ncbi.nlm.nih.gov/9209156 9209156]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/2584393 2584393]|[https://pubmed.ncbi.nlm.nih.gov/12137200 12137200]|[https://pubmed.ncbi.nlm.nih.gov/6175621 6175621]|[https://pubmed.ncbi.nlm.nih.gov/2936802 2936802]|[https://pubmed.ncbi.nlm.nih.gov/8610366 8610366]|[https://pubmed.ncbi.nlm.nih.gov/21490162 21490162]|[https://pubmed.ncbi.nlm.nih.gov/1548508 1548508]|[https://pubmed.ncbi.nlm.nih.gov/3486908 3486908]|[https://pubmed.ncbi.nlm.nih.gov/26453755 26453755]|[https://pubmed.ncbi.nlm.nih.gov/7910939 7910939]|[https://pubmed.ncbi.nlm.nih.gov/3756909 3756909]|[https://pubmed.ncbi.nlm.nih.gov/1639356 1639356]|[https://pubmed.ncbi.nlm.nih.gov/3259967 3259967]|[https://pubmed.ncbi.nlm.nih.gov/2443562 2443562]|[https://pubmed.ncbi.nlm.nih.gov/3112077 3112077]|[https://pubmed.ncbi.nlm.nih.gov/2572647 2572647]|[https://pubmed.ncbi.nlm.nih.gov/25137483 25137483]|[https://pubmed.ncbi.nlm.nih.gov/2168971 2168971]|[https://pubmed.ncbi.nlm.nih.gov/6950172 6950172] <br>
-'''term_xref''' : GlycoMotif:GGM.000099|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000099|GTC:G21856LC|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216 <br>
+ '''term_xref''' : GlycoMotif:GGM.000099|GTC:G21856LC|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216  <br>
-'''synonymns''' : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a <br>
+ '''synonyms''' : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a|ganglio-N-tetraosylceramide <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:2]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:2]|Actinomycosis[SugarBind_Ligand:2]|Lazy leukocyte syndrome[SugarBind_Ligand:2]|Pertussis[SugarBind_Ligand:2]|Cutaneous lesions[SugarBind_Ligand:2]|Melioidosis[SugarBind_Ligand:2]|Candidiasis[SugarBind_Ligand:2]|Taiwan acute respiratory agent[SugarBind_Ligand:2]|Trachoma[SugarBind_Ligand:2]|Cystitis[SugarBind_Ligand:2]|Chronic gastritis[SugarBind_Ligand:2]|Peptic ulcers[SugarBind_Ligand:2]|Gastric cancer[SugarBind_Ligand:2]|Klebsiella pneumonia infection[SugarBind_Ligand:2]|Pneumonia[SugarBind_Ligand:2]|Legionnaires' disease[SugarBind_Ligand:2]|Gonorrhea[SugarBind_Ligand:2]|Gastroenteritis[SugarBind_Ligand:2]|Toxoplasmosis[SugarBind_Ligand:2]|Plague[SugarBind_Ligand:2]|Diarrhea[SugarBind_Ligand:2] <br>
+ '''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:2]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:2]|Actinomycosis[SugarBind_Ligand:2]|Lazy leukocyte syndrome[SugarBind_Ligand:2]|Pertussis[SugarBind_Ligand:2]|Cutaneous lesions[SugarBind_Ligand:2]|Melioidosis[SugarBind_Ligand:2]|Candidiasis[SugarBind_Ligand:2]|Taiwan acute respiratory agent[SugarBind_Ligand:2]|Trachoma[SugarBind_Ligand:2]|Cystitis[SugarBind_Ligand:2]|Chronic gastritis[SugarBind_Ligand:2]|Peptic ulcers[SugarBind_Ligand:2]|Gastric cancer[SugarBind_Ligand:2]|Klebsiella pneumonia infection[SugarBind_Ligand:2]|Pneumonia[SugarBind_Ligand:2]|Legionnaires' disease[SugarBind_Ligand:2]|Gonorrhea[SugarBind_Ligand:2]|Gastroenteritis[SugarBind_Ligand:2]|Toxoplasmosis[SugarBind_Ligand:2]|Plague[SugarBind_Ligand:2]|Diarrhea[SugarBind_Ligand:2] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===B-GD1B===
-'''term (main_entry)''' : B-GD1B <br>
+[[File:G72557NR.png|thumb|G72557NR]]
-'''glycan_dictionary_accession''' : GD000020 <br>
+ '''term (main_entry)''' : B-GD1B <br>
-'''glytoucan_accession ''' : G72557NR <br>
+ '''glycan_dictionary_accession''' : GSD000020 <br>
-'''term_in_sentence''' : The Molecular Modelling and 10 ns MD simulation of Botulinum Neuro Toxin/B-GD1A and BoNT/B-GD1B complex revealed that this toxin can interact with GD1A in the single binding mode and with GD1B in two binding modes.[PMID:22929125] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72557NR G72557NR] <br>
-'''publication''' : 27956354|22929125 <br>
+ '''term_in_sentence''' : The Molecular Modelling and 10 ns MD simulation of Botulinum Neuro Toxin/B-GD1A and BoNT/B-GD1B complex revealed that this toxin can interact with GD1A in the single binding mode and with GD1B in two binding modes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27956354 27956354]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125] <br>
-'''term_xref''' : GlycoMotif:GGM.000104|CID:91847819|KEGG:G01803|CHEBI:153361 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000104|GTC:G72557NR|CID:91847819|KEGG:G01803|CHEBI:153361 <br>
+ '''term_xref''' : GlycoMotif:GGM.000104|GTC:G72557NR|CID:91847819|KEGG:G01803|CHEBI:153361 <br>
-'''synonymns''' : B-GD1b <br>
+ '''synonyms''' : B-GD1b <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===B-GM1===
-'''term (main_entry)''' : B-GM1 <br>
+[[File:G11485ID.png|thumb|G11485ID]]
-'''glycan_dictionary_accession''' : GD000021 <br>
+ '''term (main_entry)''' : B-GM1 <br>
-'''glytoucan_accession ''' : G11485ID <br>
+ '''glycan_dictionary_accession''' : GSD000021 <br>
-'''term_in_sentence''' : The contribution of GM3 and GD3, which accounted for 95% of the ganglioside sialic acid at birth, decreased during the first 3 weeks of life. GM1, fucosyl-GM1, and B-GM1 were not detected at birth. [PMID: 3680254] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G11485ID G11485ID] <br>
-'''publication''' : 3680254 <br>
+ '''term_in_sentence''' : The contribution of GM3 and GD3, which accounted for 95% of the ganglioside sialic acid at birth, decreased during the first 3 weeks of life. GM1, fucosyl-GM1, and B-GM1 were not detected at birth. [PMID: [https://pubmed.ncbi.nlm.nih.gov/3680254 3680254]] <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3680254 3680254] <br>
-'''term_xref''' : GlycoMotif:GGM.000102|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] <br>
-'''best_match''' : GlycoMotif:GGM.000102|GTC:G11485ID|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 <br>
+ '''term_xref''' : GlycoMotif:GGM.000102|GTC:G11485ID|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Cholera[SugarBind_Ligand:181] <br>
+ '''disease_associations''' : Cholera[SugarBind_Ligand:181] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453032 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453032/ Chapter 37]<br>
 ===Biantennary===
-'''term (main_entry)''' : Biantennary <br>
+ '''term (main_entry)''' : Biantennary <br>
-'''glycan_dictionary_accession''' : GD000022 <br>
+ '''glycan_dictionary_accession''' : GSD000022 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID:29249147] <br>
+ '''term_in_sentence''' : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]] <br>
-'''publication''' : 29249147|24991291|29409839|30325416|18083109|26926155|16715395|12634321|24211369|23115267|31907993|23360551|20861009|33142198|11442281|18687680|15680603|31888963|14686925|15819890|22530754|22098756|9346821|19341309|18529007|20580347|11784152|7773775|10913832|8547276|10463590|9404657|30525457|15316280|8068637|3881425|6425277|8576139|29956878|1576211|11129583|30421263|8069634|30973186|16704415|21612260|29806066|29443078 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]|[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/29409839 29409839]|[https://pubmed.ncbi.nlm.nih.gov/30325416 30325416]|[https://pubmed.ncbi.nlm.nih.gov/18083109 18083109]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/16715395 16715395]|[https://pubmed.ncbi.nlm.nih.gov/12634321 12634321]|[https://pubmed.ncbi.nlm.nih.gov/24211369 24211369]|[https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]|[https://pubmed.ncbi.nlm.nih.gov/31907993 31907993]|[https://pubmed.ncbi.nlm.nih.gov/23360551 23360551]|[https://pubmed.ncbi.nlm.nih.gov/20861009 20861009]|[https://pubmed.ncbi.nlm.nih.gov/33142198 33142198]|[https://pubmed.ncbi.nlm.nih.gov/11442281 11442281]|[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680]|[https://pubmed.ncbi.nlm.nih.gov/15680603 15680603]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756]|[https://pubmed.ncbi.nlm.nih.gov/9346821 9346821]|[https://pubmed.ncbi.nlm.nih.gov/19341309 19341309]|[https://pubmed.ncbi.nlm.nih.gov/18529007 18529007]|[https://pubmed.ncbi.nlm.nih.gov/20580347 20580347]|[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152]|[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276]|[https://pubmed.ncbi.nlm.nih.gov/10463590 10463590]|[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657]|[https://pubmed.ncbi.nlm.nih.gov/30525457 30525457]|[https://pubmed.ncbi.nlm.nih.gov/15316280 15316280]|[https://pubmed.ncbi.nlm.nih.gov/8068637 8068637]|[https://pubmed.ncbi.nlm.nih.gov/3881425 3881425]|[https://pubmed.ncbi.nlm.nih.gov/6425277 6425277]|[https://pubmed.ncbi.nlm.nih.gov/8576139 8576139]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]|[https://pubmed.ncbi.nlm.nih.gov/1576211 1576211]|[https://pubmed.ncbi.nlm.nih.gov/11129583 11129583]|[https://pubmed.ncbi.nlm.nih.gov/30421263 30421263]|[https://pubmed.ncbi.nlm.nih.gov/8069634 8069634]|[https://pubmed.ncbi.nlm.nih.gov/30973186 30973186]|[https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]|[https://pubmed.ncbi.nlm.nih.gov/21612260 21612260]|[https://pubmed.ncbi.nlm.nih.gov/29806066 29806066]|[https://pubmed.ncbi.nlm.nih.gov/29443078 29443078] <br>
-'''definition''' : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [NBK453019-Glossary] <br>
+ '''definition''' : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+  '''synonyms''' : diantennary <br>
-'''synonymns''' : diantennary <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>
-'''essentials_of_glycobiology''' : NBK453020-Chapter 9 <br>
 ===Biantennary complex===
-'''term (main_entry)''' : Biantennary complex <br>
+ '''term (main_entry)''' : Biantennary complex <br>
-'''glycan_dictionary_accession''' : GD000023 <br>
+ '''glycan_dictionary_accession''' : GSD000023 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:16704415] <br>
+ '''term_in_sentence''' : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]] <br>
-'''publication''' : 16704415|3731182|26747427|32597008|6626573|29249147|28597152|25045879|30325416|12634321|31888963|26926155|23360551|33142198|9404657|29956878|14686925|18687680|11784152|7773775|22530754|20580347|22098756|21612260|6425277|7691595|26780731|16285669|15819890|3924097|30448401|8547276|17049014|29408873 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]|[https://pubmed.ncbi.nlm.nih.gov/3731182 3731182]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]|[https://pubmed.ncbi.nlm.nih.gov/32597008 32597008]|[https://pubmed.ncbi.nlm.nih.gov/6626573 6626573]|[https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]|[https://pubmed.ncbi.nlm.nih.gov/28597152 28597152]|[https://pubmed.ncbi.nlm.nih.gov/25045879 25045879]|[https://pubmed.ncbi.nlm.nih.gov/30325416 30325416]|[https://pubmed.ncbi.nlm.nih.gov/12634321 12634321]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/23360551 23360551]|[https://pubmed.ncbi.nlm.nih.gov/33142198 33142198]|[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]|[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]|[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680]|[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152]|[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/20580347 20580347]|[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756]|[https://pubmed.ncbi.nlm.nih.gov/21612260 21612260]|[https://pubmed.ncbi.nlm.nih.gov/6425277 6425277]|[https://pubmed.ncbi.nlm.nih.gov/7691595 7691595]|[https://pubmed.ncbi.nlm.nih.gov/26780731 26780731]|[https://pubmed.ncbi.nlm.nih.gov/16285669 16285669]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/3924097 3924097]|[https://pubmed.ncbi.nlm.nih.gov/30448401 30448401]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276]|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/29408873 29408873] <br>
-'''definition''' : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] <br>
+ '''definition''' : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] <br>
-'''term_xref''' : CHEBI:156251 <br>
+ '''term_xref''' : CHEBI:156251 <br>
-'''best_match''' : CHEBI:156251 <br>
+ '''synonyms''' : diantennary complex type <br>
-'''synonymns''' : diantennary complex type <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Bisecting GlcNac===
-'''term (main_entry)''' : Bisecting GlcNac <br>
+ '''term (main_entry)''' : Bisecting GlcNac <br>
-'''glycan_dictionary_accession''' : GD000024 <br>
+ '''glycan_dictionary_accession''' : GSD000024 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:1374031] <br>
+ '''term_in_sentence''' : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]] <br>
-'''publication''' : 1374031|29909448|29274553|32719771|22476631|31375533|26467158|27429195|20816221|26109616|30542567|30144245|25727145|29593568|32612952|9006930|19508951|16000695|32597008|19053837|22530754|30405631|19940114|32719549|9560299|29655002|10589784|29959030|20661133|9061364|31065629|20395209|29549127|30305426|29632412|24108122|24282611|27821068|14686925|10816579|25032906|30025558|9661906|8542600|31585439|29699572|27443163|30315103|23808883|18812317|19776078 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]|[https://pubmed.ncbi.nlm.nih.gov/29909448 29909448]|[https://pubmed.ncbi.nlm.nih.gov/29274553 29274553]|[https://pubmed.ncbi.nlm.nih.gov/32719771 32719771]|[https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]|[https://pubmed.ncbi.nlm.nih.gov/31375533 31375533]|[https://pubmed.ncbi.nlm.nih.gov/26467158 26467158]|[https://pubmed.ncbi.nlm.nih.gov/27429195 27429195]|[https://pubmed.ncbi.nlm.nih.gov/20816221 20816221]|[https://pubmed.ncbi.nlm.nih.gov/26109616 26109616]|[https://pubmed.ncbi.nlm.nih.gov/30542567 30542567]|[https://pubmed.ncbi.nlm.nih.gov/30144245 30144245]|[https://pubmed.ncbi.nlm.nih.gov/25727145 25727145]|[https://pubmed.ncbi.nlm.nih.gov/29593568 29593568]|[https://pubmed.ncbi.nlm.nih.gov/32612952 32612952]|[https://pubmed.ncbi.nlm.nih.gov/9006930 9006930]|[https://pubmed.ncbi.nlm.nih.gov/19508951 19508951]|[https://pubmed.ncbi.nlm.nih.gov/16000695 16000695]|[https://pubmed.ncbi.nlm.nih.gov/32597008 32597008]|[https://pubmed.ncbi.nlm.nih.gov/19053837 19053837]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/30405631 30405631]|[https://pubmed.ncbi.nlm.nih.gov/19940114 19940114]|[https://pubmed.ncbi.nlm.nih.gov/32719549 32719549]|[https://pubmed.ncbi.nlm.nih.gov/9560299 9560299]|[https://pubmed.ncbi.nlm.nih.gov/29655002 29655002]|[https://pubmed.ncbi.nlm.nih.gov/10589784 10589784]|[https://pubmed.ncbi.nlm.nih.gov/29959030 29959030]|[https://pubmed.ncbi.nlm.nih.gov/20661133 20661133]|[https://pubmed.ncbi.nlm.nih.gov/9061364 9061364]|[https://pubmed.ncbi.nlm.nih.gov/31065629 31065629]|[https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]|[https://pubmed.ncbi.nlm.nih.gov/29549127 29549127]|[https://pubmed.ncbi.nlm.nih.gov/30305426 30305426]|[https://pubmed.ncbi.nlm.nih.gov/29632412 29632412]|[https://pubmed.ncbi.nlm.nih.gov/24108122 24108122]|[https://pubmed.ncbi.nlm.nih.gov/24282611 24282611]|[https://pubmed.ncbi.nlm.nih.gov/27821068 27821068]|[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]|[https://pubmed.ncbi.nlm.nih.gov/10816579 10816579]|[https://pubmed.ncbi.nlm.nih.gov/25032906 25032906]|[https://pubmed.ncbi.nlm.nih.gov/30025558 30025558]|[https://pubmed.ncbi.nlm.nih.gov/ 9661906]|[https://pubmed.ncbi.nlm.nih.gov/8542600 8542600]|[https://pubmed.ncbi.nlm.nih.gov/31585439 31585439]|[https://pubmed.ncbi.nlm.nih.gov/29699572 29699572]|[https://pubmed.ncbi.nlm.nih.gov/27443163 27443163]|[https://pubmed.ncbi.nlm.nih.gov/30315103 30315103]|[https://pubmed.ncbi.nlm.nih.gov/23808883 23808883]|[https://pubmed.ncbi.nlm.nih.gov/18812317 18812317]|[https://pubmed.ncbi.nlm.nih.gov/19776078 19776078] <br>
-'''definition''' : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: 22476631] <br>
+ '''definition''' : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: 22476631] <br>
-'''term_xref''' : SID:163312364|KEGG:G13066 <br>
+ '''term_xref''' : SID:163312364|KEGG:G13066 <br>
-'''best_match''' : SID:163312364|KEGG:G13066 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' : The bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression through modulating N-glycan/galectin interactions.[PMID: [https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]]Inhibits growth factor signaling and retards mammary tumor progression[PMID: [https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]]Integrin-mediated cell adhesion [PMID: [https://pubmed.ncbi.nlm.nih.gov/20816221 20816221]]Important in fertilization and fetal development, neuritogenesis, immune tolerance, immunoglobulin G (IgG)[PMID: [https://pubmed.ncbi.nlm.nih.gov/32719771 32719771]] <br>
-'''function''' : The bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression through modulating N-glycan/galectin interactions.[PMID: 22476631]Inhibits growth factor signaling and retards mammary tumor progression[PMID: 20395209]Integrin-mediated cell adhesion [PMID: 20816221]Important in fertilization and fetal development, neuritogenesis, immune tolerance, immunoglobulin G (IgG)[PMID: 32719771] <br>
+ '''disease_associations''' : mammary tumor.[PMID: [https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]] <br>
-'''disease_associations''' : mammary tumor.[PMID: 20395209] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
-'''essentials_of_glycobiology''' : NBK453020 <br>
 ===Bisialo-biantennary===
-'''term (main_entry)''' : Bisialo-biantennary <br>
+ '''term (main_entry)''' : Bisialo-biantennary <br>
-'''glycan_dictionary_accession''' : GD000025 <br>
+ '''glycan_dictionary_accession''' : GSD000025 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. <br>
+ '''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. <br>
-'''publication''' : 2386787|2065054 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] <br>
-'''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br>
+ '''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+  '''synonyms''' : disialo biantennary|disialo diantennary|disialylated biantennary|disialylated diantennary <br>
-'''synonymns''' : disialo biantennary|disialo diantennary|disialylated biantennary|disialylated diantennary <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Bisialo-biantennary complex-type===
-'''term (main_entry)''' : Bisialo-biantennary complex-type <br>
+ '''term (main_entry)''' : Bisialo-biantennary complex-type <br>
-'''glycan_dictionary_accession''' : GD000026 <br>
+ '''glycan_dictionary_accession''' : GSD000026 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID:2386787] <br>
+ '''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]] <br>
-'''publication''' : 2386787|26966183 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183] <br>
-'''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae.  <br>
+ '''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae.  <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' : Fully sialylated biantennary N-glycan <br>
-'''synonymns''' : Fully sialylated biantennary N-glycan <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453089/ Chapter 25] <br>
-'''essentials_of_glycobiology''' : NBK453089-Chapter 25 <br>
+===Blood group A trisaccharide===
+[[File:G00066MO.png|thumb|G00066MO]]
+ '''term (main_entry)''' : Blood group A trisaccharide <br>
+ '''glycan_dictionary_accession''' : GSD000029 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00066MO G00066MO] <br>
+ '''term_in_sentence''' : A readily detectable carbohydrate in the urine of two siblings with neuronal ceroid lipofuscinosis was found to be the blood group A trisaccharide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7249368 7249368]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19582848 19582848]|[https://pubmed.ncbi.nlm.nih.gov/7249368 7249368]|[https://pubmed.ncbi.nlm.nih.gov/8774717 8774717]|[https://pubmed.ncbi.nlm.nih.gov/2749874 2749874]|[https://pubmed.ncbi.nlm.nih.gov/28771597 28771597]|[https://pubmed.ncbi.nlm.nih.gov/30619340 30619340]|[https://pubmed.ncbi.nlm.nih.gov/2122121 2122121]|[https://pubmed.ncbi.nlm.nih.gov/11886841 11886841]|[https://pubmed.ncbi.nlm.nih.gov/2991755 2991755]|[https://pubmed.ncbi.nlm.nih.gov/12588002 12588002]|[https://pubmed.ncbi.nlm.nih.gov/3149698 3149698]|[https://pubmed.ncbi.nlm.nih.gov/7048329 7048329]|[https://pubmed.ncbi.nlm.nih.gov/7015594 7015594]|[https://pubmed.ncbi.nlm.nih.gov/10359132 10359132]|[https://pubmed.ncbi.nlm.nih.gov/8724140 8724140]|[https://pubmed.ncbi.nlm.nih.gov/1418679 1418679]|[https://pubmed.ncbi.nlm.nih.gov/1446307 1446307] <br>
+ '''definition''' : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] <br>
+ '''term_xref''' : GlycoEpitope:EP0255|GTC:G00066MO|CID:49852448|KEGG:G10638|CHEBI:61012 <br>
+ '''synonyms''' : blood group A trisaccharide|blood group A type 1 trisaccharide <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===Blood group A (Type 1)===
+[[File:G66163TI.png|thumb|G66163TI]]
+ '''term (main_entry)''' : Blood group A (Type 1) <br>
+ '''glycan_dictionary_accession''' : GSD000030 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G66163TI G66163TI] <br>
+ '''term_in_sentence''' : he basis of blood group A(1) and A(2) phenotypes has been debated for many decades, and still the chemical basis is unresolved. [PMID:[https://pubmed.ncbi.nlm.nih.gov/19121199 19121199]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10942408 10942408]|[https://pubmed.ncbi.nlm.nih.gov/19121199 19121199] <br>
+ '''definition''' : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] <br>
+ '''term_xref''' : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 <br>
+ '''synonyms''' : Blood group A(1)|blood group A antigen type 1 <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===Blood group A (Type 1) - Lewis b===
+[[File:G97501MA.png|thumb|G97501MA]]
+ '''term (main_entry)''' : Blood group A (Type 1) - Lewis b<br>
+ '''glycan_dictionary_accession''' : GSD000190<br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97501MA G97501MA] <br>
+ '''term_in_sentence''' :  Ten monoclonal antibodies and one lectin were used to study the localization and distribution of Blood Group ABH, type 1 chain (Lewis a, Lewis b) and type 2 chain (H-2, Y) antigens in 22 cases of normal uterine cervix, with known ABO and Lewis phenotype and secretor status.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]]<br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/4041428 4041428]|[https://pubmed.ncbi.nlm.nih.gov/5686860 5686860]<br>
+ '''definition''' :  A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 4 of the glucosamine. Corresponds to a partial structure of blood group A type 1 oligosaccharide.[CHEBI:62988]<br>
+ '''term_xref''' : GlycoMotif:GGM.000047|CID:53477630|CHEBI:62988|GlycoEpitope:EP0260<br>
+ '''synonyms''' :  Blood Group A Type 1 (difucosyl)|ALe^b|A-Leb|A-Le^b|A Lewis b<br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===Blood group A (type 2) - Lewis y===
-'''term (main_entry)''' : Blood group A (type 2) - Lewis y <br>
-'''glycan_dictionary_accession''' : GD000027 <br>
-'''glytoucan_accession ''' : G54826OZ <br>
-'''term_in_sentence''' : Monoclonal antibodies defining blood group A variants with difucosyl type 1 chain (ALeb) and difucosyl type 2 chain (ALey).[PMID:2417620] <br>
-'''publication''' : 2417620 <br>
-'''definition''' : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] <br>
-'''term_xref''' : GlycoEpitope:EP0261|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039 <br>
-'''best_match''' : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039 <br>
-'''synonymns''' : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===Blood group A (Type 2)===
+[[File:G74353FF.png|thumb|G74353FF]]
+ '''term (main_entry)''' : Blood group A (Type 2) <br>
+ '''glycan_dictionary_accession''' : GSD000014 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74353FF G74353FF] <br>
+ '''term_in_sentence''' : One hybridoma antibody (AH16), obtained on immunization with human gastric cancer cell MKN45, was directed to the blood group A determinant carried by both type 1 and type 2 chains. [PMID:[https://pubmed.ncbi.nlm.nih.gov/6583282 6583282]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27196314 27196314]|[https://pubmed.ncbi.nlm.nih.gov/6583282 6583282]|[https://pubmed.ncbi.nlm.nih.gov/8340255 8340255]|[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]|[https://pubmed.ncbi.nlm.nih.gov/21901093 21901093]|[https://pubmed.ncbi.nlm.nih.gov/2413709 2413709]|[https://pubmed.ncbi.nlm.nih.gov/8036794 8036794]|[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]|[https://pubmed.ncbi.nlm.nih.gov/3285099 3285099] <br>
+ '''definition''' : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] <br>
+ '''term_xref''' : GTC:G74353FF|CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 <br>
+ '''synonyms''' : A Type 2|Blood group A type 2 chain<br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===Blood group A (Type 4)===
-'''term (main_entry)''' : Blood group A (Type 4) <br>
-'''glycan_dictionary_accession''' : GD000028 <br>
-'''glytoucan_accession ''' : G37830TX <br>
-'''term_in_sentence''' : Moreover, we have found that αGal, but not αGalNAc, is a weak binder itself for DC-SIGN, which could endow an additional binding mode for the blood group B antigen, but not for blood group A.[PMID:31283166] <br>
-'''publication''' : 7800218|7521740|2458640|31283166 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000088|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48 <br>
-'''best_match''' : GlycoMotif:GGM.000088|GTC:G37830TX|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : Pyelonephritis[SugarBind_Ligand:48]|Acute cystitis[SugarBind_Ligand:48] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===Blood group A (Type 2) - Lewis y===
+[[File:G54826OZ.png|thumb|G54826OZ]]
+ '''term (main_entry)''' : Blood group A (Type 2) - Lewis y <br>
+ '''glycan_dictionary_accession''' : GSD000027 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54826OZ G54826OZ] <br>
+ '''term_in_sentence''' : Monoclonal antibodies defining blood group A variants with difucosyl type 1 chain (ALeb) and difucosyl type 2 chain (ALey).[PMID:[https://pubmed.ncbi.nlm.nih.gov/2417620 2417620]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2417620 2417620] <br>
+ '''definition''' : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] <br>
+ '''term_xref''' : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039 <br>
+ '''synonyms''' : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===Blood group A trisaccharide===
-'''term (main_entry)''' : Blood group A trisaccharide <br>
-'''glycan_dictionary_accession''' : GD000029 <br>
-'''glytoucan_accession ''' : G00066MO <br>
-'''term_in_sentence''' : A readily detectable carbohydrate in the urine of two siblings with neuronal ceroid lipofuscinosis was found to be the blood group A trisaccharide.[PMID:7249368] <br>
-'''publication''' : 19582848|7249368|8774717|2749874|28771597|30619340|2122121|11886841|2991755|12588002|3149698|7048329|7015594|10359132|8724140|1418679|1446307 <br>
-'''definition''' : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] <br>
-'''term_xref''' : GlycoEpitope:EP0255|CID:49852448|KEGG:G10638|CHEBI:61012 <br>
-'''best_match''' : GlycoEpitope:EP0255|GTC:G00066MO|CID:49852448|KEGG:G10638|CHEBI:61012 <br>
-'''synonymns''' : blood group A trisaccharide|blood group A type 1 trisaccharide <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===Blood group A (Type 3)===
+[[File:G99315PE.png|thumb|G99315PE]]
+ '''term (main_entry)''' : Blood group A (Type 3)<br>
+ '''glycan_dictionary_accession''' : GSD000187<br>
+ '''glytoucan_accession ''' : [https://glygen.org/glycan/G99315PE G99315PE]<br>
+ '''term_in_sentence''' : <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7800218 7800218]|[https://pubmed.ncbi.nlm.nih.gov/17998569 17998569]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/3191504 3191504]<br>
+ '''definition''' : <br>
+ '''term_xref''' : GlycoMotif:GGM.000011|GTC:[https://glygen.org/glycan/G99315PE G99315PE]<br>
+ '''synonyms''' :  A type 3 antigen|blood group A type 3|A antigen (type 3)<br>
+ '''function''' : <br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  [https://www.ncbi.nlm.nih.gov/books/NBK579929/ Chapter 14]<br>
-===Blood group A(1)===
+===Blood group A (Type 4)===
-'''term (main_entry)''' : Blood group A(1) <br>
+[[File:G37830TX.png|thumb|G37830TX]]
-'''glycan_dictionary_accession''' : GD000030 <br>
+ '''term (main_entry)''' : Blood group A (Type 4) <br>
-'''glytoucan_accession ''' : G66163TI <br>
+ '''glycan_dictionary_accession''' : GSD000028 <br>
-'''term_in_sentence''' : he basis of blood group A(1) and A(2) phenotypes has been debated for many decades, and still the chemical basis is unresolved. [PMID:19121199] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G37830TX G37830TX] <br>
-'''publication''' : 10942408|19121199 <br>
+ '''term_in_sentence''' : Moreover, we have found that αGal, but not αGalNAc, is a weak binder itself for DC-SIGN, which could endow an additional binding mode for the blood group B antigen, but not for blood group A.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31283166 31283166]] <br>
-'''definition''' : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7800218 7800218]|[https://pubmed.ncbi.nlm.nih.gov/7521740 7521740]|[https://pubmed.ncbi.nlm.nih.gov/2458640 2458640]|[https://pubmed.ncbi.nlm.nih.gov/31283166 31283166] <br>
-'''term_xref''' : GlycoMotif:GGM.000044|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 <br>
+ '''term_xref''' : GlycoMotif:GGM.000088|GTC:G37830TX|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48 <br>
-'''synonymns''' : Blood group A (type 1)|blood group A antigen type 1 <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:48]|Acute cystitis[SugarBind_Ligand:48] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===Blood group A1 (type 3)===
+===Blood group A1 (Type 3)===
-'''term (main_entry)''' : Blood group A1 (type 3) <br>
+[[File:G44060QH.png|thumb|G44060QH]]
-'''glycan_dictionary_accession''' : GD000031 <br>
+ '''term (main_entry)''' : Blood group A1 (Type3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                '''glycan_dictionary_accession''' : GSD000031 <br>
-'''glytoucan_accession ''' : G44060QH <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G44060QH G44060QH] <br>
-'''term_in_sentence''' : The structure is essentially a repetitive A epitope attached to type 2 chain and is hereby called type 3 chain A. [PMID:2579390] <br>
+ '''term_in_sentence''' : The structure is essentially a repetitive A epitope attached to type 2 chain and is hereby called type 3 chain A. [PMID:[https://pubmed.ncbi.nlm.nih.gov/2579390 2579390]] <br>
-'''publication''' : 2579390|19756298 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2579390 2579390]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298] <br>
-'''definition''' : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665] <br>
+ '''definition''' : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665] <br>
-'''term_xref''' : CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040 <br>
+ '''term_xref''' : GTC:G44060QH|CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040 <br>
-'''best_match''' : GTC:G44060QH|CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040 <br>
+ '''synonyms''' : Blood group A1 (type 3)|Blood Group A1 <br>
-'''synonymns''' : Blood group A1 (type 3)|Blood Group A1 <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Blood group A2 (A-associated H type 3)===
-'''term (main_entry)''' : Blood group A2 (A-associated H type 3) <br>
+[[File:G62735WZ.png|thumb|G62735WZ]]
-'''glycan_dictionary_accession''' : GD000032 <br>
+ '''term (main_entry)''' : Blood group A2 (A-associated H type 3) <br>
-'''glytoucan_accession ''' : G62735WZ <br>
+ '''glycan_dictionary_accession''' : GSD000032<br>
-'''term_in_sentence''' : The 'H NMR spectrum of the Aassociated H antigen (type 3 chain H) was characterized by
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G44060QH G62735WZ] <br>
- the unusual presence of three n-anomeric resonances ('CJ'.~ =
+ '''term_in_sentence''' : The H NMR spectrum of the associated H antigen (type 3 chain H) was characterized by the unusual presence of three n-anomeric resonances ('CJ'.~ = 3-4 Hz) in addition to five resonances from @-anomeric protons ("J1:2 = 7-9 Hz).[PMID: [https://pubmed.ncbi.nlm.nih.gov/3944091 3944091]]<br>
--4 Hz) in addition to five resonances from @-anomeric protons ("J1:2 = 7-9 Hz).[PMID: 3944091] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3944091 3944091]|[https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771]<br>
-'''publication''' : 3944091 <br>
+ '''definition''' : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543] <br>
-'''definition''' : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543] <br>
+ '''term_xref''' : CHEBI:152543|CID:91852328|GlycoMotif:GGM.000041|GTC:G62735WZ<br>
-'''term_xref''' : CHEBI:152543|CID:91852328|GlycoMotif:GGM.000041 <br>
+ '''synonyms''' : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose<br>
-'''best_match''' : CHEBI:152543|CID:91852328|GlycoMotif:GGM.000041|GTC:G62735WZ <br>
+ '''function''' :  <br>
-'''synonymns''' : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose <br>
+ '''disease_associations''' :  <br>
-'''function''' :  <br>
+ '''wikipedia''' :  <br>
-'''disease_associations''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Blood group B (Type 1)===
-'''term (main_entry)''' : Blood group B (Type 1) <br>
+[[File:G31734OS.png|thumb|G31734OS]]
-'''glycan_dictionary_accession''' : GD000033 <br>
+ '''term (main_entry)''' : Blood group B (Type 1) <br>
-'''glytoucan_accession ''' : G31734OS <br>
+ '''glycan_dictionary_accession''' : GSD000033 <br>
-'''term_in_sentence''' : It has been unknown whether NoV distinguishes between the type 1 and type 2 chains of A and B antigens. In this study, we synthesized A type 1, A type 2, B type 1, and B type 2 pentasaccharides in vitro and examined the function of the core structures in the binding between NoV virus-like particles (VLPs) and HBGAs. [PMID: 18701592] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G31734OS G31734OS] <br>
-'''publication''' : 18701592|24749871|19387828|19208633|29562255 <br>
+ '''term_in_sentence''' : The minimal binding epitope was identified as the blood group H type 1 determinant (Fucα2Galβ3GlcNAc), while an optimal binding epitope was created by addition of the terminal α3-linked galactose or N-acetylgalactosamine of the blood group B type 1 determinant (Galα3(Fucα2)Galβ3GlcNAc) and the blood group A type 1 determinant (GalNAcα3(Fucα2)-Galβ3GlcNAc). [PMID: [https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]] <br>
-'''definition''' : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]|[https://pubmed.ncbi.nlm.nih.gov/24749871 24749871]|[https://pubmed.ncbi.nlm.nih.gov/19387828 19387828]|[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]|[https://pubmed.ncbi.nlm.nih.gov/29562255 29562255] <br>
-'''term_xref''' : GlycoMotif:GGM.000043|CID:56927779|CHEBI:63242 <br>
+ '''definition''' : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242] <br>
-'''best_match''' : GlycoMotif:GGM.000043|GTC:G31734OS|CID:56927779|CHEBI:63242 <br>
+ '''term_xref''' : GlycoMotif:GGM.000043|GTC:G31734OS|CID:56927779|CHEBI:63242 <br>
-'''synonymns''' : blood group B type 1 tetrasaccharide <br>
+ '''synonyms''' : blood group B type 1 tetrasaccharide <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===Blood group B (Type 1) - Lewis b===
+[[File:G89208KM.png|thumb|G89208KM]]
+ '''term (main_entry)''' : Blood group B (Type 1) - Lewis b<br>
+ '''glycan_dictionary_accession''' : GSD000189<br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G89208KM G89208KM] <br>
+ '''term_in_sentence''' :  Ten monoclonal antibodies and one lectin were used to study the localization and distribution of Blood Group ABH, type 1 chain (Lewis a, Lewis b) and type 2 chain (H-2, Y) antigens in 22 cases of normal uterine cervix, with known ABO and Lewis phenotype and secretor status. [PMID:[https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]]<br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/30831115 30831115]<br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000046<br>
+ '''synonyms''' :  Blood Group B, type 1 chain (Lewis b)|B-Leb|B-Le^b<br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Blood group B (Type 2)===
-'''term (main_entry)''' : Blood group B (Type 2) <br>
+[[File:G34881WK.png|thumb|G34881WK]]
-'''glycan_dictionary_accession''' : GD000034 <br>
+ '''term (main_entry)''' : Blood group B (Type 2) <br>
-'''glytoucan_accession ''' : G34881WK <br>
+ '''glycan_dictionary_accession''' : GSD000034 <br>
-'''term_in_sentence''' : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID:2432062] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G34881WK G34881WK] <br>
-'''publication''' : 2432062|27196314|18701592 <br>
+ '''term_in_sentence''' : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]|[https://pubmed.ncbi.nlm.nih.gov/27196314 27196314]|[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592] <br>
-'''term_xref''' : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262|GlycoMotif:GGM.000037 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262 <br>
+ '''term_xref''' : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262 <br>
-'''synonymns''' : blood group B type 2 <br>
+ '''synonyms''' : blood group B type 2 <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Blood group B (Type 4)===
-'''term (main_entry)''' : Blood group B (Type 4) <br>
+[[File:G25216QA.png|thumb|G25216QA]]
-'''glycan_dictionary_accession''' : GD000035 <br>
+ '''term (main_entry)''' : Blood group B (Type 4) <br>
-'''glytoucan_accession ''' : G25216QA <br>
+ '''glycan_dictionary_accession''' : GSD000035 <br>
-'''term_in_sentence''' : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:1390942] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25216QA G25216QA] <br>
-'''publication''' : 1390942|1841684 <br>
+ '''term_in_sentence''' : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1390942 1390942]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1390942 1390942]|[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684] <br>
-'''term_xref''' : GlycoMotif:GGM.000087 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000087|GTC:G25216QA <br>
+ '''term_xref''' : GlycoMotif:GGM.000087|GTC:G25216QA <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Blood group H (Type 1)===
-'''term (main_entry)''' : Blood group H (Type 1) <br>
+[[File:G00294TN.png|thumb|G00294TN]]
-'''glycan_dictionary_accession''' : GD000036 <br>
+ '''term (main_entry)''' : Blood group H (Type 1) <br>
-'''glytoucan_accession ''' : G00294TN <br>
+ '''glycan_dictionary_accession''' : GSD000036 <br>
-'''term_in_sentence''' : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:7718581] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00294TN G00294TN] <br>
-'''publication''' : 7718581|6309836|19208633|27431816|2432062|24219248|6352465|8499478|3348768|3718924 <br>
+ '''term_in_sentence''' : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:[https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]|[https://pubmed.ncbi.nlm.nih.gov/6309836 6309836]|[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]|[https://pubmed.ncbi.nlm.nih.gov/27431816 27431816]|[https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]|[https://pubmed.ncbi.nlm.nih.gov/24219248 24219248]|[https://pubmed.ncbi.nlm.nih.gov/6352465 6352465]|[https://pubmed.ncbi.nlm.nih.gov/8499478 8499478]|[https://pubmed.ncbi.nlm.nih.gov/3348768 3348768]|[https://pubmed.ncbi.nlm.nih.gov/3718924 3718924] <br>
-'''term_xref''' : GlycoMotif:GGM.000042|SugarBind_Ligand:153 <br>
+ '''definition''' :  <br>
-'''best_match''' : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153 <br>
+ '''term_xref''' : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153 <br>
-'''synonymns''' : H type 1 <br>
+ '''synonyms''' : H type 1 <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:153] <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:153] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===Blood group H (Type 2)===
+[[File:G70519XK.png|alt=|thumb|G70519XK]]
+ '''term (main_entry)''' : Blood group H (Type 2) <br>
+ '''glycan_dictionary_accession''' : GSD000037 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G70519XK G70519XK] <br>
+ '''term_in_sentence''' : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9405495 9405495]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9405495 9405495]|[https://pubmed.ncbi.nlm.nih.gov/8082855 8082855]|[https://pubmed.ncbi.nlm.nih.gov/6177241 6177241]|[https://pubmed.ncbi.nlm.nih.gov/3944092 3944092]|[https://pubmed.ncbi.nlm.nih.gov/21406562 21406562]|[https://pubmed.ncbi.nlm.nih.gov/2410664 2410664]|[https://pubmed.ncbi.nlm.nih.gov/8731502 8731502]|[https://pubmed.ncbi.nlm.nih.gov/6203846 6203846]|[https://pubmed.ncbi.nlm.nih.gov/2238560 2238560]| <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GTC:G70519XK|GlycoMotif:GGM.000036 <br>
+ '''synonyms''' : Blood group H (type 2)|H type 2|H type 2 chain|H type 2 antigen|type 2 chain H|blood group H type II <br>
+ '''function''' : <br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===Blood group H (type 2)===
+===Blood group H (Type 2) - Lewis y===
-'''term (main_entry)''' : Blood group H (type 2) <br>
+[[File:G00052MO.png|alt=|thumb|G00052MO]]
-'''glycan_dictionary_accession''' : GD000037 <br>
+ '''term (main_entry)''' : Blood group H (Type 2) - Lewis y <br>
-'''glytoucan_accession ''' : G00052MO <br>
+ '''glycan_dictionary_accession''' : GSD000038 <br>
-'''term_in_sentence''' : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID:9405495] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00052MO G00052MO] <br>
-'''publication''' : 9405495|8082855|6177241|3944092|21406562|2410664|8731502|6203846|2238560| <br>
+ '''term_in_sentence''' : The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes.[PMID: [https://pubmed.ncbi.nlm.nih.gov/11479278 11479278]] <br>
-'''definition''' : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11479278 11479278] <br>
-'''term_xref''' : GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000036 <br>
+ '''definition''' : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] <br>
-'''best_match''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000036 <br>
+ '''term_xref''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045 <br>
-'''synonymns''' : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Blood group H (type 2) (Lewis Y)|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|6-deoxy-alpha-L-galactopyranosyl-(1→3)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→4)]-2-acetamido-2-deoxy-beta-D-glucopyranose|alpha-L-Fuc-(1→2)-beta-D-Gal-(1→4)-[alpha-L-Fuc-(1→3)]-beta-D-GlcNAc|alpha-L-Fucp-(1→2)-beta-D-Galp-(1→4)-[alpha-L-Fucp-(1→3)]-beta-D-GlcpNAc|Fucalpha1-2Galbeta1-4(Fucalpha1-3)GlcNAcbeta|Fucalpha1-3(Fucalpha1-2Galbeta1-4)GclNAc|Lewis y Tetrasaccharide <br>
+ '''synonyms''' : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y <br>
-'''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
+ '''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
-'''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018] <br>
+ '''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===Blood group H (type 2) - Lewis y===
+===Blood group H (Type 3)===
-'''term (main_entry)''' : Blood group H (type 2) - Lewis y <br>
+[[File:G94435QH.png|thumb|G94435QH]]
-'''glycan_dictionary_accession''' : GD000038 <br>
+ '''term (main_entry)''' : Blood group H (Type 3) <br>
-'''glytoucan_accession ''' : G00052MO <br>
+ '''glycan_dictionary_accession''' : GSD000105 <br>
-'''term_in_sentence''' : The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes.[PMID: 11479278] <br>
+ '''glytoucan_accession ''' :  [https://glygen.org/glycan/G94435QH G94435QH]<br>
-'''publication''' : 11479278 <br>
+ '''term_in_sentence''' : One particular lambody, VLRB.aGPA.23, was shown by glycan array analysis to be selective for the blood group H type 3 trisaccharide (BG-H3, Fucα1-2Galβ1-3GalNAcα), aGPA, and TFα (Galβ1-3GalNAcα), with affinity constants of 0.2, 1, and 8 nM, respectively.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23030719 23030719]] <br>
-'''definition''' : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23030719 23030719]|[https://pubmed.ncbi.nlm.nih.gov/20466654 20466654]|[https://pubmed.ncbi.nlm.nih.gov/1563908 1563908]|[https://pubmed.ncbi.nlm.nih.gov/3944092 3944092]|[https://pubmed.ncbi.nlm.nih.gov/11218748 11218748]|[https://pubmed.ncbi.nlm.nih.gov/11101633 11101633]|[https://pubmed.ncbi.nlm.nih.gov/18842005 18842005]|[https://pubmed.ncbi.nlm.nih.gov/27550195 27550195]|[https://pubmed.ncbi.nlm.nih.gov/2469783 2469783]|[https://pubmed.ncbi.nlm.nih.gov/2433836 2433836]|[https://pubmed.ncbi.nlm.nih.gov/23118206 23118206]|[https://pubmed.ncbi.nlm.nih.gov/8445257 8445257]|[https://pubmed.ncbi.nlm.nih.gov/2664192 2664192]|[https://pubmed.ncbi.nlm.nih.gov/3063304 3063304] <br>
-'''term_xref''' : GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045 <br>
+ '''definition''' :  <br>
-'''best_match''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045 <br>
+ '''term_xref''' :  GlycoMotif:GGM.000010|GTC:G94435QH<br>
-'''synonymns''' : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y <br>
+ '''synonyms''' : H type 3|H antigen (type 3)|Type 3 chain H <br>
-'''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
+ '''function''' :  <br>
-'''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018] <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
 ===Blood group H (Type 4)===
-'''term (main_entry)''' : Blood group H (Type 4) <br>
+[[File:G98465JN.png|thumb|G98465JN]]
-'''glycan_dictionary_accession''' : GD000039 <br>
+ '''term (main_entry)''' : Blood group H (Type 4) <br>
-'''glytoucan_accession ''' : G98465JN <br>
+ '''glycan_dictionary_accession''' : GSD000039 <br>
-'''term_in_sentence''' : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID:1841684] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G98465JN G98465JN] <br>
-'''publication''' : 11261842|1841684|11101633|9405495 <br>
+ '''term_in_sentence''' : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684]] <br>
-'''definition''' : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11261842 11261842]|[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684]|[https://pubmed.ncbi.nlm.nih.gov/11101633 11101633]|[https://pubmed.ncbi.nlm.nih.gov/9405495 9405495] <br>
-'''term_xref''' : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245 <br>
+ '''definition''' : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245] <br>
-'''best_match''' : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245 <br>
+ '''term_xref''' : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+  '''function''' :  <br>
-'''disease_associations''' : Pyelonephritis[SugarBind_Ligand:61] <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:61] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===C2-O-sLex===
-'''term (main_entry)''' : C2-O-sLex <br>
+[[File:G97345NY.png|thumb|G97345NY]]
-'''glycan_dictionary_accession''' : GD000040 <br>
+ '''term (main_entry)''' : C2-O-sLex <br>
-'''glytoucan_accession ''' : G97345NY <br>
+ '''glycan_dictionary_accession''' : GSD000040 <br>
-'''term_in_sentence''' : PSGL-1 lacks 6-sulfo-sLex but contains sulfated tyrosine residues (Tyr-SO3)at positions 46, 48, and 51 and sLex in a core 2-based O-glycan (C2-O-sLex) on Thr at position 57.[PMID:12736247] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97345NY G97345NY] <br>
-'''publication''' : 12736247|19267921|21283832|15596301|17072011 <br>
+ '''term_in_sentence''' : PSGL-1 lacks 6-sulfo-sLex but contains sulfated tyrosine residues (Tyr-SO3)at positions 46, 48, and 51 and sLex in a core 2-based O-glycan (C2-O-sLex) on Thr at position 57.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12736247 12736247]] <br>
-'''definition''' : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12736247 12736247]|[https://pubmed.ncbi.nlm.nih.gov/19267921 19267921]|[https://pubmed.ncbi.nlm.nih.gov/21283832 21283832]|[https://pubmed.ncbi.nlm.nih.gov/15596301 15596301]|[https://pubmed.ncbi.nlm.nih.gov/17072011 17072011] <br>
-'''term_xref''' : GlycoMotif:GGM.000053|CID:91860725|KEGG:G10899|CHEBI:155160 <br>
+ '''definition''' : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192] <br>
-'''best_match''' : GlycoMotif:GGM.000053|GTC:G97345NY|CID:91860725|KEGG:G10899|CHEBI:155160 <br>
+ '''term_xref''' : GlycoMotif:GGM.000053|GTC:G97345NY|CID:91860725|KEGG:G10899|CHEBI:155160 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Ceramide dihexosyl sulfate===
-'''term (main_entry)''' : Ceramide dihexosyl sulfate <br>
+[[File:G04416BG.png|thumb|G04416BG]]
-'''glycan_dictionary_accession''' : GD000041 <br>
+ '''term (main_entry)''' : Ceramide dihexosyl sulfate <br>
-'''glytoucan_accession ''' : G04416BG <br>
+ '''glycan_dictionary_accession''' : GSD000041 <br>
-'''term_in_sentence''' : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:818074] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G04416BG G04416BG] <br>
-'''publication''' : 818074 <br>
+ '''term_in_sentence''' : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:[https://pubmed.ncbi.nlm.nih.gov/818074 818074]] <br>
-'''definition''' : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides.[http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/818074 818074] <br>
-'''term_xref''' : GlycoMotif:GGM.000065 <br>
+ '''definition''' : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides. [http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/<nowiki>] </nowiki><br>
-'''best_match''' : GTC:G04416BG|GlycoMotif:GGM.000065 <br>
+ '''term_xref''' : GTC:G04416BG|GlycoMotif:GGM.000065 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===Chitin===
+===Chondroitin sulfate===
-'''term (main_entry)''' : Chitin <br>
+ '''term (main_entry)''' : Chondroitin sulfate <br>
-'''glycan_dictionary_accession''' : GD000042 <br>
+ '''glycan_dictionary_accession''' : GSD000043 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241] <br>
+ '''term_in_sentence''' : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: [https://pubmed.ncbi.nlm.nih.gov/31013685 31013685]] <br>
-'''publication''' : 25738328|31102247|26982439|31685194|29197571|29182521|25725011|27787767|21736263|25300540|30840869|25081074|28250359|29763421|29910219|20161969|32019265|30879650|12587986|29773374|31376451|10906950|26096004|25595947|21673932|29452181|24083454|10856926|22732132|18657571|29175166|28842199|27592817|27302593|27339323|12705640|31635752|31063786|31151236|25940531|26093316|28962761|28093332|30875044|27723949|28119189|30600008|25081085|21673932 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31013685 31013685]|[https://pubmed.ncbi.nlm.nih.gov/27526113 27526113]|[https://pubmed.ncbi.nlm.nih.gov/27194526 27194526]|[https://pubmed.ncbi.nlm.nih.gov/26980567 26980567]|[https://pubmed.ncbi.nlm.nih.gov/28847361 28847361]|[https://pubmed.ncbi.nlm.nih.gov/24413804 24413804]|[https://pubmed.ncbi.nlm.nih.gov/29891297 29891297]|[https://pubmed.ncbi.nlm.nih.gov/29600622 29600622]|[https://pubmed.ncbi.nlm.nih.gov/25129732 25129732]|[https://pubmed.ncbi.nlm.nih.gov/31317901 31317901]|[https://pubmed.ncbi.nlm.nih.gov/29181550 29181550]|31250530|[https://pubmed.ncbi.nlm.nih.gov/22265655 22265655]|[https://pubmed.ncbi.nlm.nih.gov/25756648 25756648]|[https://pubmed.ncbi.nlm.nih.gov/29402610 29402610]|[https://pubmed.ncbi.nlm.nih.gov/17928217 17928217]|[https://pubmed.ncbi.nlm.nih.gov/20236040 20236040]|[https://pubmed.ncbi.nlm.nih.gov/28091940 28091940]|[https://pubmed.ncbi.nlm.nih.gov/30824935 30824935]|[https://pubmed.ncbi.nlm.nih.gov/26572336 26572336]|[https://pubmed.ncbi.nlm.nih.gov/31207331 31207331]|[https://pubmed.ncbi.nlm.nih.gov/21110089 21110089]|[https://pubmed.ncbi.nlm.nih.gov/30599999 30599999]|[https://pubmed.ncbi.nlm.nih.gov/20399897 20399897]|[https://pubmed.ncbi.nlm.nih.gov/27226567 27226567]|[https://pubmed.ncbi.nlm.nih.gov/19388612 19388612]|[https://pubmed.ncbi.nlm.nih.gov/23186102 23186102]|[https://pubmed.ncbi.nlm.nih.gov/31494830 31494830]|[https://pubmed.ncbi.nlm.nih.gov/28982096 28982096]|[https://pubmed.ncbi.nlm.nih.gov/30241863 30241863]|[https://pubmed.ncbi.nlm.nih.gov/30295666 30295666]|[https://pubmed.ncbi.nlm.nih.gov/25366475 25366475]|[https://pubmed.ncbi.nlm.nih.gov/20521042 20521042]|[https://pubmed.ncbi.nlm.nih.gov/29456007 29456007]|[https://pubmed.ncbi.nlm.nih.gov/31304829 31304829]|[https://pubmed.ncbi.nlm.nih.gov/18661362 18661362]|[https://pubmed.ncbi.nlm.nih.gov/28576008 28576008]|[https://pubmed.ncbi.nlm.nih.gov/29494632 29494632]|[https://pubmed.ncbi.nlm.nih.gov/30016441 30016441]|[https://pubmed.ncbi.nlm.nih.gov/26906924 26906924]|[https://pubmed.ncbi.nlm.nih.gov/24861964 24861964]|[https://pubmed.ncbi.nlm.nih.gov/23774590 23774590]|[https://pubmed.ncbi.nlm.nih.gov/31887904 31887904]|[https://pubmed.ncbi.nlm.nih.gov/31339761 31339761]|[https://pubmed.ncbi.nlm.nih.gov/12512856 12512856]|[https://pubmed.ncbi.nlm.nih.gov/26957048 26957048]|[https://pubmed.ncbi.nlm.nih.gov/29625000 29625000] <br>
-'''definition''' : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029] <br>
+ '''definition''' : Any of a class of 10‚Äî60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397] <br>
-'''term_xref''' : CHEBI:17029 <br>
+ '''term_xref''' : CHEBI:37397|CID:24766 <br>
-'''best_match''' : CHEBI:17029 <br>
+ '''synonyms''' : chondroitin polysulfate|chondroitin sulfate|chondroitin sulfates|chondroitin sulfuric acid|chondroitin sulphate|Chondroitinsulfate <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
-===Chondroitin sulfate===
+===Chondroitin sulfate/dermatan sulfate===
-'''term (main_entry)''' : Chondroitin sulfate <br>
+ '''term (main_entry)''' : Chondroitin sulfate/dermatan sulfate<br>
-'''glycan_dictionary_accession''' : GD000043 <br>
+ '''glycan_dictionary_accession''' : GSD000184<br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' : <br>
-'''term_in_sentence''' : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: 31013685] <br>
+ '''term_in_sentence''' : Heparan sulfate (HS) and chondroitin sulfate/dermatan sulfate (CS/DS) proteoglycans are heavily glycosylated proteins, crucial for animal development and homeostasis. [PMID:[https://pubmed.ncbi.nlm.nih.gov/35192612 35192612]]<br>
-'''publication''' : 31013685|27526113|27194526|26980567|28847361|24413804|29891297|29600622|25129732|31317901|29181550|31250530|22265655|25756648|29402610|17928217|20236040|28091940|30824935|26572336|31207331|21110089|30599999|20399897|27226567|19388612|23186102|31494830|28982096|30241863|30295666|25366475|20521042|29456007|31304829|18661362|28576008|29494632|30016441|26906924|24861964|23774590|31887904|31339761|12512856|26957048|29625000 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/35192612 35192612]|[https://pubmed.ncbi.nlm.nih.gov/35425970 35425970]<br>
-'''definition''' : Any of a class of 10‚Äî60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397] <br>
+ '''definition''' : <br>
-'''term_xref''' : CHEBI:37397|CID:24766 <br>
+ '''term_xref''' :<br>
-'''best_match''' : CHEBI:37397| CID: 24766 <br>
+ '''synonyms''' :  CS/DS|chondroitin/dermatan sulfate<br>
-'''synonymns''' : chondroitin polysulfate|chondroitin sulfate|chondroitin sulfates|chondroitin sulfuric acid|chondroitin sulphate|Chondroitinsulfate <br>
+ '''function''' : <br>
-'''function''' :  <br>
+ '''disease_associations''' : <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===cisGM1===
-'''term (main_entry)''' : cisGM1 <br>
+[[File:G03277YI.png|thumb|G03277YI]]
-'''glycan_dictionary_accession''' : GD000044 <br>
+ '''term (main_entry)''' : cisGM1 <br>
-'''glytoucan_accession ''' : G03277YI <br>
+ '''glycan_dictionary_accession''' : GSD000044 <br>
-'''term_in_sentence''' : Macrophage ganglioside patterns dramatically increase in complexity when murine peritoneal macrophages are stimulated in vivo with the appearance of the sialidase-sensitive monosialoganglioside GM1b (cisGM1) as a major component.[PMID: 9455923] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G03277YI G03277YI] <br>
-'''publication''' : 9455923 <br>
+ '''term_in_sentence''' : Macrophage ganglioside patterns dramatically increase in complexity when murine peritoneal macrophages are stimulated in vivo with the appearance of the sialidase-sensitive monosialoganglioside GM1b (cisGM1) as a major component.[PMID: [https://pubmed.ncbi.nlm.nih.gov/9455923 9455923]] <br>
-'''definition''' : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9455923 9455923] <br>
-'''term_xref''' : GlycoMotif:GGM.000100|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 <br>
+ '''definition''' : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580] <br>
-'''best_match''' : GlycoMotif:GGM.000100|GTC:G03277YI|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 <br>
+ '''term_xref''' : GlycoMotif:GGM.000100|GTC:G03277YI|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 <br>
-'''synonymns''' : GM1b <br>
+ '''synonyms''' : GM1b <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Influenza[SugarBind_Ligand:92] <br>
+ '''disease_associations''' : Influenza[SugarBind_Ligand:92] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453054-Chapter 23 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453054/ Chapter 23] <br>
 ===Complex-type N-glycans===
-'''term (main_entry)''' : Complex-type N-glycans <br>
+ '''term (main_entry)''' : Complex-type N-glycans <br>
-'''glycan_dictionary_accession''' : GD000045 <br>
+ '''glycan_dictionary_accession''' : GSD000045 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:10988252] <br>
+ '''term_in_sentence''' : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:10988252] <br>
-'''publication''' : 29902282|29212795|29343819|27705835|26745022|18399796|16825488|21964725|15864431|22890903|12417032|28039392|19426135|30253927|16794314|19806620|22975979|25931033|15201278|19129634|19129628|24032650|22530754|31021709|30973186|28091941|23115339|20829342|27304954|29090617|21802690|29725121|30471292|16581187|26098720|31080188|1930135|31888963|30844485|24014058|11129583 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29902282 29902282]|[https://pubmed.ncbi.nlm.nih.gov/29212795 29212795]|[https://pubmed.ncbi.nlm.nih.gov/29343819 29343819]|[https://pubmed.ncbi.nlm.nih.gov/27705835 27705835]|[https://pubmed.ncbi.nlm.nih.gov/26745022 26745022]|[https://pubmed.ncbi.nlm.nih.gov/18399796 18399796]|[https://pubmed.ncbi.nlm.nih.gov/16825488 16825488]|[https://pubmed.ncbi.nlm.nih.gov/21964725 21964725]|[https://pubmed.ncbi.nlm.nih.gov/15864431 15864431]|[https://pubmed.ncbi.nlm.nih.gov/22890903 22890903]|[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]|[https://pubmed.ncbi.nlm.nih.gov/28039392 28039392]|[https://pubmed.ncbi.nlm.nih.gov/19426135 19426135]|30253927|[https://pubmed.ncbi.nlm.nih.gov/16794314 16794314]|[https://pubmed.ncbi.nlm.nih.gov/19806620 19806620]|[https://pubmed.ncbi.nlm.nih.gov/22975979 22975979]|[https://pubmed.ncbi.nlm.nih.gov/25931033 25931033]|[https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]|[https://pubmed.ncbi.nlm.nih.gov/19129634 19129634][https://pubmed.ncbi.nlm.nih.gov/19129628 19129628]|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/31021709 31021709]|[https://pubmed.ncbi.nlm.nih.gov/30973186 30973186]|[https://pubmed.ncbi.nlm.nih.gov/28091941 28091941]|[https://pubmed.ncbi.nlm.nih.gov/23115339 23115339]|[https://pubmed.ncbi.nlm.nih.gov/20829342 20829342]|[https://pubmed.ncbi.nlm.nih.gov/27304954 27304954]|[https://pubmed.ncbi.nlm.nih.gov/29090617 29090617]|[https://pubmed.ncbi.nlm.nih.gov/21802690 21802690]|[https://pubmed.ncbi.nlm.nih.gov/29725121 29725121]|[https://pubmed.ncbi.nlm.nih.gov/30471292 30471292]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26098720 26098720]|[https://pubmed.ncbi.nlm.nih.gov/31080188 31080188]|[https://pubmed.ncbi.nlm.nih.gov/1930135 1930135]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/30844485 30844485]|[https://pubmed.ncbi.nlm.nih.gov/24014058 24014058]|[https://pubmed.ncbi.nlm.nih.gov/11129583 11129583] <br>
-'''definition''' : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  <br>
+ '''definition''' : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' : Involved in protein stability.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]] <br>
-'''function''' : Involved in protein stability.[PMID:12417032] <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17] <br>
-'''essentials_of_glycobiology''' : NBK453033-Chapter 17 <br>
+===Core 1===
+[[File:G00031MO.png|thumb|G00031MO]]
+ '''term (main_entry)''' : Core 1<br>
+ '''glycan_dictionary_accession''' : GSD000186<br>
+ '''glytoucan_accession ''' : [https://glygen.org/glycan/G00031MO G00031MO]<br>
+ '''term_in_sentence''' : O-glycans are initiated by the addition of GalNAc to serine or threonine (via the ppGalNAcT family of glycosyltransferases), forming the Tn antigen (GalNAcα-O-Ser/Thr), which is used to generate the core 1 structure (Galβ1,3GalNAcα-O-Ser/Thr) on which most complex and branched O-glycans are derived. [PMID:[https://pubmed.ncbi.nlm.nih.gov/31645367 31645367]]<br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31645367 31645367]|[https://pubmed.ncbi.nlm.nih.gov/32297877 32297877]<br>
+ '''definition''' : <br>
+ '''term_xref''' : GTC:[https://glygen.org/glycan/G00031MO G00031MO]|GlycoMotif:GGM.001005 <br>
+ '''synonyms''' :  C1G<br>
+ '''function''' : <br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Core 2===
-'''term (main_entry)''' : Core 2 <br>
+[[File:G00033MO.png|thumb|G00033MO]]
-'''glycan_dictionary_accession''' : GD000046 <br>
+ '''term (main_entry)''' : Core 2 <br>
-'''glytoucan_accession ''' : G00033MO <br>
+ '''glycan_dictionary_accession''' : [https://www.glygen.org/glycan/GD000046 GSD000046] <br>
-'''term_in_sentence''' : To investigate the biological roles of core 2 O-glycans, we produced and characterized mice deficient in one or more of the three known glycosyltransferases that generate core 2 O-glycans (C2GnT1, C2GnT2, and C2GnT3).[PMID: 19349303] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00033MO G00033MO] <br>
-'''publication''' : 19349303|30315106|23640779|26677400 <br>
+ '''term_in_sentence''' : To investigate the biological roles of core 2 O-glycans, we produced and characterized mice deficient in one or more of the three known glycosyltransferases that generate core 2 O-glycans (C2GnT1, C2GnT2, and C2GnT3).[PMID: [https://pubmed.ncbi.nlm.nih.gov/19349303 19349303]]<br>
-'''definition''' : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19349303 19349303]|[https://pubmed.ncbi.nlm.nih.gov/30315106 30315106]|[https://pubmed.ncbi.nlm.nih.gov/23640779 23640779]|[https://pubmed.ncbi.nlm.nih.gov/26677400 26677400] <br>
-'''term_xref''' : CID:52921656|CHEBI:62158 <br>
+ '''definition''' : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158] <br>
-'''best_match''' : GTC:G00033MO|CID:52921656|CHEBI:62158 <br>
+ '''term_xref''' : GTC:G00033MO|CID:52921656|CHEBI:62158 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Core 3===
-'''term (main_entry)''' : Core 3 <br>
+[[File:G00035MO.png|thumb|G00035MO]]
-'''glycan_dictionary_accession''' : GD000047 <br>
+ '''term (main_entry)''' : Core 3 <br>
-'''glytoucan_accession ''' : G00035MO <br>
+ '''glycan_dictionary_accession''' : GSD000047 <br>
-'''term_in_sentence''' : Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells.[PMID: 28745318] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00035MO G00035MO] <br>
-'''publication''' : 28745318|27259834|27143302| <br>
+ '''term_in_sentence''' : Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells.[PMID: [https://pubmed.ncbi.nlm.nih.gov/28745318 28745318]] <br>
-'''definition''' : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28745318 28745318]|[https://pubmed.ncbi.nlm.nih.gov/27259834 27259834]|[https://pubmed.ncbi.nlm.nih.gov/27143302 27143302]| <br>
-'''term_xref''' : CID:25061208|CHEBI:71344 <br>
+ '''definition''' : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344] <br>
-'''best_match''' : GTC:G00035MO|CID:25061208|CHEBI:71344 <br>
+ '''term_xref''' : GTC:G00035MO|CID:25061208|CHEBI:71344 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453020-Chapter 9 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>
 ===Core 4===
-'''term (main_entry)''' : Core 4 <br>
+[[File:G00037MO.png|thumb|G00037MO]]
-'''glycan_dictionary_accession''' : GD000048 <br>
+ '''term (main_entry)''' : Core 4 <br>
-'''glytoucan_accession ''' : G00037MO <br>
+ '''glycan_dictionary_accession''' : GSD000048 <br>
-'''term_in_sentence''' : The results confirm the predicted existence of a beta1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation.[PMID: 9988682] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00037MO G00037MO] <br>
-'''publication''' : 9988682|10747980| <br>
+ '''term_in_sentence''' : The results confirm the predicted existence of a beta1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation.[PMID: [https://pubmed.ncbi.nlm.nih.gov/9988682 9988682]] <br>
-'''definition''' : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9988682 9988682]|[https://pubmed.ncbi.nlm.nih.gov/10747980 10747980]| <br>
-'''term_xref''' : CID:25229562|CHEBI:71341 <br>
+ '''definition''' : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341] <br>
-'''best_match''' : GTC:G00037MO| CID:25229562|CHEBI:71341 <br>
+ '''term_xref''' : GTC:G00037MO| CID:25229562|CHEBI:71341 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK20721-Chapter 8 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK20721/ Chapter 8] <br>
 ===Core-fucosylated===
-'''term (main_entry)''' : Core-fucosylated <br>
+[[File:G78059CC.png|thumb|G78059CC]]
-'''glycan_dictionary_accession''' : GD000049 <br>
+ '''term (main_entry)''' : Core-fucosylated <br>
-'''glytoucan_accession ''' : G78059CC <br>
+ '''glycan_dictionary_accession''' : GSD000049 <br>
-'''term_in_sentence''' : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:27678371] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
-'''publication''' : 27678371|26514868|15538974|24914453|17049014|32078267|31268672|28674882|29956878|27798819|32044029|30962950|31548313|30907281|29090617|29571940|28800497|27629418|29733746|31623829|28768188|26897254|31451706|26514868|29427759|28982386|26587313|30940702|15538974|31249452|27282921|31229844|30445455|31325506|24732908|29209018|26965517|28609658|24914453|25573275|17049014|19218400|27012207|27139574|32078267|25861849|32561391|21374780|31669139|25732060|29408166|31268672|30472795|30614075|19003000|25664929 <br>
+ '''term_in_sentence''' : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27678371 27678371]] <br>
-'''definition''' : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006]. <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27678371 27678371]|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]|[https://pubmed.ncbi.nlm.nih.gov/15538974 15538974]|[https://pubmed.ncbi.nlm.nih.gov/24914453 24914453]|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/32078267 32078267]|[https://pubmed.ncbi.nlm.nih.gov/31268672 31268672]|[https://pubmed.ncbi.nlm.nih.gov/28674882 28674882]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]|[https://pubmed.ncbi.nlm.nih.gov/27798819 27798819]|[https://pubmed.ncbi.nlm.nih.gov/32044029 32044029]|[https://pubmed.ncbi.nlm.nih.gov/30962950 30962950]|[https://pubmed.ncbi.nlm.nih.gov/31548313 31548313]|[https://pubmed.ncbi.nlm.nih.gov/30907281 30907281]|[https://pubmed.ncbi.nlm.nih.gov/29090617 29090617]|[https://pubmed.ncbi.nlm.nih.gov/29571940 29571940]|[https://pubmed.ncbi.nlm.nih.gov/28800497 28800497]|[https://pubmed.ncbi.nlm.nih.gov/27629418 27629418]|[https://pubmed.ncbi.nlm.nih.gov/29733746 29733746]|[https://pubmed.ncbi.nlm.nih.gov/31623829 31623829]|[https://pubmed.ncbi.nlm.nih.gov/28768188 28768188]|[https://pubmed.ncbi.nlm.nih.gov/26897254 26897254]|[https://pubmed.ncbi.nlm.nih.gov/31451706 31451706]|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]|[https://pubmed.ncbi.nlm.nih.gov/29427759 29427759]|[https://pubmed.ncbi.nlm.nih.gov/28982386 28982386]|[https://pubmed.ncbi.nlm.nih.gov/26587313 26587313]|[https://pubmed.ncbi.nlm.nih.gov/30940702 30940702]|[https://pubmed.ncbi.nlm.nih.gov/15538974 15538974]|[https://pubmed.ncbi.nlm.nih.gov/31249452 31249452]|[https://pubmed.ncbi.nlm.nih.gov/27282921 27282921]|[https://pubmed.ncbi.nlm.nih.gov/31229844 31229844]|[https://pubmed.ncbi.nlm.nih.gov/30445455 30445455]|[https://pubmed.ncbi.nlm.nih.gov/31325506 31325506]|[https://pubmed.ncbi.nlm.nih.gov/24732908 24732908]|[https://pubmed.ncbi.nlm.nih.gov/29209018 29209018]|[https://pubmed.ncbi.nlm.nih.gov/26965517 26965517]|[https://pubmed.ncbi.nlm.nih.gov/28609658 28609658]|[https://pubmed.ncbi.nlm.nih.gov/24914453 24914453]|[https://pubmed.ncbi.nlm.nih.gov/25573275 25573275]|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/19218400 19218400]|[https://pubmed.ncbi.nlm.nih.gov/27012207 27012207]|[https://pubmed.ncbi.nlm.nih.gov/27139574 27139574]|[https://pubmed.ncbi.nlm.nih.gov/32078267 32078267]|[https://pubmed.ncbi.nlm.nih.gov/25861849 25861849]|[https://pubmed.ncbi.nlm.nih.gov/32561391 32561391]|[https://pubmed.ncbi.nlm.nih.gov/21374780 21374780]|[https://pubmed.ncbi.nlm.nih.gov/31669139 31669139]|[https://pubmed.ncbi.nlm.nih.gov/25732060 25732060]|[https://pubmed.ncbi.nlm.nih.gov/29408166 29408166]|[https://pubmed.ncbi.nlm.nih.gov/31268672 31268672]|[https://pubmed.ncbi.nlm.nih.gov/30472795 30472795]|[https://pubmed.ncbi.nlm.nih.gov/30614075 30614075]|[https://pubmed.ncbi.nlm.nih.gov/19003000 19003000]|[https://pubmed.ncbi.nlm.nih.gov/25664929 25664929] <br>
-'''term_xref''' : CID:70679232|CHEBI:70967|CHEBI:156499 <br>
+ '''definition''' : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006<nowiki>]. </nowiki><br>
-'''best_match''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br>
+ '''term_xref''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br>
-'''synonymns''' : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc <br>
+ '''synonyms''' : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc <br>
-'''function''' : Required for signaling through TCR [PMID: 29434598]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:17132494]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:29062024] <br>
+ '''function''' : Required for signaling through TCR [PMID: [https://pubmed.ncbi.nlm.nih.gov/29434598 29434598]]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:[https://pubmed.ncbi.nlm.nih.gov/17132494 17132494]]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:[https://pubmed.ncbi.nlm.nih.gov/29062024 29062024]] <br>
-'''disease_associations''' : Emphysema|systemic lupus erythematosuslung cancer|autoimmunity|tumor metastasis <br>
+ '''disease_associations''' : Emphysema|systemic lupus erythematosuslung cancer|autoimmunity|tumor metastasis <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK20721-Chapter 8 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK20721/ Chapter 8] <br>
 ===Core-fucosylated biantennary===
-'''term (main_entry)''' : Core-fucosylated biantennary <br>
+[[File:G78059CC.png|thumb|G78059CC]]
-'''glycan_dictionary_accession''' : GD000050 <br>
+ '''term (main_entry)''' : Core-fucosylated biantennary <br>
-'''glytoucan_accession ''' : G78059CC <br>
+ '''glycan_dictionary_accession''' : GSD000050 <br>
-'''term_in_sentence''' : The IFN-alpha14c N-glycans were shown to exhibit core-fucosylated biantennary glycans , with about 10% carrying an additional alpha1,3-linked fucose unit at the antennae.[PMID:9654101] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
-'''publication''' : 9654101|15819890|28263871|26763099|22256781|23681398|25855029|10529240|26544759|8206921|33149259|8547276 <br>
+ '''term_in_sentence''' : The IFN-alpha14c N-glycans were shown to exhibit core-fucosylated biantennary glycans , with about 10% carrying an additional alpha1,3-linked fucose unit at the antennae.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9654101 9654101]] <br>
-'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9654101 9654101]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/28263871 28263871]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/22256781 22256781]|[https://pubmed.ncbi.nlm.nih.gov/23681398 23681398]|[https://pubmed.ncbi.nlm.nih.gov/25855029 25855029]|[https://pubmed.ncbi.nlm.nih.gov/10529240 10529240]|[https://pubmed.ncbi.nlm.nih.gov/26544759 26544759]|[https://pubmed.ncbi.nlm.nih.gov/8206921 8206921]|[https://pubmed.ncbi.nlm.nih.gov/33149259 33149259]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276] <br>
-'''term_xref''' : CID:70679232|CHEBI:70967|CHEBI:156499 <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br>
-'''best_match''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br>
+ '''term_xref''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br>
-'''synonymns''' : core-fucosylated diantennary <br>
+ '''synonyms''' : core-fucosylated diantennary <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK20721-Chapter 8 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK20721/ Chapter 8]<br>
 ===Core-fucosylated biantennary complex-type===
-'''term (main_entry)''' : Core-fucosylated biantennary complex-type <br>
+[[File:G78059CC.png|thumb|G78059CC]]
-'''glycan_dictionary_accession''' : GD000051 <br>
+ '''term (main_entry)''' : Core-fucosylated biantennary complex-type <br>
-'''glytoucan_accession ''' : G78059CC <br>
+ '''glycan_dictionary_accession''' : GSD000051 <br>
-'''term_in_sentence''' : The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.[PMID:10731668] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
-'''publication''' : 10731668 <br>
+ '''term_in_sentence''' : The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10731668 10731668]] <br>
-'''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10731668 10731668] <br>
-'''term_xref''' : CID:70679232|CHEBI:70967|CHEBI:156499 <br>
+ '''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br>
-'''best_match''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br>
+ '''term_xref''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br>
-'''synonymns''' : core fucosylated diantennary complex-type <br>
+ '''synonyms''' : core fucosylated diantennary complex-type <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Cyclic sialyl 6-sulfo Lewis x===
-'''term (main_entry)''' : Cyclic sialyl 6-sulfo Lewis x <br>
+[[File:G11148DZ.png|thumb|G11148DZ]]
-'''glycan_dictionary_accession''' : GD000052 <br>
+ '''term (main_entry)''' : Cyclic sialyl 6-sulfo Lewis x <br>
-'''glytoucan_accession ''' : G80722US <br>
+ '''glycan_dictionary_accession''' : GSD000052 <br>
-'''term_in_sentence''' : Stimulation of the sialyl 6-sulfo Lewis X-positive colon cancer cell line with a calcium ionophore ionomycin markedly reduced sialyl 6-sulfo Lewis X and induced cyclic sialyl 6-sulfo Lewis X expression.[PMID:10728707] <br>
+ '''glytoucan_accession ''' :  [https://www.glygen.org/glycan/G11148DZ G11148DZ]<br>
-'''publication''' : 10728707|31222115|9990070|23088960 <br>
+ '''term_in_sentence''' : Stimulation of the sialyl 6-sulfo Lewis X-positive colon cancer cell line with a calcium ionophore ionomycin markedly reduced sialyl 6-sulfo Lewis X and induced cyclic sialyl 6-sulfo Lewis X expression.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/31222115 31222115]|[https://pubmed.ncbi.nlm.nih.gov/9990070 9990070]|[https://pubmed.ncbi.nlm.nih.gov/23088960 23088960] <br>
-'''term_xref''' : GlycoMotif:GGM.000023|GlycoEpitope:EP0015|CID:70698321|CHEBI:71628 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000023|GTC:G80722US|GlycoEpitope:EP0015|CID:70698321|CHEBI:71628 <br>
+ '''term_xref''' :  GlycoEpitope:EP0017|CID:91858084|CHEBI:147484<br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' : the accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017] <br>
+  '''function''' : The accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Cytolipin R===
-'''term (main_entry)''' : Cytolipin R <br>
+[[File:G57710SU.png|thumb|G57710SU]]
-'''glycan_dictionary_accession''' : GD000053 <br>
+ '''term (main_entry)''' : Cytolipin R <br>
-'''glytoucan_accession ''' : G57710SU <br>
+ '''glycan_dictionary_accession''' : GSD000053 <br>
-'''term_in_sentence''' : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:4110375] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57710SU G57710SU] <br>
-'''publication''' : 893368|4375678|51702|186204|4110375|5068000|24174198|6072378|389925|7054174 <br>
+ '''term_in_sentence''' : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:[https://pubmed.ncbi.nlm.nih.gov/4110375 4110375]] <br>
-'''definition''' : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:5068000] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/893368 893368]|[https://pubmed.ncbi.nlm.nih.gov/4375678 4375678]|[https://pubmed.ncbi.nlm.nih.gov/51702 51702]|[https://pubmed.ncbi.nlm.nih.gov/186204 186204]|[https://pubmed.ncbi.nlm.nih.gov/4110375 4110375]|[https://pubmed.ncbi.nlm.nih.gov/5068000 5068000]|[https://pubmed.ncbi.nlm.nih.gov/24174198 24174198]|[https://pubmed.ncbi.nlm.nih.gov/6072378 6072378]|[https://pubmed.ncbi.nlm.nih.gov/389925 389925]|[https://pubmed.ncbi.nlm.nih.gov/7054174 7054174] <br>
-'''term_xref''' : GlycoMotif:GGM.000083|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17 <br>
+ '''definition''' : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/5068000 5068000]] <br>
-'''best_match''' : GlycoMotif:GGM.000083|GTC:G57710SU|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17 <br>
+ '''term_xref''' : GlycoMotif:GGM.000083|GTC:G57710SU|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Actinomycosis[SugarBind_Ligand:17] <br>
+ '''disease_associations''' : Actinomycosis[SugarBind_Ligand:17] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Dermatan sulfate===
-'''term (main_entry)''' : Dermatan sulfate <br>
+ '''term (main_entry)''' : Dermatan sulfate <br>
-'''glycan_dictionary_accession''' : GD000054 <br>
+ '''glycan_dictionary_accession''' : GSD000054 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:29111696] <br>
+ '''term_in_sentence''' : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29111696 29111696]] <br>
-'''publication''' : 27526113|29111696|29891297|26164146|30869126|7789716|8597249|12512856|31250530|17928217|12213784|27226567|31455633|28091940|19075609|31071403|15078125|18661328|20581662|17239765|15749837|2777747|20632047|8930750|7762784|31006321|26876822|1522290|131009|26986023|8161353|15315969|12543559|30637950|2525357|18156656|9692613|9200333|19661164|2299256|16075147|1126924|9774430|8537360|15563459|21077227|23275130|17137817|6447930|6209270 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27526113 27526113]|[https://pubmed.ncbi.nlm.nih.gov/29111696 29111696]|[https://pubmed.ncbi.nlm.nih.gov/29891297 29891297]|[https://pubmed.ncbi.nlm.nih.gov/26164146 26164146]|[https://pubmed.ncbi.nlm.nih.gov/30869126 30869126]|[https://pubmed.ncbi.nlm.nih.gov/7789716 7789716]|[https://pubmed.ncbi.nlm.nih.gov/8597249 8597249]|[https://pubmed.ncbi.nlm.nih.gov/12512856 12512856]|[https://pubmed.ncbi.nlm.nih.gov/31250530 31250530]|[https://pubmed.ncbi.nlm.nih.gov/17928217 17928217]|[https://pubmed.ncbi.nlm.nih.gov/12213784 12213784]|[https://pubmed.ncbi.nlm.nih.gov/27226567 27226567]|[https://pubmed.ncbi.nlm.nih.gov/31455633 31455633]|[https://pubmed.ncbi.nlm.nih.gov/28091940 28091940]|[https://pubmed.ncbi.nlm.nih.gov/19075609 19075609]|[https://pubmed.ncbi.nlm.nih.gov/31071403 31071403]|[https://pubmed.ncbi.nlm.nih.gov/15078125 15078125]|[https://pubmed.ncbi.nlm.nih.gov/18661328 18661328]|[https://pubmed.ncbi.nlm.nih.gov/20581662 20581662]|[https://pubmed.ncbi.nlm.nih.gov/17239765 17239765]|[https://pubmed.ncbi.nlm.nih.gov/15749837 15749837]|[https://pubmed.ncbi.nlm.nih.gov/2777747 2777747]|[https://pubmed.ncbi.nlm.nih.gov/20632047 20632047]|[https://pubmed.ncbi.nlm.nih.gov/8930750 8930750]|[https://pubmed.ncbi.nlm.nih.gov/7762784 7762784]|[https://pubmed.ncbi.nlm.nih.gov/31006321 31006321]|[https://pubmed.ncbi.nlm.nih.gov/26876822 26876822]|[https://pubmed.ncbi.nlm.nih.gov/1522290 1522290]|[https://pubmed.ncbi.nlm.nih.gov/131009 131009]|[https://pubmed.ncbi.nlm.nih.gov/26986023 26986023]|[https://pubmed.ncbi.nlm.nih.gov/8161353 8161353]|[https://pubmed.ncbi.nlm.nih.gov/15315969 15315969]|[https://pubmed.ncbi.nlm.nih.gov/12543559 12543559]|[https://pubmed.ncbi.nlm.nih.gov/30637950 30637950]|[https://pubmed.ncbi.nlm.nih.gov/2525357 2525357]|[https://pubmed.ncbi.nlm.nih.gov/18156656 18156656]|[https://pubmed.ncbi.nlm.nih.gov/9692613 9692613]|[https://pubmed.ncbi.nlm.nih.gov/9200333 9200333]|[https://pubmed.ncbi.nlm.nih.gov/19661164 19661164]|[https://pubmed.ncbi.nlm.nih.gov/2299256 2299256]|[https://pubmed.ncbi.nlm.nih.gov/16075147 16075147]|[https://pubmed.ncbi.nlm.nih.gov/1126924 1126924]|[https://pubmed.ncbi.nlm.nih.gov/9774430 9774430]|[https://pubmed.ncbi.nlm.nih.gov/8537360 8537360]|[https://pubmed.ncbi.nlm.nih.gov/15563459 15563459]|[https://pubmed.ncbi.nlm.nih.gov/21077227 21077227]|[https://pubmed.ncbi.nlm.nih.gov/23275130 23275130]|[https://pubmed.ncbi.nlm.nih.gov/17137817 17137817]|[https://pubmed.ncbi.nlm.nih.gov/6447930 6447930]|[https://pubmed.ncbi.nlm.nih.gov/6209270 6209270] <br>
-'''definition''' : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.
+ '''definition''' : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.[CHEBI:18376] <br>
-[CHEBI:18376] <br>
+ '''term_xref''' : CHEBI:18376|CID:32756 <br>
-'''term_xref''' : CHEBI:18376|CID:32756 <br>
+ '''synonyms''' : beta-Heparin|Chondroitin sulfate B|Dermatan L-iduronate <br>
-'''best_match''' : CHEBI:18376| CID: 32756 <br>
+ '''function''' : Wound healing[Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453034/ Chapter 7]]|maintain the structure of the dermis.[Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453056/ Chapter 41]]<br>
-'''synonymns''' : beta-Heparin|Chondroitin sulfate B|Dermatan L-iduronate <br>
+ '''disease_associations''' :  <br>
-'''function''' : Wound healing[NBK453034-Chapter 7]|maintain the structure of the dermis.[NBK453056-Chapter 41] <br>
+ '''wikipedia''' :  <br>
-'''disease_associations''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Desialylated===
-'''term (main_entry)''' : Desialylated <br>
+ '''term (main_entry)''' : Desialylated <br>
-'''glycan_dictionary_accession''' : GD000055 <br>
+ '''glycan_dictionary_accession''' : GSD000055 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Furthermore, we found no evidence for "desialylated" apoB100 glycans in any of the samples analyzed.[PMID:11588155] <br>
+ '''term_in_sentence''' : Furthermore, we found no evidence for "desialylated" apoB100 glycans in any of the samples analyzed.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11588155 11588155]] <br>
-'''publication''' : 30015642|26168491|29492899|31774586|32321401|23780974|7600681|18045697|1450583|4137057|28911304|27562992|29950245|31978220|2408573|8612720|10910970|27195066|1434544|22175031|24517196|29794068|30101537|18972200|1478792|4440781|21229239|30844664|31351722|31330845|1872910 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30015642 30015642]|[https://pubmed.ncbi.nlm.nih.gov/26168491 26168491]|[https://pubmed.ncbi.nlm.nih.gov/29492899 29492899]|[https://pubmed.ncbi.nlm.nih.gov/31774586 31774586]|[https://pubmed.ncbi.nlm.nih.gov/32321401 32321401]|[https://pubmed.ncbi.nlm.nih.gov/23780974 23780974]|[https://pubmed.ncbi.nlm.nih.gov/7600681 7600681]|[https://pubmed.ncbi.nlm.nih.gov/18045697 18045697]|[https://pubmed.ncbi.nlm.nih.gov/1450583 1450583]|[https://pubmed.ncbi.nlm.nih.gov/4137057 4137057]|[https://pubmed.ncbi.nlm.nih.gov/28911304 28911304]|[https://pubmed.ncbi.nlm.nih.gov/27562992 27562992]|[https://pubmed.ncbi.nlm.nih.gov/29950245 29950245]|[https://pubmed.ncbi.nlm.nih.gov/31978220 31978220]|[https://pubmed.ncbi.nlm.nih.gov/2408573 2408573]|[https://pubmed.ncbi.nlm.nih.gov/8612720 8612720]|[https://pubmed.ncbi.nlm.nih.gov/10910970 10910970]|[https://pubmed.ncbi.nlm.nih.gov/27195066 27195066]|[https://pubmed.ncbi.nlm.nih.gov/1434544 1434544]|[https://pubmed.ncbi.nlm.nih.gov/22175031 22175031]|[https://pubmed.ncbi.nlm.nih.gov/24517196 24517196]|[https://pubmed.ncbi.nlm.nih.gov/29794068 29794068]|[https://pubmed.ncbi.nlm.nih.gov/30101537 30101537]|[https://pubmed.ncbi.nlm.nih.gov/18972200 18972200]|[https://pubmed.ncbi.nlm.nih.gov/1478792 1478792]|[https://pubmed.ncbi.nlm.nih.gov/4440781 4440781]|[https://pubmed.ncbi.nlm.nih.gov/21229239 21229239]|[https://pubmed.ncbi.nlm.nih.gov/30844664 30844664]|[https://pubmed.ncbi.nlm.nih.gov/31351722 31351722]|[https://pubmed.ncbi.nlm.nih.gov/31330845 31330845]|[https://pubmed.ncbi.nlm.nih.gov/1872910 1872910] <br>
-'''definition''' : A glycan from which sialyl groups have been removed. [https://en.wiktionary.org/wiki/desialylated] <br>
+ '''definition''' : A glycan from which sialyl groups have been removed. [https://en.wiktionary.org/wiki/desialylated<nowiki>] </nowiki><br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Desialylated tetrasaccharide===
-'''term (main_entry)''' : Desialylated tetrasaccharide <br>
+ '''term (main_entry)''' : Desialylated tetrasaccharide <br>
-'''glycan_dictionary_accession''' : GD000056 <br>
+ '''glycan_dictionary_accession''' : GSD000056 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The structures of a desialylated tetrasaccharide , two monosialylated trisaccharides , and five other minor products were defined.[PMID:8384526] <br>
+ '''term_in_sentence''' : The structures of a desialylated tetrasaccharide , two monosialylated trisaccharides , and five other minor products were defined.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8384526 8384526]] <br>
-'''publication''' : 8384526 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/8384526 8384526] <br>
-'''definition''' : A tetrasachharide (four branches) glycan from which sialyl groups have been removed.  <br>
+ '''definition''' : A tetrasachharide (four branches) glycan from which sialyl groups have been removed.  <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17] <br>
-'''essentials_of_glycobiology''' : NBK453033-Chapter 17 <br>
 ===Difucosylated tetra-antennary N-glycans===
-'''term (main_entry)''' : Difucosylated tetra-antennary N-glycans <br>
+ '''term (main_entry)''' : Difucosylated tetra-antennary N-glycans <br>
-'''glycan_dictionary_accession''' : GD000057 <br>
+ '''glycan_dictionary_accession''' : GSD000057 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID:18214858] <br>
+ '''term_in_sentence''' : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID:[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]] <br>
-'''publication''' : 18214858 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] <br>
-'''definition''' : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added. <br>
+ '''definition''' : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' : pancreatic cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]] <br>
-'''disease_associations''' : pancreatic cancer[PMID:18214858] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Dimeric Lewis x===
-'''term (main_entry)''' : Dimeric Lewis x <br>
+[[File:G79535HZ.png|thumb|G79535HZ]]
-'''glycan_dictionary_accession''' : GD000058 <br>
+ '''term (main_entry)''' : Dimeric Lewis x <br>
-'''glytoucan_accession ''' : G79535HZ <br>
+ '''glycan_dictionary_accession''' : GSD000058 <br>
-'''term_in_sentence''' : The carbohydrate antigen dimeric Lewis X (DimLex), which accumulates in colonic and liver adenocarcinomas, is a valuable target to develop anti-cancer therapeutics.[PMID:32957489] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79535HZ G79535HZ] <br>
-'''publication''' : 32957489|31276881|12062524|15488731|1979361|8737237|17939723|7683631|11384108|11133015|17388629|15483381|12662048|3233598|18618154|21892456 <br>
+ '''term_in_sentence''' : The carbohydrate antigen dimeric Lewis X (DimLex), which accumulates in colonic and liver adenocarcinomas, is a valuable target to develop anti-cancer therapeutics.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32957489 32957489]] <br>
-'''definition''' : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32957489 32957489]|[https://pubmed.ncbi.nlm.nih.gov/31276881 31276881]|[https://pubmed.ncbi.nlm.nih.gov/12062524 12062524]|[https://pubmed.ncbi.nlm.nih.gov/15488731 15488731]|[https://pubmed.ncbi.nlm.nih.gov/1979361 1979361]|[https://pubmed.ncbi.nlm.nih.gov/8737237 8737237]|[https://pubmed.ncbi.nlm.nih.gov/17939723 17939723]|[https://pubmed.ncbi.nlm.nih.gov/7683631 7683631]|[https://pubmed.ncbi.nlm.nih.gov/11384108 11384108]|[https://pubmed.ncbi.nlm.nih.gov/11133015 11133015]|[https://pubmed.ncbi.nlm.nih.gov/17388629 17388629]|[https://pubmed.ncbi.nlm.nih.gov/15483381 15483381]|[https://pubmed.ncbi.nlm.nih.gov/12662048 12662048]|[https://pubmed.ncbi.nlm.nih.gov/3233598 3233598]|[https://pubmed.ncbi.nlm.nih.gov/18618154 18618154]|[https://pubmed.ncbi.nlm.nih.gov/21892456 21892456] <br>
-'''term_xref''' : GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031 <br>
+ '''definition''' : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325] <br>
-'''best_match''' : GTC:G79535HZ|GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031 <br>
+ '''term_xref''' : GTC:G79535HZ|GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031 <br>
-'''synonymns''' : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx <br>
+ '''synonyms''' : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx <br>
-'''function''' : cancer-associated antigen[GlycoEpitope:EP0093] <br>
+ '''function''' : cancer-associated antigen[GlycoEpitope:EP0093] <br>
-'''disease_associations''' : colonic cancer[GlycoEpitope:EP0093]|liver cancer[GlycoEpitope:EP0093] <br>
+ '''disease_associations''' : colonic cancer[GlycoEpitope:EP0093]|liver cancer[GlycoEpitope:EP0093] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042-Chapter 14 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14] <br>
 ===Diphosphorylated Man6===
-'''term (main_entry)''' : Diphosphorylated Man6 <br>
+[[File:G54792LL.png|thumb|G54792LL]]
-'''glycan_dictionary_accession''' : GD000059 <br>
+ '''term (main_entry)''' : Diphosphorylated Man6 <br>
-'''glytoucan_accession ''' : G54792LL <br>
+ '''glycan_dictionary_accession''' : GSD000059 <br>
-'''term_in_sentence''' : Here we report that the single-chain variable domain (scFv) M6P-1 is a unique antibody fragment with specificity for Man6P monosaccharide that, through an array-screening approach against a number of phosphorylated N-glycans, is shown to bind mono- and diphosphorylated Man6 and Man7 glycans that contain terminal αMan6P(1 → 2)αMan(1 → 3)αMan.[PMID:26503547] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54792LL G54792LL] <br>
-'''publication''' : 26503547 <br>
+ '''term_in_sentence''' : Here we report that the single-chain variable domain (scFv) M6P-1 is a unique antibody fragment with specificity for Man6P monosaccharide that, through an array-screening approach against a number of phosphorylated N-glycans, is shown to bind mono- and diphosphorylated Man6 and Man7 glycans that contain terminal αMan6P(1 → 2)αMan(1 → 3)αMan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26503547 26503547]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/26503547 26503547] <br>
-'''term_xref''' : GlycoMotif:GGM.000054 <br>
+ '''definition''' :  <br>
-'''best_match''' : GTC:G54792LL|GlycoMotif:GGM.000054 <br>
+ '''term_xref''' : GTC:G54792LL|GlycoMotif:GGM.000054  <br>
-'''synonymns''' : Diphosphorylated Man_6 <br>
+ '''synonyms''' : Diphosphorylated Man_6 <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Disialosyl globopentaosylceramide===
-'''term (main_entry)''' : Disialosyl globopentaosylceramide <br>
+[[File:G97932OH.png|thumb|G97932OH]]
-'''glycan_dictionary_accession''' : GD000060 <br>
+ '''term (main_entry)''' : Disialosyl globopentaosylceramide <br>
-'''glytoucan_accession ''' : G97932OH <br>
+ '''glycan_dictionary_accession''' : GSD000060 <br>
-'''term_in_sentence''' : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID:31339142] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97932OH G97932OH] <br>
-'''publication''' : 31339142|24637536|25864532|27344728|12084983|32567311|28205070|20663960|18214042 <br>
+ '''term_in_sentence''' : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]] <br>
-'''definition''' : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:28205070] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]|[https://pubmed.ncbi.nlm.nih.gov/24637536 24637536]|[https://pubmed.ncbi.nlm.nih.gov/25864532 25864532]|[https://pubmed.ncbi.nlm.nih.gov/27344728 27344728]|[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]|[https://pubmed.ncbi.nlm.nih.gov/32567311 32567311]|[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]|[https://pubmed.ncbi.nlm.nih.gov/20663960 20663960]|[https://pubmed.ncbi.nlm.nih.gov/18214042 18214042] <br>
-'''term_xref''' : GlycoMotif:GGM.000082|GlycoEpitope:EP0098|CID:91860287|KEGG:G00181|SugarBind_Ligand:57 <br>
+ '''definition''' : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]] <br>
-'''best_match''' : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID:91860287|KEGG:G00181|SugarBind_Ligand:57 <br>
+ '''term_xref''' : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID:91860287|KEGG:G00181|SugarBind_Ligand:57 <br>
-'''synonymns''' : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside <br>
+ '''synonyms''' : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside <br>
-'''function''' : promotes metastasis[PMID:28205070] <br>
+ '''function''' : promotes metastasis[PMID:[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]] <br>
-'''disease_associations''' : prostate cancer[PMID:24637536]|renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] <br>
+ '''disease_associations''' : prostate cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/24637536 24637536]]|renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Disialyl Gb5===
-'''term (main_entry)''' : Disialyl Gb5 <br>
+[[File:G97932OH.png|thumb|G97932OH]]
-'''glycan_dictionary_accession''' : GD000061 <br>
+ '''term (main_entry)''' : Disialyl Gb5 <br>
-'''glytoucan_accession ''' : G97932OH <br>
+ '''glycan_dictionary_accession''' : GSD000061 <br>
-'''term_in_sentence''' : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: 12084983] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/ G97932OH] <br>
-'''publication''' : 12084983 <br>
+ '''term_in_sentence''' : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] <br>
-'''term_xref''' : GlycoEpitope:EP0098|CID:91860287|SugarBind_Ligand:57|KEGG:G00181 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoEpitope:EP0098|GTC:G97932OH|CID:91860287|SugarBind_Ligand:57|KEGG:G00181 <br>
+ '''term_xref''' : GlycoEpitope:EP0098|GTC:G97932OH|CID:91860287|SugarBind_Ligand:57|KEGG:G00181 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] <br>
+ '''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Disialyl I===
-'''term (main_entry)''' : Disialyl I <br>
+[[File:G54937EM.png|thumb|G54937EM]]
-'''glycan_dictionary_accession''' : GD000062 <br>
+ '''term (main_entry)''' : Disialyl I <br>
-'''glytoucan_accession ''' : G54937EM <br>
+ '''glycan_dictionary_accession''' : GSD000062 <br>
-'''term_in_sentence''' : Here we present an example of promotion of binding of soluble-form FN from placenta or from hepatoma cells, having a specific carbohydrate epitope termed "disialyl-I," to K562 or VA13 cell surface in the presence of glycosphingolipid Gg3, which interacts specifically with disialyl-I[PMID:10640401] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54937EM G54937EM] <br>
-'''publication''' : 10640401 <br>
+ '''term_in_sentence''' : Here we present an example of promotion of binding of soluble-form FN from placenta or from hepatoma cells, having a specific carbohydrate epitope termed "disialyl-I," to K562 or VA13 cell surface in the presence of glycosphingolipid Gg3, which interacts specifically with disialyl-I[PMID:[https://pubmed.ncbi.nlm.nih.gov/10640401 10640401]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10640401 10640401] <br>
-'''term_xref''' : GlycoEpitope:EP0095|CID:91849523 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoEpitope:EP0095|GTC:G54937EM|CID:91849523 <br>
+ '''term_xref''' : GlycoEpitope:EP0095|GTC:G54937EM|CID:91849523 <br>
-'''synonymns''' : disialyl-I <br>
+ '''synonyms''' : disialyl-I <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Disialyl Lewis a===
-'''term (main_entry)''' : Disialyl Lewis a <br>
+[[File:G93400AK.png|thumb|G93400AK]]
-'''glycan_dictionary_accession''' : GD000063 <br>
+ '''term (main_entry)''' : Disialyl Lewis a <br>
-'''glytoucan_accession ''' : G93400AK <br>
+ '''glycan_dictionary_accession''' : GSD000063 <br>
-'''term_in_sentence''' : Biosynthesis of disialyl Lewis a (Lea) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides.[PMID:12668675] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93400AK G93400AK] <br>
-'''publication''' : 12668675|17760270|15231659|12668106|30716533|32050430|22467657 <br>
+ '''term_in_sentence''' : Biosynthesis of disialyl Lewis a (Lea) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides.[PMID:12668675] <br>
-'''definition''' : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:15231659] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12668675 12668675]|[https://pubmed.ncbi.nlm.nih.gov/17760270 17760270]|[https://pubmed.ncbi.nlm.nih.gov/15231659 15231659]|[https://pubmed.ncbi.nlm.nih.gov/12668106 12668106]|[https://pubmed.ncbi.nlm.nih.gov/30716533 30716533]|[https://pubmed.ncbi.nlm.nih.gov/32050430 32050430]|[https://pubmed.ncbi.nlm.nih.gov/22467657 22467657] <br>
-'''term_xref''' : GlycoEpitope:EP0040|CID:91854138|CHEBI:155549 <br>
+ '''definition''' : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:[https://pubmed.ncbi.nlm.nih.gov/15231659 15231659]] <br>
-'''best_match''' : GTC:G93400AK |GlycoEpitope:EP0040|CID:91854138|CHEBI:155549 <br>
+ '''term_xref''' : GTC:G93400AK |GlycoEpitope:EP0040|CID:91854138|CHEBI:155549 <br>
-'''synonymns''' : disialyl Lea <br>
+ '''synonyms''' : disialyl Lea <br>
-'''function''' : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040] <br>
+ '''function''' : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040] <br>
-'''disease_associations''' : Mucin antigen carrying 2-3 sialylated Le a antigen or 2-3, 2-6 disialylated Lc4 antigen in cancer patients had the lowest carbohydrate/protein ratio. Thus, the carbohydrate/protein ratio in the type 1 chain mucin antigens in sera of normal subjects is higher than that in sera of cancer patients.[GlycoEpitope:EP0040] <br>
+ '''disease_associations''' : Mucin antigen carrying 2-3 sialylated Le a antigen or 2-3, 2-6 disialylated Lc4 antigen in cancer patients had the lowest carbohydrate/protein ratio. Thus, the carbohydrate/protein ratio in the type 1 chain mucin antigens in sera of normal subjects is higher than that in sera of cancer patients.[GlycoEpitope:EP0040] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Disialyl T antigen===
-'''term (main_entry)''' : Disialyl T antigen <br>
+[[File:G01614ZM.png|thumb|G01614ZM]]
-'''glycan_dictionary_accession''' : GD000064 <br>
+ '''term (main_entry)''' : Disialyl T antigen <br>
-'''glytoucan_accession ''' : G01614ZM <br>
+ '''glycan_dictionary_accession''' : GSD000064 <br>
-'''term_in_sentence''' : The most potent glycoside was disialyl T antigen (NeuAcalpha2-3Galbeta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides.[PMID: 15701648] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G01614ZM G01614ZM] <br>
-'''publication''' : 29113555|17974963|33242079|12645620|15701648|26598643 <br>
+ '''term_in_sentence''' : The most potent glycoside was disialyl T antigen (NeuAcalpha2-3Galbeta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides.[PMID: [https://pubmed.ncbi.nlm.nih.gov/15701648 15701648]] <br>
-'''definition''' : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/17974963 17974963]|[https://pubmed.ncbi.nlm.nih.gov/33242079 33242079]|[https://pubmed.ncbi.nlm.nih.gov/12645620 12645620]|[https://pubmed.ncbi.nlm.nih.gov/15701648 15701648]|[https://pubmed.ncbi.nlm.nih.gov/26598643 26598643] <br>
-'''term_xref''' : GlycoMotif:GGM.000014|CID:70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027 <br>
+ '''definition''' : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602] <br>
-'''best_match''' : GlycoMotif:GGM.000014|GTC:G01614ZM|CID:70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027 <br>
+ '''term_xref''' : GlycoMotif:GGM.000014|GTC:G01614ZM|CID:70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027 <br>
-'''synonymns''' : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen <br>
+ '''synonyms''' : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen <br>
-'''function''' : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023] <br>
+ '''function''' : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Disialylated biantennary===
-'''term (main_entry)''' : Disialylated biantennary <br>
+ '''term (main_entry)''' : Disialylated biantennary <br>
-'''glycan_dictionary_accession''' : GD000065 <br>
+ '''glycan_dictionary_accession''' : GSD000065 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:8486673] <br>
+ '''term_in_sentence''' : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8486673 8486673] <br>
-'''publication''' : 22426998|17171781|25022802|24812685|24780636|26582205|9499382|22978794|22594947|8486673|20356825|1634621|9244386|12966096|1472054|24243045|19579232|27943633 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/17171781 17171781]|[https://pubmed.ncbi.nlm.nih.gov/25022802 25022802]|[https://pubmed.ncbi.nlm.nih.gov/24812685 24812685]|[https://pubmed.ncbi.nlm.nih.gov/24780636 24780636]|[https://pubmed.ncbi.nlm.nih.gov/26582205 26582205]|[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]|[https://pubmed.ncbi.nlm.nih.gov/22978794 22978794]|[https://pubmed.ncbi.nlm.nih.gov/22594947 22594947]|[https://pubmed.ncbi.nlm.nih.gov/8486673 8486673]|[https://pubmed.ncbi.nlm.nih.gov/20356825 20356825]|[https://pubmed.ncbi.nlm.nih.gov/1634621 1634621]|[https://pubmed.ncbi.nlm.nih.gov/9244386 9244386]|[https://pubmed.ncbi.nlm.nih.gov/12966096 12966096]|[https://pubmed.ncbi.nlm.nih.gov/1472054 1472054]|[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]|[https://pubmed.ncbi.nlm.nih.gov/19579232 19579232]|[https://pubmed.ncbi.nlm.nih.gov/27943633 27943633] <br>
-'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+  '''synonyms''' : disialylated diantennary <br>
-'''synonymns''' : disialylated diantennary <br>
+ '''function''' : appears in human transferrin[PMID: [https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]]|Appears in human apolipoprotein (apo) B-100.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2344297 2344297]] <br>
-'''function''' : appears in human transferrin[PMID: 24243045]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] <br>
+ '''disease_associations''' : galactosemia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]] <br>
-'''disease_associations''' : galactosemia.[PMID:9499382] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Disialylated biantennary complex-type===
-'''term (main_entry)''' : Disialylated biantennary complex-type <br>
+ '''term (main_entry)''' : Disialylated biantennary complex-type <br>
-'''glycan_dictionary_accession''' : GD000066 <br>
+ '''glycan_dictionary_accession''' : GSD000066 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:11738084] <br>
+ '''term_in_sentence''' : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11738084 11738084]] <br>
-'''publication''' : 11738084|9499382|9244386|24243045|12966096|25124522|19371135 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11738084 11738084]|[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]|[https://pubmed.ncbi.nlm.nih.gov/9244386 9244386]|[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]|[https://pubmed.ncbi.nlm.nih.gov/12966096 12966096]|[https://pubmed.ncbi.nlm.nih.gov/25124522 25124522]|[https://pubmed.ncbi.nlm.nih.gov/19371135 19371135] <br>
-'''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br>
+ '''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' : appears in human transferrin[PMID:[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]]|Appears in human apolipoprotein (apo) B-100.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2344297 2344297]] <br>
-'''function''' : appears in human transferrin[PMID:24243045]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] <br>
+ '''disease_associations''' : galactosemia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]] <br>
-'''disease_associations''' : galactosemia.[PMID:9499382] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Disialylated fucosylated===
-'''term (main_entry)''' : Disialylated fucosylated <br>
+ '''term (main_entry)''' : Disialylated fucosylated <br>
-'''glycan_dictionary_accession''' : GD000067 <br>
+ '''glycan_dictionary_accession''' : GSD000067 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.[PMID:17591618] <br>
+ '''term_in_sentence''' : Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]] <br>
-'''publication''' : 17591618 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17591618 17591618] <br>
-'''definition''' : A fucosylated glycan with two sialic acid components. <br>
+ '''definition''' : A fucosylated glycan with two sialic acid components. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45]<br>
-'''essentials_of_glycobiology''' : NBK453041 <br>
 ===Forssman antigen===
-'''term (main_entry)''' : Forssman antigen <br>
+[[File:G80062GG.png|thumb|G80062GG]]
-'''glycan_dictionary_accession''' : GD000068 <br>
+ '''term (main_entry)''' : Forssman antigen <br>
-'''glytoucan_accession ''' : G80062GG <br>
+ '''glycan_dictionary_accession''' : GSD000068 <br>
-'''term_in_sentence''' : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution.[PMID:28510705] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80062GG G80062GG] <br>
-'''publication''' : 28510705|31933576|28134301|7021748|1802714|7512587|7747818|23325748|268649|31816281|22015168|4147161|2857159|6267170|7293775|13367419|20636540|10460829|23255552|2675268|18955372|7020692|31784953|4114942|31273262|6257673|7696847|1916901|11169215|48262|26022515|6175621|31404475|6983878|8381954|10431785|3257757|6792413|25039359 <br>
+ '''term_in_sentence''' : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28510705 28510705]] <br>
-'''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28510705 28510705]|[https://pubmed.ncbi.nlm.nih.gov/31933576 31933576]|[https://pubmed.ncbi.nlm.nih.gov/28134301 28134301]|[https://pubmed.ncbi.nlm.nih.gov/7021748 7021748]|[https://pubmed.ncbi.nlm.nih.gov/1802714 1802714]|[https://pubmed.ncbi.nlm.nih.gov/7512587 7512587]|[https://pubmed.ncbi.nlm.nih.gov/7747818 7747818]|[https://pubmed.ncbi.nlm.nih.gov/23325748 23325748]|[https://pubmed.ncbi.nlm.nih.gov/268649 268649]|[https://pubmed.ncbi.nlm.nih.gov/31816281 31816281]|[https://pubmed.ncbi.nlm.nih.gov/22015168 22015168]|[https://pubmed.ncbi.nlm.nih.gov/4147161 4147161]|[https://pubmed.ncbi.nlm.nih.gov/2857159 2857159]|[https://pubmed.ncbi.nlm.nih.gov/6267170 6267170]|[https://pubmed.ncbi.nlm.nih.gov/7293775 7293775]|[https://pubmed.ncbi.nlm.nih.gov/13367419 13367419]|[https://pubmed.ncbi.nlm.nih.gov/20636540 20636540]|[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]|[https://pubmed.ncbi.nlm.nih.gov/23255552 23255552]|[https://pubmed.ncbi.nlm.nih.gov/2675268 2675268]|[https://pubmed.ncbi.nlm.nih.gov/18955372 18955372]|[https://pubmed.ncbi.nlm.nih.gov/7020692 7020692]|[https://pubmed.ncbi.nlm.nih.gov/31784953 31784953]|[https://pubmed.ncbi.nlm.nih.gov/4114942 4114942]|[https://pubmed.ncbi.nlm.nih.gov/31273262 31273262]|[https://pubmed.ncbi.nlm.nih.gov/6257673 6257673]|[https://pubmed.ncbi.nlm.nih.gov/7696847 7696847]|[https://pubmed.ncbi.nlm.nih.gov/1916901 1916901]|[https://pubmed.ncbi.nlm.nih.gov/11169215 11169215]|[https://pubmed.ncbi.nlm.nih.gov/48262 48262]|[https://pubmed.ncbi.nlm.nih.gov/26022515 26022515]|[https://pubmed.ncbi.nlm.nih.gov/6175621 6175621]|[https://pubmed.ncbi.nlm.nih.gov/31404475 31404475]|[https://pubmed.ncbi.nlm.nih.gov/6983878 6983878]|[https://pubmed.ncbi.nlm.nih.gov/8381954 8381954]|[https://pubmed.ncbi.nlm.nih.gov/10431785 10431785]|[https://pubmed.ncbi.nlm.nih.gov/3257757 3257757]|[https://pubmed.ncbi.nlm.nih.gov/6792413 6792413]|[https://pubmed.ncbi.nlm.nih.gov/25039359 25039359] <br>
-'''term_xref''' : GlycoEpitope:EP0037|CID91825690|CHEBI:85789 <br>
+ '''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789] <br>
-'''best_match''' : GTC:G80062GG |GlycoEpitope:EP0037|CID91825690|CHEBI:85789 <br>
+ '''term_xref''' : GTC:G80062GG |GlycoEpitope:EP0037|CID91825690|CHEBI:85789  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453041 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45]<br>
 ===Forssman glycolipid===
-'''term (main_entry)''' : Forssman glycolipid <br>
+ '''term (main_entry)''' : Forssman glycolipid <br>
-'''glycan_dictionary_accession''' : GD000069 <br>
+ '''glycan_dictionary_accession''' : GSD000069 <br>
-'''glytoucan_accession ''' : G80062GG <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80062GG G80062GG] <br>
-'''term_in_sentence''' : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:3040119] <br>
+ '''term_in_sentence''' : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3040119 3040119]] <br>
-'''publication''' : 3040119|268649|23240079|28134301|3495590|1138893|10460829|10506200|8855242|1955453|1933935|3355161|6773959|14573676|29898878|10431785|1747956|11214737|7423202|389939|3871816|6187373|16133832|469271|3753492|2695680|7037611|25703376|23798992|414913|1868069|7960243 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3040119 3040119]|[https://pubmed.ncbi.nlm.nih.gov/268649 268649]|[https://pubmed.ncbi.nlm.nih.gov/23240079 23240079]|[https://pubmed.ncbi.nlm.nih.gov/28134301 28134301]|[https://pubmed.ncbi.nlm.nih.gov/3495590 3495590]|[https://pubmed.ncbi.nlm.nih.gov/1138893 1138893]|[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]|[https://pubmed.ncbi.nlm.nih.gov/10506200 10506200]|[https://pubmed.ncbi.nlm.nih.gov/8855242 8855242]|[https://pubmed.ncbi.nlm.nih.gov/1955453 1955453]|[https://pubmed.ncbi.nlm.nih.gov/1933935 1933935]|[https://pubmed.ncbi.nlm.nih.gov/3355161 3355161]|[https://pubmed.ncbi.nlm.nih.gov/6773959 6773959]|[https://pubmed.ncbi.nlm.nih.gov/14573676 14573676]|[https://pubmed.ncbi.nlm.nih.gov/29898878 29898878]|[https://pubmed.ncbi.nlm.nih.gov/10431785 10431785]|[https://pubmed.ncbi.nlm.nih.gov/1747956 1747956]|[https://pubmed.ncbi.nlm.nih.gov/11214737 11214737]|[https://pubmed.ncbi.nlm.nih.gov/7423202 7423202]|[https://pubmed.ncbi.nlm.nih.gov/389939 389939]|[https://pubmed.ncbi.nlm.nih.gov/3871816 3871816]|[https://pubmed.ncbi.nlm.nih.gov/6187373 6187373]|[https://pubmed.ncbi.nlm.nih.gov/16133832 16133832]|[https://pubmed.ncbi.nlm.nih.gov/469271 469271]|[https://pubmed.ncbi.nlm.nih.gov/3753492 3753492]|[https://pubmed.ncbi.nlm.nih.gov/2695680 2695680]|[https://pubmed.ncbi.nlm.nih.gov/7037611 7037611]|[https://pubmed.ncbi.nlm.nih.gov/25703376 25703376]|[https://pubmed.ncbi.nlm.nih.gov/23798992 23798992]|[https://pubmed.ncbi.nlm.nih.gov/414913 414913]|[https://pubmed.ncbi.nlm.nih.gov/1868069 1868069]|[https://pubmed.ncbi.nlm.nih.gov/7960243 7960243] <br>
-'''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789] <br>
+ '''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789] <br>
-'''term_xref''' : GlycoMotif:GGM.000084|CID:91825690|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86 <br>
+ '''term_xref''' : GlycoMotif:GGM.000084|GTC:G80062GG|CID:91825690|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86  <br>
-'''best_match''' : GlycoMotif:GGM.000084|GTC:G80062GG|CID:91825690|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86 <br>
+ '''synonyms''' : Forssman antigen|Globopentosylceramide <br>
-'''synonymns''' : Forssman antigen|Globopentosylceramide <br>
+ '''function''' : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:[https://pubmed.ncbi.nlm.nih.gov/3495590 3495590]] <br>
-'''function''' : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:3495590] <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:86]|Acute cystitis[SugarBind_Ligand:86] <br>
-'''disease_associations''' : Pyelonephritis[SugarBind_Ligand:86]|Acute cystitis[SugarBind_Ligand:86] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45]<br>
-'''essentials_of_glycobiology''' : NBK453041 <br>
 ===Fucose-containing tetraantennary===
-'''term (main_entry)''' : Fucose-containing tetraantennary <br>
+ '''term (main_entry)''' : Fucose-containing tetraantennary <br>
-'''glycan_dictionary_accession''' : GD000070 <br>
+ '''glycan_dictionary_accession''' : GSD000070 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The two major N-linked oligosaccharides of Namalwa EPO were fucose-containing tetraantennary and fucose-containing triantennary structures.[PMID:2550193] <br>
+ '''term_in_sentence''' : The two major N-linked oligosaccharides of Namalwa EPO were fucose-containing tetraantennary and fucose-containing triantennary structures.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2550193 2550193]] <br>
-'''publication''' : 2550193 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2550193 2550193] <br>
-'''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of fucose. <br>
+ '''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of fucose. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/Forssman_antigen <br>
-'''wikipedia''' : https://en.wikipedia.org/wiki/Forssman_antigen <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
 ===Fucosyl GM1===
-'''term (main_entry)''' : Fucosyl GM1 <br>
+[[File:G18625KA.png|thumb|G18625KA]]
-'''glycan_dictionary_accession''' : GD000071 <br>
+ '''term (main_entry)''' : Fucosyl GM1 <br>
-'''glytoucan_accession ''' : G91532KA <br>
+ '''glycan_dictionary_accession''' : GSD000071 <br>
-'''term_in_sentence''' : Unique localization of fucosyl GM1 implicates its possible role in cell adhesion and recognition in the nervous system.[PMID:8068725] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G91532KA G91532KA] <br>
-'''publication''' : 6619101|16880505|9089399|29789847|8068725|19556222|1660040|2420639|9076515|15926079|19555091|2541996|16211870|1336587|21174147|14967068|18923900|30021910|16941490|27070150|8305235|10602885|2645049|7993838|10537341|3002616|8336147|15447995|8905401|11714535|9260862|32228455|3315641|8076384|2317201|3680254|6403518 <br>
+ '''term_in_sentence''' : Unique localization of fucosyl GM1 implicates its possible role in cell adhesion and recognition in the nervous system.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8068725 8068725]] <br>
-'''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6619101 6619101]|[https://pubmed.ncbi.nlm.nih.gov/16880505 16880505]|[https://pubmed.ncbi.nlm.nih.gov/9089399 9089399]|[https://pubmed.ncbi.nlm.nih.gov/29789847 29789847]|[https://pubmed.ncbi.nlm.nih.gov/8068725 8068725]|[https://pubmed.ncbi.nlm.nih.gov/19556222 19556222]|[https://pubmed.ncbi.nlm.nih.gov/1660040 1660040]|[https://pubmed.ncbi.nlm.nih.gov/2420639 2420639]|[https://pubmed.ncbi.nlm.nih.gov/9076515 9076515]|[https://pubmed.ncbi.nlm.nih.gov/15926079 15926079]|[https://pubmed.ncbi.nlm.nih.gov/19555091 19555091]|[https://pubmed.ncbi.nlm.nih.gov/2541996 2541996]|[https://pubmed.ncbi.nlm.nih.gov/16211870 16211870]|[https://pubmed.ncbi.nlm.nih.gov/1336587 1336587]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/14967068 14967068]|[https://pubmed.ncbi.nlm.nih.gov/18923900 18923900]|[https://pubmed.ncbi.nlm.nih.gov/30021910 30021910]|[https://pubmed.ncbi.nlm.nih.gov/16941490 16941490]|[https://pubmed.ncbi.nlm.nih.gov/27070150 27070150]|[https://pubmed.ncbi.nlm.nih.gov/8305235 8305235]|[https://pubmed.ncbi.nlm.nih.gov/10602885 10602885]|[https://pubmed.ncbi.nlm.nih.gov/2645049 2645049]|[https://pubmed.ncbi.nlm.nih.gov/7993838 7993838]|[https://pubmed.ncbi.nlm.nih.gov/10537341 10537341]|[https://pubmed.ncbi.nlm.nih.gov/3002616 3002616]|[https://pubmed.ncbi.nlm.nih.gov/8336147 8336147]|[https://pubmed.ncbi.nlm.nih.gov/15447995 15447995]|[https://pubmed.ncbi.nlm.nih.gov/8905401 8905401]|[https://pubmed.ncbi.nlm.nih.gov/11714535 11714535]|[https://pubmed.ncbi.nlm.nih.gov/9260862 9260862]|[https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]|[https://pubmed.ncbi.nlm.nih.gov/3315641 3315641]|[https://pubmed.ncbi.nlm.nih.gov/8076384 8076384]|[https://pubmed.ncbi.nlm.nih.gov/2317201 2317201]|[https://pubmed.ncbi.nlm.nih.gov/3680254 3680254]|[https://pubmed.ncbi.nlm.nih.gov/6403518 6403518] <br>
-'''term_xref''' : GlycoEpitope:EP0049|CID:53356699|CHEBI:62686 <br>
+ '''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686] <br>
-'''best_match''' : GTC:G91532KA |GlycoEpitope:EP0049|CID:53356699|CHEBI:62686 <br>
+ '''term_xref''' : GTC:G91532KA |GlycoEpitope:EP0049|CID:53356699|CHEBI:62686 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : small-cell lung cancer(SCLC)[GlycoEpitope:EP0049]|hepatoma[GlycoEpitope:EP0049] <br>
+ '''disease_associations''' : small-cell lung cancer(SCLC)[GlycoEpitope:EP0049]|hepatoma[GlycoEpitope:EP0049] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Fucosylated asialo-biantennary===
-'''term (main_entry)''' : Fucosylated asialo-biantennary <br>
+ '''term (main_entry)''' : Fucosylated asialo-biantennary <br>
-'''glycan_dictionary_accession''' : GD000072 <br>
+ '''glycan_dictionary_accession''' : GSD000072 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:2065054] <br>
+ '''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]] <br>
-'''publication''' : 2065054|17013932 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]|[https://pubmed.ncbi.nlm.nih.gov/17013932 17013932] <br>
-'''definition''' : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose. <br>
+ '''definition''' : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+  '''synonyms''' : fucosylated asialo-diantennary <br>
-'''synonymns''' : fucosylated asialo-diantennary <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Fucosylated biantennary===
-'''term (main_entry)''' : Fucosylated biantennary <br>
+ '''term (main_entry)''' : Fucosylated biantennary <br>
-'''glycan_dictionary_accession''' : GD000073 <br>
+ '''glycan_dictionary_accession''' : GSD000073 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class.[PMID:17956937] <br>
+ '''term_in_sentence''' : The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17956937 17956937]] <br>
-'''publication''' : 17956937|30525457|1933856 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17956937 17956937]|[https://pubmed.ncbi.nlm.nih.gov/30525457 30525457]|[https://pubmed.ncbi.nlm.nih.gov/1933856 1933856] <br>
-'''definition''' : a biantennary glycan with two GlcNAc branches linked to the core and the addition of fucose. <br>
+ '''definition''' : a biantennary glycan with two GlcNAc branches linked to the core and the addition of fucose. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+  '''synonyms''' : fucosylated bisialo-diantennary <br>
-'''synonymns''' : fucosylated bisialo-diantennary <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Fucosylated bisialo-biantennary===
-'''term (main_entry)''' : Fucosylated bisialo-biantennary <br>
+ '''term (main_entry)''' : Fucosylated bisialo-biantennary <br>
-'''glycan_dictionary_accession''' : GD000074 <br>
+ '''glycan_dictionary_accession''' : GSD000074 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:2065054] <br>
+ '''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]] <br>
-'''publication''' : 2065054 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] <br>
-'''definition''' : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added. <br>
+ '''definition''' : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+  '''synonyms''' : Fucosylated biantennary <br>
-'''synonymns''' : Fucosylated biantennary <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Fucosylated LDN===
-'''term (main_entry)''' : Fucosylated LDN <br>
+[[File:G02240AO.png|thumb|G02240AO]]
-'''glycan_dictionary_accession''' : GD000075 <br>
+ '''term (main_entry)''' : Fucosylated LDN <br>
-'''glytoucan_accession ''' : G02240AO <br>
+ '''glycan_dictionary_accession''' : GSD000075 <br>
-'''term_in_sentence''' : To date, oligomeric LDN and oligomeric fucosylated LDN (LDNF) have been found only on N-glycans from mammalian cells engineered to express Caenorhabditis elegansbeta4-GalNAc transferase and human alpha3-fucosyltransferase IX [Z. S. Kawar et al. (2005) J Biol Chem280, 12810-12819]. [PMID:16403022] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02240AO G02240AO] <br>
-'''publication''' : 16403022|28151933|19545571|22448293 <br>
+ '''term_in_sentence''' : To date, oligomeric LDN and oligomeric fucosylated LDN (LDNF) have been found only on N-glycans from mammalian cells engineered to express Caenorhabditis elegansbeta4-GalNAc transferase and human alpha3-fucosyltransferase IX [Z. S. Kawar et al. (2005) J Biol Chem280, 12810-12819]. [PMID:[https://pubmed.ncbi.nlm.nih.gov/16403022 16403022]] <br>
-'''definition''' : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16403022 16403022]|[https://pubmed.ncbi.nlm.nih.gov/28151933 28151933]|[https://pubmed.ncbi.nlm.nih.gov/19545571 19545571]|[https://pubmed.ncbi.nlm.nih.gov/22448293 22448293] <br>
-'''term_xref''' : GlycoMotif:GGM.000017|GlycoEpitope:EP0151|CID:52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594 <br>
+ '''definition''' : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864] <br>
-'''best_match''' : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID:52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594 <br>
+ '''term_xref''' : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID:52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594 <br>
-'''synonymns''' : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1 <br>
+ '''synonyms''' : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1 <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Fucosylated N-glycans===
-'''term (main_entry)''' : Fucosylated N-glycans <br>
+ '''term (main_entry)''' : Fucosylated N-glycans <br>
-'''glycan_dictionary_accession''' : GD000076 <br>
+ '''glycan_dictionary_accession''' : GSD000076 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:18214858] <br>
+ '''term_in_sentence''' : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]] <br>
-'''publication''' : 18214858|31141660|26869352|29790113|31931062 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]|[https://pubmed.ncbi.nlm.nih.gov/31141660 31141660]|[https://pubmed.ncbi.nlm.nih.gov/26869352 26869352]|[https://pubmed.ncbi.nlm.nih.gov/29790113 29790113]|[https://pubmed.ncbi.nlm.nih.gov/31931062 31931062] <br>
-'''definition''' : The fucose from GDP-fucose is transferred to N-linked glycans. <br>
+ '''definition''' : The fucose from GDP-fucose is transferred to N-linked glycans. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' : pancreatic cancer.[PMID: [https://pubmed.ncbi.nlm.nih.gov/26869352 26869352]] <br>
-'''disease_associations''' : pancreatic cancer.[PMID: 26869352] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Fucosylated triantennary===
-'''term (main_entry)''' : Fucosylated triantennary <br>
+ '''term (main_entry)''' : Fucosylated triantennary <br>
-'''glycan_dictionary_accession''' : GD000077 <br>
+ '''glycan_dictionary_accession''' : GSD000077 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:2513186] <br>
+ '''term_in_sentence''' : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2513186 2513186] <br>
-'''publication''' : 2513186|29642865|7679920|31110965|2551687|15051952|12943224 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2513186 2513186]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/15051952 15051952]|[https://pubmed.ncbi.nlm.nih.gov/12943224 12943224] <br>
-'''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose. <br>
+ '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' : appears in human alpha-fetoprotein (AFP).[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br>
-'''function''' : appears in human alpha-fetoprotein (AFP).[PMID: 7679920] <br>
+ '''disease_associations''' : neoplastic diseases of the liver[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920] ]|hepatocellular carcinoma[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]]. <br>
-'''disease_associations''' : neoplastic diseases of the liver[PMID: 7679920 ]|hepatocellular carcinoma[PMID: 7679920]. <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453068/ Chapter 43]<br>
-'''essentials_of_glycobiology''' : NBK453068 <br>
 ===Galabiosylceramide===
-'''term (main_entry)''' : Galabiosylceramide <br>
+[[File:G67988RO.png|thumb|G67988RO]]
-'''glycan_dictionary_accession''' : GD000078 <br>
+ '''term (main_entry)''' : Galabiosylceramide <br>
-'''glytoucan_accession ''' : G67988RO <br>
+ '''glycan_dictionary_accession''' : GSD000078 <br>
-'''term_in_sentence''' : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:33360824] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67988RO G67988RO] <br>
-'''publication''' : 33360824|29099167|25582508|2824515|4027258|32854306|32868283|31319156|29530250|27367163|2564247|27727434|10216186|10460829|24992926|23590301|15702404|1854798|14761135|3600200|8603914|8601603|1965141|17400502|3840690|15959771|7930586|7721812|17095952|2500499|3815386|8842706|10746023|3928791|3782065|6440894 <br>
+ '''term_in_sentence''' : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:[https://pubmed.ncbi.nlm.nih.gov/33360824 33360824]] <br>
-'''definition''' : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/33360824 33360824]|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]|[https://pubmed.ncbi.nlm.nih.gov/25582508 25582508]|[https://pubmed.ncbi.nlm.nih.gov/2824515 2824515]|[https://pubmed.ncbi.nlm.nih.gov/4027258 4027258]|[https://pubmed.ncbi.nlm.nih.gov/32854306 32854306]|[https://pubmed.ncbi.nlm.nih.gov/32868283 32868283]|[https://pubmed.ncbi.nlm.nih.gov/31319156 31319156]|[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250]|[https://pubmed.ncbi.nlm.nih.gov/27367163 27367163]|[https://pubmed.ncbi.nlm.nih.gov/2564247 2564247]|[https://pubmed.ncbi.nlm.nih.gov/27727434 27727434]|[https://pubmed.ncbi.nlm.nih.gov/10216186 10216186]|[https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]|[https://pubmed.ncbi.nlm.nih.gov/24992926 24992926]|[https://pubmed.ncbi.nlm.nih.gov/23590301 23590301]|[https://pubmed.ncbi.nlm.nih.gov/15702404 15702404]|[https://pubmed.ncbi.nlm.nih.gov/1854798 1854798]|[https://pubmed.ncbi.nlm.nih.gov/14761135 14761135]|[https://pubmed.ncbi.nlm.nih.gov/3600200 3600200]|[https://pubmed.ncbi.nlm.nih.gov/8603914 8603914]|[https://pubmed.ncbi.nlm.nih.gov/8601603 8601603]|[https://pubmed.ncbi.nlm.nih.gov/1965141 1965141]|[https://pubmed.ncbi.nlm.nih.gov/17400502 17400502]|[https://pubmed.ncbi.nlm.nih.gov/3840690 3840690]|[https://pubmed.ncbi.nlm.nih.gov/15959771 15959771]|[https://pubmed.ncbi.nlm.nih.gov/7930586 7930586]|[https://pubmed.ncbi.nlm.nih.gov/7721812 7721812]|[https://pubmed.ncbi.nlm.nih.gov/17095952 17095952]|[https://pubmed.ncbi.nlm.nih.gov/2500499 2500499]|[https://pubmed.ncbi.nlm.nih.gov/3815386 3815386]|[https://pubmed.ncbi.nlm.nih.gov/8842706 8842706]|[https://pubmed.ncbi.nlm.nih.gov/10746023 10746023]|[https://pubmed.ncbi.nlm.nih.gov/3928791 3928791]|[https://pubmed.ncbi.nlm.nih.gov/3782065 3782065]|[https://pubmed.ncbi.nlm.nih.gov/6440894 6440894] <br>
-'''term_xref''' : GlycoEpitope:EP0113|CID:5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314 <br>
+ '''definition''' : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314] <br>
-'''best_match''' : GlycoEpitope:EP0113|GTC:G67988RO|CID:5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314 <br>
+ '''term_xref''' : GlycoEpitope:EP0113|GTC:G67988RO|CID:5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : tumor/lung[GlycoEpitope:EP0113]|tumor/gallbladder[GlycoEpitope:EP0113]|tumor/kidney[GlycoEpitope:EP0113]|tumor/pancreas[GlycoEpitope:EP0113] <br>
+ '''disease_associations''' : tumor/lung[GlycoEpitope:EP0113]|tumor/gallbladder[GlycoEpitope:EP0113]|tumor/kidney[GlycoEpitope:EP0113]|tumor/pancreas[GlycoEpitope:EP0113] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Galactosylceramide===
-'''term (main_entry)''' : Galactosylceramide <br>
+[[File:G65889KE.png|thumb|G65889KE]]
-'''glycan_dictionary_accession''' : GD000079 <br>
+ '''term (main_entry)''' : Galactosylceramide <br>
-'''glytoucan_accession ''' : G65889KE <br>
+ '''glycan_dictionary_accession''' : GSD000079 <br>
-'''term_in_sentence''' : Galactosylceramide improved behavioral, neuropathological, and biochemical parameters in Cln3 Cln3 Δex7/8 mice, paving the way for effective therapy for CLN3 disease and use of serum ceramide as a potential biomarker to track impact of therapies.[PMID:31393621] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G65889KE G65889KE] <br>
-'''publication''' : 31393621|19941861|9883654|33006978|26735924|22032265|18035062|25129050|2802541|1761517|28660574|475780|2302222 <br>
+ '''term_in_sentence''' : Galactosylceramide improved behavioral, neuropathological, and biochemical parameters in Cln3 Cln3 Δex7/8 mice, paving the way for effective therapy for CLN3 disease and use of serum ceramide as a potential biomarker to track impact of therapies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31393621 31393621]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31393621 31393621]|[https://pubmed.ncbi.nlm.nih.gov/19941861 19941861]|[https://pubmed.ncbi.nlm.nih.gov/9883654 9883654]|[https://pubmed.ncbi.nlm.nih.gov/33006978 33006978]|[https://pubmed.ncbi.nlm.nih.gov/26735924 26735924]|[https://pubmed.ncbi.nlm.nih.gov/22032265 22032265]|[https://pubmed.ncbi.nlm.nih.gov/18035062 18035062]|[https://pubmed.ncbi.nlm.nih.gov/25129050 25129050]|[https://pubmed.ncbi.nlm.nih.gov/2802541 2802541]|[https://pubmed.ncbi.nlm.nih.gov/1761517 1761517]|[https://pubmed.ncbi.nlm.nih.gov/28660574 28660574]|[https://pubmed.ncbi.nlm.nih.gov/475780 475780]|[https://pubmed.ncbi.nlm.nih.gov/2302222 2302222] <br>
-'''term_xref''' : GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061 <br>
+ '''definition''' :  <br>
-'''best_match''' : GTC:G65889KE|GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061 <br>
+ '''term_xref''' : GTC:G65889KE|GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061 <br>
-'''synonymns''' : GalCer|Galactocerebroside|LC <br>
+ '''synonyms''' : GalCer|Galactocerebroside|LC <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:1]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:1]|Lyme disease[SugarBind_Ligand:1]|Plague[SugarBind_Ligand:1]|Acquired immune deficiency syndrome[SugarBind_Ligand:1] <br>
+ '''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:1]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:1]|Lyme disease[SugarBind_Ligand:1]|Plague[SugarBind_Ligand:1]|Acquired immune deficiency syndrome[SugarBind_Ligand:1] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Galnac disialyl Lc4 (Hexasaccharide)===
-'''term (main_entry)''' : Galnac disialyl Lc4 (Hexasaccharide) <br>
+[[File:G33532XU.png|thumb|G33532XU]]
-'''glycan_dictionary_accession''' : GD000080 <br>
+ '''term (main_entry)''' : Galnac disialyl Lc4 (Hexasaccharide) <br>
-'''glytoucan_accession ''' : G33532XU <br>
+ '''glycan_dictionary_accession''' : GSD000080 <br>
-'''term_in_sentence''' : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: 12084983] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G33532XU G33532XU] <br>
-'''publication''' : 15704108|11278988|12084983|7509790 <br>
+ '''term_in_sentence''' : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] <br>
-'''definition''' : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID:91857945] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15704108 15704108]|[https://pubmed.ncbi.nlm.nih.gov/11278988 11278988]|[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]|[https://pubmed.ncbi.nlm.nih.gov/7509790 7509790] <br>
-'''term_xref''' : GlycoEpitope:EP0097|CID:91857945|CHEBI:149360 <br>
+ '''definition''' : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID:91857945] <br>
-'''best_match''' : GlycoEpitope:EP0097|GTC:G33532XU|CID:91857945|CHEBI:149360 <br>
+ '''term_xref''' : GlycoEpitope:EP0097|GTC:G33532XU|CID:91857945|CHEBI:149360 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : prostate cancer[GlycoEpitope:EP0097]|renal cell carcinoma/RCC[GlycoEpitope:EP0097] <br>
+ '''disease_associations''' : prostate cancer[GlycoEpitope:EP0097]|renal cell carcinoma/RCC[GlycoEpitope:EP0097] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Gb5===
-'''term (main_entry)''' : Gb5 <br>
+[[File:G99053DY.png|thumb|G99053DY]]
-'''glycan_dictionary_accession''' : GD000081 <br>
+ '''term (main_entry)''' : Gb5 <br>
-'''glytoucan_accession ''' : G99053DY <br>
+ '''glycan_dictionary_accession''' : GSD000081 <br>
-'''term_in_sentence''' : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:25839135] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99053DY G99053DY] <br>
-'''publication''' : 12401210|25839135|31540393|31140679|3028540|3674263|31339142|30026902|10721708|30671362|26176557|25039255|24044869|32567311|27857717|21491978|24910250|29077212|8014006|27107335|32679486|1747956|8679447|28352526|11341836|10837462|7960243|16158941|3297853|2431136|21734356|8625206|30732055|12716912|20128040|2582447|14659673 <br>
+ '''term_in_sentence''' : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25839135 25839135]] <br>
-'''definition''' : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]|[https://pubmed.ncbi.nlm.nih.gov/25839135 25839135]|[https://pubmed.ncbi.nlm.nih.gov/31540393 31540393]|[https://pubmed.ncbi.nlm.nih.gov/31140679 31140679]|[https://pubmed.ncbi.nlm.nih.gov/3028540 3028540]|[https://pubmed.ncbi.nlm.nih.gov/3674263 3674263]|[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]|[https://pubmed.ncbi.nlm.nih.gov/30026902 30026902]|[https://pubmed.ncbi.nlm.nih.gov/10721708 10721708]|[https://pubmed.ncbi.nlm.nih.gov/30671362 30671362]|[https://pubmed.ncbi.nlm.nih.gov/26176557 26176557]|[https://pubmed.ncbi.nlm.nih.gov/25039255 25039255]|[https://pubmed.ncbi.nlm.nih.gov/24044869 24044869]|[https://pubmed.ncbi.nlm.nih.gov/32567311 32567311]|[https://pubmed.ncbi.nlm.nih.gov/27857717 27857717]|[https://pubmed.ncbi.nlm.nih.gov/21491978 21491978]|[https://pubmed.ncbi.nlm.nih.gov/24910250 24910250]|[https://pubmed.ncbi.nlm.nih.gov/29077212 29077212]|[https://pubmed.ncbi.nlm.nih.gov/8014006 8014006]|[https://pubmed.ncbi.nlm.nih.gov/27107335 27107335]|[https://pubmed.ncbi.nlm.nih.gov/32679486 32679486]|[https://pubmed.ncbi.nlm.nih.gov/1747956 1747956]|[https://pubmed.ncbi.nlm.nih.gov/8679447 8679447]|[https://pubmed.ncbi.nlm.nih.gov/28352526 28352526]|[https://pubmed.ncbi.nlm.nih.gov/11341836 11341836]|[https://pubmed.ncbi.nlm.nih.gov/10837462 10837462]|[https://pubmed.ncbi.nlm.nih.gov/7960243 7960243]|[https://pubmed.ncbi.nlm.nih.gov/16158941 16158941]|[https://pubmed.ncbi.nlm.nih.gov/3297853 3297853]|[https://pubmed.ncbi.nlm.nih.gov/2431136 2431136]|[https://pubmed.ncbi.nlm.nih.gov/21734356 21734356]|[https://pubmed.ncbi.nlm.nih.gov/8625206 8625206]|[https://pubmed.ncbi.nlm.nih.gov/30732055 30732055]|[https://pubmed.ncbi.nlm.nih.gov/12716912 12716912]|[https://pubmed.ncbi.nlm.nih.gov/20128040 20128040]|[https://pubmed.ncbi.nlm.nih.gov/2582447 2582447]|[https://pubmed.ncbi.nlm.nih.gov/14659673 14659673] <br>
-'''term_xref''' : GlycoMotif:GGM.000076|CID:53239691|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12 <br>
+ '''definition''' : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842] <br>
-'''best_match''' : GlycoMotif:GGM.000076|GTC:G99053DY|CID:53239691|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12 <br>
+ '''term_xref''' : GlycoMotif:GGM.000076|GTC:G99053DY|CID:53239691|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12 <br>
-'''synonymns''' : Globopentaosylceramide <br>
+ '''synonyms''' : Globopentaosylceramide <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Pyelonephritis[SugarBind_Ligand:12]|Actinomycosis[SugarBind_Ligand:12|Influenza[SugarBind_Ligand:12] <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:12]|Actinomycosis[SugarBind_Ligand:12|Influenza[SugarBind_Ligand:12] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
 ===GD1===
-'''term (main_entry)''' : GD1 <br>
+[[File:G81983KG.png|thumb|G81983KG]]
-'''glycan_dictionary_accession''' : GD000082 <br>
+ '''term (main_entry)''' : GD1 <br>
-'''glytoucan_accession ''' : G81983KG <br>
+ '''glycan_dictionary_accession''' : GSD000082 <br>
-'''term_in_sentence''' : Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1.[PMID:31791361] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G81983KG G81983KG] <br>
-'''publication''' : 5652802|25345088|31791361|29361370|31234327|30264864|25250137|7528216|31669751|20684311|16306603|10420586|7766692|31614613|26384672|31613991|19210136|8926633|29696051|32300455|7513313|26674302|20336376|24259734|31704237|21067946|30516933|27979707|26345314|30516941|31849452|27789132|30218706|29388611|20177787 <br>
+ '''term_in_sentence''' : Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31791361 31791361]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/5652802 5652802]|[https://pubmed.ncbi.nlm.nih.gov/25345088 25345088]|[https://pubmed.ncbi.nlm.nih.gov/31791361 31791361]|[https://pubmed.ncbi.nlm.nih.gov/29361370 29361370]|[https://pubmed.ncbi.nlm.nih.gov/31234327 31234327]|[https://pubmed.ncbi.nlm.nih.gov/30264864 30264864]|[https://pubmed.ncbi.nlm.nih.gov/25250137 25250137]|[https://pubmed.ncbi.nlm.nih.gov/7528216 7528216]|[https://pubmed.ncbi.nlm.nih.gov/31669751 31669751]|[https://pubmed.ncbi.nlm.nih.gov/20684311 20684311]|[https://pubmed.ncbi.nlm.nih.gov/16306603 16306603]|[https://pubmed.ncbi.nlm.nih.gov/10420586 10420586]|[https://pubmed.ncbi.nlm.nih.gov/7766692 7766692]|[https://pubmed.ncbi.nlm.nih.gov/31614613 31614613]|[https://pubmed.ncbi.nlm.nih.gov/26384672 26384672]|[https://pubmed.ncbi.nlm.nih.gov/31613991 31613991]|[https://pubmed.ncbi.nlm.nih.gov/19210136 19210136]|[https://pubmed.ncbi.nlm.nih.gov/8926633 8926633]|[https://pubmed.ncbi.nlm.nih.gov/29696051 29696051]|[https://pubmed.ncbi.nlm.nih.gov/32300455 32300455]|[https://pubmed.ncbi.nlm.nih.gov/7513313 7513313]|[https://pubmed.ncbi.nlm.nih.gov/26674302 26674302]|[https://pubmed.ncbi.nlm.nih.gov/20336376 20336376]|[https://pubmed.ncbi.nlm.nih.gov/24259734 24259734]|[https://pubmed.ncbi.nlm.nih.gov/31704237 31704237]|[https://pubmed.ncbi.nlm.nih.gov/21067946 21067946]|[https://pubmed.ncbi.nlm.nih.gov/30516933 30516933]|[https://pubmed.ncbi.nlm.nih.gov/27979707 27979707]|[https://pubmed.ncbi.nlm.nih.gov/26345314 26345314]|[https://pubmed.ncbi.nlm.nih.gov/30516941 30516941]|[https://pubmed.ncbi.nlm.nih.gov/31849452 31849452]|[https://pubmed.ncbi.nlm.nih.gov/27789132 27789132]|[https://pubmed.ncbi.nlm.nih.gov/30218706 30218706]|[https://pubmed.ncbi.nlm.nih.gov/29388611 29388611]|[https://pubmed.ncbi.nlm.nih.gov/20177787 20177787] <br>
-'''term_xref''' : GlycoMotif:GGM.000105|CID:91859783|KEGG:G00126 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000105|GTC:G81983KG|CID:91859783|KEGG:G00126 <br>
+ '''term_xref''' : GlycoMotif:GGM.000105|GTC:G81983KG|CID:91859783|KEGG:G00126  <br>
-'''synonymns''' : GD1c <br>
+ '''synonyms''' : GD1c <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===GD1a===
-'''term (main_entry)''' : GD1a <br>
+[[File:G46677TE.png|thumb|G46677TE]]
-'''glycan_dictionary_accession''' : GD000083 <br>
+[[File:G45714BQ.png|thumb|G45714BQ]]
-'''glytoucan_accession ''' : G46677TE <br>
+ '''term (main_entry)''' : GD1a <br>
-'''term_in_sentence''' : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: 28899916] <br>
+ '''glycan_dictionary_accession''' : GSD000083 <br>
-'''publication''' : 28899916|26860251|21930390|32906699|26054879|29951721|11745410|17653976|26119566|21554929|18435913|15342262|26865725|21151139|15716397|21492147|16942752|26973195|24449473|14999485|22735313|20589721|10521808|22929125|7827024|16897174|25062498|17227759 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G46677TE G46677TE] | [https://glygen.org/glycan/G45714BQ G45714BQ]<br>
-'''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209] <br>
+ '''term_in_sentence''' : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: [https://pubmed.ncbi.nlm.nih.gov/28899916 28899916]] <br>
-'''term_xref''' : GlycoMotif:GGM.000107|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28899916 28899916]|[https://pubmed.ncbi.nlm.nih.gov/26860251 26860251]|[https://pubmed.ncbi.nlm.nih.gov/21930390 21930390]|[https://pubmed.ncbi.nlm.nih.gov/32906699 32906699]|[https://pubmed.ncbi.nlm.nih.gov/26054879 26054879]|[https://pubmed.ncbi.nlm.nih.gov/29951721 29951721]|[https://pubmed.ncbi.nlm.nih.gov/11745410 11745410]|[https://pubmed.ncbi.nlm.nih.gov/17653976 17653976]|[https://pubmed.ncbi.nlm.nih.gov/26119566 26119566]|[https://pubmed.ncbi.nlm.nih.gov/21554929 21554929]|[https://pubmed.ncbi.nlm.nih.gov/18435913 18435913]|[https://pubmed.ncbi.nlm.nih.gov/15342262 15342262]|[https://pubmed.ncbi.nlm.nih.gov/26865725 26865725]|[https://pubmed.ncbi.nlm.nih.gov/21151139 21151139]|[https://pubmed.ncbi.nlm.nih.gov/15716397 15716397]|[https://pubmed.ncbi.nlm.nih.gov/21492147 21492147]|[https://pubmed.ncbi.nlm.nih.gov/16942752 16942752]|[https://pubmed.ncbi.nlm.nih.gov/26973195 26973195]|[https://pubmed.ncbi.nlm.nih.gov/24449473 24449473]|[https://pubmed.ncbi.nlm.nih.gov/14999485 14999485]|[https://pubmed.ncbi.nlm.nih.gov/22735313 22735313]|[https://pubmed.ncbi.nlm.nih.gov/20589721 20589721]|[https://pubmed.ncbi.nlm.nih.gov/10521808 10521808]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]|[https://pubmed.ncbi.nlm.nih.gov/7827024 7827024]|[https://pubmed.ncbi.nlm.nih.gov/16897174 16897174]|[https://pubmed.ncbi.nlm.nih.gov/25062498 25062498]|[https://pubmed.ncbi.nlm.nih.gov/17227759 17227759] <br>
-'''best_match''' : GlycoMotif:GGM.000107|GTC:G46677TE|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111 <br>
+ '''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209] <br>
-'''synonymns''' : GD1alpha <br>
+ '''term_xref''' : GlycoMotif:GGM.000106|GlycoMotif:GGM.000107|GTC:G46677TE|GTC:G45714BQ|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111  <br>
-'''function''' :  <br>
+ '''synonyms''' : GD1alpha <br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:22]|Actinomycosis[SugarBind_Ligand:22]|Lazy leukocyte syndrome[SugarBind_Ligand:22]|Toxoplasmosis[SugarBind_Ligand:22]|Lyme disease[SugarBind_Ligand:22]|Botulism[SugarBind_Ligand:22]|Keratoconjunctivitis[SugarBind_Ligand:22]|Influenza[SugarBind_Ligand:22] <br>
+ '''function''' :  <br>
-'''wikipedia''' :  <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:22]|Actinomycosis[SugarBind_Ligand:22]|Lazy leukocyte syndrome[SugarBind_Ligand:22]|Toxoplasmosis[SugarBind_Ligand:22]|Lyme disease[SugarBind_Ligand:22]|Botulism[SugarBind_Ligand:22]|Keratoconjunctivitis[SugarBind_Ligand:22]|Influenza[SugarBind_Ligand:22] <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===GD1b===
-'''term (main_entry)''' : GD1b <br>
+[[File:G37184KW.png|thumb|G37184KW]]
-'''glycan_dictionary_accession''' : GD000084 <br>
+ '''term (main_entry)''' : GD1b <br>
-'''glytoucan_accession ''' : G37184KW <br>
+ '''glycan_dictionary_accession''' : GSD000084 <br>
-'''term_in_sentence''' : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: 27144558] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G37184KW G37184KW] <br>
-'''publication''' : 27144558|24859332|18625966|7945223|32518172|26710925|31837178|20594196|30985655|11511306|1742806|11123278|7685064|2709011|33279873|22929125|9179156|17964572|8821498|32726962|26560950|2611779|10072058|20030259|16415013|10797556|11342695|8619520|21519903|16199892|23777091|30246056|10481046 <br>
+ '''term_in_sentence''' : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27144558 27144558]] <br>
-'''definition''' : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27144558 27144558]|[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332]|[https://pubmed.ncbi.nlm.nih.gov/18625966 18625966]|[https://pubmed.ncbi.nlm.nih.gov/7945223 7945223]|[https://pubmed.ncbi.nlm.nih.gov/32518172 32518172]|[https://pubmed.ncbi.nlm.nih.gov/26710925 26710925]|[https://pubmed.ncbi.nlm.nih.gov/31837178 31837178]|[https://pubmed.ncbi.nlm.nih.gov/20594196 20594196]|[https://pubmed.ncbi.nlm.nih.gov/30985655 30985655]|[https://pubmed.ncbi.nlm.nih.gov/11511306 11511306]|[https://pubmed.ncbi.nlm.nih.gov/1742806 1742806]|[https://pubmed.ncbi.nlm.nih.gov/11123278 11123278]|[https://pubmed.ncbi.nlm.nih.gov/7685064 7685064]|[https://pubmed.ncbi.nlm.nih.gov/2709011 2709011]|[https://pubmed.ncbi.nlm.nih.gov/33279873 33279873]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]|[https://pubmed.ncbi.nlm.nih.gov/9179156 9179156]|[https://pubmed.ncbi.nlm.nih.gov/17964572 17964572]|[https://pubmed.ncbi.nlm.nih.gov/8821498 8821498]|[https://pubmed.ncbi.nlm.nih.gov/32726962 32726962]|[https://pubmed.ncbi.nlm.nih.gov/26560950 26560950]|[https://pubmed.ncbi.nlm.nih.gov/2611779 2611779]|[https://pubmed.ncbi.nlm.nih.gov/10072058 10072058]|[https://pubmed.ncbi.nlm.nih.gov/20030259 20030259]|[https://pubmed.ncbi.nlm.nih.gov/16415013 16415013]|[https://pubmed.ncbi.nlm.nih.gov/10797556 10797556]|[https://pubmed.ncbi.nlm.nih.gov/11342695 11342695]|[https://pubmed.ncbi.nlm.nih.gov/8619520 8619520]|[https://pubmed.ncbi.nlm.nih.gov/21519903 21519903]|[https://pubmed.ncbi.nlm.nih.gov/16199892 16199892]|[https://pubmed.ncbi.nlm.nih.gov/23777091 23777091]|[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056]|[https://pubmed.ncbi.nlm.nih.gov/10481046 10481046] <br>
-'''term_xref''' : GlycoMotif:GGM.000108|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14 <br>
+ '''definition''' : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222] <br>
-'''best_match''' : GlycoMotif:0GGM.00108|GTC:G37184KW|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14 <br>
+ '''term_xref''' : GlycoMotif:GGM.000108|GTC:G37184KW|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453023 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
 ===GD2===
-'''term (main_entry)''' : GD2 <br>
+[[File:G02657AK.png|thumb|G02657AK]]
-'''glycan_dictionary_accession''' : GD000085 <br>
+ '''term (main_entry)''' : GD2 <br>
-'''glytoucan_accession ''' : G02657AK <br>
+ '''glycan_dictionary_accession''' : GSD000085 <br>
-'''term_in_sentence''' : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: 25440605] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02657AK G02657AK] <br>
-'''publication''' : 28154831|32002293|32733795|28145567|31500597|31903906|29180536|28415563|25440605|30617136|25604432|30198960|31075227|31721713|30955398|32195035|27304202|31015228|31653037|31016728|30670592|30613134|29221154|30027525|29442009|31762628|30485077|25642322|29436609|29151270|24773917|30612272|27654028|26298772 <br>
+ '''term_in_sentence''' : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: [https://pubmed.ncbi.nlm.nih.gov/25440605 25440605]] <br>
-'''definition''' : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28154831 28154831]|[https://pubmed.ncbi.nlm.nih.gov/32002293 32002293]|[https://pubmed.ncbi.nlm.nih.gov/32733795 32733795]|[https://pubmed.ncbi.nlm.nih.gov/28145567 28145567]|[https://pubmed.ncbi.nlm.nih.gov/31500597 31500597]|[https://pubmed.ncbi.nlm.nih.gov/31903906 31903906]|[https://pubmed.ncbi.nlm.nih.gov/29180536 29180536]|[https://pubmed.ncbi.nlm.nih.gov/28415563 28415563]|[https://pubmed.ncbi.nlm.nih.gov/25440605 25440605]|[https://pubmed.ncbi.nlm.nih.gov/30617136 30617136]|[https://pubmed.ncbi.nlm.nih.gov/25604432 25604432]|[https://pubmed.ncbi.nlm.nih.gov/30198960 30198960]|[https://pubmed.ncbi.nlm.nih.gov/31075227 31075227]|[https://pubmed.ncbi.nlm.nih.gov/31721713 31721713]|[https://pubmed.ncbi.nlm.nih.gov/30955398 30955398]|[https://pubmed.ncbi.nlm.nih.gov/32195035 32195035]|[https://pubmed.ncbi.nlm.nih.gov/27304202 27304202]|[https://pubmed.ncbi.nlm.nih.gov/31015228 31015228]|[https://pubmed.ncbi.nlm.nih.gov/31653037 31653037]|[https://pubmed.ncbi.nlm.nih.gov/31016728 31016728]|[https://pubmed.ncbi.nlm.nih.gov/30670592 30670592]|[https://pubmed.ncbi.nlm.nih.gov/30613134 30613134]|[https://pubmed.ncbi.nlm.nih.gov/29221154 29221154]|[https://pubmed.ncbi.nlm.nih.gov/30027525 30027525]|[https://pubmed.ncbi.nlm.nih.gov/29442009 29442009]|[https://pubmed.ncbi.nlm.nih.gov/31762628 31762628]|[https://pubmed.ncbi.nlm.nih.gov/30485077 30485077]|[https://pubmed.ncbi.nlm.nih.gov/25642322 25642322]|[https://pubmed.ncbi.nlm.nih.gov/29436609 29436609]|[https://pubmed.ncbi.nlm.nih.gov/29151270 29151270]|[https://pubmed.ncbi.nlm.nih.gov/24773917 24773917]|[https://pubmed.ncbi.nlm.nih.gov/30612272 30612272]|[https://pubmed.ncbi.nlm.nih.gov/27654028 27654028]|[https://pubmed.ncbi.nlm.nih.gov/26298772 26298772] <br>
-'''term_xref''' : GlycoMotif:GGM.000094|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88 <br>
+ '''definition''' : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218] <br>
-'''best_match''' : GlycoMotif:GGM.000094|GTC:G02657AK|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88 <br>
+ '''term_xref''' : GlycoMotif:GGM.000094|GTC:G02657AK|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : breast cancer[PMID:28415563] <br>
+ '''disease_associations''' : breast cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/28415563 28415563]] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016|NBK453073 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]|[https://www.ncbi.nlm.nih.gov/books/NBK453073/ Chatper 35]<br>
 ===GD3===
-'''term (main_entry)''' : GD3 <br>
+[[File:G98544DH.png|thumb|G98544DH]]
-'''glycan_dictionary_accession''' : GD000086 <br>
+ '''term (main_entry)''' : GD3 <br>
-'''glytoucan_accession ''' : G98544DH <br>
+ '''glycan_dictionary_accession''' : GSD000086 <br>
-'''term_in_sentence''' : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: 12531552] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G98544DH G98544DH] <br>
-'''publication''' : 30245960|27591028|12531552|29069780|12470841|29436609|28295752|27304202|31138648|27288875|30446565|8721669|3903474|16081368|32743804|24372645|26792897|20890432|25330147|20581115|11174200|16040804|23783008|17368571|11023989|12901230|21807667|7061953|2231782|19423750|22632091|18202973|6392333|15896784|8261439|20052288|12847141|12486096|12118012|19912988|22795094|18655184|17043769|21395555|2472199|19776077 <br>
+ '''term_in_sentence''' : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: [https://pubmed.ncbi.nlm.nih.gov/12531552 12531552]] <br>
-'''definition''' : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30245960 30245960]|[https://pubmed.ncbi.nlm.nih.gov/27591028 27591028]|[https://pubmed.ncbi.nlm.nih.gov/12531552 12531552]|[https://pubmed.ncbi.nlm.nih.gov/29069780 29069780]|[https://pubmed.ncbi.nlm.nih.gov/12470841 12470841]|[https://pubmed.ncbi.nlm.nih.gov/29436609 29436609]|[https://pubmed.ncbi.nlm.nih.gov/28295752 28295752]|[https://pubmed.ncbi.nlm.nih.gov/27304202 27304202]|[https://pubmed.ncbi.nlm.nih.gov/31138648 31138648]|[https://pubmed.ncbi.nlm.nih.gov/27288875 27288875]|[https://pubmed.ncbi.nlm.nih.gov/30446565 30446565]|[https://pubmed.ncbi.nlm.nih.gov/8721669 8721669]|[https://pubmed.ncbi.nlm.nih.gov/3903474 3903474]|[https://pubmed.ncbi.nlm.nih.gov/16081368 16081368]|[https://pubmed.ncbi.nlm.nih.gov/32743804 32743804]|[https://pubmed.ncbi.nlm.nih.gov/24372645 24372645]|[https://pubmed.ncbi.nlm.nih.gov/26792897 26792897]|[https://pubmed.ncbi.nlm.nih.gov/20890432 20890432]|[https://pubmed.ncbi.nlm.nih.gov/25330147 25330147]|[https://pubmed.ncbi.nlm.nih.gov/20581115 20581115]|[https://pubmed.ncbi.nlm.nih.gov/11174200 11174200]|[https://pubmed.ncbi.nlm.nih.gov/16040804 16040804]|[https://pubmed.ncbi.nlm.nih.gov/23783008 23783008]|[https://pubmed.ncbi.nlm.nih.gov/17368571 17368571]|[https://pubmed.ncbi.nlm.nih.gov/11023989 11023989]|[https://pubmed.ncbi.nlm.nih.gov/12901230 12901230]|[https://pubmed.ncbi.nlm.nih.gov/21807667 21807667]|[https://pubmed.ncbi.nlm.nih.gov/7061953 7061953]|[https://pubmed.ncbi.nlm.nih.gov/2231782 2231782]|[https://pubmed.ncbi.nlm.nih.gov/19423750 19423750]|[https://pubmed.ncbi.nlm.nih.gov/22632091 22632091]|[https://pubmed.ncbi.nlm.nih.gov/18202973 18202973]|[https://pubmed.ncbi.nlm.nih.gov/6392333 6392333]|[https://pubmed.ncbi.nlm.nih.gov/15896784 15896784]|[https://pubmed.ncbi.nlm.nih.gov/8261439 8261439]|[https://pubmed.ncbi.nlm.nih.gov/20052288 20052288]|[https://pubmed.ncbi.nlm.nih.gov/12847141 12847141]|[https://pubmed.ncbi.nlm.nih.gov/12486096 12486096]|[https://pubmed.ncbi.nlm.nih.gov/12118012 12118012]|[https://pubmed.ncbi.nlm.nih.gov/19912988 19912988]|[https://pubmed.ncbi.nlm.nih.gov/22795094 22795094]|[https://pubmed.ncbi.nlm.nih.gov/18655184 18655184]|[https://pubmed.ncbi.nlm.nih.gov/17043769 17043769]|[https://pubmed.ncbi.nlm.nih.gov/21395555 21395555]|[https://pubmed.ncbi.nlm.nih.gov/2472199 2472199]|[https://pubmed.ncbi.nlm.nih.gov/19776077 19776077] <br>
-'''term_xref''' : GlycoMotif:GGM.000091|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062 <br>
+ '''definition''' : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210] <br>
-'''best_match''' : GlycoMotif:GGM.000091|GTC:G98544DH|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062 <br>
+ '''term_xref''' : GlycoMotif:GGM.000091|GTC:G98544DH|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Cholera[SugarBind_Ligand:89]|Influenza[SugarBind_Ligand:89] <br>
+ '''disease_associations''' : Cholera[SugarBind_Ligand:89]|Influenza[SugarBind_Ligand:89] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
 ===Globoside===
-'''term (main_entry)''' : Globoside <br>
+[[File:G00061MO.png|thumb|G00061MO]]
-'''glycan_dictionary_accession''' : GD000087 <br>
+ '''term (main_entry)''' : Globoside <br>
-'''glytoucan_accession ''' : G00061MO <br>
+ '''glycan_dictionary_accession''' : GSD000087 <br>
-'''term_in_sentence''' : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:10993897] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br>
-'''publication''' : 10993897 <br>
+ '''term_in_sentence''' : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:[https://pubmed.ncbi.nlm.nih.gov/10993897 10993897]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10993897 10993897] <br>
-'''term_xref''' : GlycoMotif:GGM.000070 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000070|GTC:G00061MO <br>
+ '''term_xref''' : GlycoMotif:GGM.000070|GTC:G00061MO <br>
-'''synonymns''' : Cytolipin K|Gb4|Globoside I|Globotetraosylceramide|P antigen <br>
+ '''synonyms''' : Cytolipin K|Gb4|Globoside I|Globotetraosylceramide|P antigen <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453023 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
 ===Globotetraosylceramide===
-'''term (main_entry)''' : Globotetraosylceramide <br>
+[[File:G00061MO.png|thumb|G00061MO]]
-'''glycan_dictionary_accession''' : GD000088 <br>
+ '''term (main_entry)''' : Globotetraosylceramide <br>
-'''glytoucan_accession ''' : G00061MO <br>
+ '''glycan_dictionary_accession''' : GSD000088 <br>
-'''term_in_sentence''' : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:28392398] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br>
-'''publication''' : 28392398|25787850|23471986|2559078|32455599|2663859|32796033|3517161|20082214|30853699|15279935|26104834|20732996|30224239|31142708|30338271|25033755|30413389|7104376|29866658|24983355|6794884|31361021|21740983|33168837|31752441|28123520|29068380|24841197|27932383|28535204|31691795|27916888|27558838|10227680|26464281|22348006|22279060|25156739|32314902|22718629|23701631|23906628|8613382|23555772|20059899|7868240 <br>
+ '''term_in_sentence''' : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:[https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]] <br>
-'''definition''' : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]|[https://pubmed.ncbi.nlm.nih.gov/25787850 25787850]|[https://pubmed.ncbi.nlm.nih.gov/23471986 23471986]|[https://pubmed.ncbi.nlm.nih.gov/2559078 2559078]|[https://pubmed.ncbi.nlm.nih.gov/32455599 32455599]|[https://pubmed.ncbi.nlm.nih.gov/2663859 2663859]|[https://pubmed.ncbi.nlm.nih.gov/32796033 32796033]|[https://pubmed.ncbi.nlm.nih.gov/3517161 3517161]|[https://pubmed.ncbi.nlm.nih.gov/20082214 20082214]|[https://pubmed.ncbi.nlm.nih.gov/30853699 30853699]|[https://pubmed.ncbi.nlm.nih.gov/15279935 15279935]|[https://pubmed.ncbi.nlm.nih.gov/26104834 26104834]|[https://pubmed.ncbi.nlm.nih.gov/20732996 20732996]|[https://pubmed.ncbi.nlm.nih.gov/30224239 30224239]|[https://pubmed.ncbi.nlm.nih.gov/31142708 31142708]|[https://pubmed.ncbi.nlm.nih.gov/30338271 30338271]|[https://pubmed.ncbi.nlm.nih.gov/25033755 25033755]|[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389]|[https://pubmed.ncbi.nlm.nih.gov/7104376 7104376]|[https://pubmed.ncbi.nlm.nih.gov/29866658 29866658]|[https://pubmed.ncbi.nlm.nih.gov/24983355 24983355]|[https://pubmed.ncbi.nlm.nih.gov/6794884 6794884]|[https://pubmed.ncbi.nlm.nih.gov/31361021 31361021]|[https://pubmed.ncbi.nlm.nih.gov/21740983 21740983]|[https://pubmed.ncbi.nlm.nih.gov/33168837 33168837]|[https://pubmed.ncbi.nlm.nih.gov/31752441 31752441]|[https://pubmed.ncbi.nlm.nih.gov/28123520 28123520]|[https://pubmed.ncbi.nlm.nih.gov/29068380 29068380]|[https://pubmed.ncbi.nlm.nih.gov/24841197 24841197]|[https://pubmed.ncbi.nlm.nih.gov/27932383 27932383]|[https://pubmed.ncbi.nlm.nih.gov/28535204 28535204]|[https://pubmed.ncbi.nlm.nih.gov/31691795 31691795]|[https://pubmed.ncbi.nlm.nih.gov/27916888 27916888]|[https://pubmed.ncbi.nlm.nih.gov/27558838 27558838]|[https://pubmed.ncbi.nlm.nih.gov/10227680 10227680]|[https://pubmed.ncbi.nlm.nih.gov/26464281 26464281]|[https://pubmed.ncbi.nlm.nih.gov/22348006 22348006]|[https://pubmed.ncbi.nlm.nih.gov/22279060 22279060]|[https://pubmed.ncbi.nlm.nih.gov/25156739 25156739]|[https://pubmed.ncbi.nlm.nih.gov/32314902 32314902]|[https://pubmed.ncbi.nlm.nih.gov/22718629 22718629]|[https://pubmed.ncbi.nlm.nih.gov/23701631 23701631]|[https://pubmed.ncbi.nlm.nih.gov/23906628 23906628]|[https://pubmed.ncbi.nlm.nih.gov/8613382 8613382]|[https://pubmed.ncbi.nlm.nih.gov/23555772 23555772]|[https://pubmed.ncbi.nlm.nih.gov/20059899 20059899]|[https://pubmed.ncbi.nlm.nih.gov/7868240 7868240] <br>
-'''term_xref''' : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID:5288889|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032 <br>
+ '''definition''' : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] <br>
-'''best_match''' :  l;' <br>
+ '''term_xref''' : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID:5288889|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032<br>
-'''synonymns''' : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K <br>
+  '''synonyms''' : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Actinomycosis[SugarBind_Ligand:18]|Pyelonephritis[SugarBind_Ligand:18]|Acute cystitis[SugarBind_Ligand:18]|Shigellosis[SugarBind_Ligand:18]|Lazy leukocyte syndrome[SugarBind_Ligand:18]|Influenza[SugarBind_Ligand:18] <br>
+ '''disease_associations''' : Actinomycosis[SugarBind_Ligand:18]|Pyelonephritis[SugarBind_Ligand:18]|Acute cystitis[SugarBind_Ligand:18]|Shigellosis[SugarBind_Ligand:18]|Lazy leukocyte syndrome[SugarBind_Ligand:18]|Influenza[SugarBind_Ligand:18] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
 ===Globotriaosylceramide===
-'''term (main_entry)''' : Globotriaosylceramide <br>
+[[File:G00059MO.png|thumb|G00059MO]]
-'''glycan_dictionary_accession''' : GD000089 <br>
+ '''term (main_entry)''' : Globotriaosylceramide <br>
-'''glytoucan_accession ''' : G00059MO <br>
+ '''glycan_dictionary_accession''' : GSD000089 <br>
-'''term_in_sentence''' : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:32127409] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00059MO G00059MO] <br>
-'''publication''' : 32127409|28674962|30875019|30413389|31778662|31101366|24335674|31241709|24158513|28947349|31566927|28672034|31939530|29530250|27851774|26426881|25031264|29982630|24496231|29983334|28756410|27190352|29274327|29099167|28402705|23680766|28625968|26960552|26797827|22742555|27756537|31630715|3827883|28384397|29523338|31010832|27195818|26661087|23093409|30879639|27081853|17409683|29921669|25575293|26291612|23146289|25857295|26070511 <br>
+ '''term_in_sentence''' : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]] <br>
-'''definition''' : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]|[https://pubmed.ncbi.nlm.nih.gov/28674962 28674962]|[https://pubmed.ncbi.nlm.nih.gov/30875019 30875019]|[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389]|[https://pubmed.ncbi.nlm.nih.gov/31778662 31778662]|[https://pubmed.ncbi.nlm.nih.gov/31101366 31101366]|[https://pubmed.ncbi.nlm.nih.gov/24335674 24335674]|[https://pubmed.ncbi.nlm.nih.gov/31241709 31241709]|[https://pubmed.ncbi.nlm.nih.gov/24158513 24158513]|[https://pubmed.ncbi.nlm.nih.gov/28947349 28947349]|[https://pubmed.ncbi.nlm.nih.gov/31566927 31566927]|[https://pubmed.ncbi.nlm.nih.gov/28672034 28672034]|[https://pubmed.ncbi.nlm.nih.gov/31939530 31939530]|[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250]|[https://pubmed.ncbi.nlm.nih.gov/27851774 27851774]|[https://pubmed.ncbi.nlm.nih.gov/26426881 26426881]|[https://pubmed.ncbi.nlm.nih.gov/25031264 25031264]|[https://pubmed.ncbi.nlm.nih.gov/29982630 29982630]|[https://pubmed.ncbi.nlm.nih.gov/24496231 24496231]|[https://pubmed.ncbi.nlm.nih.gov/29983334 29983334]|[https://pubmed.ncbi.nlm.nih.gov/28756410 28756410]|[https://pubmed.ncbi.nlm.nih.gov/27190352 27190352]|[https://pubmed.ncbi.nlm.nih.gov/29274327 29274327]|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]|[https://pubmed.ncbi.nlm.nih.gov/28402705 28402705]|[https://pubmed.ncbi.nlm.nih.gov/23680766 23680766]|[https://pubmed.ncbi.nlm.nih.gov/28625968 28625968]|[https://pubmed.ncbi.nlm.nih.gov/26960552 26960552]|[https://pubmed.ncbi.nlm.nih.gov/26797827 26797827]|[https://pubmed.ncbi.nlm.nih.gov/22742555 22742555]|[https://pubmed.ncbi.nlm.nih.gov/27756537 27756537]|[https://pubmed.ncbi.nlm.nih.gov/31630715 31630715]|[https://pubmed.ncbi.nlm.nih.gov/3827883 3827883]|[https://pubmed.ncbi.nlm.nih.gov/28384397 28384397]|[https://pubmed.ncbi.nlm.nih.gov/29523338 29523338]|[https://pubmed.ncbi.nlm.nih.gov/31010832 31010832]|[https://pubmed.ncbi.nlm.nih.gov/27195818 27195818]|[https://pubmed.ncbi.nlm.nih.gov/26661087 26661087]|[https://pubmed.ncbi.nlm.nih.gov/23093409 23093409]|[https://pubmed.ncbi.nlm.nih.gov/30879639 30879639]|[https://pubmed.ncbi.nlm.nih.gov/27081853 27081853]|[https://pubmed.ncbi.nlm.nih.gov/17409683 17409683]|[https://pubmed.ncbi.nlm.nih.gov/29921669 29921669]|[https://pubmed.ncbi.nlm.nih.gov/25575293 25575293]|[https://pubmed.ncbi.nlm.nih.gov/26291612 26291612]|[https://pubmed.ncbi.nlm.nih.gov/23146289 23146289]|[https://pubmed.ncbi.nlm.nih.gov/25857295 25857295]|[https://pubmed.ncbi.nlm.nih.gov/26070511 26070511] <br>
-'''term_xref''' : GlycoMotif:GGM.000068|GlycoEpitope:EP0071|CID:5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27 <br>
+ '''definition''' : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] <br>
-'''best_match''' : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID:5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27 <br>
+ '''term_xref''' : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID:5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27 <br>
-'''synonymns''' : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide <br>
+ '''synonyms''' : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Pyelonephritis[SugarBind_Ligand:27]|Acute cystitis[SugarBind_Ligand:27]|Shigellosis[SugarBind_Ligand:27]|Lyme disease[SugarBind_Ligand:27]|Cutaneous lesions[SugarBind_Ligand:27]|Diarrhea[SugarBind_Ligand:27] <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:27]|Acute cystitis[SugarBind_Ligand:27]|Shigellosis[SugarBind_Ligand:27]|Lyme disease[SugarBind_Ligand:27]|Cutaneous lesions[SugarBind_Ligand:27]|Diarrhea[SugarBind_Ligand:27] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Glucosylceramide===
-'''term (main_entry)''' : Glucosylceramide <br>
+[[File:G71142DF.png|thumb|G71142DF]]
-'''glycan_dictionary_accession''' : GD000090 <br>
+ '''term (main_entry)''' : Glucosylceramide <br>
-'''glytoucan_accession ''' : G71142DF <br>
+ '''glycan_dictionary_accession''' : GSD000090 <br>
-'''term_in_sentence''' : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G71142DF G71142DF] <br>
-'''publication''' : 31265321|29290548|29627573|20919653|28427052|30550553|24415933|31914593|31051284|23073611|30146946|31619618|26840726|29750412|8065509|27412675|27840079|30611744|31353719|25661072|28686011|25803043|28865794|28154347|31466334|30242129|12531551|30639288|30864417|27711049|22764777|27905603|29077010|28744000|23555901|24115322|12803919|29204666|23628459|28851512|26136173|23563543|30110701|26572681|2193825|29926415|31727994|27479571 <br>
+ '''term_in_sentence''' : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]] <br>
-'''definition''' : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]|[https://pubmed.ncbi.nlm.nih.gov/29290548 29290548]|[https://pubmed.ncbi.nlm.nih.gov/29627573 29627573]|[https://pubmed.ncbi.nlm.nih.gov/20919653 20919653]|[https://pubmed.ncbi.nlm.nih.gov/28427052 28427052]|[https://pubmed.ncbi.nlm.nih.gov/30550553 30550553]|[https://pubmed.ncbi.nlm.nih.gov/24415933 24415933]|[https://pubmed.ncbi.nlm.nih.gov/31914593 31914593]|[https://pubmed.ncbi.nlm.nih.gov/31051284 31051284]|[https://pubmed.ncbi.nlm.nih.gov/23073611 23073611]|[https://pubmed.ncbi.nlm.nih.gov/30146946 30146946]|[https://pubmed.ncbi.nlm.nih.gov/31619618 31619618]|[https://pubmed.ncbi.nlm.nih.gov/26840726 26840726]|[https://pubmed.ncbi.nlm.nih.gov/29750412 29750412]|[https://pubmed.ncbi.nlm.nih.gov/8065509 8065509]|[https://pubmed.ncbi.nlm.nih.gov/27412675 27412675]|[https://pubmed.ncbi.nlm.nih.gov/27840079 27840079]|[https://pubmed.ncbi.nlm.nih.gov/30611744 30611744]|[https://pubmed.ncbi.nlm.nih.gov/31353719 31353719]|[https://pubmed.ncbi.nlm.nih.gov/25661072 25661072]|[https://pubmed.ncbi.nlm.nih.gov/28686011 28686011]|[https://pubmed.ncbi.nlm.nih.gov/25803043 25803043]|[https://pubmed.ncbi.nlm.nih.gov/28865794 28865794]|[https://pubmed.ncbi.nlm.nih.gov/28154347 28154347]|[https://pubmed.ncbi.nlm.nih.gov/31466334 31466334]|[https://pubmed.ncbi.nlm.nih.gov/30242129 30242129]|[https://pubmed.ncbi.nlm.nih.gov/12531551 12531551]|[https://pubmed.ncbi.nlm.nih.gov/30639288 30639288]|[https://pubmed.ncbi.nlm.nih.gov/30864417 30864417]|[https://pubmed.ncbi.nlm.nih.gov/27711049 27711049]|[https://pubmed.ncbi.nlm.nih.gov/22764777 22764777]|[https://pubmed.ncbi.nlm.nih.gov/27905603 27905603]|[https://pubmed.ncbi.nlm.nih.gov/29077010 29077010]|[https://pubmed.ncbi.nlm.nih.gov/28744000 28744000]|[https://pubmed.ncbi.nlm.nih.gov/23555901 23555901]|[https://pubmed.ncbi.nlm.nih.gov/24115322 24115322]|[https://pubmed.ncbi.nlm.nih.gov/12803919 12803919]|[https://pubmed.ncbi.nlm.nih.gov/29204666 29204666]|[https://pubmed.ncbi.nlm.nih.gov/23628459 23628459]|[https://pubmed.ncbi.nlm.nih.gov/28851512 28851512]|[https://pubmed.ncbi.nlm.nih.gov/26136173 26136173]|[https://pubmed.ncbi.nlm.nih.gov/23563543 23563543]|[https://pubmed.ncbi.nlm.nih.gov/30110701 30110701]|[https://pubmed.ncbi.nlm.nih.gov/26572681 26572681]|[https://pubmed.ncbi.nlm.nih.gov/2193825 2193825]|[https://pubmed.ncbi.nlm.nih.gov/29926415 29926415]|[https://pubmed.ncbi.nlm.nih.gov/31727994 31727994]|[https://pubmed.ncbi.nlm.nih.gov/27479571 27479571] <br>
-'''term_xref''' : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264 <br>
+ '''definition''' : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963] <br>
-'''best_match''' : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF <br>
+ '''term_xref''' : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF  <br>
-'''synonymns''' : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH <br>
+ '''synonyms''' : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH <br>
-'''function''' : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:30611744]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321] <br>
+ '''function''' : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30611744 30611744]]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]] <br>
-'''disease_associations''' : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br>
+ '''disease_associations''' : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453065 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453065/ Chapter 31]<br>
 ===GM1===
-'''term (main_entry)''' : GM1 <br>
+[[File:G48558GR.png|thumb|G48558GR]]
-'''glycan_dictionary_accession''' : GD000091 <br>
+ '''term (main_entry)''' : GM1 <br>
-'''glytoucan_accession ''' : G48558GR <br>
+ '''glycan_dictionary_accession''' : GSD000091 <br>
-'''term_in_sentence''' : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G48558GR G48558GR] <br>
-'''publication''' : 18524657|31761138|29920238|31937438|25762012|25931034|31776384|32013258|30776097|31048748|31447771|30292198|28796418|27806275|21076871|27552916|17986147|26960162|27815022|25851126|32916822|11462671|28236574|15911874|28577204|28497346|1794005|31934908|30267299|16902585|29439846|32325905|29747823|27576485|26338710|27858734|24501414|26818965|26629687|26958633|1854596|32134593|32198666|6619101 <br>
+ '''term_in_sentence''' : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: [https://pubmed.ncbi.nlm.nih.gov/29920238 29920238]] <br>
-'''definition''' : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18524657 18524657]|[https://pubmed.ncbi.nlm.nih.gov/31761138 31761138]|[https://pubmed.ncbi.nlm.nih.gov/36180805 36180805]|[https://pubmed.ncbi.nlm.nih.gov/29920238 29920238]|[https://pubmed.ncbi.nlm.nih.gov/33859490 33859490]'''|'''[https://pubmed.ncbi.nlm.nih.gov/31937438 31937438]|[https://pubmed.ncbi.nlm.nih.gov/25762012 25762012]|[https://pubmed.ncbi.nlm.nih.gov/25931034 25931034]|[https://pubmed.ncbi.nlm.nih.gov/31776384 31776384]|[https://pubmed.ncbi.nlm.nih.gov/32013258 32013258]|[https://pubmed.ncbi.nlm.nih.gov/30776097 30776097]|[https://pubmed.ncbi.nlm.nih.gov/31048748 31048748]|[https://pubmed.ncbi.nlm.nih.gov/31447771 31447771]|[https://pubmed.ncbi.nlm.nih.gov/30292198 30292198]|[https://pubmed.ncbi.nlm.nih.gov/28796418 28796418]|[https://pubmed.ncbi.nlm.nih.gov/27806275 27806275]|[https://pubmed.ncbi.nlm.nih.gov/21076871 21076871]|[https://pubmed.ncbi.nlm.nih.gov/27552916 27552916]|[https://pubmed.ncbi.nlm.nih.gov/17986147 17986147]|[https://pubmed.ncbi.nlm.nih.gov/26960162 26960162]|[https://pubmed.ncbi.nlm.nih.gov/27815022 27815022]|[https://pubmed.ncbi.nlm.nih.gov/25851126 25851126]|[https://pubmed.ncbi.nlm.nih.gov/32916822 32916822]|[https://pubmed.ncbi.nlm.nih.gov/11462671 11462671]|[https://pubmed.ncbi.nlm.nih.gov/28236574 28236574]|[https://pubmed.ncbi.nlm.nih.gov/15911874 15911874]|[https://pubmed.ncbi.nlm.nih.gov/28577204 28577204]|[https://pubmed.ncbi.nlm.nih.gov/28497346 28497346]|[https://pubmed.ncbi.nlm.nih.gov/1794005 1794005]|[https://pubmed.ncbi.nlm.nih.gov/31934908 31934908]|[https://pubmed.ncbi.nlm.nih.gov/30267299 30267299]|[https://pubmed.ncbi.nlm.nih.gov/16902585 16902585]|[https://pubmed.ncbi.nlm.nih.gov/29439846 29439846]|[https://pubmed.ncbi.nlm.nih.gov/32325905 32325905]|[https://pubmed.ncbi.nlm.nih.gov/29747823 29747823]|[https://pubmed.ncbi.nlm.nih.gov/27576485 27576485]|[https://pubmed.ncbi.nlm.nih.gov/26338710 26338710]|[https://pubmed.ncbi.nlm.nih.gov/27858734 27858734]|[https://pubmed.ncbi.nlm.nih.gov/24501414 24501414]|[https://pubmed.ncbi.nlm.nih.gov/26818965 26818965]|[https://pubmed.ncbi.nlm.nih.gov/26629687 26629687]|[https://pubmed.ncbi.nlm.nih.gov/26958633 26958633]|[https://pubmed.ncbi.nlm.nih.gov/1854596 1854596]|[https://pubmed.ncbi.nlm.nih.gov/32134593 32134593]|[https://pubmed.ncbi.nlm.nih.gov/32198666 32198666]|[https://pubmed.ncbi.nlm.nih.gov/6619101 6619101] <br>
-'''term_xref''' : GlycoMotif:GGM.000098|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br>
+ '''definition''' : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] <br>
-'''best_match''' : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br>
+ '''term_xref''' : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  GM1 ganglioside|GM1-ganglioside<br>
-'''function''' :  <br>
+ '''function''' :  The branched pentasaccharide chain of ganglioside GM1 is a prominent cell surface ligand, for example, for cholera toxin or tumor growth-regulatory homodimeric galectins.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16267866/ 16267866]]<br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13] <br>
+ '''disease_associations''' : GM1 gangliosidosis (GM1) [PMID: [https://pubmed.ncbi.nlm.nih.gov/33859490/ 33859490]]|Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/GM1 <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]| [https://www.ncbi.nlm.nih.gov/books/NBK579929/ Chapter 14] <br>
 ===GM2===
-'''term (main_entry)''' : GM2 <br>
+[[File:G79389NT.png|thumb|G79389NT]]
-'''glycan_dictionary_accession''' : GD000092 <br>
+ '''term (main_entry)''' : GM2 <br>
-'''glytoucan_accession ''' : G79389NT <br>
+ '''glycan_dictionary_accession''' : GSD000092 <br>
-'''term_in_sentence''' : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: 27491214] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79389NT G79389NT] <br>
-'''publication''' : 29618308|27491214|32867370|30030044|27499644|31097363|29100724|27402091|31852956|30389374|30988135|8786814|14533808|23370522|28192816|32692591|29106755|28833537|11339652|9728335|27270764|9714704|26175473|27018595|28615102|28974375|32951593|11462672|28955902|17192692|26538065|25421609|9572057|11596983|15264019|23236285|11596984|31261761|30113798|24391178|24309906|22224667|7980537|18272501|9006924| <br>
+ '''term_in_sentence''' : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27491214 27491214]] <br>
-'''definition''' : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29618308 29618308]|[https://pubmed.ncbi.nlm.nih.gov/27491214 27491214]|[https://pubmed.ncbi.nlm.nih.gov/32867370 32867370]|[https://pubmed.ncbi.nlm.nih.gov/30030044 30030044]|[https://pubmed.ncbi.nlm.nih.gov/27499644 27499644]|[https://pubmed.ncbi.nlm.nih.gov/31097363 31097363]|[https://pubmed.ncbi.nlm.nih.gov/29100724 29100724]|[https://pubmed.ncbi.nlm.nih.gov/27402091 27402091]|[https://pubmed.ncbi.nlm.nih.gov/31852956 31852956]|[https://pubmed.ncbi.nlm.nih.gov/30389374 30389374]|[https://pubmed.ncbi.nlm.nih.gov/30988135 30988135]|[https://pubmed.ncbi.nlm.nih.gov/8786814 8786814]|[https://pubmed.ncbi.nlm.nih.gov/14533808 14533808]|[https://pubmed.ncbi.nlm.nih.gov/23370522 23370522]|[https://pubmed.ncbi.nlm.nih.gov/28192816 28192816]|[https://pubmed.ncbi.nlm.nih.gov/32692591 32692591]|[https://pubmed.ncbi.nlm.nih.gov/29106755 29106755]|[https://pubmed.ncbi.nlm.nih.gov/28833537 28833537]|[https://pubmed.ncbi.nlm.nih.gov/11339652 11339652]|[https://pubmed.ncbi.nlm.nih.gov/9728335 9728335]|[https://pubmed.ncbi.nlm.nih.gov/27270764 27270764]|[https://pubmed.ncbi.nlm.nih.gov/9714704 9714704]|[https://pubmed.ncbi.nlm.nih.gov/26175473 26175473]|[https://pubmed.ncbi.nlm.nih.gov/27018595 27018595]|[https://pubmed.ncbi.nlm.nih.gov/28615102 28615102]|[https://pubmed.ncbi.nlm.nih.gov/28974375 28974375]|[https://pubmed.ncbi.nlm.nih.gov/32951593 32951593]|[https://pubmed.ncbi.nlm.nih.gov/11462672 11462672]|[https://pubmed.ncbi.nlm.nih.gov/28955902 28955902]|[https://pubmed.ncbi.nlm.nih.gov/17192692 17192692]|[https://pubmed.ncbi.nlm.nih.gov/26538065 26538065]|[https://pubmed.ncbi.nlm.nih.gov/25421609 25421609]|[https://pubmed.ncbi.nlm.nih.gov/9572057 9572057]|[https://pubmed.ncbi.nlm.nih.gov/11596983 11596983]|[https://pubmed.ncbi.nlm.nih.gov/15264019 15264019]|[https://pubmed.ncbi.nlm.nih.gov/23236285 23236285]|[https://pubmed.ncbi.nlm.nih.gov/11596984 11596984]|[https://pubmed.ncbi.nlm.nih.gov/31261761 31261761]|[https://pubmed.ncbi.nlm.nih.gov/30113798 30113798]|[https://pubmed.ncbi.nlm.nih.gov/24391178 24391178]|[https://pubmed.ncbi.nlm.nih.gov/24309906 24309906]|[https://pubmed.ncbi.nlm.nih.gov/22224667 22224667]|[https://pubmed.ncbi.nlm.nih.gov/7980537 7980537]|[https://pubmed.ncbi.nlm.nih.gov/18272501 18272501]|[https://pubmed.ncbi.nlm.nih.gov/9006924 9006924]| <br>
-'''term_xref''' : GlycoMotif:GGM.000095|CID:45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351 <br>
+ '''definition''' : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
-'''best_match''' : GlycoMotif:GGM.000095|GTC:G79389NT|CID:45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351 <br>
+ '''term_xref''' : GlycoMotif:GGM.000095|GTC:G79389NT|CID:45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]|Gastroenteritis[SugarBind_Ligand:39]|Cholera[SugarBind_Ligand:39]|Clostridial myonecrosis[SugarBind_Ligand:39]|Tetanus[SugarBind_Ligand:39] <br>
+ '''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]|Gastroenteritis[SugarBind_Ligand:39]|Cholera[SugarBind_Ligand:39]|Clostridial myonecrosis[SugarBind_Ligand:39]|Tetanus[SugarBind_Ligand:39] <br>
-'''wikipedia''' : https://en.wikipedia.org/wiki/GM1_gangliosidoses <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/GM1_gangliosidoses <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
 ===GM3===
-'''term (main_entry)''' : GM3 <br>
+[[File:G91237TK.png|thumb|G91237TK]]
-'''glycan_dictionary_accession''' : GD000093 <br>
+ '''term (main_entry)''' : GM3 <br>
-'''glytoucan_accession ''' : G91237TK <br>
+ '''glycan_dictionary_accession''' : GSD000093 <br>
-'''term_in_sentence''' : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: 29747813] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G91237TK G91237TK] <br>
-'''publication''' : 29376491|29747813|25613425|30318083|31526872|31004109|28019668|26434718|27313500|27539856|30111401|28544772|29407985|19364317|30190430|31297734|30091781|26043887|32183071|30665141|27873002|25801320|30209782|32378734|23050851|22768242|14993837|24934090|17638075|21518140|26102277|19759399|24502144|25303960|23564406|16636105|16491123|11259118|15102521|12724312|24985965|8496625|25403557|15690123|15939439|25893133|23591593|20634908|2004380|739008| <br>
+ '''term_in_sentence''' : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: [https://pubmed.ncbi.nlm.nih.gov/29747813 29747813]] <br>
-'''definition''' : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29376491 29376491]|[https://pubmed.ncbi.nlm.nih.gov/29747813 29747813]|[https://pubmed.ncbi.nlm.nih.gov/25613425 25613425]|[https://pubmed.ncbi.nlm.nih.gov/30318083 30318083]|[https://pubmed.ncbi.nlm.nih.gov/31526872 31526872]|[https://pubmed.ncbi.nlm.nih.gov/31004109 31004109]|[https://pubmed.ncbi.nlm.nih.gov/28019668 28019668]|[https://pubmed.ncbi.nlm.nih.gov/26434718 26434718]|[https://pubmed.ncbi.nlm.nih.gov/27313500 27313500]|[https://pubmed.ncbi.nlm.nih.gov/27539856 27539856]|[https://pubmed.ncbi.nlm.nih.gov/30111401 30111401]|[https://pubmed.ncbi.nlm.nih.gov/28544772 28544772]|[https://pubmed.ncbi.nlm.nih.gov/29407985 29407985]|[https://pubmed.ncbi.nlm.nih.gov/19364317 19364317]|[https://pubmed.ncbi.nlm.nih.gov/30190430 30190430]|[https://pubmed.ncbi.nlm.nih.gov/31297734 31297734]|[https://pubmed.ncbi.nlm.nih.gov/30091781 30091781]|[https://pubmed.ncbi.nlm.nih.gov/26043887 26043887]|[https://pubmed.ncbi.nlm.nih.gov/32183071 32183071]|[https://pubmed.ncbi.nlm.nih.gov/30665141 30665141]|[https://pubmed.ncbi.nlm.nih.gov/27873002 27873002]|[https://pubmed.ncbi.nlm.nih.gov/25801320 25801320]|[https://pubmed.ncbi.nlm.nih.gov/30209782 30209782]|[https://pubmed.ncbi.nlm.nih.gov/32378734 32378734]|[https://pubmed.ncbi.nlm.nih.gov/23050851 23050851]|[https://pubmed.ncbi.nlm.nih.gov/22768242 22768242]|[https://pubmed.ncbi.nlm.nih.gov/14993837 14993837]|[https://pubmed.ncbi.nlm.nih.gov/24934090 24934090]|[https://pubmed.ncbi.nlm.nih.gov/17638075 17638075]|[https://pubmed.ncbi.nlm.nih.gov/21518140 21518140]|[https://pubmed.ncbi.nlm.nih.gov/26102277 26102277]|[https://pubmed.ncbi.nlm.nih.gov/19759399 19759399]|[https://pubmed.ncbi.nlm.nih.gov/24502144 24502144]|[https://pubmed.ncbi.nlm.nih.gov/25303960 25303960]|[https://pubmed.ncbi.nlm.nih.gov/23564406 23564406]|[https://pubmed.ncbi.nlm.nih.gov/16636105 16636105]|[https://pubmed.ncbi.nlm.nih.gov/16491123 16491123]|[https://pubmed.ncbi.nlm.nih.gov/11259118 11259118]|[https://pubmed.ncbi.nlm.nih.gov/15102521 15102521]|[https://pubmed.ncbi.nlm.nih.gov/12724312 12724312]|[https://pubmed.ncbi.nlm.nih.gov/24985965 24985965]|[https://pubmed.ncbi.nlm.nih.gov/8496625 8496625]|[https://pubmed.ncbi.nlm.nih.gov/25403557 25403557]|[https://pubmed.ncbi.nlm.nih.gov/15690123 15690123]|[https://pubmed.ncbi.nlm.nih.gov/15939439 15939439]|[https://pubmed.ncbi.nlm.nih.gov/25893133 25893133]|[https://pubmed.ncbi.nlm.nih.gov/23591593 23591593]|[https://pubmed.ncbi.nlm.nih.gov/20634908 20634908]|[https://pubmed.ncbi.nlm.nih.gov/2004380 2004380]|[https://pubmed.ncbi.nlm.nih.gov/739008 739008]| <br>
-'''term_xref''' : GlycoMotif:GGM.000090|CID:5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 <br>
+ '''definition''' : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] <br>
-'''best_match''' : GlycoMotif:GGM.000090|GTC:G91237TK|CID:5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 <br>
+ '''term_xref''' : GlycoMotif:GGM.000090|GTC:G91237TK|CID:5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844] <br>
+ '''function''' : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844] <br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35]|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35] <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35]|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453032 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453032/ Chapter 37]<br>
 ===GM4===
-'''term (main_entry)''' : GM4 <br>
+[[File:G30207PZ.png|thumb|G30207PZ]]
-'''glycan_dictionary_accession''' : GD000094 <br>
+ '''term (main_entry)''' : GM4 <br>
-'''glytoucan_accession ''' : G30207PZ <br>
+ '''glycan_dictionary_accession''' : GSD000094 <br>
-'''term_in_sentence''' : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:23999868] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G30207PZ G30207PZ] <br>
-'''publication''' : 23999868|2332419|12091485|19542236|8407875|23320941|28808804|3621237|23203271|7057115|26362868|6170387|18034482|7076644|2391348|25464080|3701369|11217952|6201236|30744426|9388026|27177620|30246056|15979459|7586078|6779816|29402905|7335153|3306476|17499534|7074082|9668345|3701884|26862430|6831238|27311552|26831445|24417799|7097284|4169231|16854400|26483798 <br>
+ '''term_in_sentence''' : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:[https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]] <br>
-'''definition''' : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]|[https://pubmed.ncbi.nlm.nih.gov/2332419 2332419]|[https://pubmed.ncbi.nlm.nih.gov/12091485 12091485]|[https://pubmed.ncbi.nlm.nih.gov/19542236 19542236]|[https://pubmed.ncbi.nlm.nih.gov/8407875 8407875]|[https://pubmed.ncbi.nlm.nih.gov/23320941 23320941]|[https://pubmed.ncbi.nlm.nih.gov/28808804 28808804]|[https://pubmed.ncbi.nlm.nih.gov/3621237 3621237]|[https://pubmed.ncbi.nlm.nih.gov/23203271 23203271]|[https://pubmed.ncbi.nlm.nih.gov/7057115 7057115]|[https://pubmed.ncbi.nlm.nih.gov/26362868 26362868]|[https://pubmed.ncbi.nlm.nih.gov/6170387 6170387]|[https://pubmed.ncbi.nlm.nih.gov/18034482 18034482]|[https://pubmed.ncbi.nlm.nih.gov/7076644 7076644]|[https://pubmed.ncbi.nlm.nih.gov/2391348 2391348]|[https://pubmed.ncbi.nlm.nih.gov/25464080 25464080]|[https://pubmed.ncbi.nlm.nih.gov/3701369 3701369]|[https://pubmed.ncbi.nlm.nih.gov/11217952 11217952]|[https://pubmed.ncbi.nlm.nih.gov/6201236 6201236]|[https://pubmed.ncbi.nlm.nih.gov/30744426 30744426]|[https://pubmed.ncbi.nlm.nih.gov/9388026 9388026]|[https://pubmed.ncbi.nlm.nih.gov/27177620 27177620]|[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056]|[https://pubmed.ncbi.nlm.nih.gov/15979459 15979459]|[https://pubmed.ncbi.nlm.nih.gov/7586078 7586078]|[https://pubmed.ncbi.nlm.nih.gov/6779816 6779816]|[https://pubmed.ncbi.nlm.nih.gov/29402905 29402905]|[https://pubmed.ncbi.nlm.nih.gov/7335153 7335153]|[https://pubmed.ncbi.nlm.nih.gov/3306476 3306476]|[https://pubmed.ncbi.nlm.nih.gov/17499534 17499534]|[https://pubmed.ncbi.nlm.nih.gov/7074082 7074082]|[https://pubmed.ncbi.nlm.nih.gov/9668345 9668345]|[https://pubmed.ncbi.nlm.nih.gov/3701884 3701884]|[https://pubmed.ncbi.nlm.nih.gov/26862430 26862430]|[https://pubmed.ncbi.nlm.nih.gov/6831238 6831238]|[https://pubmed.ncbi.nlm.nih.gov/27311552 27311552]|[https://pubmed.ncbi.nlm.nih.gov/26831445 26831445]|[https://pubmed.ncbi.nlm.nih.gov/24417799 24417799]|[https://pubmed.ncbi.nlm.nih.gov/7097284 7097284]|[https://pubmed.ncbi.nlm.nih.gov/4169231 4169231]|[https://pubmed.ncbi.nlm.nih.gov/16854400 16854400]|[https://pubmed.ncbi.nlm.nih.gov/26483798 26483798] <br>
-[CHEBI:63155] <br>
+ '''definition''' : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position
-'''term_xref''' : GlycoMotif:GGM.000089|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 <br>
+ [CHEBI:63155] <br>
-'''best_match''' : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 <br>
+ '''term_xref''' : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  Sialylated GalCer<br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Chronic gastritis[SugarBind_Ligand:110]|Peptic ulcers[SugarBind_Ligand:110]|Gastric cancer[SugarBind_Ligand:110] <br>
+ '''disease_associations''' : Chronic gastritis[SugarBind_Ligand:110]|Peptic ulcers[SugarBind_Ligand:110]|Gastric cancer[SugarBind_Ligand:110] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016|NBK453095|NBK453018|NBK453082| <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]|[https://www.ncbi.nlm.nih.gov/books/NBK453082/ Chapter 15]|[https://www.ncbi.nlm.nih.gov/books/NBK453095/ Chapter 44]|[https://www.ncbi.nlm.nih.gov/books/NBK453018/ Appendix 45A] <br>
 ===GP1c===
-'''term (main_entry)''' : GP1c <br>
+[[File:G93805MV.png|thumb|G93805MV]]
-'''glycan_dictionary_accession''' : GD000095 <br>
+ '''term (main_entry)''' : GP1c <br>
-'''glytoucan_accession ''' : G93805MV <br>
+ '''glycan_dictionary_accession''' : GSD000095 <br>
-'''term_in_sentence''' : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:19053458] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93805MV G93805MV] <br>
-'''publication''' : 1606358|19053458|1695858|4091974|10775425|2468656|2299350|3064875|11432974|9613831|11831845|1879553|10699494|8969459|8474578|12031286|1304332|9153001|10564776 <br>
+ '''term_in_sentence''' : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]]|[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]|[https://pubmed.ncbi.nlm.nih.gov/4091974 4091974]|[https://pubmed.ncbi.nlm.nih.gov/10775425 10775425]|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350]|[https://pubmed.ncbi.nlm.nih.gov/3064875 3064875]|[https://pubmed.ncbi.nlm.nih.gov/11432974 11432974]|[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]|[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845]|[https://pubmed.ncbi.nlm.nih.gov/1879553 1879553]|[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]|[https://pubmed.ncbi.nlm.nih.gov/8969459 8969459]|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]| [https://pubmed.ncbi.nlm.nih.gov/12031286 12031286]|[https://pubmed.ncbi.nlm.nih.gov/1304332 1304332]|[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001]| [https://pubmed.ncbi.nlm.nih.gov/10564776 10564776] <br>
-'''term_xref''' : GlycoMotif:GGM.000118 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000118|GTC:G93805MV <br>
+ '''term_xref''' : GlycoMotif:GGM.000118|GTC:G93805MV <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016|NBK453023|NBK453042|NBK453088|/NBK453073|NBK453076|NBK453041 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]|[https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]|[https://www.ncbi.nlm.nih.gov/books/NBK453076/ Chapter 27]|[https://www.ncbi.nlm.nih.gov/books/NBK453073/ Chapter 35]|[https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45] |[https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]|[https://www.ncbi.nlm.nih.gov/books/NBK453088/ Chapter 49] <br>
 ===GQ1b===
-'''term (main_entry)''' : GQ1b <br>
+[[File:G99524KA.png|thumb|G99524KA]]
-'''glycan_dictionary_accession''' : GD000096 <br>
+ '''term (main_entry)''' : GQ1b <br>
-'''glytoucan_accession ''' : G18625KA <br>
+ '''glycan_dictionary_accession''' : GSD000096 <br>
-'''term_in_sentence''' : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:31186474] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18625KA G18625KA] <br>
-'''publication''' : 30798387|31186474|26704905|23677659|26984947|24184316|23804237|9819299|18514410|22189683|24859332 <br>
+ '''term_in_sentence''' : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]] <br>
-'''definition''' : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30798387 30798387]|[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]|[https://pubmed.ncbi.nlm.nih.gov/26704905 26704905]|[https://pubmed.ncbi.nlm.nih.gov/23677659 23677659]|[https://pubmed.ncbi.nlm.nih.gov/26984947 26984947]|[https://pubmed.ncbi.nlm.nih.gov/24184316 24184316]| [https://pubmed.ncbi.nlm.nih.gov/23804237 23804237]|[https://pubmed.ncbi.nlm.nih.gov/9819299 9819299]|[https://pubmed.ncbi.nlm.nih.gov/18514410 18514410]|[https://pubmed.ncbi.nlm.nih.gov/22189683 22189683]|[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332] <br>
-'''term_xref''' : GlycoMotif:GGM.000115|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212 <br>
+ '''definition''' : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] <br>
-'''best_match''' : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212 <br>
+ '''term_xref''' : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
 ===GQ1ba===
-'''term (main_entry)''' : GQ1ba <br>
+[[File:G54733XO.png|thumb|G54733XO]]
-'''glycan_dictionary_accession''' : GD000097 <br>
+ '''term (main_entry)''' : GQ1ba <br>
-'''glytoucan_accession ''' : G54733XO <br>
+ '''glycan_dictionary_accession''' : GSD000097 <br>
-'''term_in_sentence''' : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:25024341] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54733XO G54733XO] <br>
-'''publication''' : 25024341|23717411|17870542|10702226|21137678|26748510|8662799|21274438|24649890|16580208|28124591|20095613|17507233|23565921|14505645|20930939|9201997 <br>
+ '''term_in_sentence''' : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25024341 25024341]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/25024341 25024341]|[https://pubmed.ncbi.nlm.nih.gov/23717411 23717411]|[https://pubmed.ncbi.nlm.nih.gov/17870542 17870542]|[https://pubmed.ncbi.nlm.nih.gov/10702226 10702226]|[https://pubmed.ncbi.nlm.nih.gov/21137678 21137678]|[https://pubmed.ncbi.nlm.nih.gov/26748510 26748510]|[https://pubmed.ncbi.nlm.nih.gov/8662799 8662799]|[https://pubmed.ncbi.nlm.nih.gov/21274438 21274438]|[https://pubmed.ncbi.nlm.nih.gov/24649890 24649890]|[https://pubmed.ncbi.nlm.nih.gov/16580208 16580208]|[https://pubmed.ncbi.nlm.nih.gov/28124591 28124591]|[https://pubmed.ncbi.nlm.nih.gov/20095613 20095613]|[https://pubmed.ncbi.nlm.nih.gov/17507233 17507233]|[https://pubmed.ncbi.nlm.nih.gov/23565921 23565921]|[https://pubmed.ncbi.nlm.nih.gov/14505645 14505645]|[https://pubmed.ncbi.nlm.nih.gov/20930939 20930939]|[https://pubmed.ncbi.nlm.nih.gov/9201997 9201997] <br>
-'''term_xref''' : GlycoMotif:GGM.000116 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000116|GTC:G54733XO <br>
+ '''term_xref''' : GlycoMotif:GGM.000116|GTC:G54733XO <br>
-'''synonymns''' : GQ1balpha <br>
+ '''synonyms''' : GQ1balpha <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===GQ1c===
-'''term (main_entry)''' : GQ1c <br>
+ '''term (main_entry)''' : GQ1c <br>
-'''glycan_dictionary_accession''' : GD000098 <br>
+ '''glycan_dictionary_accession''' : GSD000098 <br>
-'''glytoucan_accession ''' : G99524KA <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99524KA G99524KA] <br>
-'''term_in_sentence''' : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: 6640289] <br>
+ '''term_in_sentence''' : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: 6640289] <br>
-'''publication''' : 6640289|1695858|7798936|1729139|2468656|20368669|2723647|1814411|3064875|6085330|1613492|17883393|11831845|10775425|8219015|8804704|1384262|7066685|2299192|9613831|10350354|1304337|9153001|11959025|8474578|2299350|10564776|10699494|3942818|12031286|7361620 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]|[https://pubmed.ncbi.nlm.nih.gov/7798936 7798936]|[https://pubmed.ncbi.nlm.nih.gov/1729139 1729139]|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/20368669 20368669]| [https://pubmed.ncbi.nlm.nih.gov/2723647 2723647]|[https://pubmed.ncbi.nlm.nih.gov/1814411 1814411]|[https://pubmed.ncbi.nlm.nih.gov/3064875 3064875]|[https://pubmed.ncbi.nlm.nih.gov/6085330 6085330]|[https://pubmed.ncbi.nlm.nih.gov/1613492 1613492]|[https://pubmed.ncbi.nlm.nih.gov/17883393 17883393]|[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845]|[https://pubmed.ncbi.nlm.nih.gov/10775425 10775425]|[https://pubmed.ncbi.nlm.nih.gov/8219015 8219015]|[https://pubmed.ncbi.nlm.nih.gov/8804704 8804704]|[https://pubmed.ncbi.nlm.nih.gov/1384262 1384262]|[https://pubmed.ncbi.nlm.nih.gov/7066685 7066685]|[https://pubmed.ncbi.nlm.nih.gov/2299192 2299192]|[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]|[https://pubmed.ncbi.nlm.nih.gov/10350354 10350354]|[https://pubmed.ncbi.nlm.nih.gov/1304337 1304337]|[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001]|[https://pubmed.ncbi.nlm.nih.gov/11959025 11959025]| [https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]|[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350]|[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]|[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]|[https://pubmed.ncbi.nlm.nih.gov/3942818 3942818]|[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286]| [https://pubmed.ncbi.nlm.nih.gov/7361620 7361620] <br>
-'''definition''' : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID:91860352] <br>
+ '''definition''' : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID:91860352] <br>
-'''term_xref''' : GlycoMotif:GGM.000117|CID:91860352|CHEBI:145645|KEGG:G00121 <br>
+ '''term_xref''' : GlycoMotif:GGM.000117|GTC:G99524KA|CID:91860352|CHEBI:145645|KEGG:G00121 <br>
-'''best_match''' : GlycoMotif:GGM.000117|GTC:G99524KA|CID:91860352|CHEBI:145645|KEGG:G00121 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453044/ Chapter 46]<br>
-'''essentials_of_glycobiology''' : NBK453044 <br>
 ===GT1a===
-'''term (main_entry)''' : GT1a <br>
+[[File:G68110IF.png|thumb|G68110IF]]
-'''glycan_dictionary_accession''' : GD000099 <br>
+ '''term (main_entry)''' : GT1a <br>
-'''glytoucan_accession ''' : G68110IF <br>
+ '''glycan_dictionary_accession''' : GSD000099 <br>
-'''term_in_sentence''' : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:26197476] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G68110IF G68110IF] <br>
-'''publication''' : 12023422|32623212|26197476|9585812|29747820|23804237|11993188|31683059|19631994|9742882|29709941|8971119|8706663|893404|31829433|8910600|30600291|29319803|26176883|29063860|6766128|31602715|29808463|30711390|29847988|30116054|28187751 <br>
+ '''term_in_sentence''' : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]] <br>
-'''definition''' : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12023422 12023422]|[https://pubmed.ncbi.nlm.nih.gov/32623212 32623212]|[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]|[https://pubmed.ncbi.nlm.nih.gov/9585812 9585812]|[https://pubmed.ncbi.nlm.nih.gov/29747820 29747820]|[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237]|[https://pubmed.ncbi.nlm.nih.gov/11993188 11993188]|[https://pubmed.ncbi.nlm.nih.gov/31683059 31683059]|[https://pubmed.ncbi.nlm.nih.gov/19631994 19631994]|[https://pubmed.ncbi.nlm.nih.gov/9742882 9742882]|[https://pubmed.ncbi.nlm.nih.gov/29709941 29709941]|[https://pubmed.ncbi.nlm.nih.gov/8971119 8971119]|[https://pubmed.ncbi.nlm.nih.gov/8706663 8706663]|[https://pubmed.ncbi.nlm.nih.gov/893404 893404]|[https://pubmed.ncbi.nlm.nih.gov/31829433 31829433]|[https://pubmed.ncbi.nlm.nih.gov/8910600 8910600]|[https://pubmed.ncbi.nlm.nih.gov/30600291 30600291]|[https://pubmed.ncbi.nlm.nih.gov/29319803 29319803]|[https://pubmed.ncbi.nlm.nih.gov/26176883 26176883]|[https://pubmed.ncbi.nlm.nih.gov/29063860 29063860]|[https://pubmed.ncbi.nlm.nih.gov/6766128 6766128]|[https://pubmed.ncbi.nlm.nih.gov/31602715 31602715]|[https://pubmed.ncbi.nlm.nih.gov/29808463 29808463]|[https://pubmed.ncbi.nlm.nih.gov/30711390 30711390]|[https://pubmed.ncbi.nlm.nih.gov/29847988 29847988]|[https://pubmed.ncbi.nlm.nih.gov/30116054 30116054]|[https://pubmed.ncbi.nlm.nih.gov/28187751 28187751] <br>
-'''term_xref''' : CID:45266863|GlycoMotif:GGM.000110|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215 <br>
+ '''definition''' : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] <br>
-'''best_match''' : CID:45266863|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215 <br>
+ '''term_xref''' : CID:45266863|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===GT1a alpha===
-'''term (main_entry)''' : GT1a alpha <br>
+[[File:G02149VR.png|thumb|G02149VR]]
-'''glycan_dictionary_accession''' : GD000100 <br>
+ '''term (main_entry)''' : GT1a alpha <br>
-'''glytoucan_accession ''' : G02149VR <br>
+ '''glycan_dictionary_accession''' : GSD000100 <br>
-'''term_in_sentence''' : A new class of gangliosides, GT1a alpha and GQ1b alpha, were initially identified as cholinergic neuron-specific antigens in bovine brain. [PMID:8082783] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02149VR G02149VR] <br>
-'''publication''' : 7710562|8082783|10972137|9468624|9143254|8221098|9679279|11368158|11878808 <br>
+ '''term_in_sentence''' : A new class of gangliosides, GT1a alpha and GQ1b alpha, were initially identified as cholinergic neuron-specific antigens in bovine brain. [PMID:[https://pubmed.ncbi.nlm.nih.gov/8082783 8082783]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7710562 7710562]|[https://pubmed.ncbi.nlm.nih.gov/8082783 8082783]|[https://pubmed.ncbi.nlm.nih.gov/10972137 10972137]|[https://pubmed.ncbi.nlm.nih.gov/9468624 9468624]|[https://pubmed.ncbi.nlm.nih.gov/9143254 9143254]|[https://pubmed.ncbi.nlm.nih.gov/8221098 8221098]|[https://pubmed.ncbi.nlm.nih.gov/9679279 9679279]|[https://pubmed.ncbi.nlm.nih.gov/11368158 11368158]|[https://pubmed.ncbi.nlm.nih.gov/11878808 11878808] <br>
-'''term_xref''' : GlycoMotif:GGM.000111|GlycoEpitope:EP0111|CID:91851751|CHEBI:156678|KEGG:G00128 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID:91851751|CHEBI:156678|KEGG:G00128 <br>
+ '''term_xref''' : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID:91851751|CHEBI:156678|KEGG:G00128  <br>
-'''synonymns''' : GT1aa <br>
+ '''synonyms''' : GT1aa <br>
-'''function''' : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111] <br>
+ '''function''' : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===GT1b===
-'''term (main_entry)''' : GT1b <br>
+[[File:G40183QN.png|thumb|G40183QN]]
-'''glycan_dictionary_accession''' : GD000101 <br>
+ '''term (main_entry)''' : GT1b <br>
-'''glytoucan_accession ''' : G40183QN <br>
+ '''glycan_dictionary_accession''' : GSD000101 <br>
-'''term_in_sentence''' : GT1b ganglioside is axonally transported to the spinal cord dorsal horn and contributes to characteristics of neuropathic pain such as mechanical and thermal hypersensitivity.[PMID: 32030804] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G40183QN G40183QN] <br>
-'''publication''' : 32030804|26370787|32046393|9712688|7636307|9931455|25520869|19605473|17188834|10233751|22735313|20540782|22746533|1861141|19490186|9521848|11921200|10731661|31431523|15274627|32726962|12573517|18277613|11370834|11234774|11123278|18704164|16291967|11411041|27549393|25253868|22720883|10686582|11511306|29904724|31472390|19156870 <br>
+ '''term_in_sentence''' : GT1b ganglioside is axonally transported to the spinal cord dorsal horn and contributes to characteristics of neuropathic pain such as mechanical and thermal hypersensitivity.[PMID: [https://pubmed.ncbi.nlm.nih.gov/32030804 32030804]] <br>
-'''definition''' : A branched amino heptasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries an N-acetyl-α-neuraminyl-(2→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl trisaccharide unit and an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide unit through (2→4) and (2→3) linkages respectively. It corresponds to the carbohydrate portion of ganglioside GT1b.[CHEBI:59225] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32030804 32030804]|[https://pubmed.ncbi.nlm.nih.gov/26370787 26370787]|[https://pubmed.ncbi.nlm.nih.gov/32046393 32046393]|[https://pubmed.ncbi.nlm.nih.gov/9712688 9712688]|[https://pubmed.ncbi.nlm.nih.gov/7636307 7636307]|[https://pubmed.ncbi.nlm.nih.gov/9931455 9931455]|[https://pubmed.ncbi.nlm.nih.gov/25520869 25520869]|[https://pubmed.ncbi.nlm.nih.gov/19605473 19605473]|[https://pubmed.ncbi.nlm.nih.gov/17188834 17188834]|[https://pubmed.ncbi.nlm.nih.gov/10233751 10233751]|[https://pubmed.ncbi.nlm.nih.gov/22735313 22735313]|[https://pubmed.ncbi.nlm.nih.gov/20540782 20540782]|[https://pubmed.ncbi.nlm.nih.gov/22746533 22746533]|[https://pubmed.ncbi.nlm.nih.gov/1861141 1861141]|[https://pubmed.ncbi.nlm.nih.gov/19490186 19490186]|[https://pubmed.ncbi.nlm.nih.gov/9521848 9521848]|[https://pubmed.ncbi.nlm.nih.gov/11921200 11921200]|[https://pubmed.ncbi.nlm.nih.gov/10731661 10731661]|[https://pubmed.ncbi.nlm.nih.gov/31431523 31431523]|[https://pubmed.ncbi.nlm.nih.gov/15274627 15274627]|[https://pubmed.ncbi.nlm.nih.gov/32726962 32726962]|[https://pubmed.ncbi.nlm.nih.gov/12573517 12573517]|[https://pubmed.ncbi.nlm.nih.gov/18277613 18277613]|[https://pubmed.ncbi.nlm.nih.gov/11370834 11370834]|[https://pubmed.ncbi.nlm.nih.gov/11234774 11234774]|[https://pubmed.ncbi.nlm.nih.gov/11123278 11123278]|[https://pubmed.ncbi.nlm.nih.gov/18704164 18704164]|[https://pubmed.ncbi.nlm.nih.gov/16291967 16291967]|[https://pubmed.ncbi.nlm.nih.gov/11411041 11411041]|[https://pubmed.ncbi.nlm.nih.gov/27549393 27549393]|[https://pubmed.ncbi.nlm.nih.gov/25253868 25253868]|[https://pubmed.ncbi.nlm.nih.gov/22720883 22720883]|[https://pubmed.ncbi.nlm.nih.gov/10686582 10686582]|[https://pubmed.ncbi.nlm.nih.gov/11511306 11511306]|[https://pubmed.ncbi.nlm.nih.gov/29904724 29904724]|[https://pubmed.ncbi.nlm.nih.gov/31472390 31472390]|[https://pubmed.ncbi.nlm.nih.gov/19156870 19156870] <br>
-'''term_xref''' : GlycoMotif:GGM.000112|GlycoEpitopeEP0067|CID:45266781|CHEBI:59225|GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116 <br>
+ '''definition''' : A branched amino heptasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries an N-acetyl-α-neuraminyl-(2→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl trisaccharide unit and an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide unit through (2→4) and (2→3) linkages respectively. It corresponds to the carbohydrate portion of ganglioside GT1b.[CHEBI:59225] <br>
-'''best_match''' : GlycoMotif:GGM.000112|GTC:G40183QN|GlycoEpitopeEP0067|CID:45266781|CHEBI:59225| GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116 <br>
+ '''term_xref''' : GlycoMotif:GGM.000112|GTC:G40183QN|GlycoEpitopeEP0067|CID:45266781|CHEBI:59225| GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116<br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Toxoplasmosis[SugarBind_Ligand:26]|Lyme disease[SugarBind_Ligand:26]|Cholera[SugarBind_Ligand:26]|Botulism[SugarBind_Ligand:26]|Tetanus[SugarBind_Ligand:26]|Influenza[SugarBind_Ligand:26] <br>
+ '''disease_associations''' : Toxoplasmosis[SugarBind_Ligand:26]|Lyme disease[SugarBind_Ligand:26]|Cholera[SugarBind_Ligand:26]|Botulism[SugarBind_Ligand:26]|Tetanus[SugarBind_Ligand:26]|Influenza[SugarBind_Ligand:26] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===GT1c===
-'''term (main_entry)''' : GT1c <br>
+[[File:G78818SP.png|thumb|G78818SP]]
-'''glycan_dictionary_accession''' : GD000102 <br>
+ '''term (main_entry)''' : GT1c <br>
-'''glytoucan_accession ''' : G78818SP <br>
+ '''glycan_dictionary_accession''' : GSD000102 <br>
-'''term_in_sentence''' : We show here that VVH associates with ganglioside GM1a, Fucosyl-GM1, GD1a, GT1c, and GD1b by glycan array.[PMID: 32228455] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78818SP G78818SP] <br>
-'''publication''' : 28088450|30085356|32228455|2468656|19841910|23877172|1695858|10564776|1613492|8474578|7798936|11180643|2723647|7066685|9613831|7361620|10699494 <br>
+ '''term_in_sentence''' : We show here that VVH associates with ganglioside GM1a, Fucosyl-GM1, GD1a, GT1c, and GD1b by glycan array.[PMID: [https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]] <br>
-'''definition''' : A branched amino heptasaccharide consisting of a linear tetrasaccharide of β-D-galactose, N-acetyl-β-D-galactosamine, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→4) and (1→4), to the galactose residue proximal to the reducing end is also linked (2→3) an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl trisaccharide side-chain. The carbohydrate moiety of ganglioside GT1c.[CHEBI:90509] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28088450 28088450]|[https://pubmed.ncbi.nlm.nih.gov/30085356 30085356]|[https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/23877172 23877172]|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]|[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]|[https://pubmed.ncbi.nlm.nih.gov/1613492 1613492]|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]|[https://pubmed.ncbi.nlm.nih.gov/7798936 7798936]|[https://pubmed.ncbi.nlm.nih.gov/11180643 11180643]|[https://pubmed.ncbi.nlm.nih.gov/2723647 2723647]|[https://pubmed.ncbi.nlm.nih.gov/7066685 7066685]|[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]|[https://pubmed.ncbi.nlm.nih.gov/7361620 7361620]|[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494] <br>
-'''term_xref''' : GlycoMotif:GGM.000113|CID:91846734|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120 <br>
+ '''definition''' : A branched amino heptasaccharide consisting of a linear tetrasaccharide of β-D-galactose, N-acetyl-β-D-galactosamine, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→4) and (1→4), to the galactose residue proximal to the reducing end is also linked (2→3) an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl trisaccharide side-chain. The carbohydrate moiety of ganglioside GT1c.[CHEBI:90509] <br>
-'''best_match''' : GlycoMotif:GGM.000113|GTC:G78818SP|CID:91846734|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120 <br>
+ '''term_xref''' : GlycoMotif:GGM.000113|GTC:G78818SP|CID:91846734|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===GT2===
-'''term (main_entry)''' : GT2 <br>
+[[File:G36476BA.png|thumb|G36476BA]]
-'''glycan_dictionary_accession''' : GD000103 <br>
+ '''term (main_entry)''' : GT2 <br>
-'''glytoucan_accession ''' : G36476BA <br>
+ '''glycan_dictionary_accession''' : GSD000103 <br>
-'''term_in_sentence''' : Biosynthesis of the c-series gangliosides GT3, GT2 and GP1c was studied in Golgi derived from rat liver.[PMID:1606358] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G36476BA G36476BA] <br>
-'''publication''' : 1606358|15498585|16005859|27540730|31533196|31201844 <br>
+ '''term_in_sentence''' : Biosynthesis of the c-series gangliosides GT3, GT2 and GP1c was studied in Golgi derived from rat liver.[PMID: [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]] <br>
-'''definition''' : A branched amino hexasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-galactosaminyl residue. The carbohydrate moiety of ganglioside GT2.[CHEBI:72446] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]|[https://pubmed.ncbi.nlm.nih.gov/15498585 15498585]|[https://pubmed.ncbi.nlm.nih.gov/16005859 16005859]|[https://pubmed.ncbi.nlm.nih.gov/27540730 27540730]|[https://pubmed.ncbi.nlm.nih.gov/31533196 31533196]|[https://pubmed.ncbi.nlm.nih.gov/31201844 31201844] <br>
-'''term_xref''' : GlycoMotif:GGM.000109|CID:70788971|CHEBI:72446|KEGG:G00119 <br>
+ '''definition''' : A branched amino hexasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-galactosaminyl residue. The carbohydrate moiety of ganglioside GT2.[CHEBI:72446] <br>
-'''best_match''' : GlycoMotif:GGM.000109|GTC:G36476BA|CID:70788971|CHEBI:72446|KEGG:G00119 <br>
+ '''term_xref''' : GlycoMotif:GGM.000109|GTC:G36476BA|CID:70788971|CHEBI:72446|KEGG:G00119 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
 ===GT3===
-'''term (main_entry)''' : GT3 <br>
+[[File:G93899SO.png|thumb|G93899SO]]
-'''glycan_dictionary_accession''' : GD000104 <br>
+ '''term (main_entry)''' : GT3 <br>
-'''glytoucan_accession ''' : G93899SO <br>
+ '''glycan_dictionary_accession''' : GSD000104 <br>
-'''term_in_sentence''' : The purpose of this study was two-fold: (1) to formulate γ-tocotrienol (GT3) in a nanoemulsion formulation as a prophylactic orally administered radioprotective agent; and (2) to optimize the storage conditions to preserve the structural integrity of both the formulation and the compound.[PMID: 28029115] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93899SO G93899SO] <br>
-'''publication''' : 28029115|31355968|30987413|27869747|27216753|8631981|29672891|10385047|29642403|10412028|27193023|30068561|23415908|8858920|2303428|27153057|27128741|2654294|26930378|7561885|25860286|30845647|24712339|30070965|8910600|1606358|27356050|8514740|18509108|23000517|29769046|29566611 <br>
+ '''term_in_sentence''' : The purpose of this study was two-fold: (1) to formulate γ-tocotrienol (GT3) in a nanoemulsion formulation as a prophylactic orally administered radioprotective agent; and (2) to optimize the storage conditions to preserve the structural integrity of both the formulation and the compound.[PMID: [https://pubmed.ncbi.nlm.nih.gov/28029115 28029115]] <br>
-'''definition''' : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28029115 28029115]|[https://pubmed.ncbi.nlm.nih.gov/31355968 31355968]|[https://pubmed.ncbi.nlm.nih.gov/30987413 30987413]|[https://pubmed.ncbi.nlm.nih.gov/27869747 27869747]|[https://pubmed.ncbi.nlm.nih.gov/27216753 27216753]|[https://pubmed.ncbi.nlm.nih.gov/8631981 8631981]|[https://pubmed.ncbi.nlm.nih.gov/29672891 29672891]|[https://pubmed.ncbi.nlm.nih.gov/10385047 10385047]|[https://pubmed.ncbi.nlm.nih.gov/29642403 29642403]|[https://pubmed.ncbi.nlm.nih.gov/10412028 10412028]|[https://pubmed.ncbi.nlm.nih.gov/27193023 27193023]|[https://pubmed.ncbi.nlm.nih.gov/30068561 30068561]|[https://pubmed.ncbi.nlm.nih.gov/23415908 23415908]|[https://pubmed.ncbi.nlm.nih.gov/8858920 8858920]|[https://pubmed.ncbi.nlm.nih.gov/2303428 2303428]|[https://pubmed.ncbi.nlm.nih.gov/27153057 27153057]|[https://pubmed.ncbi.nlm.nih.gov/27128741 27128741]|[https://pubmed.ncbi.nlm.nih.gov/2654294 2654294]|[https://pubmed.ncbi.nlm.nih.gov/26930378 26930378]|[https://pubmed.ncbi.nlm.nih.gov/7561885 7561885]|[https://pubmed.ncbi.nlm.nih.gov/25860286 25860286]|[https://pubmed.ncbi.nlm.nih.gov/30845647 30845647]|[https://pubmed.ncbi.nlm.nih.gov/24712339 24712339]|[https://pubmed.ncbi.nlm.nih.gov/30070965 30070965]|[https://pubmed.ncbi.nlm.nih.gov/8910600 8910600]|[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]|[https://pubmed.ncbi.nlm.nih.gov/27356050 27356050]|[https://pubmed.ncbi.nlm.nih.gov/8514740 8514740]|[https://pubmed.ncbi.nlm.nih.gov/18509108 18509108]|[https://pubmed.ncbi.nlm.nih.gov/23000517 23000517]|[https://pubmed.ncbi.nlm.nih.gov/29769046 29769046]|[https://pubmed.ncbi.nlm.nih.gov/29566611 29566611] <br>
-'''term_xref''' : GlycoEpitope:EP0070|KEGG:G00118|CID:70788970|GlycoMotif:GGM.000092|CHEBI:72444 <br>
+ '''definition''' : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444] <br>
-'''best_match''' : GlycoEpitope:EP0070|KEGG:G00118|CID:70788970|GlycoMotif:GGM.000092|GTC:G93899SO|CHEBI:72444 <br>
+ '''term_xref''' : GlycoEpitope:EP0070|KEGG:G00118|CID:70788970|GlycoMotif:GGM.000092|GTC:G93899SO|CHEBI:72444 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
+===Heparan sulfate===
+ '''term (main_entry)''' : Heparan sulfate <br>
+ '''glycan_dictionary_accession''' : GSD000106 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : In Niemann-Pick C-1 fibroblasts, where deaminative degradation of heparan sulfate is defective, carbonylated proteins were abundant.[PMID: 17540770] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32266657 32266657]|[https://pubmed.ncbi.nlm.nih.gov/29554552 29554552]|[https://pubmed.ncbi.nlm.nih.gov/29032302 29032302]|[https://pubmed.ncbi.nlm.nih.gov/30003471 30003471]|[https://pubmed.ncbi.nlm.nih.gov/25197032 25197032]|[https://pubmed.ncbi.nlm.nih.gov/28538085 28538085]|[https://pubmed.ncbi.nlm.nih.gov/26236728 26236728]|[https://pubmed.ncbi.nlm.nih.gov/16917509 16917509]|[https://pubmed.ncbi.nlm.nih.gov/22899865 22899865]|[https://pubmed.ncbi.nlm.nih.gov/17080204 17080204]|[https://pubmed.ncbi.nlm.nih.gov/23042481 23042481]|[https://pubmed.ncbi.nlm.nih.gov/28982096 28982096]|[https://pubmed.ncbi.nlm.nih.gov/24146040 24146040]|[https://pubmed.ncbi.nlm.nih.gov/25081076 25081076]|[https://pubmed.ncbi.nlm.nih.gov/15719168 15719168]|[https://pubmed.ncbi.nlm.nih.gov/17453622 17453622]|[https://pubmed.ncbi.nlm.nih.gov/25325954 25325954]|[https://pubmed.ncbi.nlm.nih.gov/21110089 21110089]|[https://pubmed.ncbi.nlm.nih.gov/29797526 29797526]|[https://pubmed.ncbi.nlm.nih.gov/21967329 21967329]|[https://pubmed.ncbi.nlm.nih.gov/23313092 23313092]|[https://pubmed.ncbi.nlm.nih.gov/11212344 11212344]|[https://pubmed.ncbi.nlm.nih.gov/28465034 28465034]|[https://pubmed.ncbi.nlm.nih.gov/11746174 11746174]|[https://pubmed.ncbi.nlm.nih.gov/12512855 12512855]|[https://pubmed.ncbi.nlm.nih.gov/8836040 8836040]|[https://pubmed.ncbi.nlm.nih.gov/28394734 28394734]|[https://pubmed.ncbi.nlm.nih.gov/24182748 24182748]|[https://pubmed.ncbi.nlm.nih.gov/28264929 28264929]|[https://pubmed.ncbi.nlm.nih.gov/28745308 28745308]|[https://pubmed.ncbi.nlm.nih.gov/26555370 26555370]|[https://pubmed.ncbi.nlm.nih.gov/14718374 14718374]|[https://pubmed.ncbi.nlm.nih.gov/16767693 16767693]|[https://pubmed.ncbi.nlm.nih.gov/25246018 25246018]|[https://pubmed.ncbi.nlm.nih.gov/19584012 19584012]|[https://pubmed.ncbi.nlm.nih.gov/8274190 8274190]|[https://pubmed.ncbi.nlm.nih.gov/25034023 25034023]|[https://pubmed.ncbi.nlm.nih.gov/8370471 8370471]|[https://pubmed.ncbi.nlm.nih.gov/26571620 26571620]|[https://pubmed.ncbi.nlm.nih.gov/29920400 29920400]|[https://pubmed.ncbi.nlm.nih.gov/31731076 31731076]|[https://pubmed.ncbi.nlm.nih.gov/20816205 20816205]|[https://pubmed.ncbi.nlm.nih.gov/16880267 16880267]|[https://pubmed.ncbi.nlm.nih.gov/31547957 31547957]|[https://pubmed.ncbi.nlm.nih.gov/11457867 11457867]|[https://pubmed.ncbi.nlm.nih.gov/27241222 27241222]|[https://pubmed.ncbi.nlm.nih.gov/28718936 28718936]|[https://pubmed.ncbi.nlm.nih.gov/21204109 21204109]|[https://pubmed.ncbi.nlm.nih.gov/31016560 31016560]|[https://pubmed.ncbi.nlm.nih.gov/11166215 11166215]|[https://pubmed.ncbi.nlm.nih.gov/11457866 11457866] <br>
+ '''definition''' : A linear polysaccharide in which the backbone consists of a variably sulfated repeating disaccharide unit.[CHEBI:28815] <br>
+ '''term_xref''' : CHEBI:28815|CID: 53477715|GlycoEpitope: EP0086 <br>
+ '''synonyms''' : Heparan N-sulfate|Heparan sulfate|Heparan sulphate|Heparatan sulfate|Heparin monosulfate| Heparin sulfate|Heparitin monosulfate|Heparitin sulfate|N-Acetylheparan sulfate <br>
+ '''function''' : Heparan sulfate proteoglycans (HSPGs) play crucial roles regulating key developmental signaling pathways, such as the Wnt, Hedgehog, transforming growth factor-beta, and fibroblast growth factor pathways.[GlycoEpitope: EP0086] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===H type 3===
-'''term (main_entry)''' : H type 3 <br>
-'''glycan_dictionary_accession''' : GD000105 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The expression of type 3 chain H and A antigens was always compatible with the ABO blood type of the individual and seems to be regulated by the secretor genes, as secretors [Lewis (a-b+)] expressed more A and H type 3 chains than nonsecretors [Lewis (a+b-)].[PMID:1563908] <br>
-'''publication''' : 1563908|3944092|11218748|11101633|18842005|27550195|2469783|2433836|23118206|8445257|2664192|3063304 <br>
-'''definition''' :  <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : H antigen (type 3)|Type 3 chain H <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+===Heparin===
+ '''term (main_entry)''' : Heparin <br>
+ '''glycan_dictionary_accession''' : GSD000107 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Two cellulose-based membranes, containing 5 and 20% N, N-diethyl-aminoethyl cellulose (DEAE) respectively, were investigated for ionic attachment of heparin and heparin release.[PMID:[https://pubmed.ncbi.nlm.nih.gov/6416324 6416324]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27100512 27100512]|[https://pubmed.ncbi.nlm.nih.gov/22566218 22566218]|[https://pubmed.ncbi.nlm.nih.gov/27264866 27264866]|[https://pubmed.ncbi.nlm.nih.gov/30094590 30094590]|[https://pubmed.ncbi.nlm.nih.gov/31077659 31077659]|[https://pubmed.ncbi.nlm.nih.gov/26975675 26975675]|[https://pubmed.ncbi.nlm.nih.gov/2083874 2083874]|[https://pubmed.ncbi.nlm.nih.gov/25088334 25088334]|[https://pubmed.ncbi.nlm.nih.gov/3333067 3333067]|[https://pubmed.ncbi.nlm.nih.gov/2191809 2191809]|[https://pubmed.ncbi.nlm.nih.gov/28118750 28118750]|[https://pubmed.ncbi.nlm.nih.gov/28224913 28224913]|[https://pubmed.ncbi.nlm.nih.gov/22495506 22495506]|[https://pubmed.ncbi.nlm.nih.gov/29385025 29385025]|[https://pubmed.ncbi.nlm.nih.gov/10332503 10332503]|[https://pubmed.ncbi.nlm.nih.gov/22393937 22393937]|[https://pubmed.ncbi.nlm.nih.gov/19947315 19947315]|[https://pubmed.ncbi.nlm.nih.gov/27655335 27655335]|[https://pubmed.ncbi.nlm.nih.gov/14529394 14529394]|[https://pubmed.ncbi.nlm.nih.gov/2419035 2419035]|[https://pubmed.ncbi.nlm.nih.gov/22048616 22048616]|[https://pubmed.ncbi.nlm.nih.gov/23849978 23849978]|[https://pubmed.ncbi.nlm.nih.gov/10204652 10204652]|[https://pubmed.ncbi.nlm.nih.gov/28958760 28958760]|[https://pubmed.ncbi.nlm.nih.gov/12627673 12627673]|[https://pubmed.ncbi.nlm.nih.gov/9042555 9042555]|[https://pubmed.ncbi.nlm.nih.gov/15639107 15639107]|[https://pubmed.ncbi.nlm.nih.gov/28880550 28880550]|[https://pubmed.ncbi.nlm.nih.gov/27238483 27238483]|[https://pubmed.ncbi.nlm.nih.gov/1964668 1964668]|[https://pubmed.ncbi.nlm.nih.gov/16716101 16716101]|[https://pubmed.ncbi.nlm.nih.gov/10796377 10796377]|[https://pubmed.ncbi.nlm.nih.gov/25981976 25981976]|[https://pubmed.ncbi.nlm.nih.gov/24680753 24680753]|[https://pubmed.ncbi.nlm.nih.gov/2191118 2191118]|[https://pubmed.ncbi.nlm.nih.gov/21166465 21166465]|[https://pubmed.ncbi.nlm.nih.gov/30582884 30582884]|[https://pubmed.ncbi.nlm.nih.gov/1322434 1322434]|[https://pubmed.ncbi.nlm.nih.gov/15330727 15330727]|[https://pubmed.ncbi.nlm.nih.gov/9752370 9752370]|[https://pubmed.ncbi.nlm.nih.gov/6416324 6416324]|[https://pubmed.ncbi.nlm.nih.gov/14996629 14996629]|[https://pubmed.ncbi.nlm.nih.gov/20452241 20452241]|[https://pubmed.ncbi.nlm.nih.gov/1340407 1340407]|[https://pubmed.ncbi.nlm.nih.gov/29050610 29050610]|[https://pubmed.ncbi.nlm.nih.gov/345399 345399]|[https://pubmed.ncbi.nlm.nih.gov/6916469 6916469]|[https://pubmed.ncbi.nlm.nih.gov/6565376 6565376]|[https://pubmed.ncbi.nlm.nih.gov/26714061 26714061] <br>
+ '''definition''' : A highly sulfated linear glycosaminoglycan comprising complex patterns of uronic acid-(1→4)-D-glucosamine repeating subunits. Used as an injectable anticoagulant, it has the highest negative charge density of any known biological molecule.[CHEBI:28304] <br>
+ '''term_xref''' : CID:772|CHEBI:28304 <br>
+ '''synonyms''' : bemiparin|bemiparin|certoparin|Cy 222|enoxaparin|fluxum|Heparin|Heparinic acid|parnaparin|reviparin|sandoparin <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===Heparan sulfate===
-'''term (main_entry)''' : Heparan sulfate <br>
-'''glycan_dictionary_accession''' : GD000106 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In Niemann-Pick C-1 fibroblasts, where deaminative degradation of heparan sulfate is defective, carbonylated proteins were abundant.[PMID: 17540770] <br>
-'''publication''' : 32266657|29554552|29032302|30003471|25197032|28538085|26236728|22899865|17080204|23042481|28982096|24146040|25081076|15719168|17453622|25325954|21110089|29797526|21967329|23313092|11212344|28465034|11746174|12512855|8836040|28394734|24182748|28264929|28745308|26555370|14718374|16767693|25246018|19584012|8274190|25034023|8370471|26571620|29920400|31731076|20816205|16880267|31547957|11457867|27241222|28718936|21204109|31016560|11166215|11457866 <br>
-'''definition''' : A linear polysaccharide in which the backbone consists of a variably sulfated repeating disaccharide unit.[CHEBI:28815] <br>
-'''term_xref''' : CHEBI:28815|CID:53477715|GlycoEpitope:EP0086 <br>
-'''best_match''' : CHEBI:28815|CID: 53477715|GlycoEpitope: EP0086 <br>
-'''synonymns''' : Heparan N-sulfate|Heparan sulfate|Heparan sulphate|Heparatan sulfate|Heparin monosulfate| Heparin sulfate|Heparitin monosulfate|Heparitin sulfate|N-Acetylheparan sulfate <br>
-'''function''' : Heparan sulfate proteoglycans (HSPGs) play crucial roles regulating key developmental signaling pathways, such as the Wnt, Hedgehog, transforming growth factor-beta, and fibroblast growth factor pathways.[GlycoEpitope: EP0086] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===Heparan sulfate/heparin===
-===Heparin===
+ '''term (main_entry)''' : Heparan sulfate/heparin<br>
-'''term (main_entry)''' : Heparin <br>
+ '''glycan_dictionary_accession''' : GSD000185<br>
-'''glycan_dictionary_accession''' : GD000107 <br>
+ '''glytoucan_accession ''' : <br>
-'''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Heparan sulfate (HS)/heparin is a structurally complex class of glycosaminoglycans (GAGs) that have been implicated in a wide range of biological activities. [PMID:[https://pubmed.ncbi.nlm.nih.gov/31016560 31016560]]<br>
-'''term_in_sentence''' : Two cellulose-based membranes, containing 5 and 20% N, N-diethyl-aminoethyl cellulose (DEAE) respectively, were investigated for ionic attachment of heparin and heparin release.[PMID:6416324] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23313092 23313092]|[https://pubmed.ncbi.nlm.nih.gov/31016560 31016560]|[https://pubmed.ncbi.nlm.nih.gov/23152789 23152789]<br>
-'''publication''' : 27100512|22566218|27264866|30094590|31077659|26975675|2083874|25088334|3333067|2191809|28118750|28224913|22495506|29385025|10332503|22393937|19947315|27655335|14529394|2419035|22048616|23849978|10204652|28958760|12627673|9042555|15639107|28880550|27238483|1964668|16716101|10796377|25981976|24680753|2191118|21166465|30582884|1322434|15330727|9752370|6416324|14996629|20452241|1340407|29050610|345399|6916469|6565376|26714061 <br>
+ '''definition''' : <br>
-'''definition''' : A highly sulfated linear glycosaminoglycan comprising complex patterns of uronic acid-(1→4)-D-glucosamine repeating subunits. Used as an injectable anticoagulant, it has the highest negative charge density of any known biological molecule.[CHEBI:28304] <br>
+ '''term_xref''' : <br>
-'''term_xref''' : CID:772|CHEBI:28304 <br>
+ '''synonyms''' :  HS/heparin|heparan sufate (HS)/heparin|H/HS<br>
-'''best_match''' : CID:772|CHEBI:28304 <br>
+ '''function''' : <br>
-'''synonymns''' : bemiparin|bemiparin|certoparin|Cy 222|enoxaparin|fluxum|Heparin|Heparinic acid|parnaparin|reviparin|sandoparin <br>
+ '''disease_associations''' : <br>
-'''function''' :  <br>
+ '''wikipedia''' :  <br>
-'''disease_associations''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===High mannose===
-'''term (main_entry)''' : High mannose <br>
+[[File:G55220VL.png|thumb|G55220VL]]
-'''glycan_dictionary_accession''' : GD000108 <br>
+ '''term (main_entry)''' : High mannose <br>
-'''glytoucan_accession ''' : G55220VL <br>
+ '''glycan_dictionary_accession''' : GSD000108 <br>
-'''term_in_sentence''' : Each glycoform contained a number of peaks differing by 162 Da indicating heterogeneity and suggesting the presence of high-mannose sugars.[PMID:11258925] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G55220VL G55220VL] <br>
-'''publication''' : 11258925|17956937|2059624|2065054|26791533|4077844|7780197|9136890|30659065|30075362|21421994|31076349|29738673|29508223|26747427|30634645|23007868|29051951|24549150|12417032|26724786|26956389|26493153|31102532|29673624|8348230|25586968|24975601|29803109|28465212|25776945|30151520|21097542|24326091|27995699|26003537|6722291|2925680|25565276|21460211|25196214|27387600|22373601|3729933|16423983|24174266|30605318 <br>
+ '''term_in_sentence''' : Each glycoform contained a number of peaks differing by 162 Da indicating heterogeneity and suggesting the presence of high-mannose sugars.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11258925 11258925]] <br>
-'''definition''' : An N-linked oligosaccharide that possesses between five and nine mannose residues attached to the chitobiose [(GlcNAc)2] core. [CHEBI:5717] None of the Man residues are substituted with any monosaccharide other than Man . <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11258925 11258925]|[https://pubmed.ncbi.nlm.nih.gov/17956937 17956937]|[https://pubmed.ncbi.nlm.nih.gov/2059624 2059624]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]|[https://pubmed.ncbi.nlm.nih.gov/26791533 26791533]|[https://pubmed.ncbi.nlm.nih.gov/4077844 4077844]|[https://pubmed.ncbi.nlm.nih.gov/7780197 7780197]|[https://pubmed.ncbi.nlm.nih.gov/9136890 9136890]|[https://pubmed.ncbi.nlm.nih.gov/30659065 30659065]|[https://pubmed.ncbi.nlm.nih.gov/30075362 30075362]|[https://pubmed.ncbi.nlm.nih.gov/21421994 21421994]|[https://pubmed.ncbi.nlm.nih.gov/31076349 31076349]|[https://pubmed.ncbi.nlm.nih.gov/29738673 29738673]|[https://pubmed.ncbi.nlm.nih.gov/29508223 29508223]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]|[https://pubmed.ncbi.nlm.nih.gov/30634645 30634645]|[https://pubmed.ncbi.nlm.nih.gov/23007868 23007868]|[https://pubmed.ncbi.nlm.nih.gov/29051951 29051951]|[https://pubmed.ncbi.nlm.nih.gov/24549150 24549150]|[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]|[https://pubmed.ncbi.nlm.nih.gov/26724786 26724786]|[https://pubmed.ncbi.nlm.nih.gov/26956389 26956389]|[https://pubmed.ncbi.nlm.nih.gov/26493153 26493153]|[https://pubmed.ncbi.nlm.nih.gov/31102532 31102532]|[https://pubmed.ncbi.nlm.nih.gov/29673624 29673624]|[https://pubmed.ncbi.nlm.nih.gov/8348230 8348230]|[https://pubmed.ncbi.nlm.nih.gov/25586968 25586968]|[https://pubmed.ncbi.nlm.nih.gov/24975601 24975601]|[https://pubmed.ncbi.nlm.nih.gov/29803109 29803109]|[https://pubmed.ncbi.nlm.nih.gov/28465212 28465212]|[https://pubmed.ncbi.nlm.nih.gov/25776945 25776945]|[https://pubmed.ncbi.nlm.nih.gov/30151520 30151520]|[https://pubmed.ncbi.nlm.nih.gov/21097542 21097542]|[https://pubmed.ncbi.nlm.nih.gov/24326091 24326091]|[https://pubmed.ncbi.nlm.nih.gov/27995699 27995699]|[https://pubmed.ncbi.nlm.nih.gov/26003537 26003537]|[https://pubmed.ncbi.nlm.nih.gov/6722291 6722291]|[https://pubmed.ncbi.nlm.nih.gov/2925680 2925680]|[https://pubmed.ncbi.nlm.nih.gov/25565276 25565276]|[https://pubmed.ncbi.nlm.nih.gov/21460211 21460211]|[https://pubmed.ncbi.nlm.nih.gov/25196214 25196214]|[https://pubmed.ncbi.nlm.nih.gov/27387600 27387600]|[https://pubmed.ncbi.nlm.nih.gov/22373601 22373601]|[https://pubmed.ncbi.nlm.nih.gov/3729933 3729933]|[https://pubmed.ncbi.nlm.nih.gov/16423983 16423983]|[https://pubmed.ncbi.nlm.nih.gov/24174266 24174266]|[https://pubmed.ncbi.nlm.nih.gov/30605318 30605318]|[https://pubmed.ncbi.nlm.nih.gov/32371950 32371950]<br>
-'''term_xref''' : CID:70698382|CHEBI:71514 <br>
+ '''definition''' : An N-linked oligosaccharide that possesses between five and nine mannose residues attached to the chitobiose [(GlcNAc)2] core. [CHEBI:5717] None of the Man residues are substituted with any monosaccharide other than Man . <br>
-'''best_match''' : GTC:G55220VL|CID:70698382|CHEBI:71514 <br>
+ '''term_xref''' : GTC:G55220VL|CID:70698382|CHEBI:71514<br>
-'''synonymns''' : oligomannose <br>
+ '''synonyms''' : oligomannose, high-mannose, oligomannose-type <br>
-'''function''' : Involved in promotion of protein folding in ER. [PMID:12417032].|High Man glycans are enriched at cell surface during apoptosis.[PMID: 17516205] <br>
+ '''function''' : Involved in promotion of protein folding in ER. [PMID:[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]].|High Man glycans are enriched at cell surface during apoptosis.[PMID: 17516205] <br>
-'''disease_associations''' : Relative abundance changes in multiple CDGs [PMID: 30770376][PMID: 28484880] <br>
+ '''disease_associations''' : Relative abundance changes in multiple CDGs [PMID: [https://pubmed.ncbi.nlm.nih.gov/30770376 30770376][PMID: [https://pubmed.ncbi.nlm.nih.gov/28484880 28484880] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453033-Chapter 17 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17] <br>
 ===HNK-1===
-'''term (main_entry)''' : HNK-1 <br>
+[[File:G54406UD.png|thumb|G54406UD]]
-'''glycan_dictionary_accession''' : GD000109 <br>
+ '''term (main_entry)''' : HNK-1 <br>
-'''glytoucan_accession ''' : G54406UD <br>
+ '''glycan_dictionary_accession''' : GSD000109 <br>
-'''term_in_sentence''' : The human natural killer-1 (HNK-1) carbohydrate, a unique trisaccharide possessing sulfated glucuronic acid in a non-reducing terminus (HSO3-3GlcAß1-3Galß1-4GlcNAc-), is highly expressed in the nervous system and its spatiotemporal expression is strictly regulated.[PMID:28709864] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54406UD G54406UD] <br>
-'''publication''' : 28709864|31738061|26738850|30306736|11070366|20855890|18024472|22669261|19729452|19796667|26850637|11769463|18263654|15843379|26659409|9003039|22087768|21771787|15173636|9210489|15258996|17924534|26382082|16171882|18802400|9800516|7504418|11891229|15232286|9013478|21621858|11677051|18668221|11414798|19265195|8982638|8798480|28403522|17935701|1691305|10998116|9364602|7528651|12472892|21176892|28416698|19389918|28427937|25450311 <br>
+ '''term_in_sentence''' : The human natural killer-1 (HNK-1) carbohydrate, a unique trisaccharide possessing sulfated glucuronic acid in a non-reducing terminus (HSO3-3GlcAß1-3Galß1-4GlcNAc-), is highly expressed in the nervous system and its spatiotemporal expression is strictly regulated.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28709864 28709864]] <br>
-'''definition''' : An amino trisaccharide consisting of a 3-O-sulfo-β-D-glucuronic acid residue, a D-galactosyl residue and an N-acetyl-D-glucosamine residue (at the reducing end) in a linear sequence.[CHEBI:60322] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28709864 28709864]|[https://pubmed.ncbi.nlm.nih.gov/31738061 31738061]|[https://pubmed.ncbi.nlm.nih.gov/26738850 26738850]|[https://pubmed.ncbi.nlm.nih.gov/30306736 30306736]|[https://pubmed.ncbi.nlm.nih.gov/11070366 11070366]|[https://pubmed.ncbi.nlm.nih.gov/20855890 20855890]|[https://pubmed.ncbi.nlm.nih.gov/18024472 18024472]|[https://pubmed.ncbi.nlm.nih.gov/22669261 22669261]|[https://pubmed.ncbi.nlm.nih.gov/19729452 19729452]|[https://pubmed.ncbi.nlm.nih.gov/19796667 19796667]|[https://pubmed.ncbi.nlm.nih.gov/26850637 26850637]|[https://pubmed.ncbi.nlm.nih.gov/11769463 11769463]|[https://pubmed.ncbi.nlm.nih.gov/18263654 18263654]|[https://pubmed.ncbi.nlm.nih.gov/15843379 15843379]|[https://pubmed.ncbi.nlm.nih.gov/26659409 26659409]|[https://pubmed.ncbi.nlm.nih.gov/9003039 9003039]|[https://pubmed.ncbi.nlm.nih.gov/22087768 22087768]|[https://pubmed.ncbi.nlm.nih.gov/21771787 21771787]|[https://pubmed.ncbi.nlm.nih.gov/15173636 15173636]|[https://pubmed.ncbi.nlm.nih.gov/9210489 9210489]|[https://pubmed.ncbi.nlm.nih.gov/15258996 15258996]|[https://pubmed.ncbi.nlm.nih.gov/17924534 17924534]|[https://pubmed.ncbi.nlm.nih.gov/26382082 26382082]|[https://pubmed.ncbi.nlm.nih.gov/16171882 16171882]|[https://pubmed.ncbi.nlm.nih.gov/18802400 18802400]|[https://pubmed.ncbi.nlm.nih.gov/9800516 9800516]|[https://pubmed.ncbi.nlm.nih.gov/7504418 7504418]|[https://pubmed.ncbi.nlm.nih.gov/11891229 11891229]|[https://pubmed.ncbi.nlm.nih.gov/15232286 15232286]|[https://pubmed.ncbi.nlm.nih.gov/9013478 9013478]|[https://pubmed.ncbi.nlm.nih.gov/21621858 21621858]|[https://pubmed.ncbi.nlm.nih.gov/11677051 11677051]|[https://pubmed.ncbi.nlm.nih.gov/18668221 18668221]|[https://pubmed.ncbi.nlm.nih.gov/11414798 11414798]|[https://pubmed.ncbi.nlm.nih.gov/19265195 19265195]|[https://pubmed.ncbi.nlm.nih.gov/8982638 8982638]|[https://pubmed.ncbi.nlm.nih.gov/8798480 8798480]|[https://pubmed.ncbi.nlm.nih.gov/28403522 28403522]|[https://pubmed.ncbi.nlm.nih.gov/17935701 17935701]|[https://pubmed.ncbi.nlm.nih.gov/1691305 1691305]|[https://pubmed.ncbi.nlm.nih.gov/10998116 10998116]|[https://pubmed.ncbi.nlm.nih.gov/9364602 9364602]|[https://pubmed.ncbi.nlm.nih.gov/7528651 7528651]|[https://pubmed.ncbi.nlm.nih.gov/12472892 12472892]|[https://pubmed.ncbi.nlm.nih.gov/21176892 21176892]|[https://pubmed.ncbi.nlm.nih.gov/28416698 28416698]|[https://pubmed.ncbi.nlm.nih.gov/19389918 19389918]|[https://pubmed.ncbi.nlm.nih.gov/28427937 28427937]|[https://pubmed.ncbi.nlm.nih.gov/25450311 25450311] <br>
-'''term_xref''' : GlycoEpitope:EP0001|CID:46906103|CHEBI:60322|GGM.00058 <br>
+ '''definition''' : An amino trisaccharide consisting of a 3-O-sulfo-β-D-glucuronic acid residue, a D-galactosyl residue and an N-acetyl-D-glucosamine residue (at the reducing end) in a linear sequence.[CHEBI:60322] <br>
-'''best_match''' : GTC:G54406UD |GlycoEpitope:EP0001|CID:46906103|CHEBI:60322 <br>
+ '''term_xref''' : GTC:G54406UD|GlycoEpitope:EP0001|CID:46906103|CHEBI:60322|GlycoMotif:GGM.000058 <br>
-'''synonymns''' : HNK-1 carbohydrate epitope| CD57|HNK-1 antigen <br>
+ '''synonyms''' : HNK-1 carbohydrate epitope| CD57|HNK-1 antigen <br>
-'''function''' : learning and memory[GlycoEpitope:EP0001]|neural crest cell migration[GlycoEpitope:EP0001]|neurite extension[GlycoEpitope:EP0001]|neuron-astrocyte adhesion[GlycoEpitope:EP0001] <br>
+ '''function''' : learning and memory[GlycoEpitope:EP0001]|neural crest cell migration[GlycoEpitope:EP0001]|neurite extension[GlycoEpitope:EP0001]|neuron-astrocyte adhesion[GlycoEpitope:EP0001] <br>
-'''disease_associations''' : schizophrenia-like psychosis[GlycoEpitope:EP0001]|neuropathy[GlycoEpitope:EP0001]|exfoliation syndrome[GlycoEpitope:EP0001]|secondary cataract[GlycoEpitope:EP0001] <br>
+ '''disease_associations''' : schizophrenia-like psychosis[GlycoEpitope:EP0001]|neuropathy[GlycoEpitope:EP0001]|exfoliation syndrome[GlycoEpitope:EP0001]|secondary cataract[GlycoEpitope:EP0001] <br>
-'''wikipedia''' : https://en.wikipedia.org/wiki/N-linked_glycosylation <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/N-linked_glycosylation <br>
-'''essentials_of_glycobiology''' : NBK453033-Chapter 17 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17]<br>
 ===Hybrid===
-'''term (main_entry)''' : Hybrid <br>
+[[File:G16828VN.png|thumb|G16828VN]]
-'''glycan_dictionary_accession''' : GD000110 <br>
+ '''term (main_entry)''' : Hybrid <br>
-'''glytoucan_accession ''' : G16828VN <br>
+ '''glycan_dictionary_accession''' : GSD000110 <br>
-'''term_in_sentence''' : A hybrid-type N-glycan was accessed by total synthesis, converted to an oxazoline, and used as a donor substrate with both wild type Endo M and an N175Q glycosynthase Endo M mutant allowing the convergent synthesis of a glycosylated amino acid bearing a hybrid N-glycan structure. [PMID:27058295] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G16828VN G16828VN] <br>
-'''publication''' : 27058295|15044398|28714086|29578688|26999365 <br>
+ '''term_in_sentence''' : A hybrid-type N-glycan was accessed by total synthesis, converted to an oxazoline, and used as a donor substrate with both wild type Endo M and an N175Q glycosynthase Endo M mutant allowing the convergent synthesis of a glycosylated amino acid bearing a hybrid N-glycan structure. [PMID:[https://pubmed.ncbi.nlm.nih.gov/27058295 27058295]] <br>
-'''definition''' : An N-linked glycan in which the Manα1-6 arm of the trimannosyl core Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1–4GlcNAcβ1–Asn-X-Ser/Thr is substituted by one or more additional Man residues and the Manα1-3 arm is substituted by a GlcNAc residue added by GlcNAcT1. The GlcNAc linked to the a3 Man can be extended in the same manner as any complex glycan antenna. The trimannosyl core can also be core fucosylated and/or bisected by the addition of a GlcNAc to the 3 position of the α-linked Man residue.[NBK453020-Chapter 9] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27058295 27058295]|[https://pubmed.ncbi.nlm.nih.gov/15044398 15044398]|[https://pubmed.ncbi.nlm.nih.gov/28714086 28714086]|[https://pubmed.ncbi.nlm.nih.gov/29578688 29578688]|[https://pubmed.ncbi.nlm.nih.gov/26999365 26999365] <br>
-'''term_xref''' : CID:91847108|CHEBI:147471 <br>
+ '''definition''' : An N-linked glycan in which the Manα1-6 arm of the trimannosyl core Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1–4GlcNAcβ1–Asn-X-Ser/Thr is substituted by one or more additional Man residues and the Manα1-3 arm is substituted by a GlcNAc residue added by GlcNAcT1. The GlcNAc linked to the a3 Man can be extended in the same manner as any complex glycan antenna. The trimannosyl core can also be core fucosylated and/or bisected by the addition of a GlcNAc to the 3 position of the α-linked Man residue.[Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]] <br>
-'''best_match''' : GTC:G16828VN|CID:91847108|CHEBI:147471 <br>
+ '''term_xref''' : GTC:G16828VN|CID:91847108|CHEBI:147471 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453020 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
+===Hyaluronan===
+[[File:G29086KO.png|thumb|G29086KO]]
+ '''term (main_entry)''' : Hyaluronan<br>
+ '''glycan_dictionary_accession''' : GSD000183<br>
+ '''glytoucan_accession ''' : [https://glygen.org/glycan/G29086KO G29086KO]<br>
+ '''term_in_sentence''' : Hyaluronan (HA) comprises a major component of the extracellular matrix (ECM) in vertebrate connective tissues and is abundant in the cartilage, skin, brain, vitreous body, umbilical cord, and synovial fluid. [PMID:33171800]<br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/33171800 33171800]|[https://pubmed.ncbi.nlm.nih.gov/34209222 34209222]<br>
+ '''definition''' : <br>
+ '''term_xref''' : GTC:[https://glygen.org/glycan/G29086KO G29086KO]<br>
+ '''synonyms''' :  HA<br>
+ '''function''' : <br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :
 ===i antigen===
-'''term (main_entry)''' : i antigen <br>
+[[File:G00058MO.png|thumb|G00058MO]]
-'''glycan_dictionary_accession''' : GD000111 <br>
+[[File:G46055MA.png|thumb|G46055MA]]
-'''glytoucan_accession ''' : G00058MO|G46055MA <br>
+ '''term (main_entry)''' : i antigen <br>
-'''term_in_sentence''' : Inasmuch as the hybridoma was established by hybridization of lymphocytes derived from regional lymph nodes of lung cancer, and the antigen was found in the patient's lung cancer tissue, the i antigen in lung cancer is probably recognized as a tumor-associated antigen by the host's immune cell system.[PMID:2422274] <br>
+ '''glycan_dictionary_accession''' : GSD000111 <br>
-'''publication''' : 2422274|15679458|21912254|12468428|28508465|6203982|30728302|8449405|9122902|10360315|6159787|6183759|518539|6715951|21933024 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00058MO G00058MO]|[https://www.glygen.org/glycan/G46055MA G46055MA] <br>
-'''definition''' :  <br>
+ '''term_in_sentence''' : Inasmuch as the hybridoma was established by hybridization of lymphocytes derived from regional lymph nodes of lung cancer, and the antigen was found in the patient's lung cancer tissue, the i antigen in lung cancer is probably recognized as a tumor-associated antigen by the host's immune cell system.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2422274 2422274]] <br>
-'''term_xref''' : GlycoMotif:GGM.000004|GlycoMotif:GGM.000002 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2422274 2422274]|[https://pubmed.ncbi.nlm.nih.gov/15679458 15679458]| [https://pubmed.ncbi.nlm.nih.gov/21912254 21912254]|[https://pubmed.ncbi.nlm.nih.gov/12468428 12468428]|[https://pubmed.ncbi.nlm.nih.gov/28508465 28508465]|[https://pubmed.ncbi.nlm.nih.gov/6203982 6203982]|[https://pubmed.ncbi.nlm.nih.gov/30728302 30728302]|[https://pubmed.ncbi.nlm.nih.gov/8449405 8449405]|[https://pubmed.ncbi.nlm.nih.gov/9122902 9122902]|[https://pubmed.ncbi.nlm.nih.gov/10360315 10360315]|[https://pubmed.ncbi.nlm.nih.gov/6159787 6159787]|[https://pubmed.ncbi.nlm.nih.gov/6183759 6183759]|[https://pubmed.ncbi.nlm.nih.gov/518539 518539]|[https://pubmed.ncbi.nlm.nih.gov/6715951 6715951]|[https://pubmed.ncbi.nlm.nih.gov/21933024 21933024] <br>
-'''best_match''' : GlycoMotif:GGM.000004|GlycoMotif:GGM.000002|GTC:G46055MA|GTC:G00058MO <br>
+ '''definition''' :  <br>
-'''synonymns''' : Type 2 LN2 <br>
+ '''term_xref''' : GlycoMotif:GGM.000004|GlycoMotif:GGM.000002|GTC:G46055MA|GTC:G00058MO <br>
-'''function''' :  <br>
+ '''synonyms''' : Type 2 LN2 <br>
-'''disease_associations''' :  <br>
+ '''function''' :  <br>
-'''wikipedia''' :  <br>
+ '''disease_associations''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===I antigen===
-'''term (main_entry)''' : I antigen <br>
+[[File:G56045WU.png|thumb|G56045WU]]
-'''glycan_dictionary_accession''' : GD000112 <br>
+ '''term (main_entry)''' : I antigen <br>
-'''glytoucan_accession ''' : G56045WU <br>
+ '''glycan_dictionary_accession''' : GSD000112 <br>
-'''term_in_sentence''' : The I antigen is formed by the action of an enzyme (a glycosyltransferase), which adds branches onto the i antigen.[PMID:15679458] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56045WU G56045WU] <br>
-'''publication''' : 15679458|21912254|30705292|33403394|6715951|12468428|6088627|6159787 <br>
+ '''term_in_sentence''' : The I antigen is formed by the action of an enzyme (a glycosyltransferase), which adds branches onto the i antigen.[PMID:[https://pubmed.ncbi.nlm.nih.gov/15679458 15679458]] <br>
-'''definition''' : N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S,6R)-4-[(2R,3R,4R,5S,6R)-3-Acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[[(2R,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide (CHEBI:151390) is a amino sugar.[CHEBI:151390] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15679458 15679458]|[https://pubmed.ncbi.nlm.nih.gov/21912254 21912254]|[https://pubmed.ncbi.nlm.nih.gov/30705292 30705292]|[https://pubmed.ncbi.nlm.nih.gov/33403394 33403394]|[https://pubmed.ncbi.nlm.nih.gov/6715951 6715951]| [https://pubmed.ncbi.nlm.nih.gov/12468428 12468428]|[https://pubmed.ncbi.nlm.nih.gov/6088627 6088627]| [https://pubmed.ncbi.nlm.nih.gov/6159787 6159787] <br>
-'''term_xref''' : GlycoMotif:GGM.000003|GlycoEpitope:EP0138|CID:91852915|CHEBI:151390 <br>
+ '''definition''' : N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S,6R)-4-[(2R,3R,4R,5S,6R)-3-Acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[[(2R,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide (CHEBI:151390) is a amino sugar.[CHEBI:151390] <br>
-'''best_match''' : GlycoMotif:GGM.000003|GlycoEpitope:EP0138|GTC:G56045WU|CID:91852915|CHEBI:151390 <br>
+ '''term_xref''' : GlycoMotif:GGM.000003|GlycoEpitope:EP0138|GTC:G56045WU|CID:91852915|CHEBI:151390<br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453020-Chapter 9 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
 ===Isoglobotetraosylceramide===
-'''term (main_entry)''' : Isoglobotetraosylceramide <br>
+ '''term (main_entry)''' : Isoglobotetraosylceramide <br>
-'''glycan_dictionary_accession''' : GD000113 <br>
+ '''glycan_dictionary_accession''' : GSD000113 <br>
-'''glytoucan_accession ''' : G57710SU <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57710SU G57710SU] <br>
-'''term_in_sentence''' : Furthermore, isoglobotetraosylceramide seems to play a direct role in the metastatic process since the blocking of exposed antigen with monoclonal antibodies, or their Fab fragments, results in a highly significant decrease in lung colony formation.[PMID:8504431] <br>
+ '''term_in_sentence''' : Furthermore, isoglobotetraosylceramide seems to play a direct role in the metastatic process since the blocking of exposed antigen with monoclonal antibodies, or their Fab fragments, results in a highly significant decrease in lung colony formation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8504431 8504431]] <br>
-'''publication''' : 1396705|8504431|2713378|3489485|18997175|7053385|3379797|2465279|3743633|11479210 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1396705 1396705]|[https://pubmed.ncbi.nlm.nih.gov/8504431 8504431]|[https://pubmed.ncbi.nlm.nih.gov/2713378 2713378]|[https://pubmed.ncbi.nlm.nih.gov/3489485 3489485]|[https://pubmed.ncbi.nlm.nih.gov/18997175 18997175]|[https://pubmed.ncbi.nlm.nih.gov/7053385 7053385]|[https://pubmed.ncbi.nlm.nih.gov/3379797 3379797]|[https://pubmed.ncbi.nlm.nih.gov/2465279 2465279]|[https://pubmed.ncbi.nlm.nih.gov/3743633 3743633]|[https://pubmed.ncbi.nlm.nih.gov/11479210 11479210] <br>
-'''definition''' :  <br>
+ '''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000071|CID:91849719|KEGG:G03211|CHEBI:148232|SugarBind_Ligand:17 <br>
+ '''term_xref''' : GlycoMotif:GGM.000071|GTC:G57710SU|CID: 91849719|KEGG:G03211|CHEBI:148232|SugarBind_Ligand:17 <br>
-'''best_match''' : GlycoMotif:GGM.000071|GTC:G57710SU|CID:91849719|KEGG:G03211|CHEBI:148232|SugarBind_Ligand:17 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' : a marker for highly metastatic cells in rat mammary adenocarcinomas[PMID:[https://pubmed.ncbi.nlm.nih.gov/8504431 8504431]] <br>
-'''function''' : a marker for highly metastatic cells in rat mammary adenocarcinomas[PMID:8504431] <br>
+ '''disease_associations''' : Actinomycosis[SugarBind_Ligand:17] <br>
-'''disease_associations''' : Actinomycosis[SugarBind_Ligand:17] <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/Ii_antigen_system <br>
-'''wikipedia''' : https://en.wikipedia.org/wiki/Ii_antigen_system <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Keratan sulfate===
-'''term (main_entry)''' : Keratan sulfate <br>
+[[File:G82109MW.png|thumb|G82109MW]]
-'''glycan_dictionary_accession''' : GD000114 <br>
+ '''term (main_entry)''' : Keratan sulfate <br>
-'''glytoucan_accession ''' :  G82109MW <br>
+ '''glycan_dictionary_accession''' : GSD000114 <br>
-'''term_in_sentence''' : Compared to the other classes of glycosaminoglycans (GAGs), that is, chondroitin/dermatan sulfate, heparin/heparan sulfate and hyaluronan, keratan sulfate (KS), have the least known of its interactive properties.[PMID: 30578672] <br>
+ '''glytoucan_accession ''' :  [https://www.glygen.org/glycan/G82109MW G82109MW] <br>
-'''publication''' : 29340594|30578672|12512857|29625490|25325967|30025865|29924315|9549787|11030741|28078490|8298243|29096187|30059256|26958998|26773479|22840010|15597951|28110685|28535934|2942429|18234072|8641829|8940154|2027120|30849116|41589|6238957|1907283|7722002|29275050|24274541|2527236|1731862|8991509|24291704|10517185|6451953|7688312|8663590|139406|25770829|25036480|9275006|25179279|32627425|26903438|27941632|12807022|32266652|21624346 <br>
+ '''term_in_sentence''' : Compared to the other classes of glycosaminoglycans (GAGs), that is, chondroitin/dermatan sulfate, heparin/heparan sulfate and hyaluronan, keratan sulfate (KS), have the least known of its interactive properties.[PMID: [https://pubmed.ncbi.nlm.nih.gov/30578672 30578672]] <br>
-'''definition''' : A sulfated glycosaminoglycan, a linear polymer that consists of the repeating disaccharide [3)-β-Gal-(1→4)-β-GlcNAc-(1→] and containing sulfo groups located at random positions.[CHEBI:60924] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29340594 29340594]|[https://pubmed.ncbi.nlm.nih.gov/30578672 30578672]|[https://pubmed.ncbi.nlm.nih.gov/12512857 12512857]|[https://pubmed.ncbi.nlm.nih.gov/29625490 29625490]|[https://pubmed.ncbi.nlm.nih.gov/25325967 25325967]|[https://pubmed.ncbi.nlm.nih.gov/30025865 30025865]|[https://pubmed.ncbi.nlm.nih.gov/29924315 29924315]|[https://pubmed.ncbi.nlm.nih.gov/9549787 9549787]|[https://pubmed.ncbi.nlm.nih.gov/11030741 11030741]|[https://pubmed.ncbi.nlm.nih.gov/28078490 28078490]|[https://pubmed.ncbi.nlm.nih.gov/8298243 8298243]|[https://pubmed.ncbi.nlm.nih.gov/29096187 29096187]|[https://pubmed.ncbi.nlm.nih.gov/30059256 30059256]|[https://pubmed.ncbi.nlm.nih.gov/26958998 26958998]|[https://pubmed.ncbi.nlm.nih.gov/26773479 26773479]|[https://pubmed.ncbi.nlm.nih.gov/22840010 22840010]|[https://pubmed.ncbi.nlm.nih.gov/15597951 15597951]|[https://pubmed.ncbi.nlm.nih.gov/28110685 28110685]|[https://pubmed.ncbi.nlm.nih.gov/28535934 28535934]|[https://pubmed.ncbi.nlm.nih.gov/2942429 2942429]|[https://pubmed.ncbi.nlm.nih.gov/18234072 18234072]|[https://pubmed.ncbi.nlm.nih.gov/8641829 8641829]|[https://pubmed.ncbi.nlm.nih.gov/8940154 8940154]|[https://pubmed.ncbi.nlm.nih.gov/2027120 2027120]|[https://pubmed.ncbi.nlm.nih.gov/30849116 30849116]|[https://pubmed.ncbi.nlm.nih.gov/41589 41589]|[https://pubmed.ncbi.nlm.nih.gov/6238957 6238957]|[https://pubmed.ncbi.nlm.nih.gov/1907283 1907283]|[https://pubmed.ncbi.nlm.nih.gov/7722002 7722002]|[https://pubmed.ncbi.nlm.nih.gov/29275050 29275050]|[https://pubmed.ncbi.nlm.nih.gov/24274541 24274541]|[https://pubmed.ncbi.nlm.nih.gov/2527236 2527236]|[https://pubmed.ncbi.nlm.nih.gov/1731862 1731862]|[https://pubmed.ncbi.nlm.nih.gov/8991509 8991509]|[https://pubmed.ncbi.nlm.nih.gov/24291704 24291704]|[https://pubmed.ncbi.nlm.nih.gov/10517185 10517185]|[https://pubmed.ncbi.nlm.nih.gov/6451953 6451953]|[https://pubmed.ncbi.nlm.nih.gov/7688312 7688312]|[https://pubmed.ncbi.nlm.nih.gov/8663590 8663590]|[https://pubmed.ncbi.nlm.nih.gov/139406 139406] |[https://pubmed.ncbi.nlm.nih.gov/25770829 25770829]|[https://pubmed.ncbi.nlm.nih.gov/25036480 25036480]|[https://pubmed.ncbi.nlm.nih.gov/9275006 9275006]|[https://pubmed.ncbi.nlm.nih.gov/25179279 25179279]|[https://pubmed.ncbi.nlm.nih.gov/32627425 32627425]|[https://pubmed.ncbi.nlm.nih.gov/26903438 26903438]|[https://pubmed.ncbi.nlm.nih.gov/27941632 27941632]|[https://pubmed.ncbi.nlm.nih.gov/12807022 12807022]|[https://pubmed.ncbi.nlm.nih.gov/32266652 32266652]|[https://pubmed.ncbi.nlm.nih.gov/21624346 21624346] <br>
-'''term_xref''' : CHEBI:60924|CID:446715|GlycoEpitope:EP0085 <br>
+ '''definition''' : A sulfated glycosaminoglycan, a linear polymer that consists of the repeating disaccharide [3)-β-Gal-(1→4)-β-GlcNAc-(1→] and containing sulfo groups located at random positions.[CHEBI:60924] <br>
-'''best_match''' : CHEBI:60924|CID:446715|GlycoEpitope: EP0085|GTC: G82109MW <br>
+ '''term_xref''' : CHEBI:60924|CID:446715|GlycoEpitope: EP0085|GTC: G82109MW <br>
-'''synonymns''' : keratan| Kerato sulphate|Kerato sulfate|Keratan sulphate|kerato 6'-sulfate|keratan 6'-sulfate|Kerato 6'-sulphate|Keratan 6'-sulphate <br>
+ '''synonyms''' : keratan| Kerato sulphate|Kerato sulfate|Keratan sulphate|kerato 6'-sulfate|keratan 6'-sulfate|Kerato 6'-sulphate|Keratan 6'-sulphate <br>
-'''function''' : Tissue hydration.[PMID: 11030741] <br>
+ '''function''' : Tissue hydration.[PMID: [https://pubmed.ncbi.nlm.nih.gov/11030741 11030741]] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===LacdiNac===
-'''term (main_entry)''' : LacdiNac <br>
+[[File:G31736BK.png|thumb|G31736BK]]
-'''glycan_dictionary_accession''' : GD000115 <br>
+ '''term (main_entry)''' : LacdiNac <br>
-'''glytoucan_accession ''' : G31736BK <br>
+ '''glycan_dictionary_accession''' : GSD000115 <br>
-'''term_in_sentence''' : We previously showed that the expression level of the LacdiNAc group in N-glycans decreases dramatically during the progression of human breast cancer.[PMID:25003135] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G31736BK G31736BK] <br>
-'''publication''' : 25003135|31711843|31145522|27601469|30669833|25210040|24633693|24755437|22653491|30898876|7758724|22474328|21305673|31558607|31271862|28549117|26213980|9134425|25561735|31756927|31170332|16282603|15265923|32267274|23015818|32676595|16728562|10814702|9591048|22245701|29751628|22997242|15535969|31911241|30622255|29888905|30236114|30298790|29373511|22298779|19179461|31606752|15653684|16403022|11162373|32005658|30529570 <br>
+ '''term_in_sentence''' : We previously showed that the expression level of the LacdiNAc group in N-glycans decreases dramatically during the progression of human breast cancer.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25003135 25003135]] <br>
-'''definition''' : An amino disaccharide consisting of N-acetylglucosamine having an N-acetylgalactosaminyl resiude attached at the 4-position via a β-linkage.[CHEBI:61190] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/25003135 25003135]|[https://pubmed.ncbi.nlm.nih.gov/31711843 31711843]|[https://pubmed.ncbi.nlm.nih.gov/31145522 31145522]|[https://pubmed.ncbi.nlm.nih.gov/27601469 27601469]|[https://pubmed.ncbi.nlm.nih.gov/30669833 30669833]|[https://pubmed.ncbi.nlm.nih.gov/25210040 25210040]|[https://pubmed.ncbi.nlm.nih.gov/24633693 24633693]|[https://pubmed.ncbi.nlm.nih.gov/24755437 24755437]|[https://pubmed.ncbi.nlm.nih.gov/22653491 22653491]|[https://pubmed.ncbi.nlm.nih.gov/30898876 30898876]|[https://pubmed.ncbi.nlm.nih.gov/7758724 7758724]|[https://pubmed.ncbi.nlm.nih.gov/22474328 22474328]|[https://pubmed.ncbi.nlm.nih.gov/21305673 21305673]|[https://pubmed.ncbi.nlm.nih.gov/31558607 31558607]|[https://pubmed.ncbi.nlm.nih.gov/31271862 31271862]|[https://pubmed.ncbi.nlm.nih.gov/28549117 28549117]|[https://pubmed.ncbi.nlm.nih.gov/26213980 26213980]|[https://pubmed.ncbi.nlm.nih.gov/9134425 9134425]|[https://pubmed.ncbi.nlm.nih.gov/25561735 25561735]|[https://pubmed.ncbi.nlm.nih.gov/31756927 31756927]|[https://pubmed.ncbi.nlm.nih.gov/31170332 31170332]|[https://pubmed.ncbi.nlm.nih.gov/16282603 16282603]|[https://pubmed.ncbi.nlm.nih.gov/15265923 15265923]|[https://pubmed.ncbi.nlm.nih.gov/32267274 32267274]|[https://pubmed.ncbi.nlm.nih.gov/23015818 23015818]|[https://pubmed.ncbi.nlm.nih.gov/32676595 32676595]|[https://pubmed.ncbi.nlm.nih.gov/16728562 16728562]|[https://pubmed.ncbi.nlm.nih.gov/10814702 10814702]|[https://pubmed.ncbi.nlm.nih.gov/9591048 9591048]|[https://pubmed.ncbi.nlm.nih.gov/22245701 22245701]|[https://pubmed.ncbi.nlm.nih.gov/29751628 29751628]|[https://pubmed.ncbi.nlm.nih.gov/22997242 22997242]|[https://pubmed.ncbi.nlm.nih.gov/15535969 15535969]|[https://pubmed.ncbi.nlm.nih.gov/31911241 31911241]|[https://pubmed.ncbi.nlm.nih.gov/30622255 30622255]|[https://pubmed.ncbi.nlm.nih.gov/29888905 29888905]|[https://pubmed.ncbi.nlm.nih.gov/30236114 30236114]| [https://pubmed.ncbi.nlm.nih.gov/30298790 30298790]|[https://pubmed.ncbi.nlm.nih.gov/29373511 29373511]|[https://pubmed.ncbi.nlm.nih.gov/22298779 22298779]|[https://pubmed.ncbi.nlm.nih.gov/19179461 19179461]|[https://pubmed.ncbi.nlm.nih.gov/31606752 31606752]|[https://pubmed.ncbi.nlm.nih.gov/15653684 15653684]|[https://pubmed.ncbi.nlm.nih.gov/16403022 16403022]|[https://pubmed.ncbi.nlm.nih.gov/11162373 11162373]|[https://pubmed.ncbi.nlm.nih.gov/32005658 32005658]|[https://pubmed.ncbi.nlm.nih.gov/30529570 30529570] <br>
-'''term_xref''' : GlycoEpitope:P0150|CID:25257164|CHEBI:61190|GlycoMotif:GGM.000016 <br>
+ '''definition''' : An amino disaccharide consisting of N-acetylglucosamine having an N-acetylgalactosaminyl resiude attached at the 4-position via a β-linkage.[CHEBI:61190] <br>
-'''best_match''' : GTC:G31736BK|GlycoEpitope:P0150|CID:25257164|CHEBI:61190|GlycoMotif:GGM.000016 <br>
+ '''term_xref''' : GTC:G31736BK|GlycoEpitope:P0150|CID:25257164 25257164|CHEBI:61190|GlycoMotif:GGM.000016  <br>
-'''synonymns''' : LDN <br>
+ '''synonyms''' : LDN <br>
-'''function''' : Has a role of epitope.[CHEBI:61190] <br>
+ '''function''' : Has a role of epitope.[CHEBI:61190] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Lactosylceramide===
-'''term (main_entry)''' : Lactosylceramide <br>
+[[File:G84224TW.png|thumb|G84224TW]]
-'''glycan_dictionary_accession''' : GD000116 <br>
+ '''term (main_entry)''' : Lactosylceramide <br>
-'''glytoucan_accession ''' : G84224TW <br>
+ '''glycan_dictionary_accession''' : GSD000116 <br>
-'''term_in_sentence''' : In the 1970s, a neutral glycosphingolipid lactosylceramide (LacCer) was found to bind specifically to several kinds of microorganisms.[PMID:30175814] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G84224TW G84224TW] <br>
-'''publication''' : 30175814|26900161|30502090|29624959|28444900|25408340|31801289|29099167|25595946|32592089|27729551|24658420|25216636|25638276|9499377|17986153|8143857|23801329|18077097|32708181|15346887|19015977|18393821|25279740|21057870|11915327|25212460|23882130|11915329|8195125|8808768|3396945|22128256|6733104|24968752|32518749|30688114|7666005|8200356|24718572|6193809|25781947|12383912|26086247|30606995|12419803 <br>
+ '''term_in_sentence''' : In the 1970s, a neutral glycosphingolipid lactosylceramide (LacCer) was found to bind specifically to several kinds of microorganisms.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30175814 30175814]] <br>
-'''definition''' : Glycosphingolipids which contain as their polar head group a lactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in lactosylceramide beta-galactosidase, is the cause of lactosylceramidosis.[MeSH:D007790] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30175814 30175814]|[https://pubmed.ncbi.nlm.nih.gov/26900161 26900161]|[https://pubmed.ncbi.nlm.nih.gov/30502090 30502090]|[https://pubmed.ncbi.nlm.nih.gov/29624959 29624959]|[https://pubmed.ncbi.nlm.nih.gov/28444900 28444900]|[https://pubmed.ncbi.nlm.nih.gov/25408340 25408340]|[https://pubmed.ncbi.nlm.nih.gov/31801289 31801289]|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]|[https://pubmed.ncbi.nlm.nih.gov/25595946 25595946]|[https://pubmed.ncbi.nlm.nih.gov/32592089 32592089]|[https://pubmed.ncbi.nlm.nih.gov/27729551 27729551]|[https://pubmed.ncbi.nlm.nih.gov/24658420 24658420]|[https://pubmed.ncbi.nlm.nih.gov/25216636 25216636]|[https://pubmed.ncbi.nlm.nih.gov/25638276 25638276]|[https://pubmed.ncbi.nlm.nih.gov/9499377 9499377]|[https://pubmed.ncbi.nlm.nih.gov/17986153 17986153]|[https://pubmed.ncbi.nlm.nih.gov/8143857 8143857]|[https://pubmed.ncbi.nlm.nih.gov/23801329 23801329]|[https://pubmed.ncbi.nlm.nih.gov/18077097 18077097]|[https://pubmed.ncbi.nlm.nih.gov/32708181 32708181]|[https://pubmed.ncbi.nlm.nih.gov/15346887 15346887]|[https://pubmed.ncbi.nlm.nih.gov/19015977 19015977]|[https://pubmed.ncbi.nlm.nih.gov/18393821 18393821]|[https://pubmed.ncbi.nlm.nih.gov/25279740 25279740]|[https://pubmed.ncbi.nlm.nih.gov/21057870 21057870]|[https://pubmed.ncbi.nlm.nih.gov/11915327 11915327]|[https://pubmed.ncbi.nlm.nih.gov/25212460 25212460]|[https://pubmed.ncbi.nlm.nih.gov/23882130 23882130]|[https://pubmed.ncbi.nlm.nih.gov/11915329 11915329]|[https://pubmed.ncbi.nlm.nih.gov/8195125 8195125]|[https://pubmed.ncbi.nlm.nih.gov/8808768 8808768]|[https://pubmed.ncbi.nlm.nih.gov/3396945 3396945]|[https://pubmed.ncbi.nlm.nih.gov/22128256 22128256]|[https://pubmed.ncbi.nlm.nih.gov/6733104 6733104]|[https://pubmed.ncbi.nlm.nih.gov/24968752 24968752]|[https://pubmed.ncbi.nlm.nih.gov/32518749 32518749]|[https://pubmed.ncbi.nlm.nih.gov/30688114 30688114]|[https://pubmed.ncbi.nlm.nih.gov/7666005 7666005]|[https://pubmed.ncbi.nlm.nih.gov/8200356 8200356]|[https://pubmed.ncbi.nlm.nih.gov/24718572 24718572]|[https://pubmed.ncbi.nlm.nih.gov/6193809 6193809]|[https://pubmed.ncbi.nlm.nih.gov/25781947 25781947]|[https://pubmed.ncbi.nlm.nih.gov/12383912 12383912]|[https://pubmed.ncbi.nlm.nih.gov/26086247 26086247]|[https://pubmed.ncbi.nlm.nih.gov/30606995 30606995]|[https://pubmed.ncbi.nlm.nih.gov/12419803 12419803] <br>
-'''term_xref''' : MeSH:D007790|GlycoMotif:GGM.000064|GlycoEpitope:EP0078|SugarBind_Ligand:3 <br>
+ '''definition''' : Glycosphingolipids which contain as their polar head group a lactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in lactosylceramide beta-galactosidase, is the cause of lactosylceramidosis.[MeSH:D007790] <br>
-'''best_match''' : GTC:G84224TW|MeSH:D007790|GlycoMotif:GGM.000064|GlycoEpitope:EP0078|SugarBind_Ligand:3 <br>
+ '''term_xref''' : GTC:G84224TW|MeSH:D007790|GlycoMotif:GGM.000064|GlycoEpitope:EP0078|SugarBind_Ligand:3 <br>
-'''synonymns''' : LacCer|Lc2|CDH <br>
+ '''synonyms''' : LacCer|Lc2|CDH <br>
-'''function''' : mammalian cell receptors for Neisseria gonorrhoeae recognized by Helicobacter pylori[GlycoEpitope:EP0078] <br>
+ '''function''' : mammalian cell receptors for Neisseria gonorrhoeae recognized by Helicobacter pylori[GlycoEpitope:EP0078] <br>
-'''disease_associations''' : chronic gastritis[GlycoEpitope:EP0078,SugarBind_Ligand:3]|duodenal ulcers[GlycoEpitope:EP0078]|gastric adenocarcinoma[GlycoEpitope:EP0078,SugarBind_Ligand:3]|gastric ulcers[GlycoEpitope:EP0078]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Actinomycosis[SugarBind_Ligand:3]|Pertussis[SugarBind_Ligand:3]|Candidiasis[SugarBind_Ligand:3]|Cryptococcosis[SugarBind_Ligand:3]|Hemorrhagic colitis[SugarBind_Ligand:3]|Peptic ulcers[SugarBind_Ligand:3]|Histoplasmosis[SugarBind_Ligand:3]|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Gonorrhea[SugarBind_Ligand:3]|Sporotrichosis[SugarBind_Ligand:3]|Plague[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br>
+ '''disease_associations''' : chronic gastritis[GlycoEpitope:EP0078,SugarBind_Ligand:3]|duodenal ulcers[GlycoEpitope:EP0078]|gastric adenocarcinoma[GlycoEpitope:EP0078,SugarBind_Ligand:3]|gastric ulcers[GlycoEpitope:EP0078]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Actinomycosis[SugarBind_Ligand:3]|Pertussis[SugarBind_Ligand:3]|Candidiasis[SugarBind_Ligand:3]|Cryptococcosis[SugarBind_Ligand:3]|Hemorrhagic colitis[SugarBind_Ligand:3]|Peptic ulcers[SugarBind_Ligand:3]|Histoplasmosis[SugarBind_Ligand:3]|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Gonorrhea[SugarBind_Ligand:3]|Sporotrichosis[SugarBind_Ligand:3]|Plague[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453033-Chapter 17 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17] <br>
 ===Lactotriaosylceramide===
-'''term (main_entry)''' : Lactotriaosylceramide <br>
+[[File:G06239NA.png|thumb|G06239NA]]
-'''glycan_dictionary_accession''' : GD000117 <br>
+ '''term (main_entry)''' : Lactotriaosylceramide <br>
-'''glytoucan_accession ''' : G06239NA <br>
+ '''glycan_dictionary_accession''' : GSD000117 <br>
-'''term_in_sentence''' : The results showed that AML patients had higher expression of the GSL lactotriaosylceramide (Lc3), GM3 and neolactotetraosylceramide (nLc4) in their bone marrow than did the healthy donors (P < 0.05), especially the M1 subtype of AML.[PMID:22411838] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G06239NA G06239NA] <br>
-'''publication''' : 22411838|20693232|26104834|27435676|26405105|32340400|25241919|23404501|32452379|2960671|272643|27711049|33202844|4060695|27638607|20547865|2277039|6238026|8448388|8489255|9363437|11836161|6892925|1551117|6811267|8059935|7861954|11283017|8514762|1291049|3805024|10816509|12393713|6417117|11054095|8781973|1692829 <br>
+ '''term_in_sentence''' : The results showed that AML patients had higher expression of the GSL lactotriaosylceramide (Lc3), GM3 and neolactotetraosylceramide (nLc4) in their bone marrow than did the healthy donors (P < 0.05), especially the M1 subtype of AML.[PMID:[https://pubmed.ncbi.nlm.nih.gov/22411838 22411838]] <br>
-'''definition''' : A linear amino trisaccharide consisting of β-D-glucose at the reducing end having an N-acetyl-β-D-glucosaminyl-(1→3)-β-D-galactosyl group attached at the 4-position.[CHEBI:61758] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/22411838 22411838]|[https://pubmed.ncbi.nlm.nih.gov/20693232 20693232]|[https://pubmed.ncbi.nlm.nih.gov/26104834 26104834]|[https://pubmed.ncbi.nlm.nih.gov/27435676 27435676]|[https://pubmed.ncbi.nlm.nih.gov/26405105 26405105]|[https://pubmed.ncbi.nlm.nih.gov/32340400 32340400]|[https://pubmed.ncbi.nlm.nih.gov/25241919 25241919]|[https://pubmed.ncbi.nlm.nih.gov/23404501 23404501]|[https://pubmed.ncbi.nlm.nih.gov/32452379 32452379]|[https://pubmed.ncbi.nlm.nih.gov/2960671 2960671]|272643|[https://pubmed.ncbi.nlm.nih.gov/27711049 27711049]|[https://pubmed.ncbi.nlm.nih.gov/33202844 33202844]|[https://pubmed.ncbi.nlm.nih.gov/4060695 4060695]|[https://pubmed.ncbi.nlm.nih.gov/27638607 27638607]|[https://pubmed.ncbi.nlm.nih.gov/20547865 20547865]|[https://pubmed.ncbi.nlm.nih.gov/2277039 2277039]|[https://pubmed.ncbi.nlm.nih.gov/6238026 6238026]|[https://pubmed.ncbi.nlm.nih.gov/8448388 8448388]|[https://pubmed.ncbi.nlm.nih.gov/8489255 8489255]|[https://pubmed.ncbi.nlm.nih.gov/9363437 9363437]|[https://pubmed.ncbi.nlm.nih.gov/11836161 11836161]|[https://pubmed.ncbi.nlm.nih.gov/6892925 6892925]|[https://pubmed.ncbi.nlm.nih.gov/1551117 1551117]|[https://pubmed.ncbi.nlm.nih.gov/6811267 6811267]|[https://pubmed.ncbi.nlm.nih.gov/8059935 8059935]|[https://pubmed.ncbi.nlm.nih.gov/7861954 7861954]|[https://pubmed.ncbi.nlm.nih.gov/11283017 11283017]|[https://pubmed.ncbi.nlm.nih.gov/8514762 8514762]|[https://pubmed.ncbi.nlm.nih.gov/1291049 1291049]|[https://pubmed.ncbi.nlm.nih.gov/3805024 3805024]|[https://pubmed.ncbi.nlm.nih.gov/10816509 10816509]|[https://pubmed.ncbi.nlm.nih.gov/12393713 12393713]|[https://pubmed.ncbi.nlm.nih.gov/6417117 6417117]|[https://pubmed.ncbi.nlm.nih.gov/11054095 11054095]|[https://pubmed.ncbi.nlm.nih.gov/8781973 8781973]|[https://pubmed.ncbi.nlm.nih.gov/1692829 1692829] <br>
-'''term_xref''' : GlycoMotif:GGM.000067|MeSH:C025575|CID:10230777|CHEBI:61758|SugarBind_Ligand:20 <br>
+ '''definition''' : A linear amino trisaccharide consisting of β-D-glucose at the reducing end having an N-acetyl-β-D-glucosaminyl-(1→3)-β-D-galactosyl group attached at the 4-position.[CHEBI:61758] <br>
-'''best_match''' : GTC:G06239NA|GlycoMotif:GGM.000067|MeSH:C025575|CID:10230777|CHEBI:61758|SugarBind_Ligand:20 <br>
+ '''term_xref''' : GTC:G06239NA|GlycoMotif:GGM.000067|MeSH:C025575|CID:10230777|CHEBI:61758|SugarBind_Ligand:20 <br>
-'''synonymns''' : Lc3|Lc(3)Cer|Lc_3 <br>
+ '''synonyms''' : Lc3|Lc(3)Cer|Lc_3 <br>
-'''function''' : acute myeloid leukemia-associated glycosphingolipids lactotriaosylceramide, GM3 and neolactotetraosylceramide are possibly involved in initiation and differentiation of acute myeloid leukemia.[PMID:22411838] <br>
+ '''function''' : acute myeloid leukemia-associated glycosphingolipids lactotriaosylceramide, GM3 and neolactotetraosylceramide are possibly involved in initiation and differentiation of acute myeloid leukemia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/22411838 22411838]] <br>
-'''disease_associations''' : Pharyngitis[SugarBind_Ligand:20]|Tracheobronchitis[SugarBind_Ligand:20]|Gonorrhea[SugarBind_Ligand:20]|Actinomycosis[SugarBind_Ligand:20]|Diarrhea[SugarBind_Ligand:20] <br>
+ '''disease_associations''' : Pharyngitis[SugarBind_Ligand:20]|Tracheobronchitis[SugarBind_Ligand:20]|Gonorrhea[SugarBind_Ligand:20]|Actinomycosis[SugarBind_Ligand:20]|Diarrhea[SugarBind_Ligand:20] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
 ===LcGg4===
-'''term (main_entry)''' : LcGg4 <br>
+[[File:G62554JH.png|thumb|G62554JH]]
-'''glycan_dictionary_accession''' : GD000118 <br>
+ '''term (main_entry)''' : LcGg4 <br>
-'''glytoucan_accession ''' : G62554JH <br>
+ '''glycan_dictionary_accession''' : GSD000118 <br>
-'''term_in_sentence''' : Murine leukemia cells (M1), in their undifferentiated state, have been characterized by the presence of cancer-associated lactoganglio-series glycolipids, one of which was identified as lactogangliotetraosylceramide (LcGg4) having a novel branching at the II-Gal of lactosylceramide through GlcNAc beta 1----3 and GalNAc beta 1----4 linkage, as shown below (Kannagi, R., Levery, S.B., and Hakomori, S. (1984) J. Biol. Chem., 259, 8444-8451): GalNAc beta 1----4 Gal beta 1----4Glc beta 1----1Cer GlcNac beta 1----3 [PMID: 3805024] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G62554JH G62554JH] <br>
-'''publication''' : 3805024|33395290 <br>
+ '''term_in_sentence''' : Murine leukemia cells (M1), in their undifferentiated state, have been characterized by the presence of cancer-associated lactoganglio-series glycolipids, one of which was identified as lactogangliotetraosylceramide (LcGg4) having a novel branching at the II-Gal of lactosylceramide through GlcNAc beta 1----3 and GalNAc beta 1----4 linkage, as shown below (Kannagi, R., Levery, S.B., and Hakomori, S. (1984) J. Biol. Chem., 259, 8444-8451): GalNAc beta 1----4 Gal beta 1----4Glc beta 1----1Cer GlcNac beta 1----3 [PMID: [https://pubmed.ncbi.nlm.nih.gov/3805024 3805024]] <br>
-'''definition''' : N-[(2S,3R,4R,5R,6R)-2-[(2R,3S,4R,5R,6S)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide is an oligosaccharide.[CHEBI:152521] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3805024 3805024]|[https://pubmed.ncbi.nlm.nih.gov/33395290 33395290] <br>
-'''term_xref''' : GlycoMotif:GGM.000075|CID:91850076|CHEBI:152521|GlycoEpitope:EP0035 <br>
+ '''definition''' : N-[(2S,3R,4R,5R,6R)-2-[(2R,3S,4R,5R,6S)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide is an oligosaccharide.[CHEBI:152521] <br>
-'''best_match''' : GlycoMotif:GGM.000075|GTC:G62554JH|CID:91850076|CHEBI:152521|GlycoEpitope:EP0035 <br>
+ '''term_xref''' : GlycoMotif:GGM.000075|GTC:G62554JH|CID:91850076|CHEBI:152521|GlycoEpitope:EP0035 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
 ===Lewis a===
-'''term (main_entry)''' : Lewis a <br>
+[[File:G00047MO.png|thumb|G00047MO]]
-'''glycan_dictionary_accession''' : GD000119 <br>
+ '''term (main_entry)''' : Lewis a <br>
-'''glytoucan_accession ''' : G00047MO <br>
+ '''glycan_dictionary_accession''' : GSD000119 <br>
-'''term_in_sentence''' : Regardless of the vaccine administered, significantly fewer of the children with Lewis A phenotype (0/14) seroconverted after receiving the first vaccine dose compared to 26% (45/175) of those with the Lewis B phenotype and 32% (15/47) of the Lewis negative individuals (P < 0.01). [PMID:29367698] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00047MO G00047MO] <br>
-'''publication''' : 29367698|27187324|30562693|27646625|26911286|30225822|28600306|32527016|2385097|11064310|23809433|30050155|1615929|29527514|9207264|1675497|3677023|27705835|7593252|2579997|17630273|9350993|9098001 <br>
+ '''term_in_sentence''' : Regardless of the vaccine administered, significantly fewer of the children with Lewis A phenotype (0/14) seroconverted after receiving the first vaccine dose compared to 26% (45/175) of those with the Lewis B phenotype and 32% (15/47) of the Lewis negative individuals (P < 0.01). [PMID:[https://pubmed.ncbi.nlm.nih.gov/29367698 29367698]] <br>
-'''definition''' : A lewis blood group antigen with structure beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an alpha-linkage and a galactosyl residue attached at the 3-position via a beta-linkage. It has a role as an epitope and an antigen. It is an amino trisaccharide and a glucosamine oligosaccharide.[CHEBI:62265] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29367698 29367698]|[https://pubmed.ncbi.nlm.nih.gov/27187324 27187324]|[https://pubmed.ncbi.nlm.nih.gov/30562693 30562693]| [https://pubmed.ncbi.nlm.nih.gov/27646625 27646625]|[https://pubmed.ncbi.nlm.nih.gov/26911286 26911286]|[https://pubmed.ncbi.nlm.nih.gov/30225822 30225822]|[https://pubmed.ncbi.nlm.nih.gov/28600306 28600306]|[https://pubmed.ncbi.nlm.nih.gov/32527016 32527016]| [https://pubmed.ncbi.nlm.nih.gov/2385097 2385097]|[https://pubmed.ncbi.nlm.nih.gov/11064310 11064310]|[https://pubmed.ncbi.nlm.nih.gov/23809433 23809433]|[https://pubmed.ncbi.nlm.nih.gov/30050155 30050155]|[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]| [https://pubmed.ncbi.nlm.nih.gov/29527514 29527514]| [https://pubmed.ncbi.nlm.nih.gov/9207264 9207264]|[https://pubmed.ncbi.nlm.nih.gov/1675497 1675497]| [https://pubmed.ncbi.nlm.nih.gov/3677023 3677023]|[https://pubmed.ncbi.nlm.nih.gov/27705835 27705835]|[https://pubmed.ncbi.nlm.nih.gov/7593252 7593252]| [https://pubmed.ncbi.nlm.nih.gov/2579997 2579997]|[https://pubmed.ncbi.nlm.nih.gov/17630273 17630273]|[https://pubmed.ncbi.nlm.nih.gov/9350993 9350993]|[https://pubmed.ncbi.nlm.nih.gov/9098001 9098001] <br>
-'''term_xref''' : CID:22806751|CHEBI:62265|GlycoMotif:GGM.000020|SugarBind_Ligand:155 <br>
+ '''definition''' : A lewis blood group antigen with structure beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an alpha-linkage and a galactosyl residue attached at the 3-position via a beta-linkage. It has a role as an epitope and an antigen. It is an amino trisaccharide and a glucosamine oligosaccharide.[CHEBI:62265] <br>
-'''best_match''' : GTC:G00047MO|CID:22806751|CHEBI:62265|GlycoMotif:GGM.000020|SugarBind_Ligand:155 <br>
+ '''term_xref''' : GTC:G00047MO|CID:22806751|CHEBI:62265|GlycoMotif:GGM.000020|SugarBind_Ligand:155 <br>
-'''synonymns''' : Le(a)|Lea-3|Lea|Le^a <br>
+ '''synonyms''' : Le(a)|Lea-3|Lea|Le^a <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:155] <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:155] <br>
-'''wikipedia''' : https://www.wikidata.org/wiki/Q50687009 <br>
+ '''wikipedia''' : https://www.wikidata.org/wiki/Q50687009] <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Lewis b===
-'''term (main_entry)''' : Lewis b <br>
+[[File:G39211DH.png|thumb|G39211DH]]
-'''glycan_dictionary_accession''' : GD000120 <br>
+ '''term (main_entry)''' : Lewis b <br>
-'''glytoucan_accession ''' : G39211DH <br>
+ '''glycan_dictionary_accession''' : GSD000120 <br>
-'''term_in_sentence''' : Human mannose-binding lectin preferentially binds to human colon adenocarcinoma cell lines expressing high amount of Lewis A and Lewis B antigens.[PMID:10328552] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G39211DH G39211DH] <br>
-'''publication''' : 10328552|23408949|31927399|26601230|28279343|32527016|30831115|27318698|9207264|23828675|29527514|1615929|2385097|2579997|25516619|3677023|8509439|19832116|15270746|3166398|30909206|7718581|18400963|29751628|8982241|30284922|24576035|30974776|9098001|31768613|1651804|25428879|15946883|30298790|30544260|29197783|8632739|7679772|18666312|20231766|29922666|95124|2247887|21519121|25153235|28751211 <br>
+ '''term_in_sentence''' : Human mannose-binding lectin preferentially binds to human colon adenocarcinoma cell lines expressing high amount of Lewis A and Lewis B antigens.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10328552 10328552]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10328552 10328552]|[https://pubmed.ncbi.nlm.nih.gov/23408949 23408949]|[https://pubmed.ncbi.nlm.nih.gov/31927399 31927399]|[https://pubmed.ncbi.nlm.nih.gov/26601230 26601230]|[https://pubmed.ncbi.nlm.nih.gov/28279343 28279343]|[https://pubmed.ncbi.nlm.nih.gov/32527016 32527016]|[https://pubmed.ncbi.nlm.nih.gov/30831115 30831115]|[https://pubmed.ncbi.nlm.nih.gov/27318698 27318698]|[https://pubmed.ncbi.nlm.nih.gov/9207264 9207264]|[https://pubmed.ncbi.nlm.nih.gov/23828675 23828675]| [https://pubmed.ncbi.nlm.nih.gov/29527514 29527514]|[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]|[https://pubmed.ncbi.nlm.nih.gov/2385097 2385097]|[https://pubmed.ncbi.nlm.nih.gov/2579997 2579997]|[https://pubmed.ncbi.nlm.nih.gov/25516619 25516619]|[https://pubmed.ncbi.nlm.nih.gov/3677023 3677023]|[https://pubmed.ncbi.nlm.nih.gov/8509439 8509439]|[https://pubmed.ncbi.nlm.nih.gov/19832116 19832116]|[https://pubmed.ncbi.nlm.nih.gov/15270746 15270746]|[https://pubmed.ncbi.nlm.nih.gov/3166398 3166398]|[https://pubmed.ncbi.nlm.nih.gov/30909206 30909206]|[https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]|[https://pubmed.ncbi.nlm.nih.gov/18400963 18400963]| [https://pubmed.ncbi.nlm.nih.gov/29751628 29751628]|[https://pubmed.ncbi.nlm.nih.gov/8982241 8982241]|[https://pubmed.ncbi.nlm.nih.gov/30284922 30284922]|[https://pubmed.ncbi.nlm.nih.gov/24576035 24576035]|[https://pubmed.ncbi.nlm.nih.gov/30974776 30974776]| [https://pubmed.ncbi.nlm.nih.gov/9098001 9098001]|[https://pubmed.ncbi.nlm.nih.gov/31768613 31768613]|[https://pubmed.ncbi.nlm.nih.gov/1651804 1651804]|[https://pubmed.ncbi.nlm.nih.gov/25428879 25428879]|[https://pubmed.ncbi.nlm.nih.gov/15946883 15946883]|[https://pubmed.ncbi.nlm.nih.gov/30298790 30298790]|[https://pubmed.ncbi.nlm.nih.gov/30544260 30544260]|[https://pubmed.ncbi.nlm.nih.gov/29197783 29197783]|[https://pubmed.ncbi.nlm.nih.gov/8632739 8632739]|[https://pubmed.ncbi.nlm.nih.gov/7679772 7679772]|[https://pubmed.ncbi.nlm.nih.gov/18666312 18666312]|[https://pubmed.ncbi.nlm.nih.gov/20231766 20231766]|[https://pubmed.ncbi.nlm.nih.gov/29922666 29922666]|[https://pubmed.ncbi.nlm.nih.gov/95124 95124]|[https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]|[https://pubmed.ncbi.nlm.nih.gov/21519121 21519121]|[https://pubmed.ncbi.nlm.nih.gov/25153235 25153235]|[https://pubmed.ncbi.nlm.nih.gov/28751211 28751211] <br>
-'''term_xref''' : GlycoMotif:GGM.000021|SugarBind_Ligand:146|CID:45480568|CHEBI:59440 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000021|SugarBind_Ligand:146|GTC:G39211DH|CID:45480568|CHEBI:59440 <br>
+ '''term_xref''' : GlycoMotif:GGM.000021|SugarBind_Ligand:146|GTC:G39211DH|CID: 45480568|CHEBI:59440 <br>
-'''synonymns''' : Le(b)|Lewis(b)|Le^b <br>
+ '''synonyms''' : Le(b)|Lewis(b)|Le^b <br>
-'''function''' : possible receptor for Helicobacter pylori[https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/blood-group-lewis-system] <br>
+ '''function''' : possible receptor for Helicobacter pylori[https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/blood-group-lewis-system<nowiki>] </nowiki><br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:146] <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:146] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Lewis x===
-'''term (main_entry)''' : Lewis x <br>
+[[File:G00051MO.png|thumb|G00051MO]]
-'''glycan_dictionary_accession''' : GD000121 <br>
+ '''term (main_entry)''' : Lewis x <br>
-'''glytoucan_accession ''' : G00051MO <br>
+ '''glycan_dictionary_accession''' : GSD000121 <br>
-'''term_in_sentence''' : In particular, the observation of oxonium ions at m/z 512.2 and 803.2 is useful for probing outer non-reducing terminal fucosylation, which represented carbohydrate structures consisting of Hex Hex , dHex Hex , and HexNAc , and NeuNAc , Hex Hex , dHex Hex , and HexNAc , respectively, from which the Lewis X structure (Galbeta1-4(Fucalpha1-3)GlcNAc) was readily deduced.[PMID:15536627] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00051MO G00051MO] <br>
-'''publication''' : 15536627|31666308|29019053|28296340|29593094|17607374|16581086|20858014|19962782|7912739|25121780|24059473|29210428|31276881|9015359|7628844|7499837|16850248|28425129|28869691|19576189|10223649|22593503|15632313|27198630|26582608|11500392|31256373|23399157|21984435|26244810|26162743|17335083|15388363|9556613|10760152|11267844|20876654|12131290 <br>
+ '''term_in_sentence''' : In particular, the observation of oxonium ions at m/z 512.2 and 803.2 is useful for probing outer non-reducing terminal fucosylation, which represented carbohydrate structures consisting of Hex Hex , dHex Hex , and HexNAc , and NeuNAc , Hex Hex , dHex Hex , and HexNAc , respectively, from which the Lewis X structure (Galbeta1-4(Fucalpha1-3)GlcNAc) was readily deduced.[PMID:[https://pubmed.ncbi.nlm.nih.gov/15536627 15536627]] <br>
-'''definition''' : A Lewis blood group antigen with structure α-L-Fucp-(1→3)-[β-D-Galp-(1→4)]-D-GlcpNAc where the glucosamine at the reducing end has β-configuration at its anomeric centre. Commonly known as Lewis x trisaccharide or Lex.[CHEBI:59294] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15536627 15536627]|[https://pubmed.ncbi.nlm.nih.gov/31666308 31666308]|[https://pubmed.ncbi.nlm.nih.gov/29019053 29019053]|[https://pubmed.ncbi.nlm.nih.gov/28296340 28296340]|[https://pubmed.ncbi.nlm.nih.gov/29593094 29593094]|[https://pubmed.ncbi.nlm.nih.gov/17607374 17607374]|[https://pubmed.ncbi.nlm.nih.gov/16581086 16581086]|[https://pubmed.ncbi.nlm.nih.gov/20858014 20858014]|[https://pubmed.ncbi.nlm.nih.gov/19962782 19962782]|[https://pubmed.ncbi.nlm.nih.gov/7912739 7912739]|[https://pubmed.ncbi.nlm.nih.gov/25121780 25121780]|[https://pubmed.ncbi.nlm.nih.gov/24059473 24059473]|[https://pubmed.ncbi.nlm.nih.gov/29210428 29210428]|[https://pubmed.ncbi.nlm.nih.gov/31276881 31276881]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/7628844 7628844]|[https://pubmed.ncbi.nlm.nih.gov/7499837 7499837]|[https://pubmed.ncbi.nlm.nih.gov/16850248 16850248]|[https://pubmed.ncbi.nlm.nih.gov/28425129 28425129]|[https://pubmed.ncbi.nlm.nih.gov/28869691 28869691]|[https://pubmed.ncbi.nlm.nih.gov/19576189 19576189]|[https://pubmed.ncbi.nlm.nih.gov/10223649 10223649]|[https://pubmed.ncbi.nlm.nih.gov/22593503 22593503]|[https://pubmed.ncbi.nlm.nih.gov/15632313 15632313]|[https://pubmed.ncbi.nlm.nih.gov/27198630 27198630]|[https://pubmed.ncbi.nlm.nih.gov/26582608 26582608]|[https://pubmed.ncbi.nlm.nih.gov/11500392 11500392]|[https://pubmed.ncbi.nlm.nih.gov/31256373 31256373]|[https://pubmed.ncbi.nlm.nih.gov/23399157 23399157]|[https://pubmed.ncbi.nlm.nih.gov/21984435 21984435]|[https://pubmed.ncbi.nlm.nih.gov/26244810 26244810]|[https://pubmed.ncbi.nlm.nih.gov/26162743 26162743]|[https://pubmed.ncbi.nlm.nih.gov/17335083 17335083]|[https://pubmed.ncbi.nlm.nih.gov/15388363 15388363]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/10760152 10760152]|[https://pubmed.ncbi.nlm.nih.gov/11267844 11267844]|[https://pubmed.ncbi.nlm.nih.gov/20876654 20876654]|[https://pubmed.ncbi.nlm.nih.gov/12131290 12131290] <br>
-'''term_xref''' : GlycoEpitope:EP0011|CID:44611539|CHEBI:59294|GlycoMotif:GGM.000018 <br>
+ '''definition''' : A Lewis blood group antigen with structure α-L-Fucp-(1→3)-[β-D-Galp-(1→4)]-D-GlcpNAc where the glucosamine at the reducing end has β-configuration at its anomeric centre. Commonly known as Lewis x trisaccharide or Lex.[CHEBI:59294] <br>
-'''best_match''' : GTC:G00051MO |GlycoEpitope:EP0011|CID:44611539|CHEBI:59294|GlycoMotif:GGM.000018 <br>
+ '''term_xref''' : GTC:G00051MO |GlycoEpitope:EP0011|CID:[https://pubmed.ncbi.nlm.nih.gov/44611539 44611539]|CHEBI:59294|GlycoMotif:GGM.000018  <br>
-'''synonymns''' : Lex|Galbeta1-4(Fucalpha1-3)GlcNAc|Lewis x trisaccharide|Le(X)|Le^x|SSEA-1 <br>
+ '''synonyms''' : Lex|Galbeta1-4(Fucalpha1-3)GlcNAc|Lewis x trisaccharide|Le(X)|Le^x|SSEA-1 <br>
-'''function''' : Involved in carbohydrate-carbohydrate interaction[Glycoepitope:EP0011].|Also implicated in apoptosis.[Glycoepitope:EP0011]|influence antigenic presentation and interfere with pathogen transfer in breastfed infants.[Glycoepitope:EP0011] <br>
+ '''function''' : Involved in carbohydrate-carbohydrate interaction[Glycoepitope:EP0011].|Also implicated in apoptosis.[Glycoepitope:EP0011]|influence antigenic presentation and interfere with pathogen transfer in breastfed infants.[Glycoepitope:EP0011] <br>
-'''disease_associations''' : acute leukemia[GlycoEpitope:EP0011]|lymphoma[GlycoEpitope:EP0011] <br>
+ '''disease_associations''' : acute leukemia[GlycoEpitope:EP0011]|lymphoma[GlycoEpitope:EP0011] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
 ===Lewis y===
-'''term (main_entry)''' : Lewis y <br>
+[[File:G00052MO.png|alt=|thumb|G00052MO]]
-'''glycan_dictionary_accession''' : GD000122 <br>
+ '''term (main_entry)''' : Lewis y <br>
-'''glytoucan_accession ''' : G00052MO <br>
+ '''glycan_dictionary_accession''' : GSD000122 <br>
-'''term_in_sentence''' : In conclusion, Lewis y antigen and CD147 were significantly upregulated in ovarian tumors, and the altered expression of Lewis y may cause changes in CD147.[PMID:30816446] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00052MO G00052MO] <br>
-'''publication''' : 30816446|20003467|24692145|24998328|25726913|29299130|30816446|20003467|24692145|24998328|20127027|22138668|23894390|25726913|25416440|27646625|23725446|21294926|22312289|25973320|23242548|30328452|21119363|29130097|23443083|23708102|28671040|19715603|23468946|27723168|21747684|19771739 <br>
+ '''term_in_sentence''' : In conclusion, Lewis y antigen and CD147 were significantly upregulated in ovarian tumors, and the altered expression of Lewis y may cause changes in CD147.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30816446 30816446]] <br>
-'''definition''' : A Lewis blood group antigen which is a branched amino tetrasaccharide with structure alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc, consisting of consisting of N-acetyl-beta-D-glucosamine at the reducing end having an alpha-L-fucosyl residue attached at the 3-position and an alpha-L-fucosyl-(1→2)-beta-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure. It has a role as an antigen and an epitope. [CHEBI:59045]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30816446 30816446]]|[https://pubmed.ncbi.nlm.nih.gov/20003467 20003467]| [https://pubmed.ncbi.nlm.nih.gov/24692145 24692145]| [https://pubmed.ncbi.nlm.nih.gov/24998328 24998328]|[https://pubmed.ncbi.nlm.nih.gov/25726913 25726913]|[https://pubmed.ncbi.nlm.nih.gov/29299130 29299130]|[https://pubmed.ncbi.nlm.nih.gov/30816446 30816446]| [https://pubmed.ncbi.nlm.nih.gov/20003467 20003467]|[https://pubmed.ncbi.nlm.nih.gov/24692145 24692145]| [https://pubmed.ncbi.nlm.nih.gov/24998328 24998328]|[https://pubmed.ncbi.nlm.nih.gov/20127027 20127027]|[https://pubmed.ncbi.nlm.nih.gov/22138668 22138668]|[https://pubmed.ncbi.nlm.nih.gov/23894390 23894390]| [https://pubmed.ncbi.nlm.nih.gov/25726913 25726913]|[https://pubmed.ncbi.nlm.nih.gov/25416440 25416440]|[https://pubmed.ncbi.nlm.nih.gov/27646625 27646625]|[https://pubmed.ncbi.nlm.nih.gov/23725446 23725446]|[https://pubmed.ncbi.nlm.nih.gov/21294926 21294926]|[https://pubmed.ncbi.nlm.nih.gov/22312289 22312289]|[https://pubmed.ncbi.nlm.nih.gov/25973320 25973320]|[https://pubmed.ncbi.nlm.nih.gov/23242548 23242548]|[https://pubmed.ncbi.nlm.nih.gov/30328452 30328452]|[https://pubmed.ncbi.nlm.nih.gov/21119363 21119363]|[https://pubmed.ncbi.nlm.nih.gov/29130097 29130097]|[https://pubmed.ncbi.nlm.nih.gov/23443083 23443083]|[https://pubmed.ncbi.nlm.nih.gov/23708102 23708102]|[https://pubmed.ncbi.nlm.nih.gov/28671040 28671040]|[https://pubmed.ncbi.nlm.nih.gov/19715603 19715603]|[https://pubmed.ncbi.nlm.nih.gov/23468946 23468946]|[https://pubmed.ncbi.nlm.nih.gov/27723168 27723168]|[https://pubmed.ncbi.nlm.nih.gov/21747684 21747684]|[https://pubmed.ncbi.nlm.nih.gov/19771739 19771739] <br>
-'''term_xref''' : GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000019 <br>
+ '''definition''' : A Lewis blood group antigen which is a branched amino tetrasaccharide with structure alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc, consisting of consisting of N-acetyl-beta-D-glucosamine at the reducing end having an alpha-L-fucosyl residue attached at the 3-position and an alpha-L-fucosyl-(1→2)-beta-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure. It has a role as an antigen and an epitope. [CHEBI:59045] <br>
-'''best_match''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000019 <br>
+ '''term_xref''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000019 <br>
-'''synonymns''' : LeY|Le(y)|Ley|Le^y <br>
+ '''synonyms''' : LeY|Le(y)|Ley|Le^y <br>
-'''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
+ '''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
-'''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018] <br>
+ '''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
 ===Monosialylated===
-'''term (main_entry)''' : Monosialylated <br>
+ '''term (main_entry)''' : Monosialylated <br>
-'''glycan_dictionary_accession''' : GD000123 <br>
+ '''glycan_dictionary_accession''' : GSD000123 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The structures of the asparagine-linked sugar chains of U- CD59 were biantennary complex type , only 4.2% of which are monosialylated.[PMID:7514386] <br>
+ '''term_in_sentence''' : The structures of the asparagine-linked sugar chains of U- CD59 were biantennary complex type , only 4.2% of which are monosialylated.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7514386 7514386]] <br>
-'''publication''' : 7514386|8477709|8942648|29752599|31669586|29747818|16425369|12089170|31390883|1632647|29733234|31110965|31566965|30555678|28263871|29652662|25915761|16381065|29247593|28370937|23896595|26633899|32155999|25261856|2737211|26945091|27065039|26784838|26582205 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7514386 7514386]|[https://pubmed.ncbi.nlm.nih.gov/8477709 8477709]|[https://pubmed.ncbi.nlm.nih.gov/8942648 8942648]|[https://pubmed.ncbi.nlm.nih.gov/29752599 29752599]|[https://pubmed.ncbi.nlm.nih.gov/31669586 31669586]|[https://pubmed.ncbi.nlm.nih.gov/29747818 29747818]|[https://pubmed.ncbi.nlm.nih.gov/16425369 16425369]|[https://pubmed.ncbi.nlm.nih.gov/12089170 12089170]|[https://pubmed.ncbi.nlm.nih.gov/31390883 31390883]|[https://pubmed.ncbi.nlm.nih.gov/1632647 1632647]|[https://pubmed.ncbi.nlm.nih.gov/29733234 29733234]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/30555678 30555678]|[https://pubmed.ncbi.nlm.nih.gov/28263871 28263871]|[https://pubmed.ncbi.nlm.nih.gov/29652662 29652662]|[https://pubmed.ncbi.nlm.nih.gov/25915761 25915761]|[https://pubmed.ncbi.nlm.nih.gov/16381065 16381065]|[https://pubmed.ncbi.nlm.nih.gov/29247593 29247593]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/23896595 23896595]|[https://pubmed.ncbi.nlm.nih.gov/26633899 26633899]|[https://pubmed.ncbi.nlm.nih.gov/32155999 32155999]|[https://pubmed.ncbi.nlm.nih.gov/25261856 25261856]|[https://pubmed.ncbi.nlm.nih.gov/2737211 2737211]|[https://pubmed.ncbi.nlm.nih.gov/26945091 26945091]|[https://pubmed.ncbi.nlm.nih.gov/27065039 27065039]|[https://pubmed.ncbi.nlm.nih.gov/26784838 26784838]|[https://pubmed.ncbi.nlm.nih.gov/26582205 26582205] <br>
-'''definition''' : A glycan that have the addition of one sialic acid residues. <br>
+ '''definition''' : A glycan that have the addition of one sialic acid residues. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' : appears in bovine brain gangliosides.[PMID: [https://pubmed.ncbi.nlm.nih.gov/29752599 29752599]] <br>
-'''function''' : appears in bovine brain gangliosides.[PMID: 29752599] <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Monosialyl-biantennary===
-'''term (main_entry)''' : Monosialyl-biantennary <br>
+ '''term (main_entry)''' : Monosialyl-biantennary <br>
-'''glycan_dictionary_accession''' : GD000124 <br>
+ '''glycan_dictionary_accession''' : GSD000124 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In contrast, the sugar chain structure of HCC highly specific AFP isoform was found to comprise a monosialyl-biantennary sugar chain with additional fucosylation of the proximal N-acetylglucosamine.[PMID:7686446] <br>
+ '''term_in_sentence''' : In contrast, the sugar chain structure of HCC highly specific AFP isoform was found to comprise a monosialyl-biantennary sugar chain with additional fucosylation of the proximal N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7686446 7686446]] <br>
-'''publication''' : 7686446|1374031|9648261|10460833|19524219|10207016|15797573|15218190 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7686446 7686446]|[https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]|[https://pubmed.ncbi.nlm.nih.gov/9648261 9648261]|[https://pubmed.ncbi.nlm.nih.gov/10460833 10460833]|[https://pubmed.ncbi.nlm.nih.gov/19524219 19524219]|[https://pubmed.ncbi.nlm.nih.gov/10207016 10207016]|[https://pubmed.ncbi.nlm.nih.gov/15797573 15797573]|[https://pubmed.ncbi.nlm.nih.gov/15218190 15218190] <br>
-'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+  '''synonyms''' : monosialyl biantennary|sialylated diantennary|sialylated biantennary <br>
-'''synonymns''' : monosialyl biantennary|sialylated diantennary|sialylated biantennary <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Monosialyl-Gb5===
-'''term (main_entry)''' : Monosialyl-Gb5 <br>
+[[File:G32254QI.png|thumb|G32254QI]]
-'''glycan_dictionary_accession''' : GD000125 <br>
+ '''term (main_entry)''' : Monosialyl-Gb5 <br>
-'''glytoucan_accession ''' : G32254QI <br>
+ '''glycan_dictionary_accession''' : GSD000125 <br>
-'''term_in_sentence''' : Thus, malignancy of MCF-7 is highly dependent on monosialyl-Gb5, and its activation of cSrc and FAK in GEM.[PMID:12401210] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G32254QI G32254QI] <br>
-'''publication''' : 12401210|16995838|27318475 <br>
+ '''term_in_sentence''' : Thus, malignancy of MCF-7 is highly dependent on monosialyl-Gb5, and its activation of cSrc and FAK in GEM.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]] <br>
-'''definition''' : alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp is a linear amino hexasaccharide comprising β-D-glucose at the reducing end with at the 4-position a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety, α(2→3)-sialylated at the terminal galactosyl residue.[CHEBI:62313] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]|[https://pubmed.ncbi.nlm.nih.gov/16995838 16995838]|[https://pubmed.ncbi.nlm.nih.gov/27318475 27318475] <br>
-'''term_xref''' : GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID:73427363|CHEBI:62313 <br>
+ '''definition''' : alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp is a linear amino hexasaccharide comprising β-D-glucose at the reducing end with at the 4-position a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety, α(2→3)-sialylated at the terminal galactosyl residue.[CHEBI:62313] <br>
-'''best_match''' : GTC:G32254QI|GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID:73427363|CHEBI:62313 <br>
+ '''term_xref''' : GTC:G32254QI|GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID:73427363|CHEBI:62313 <br>
-'''synonymns''' : GL-7 globoseries ganglioside (SSEA-4)|Monosialyl Gb5|Sialosyl galactosyl globoside|GL-7 globoseries ganglioside|SSEA-4 <br>
+ '''synonyms''' : GL-7 globoseries ganglioside (SSEA-4)|Monosialyl Gb5|Sialosyl galactosyl globoside|GL-7 globoseries ganglioside|SSEA-4 <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0099] <br>
+ '''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0099] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Mono-sulfated globopentaosylceramide===
-'''term (main_entry)''' : Mono-sulfated globopentaosylceramide <br>
+[[File:G80193TN.png|thumb|G80193TN]]
-'''glycan_dictionary_accession''' : GD000126 <br>
+ '''term (main_entry)''' : Mono-sulfated globopentaosylceramide <br>
-'''glytoucan_accession ''' : G80193TN <br>
+ '''glycan_dictionary_accession''' : GSD000126 <br>
-'''term_in_sentence''' : Mono-sulfated Globopentaosylceramide from HumanKidney.[PMID:2777788] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80193TN G80193TN] <br>
-'''publication''' : 2777788 <br>
+ '''term_in_sentence''' : Mono-sulfated globopentaosylceramide from human kidney.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2777788 2777788]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2777788 2777788] <br>
-'''term_xref''' : GlycoMotif:GGM.000072 <br>
+ '''definition''' :  <br>
-'''best_match''' : GTC:G80193TN <br>
+ '''term_xref''' : GlycoMotif:GGM.000072|GTC:G80193TN <br>
-'''synonymns''' : Monosulfated globopentaosylceramide <br>
+ '''synonyms''' : Monosulfated globopentaosylceramide <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Mono-sulfated globotetraosylceramide===
-'''term (main_entry)''' : Mono-sulfated globotetraosylceramide <br>
+[[File:G05297EK.png|thumb|G05297EK]]
-'''glycan_dictionary_accession''' : GD000127 <br>
+ '''term (main_entry)''' : Mono-sulfated globotetraosylceramide <br>
-'''glytoucan_accession ''' : G05297EK <br>
+ '''glycan_dictionary_accession''' : GSD000127 <br>
-'''term_in_sentence''' : Mono-sulfated globotetraosylceramide from human kidney.[PMID:2559078] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G05297EK G05297EK] <br>
-'''publication''' : 2559078 <br>
+ '''term_in_sentence''' : Mono-sulfated globotetraosylceramide from human kidney.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2559078 2559078]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2559078 2559078] <br>
-'''term_xref''' : GlycoMotif:GGM.000073 <br>
+ '''definition''' :  <br>
-'''best_match''' : GTC:G05297EK <br>
+ '''term_xref''' : GlycoMotif:GGM.000073|GTC:G05297EK<br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===N-acetyl GM2===
-'''term (main_entry)''' : N-acetyl GM2 <br>
+ '''term (main_entry)''' : N-acetyl GM2 <br>
-'''glycan_dictionary_accession''' : GD000128 <br>
+ '''glycan_dictionary_accession''' : GSD000128 <br>
-'''glytoucan_accession ''' : G79389NT <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79389NT G79389NT] <br>
-'''term_in_sentence''' : The appearance of the N-acetyl GM2 antigen correlated well with the degree of differentiation of the cancer cells in patients with squamous cell carcinoma and adenocarcinoma of the lung.[PMID:3167861] <br>
+ '''term_in_sentence''' : The appearance of the N-acetyl GM2 antigen correlated well with the degree of differentiation of the cancer cells in patients with squamous cell carcinoma and adenocarcinoma of the lung.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]] <br>
-'''publication''' : 3167861|2153431|25673107 <br>
+ '''publication''' :[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]|[https://pubmed.ncbi.nlm.nih.gov/2153431 2153431]| [https://pubmed.ncbi.nlm.nih.gov/25673107 25673107] <br>
-'''definition''' : beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp is a branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
+ '''definition''' : beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp is a branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
-'''term_xref''' : GlycoEpitope:EP0051|CID:45266845|CHEBI:59220 <br>
+ '''term_xref''' : GTC:G79389NT|GlycoEpitope:EP0051|CID: 45266845|CHEBI:59220 <br>
-'''best_match''' : GTC:G79389NT|GlycoEpitope:EP0051|CID:45266845|CHEBI:59220 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' : The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.[CHEBI:59220] <br>
-'''function''' : The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.[CHEBI:59220] <br>
+ '''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051] <br>
-'''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===N-acetyllactosamine (Type 1)===
+[[File:G00056MO.png|alt=|thumb|G00056MO]]
+ '''term (main_entry)''' : N-acetyllactosamine (Type 1)<br>
+ '''glycan_dictionary_accession''' : GSD000181<br>
+ '''glytoucan_accession ''' : [https://glygen.org/glycan/G00056MO G00056MO]<br>
+ '''term_in_sentence''' : The N-acetyllactosamine type 1 (LacNAc type 1, Galβ1,3GlcNAc) is a well-known precursor of several important blood group epitopes, such as Lewis A, Lewis B, or sialyl Lewis A [1], which are involved in many biological processes, e.g., fertilization [2] and pathogen adhesion [3]. [PMID:[https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]]<br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]|[https://pubmed.ncbi.nlm.nih.gov/28167527 28167527]<br>
+ '''definition''' : <br>
+ '''term_xref''' : GTC:G00056MO|GlycoMotif:GGM.000005<br>
+ '''synonyms''' : LacNAc type 1|Type 1 LN|Type-1 lactosamine<br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :<br>
-===N-acetyllactosamine===
+===N-acetyllactosamine (Type 2)===
-'''term (main_entry)''' : N-acetyllactosamine <br>
+[[File:G00055MO.png|thumb|G00055MO]]
-'''glycan_dictionary_accession''' : GD000129 <br>
+ '''term (main_entry)''' : N-acetyllactosamine (Type 2)<br>
-'''glytoucan_accession ''' : G00055MO <br>
+ '''glycan_dictionary_accession''' : GSD000129 <br>
-'''term_in_sentence''' : Utilising a fast and sensitive screening method based on imidazolium-tagged probes, we report unprecedented reversible activity of bacterial beta1,4-galactosyltransferases to catalyse the transgalactosylation from lactose to N-acetylglucosamine to form N-acetyllactosamine in the presence of UDP.[PMID:31165848] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00055MO G00055MO] <br>
-'''publication''' : 31165848|31126011|28796164|6236210|9751793|29740087|9151975|10567443|21472942|26477523|6548353|28167527|20056550|7737204|22052010|10223649|11323440|10420596|7766648|25257940|17977857|15556936|26541999|23650594|9692202|29429899|21062783|25034434|8985145|28503789|8720464/ <br>
+ '''term_in_sentence''' : Utilising a fast and sensitive screening method based on imidazolium-tagged probes, we report unprecedented reversible activity of bacterial beta1,4-galactosyltransferases to catalyse the transgalactosylation from lactose to N-acetylglucosamine to form N-acetyllactosamine in the presence of UDP.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31165848 31165848]] <br>
-'''definition''' : N-acetyllactosamine is a beta-D-galactopyranosyl-(1→4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. It is also known as galb1-4glcnacb or lacnac, belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group. N-Acetyllactosamine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Acetyllactosamine exists in all living organisms, ranging from bacteria to humans.[CHEBI:16153,HMDB0001542] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31165848 31165848]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]|[https://pubmed.ncbi.nlm.nih.gov/6236210 6236210]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29740087 29740087]|[https://pubmed.ncbi.nlm.nih.gov/9151975 9151975]|[https://pubmed.ncbi.nlm.nih.gov/10567443 10567443]|[https://pubmed.ncbi.nlm.nih.gov/21472942 21472942]|[https://pubmed.ncbi.nlm.nih.gov/26477523 26477523]|[https://pubmed.ncbi.nlm.nih.gov/6548353 6548353]|[https://pubmed.ncbi.nlm.nih.gov/28167527 28167527]|[https://pubmed.ncbi.nlm.nih.gov/20056550 20056550]|[https://pubmed.ncbi.nlm.nih.gov/7737204 7737204]|[https://pubmed.ncbi.nlm.nih.gov/22052010 22052010]|[https://pubmed.ncbi.nlm.nih.gov/10223649 10223649]|[https://pubmed.ncbi.nlm.nih.gov/11323440 11323440]|[https://pubmed.ncbi.nlm.nih.gov/10420596 10420596]|[https://pubmed.ncbi.nlm.nih.gov/7766648 7766648]|[https://pubmed.ncbi.nlm.nih.gov/25257940 25257940]|[https://pubmed.ncbi.nlm.nih.gov/17977857 17977857]|[https://pubmed.ncbi.nlm.nih.gov/15556936 15556936]|[https://pubmed.ncbi.nlm.nih.gov/26541999 26541999]|[https://pubmed.ncbi.nlm.nih.gov/23650594 23650594]|[https://pubmed.ncbi.nlm.nih.gov/9692202 9692202]|[https://pubmed.ncbi.nlm.nih.gov/29429899 29429899]|[https://pubmed.ncbi.nlm.nih.gov/21062783 21062783]|[https://pubmed.ncbi.nlm.nih.gov/25034434 25034434]|[https://pubmed.ncbi.nlm.nih.gov/8985145 8985145]|[https://pubmed.ncbi.nlm.nih.gov/28503789 28503789]|[https://pubmed.ncbi.nlm.nih.gov/8720464 8720464]/ <br>
-'''term_xref''' : CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001 <br>
+ '''definition''' : N-acetyllactosamine is a beta-D-galactopyranosyl-(1→4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. It is also known as galb1-4glcnacb or lacnac, belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group. N-Acetyllactosamine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Acetyllactosamine exists in all living organisms, ranging from bacteria to humans.[CHEBI:16153,HMDB0001542] <br>
-'''best_match''' : GTC:G00055MO|CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001 <br>
+ '''term_xref''' : GTC:G00055MO|CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001 <br>
-'''synonymns''' : LacNAc|Type 2 LN <br>
+ '''synonyms''' : LacNAc|Type 2 LN <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===N-Glycolyl-GM2===
-'''term (main_entry)''' : N-Glycolyl-GM2 <br>
+[[File:G56478LD.png|thumb|G56478LD]]
-'''glycan_dictionary_accession''' : GD000130 <br>
+ '''term (main_entry)''' : N-Glycolyl-GM2 <br>
-'''glytoucan_accession ''' : G56478LD <br>
+ '''glycan_dictionary_accession''' : GSD000130 <br>
-'''term_in_sentence''' : The monoclonal antibodies MK2-34 and MK1-16 (both IgM), which specifically detect N-glycolyl GM2 and N-acetyl GM2, respectively, were generated by immunizing mice with liposomes containing monophosphoryl lipid A, trehalose dimycolate, and the antigenic ganglioside.[PMID:3167861] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56478LD G56478LD] <br>
-'''publication''' : 3167861|11861662|17980710|3731079|25673107 <br>
+ '''term_in_sentence''' : The monoclonal antibodies MK2-34 and MK1-16 (both IgM), which specifically detect N-glycolyl GM2 and N-acetyl GM2, respectively, were generated by immunizing mice with liposomes containing monophosphoryl lipid A, trehalose dimycolate, and the antigenic ganglioside.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]] <br>
-'''definition''' : (2S,4S,5R,6R)-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of carbohydrates and carbohydrate derivatives.[CHEBI:151464] <br>
+ '''publication''' : [[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]|[https://pubmed.ncbi.nlm.nih.gov/11861662 11861662]|[https://pubmed.ncbi.nlm.nih.gov/17980710 17980710]|[https://pubmed.ncbi.nlm.nih.gov/3731079 3731079]| [https://pubmed.ncbi.nlm.nih.gov/25673107 25673107]] <br>
-'''term_xref''' : GlycoEpitope:EP0052|CID:91845742|CHEBI:151464|GlycoEpitope:GGM.000096 <br>
+ '''definition''' : (2S,4S,5R,6R)-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of carbohydrates and carbohydrate derivatives.[CHEBI:151464] <br>
-'''best_match''' : GTC:G56478LD |GlycoEpitope:EP0052|CID:91845742|CHEBI:151464|GlycoEpitope:GGM.000096 <br>
+ '''term_xref''' : GTC:G56478LD |GlycoEpitope:EP0052|CID:91845742|CHEBI:151464|GlycoEpitope:GGM.000096  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : choriocarcinoma[GlycoEpitope:EP0052]|teratocarcinoma|[GlycoEpitope:EP0052]yolk sac tumor[GlycoEpitope:EP0052] <br>
+ '''disease_associations''' : choriocarcinoma[GlycoEpitope:EP0052]|teratocarcinoma|[GlycoEpitope:EP0052]yolk sac tumor[GlycoEpitope:EP0052] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===N-linked glycans===
-'''term (main_entry)''' : N-linked glycans <br>
+[[File:G78059CC.png|thumb|G78059CC]]
-'''glycan_dictionary_accession''' : GD000131 <br>
+ '''term (main_entry)''' : N-linked glycans <br>
-'''glytoucan_accession ''' : G78059CC <br>
+ '''glycan_dictionary_accession''' : GSD000131 <br>
-'''term_in_sentence''' : Our study identifies extracellular N-linked glycans-and the glycoprotein neurexin 1β specifically-as key modulators of neuronal uptake of αSacetyl, drawing attention to the potential therapeutic value of αSacetyl-glycan interactions.[PMID:31211781] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
-'''publication''' : 31211781|28384382|30305477|31364612|26899268|29945790|29652253|29723274|30962676|29778448|25325701|31100702|28898525|22944671|19277537|24473128|17957771|27554083|15189166|11269317|19577919|24303005|12042249|22191536|28324664|25965797|25434632|30484244|28110657|29865036|20129637|27346875|30280442|26911286|22491358|26582281|26398792|31548313|31066275|28331984|25482090|28518173|30733536|22326428|30063825|30315103|21558494|31676555|31256374 <br>
+ '''term_in_sentence''' : Our study identifies extracellular N-linked glycans-and the glycoprotein neurexin 1β specifically-as key modulators of neuronal uptake of αSacetyl, drawing attention to the potential therapeutic value of αSacetyl-glycan interactions.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]] <br>
-'''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the nitrogen of an asparagine side-chain.[CHEBI:59520] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]|[https://pubmed.ncbi.nlm.nih.gov/28384382 28384382]|[https://pubmed.ncbi.nlm.nih.gov/30305477 30305477]|[https://pubmed.ncbi.nlm.nih.gov/31364612 31364612]|[https://pubmed.ncbi.nlm.nih.gov/26899268 26899268]|[https://pubmed.ncbi.nlm.nih.gov/29945790 29945790]|[https://pubmed.ncbi.nlm.nih.gov/29652253 29652253]|[https://pubmed.ncbi.nlm.nih.gov/29723274 29723274]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/29778448 29778448]|[https://pubmed.ncbi.nlm.nih.gov/25325701 25325701]|[https://pubmed.ncbi.nlm.nih.gov/31100702 31100702]|[https://pubmed.ncbi.nlm.nih.gov/28898525 28898525]|[https://pubmed.ncbi.nlm.nih.gov/22944671 22944671]|[https://pubmed.ncbi.nlm.nih.gov/19277537 19277537]|[https://pubmed.ncbi.nlm.nih.gov/24473128 24473128]|[https://pubmed.ncbi.nlm.nih.gov/17957771 17957771]|[https://pubmed.ncbi.nlm.nih.gov/27554083 27554083]|[https://pubmed.ncbi.nlm.nih.gov/15189166 15189166]|[https://pubmed.ncbi.nlm.nih.gov/11269317 11269317]|[https://pubmed.ncbi.nlm.nih.gov/19577919 19577919]|[https://pubmed.ncbi.nlm.nih.gov/24303005 24303005]|[https://pubmed.ncbi.nlm.nih.gov/12042249 12042249]|[https://pubmed.ncbi.nlm.nih.gov/22191536 22191536]|[https://pubmed.ncbi.nlm.nih.gov/28324664 28324664]|[https://pubmed.ncbi.nlm.nih.gov/25965797 25965797]|[https://pubmed.ncbi.nlm.nih.gov/25434632 25434632]|[https://pubmed.ncbi.nlm.nih.gov/30484244 30484244]|[https://pubmed.ncbi.nlm.nih.gov/28110657 28110657]| [https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/27346875 27346875]|[https://pubmed.ncbi.nlm.nih.gov/30280442 30280442]|[https://pubmed.ncbi.nlm.nih.gov/26911286 26911286]|[https://pubmed.ncbi.nlm.nih.gov/22491358 22491358]|[https://pubmed.ncbi.nlm.nih.gov/26582281 26582281]|[https://pubmed.ncbi.nlm.nih.gov/26398792 26398792]|[https://pubmed.ncbi.nlm.nih.gov/31548313 31548313]|[https://pubmed.ncbi.nlm.nih.gov/31066275 31066275]|[https://pubmed.ncbi.nlm.nih.gov/28331984 28331984]|[https://pubmed.ncbi.nlm.nih.gov/25482090 25482090]| [https://pubmed.ncbi.nlm.nih.gov/28518173 28518173]|[https://pubmed.ncbi.nlm.nih.gov/30733536 30733536]|[https://pubmed.ncbi.nlm.nih.gov/22326428 22326428]|[https://pubmed.ncbi.nlm.nih.gov/30063825 30063825]|[https://pubmed.ncbi.nlm.nih.gov/30315103 30315103]|[https://pubmed.ncbi.nlm.nih.gov/21558494 21558494]|[https://pubmed.ncbi.nlm.nih.gov/31676555 31676555]|[https://pubmed.ncbi.nlm.nih.gov/31256374 31256374] <br>
-'''term_xref''' : CID:70679232|CHEBI:70967 <br>
+ '''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the nitrogen of an asparagine side-chain.[CHEBI:59520] <br>
-'''best_match''' : GTC:G78059CC|CID:70679232|CHEBI:70967 <br>
+ '''term_xref''' : GTC:G78059CC|CID: 70679232|CHEBI:70967 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' : N-glycans modulate the function of several cell surface proteins which involved in migration, adhesion and which are responsible for regulating myelination.[PMID: 25151374]|Affect transportation of the glycosylated proteins in the Golgi.[PMID: 25151374]|Affects cell-cell interaction, adhesion, expression, proper folding.[PMID: 25151374]|extracellular N-glycans act as key modulators of neuronal uptake of αacetyl [PMID: 31211781]. <br>
+ '''function''' : N-glycans modulate the function of several cell surface proteins which involved in migration, adhesion and which are responsible for regulating myelination.[PMID: 25151374]|Affect transportation of the glycosylated proteins in the Golgi.[PMID: 25151374]|Affects cell-cell interaction, adhesion, expression, proper folding.[PMID: 25151374]|extracellular N-glycans act as key modulators of neuronal uptake of αacetyl [PMID: [https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]]. <br>
-'''disease_associations''' : Rheumatoid arthritis[PMID:17392038]|Type 1 Diabetes[PMID:29146600]|Lung Cancer[PMID: 23766031] <br>
+ '''disease_associations''' : Rheumatoid arthritis[PMID:17392038]|Type 1 Diabetes[PMID:29146600]|Lung Cancer[PMID: 23766031] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
 ===Nonfucosylated===
-'''term (main_entry)''' : Nonfucosylated <br>
+ '''term (main_entry)''' : Nonfucosylated <br>
-'''glycan_dictionary_accession''' : GD000132 <br>
+ '''glycan_dictionary_accession''' : GSD000132 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In the carbohydrate moiety , alpha-subunit from normal pregnancy hCG contained nonfucosylated , mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).[PMID:9449027] <br>
+ '''term_in_sentence''' : In the carbohydrate moiety , alpha-subunit from normal pregnancy hCG contained nonfucosylated , mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] <br>
-'''publication''' : 9449027|30258536|23554380|16675584|26747427|22457527|24362443|19657637|8811881|19218011|20022111|17363544|17368483|20564614|27054024|28397880|31490688|31860772|17012310|29633346|9442021|30350565|30296068|31800250|30021910|31133022|29224385|28630087|26444434|31697975|30991260 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] |[https://pubmed.ncbi.nlm.nih.gov/30258536 30258536]|[https://pubmed.ncbi.nlm.nih.gov/23554380 23554380]|[https://pubmed.ncbi.nlm.nih.gov/16675584 16675584]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]|[https://pubmed.ncbi.nlm.nih.gov/22457527 22457527]|[https://pubmed.ncbi.nlm.nih.gov/24362443 24362443]|[https://pubmed.ncbi.nlm.nih.gov/19657637 19657637]|[https://pubmed.ncbi.nlm.nih.gov/8811881 8811881]|[https://pubmed.ncbi.nlm.nih.gov/19218011 19218011]|[https://pubmed.ncbi.nlm.nih.gov/20022111 20022111]|[https://pubmed.ncbi.nlm.nih.gov/17363544 17363544]|[https://pubmed.ncbi.nlm.nih.gov/17368483 17368483]|[https://pubmed.ncbi.nlm.nih.gov/20564614 20564614]|[https://pubmed.ncbi.nlm.nih.gov/27054024 27054024]|[https://pubmed.ncbi.nlm.nih.gov/28397880 28397880]|[https://pubmed.ncbi.nlm.nih.gov/31490688 31490688]|[https://pubmed.ncbi.nlm.nih.gov/31860772 31860772]|[https://pubmed.ncbi.nlm.nih.gov/17012310 17012310]|[https://pubmed.ncbi.nlm.nih.gov/29633346 29633346]|[https://pubmed.ncbi.nlm.nih.gov/9442021 9442021]|[https://pubmed.ncbi.nlm.nih.gov/30350565 30350565]|[https://pubmed.ncbi.nlm.nih.gov/30296068 30296068]|[https://pubmed.ncbi.nlm.nih.gov/31800250 31800250]|[https://pubmed.ncbi.nlm.nih.gov/30021910 30021910]|[https://pubmed.ncbi.nlm.nih.gov/31133022 31133022]| [https://pubmed.ncbi.nlm.nih.gov/29224385 29224385]|[https://pubmed.ncbi.nlm.nih.gov/28630087 28630087]|[https://pubmed.ncbi.nlm.nih.gov/26444434 26444434]|[https://pubmed.ncbi.nlm.nih.gov/31697975 31697975]|[https://pubmed.ncbi.nlm.nih.gov/30991260 30991260] <br>
-'''definition''' : glycans without a fucose component/monosaccharide residue. <br>
+ '''definition''' : glycans without a fucose component/monosaccharide residue. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Nonfucosylated biantennary===
-'''term (main_entry)''' : Nonfucosylated biantennary <br>
+ '''term (main_entry)''' : Nonfucosylated biantennary <br>
-'''glycan_dictionary_accession''' : GD000133 <br>
+ '''glycan_dictionary_accession''' : GSD000133 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Structural analysis combining methylation-mass spectrometry and 400 MHz 1H-n.m.r. spectrometry of oligosaccharide alditols released from human leucocyte lactotransferrin shows the presence of two disialylated and non-fucosylated biantennary glycans of the N-acetyl-lactosaminic type.[PMID:2390069] <br>
+ '''term_in_sentence''' : Structural analysis combining methylation-mass spectrometry and 400 MHz 1H-n.m.r. spectrometry of oligosaccharide alditols released from human leucocyte lactotransferrin shows the presence of two disialylated and non-fucosylated biantennary glycans of the N-acetyl-lactosaminic type.[PMID: [https://pubmed.ncbi.nlm.nih.gov/2390069 2390069]] <br>
-'''publication''' : 2390069|9449027|1375510|9101715|2390069|2332109 <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/2390069 2390069]| [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] |[https://pubmed.ncbi.nlm.nih.gov/1375510 1375510]|[https://pubmed.ncbi.nlm.nih.gov/9101715 9101715]|[https://pubmed.ncbi.nlm.nih.gov/2332109 2332109] <br>
-'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
-'''essentials_of_glycobiology''' : NBK453020 <br>
 ===Nonfucosylated biantennary N-Linked structures===
-'''term (main_entry)''' : Nonfucosylated biantennary N-Linked structures <br>
+ '''term (main_entry)''' : Nonfucosylated biantennary N-Linked structures <br>
-'''glycan_dictionary_accession''' : GD000134 <br>
+ '''glycan_dictionary_accession''' : GSD000134 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).[PMID:9449027] <br>
+ '''term_in_sentence''' : The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] <br>
-'''publication''' : 9449027 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] <br>
-'''definition''' : A biantennary N-linked glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
+ '''definition''' : A biantennary N-linked glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Nonfucosylated triantennary===
-'''term (main_entry)''' : Nonfucosylated triantennary <br>
+ '''term (main_entry)''' : Nonfucosylated triantennary <br>
-'''glycan_dictionary_accession''' : GD000135 <br>
+ '''glycan_dictionary_accession''' : GSD000135 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans.[PMID:7679920] <br>
+ '''term_in_sentence''' : Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br>
-'''publication''' : 7679920|23274891 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/23274891 23274891] <br>
-'''definition''' : A triantennary N-linked glycan with three GlcNAc branches linked to the core and no fucose appears. <br>
+ '''definition''' : A triantennary N-linked glycan with three GlcNAc branches linked to the core and no fucose appears. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' : Appears in human alpha-fetoprotein (AFP).[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br>
-'''function''' : Appears in human alpha-fetoprotein (AFP).[PMID:7679920] <br>
+ '''disease_associations''' : hepatocellular carcinoma[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]]. <br>
-'''disease_associations''' : hepatocellular carcinoma[PMID:7679920]. <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Nonsialylated===
-'''term (main_entry)''' : Nonsialylated <br>
+ '''term (main_entry)''' : Nonsialylated <br>
-'''glycan_dictionary_accession''' : GD000136 <br>
+ '''glycan_dictionary_accession''' : GSD000136 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The pattern of nonsialylated oligosaccharides was used for interpretation of the fully sialylated species using bioinformatics tools. From pooled human plasma, we find 90, 101, and 64 different glycan compositions for genetic variants ORM1*F1, ORM1*S, and ORM2, respectively. Glycan structures carry dominantly between 15 and 16 sialic acids indicating an almost complete termination of all antenae with sialic acid.[PMID:30295034] <br>
+ '''term_in_sentence''' : The pattern of nonsialylated oligosaccharides was used for interpretation of the fully sialylated species using bioinformatics tools. From pooled human plasma, we find 90, 101, and 64 different glycan compositions for genetic variants ORM1*F1, ORM1*S, and ORM2, respectively. Glycan structures carry dominantly between 15 and 16 sialic acids indicating an almost complete termination of all antenae with sialic acid.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]] <br>
-'''publication''' : 14533820|1377689|9705949|30788437|28090561|12498371|26839900|31490688|2656426|30295034|31545048|12381155|25730103|26787879|25646460|29224385|26063435|26954852|32889432|2825412|27504786|22431161 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/14533820 14533820]|[https://pubmed.ncbi.nlm.nih.gov/1377689 1377689]|[https://pubmed.ncbi.nlm.nih.gov/9705949 9705949]|[https://pubmed.ncbi.nlm.nih.gov/30788437 30788437]|[https://pubmed.ncbi.nlm.nih.gov/28090561 28090561]|[https://pubmed.ncbi.nlm.nih.gov/12498371 12498371]|[https://pubmed.ncbi.nlm.nih.gov/26839900 26839900]| [https://pubmed.ncbi.nlm.nih.gov/31490688 31490688]|[https://pubmed.ncbi.nlm.nih.gov/2656426 2656426]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31545048 31545048]|[https://pubmed.ncbi.nlm.nih.gov/12381155 12381155]|[https://pubmed.ncbi.nlm.nih.gov/25730103 25730103]|[https://pubmed.ncbi.nlm.nih.gov/26787879 26787879]|[https://pubmed.ncbi.nlm.nih.gov/25646460 25646460]| [https://pubmed.ncbi.nlm.nih.gov/29224385 29224385]|[https://pubmed.ncbi.nlm.nih.gov/26063435 26063435]|[https://pubmed.ncbi.nlm.nih.gov/26954852 26954852]|[https://pubmed.ncbi.nlm.nih.gov/32889432 32889432]|[https://pubmed.ncbi.nlm.nih.gov/2825412 2825412]|[https://pubmed.ncbi.nlm.nih.gov/27504786 27504786]|[https://pubmed.ncbi.nlm.nih.gov/22431161 22431161] <br>
-'''definition''' : A glycan which is not sialylated. <br>
+ '''definition''' : A glycan which is not sialylated. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===O-fucose glycans===
-'''term (main_entry)''' : O-fucose glycans <br>
+[[File:G39294YF.png|thumb|G39294YF]]
-'''glycan_dictionary_accession''' : GD000137 <br>
+ '''term (main_entry)''' : O-fucose glycans <br>
-'''glytoucan_accession ''' : G39294YF <br>
+ '''glycan_dictionary_accession''' : GSD000137 <br>
-'''term_in_sentence''' : Recently, a number of laboratories have shown that O-fucose glycans on the epidermal growth factor (EGF)-like repeats of the Notch extracellular domain modulate Notch signaling.[PMID:12417415] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G39294YF G39294YF] <br>
-'''publication''' : 19594638|30690220|18952191|22415200|12417415|16400812|18948267|21464368|20816394|30207383|20301232|27129198|17132502|22492969|30030822|30214079|26175457|25378397|18272537|28729422|11524432|31722217|23045360|24803430|28876865|25700513|32518939|30523691|18227520|20816217|24909690|17964136|12036964|27268051|15653671|19948734|31590629|32201074|15189151|17263732|32913123|12909620|28785176|17132500|22949680|25053492|28939751 <br>
+ '''term_in_sentence''' : Recently, a number of laboratories have shown that O-fucose glycans on the epidermal growth factor (EGF)-like repeats of the Notch extracellular domain modulate Notch signaling.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12417415 12417415]] <br>
-'''definition''' : Form of glycosylation where the protein is modified by a fucose residue and can be extended futher to form a tetrasaccharide in certain cases. alpha-linked o-fucose have a consensus motif of C2X4(s/T)C3 where C2 and C3 are conserved cysteines number 2 and 3 respectively of the EGFR like repeats. [NBK453017-Chapter13] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19594638 19594638]|[https://pubmed.ncbi.nlm.nih.gov/30690220 30690220]| [https://pubmed.ncbi.nlm.nih.gov/18952191 18952191]|[https://pubmed.ncbi.nlm.nih.gov/22415200 22415200]|[https://pubmed.ncbi.nlm.nih.gov/12417415 12417415]|[https://pubmed.ncbi.nlm.nih.gov/16400812 16400812]|[https://pubmed.ncbi.nlm.nih.gov/18948267 18948267]|[https://pubmed.ncbi.nlm.nih.gov/21464368 21464368]|[https://pubmed.ncbi.nlm.nih.gov/20816394 20816394]|[https://pubmed.ncbi.nlm.nih.gov/30207383 30207383]|[https://pubmed.ncbi.nlm.nih.gov/20301232 20301232]|[https://pubmed.ncbi.nlm.nih.gov/27129198 27129198]|[https://pubmed.ncbi.nlm.nih.gov/17132502 17132502]|[https://pubmed.ncbi.nlm.nih.gov/22492969 22492969]|[https://pubmed.ncbi.nlm.nih.gov/30030822 30030822]|[https://pubmed.ncbi.nlm.nih.gov/30214079 30214079]|[https://pubmed.ncbi.nlm.nih.gov/26175457 26175457]|[https://pubmed.ncbi.nlm.nih.gov/25378397 25378397]|[https://pubmed.ncbi.nlm.nih.gov/18272537 18272537]|[https://pubmed.ncbi.nlm.nih.gov/28729422 28729422]|[https://pubmed.ncbi.nlm.nih.gov/11524432 11524432]|[https://pubmed.ncbi.nlm.nih.gov/31722217 31722217]|[https://pubmed.ncbi.nlm.nih.gov/23045360 23045360]|[https://pubmed.ncbi.nlm.nih.gov/24803430 24803430]|[https://pubmed.ncbi.nlm.nih.gov/28876865 28876865]|[https://pubmed.ncbi.nlm.nih.gov/25700513 25700513]|[https://pubmed.ncbi.nlm.nih.gov/32518939 32518939]|[https://pubmed.ncbi.nlm.nih.gov/30523691 30523691]|[https://pubmed.ncbi.nlm.nih.gov/18227520 18227520]|[https://pubmed.ncbi.nlm.nih.gov/20816217 20816217]|[https://pubmed.ncbi.nlm.nih.gov/24909690 24909690]|[https://pubmed.ncbi.nlm.nih.gov/17964136 17964136]|[https://pubmed.ncbi.nlm.nih.gov/12036964 12036964]|[https://pubmed.ncbi.nlm.nih.gov/27268051 27268051]|[https://pubmed.ncbi.nlm.nih.gov/15653671 15653671]|[https://pubmed.ncbi.nlm.nih.gov/19948734 19948734]|[https://pubmed.ncbi.nlm.nih.gov/31590629 31590629]|[https://pubmed.ncbi.nlm.nih.gov/32201074 32201074]|[https://pubmed.ncbi.nlm.nih.gov/15189151 15189151]|[https://pubmed.ncbi.nlm.nih.gov/17263732 17263732]|[https://pubmed.ncbi.nlm.nih.gov/32913123 32913123]|[https://pubmed.ncbi.nlm.nih.gov/12909620 12909620]|[https://pubmed.ncbi.nlm.nih.gov/28785176 28785176]|[https://pubmed.ncbi.nlm.nih.gov/17132500 17132500]|[https://pubmed.ncbi.nlm.nih.gov/22949680 22949680]|[https://pubmed.ncbi.nlm.nih.gov/25053492 25053492]|[https://pubmed.ncbi.nlm.nih.gov/28939751 28939751] <br>
-'''term_xref''' : GlycoEpitope:EP0005 <br>
+ '''definition''' : Form of glycosylation where the protein is modified by a fucose residue and can be extended futher to form a tetrasaccharide in certain cases. alpha-linked o-fucose have a consensus motif of C2X4(s/T)C3 where C2 and C3 are conserved cysteines number 2 and 3 respectively of the EGFR like repeats. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453017/ Chapter13]] <br>
-'''best_match''' : GTC:G39294YF|GlycoEpitope:EP0005 <br>
+ '''term_xref''' : GTC:G39294YF|GlycoEpitope:EP0005<br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' : modification of Notch signaling.[GlycoEpitope:EP0005] <br>
+ '''function''' : modification of Notch signaling.[GlycoEpitope:EP0005] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===O-GlcNAc===
-'''term (main_entry)''' : O-GlcNAc <br>
+[[File:G49108TO.png|thumb|G49108TO]]
-'''glycan_dictionary_accession''' : GD000138 <br>
+ '''term (main_entry)''' : O-GlcNAc <br>
-'''glytoucan_accession ''' : G49108TO <br>
+ '''glycan_dictionary_accession''' : GSD000138 <br>
-'''term_in_sentence''' : A better understanding of the mechanisms of OGT/OGA action would enable us to derive therapeutic benefits of resetting cellular O-GlcNAc levels within an optimal range.[PMID:30464755] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G49108TO G49108TO] <br>
-'''publication''' : 30464755|29049853|29594839|31654859|29404877|30105004|30669087|29790000|28408483|26862193|30523150|30037904|28408480|29352075|29456783|29577901|29223644|28638491|30221662|29904918|32155042|30298013|31630803|31847126|29784830|30181664|28768194|30134155|25336654|30356792|30199580|32329777|28408494|29774032|29044951|23836420|20301273|29772801|28922739|30100348|30793403|30657688|31237748|29756380|29954943|30018219|32207184|25566193|30626734|24759912| <br>
+ '''term_in_sentence''' : A better understanding of the mechanisms of OGT/OGA action would enable us to derive therapeutic benefits of resetting cellular O-GlcNAc levels within an optimal range.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30464755 30464755]] <br>
-'''definition''' : Form of glycosylation which exclusively occurs in the mitochondrial, cytoplasmic or nuclear compartments of the cell where the protein is modified by a GlcNAc monosaccharide on the serine or threonine residues and is generally not modified or elongated further to form more complex structures. [NBK453063-Chapter19] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30464755 30464755]|[https://pubmed.ncbi.nlm.nih.gov/29049853 29049853]|[https://pubmed.ncbi.nlm.nih.gov/29594839 29594839]|[https://pubmed.ncbi.nlm.nih.gov/31654859 31654859]|[https://pubmed.ncbi.nlm.nih.gov/29404877 29404877]|[https://pubmed.ncbi.nlm.nih.gov/30105004 30105004]|[https://pubmed.ncbi.nlm.nih.gov/30669087 30669087]|[https://pubmed.ncbi.nlm.nih.gov/29790000 29790000]|[https://pubmed.ncbi.nlm.nih.gov/28408483 28408483]|[https://pubmed.ncbi.nlm.nih.gov/26862193 26862193]|[https://pubmed.ncbi.nlm.nih.gov/30523150 30523150]|[https://pubmed.ncbi.nlm.nih.gov/30037904 30037904]|[https://pubmed.ncbi.nlm.nih.gov/28408480 28408480]|[https://pubmed.ncbi.nlm.nih.gov/29352075 29352075]|[https://pubmed.ncbi.nlm.nih.gov/29456783 29456783]|[https://pubmed.ncbi.nlm.nih.gov/29577901 29577901]|[https://pubmed.ncbi.nlm.nih.gov/29223644 29223644]|[https://pubmed.ncbi.nlm.nih.gov/28638491 28638491]|[https://pubmed.ncbi.nlm.nih.gov/30221662 30221662]|[https://pubmed.ncbi.nlm.nih.gov/29904918 29904918]|[https://pubmed.ncbi.nlm.nih.gov/32155042 32155042]|[https://pubmed.ncbi.nlm.nih.gov/30298013 30298013]|[https://pubmed.ncbi.nlm.nih.gov/31630803 31630803]|[https://pubmed.ncbi.nlm.nih.gov/31847126 31847126]|[https://pubmed.ncbi.nlm.nih.gov/29784830 29784830]|[https://pubmed.ncbi.nlm.nih.gov/30181664 30181664]|[https://pubmed.ncbi.nlm.nih.gov/28768194 28768194]|[https://pubmed.ncbi.nlm.nih.gov/30134155 30134155]|[https://pubmed.ncbi.nlm.nih.gov/25336654 25336654]|[https://pubmed.ncbi.nlm.nih.gov/30356792 30356792]|[https://pubmed.ncbi.nlm.nih.gov/30199580 30199580]|[https://pubmed.ncbi.nlm.nih.gov/32329777 32329777]|[https://pubmed.ncbi.nlm.nih.gov/28408494 28408494]|[https://pubmed.ncbi.nlm.nih.gov/29774032 29774032]|[https://pubmed.ncbi.nlm.nih.gov/29044951 29044951]|[https://pubmed.ncbi.nlm.nih.gov/23836420 23836420]|[https://pubmed.ncbi.nlm.nih.gov/20301273 20301273]|[https://pubmed.ncbi.nlm.nih.gov/29772801 29772801]|[https://pubmed.ncbi.nlm.nih.gov/28922739 28922739]|[https://pubmed.ncbi.nlm.nih.gov/30100348 30100348]|[https://pubmed.ncbi.nlm.nih.gov/30793403 30793403]|[https://pubmed.ncbi.nlm.nih.gov/30657688 30657688]|[https://pubmed.ncbi.nlm.nih.gov/31237748 31237748]|[https://pubmed.ncbi.nlm.nih.gov/29756380 29756380]|[https://pubmed.ncbi.nlm.nih.gov/29954943 29954943]|[https://pubmed.ncbi.nlm.nih.gov/30018219 30018219]|[https://pubmed.ncbi.nlm.nih.gov/32207184 32207184]|[https://pubmed.ncbi.nlm.nih.gov/25566193 25566193]|[https://pubmed.ncbi.nlm.nih.gov/30626734 30626734]|[https://pubmed.ncbi.nlm.nih.gov/24759912 24759912]| <br>
-'''term_xref''' : GlycoEpitope:EP0004|CID:24139|HMDB:HMDB0000803 <br>
+ '''definition''' : Form of glycosylation which exclusively occurs in the mitochondrial, cytoplasmic or nuclear compartments of the cell where the protein is modified by a GlcNAc monosaccharide on the serine or threonine residues and is generally not modified or elongated further to form more complex structures. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453063/ Chapter19]] <br>
-'''best_match''' : GTC:G49108TO|GlycoEpitope:EP0004|CID:24139|HMDB:HMDB0000803 <br>
+ '''term_xref''' : GTC:G49108TO|GlycoEpitope:EP0004|CID:24139|HMDB:HMDB0000803  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===O-linked glycans===
-'''term (main_entry)''' : O-linked glycans <br>
+ '''term (main_entry)''' : O-linked glycans <br>
-'''glycan_dictionary_accession''' : GD000139 <br>
+ '''glycan_dictionary_accession''' : GSD000139 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.[PMID:29865036] <br>
+ '''term_in_sentence''' : Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]] <br>
-'''publication''' : 29865036|30952424|31611643|19577919|32019882|19139197|26184710|11159917|21536259|25186198|19277556|22261557|24115046|18725413|15966855|24256304|25477510|10359703|24406064|22259135|29279989|15966855|30619255|9673446|31676555|28745859|28196325|27975143|30591584|28518173|17522109|26328495|32178593|27529638|24663386|22474328|28096352|27496768|18952191|11135308|24917611|11532966|22786570|11891229|18332077|26867212|26925665|16769205|23475718|16005634|28785176 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]|[https://pubmed.ncbi.nlm.nih.gov/30952424 30952424]|[https://pubmed.ncbi.nlm.nih.gov/31611643 31611643]|[https://pubmed.ncbi.nlm.nih.gov/19577919 19577919]|[https://pubmed.ncbi.nlm.nih.gov/32019882 32019882]|[https://pubmed.ncbi.nlm.nih.gov/19139197 19139197]|[https://pubmed.ncbi.nlm.nih.gov/26184710 26184710]|[https://pubmed.ncbi.nlm.nih.gov/11159917 11159917]|[https://pubmed.ncbi.nlm.nih.gov/21536259 21536259]|[https://pubmed.ncbi.nlm.nih.gov/25186198 25186198]|[https://pubmed.ncbi.nlm.nih.gov/19277556 19277556]|[https://pubmed.ncbi.nlm.nih.gov/22261557 22261557]|[https://pubmed.ncbi.nlm.nih.gov/24115046 24115046]|[https://pubmed.ncbi.nlm.nih.gov/18725413 18725413]|[https://pubmed.ncbi.nlm.nih.gov/15966855 15966855]|[https://pubmed.ncbi.nlm.nih.gov/24256304 24256304]|[https://pubmed.ncbi.nlm.nih.gov/25477510 25477510]|[https://pubmed.ncbi.nlm.nih.gov/10359703 10359703]|[https://pubmed.ncbi.nlm.nih.gov/24406064 24406064]|[https://pubmed.ncbi.nlm.nih.gov/22259135 22259135]|[https://pubmed.ncbi.nlm.nih.gov/29279989 29279989]| [https://pubmed.ncbi.nlm.nih.gov/15966855 15966855]|[https://pubmed.ncbi.nlm.nih.gov/30619255 30619255]|[https://pubmed.ncbi.nlm.nih.gov/9673446 9673446]| [https://pubmed.ncbi.nlm.nih.gov/31676555 31676555]|[https://pubmed.ncbi.nlm.nih.gov/28745859 28745859]|[https://pubmed.ncbi.nlm.nih.gov/28196325 28196325]|[https://pubmed.ncbi.nlm.nih.gov/27975143 27975143]|[https://pubmed.ncbi.nlm.nih.gov/30591584 30591584]| [https://pubmed.ncbi.nlm.nih.gov/28518173 28518173]|[https://pubmed.ncbi.nlm.nih.gov/17522109 17522109]| [https://pubmed.ncbi.nlm.nih.gov/26328495 26328495]|[https://pubmed.ncbi.nlm.nih.gov/32178593 32178593]|[https://pubmed.ncbi.nlm.nih.gov/27529638 27529638]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/22474328 22474328]|[https://pubmed.ncbi.nlm.nih.gov/28096352 28096352]|[https://pubmed.ncbi.nlm.nih.gov/27496768 27496768]| [https://pubmed.ncbi.nlm.nih.gov/18952191 18952191]|[https://pubmed.ncbi.nlm.nih.gov/11135308 11135308]|[https://pubmed.ncbi.nlm.nih.gov/24917611 24917611]|[https://pubmed.ncbi.nlm.nih.gov/11532966 11532966]|[https://pubmed.ncbi.nlm.nih.gov/22786570 22786570]|[https://pubmed.ncbi.nlm.nih.gov/11891229 11891229]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/26867212 26867212]|[https://pubmed.ncbi.nlm.nih.gov/26925665 26925665]|[https://pubmed.ncbi.nlm.nih.gov/16769205 16769205]|[https://pubmed.ncbi.nlm.nih.gov/23475718 23475718]|[https://pubmed.ncbi.nlm.nih.gov/16005634 16005634]|[https://pubmed.ncbi.nlm.nih.gov/28785176 28785176] <br>
-'''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the hydroxyl oxygen of serine, threonine, hydroxylysine or hydroxyproline side-chains.[CHEBI:59521] <br>
+ '''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the hydroxyl oxygen of serine, threonine, hydroxylysine or hydroxyproline side-chains.[CHEBI:59521] <br>
-'''term_xref''' : CHEBI:59521 <br>
+ '''term_xref''' : CHEBI:59521 <br>
-'''best_match''' : CHEBI:59521 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' : Affects several important activities like protein stability, modulation of signaling molecules and enzyme activity.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9673446 9673446]] <br>
-'''function''' : Affects several important activities like protein stability, modulation of signaling molecules and enzyme activity.[PMID:9673446] <br>
+ '''disease_associations''' : <br>
-'''disease_associations''' : Cancers[https://doi.org/10.1016/bs.acr.2014.11.002] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===O-linked mannose===
-'''term (main_entry)''' : O-linked mannose <br>
+[[File:G59126YU.png|thumb|G59126YU]]
-'''glycan_dictionary_accession''' : GD000140 <br>
+ '''term (main_entry)''' : O-linked mannose <br>
-'''glytoucan_accession ''' : G59126YU <br>
+ '''glycan_dictionary_accession''' : GSD000140 <br>
-'''term_in_sentence''' : Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2) catalyzes the first step toward the functional matriglycan structure on alpha-dystroglycan that is responsible for binding extracellular matrix proteins and certain arenaviruses.[PMID: 27932460] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G59126YU G59126YU] <br>
-'''publication''' : 27932460|24526361|25381909|26644575|23851827|28810660|19054127|23929950|21684258|22608994|28973932|24733390|31851597|29884773|28711406|14577328|21089343|14617637|9838223|17072003|26328495|11181560|31949166|31988979|20362685|27733679|27493216|20044576|30643095|29732660|10580142|14568618|28079948|15467391|27812179|23761899|25737452|32930586|25381372|23434682|16857188|21452199|19429925|25361541|24297939|30322079|23428289|28427937|22746206|27533452|17502374|20816174|27496765 <br>
+ '''term_in_sentence''' : Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2) catalyzes the first step toward the functional matriglycan structure on alpha-dystroglycan that is responsible for binding extracellular matrix proteins and certain arenaviruses.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27932460 27932460]] <br>
-'''definition''' : O-linked glycans that are initiated by the addtion of a Man residue to Ser or Thr. Subsequent extension of the Man defines the O-Man core type, either M1, M2, or M3. The M1 type is initated by addition of a GlcNAc in β-linkage to the 2 position of the Man residue. M2 is initiated by addition of another GlcNAc to the 6 position of the M1 core. M3 is initiated by the addition of a GlcNAc in β-linkage to the 4 position of the Man residue. M1 and M2 type core glycans can be extended and branched with Gal, Fuc, Sialic Acid, and GlcA. The M3 core is uniquely extended by a multienzyme system to generate the matriglycan polysaccharide, a protein-specific modification found only on alpha-dystroglycan. [CHEBI:87761] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27932460 27932460]|[https://pubmed.ncbi.nlm.nih.gov/24526361 24526361]|[https://pubmed.ncbi.nlm.nih.gov/25381909 25381909]|[https://pubmed.ncbi.nlm.nih.gov/26644575 26644575]|[https://pubmed.ncbi.nlm.nih.gov/23851827 23851827]|[https://pubmed.ncbi.nlm.nih.gov/28810660 28810660]|[https://pubmed.ncbi.nlm.nih.gov/19054127 19054127]|[https://pubmed.ncbi.nlm.nih.gov/23929950 23929950]|[https://pubmed.ncbi.nlm.nih.gov/21684258 21684258]|[https://pubmed.ncbi.nlm.nih.gov/22608994 22608994]|[https://pubmed.ncbi.nlm.nih.gov/28973932 28973932]|[https://pubmed.ncbi.nlm.nih.gov/24733390 24733390]|[https://pubmed.ncbi.nlm.nih.gov/31851597 31851597]|[https://pubmed.ncbi.nlm.nih.gov/29884773 29884773]|[https://pubmed.ncbi.nlm.nih.gov/28711406 28711406]|[https://pubmed.ncbi.nlm.nih.gov/14577328 14577328]|[https://pubmed.ncbi.nlm.nih.gov/21089343 21089343]|[https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]|[https://pubmed.ncbi.nlm.nih.gov/9838223 9838223]|[https://pubmed.ncbi.nlm.nih.gov/17072003 17072003]| [https://pubmed.ncbi.nlm.nih.gov/26328495 26328495]|[https://pubmed.ncbi.nlm.nih.gov/11181560 11181560]|[https://pubmed.ncbi.nlm.nih.gov/31949166 31949166]|[https://pubmed.ncbi.nlm.nih.gov/31988979 31988979]|[https://pubmed.ncbi.nlm.nih.gov/20362685 20362685]|[https://pubmed.ncbi.nlm.nih.gov/27733679 27733679]|[https://pubmed.ncbi.nlm.nih.gov/27493216 27493216]|[https://pubmed.ncbi.nlm.nih.gov/20044576 20044576]|[https://pubmed.ncbi.nlm.nih.gov/30643095 30643095]|[https://pubmed.ncbi.nlm.nih.gov/29732660 29732660]|[https://pubmed.ncbi.nlm.nih.gov/10580142 10580142]|[https://pubmed.ncbi.nlm.nih.gov/14568618 14568618]|[https://pubmed.ncbi.nlm.nih.gov/28079948 28079948]|[https://pubmed.ncbi.nlm.nih.gov/15467391 15467391]|[https://pubmed.ncbi.nlm.nih.gov/27812179 27812179]|[https://pubmed.ncbi.nlm.nih.gov/23761899 23761899]|[https://pubmed.ncbi.nlm.nih.gov/25737452 25737452]|[https://pubmed.ncbi.nlm.nih.gov/32930586 32930586]|[https://pubmed.ncbi.nlm.nih.gov/25381372 25381372]|[https://pubmed.ncbi.nlm.nih.gov/23434682 23434682]|[https://pubmed.ncbi.nlm.nih.gov/16857188 16857188]|[https://pubmed.ncbi.nlm.nih.gov/21452199 21452199]|[https://pubmed.ncbi.nlm.nih.gov/19429925 19429925]|[https://pubmed.ncbi.nlm.nih.gov/25361541 25361541]|[https://pubmed.ncbi.nlm.nih.gov/24297939 24297939]|[https://pubmed.ncbi.nlm.nih.gov/30322079 30322079]|[https://pubmed.ncbi.nlm.nih.gov/23428289 23428289]|[https://pubmed.ncbi.nlm.nih.gov/28427937 28427937]|[https://pubmed.ncbi.nlm.nih.gov/22746206 22746206]|[https://pubmed.ncbi.nlm.nih.gov/27533452 27533452]|[https://pubmed.ncbi.nlm.nih.gov/17502374 17502374]|[https://pubmed.ncbi.nlm.nih.gov/20816174 20816174]|[https://pubmed.ncbi.nlm.nih.gov/27496765 27496765] <br>
-'''term_xref''' : GlycoMotif:GGM.000055|CHEBI:87761|GlycoEpitope:EP0002|CID:91859038 <br>
+ '''definition''' : O-linked glycans that are initiated by the addtion of a Man residue to Ser or Thr. Subsequent extension of the Man defines the O-Man core type, either M1, M2, or M3. The M1 type is initated by addition of a GlcNAc in β-linkage to the 2 position of the Man residue. M2 is initiated by addition of another GlcNAc to the 6 position of the M1 core. M3 is initiated by the addition of a GlcNAc in β-linkage to the 4 position of the Man residue. M1 and M2 type core glycans can be extended and branched with Gal, Fuc, Sialic Acid, and GlcA. The M3 core is uniquely extended by a multienzyme system to generate the matriglycan polysaccharide, a protein-specific modification found only on alpha-dystroglycan. [CHEBI:87761] <br>
-'''best_match''' : GlycoMotif:000055|GTC:G59126YU|CHEBI:87761|GlycoEpitope:EP0002|CID:91859038 <br>
+ '''term_xref''' : GlycoMotif:GGM.000055|GTC:G59126YU|CHEBI:87761|GlycoEpitope:EP0002|CID: 91859038<br>
-'''synonymns''' : O-mannosyl glycan <br>
+ '''synonyms''' : O-mannosyl glycan <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : MEB/muscle-eye-brain disease[GlycoEpitope:EP0002]|WWS/walker-warburg syndrome |muscular dystrophy[GlycoEpitope:EP0002]|neuronal migration disorder[GlycoEpitope:EP0002]|Muscle-Eye-Brain disease (MEB) and Walker-Warburg Syndrome (WWS) have mutations in genes encoding glycosyltransferases needed for O -mannosyl oligosaccharide synthesis[GlycoEpitope:EP0002]|Muscular dystrophy and neuronal migration disorder are caused by mutations in a glycosyltransferase, POMGnT1.[GlycoEpitope:EP0002] <br>
+ '''disease_associations''' : MEB/muscle-eye-brain disease[GlycoEpitope:EP0002]|WWS/walker-warburg syndrome |muscular dystrophy[GlycoEpitope:EP0002]|neuronal migration disorder[GlycoEpitope:EP0002]|Muscle-Eye-Brain disease (MEB) and Walker-Warburg Syndrome (WWS) have mutations in genes encoding glycosyltransferases needed for O -mannosyl oligosaccharide synthesis[GlycoEpitope:EP0002]|Muscular dystrophy and neuronal migration disorder are caused by mutations in a glycosyltransferase, POMGnT1.[GlycoEpitope:EP0002] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===P1 antigen===
-'''term (main_entry)''' : P1 antigen <br>
+[[File:G12460DL.png|thumb|G12460DL]]
-'''glycan_dictionary_accession''' : GD000141 <br>
+ '''term (main_entry)''' : P1 antigen <br>
-'''glytoucan_accession ''' : G12460DL <br>
+ '''glycan_dictionary_accession''' : GSD000141 <br>
-'''term_in_sentence''' : The P1 antigen was disovered in 1927 by Landsteiner and Levine, and Pk and NOR were described in 1951 and 1982, respectively.[PMID: 24046920] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G12460DL G12460DL] <br>
-'''publication''' : 29622537|26773500|24046920|6207232|8550516|6609976|6375319|817855|2428855|3312011|15364312|1937801|7729906 <br>
+ '''term_in_sentence''' : The P1 antigen was disovered in 1927 by Landsteiner and Levine, and Pk and NOR were described in 1951 and 1982, respectively.[PMID: [https://pubmed.ncbi.nlm.nih.gov/24046920 24046920]] <br>
-'''definition''' : An amino pentasaccharide consisting of α-D-galactose, β-D-galactose N-acetyl-α-D-glucosamine, β-D-galactose, and β-D-glucose residues joined in sequence with ((1→4)-, (1→4)-, (1→3)- and (1→4)-linkages, respectively.[CHEBI:68484] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29622537 29622537]|[https://pubmed.ncbi.nlm.nih.gov/26773500 26773500]|[https://pubmed.ncbi.nlm.nih.gov/24046920 24046920]|[https://pubmed.ncbi.nlm.nih.gov/6207232 6207232]|[https://pubmed.ncbi.nlm.nih.gov/8550516 8550516]|[https://pubmed.ncbi.nlm.nih.gov/6609976 6609976]|[https://pubmed.ncbi.nlm.nih.gov/6375319 6375319]|817855|[https://pubmed.ncbi.nlm.nih.gov/2428855 2428855]|[https://pubmed.ncbi.nlm.nih.gov/3312011 3312011]|[https://pubmed.ncbi.nlm.nih.gov/15364312 15364312]|[https://pubmed.ncbi.nlm.nih.gov/1937801 1937801]|[https://pubmed.ncbi.nlm.nih.gov/7729906 7729906] <br>
-'''term_xref''' : GlycoMotif:GGM.000069|CID:71296137|CHEBI:68484|SugarBind_Ligand:160 <br>
+ '''definition''' : An amino pentasaccharide consisting of α-D-galactose, β-D-galactose N-acetyl-α-D-glucosamine, β-D-galactose, and β-D-glucose residues joined in sequence with ((1→4)-, (1→4)-, (1→3)- and (1→4)-linkages, respectively.[CHEBI:68484] <br>
-'''best_match''' : GlycoMotif:GGM.000069|GTC:G12460DL|CID:71296137|CHEBI:68484|SugarBind_Ligand:160 <br>
+ '''term_xref''' : GlycoMotif:GGM.000069|GTC:G12460DL|CID:71296137|CHEBI:68484|SugarBind_Ligand:160  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Shigellosis[SugarBind_Ligand:160] <br>
+ '''disease_associations''' : Shigellosis[SugarBind_Ligand:160] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453054 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453054/ Chapter 23]<br>
 ===Para-Forssman glycolipid===
-'''term (main_entry)''' : Para-Forssman glycolipid <br>
+[[File:G51699SI.png|thumb|G51699SI]]
-'''glycan_dictionary_accession''' : GD000142 <br>
+ '''term (main_entry)''' : Para-Forssman glycolipid <br>
-'''glytoucan_accession ''' : G51699SI <br>
+ '''glycan_dictionary_accession''' : GSD000142 <br>
-'''term_in_sentence''' : A novel pentaglycosyl ceramide containing di-beta-N-acetylgalactos-aminyl residue (Para-Forssman glycolipid) isolated from human erythrocyte membrane. [PMID:6814203] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G51699SI G51699SI] <br>
-'''publication''' : 6814203 <br>
+ '''term_in_sentence''' : A novel pentaglycosyl ceramide containing di-beta-N-acetylgalactos-aminyl residue (Para-Forssman glycolipid) isolated from human erythrocyte membrane. [PMID:[https://pubmed.ncbi.nlm.nih.gov/6814203 6814203]] <br>
-'''definition''' : GalNAcβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1Cer [https://doi.org/10.1016/S0040-4039(01)93814-6] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6814203 6814203] <br>
-'''term_xref''' : GlycoMotif:GGM.000085|CID:56836111|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565 <br>
+ '''definition''' : GalNAcβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1Cer [https://doi.org/10.1016/S0040-4039(01)93814-6<nowiki>] </nowiki><br>
-'''best_match''' : GlycoMotif:GGM.000085|GTC:G51699SI|CID:56836111|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565 <br>
+ '''term_xref''' : GlycoMotif:GGM.000085|GTC:G51699SI|CID:56836111|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Actinomycosis[SugarBind_Ligand:19] <br>
+ '''disease_associations''' : Actinomycosis[SugarBind_Ligand:19] <br>
-'''wikipedia''' : https://en.wikipedia.org/wiki/P1PK_blood_group_system <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/P1PK_blood_group_system <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Paragloboside===
-'''term (main_entry)''' : Paragloboside <br>
+[[File:G58896AZ.png|thumb|G58896AZ]]
-'''glycan_dictionary_accession''' : GD000143 <br>
+ '''term (main_entry)''' : Paragloboside <br>
-'''glytoucan_accession ''' : G58896AZ <br>
+ '''glycan_dictionary_accession''' : GSD000143 <br>
-'''term_in_sentence''' : Galactosyltransferase activities in sera of cancer patients were determined by assaying the formation of paragloboside from UDP-galactose and lactotriaosylceramide immobilized on microtiter plates by means of the enzyme-linked immunosorbent assay using a monoclonal antibody, H-11, directed to paragloboside. [PMID: 1551117] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G58896AZ G58896AZ] <br>
-'''publication''' : 3345524|850070|10569746|30624951|29438961|6816790|1551117|6865961|25039255 <br>
+ '''term_in_sentence''' : Galactosyltransferase activities in sera of cancer patients were determined by assaying the formation of paragloboside from UDP-galactose and lactotriaosylceramide immobilized on microtiter plates by means of the enzyme-linked immunosorbent assay using a monoclonal antibody, H-11, directed to paragloboside. [PMID: [https://pubmed.ncbi.nlm.nih.gov/1551117 1551117]] <br>
-'''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is α.[CHEBI:65257] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3345524 3345524]|[https://pubmed.ncbi.nlm.nih.gov/850070 850070]|[https://pubmed.ncbi.nlm.nih.gov/10569746 10569746]|[https://pubmed.ncbi.nlm.nih.gov/30624951 30624951]|[https://pubmed.ncbi.nlm.nih.gov/29438961 29438961]|[https://pubmed.ncbi.nlm.nih.gov/6816790 6816790]|[https://pubmed.ncbi.nlm.nih.gov/1551117 1551117]|[https://pubmed.ncbi.nlm.nih.gov/6865961 6865961]|[https://pubmed.ncbi.nlm.nih.gov/25039255 25039255] <br>
-'''term_xref''' : GlycoMotif:GGM.000077|CID:21670519|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15 <br>
+ '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is α.[CHEBI:65257] <br>
-'''best_match''' : GlycoMotif:GGM.000077|GTC:G58896AZ|CID:21670519|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15 <br>
+ '''term_xref''' : GlycoMotif:GGM.000077|GTC:G58896AZ|CID: 21670519|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : Pharyngitis[SugarBind_Ligand:15]|Tracheobronchitis[SugarBind_Ligand:15]|Gonorrhea[SugarBind_Ligand:15]|Actinomycosis[SugarBind_Ligand:15]|Diarrhea[SugarBind_Ligand:15]|Hemorrhagic colitis[SugarBind_Ligand:15]|Chronic gastritis[SugarBind_Ligand:15]|Peptic ulcers[SugarBind_Ligand:15]|Gastric cancer[SugarBind_Ligand:15]|Influenza[SugarBind_Ligand:15] <br>
+ '''disease_associations''' : Pharyngitis[SugarBind_Ligand:15]|Tracheobronchitis[SugarBind_Ligand:15]|Gonorrhea[SugarBind_Ligand:15]|Actinomycosis[SugarBind_Ligand:15]|Diarrhea[SugarBind_Ligand:15]|Hemorrhagic colitis[SugarBind_Ligand:15]|Chronic gastritis[SugarBind_Ligand:15]|Peptic ulcers[SugarBind_Ligand:15]|Gastric cancer[SugarBind_Ligand:15]|Influenza[SugarBind_Ligand:15] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
 ===Paucimannose===
-'''term (main_entry)''' : Paucimannose <br>
+ '''term (main_entry)''' : Paucimannose <br>
-'''glycan_dictionary_accession''' : GD000144 <br>
+ '''glycan_dictionary_accession''' : GSD000144 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The galactosylation of core fucose (GalFuc epitope) in paucimannose and complex-type N-glycans is characteristic of protostome organisms, including flatworms (planarians).[PMID:29475940] <br>
+ '''term_in_sentence''' : The galactosylation of core fucose (GalFuc epitope) in paucimannose and complex-type N-glycans is characteristic of protostome organisms, including flatworms (planarians).[PMID:[https://pubmed.ncbi.nlm.nih.gov/29475940 29475940]] <br>
-'''publication''' : 29475940|29803109|12603202|31817246|31719144|21057214|31932305|17132514|30382146|27731363|31325506|25746926|26513758|16522637|21169367|25190359|27928741|22496646|27384337|16897177|15228383|27379103|27189951|23475714|24907509|20558211|28060516|20441997|27720757|28817611|24550396|19494052|19515361|28630087|31320997|30651366|30253927|25922361|31655162|18056652|24467287|32367383 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29475940 29475940]|[https://pubmed.ncbi.nlm.nih.gov/29803109 29803109]|[https://pubmed.ncbi.nlm.nih.gov/12603202 12603202]|[https://pubmed.ncbi.nlm.nih.gov/31817246 31817246]|[https://pubmed.ncbi.nlm.nih.gov/31719144 31719144]|[https://pubmed.ncbi.nlm.nih.gov/21057214 21057214]|[https://pubmed.ncbi.nlm.nih.gov/31932305 31932305]|[https://pubmed.ncbi.nlm.nih.gov/17132514 17132514]|[https://pubmed.ncbi.nlm.nih.gov/30382146 30382146]|[https://pubmed.ncbi.nlm.nih.gov/27731363 27731363]|[https://pubmed.ncbi.nlm.nih.gov/31325506 31325506]|[https://pubmed.ncbi.nlm.nih.gov/25746926 25746926]|[https://pubmed.ncbi.nlm.nih.gov/26513758 26513758]|[https://pubmed.ncbi.nlm.nih.gov/16522637 16522637]|[https://pubmed.ncbi.nlm.nih.gov/21169367 21169367]|[https://pubmed.ncbi.nlm.nih.gov/25190359 25190359]|[https://pubmed.ncbi.nlm.nih.gov/27928741 27928741]|[https://pubmed.ncbi.nlm.nih.gov/22496646 22496646]|[https://pubmed.ncbi.nlm.nih.gov/27384337 27384337]|[https://pubmed.ncbi.nlm.nih.gov/16897177 16897177]|[https://pubmed.ncbi.nlm.nih.gov/15228383 15228383]|[https://pubmed.ncbi.nlm.nih.gov/27379103 27379103]|[https://pubmed.ncbi.nlm.nih.gov/27189951 27189951]|[https://pubmed.ncbi.nlm.nih.gov/23475714 23475714]|[https://pubmed.ncbi.nlm.nih.gov/24907509 24907509]|[https://pubmed.ncbi.nlm.nih.gov/20558211 20558211]|[https://pubmed.ncbi.nlm.nih.gov/28060516 28060516]|[https://pubmed.ncbi.nlm.nih.gov/20441997 20441997]|[https://pubmed.ncbi.nlm.nih.gov/27720757 27720757]|[https://pubmed.ncbi.nlm.nih.gov/28817611 28817611]|[https://pubmed.ncbi.nlm.nih.gov/24550396 24550396]|[https://pubmed.ncbi.nlm.nih.gov/19494052 19494052]|[https://pubmed.ncbi.nlm.nih.gov/19515361 19515361]|[https://pubmed.ncbi.nlm.nih.gov/28630087 28630087]|[https://pubmed.ncbi.nlm.nih.gov/31320997 31320997]|[https://pubmed.ncbi.nlm.nih.gov/30651366 30651366]|[https://pubmed.ncbi.nlm.nih.gov/30253927 30253927]|[https://pubmed.ncbi.nlm.nih.gov/25922361 25922361]|[https://pubmed.ncbi.nlm.nih.gov/31655162 31655162]|[https://pubmed.ncbi.nlm.nih.gov/18056652 18056652]|[https://pubmed.ncbi.nlm.nih.gov/24467287 24467287]|[https://pubmed.ncbi.nlm.nih.gov/32367383 32367383] <br>
-'''definition''' : Any N-linked glycan derivative with composition Man1-4Fuc0-1 GlcNAc2, in which the chitobiose core (GlcNAc2) is intact. Found in relatively large amounts in invertebrates and plants, they are formed by removal of the non-reducing terminal GlcNAc (\added by GlcNAcT1) from GlcNAcMan3-5GlcNAc2 by a Golgi hexosaminidase and subsequent removal of Man residues by Golgi mannosidases. Pauscimannose glycans have also been detected in vertebrates.[CHEBI:144386] <br>
+ '''definition''' : Any N-linked glycan derivative with composition Man1-4Fuc0-1 GlcNAc2, in which the chitobiose core (GlcNAc2) is intact. Found in relatively large amounts in invertebrates and plants, they are formed by removal of the non-reducing terminal GlcNAc (\added by GlcNAcT1) from GlcNAcMan3-5GlcNAc2 by a Golgi hexosaminidase and subsequent removal of Man residues by Golgi mannosidases. Pauscimannose glycans have also been detected in vertebrates.[CHEBI:144386] <br>
-'''term_xref''' : CHEBI:144386 <br>
+ '''term_xref''' : CHEBI:144386 <br>
-'''best_match''' : CHEBI:144386 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===Polysialic acid===
+ '''term (main_entry)''' : Polysialic acid<br>
+ '''glycan_dictionary_accession''' : GSD000182<br>
+ '''glytoucan_accession ''' : <br>
+ '''term_in_sentence''' : Polysialic acid (PSA) is a carbohydrate composed of a linear polymer of α2,8-linked sialic acids, primarily attached to the Neural Cell Adhesion Molecule (NCAM). [PMID:36076963]<br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/36076963 36076963]|[https://pubmed.ncbi.nlm.nih.gov/35222358 35222358]<br>
+ '''definition''' : <br>
+ '''term_xref''' : GlycoMotif:GGM.000252<br>
+ '''synonyms''' :  polySia|PSA<br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : <br>
 ===Sd(A)/Cad===
-'''term (main_entry)''' : Sd(A)/Cad <br>
+[[File:G41052GC.png|thumb|G41052GC]]
-'''glycan_dictionary_accession''' : GD000145 <br>
+ '''term (main_entry)''' : Sd(A)/Cad <br>
-'''glytoucan_accession ''' : G41052GC <br>
+ '''glycan_dictionary_accession''' : GSD000145 <br>
-'''term_in_sentence''' : The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2.[PMID:24112972] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G41052GC G41052GC] <br>
-'''publication''' : 24112972|11577689|30067891|15361072 <br>
+ '''term_in_sentence''' : The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24112972 24112972]] <br>
-'''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, β-D-galactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the galactose residue of which is also linked (1→4) an N-acetyl-β-L-galactosamine residue.
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24112972 24112972]|[https://pubmed.ncbi.nlm.nih.gov/11577689 11577689]|[https://pubmed.ncbi.nlm.nih.gov/30067891 30067891]|[https://pubmed.ncbi.nlm.nih.gov/15361072 15361072] <br>
-[CHEBI:71561] <br>
+ '''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, β-D-galactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the galactose residue of which is also linked (1→4) an N-acetyl-β-L-galactosamine residue.
-'''term_xref''' : GlycoMotif:GGM.000051|CID:70698375|CHEBI:71561 <br>
+ [CHEBI:71561] <br>
-'''best_match''' : GlycoMotif:GGM.000051|GTC:G41052GC|CID:70698375|CHEBI:71561 <br>
+ '''term_xref''' : GlycoMotif:GGM.000051|GTC:G41052GC|CID:70698375|CHEBI:71561 <br>
-'''synonymns''' : Sd^a /Cad <br>
+ '''synonyms''' : Sd^a /Cad <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453020-Chapter 9 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>
 ===SDlex===
-'''term (main_entry)''' : SDlex <br>
+[[File:G19619KS.png|thumb|G19619KS]]
-'''glycan_dictionary_accession''' : GD000146 <br>
+ '''term (main_entry)''' : SDlex <br>
-'''glytoucan_accession ''' : G19619KS <br>
+ '''glycan_dictionary_accession''' : GSD000146 <br>
-'''term_in_sentence''' : Hepatic expression of sialylated difucosyl Lex antigen (SDLex, NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-) was studied with monoclonal antibody FH6, which defines this structure.[PMID: 3341453] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G19619KS G19619KS] <br>
-'''publication''' : 30226570|3341453|12725333 <br>
+ '''term_in_sentence''' : Hepatic expression of sialylated difucosyl Lex antigen (SDLex, NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-) was studied with monoclonal antibody FH6, which defines this structure.[PMID: [https://pubmed.ncbi.nlm.nih.gov/3341453 3341453]] <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:148203] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30226570 30226570]|[https://pubmed.ncbi.nlm.nih.gov/3341453 3341453]|[https://pubmed.ncbi.nlm.nih.gov/12725333 12725333] <br>
-'''term_xref''' : GlycoMotif:GGM.000032|CID:91856705|CHEBI:148203 <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:148203] <br>
-'''best_match''' : GlycoMotif:GGM.000032|GTC:G19619KS|CID:91856705|CHEBI:148203 <br>
+ '''term_xref''' : GlycoMotif:GGM.000032|GTC:G19619KS|CID:91856705|CHEBI:148203  <br>
-'''synonymns''' : Sdlex|SDLe^x|SDLex <br>
+ '''synonyms''' : Sdlex|SDLe^x|SDLex <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
 ===Seminolipid===
-'''term (main_entry)''' : Seminolipid <br>
+[[File:G72548RZ.png|thumb|G72548RZ]]
-'''glycan_dictionary_accession''' : GD000147 <br>
+ '''term (main_entry)''' : Seminolipid <br>
-'''glytoucan_accession ''' : G72548RZ <br>
+ '''glycan_dictionary_accession''' : GSD000147 <br>
-'''term_in_sentence''' : A concise total synthesis of seminolipid, a sulfoglycolipid, has been achieved; key features include regioselective, tin-free sulfation of allyl β-d-galactopyranoside using 2,6-bis(trifluoromethyl)phenylboronic acid as protective reagent, stereoselective epoxidation, and site-selective acylation. [PMID: 31353379] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72548RZ G72548RZ] <br>
-'''publication''' : 31353379|31736776|12810822|19582571|19542524|20670037|15659616|20817833|870059|10801776|21965315|8095813|1280685|4690236|34199863|4207869|2373957|845131 <br>
+ '''term_in_sentence''' : A concise total synthesis of seminolipid, a sulfoglycolipid, has been achieved; key features include regioselective, tin-free sulfation of allyl β-d-galactopyranoside using 2,6-bis(trifluoromethyl)phenylboronic acid as protective reagent, stereoselective epoxidation, and site-selective acylation. [PMID: [https://pubmed.ncbi.nlm.nih.gov/31353379 31353379]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31353379 31353379]|[https://pubmed.ncbi.nlm.nih.gov/31736776 31736776]|[https://pubmed.ncbi.nlm.nih.gov/12810822 12810822]|[https://pubmed.ncbi.nlm.nih.gov/19582571 19582571]|[https://pubmed.ncbi.nlm.nih.gov/19542524 19542524]|[https://pubmed.ncbi.nlm.nih.gov/20670037 20670037]|[https://pubmed.ncbi.nlm.nih.gov/15659616 15659616]|[https://pubmed.ncbi.nlm.nih.gov/20817833 20817833]|[https://pubmed.ncbi.nlm.nih.gov/870059 870059]|[https://pubmed.ncbi.nlm.nih.gov/10801776 10801776]|[https://pubmed.ncbi.nlm.nih.gov/21965315 21965315]|[https://pubmed.ncbi.nlm.nih.gov/8095813 8095813]|[https://pubmed.ncbi.nlm.nih.gov/1280685 1280685]|[https://pubmed.ncbi.nlm.nih.gov/4690236 4690236]|[https://pubmed.ncbi.nlm.nih.gov/34199863 34199863]|[https://pubmed.ncbi.nlm.nih.gov/4207869 4207869]|[https://pubmed.ncbi.nlm.nih.gov/2373957 2373957]|[https://pubmed.ncbi.nlm.nih.gov/845131 845131] <br>
-'''term_xref''' : GlycoMotif:GGM.000062 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000062|GTC:G72548RZ <br>
+ '''term_xref''' : GlycoMotif:GGM.000062|GTC:G72548RZ<br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
 ===Sialopentaosylceramide===
-'''term (main_entry)''' : Sialopentaosylceramide <br>
+[[File:G13224CR.png|thumb|G13224CR]]
-'''glycan_dictionary_accession''' : GD000148 <br>
+ '''term (main_entry)''' : Sialopentaosylceramide <br>
-'''glytoucan_accession ''' : G13224CR <br>
+ '''glycan_dictionary_accession''' : GSD000148 <br>
-'''term_in_sentence''' : Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosap[PMID: 2139874] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G13224CR G13224CR] <br>
-'''publication''' : 2139874 <br>
+ '''term_in_sentence''' : Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosap[PMID: [https://pubmed.ncbi.nlm.nih.gov/2139874 2139874]] <br>
-'''definition''' : A ganglioside in which the oligosaccharide portion is composed of a pentasaccharide containing one or more sialic acid residues.[CHEBI:36542] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2139874 2139874] <br>
-'''term_xref''' : GlycoMotif:GGM.000097|CID:91859576|CHEBI:148045|KEGG:G00883|CHEBI:36542 <br>
+ '''definition''' : A ganglioside in which the oligosaccharide portion is composed of a pentasaccharide containing one or more sialic acid residues.[CHEBI:36542] <br>
-'''best_match''' : GlycoMotif:GGM.000097|GTC:G13224CR|CID:91859576|CHEBI:148045|KEGG:G00883|CHEBI:36542 <br>
+ '''term_xref''' : GlycoMotif:GGM.000097|GTC:G13224CR|CID: 91859576|CHEBI:148045|KEGG:G00883|CHEBI:36542 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Sialosyl paragloboside===
-'''term (main_entry)''' : Sialosyl paragloboside <br>
+[[File:G50123ZO.png|thumb|G50123ZO]]
-'''glycan_dictionary_accession''' : GD000149 <br>
+ '''term (main_entry)''' : Sialosyl paragloboside <br>
-'''glytoucan_accession ''' : G50123ZO <br>
+ '''glycan_dictionary_accession''' : GSD000149 <br>
-'''term_in_sentence''' : Unlike CNS myelin, human peripheral nerve myelin has the acidic glycosphingolipids sialosyl paragloboside (SPG), sialosyl lactosaminyl paragloboside (SLPG), and sulfated glucuronyl paragloboside (SGPG).[PMID:8862128] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G50123ZO G50123ZO] <br>
-'''publication''' : 8862128|7236652|2370108|3133978|2905604|1749114|1573418 <br>
+ '''term_in_sentence''' : Unlike CNS myelin, human peripheral nerve myelin has the acidic glycosphingolipids sialosyl paragloboside (SPG), sialosyl lactosaminyl paragloboside (SLPG), and sulfated glucuronyl paragloboside (SGPG).[PMID:[https://pubmed.ncbi.nlm.nih.gov/8862128 8862128]] <br>
-'''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-D-GlcpNAc with β configuration at the anomeric position of the reducing-end N-acetyl-D-glucosamine residue.[CHEBI:71612] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/8862128 8862128]|[https://pubmed.ncbi.nlm.nih.gov/7236652 7236652]|[https://pubmed.ncbi.nlm.nih.gov/2370108 2370108]|[https://pubmed.ncbi.nlm.nih.gov/3133978 3133978]|[https://pubmed.ncbi.nlm.nih.gov/2905604 2905604]|[https://pubmed.ncbi.nlm.nih.gov/1749114 1749114]|[https://pubmed.ncbi.nlm.nih.gov/1573418 1573418] <br>
-'''term_xref''' : GlycoMotif:GGM.000081|CID:91845504|KEGG:G01429|CHEBI:151914 <br>
+ '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-D-GlcpNAc with β configuration at the anomeric position of the reducing-end N-acetyl-D-glucosamine residue.[CHEBI:71612] <br>
-'''best_match''' : GlycoMotif:GGM.000081|GTC:G50123ZO|CID:91845504|KEGG:G01429|CHEBI:151914 <br>
+ '''term_xref''' : GlycoMotif:GGM.000081|GTC:G50123ZO|CID:91845504|KEGG:G01429|CHEBI:151914  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Sialyl Lewis a===
-'''term (main_entry)''' : Sialyl Lewis a <br>
+[[File:G00053MO.png|thumb|G00053MO]]
-'''glycan_dictionary_accession''' : GD000150 <br>
+ '''term (main_entry)''' : Sialyl Lewis a <br>
-'''glytoucan_accession ''' : G00053MO <br>
+ '''glycan_dictionary_accession''' : GSD000150 <br>
-'''term_in_sentence''' : By comparing the serum O-glycan profiles from healthy controls with those of cancer patients, we identified a marker candidate, core 1 sialyl Lewis A (NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal) (abbreviated C1SLA), whose concentration appeared to be weakly correlated with CA19-9 values.[PMID:26641888] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00053MO G00053MO] <br>
-'''publication''' : 26641888|31424423|26530370|17760270|18343410|16033091|8829184|11907351|20592391|26641888|24128856|30249386|10773785|16149606|10996727|10436809|10667238|7720892|7630017|10612415|9836451|12511721|22623153 <br>
+ '''term_in_sentence''' : By comparing the serum O-glycan profiles from healthy controls with those of cancer patients, we identified a marker candidate, core 1 sialyl Lewis A (NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal) (abbreviated C1SLA), whose concentration appeared to be weakly correlated with CA19-9 values.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]] <br>
-'''definition''' : A sialyated version of Lewis A with a branched structure of amino tetrasaccharide consisting of a sialyl residue, linked (2→3) to a galactosyl residue that in turn is linked (1→3) to a glucosaminyl residue at the reducing end, which is also carrying a fucosyl residue at the 4-position.[CHEBI:62681] <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]|[https://pubmed.ncbi.nlm.nih.gov/31424423 31424423]|[https://pubmed.ncbi.nlm.nih.gov/26530370 26530370]|[https://pubmed.ncbi.nlm.nih.gov/17760270 17760270]|[https://pubmed.ncbi.nlm.nih.gov/18343410 18343410]|[https://pubmed.ncbi.nlm.nih.gov/16033091 16033091]|[https://pubmed.ncbi.nlm.nih.gov/8829184 8829184]|[https://pubmed.ncbi.nlm.nih.gov/11907351 11907351]|[https://pubmed.ncbi.nlm.nih.gov/20592391 20592391]|[https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]|[https://pubmed.ncbi.nlm.nih.gov/24128856 24128856]|[https://pubmed.ncbi.nlm.nih.gov/30249386 30249386]|[https://pubmed.ncbi.nlm.nih.gov/10773785 10773785]|[https://pubmed.ncbi.nlm.nih.gov/16149606 16149606]|[https://pubmed.ncbi.nlm.nih.gov/10996727 10996727]|[https://pubmed.ncbi.nlm.nih.gov/10436809 10436809]|[https://pubmed.ncbi.nlm.nih.gov/10667238 10667238]|[https://pubmed.ncbi.nlm.nih.gov/7720892 7720892]|[https://pubmed.ncbi.nlm.nih.gov/7630017 7630017]|[https://pubmed.ncbi.nlm.nih.gov/10612415 10612415]|[https://pubmed.ncbi.nlm.nih.gov/9836451 9836451]|[https://pubmed.ncbi.nlm.nih.gov/12511721 12511721]|[https://pubmed.ncbi.nlm.nih.gov/22623153 22623153] <br>
-'''term_xref''' : GlycoEpitope:EP0008|CID:53356732|CHEBI:62681|GlycoMotif:GGM.000024 <br>
+ '''definition''' : A sialyated version of Lewis A with a branched structure of amino tetrasaccharide consisting of a sialyl residue, linked (2→3) to a galactosyl residue that in turn is linked (1→3) to a glucosaminyl residue at the reducing end, which is also carrying a fucosyl residue at the 4-position.[CHEBI:62681] <br>
-'''best_match''' : GTC:G00053MO|GlycoEpitope:EP0008|CID:53356732|CHEBI:62681|GlycoMotif:GGM.000024 <br>
+ '''term_xref''' : GTC:G00053MO|GlycoEpitope:EP0008|CID:53356732|CHEBI:62681|GlycoMotif:GGM.000024<br>
-'''synonymns''' : SLea|CA19-9|CA19-9 antigen|SLe^a|Slea <br>
+ '''synonyms''' : SLea|CA19-9|CA19-9 antigen|SLe^a|Slea <br>
-'''function''' : The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0008] <br>
+ '''function''' : The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0008] <br>
-'''disease_associations''' : pancreatic adenocarcinoma[GlycoEpitope:EP0008]|hepatocellular cancer[GlycoEpitope:EP0008]|cholangiocellular cancer[GlycoEpitope:EP0008]|gastric cancer|[GlycoEpitope:EP0008]colorectal cancer[GlycoEpitope:EP0008]|ovarian cancer[GlycoEpitope:EP0008]|lung cancer[GlycoEpitope:EP0008]|breast cancer[GlycoEpitope:EP0008]|uterine cancer[GlycoEpitope:EP0008] <br>
+ '''disease_associations''' : pancreatic adenocarcinoma[GlycoEpitope:EP0008]|hepatocellular cancer[GlycoEpitope:EP0008]|cholangiocellular cancer[GlycoEpitope:EP0008]|gastric cancer|[GlycoEpitope:EP0008]colorectal cancer[GlycoEpitope:EP0008]|ovarian cancer[GlycoEpitope:EP0008]|lung cancer[GlycoEpitope:EP0008]|breast cancer[GlycoEpitope:EP0008]|uterine cancer[GlycoEpitope:EP0008] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Sialyl Lewis x===
-'''term (main_entry)''' : Sialyl Lewis x <br>
+[[File:G00054MO.png|thumb|G00054MO]]
-'''glycan_dictionary_accession''' : GD000151 <br>
+ '''term (main_entry)''' : Sialyl Lewis x <br>
-'''glytoucan_accession ''' : G00054MO <br>
+ '''glycan_dictionary_accession''' : GSD000151 <br>
-'''term_in_sentence''' : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:12828079] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00054MO G00054MO] <br>
-'''publication''' : 12828079|8940172|10075923|19054801|9642161|31054033|15229399|29061785|16033070|10728707|9556613|8940172|9298692|18607721|22593503|25944902|9642161|15780091|20401888 <br>
+ '''term_in_sentence''' : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]] <br>
-'''definition''' : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH:2030970,CHEI:71622] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]|[https://pubmed.ncbi.nlm.nih.gov/8940172 8940172]|[https://pubmed.ncbi.nlm.nih.gov/10075923 10075923]|[https://pubmed.ncbi.nlm.nih.gov/19054801 19054801]|[https://pubmed.ncbi.nlm.nih.gov/9642161 9642161]|[https://pubmed.ncbi.nlm.nih.gov/31054033 31054033]|[https://pubmed.ncbi.nlm.nih.gov/15229399 15229399]|[https://pubmed.ncbi.nlm.nih.gov/29061785 29061785]|[https://pubmed.ncbi.nlm.nih.gov/16033070 16033070]|[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/8940172 8940172]|[https://pubmed.ncbi.nlm.nih.gov/9298692 9298692]|[https://pubmed.ncbi.nlm.nih.gov/18607721 18607721]|[https://pubmed.ncbi.nlm.nih.gov/22593503 22593503]|[https://pubmed.ncbi.nlm.nih.gov/25944902 25944902]| [https://pubmed.ncbi.nlm.nih.gov/9642161 9642161]|[https://pubmed.ncbi.nlm.nih.gov/15780091 15780091]|[https://pubmed.ncbi.nlm.nih.gov/20401888 20401888] <br>
-'''term_xref''' : GlycoEpitope:EP0012|CID:44456859|CHEBI:71622|MESH:2030970|GlycoMotif:GGM.000022 <br>
+ '''definition''' : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH:2030970],CHEI:71622 <br>
-'''best_match''' : GTC:G00054MO |GlycoEpitope:EP0012|CID:44456859|CHEBI:71622|MESH:2030970|GlycoMotif:GGM.000022 <br>
+ '''term_xref''' : GTC:G00054MO |GlycoEpitope:EP0012|CID: 44456859|CHEBI:71622|MESH:2030970|GlycoMotif:GGM.000022 <br>
-'''synonymns''' : SLe(x)|SLe^x|SLex|Slex <br>
+ '''synonyms''' : SLe(x)|SLe^x|SLex|Slex <br>
-'''function''' : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012] <br>
+ '''function''' : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012] <br>
-'''disease_associations''' : colon cancer[GlycoEpitope:EP0012]|colorectal cancer[GlycoEpitope:EP0012] <br>
+ '''disease_associations''' : colon cancer[GlycoEpitope:EP0012]|colorectal cancer[GlycoEpitope:EP0012] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Sialyl Lewis x-i===
-'''term (main_entry)''' : Sialyl Lewis x-i <br>
+[[File:G06597DS.png|thumb|G06597DS]]
-'''glycan_dictionary_accession''' : GD000152 <br>
+ '''term (main_entry)''' : Sialyl Lewis x-i <br>
-'''glytoucan_accession ''' : G06597DS <br>
+ '''glycan_dictionary_accession''' : GSD000152 <br>
-'''term_in_sentence''' : Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001).[PMID:9815711] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G06597DS G06597DS] <br>
-'''publication''' : 9815711|9730796|11867833|9713476|2819663|9372327|9615762|1352835|2575680|9330526|8753037|2210805|12680155|11974864|10453898|2565704|17144590 <br>
+ '''term_in_sentence''' : Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9815711 9815711]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9815711 9815711]|[https://pubmed.ncbi.nlm.nih.gov/9730796 9730796]|[https://pubmed.ncbi.nlm.nih.gov/11867833 11867833]|[https://pubmed.ncbi.nlm.nih.gov/9713476 9713476]|[https://pubmed.ncbi.nlm.nih.gov/2819663 2819663]|[https://pubmed.ncbi.nlm.nih.gov/9372327 9372327]|[https://pubmed.ncbi.nlm.nih.gov/9615762 9615762]|[https://pubmed.ncbi.nlm.nih.gov/1352835 1352835]|[https://pubmed.ncbi.nlm.nih.gov/2575680 2575680]|[https://pubmed.ncbi.nlm.nih.gov/9330526 9330526]|[https://pubmed.ncbi.nlm.nih.gov/8753037 8753037]|[https://pubmed.ncbi.nlm.nih.gov/2210805 2210805]|[https://pubmed.ncbi.nlm.nih.gov/12680155 12680155]|[https://pubmed.ncbi.nlm.nih.gov/11974864 11974864]|[https://pubmed.ncbi.nlm.nih.gov/10453898 10453898]|[https://pubmed.ncbi.nlm.nih.gov/2565704 2565704]|[https://pubmed.ncbi.nlm.nih.gov/17144590 17144590] <br>
-'''term_xref''' : GlycoEpitope:EP0043|CID:91855346|CHEBI:147019 <br>
+ '''definition''' :  <br>
-'''best_match''' : GTC:G06597DS|GlycoEpitope:EP0043|CID:91855346|CHEBI:147019 <br>
+ '''term_xref''' : GTC:G06597DS|GlycoEpitope:EP0043|CID: 91855346|CHEBI:147019 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043] <br>
+ '''function''' : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043] <br>
-'''disease_associations''' : lung cancer[GlycoEpitope:EP0043]|ovarian cancer[GlycoEpitope:EP0043]|pancreatic adenocarcinoma[GlycoEpitope:EP0043] <br>
+ '''disease_associations''' : lung cancer[GlycoEpitope:EP0043]|ovarian cancer[GlycoEpitope:EP0043]|pancreatic adenocarcinoma[GlycoEpitope:EP0043] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Sialyl T antigen===
-'''term (main_entry)''' : Sialyl T antigen <br>
+[[File:G65562ZE.png|thumb|G65562ZE]]
-'''glycan_dictionary_accession''' : GD000153 <br>
+ '''term (main_entry)''' : Sialyl T antigen <br>
-'''glytoucan_accession ''' : G65562ZE <br>
+ '''glycan_dictionary_accession''' : GSD000153 <br>
-'''term_in_sentence''' : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:32583304] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G65562ZE G65562ZE] <br>
-'''publication''' : 32583304|31897478|31719620|10365852|25727149|11523928|20407596|25464017|30864133|26391208|19811634|29796594|23725156|8905873|11192238|18275089|27037304|11949946|15604091|24118321 <br>
+ '''term_in_sentence''' : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]] <br>
-'''definition''' : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]|[https://pubmed.ncbi.nlm.nih.gov/31897478 31897478]|[https://pubmed.ncbi.nlm.nih.gov/31719620 31719620]| [https://pubmed.ncbi.nlm.nih.gov/10365852 10365852]|[https://pubmed.ncbi.nlm.nih.gov/25727149 25727149]|[https://pubmed.ncbi.nlm.nih.gov/11523928 11523928]|[https://pubmed.ncbi.nlm.nih.gov/20407596 20407596]|[https://pubmed.ncbi.nlm.nih.gov/25464017 25464017]|[https://pubmed.ncbi.nlm.nih.gov/30864133 30864133]|[https://pubmed.ncbi.nlm.nih.gov/26391208 26391208]|[https://pubmed.ncbi.nlm.nih.gov/19811634 19811634]|[https://pubmed.ncbi.nlm.nih.gov/29796594 29796594]|[https://pubmed.ncbi.nlm.nih.gov/23725156 23725156]|[https://pubmed.ncbi.nlm.nih.gov/8905873 8905873]|[https://pubmed.ncbi.nlm.nih.gov/11192238 11192238]|[https://pubmed.ncbi.nlm.nih.gov/18275089 18275089]|[https://pubmed.ncbi.nlm.nih.gov/27037304 27037304]|[https://pubmed.ncbi.nlm.nih.gov/11949946 11949946]|[https://pubmed.ncbi.nlm.nih.gov/15604091 15604091]|[https://pubmed.ncbi.nlm.nih.gov/24118321 24118321] <br>
-'''term_xref''' : GlycoMotif:GGM.000013|CID:44611726|CHEBI:65257 <br>
+ '''definition''' : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257] <br>
-'''best_match''' : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:44611726|CHEBI:65257 <br>
+ '''term_xref''' : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:44611726|CHEBI:65257  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Sialylated biantennary===
-'''term (main_entry)''' : Sialylated biantennary <br>
+ '''term (main_entry)''' : Sialylated biantennary <br>
-'''glycan_dictionary_accession''' : GD000154 <br>
+ '''glycan_dictionary_accession''' : GSD000154 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Simbucus nigra agglutinin or an antibody specific to sialylated lactosamine with a preference for Neu5Acalpha2-6Gal rather than Neu5Acalpha2-3Gal reduced sperm binding to oviduct isthmic cells, as did occupying putative receptors on sperm with sialylated biantennary glycans.[PMID:23115267] <br>
+ '''term_in_sentence''' : Simbucus nigra agglutinin or an antibody specific to sialylated lactosamine with a preference for Neu5Acalpha2-6Gal rather than Neu5Acalpha2-3Gal reduced sperm binding to oviduct isthmic cells, as did occupying putative receptors on sperm with sialylated biantennary glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]] <br>
-'''publication''' : 23115267|31510952|29265394|31589880|3979568|26045275|29029079|30252064 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]|[https://pubmed.ncbi.nlm.nih.gov/31510952 31510952]|[https://pubmed.ncbi.nlm.nih.gov/29265394 29265394]|[https://pubmed.ncbi.nlm.nih.gov/31589880 31589880]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/26045275 26045275]|[https://pubmed.ncbi.nlm.nih.gov/29029079 29029079]|[https://pubmed.ncbi.nlm.nih.gov/30252064 30252064] <br>
-'''definition''' : A binantennary glycan with one or two sialic acid residues as non-reducing terminal residues on one or both antennae. [RN] <br>
+ '''definition''' : A binantennary glycan with one or two sialic acid residues as non-reducing terminal residues on one or both antennae. [RN] <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+  '''synonyms''' : sialyl biantennary <br>
-'''synonymns''' : sialyl biantennary <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Sialylated complex-type===
-'''term (main_entry)''' : Sialylated complex-type <br>
+ '''term (main_entry)''' : Sialylated complex-type <br>
-'''glycan_dictionary_accession''' : GD000155 <br>
+ '''glycan_dictionary_accession''' : GSD000155 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : By using 1H-NMR spectroscopy we were able to establish that our product contains a single N-linked biantennary , fully sialylated complex-type oligosaccharide , typical of human hepatomas.[PMID:1694115] <br>
+ '''term_in_sentence''' : By using 1H-NMR spectroscopy we were able to establish that our product contains a single N-linked biantennary , fully sialylated complex-type oligosaccharide , typical of human hepatomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1694115 1694115]] <br>
-'''publication''' : 1694115|15201278|30471292|30969765|11058758|28342150 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1694115 1694115]|[https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]|[https://pubmed.ncbi.nlm.nih.gov/30471292 30471292]|[https://pubmed.ncbi.nlm.nih.gov/30969765 30969765]|[https://pubmed.ncbi.nlm.nih.gov/11058758 11058758]|[https://pubmed.ncbi.nlm.nih.gov/28342150 28342150] <br>
-'''definition''' : Complex N-linked glycan that have added GlcNAc residues at both the α-3 and α-6 mannose sites and do not contain mannose residues apart from the core structure but with sialic acid residues. <br>
+ '''definition''' : Complex N-linked glycan that have added GlcNAc residues at both the α-3 and α-6 mannose sites and do not contain mannose residues apart from the core structure but with sialic acid residues. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+  '''synonyms''' : sialo-complex type <br>
-'''synonymns''' : sialo-complex type <br>
+ '''function''' : enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes [PMID: [https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]] Appears in IgG-Fc.[PMID:[https://pubmed.ncbi.nlm.nih.gov/20647032 20647032] ] <br>
-'''function''' : enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes [PMID: 15201278] Appears in IgG-Fc.[PMID:20647032 ] <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
-'''essentials_of_glycobiology''' : NBK453030 <br>
+===Sialylated LacdiNAc===
+[[File:G55583HW.png|thumb|G55583HW]]
+ '''term (main_entry)''' : Sialylated LacdiNAc<br>
+ '''glycan_dictionary_accession''' : GSD000192<br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G55583HW G55583HW] <br>
+ '''term_in_sentence''' :  The major non-reducing epitopes in the complex-type glycans are: Gal beta 1-4GlcNAc (lacNAc), GalNAc beta 1-4GlcNAc (lacdiNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacdiNAc), Gal beta 1-4(Fuc alpha 1-3)GlcNAc (Lewisx), and GalNAc beta 1-4(Fuc alpha 1-3)GlcNAc (lacdiNAc analogue of Lewisx).[PMID:7592613]<br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/7592613 7592613]|[https://pubmed.ncbi.nlm.nih.gov/34192302 34192302]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/16286643 16286643]<br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000050<br>
+ '''synonyms''' :  sialylated-LacdiNAc|Sialylated LDN<br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Sialylated tetraantennary===
-'''term (main_entry)''' : Sialylated tetraantennary <br>
+ '''term (main_entry)''' : Sialylated tetraantennary <br>
-'''glycan_dictionary_accession''' : GD000156 <br>
+ '''glycan_dictionary_accession''' : GSD000156 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:16321355] <br>
+ '''term_in_sentence''' : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]] <br>
-'''publication''' : 16321355|1940447|27501865 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]|[https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865] <br>
-'''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
+ '''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Sialyl-Tn antigen===
-'''term (main_entry)''' : Sialyl-Tn antigen <br>
+[[File:G36123IU.png|thumb|G36123IU]]
-'''glycan_dictionary_accession''' : GD000157 <br>
+ '''term (main_entry)''' : Sialyl-Tn antigen <br>
-'''glytoucan_accession ''' : G36123IU <br>
+ '''glycan_dictionary_accession''' : GSD000157 <br>
-'''term_in_sentence''' : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:23035012] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G36123IU G36123IU] <br>
-'''publication''' : 23035012|29273237|15770530|31595388|26617889|1720922|15466199|10971172|14652017|8616877|1543361|16965854|21566901|9269833|9834267|24970145|22367369|10778170|30018351|28628803|16149605|32134186|28632300|11308020|10365852|17195456|23567325|11014575|2342728|8575847|1851822|11735169|20960853|7846011 <br>
+ '''term_in_sentence''' : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]] <br>
-'''definition''' : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]|[https://pubmed.ncbi.nlm.nih.gov/29273237 29273237]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/31595388 31595388]|[https://pubmed.ncbi.nlm.nih.gov/26617889 26617889]|[https://pubmed.ncbi.nlm.nih.gov/1720922 1720922]|[https://pubmed.ncbi.nlm.nih.gov/15466199 15466199]|[https://pubmed.ncbi.nlm.nih.gov/10971172 10971172]|[https://pubmed.ncbi.nlm.nih.gov/14652017 14652017]|[https://pubmed.ncbi.nlm.nih.gov/8616877 8616877]|[https://pubmed.ncbi.nlm.nih.gov/1543361 1543361]|[https://pubmed.ncbi.nlm.nih.gov/16965854 16965854]|[https://pubmed.ncbi.nlm.nih.gov/21566901 21566901]|[https://pubmed.ncbi.nlm.nih.gov/9269833 9269833]|[https://pubmed.ncbi.nlm.nih.gov/9834267 9834267]|[https://pubmed.ncbi.nlm.nih.gov/24970145 24970145]|[https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]|[https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/30018351 30018351]|[https://pubmed.ncbi.nlm.nih.gov/28628803 28628803]|[https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/28632300 28632300]|[https://pubmed.ncbi.nlm.nih.gov/11308020 11308020]| [https://pubmed.ncbi.nlm.nih.gov/10365852 10365852]|[https://pubmed.ncbi.nlm.nih.gov/17195456 17195456]|[https://pubmed.ncbi.nlm.nih.gov/23567325 23567325]|[https://pubmed.ncbi.nlm.nih.gov/11014575 11014575]|[https://pubmed.ncbi.nlm.nih.gov/2342728 2342728]|[https://pubmed.ncbi.nlm.nih.gov/8575847 8575847]|[https://pubmed.ncbi.nlm.nih.gov/1851822 1851822]|[https://pubmed.ncbi.nlm.nih.gov/11735169 11735169]|[https://pubmed.ncbi.nlm.nih.gov/20960853 20960853]|[https://pubmed.ncbi.nlm.nih.gov/7846011 7846011] <br>
-'''term_xref''' : GlycoEpitope:EP0022|CID:51351800|CHEBI:61818 <br>
+ '''definition''' : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818] <br>
-'''best_match''' : GTC:G36123IU|GlycoEpitope:EP0022|CID:51351800|CHEBI:61818 <br>
+ '''term_xref''' : GTC:G36123IU|GlycoEpitope:EP0022|CID:51351800|CHEBI:61818 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022] <br>
+ '''function''' : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022] <br>
-'''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0022]|Barrett's esophagus[GlycoEpitope:EP0022]|bladder cancer[GlycoEpitope:EP0022]|breast cancer[GlycoEpitope:EP0022]|colon cancer[GlycoEpitope:EP0022]|colorectal cancer[GlycoEpitope:EP0022]|erythroblastic leukemia[GlycoEpitope:EP0022]|esophageal cancer[GlycoEpitope:EP0022]|gastric cancer[GlycoEpitope:EP0022]|helicobacter pylori chronic gastritis(HpCG)[GlycoEpitope:EP0022]|liver cancer[GlycoEpitope:EP0022]|iterome cancer[GlycoEpitope:EP0022]|ovary tumor[GlycoEpitope:EP0022]|pancreas cancer[GlycoEpitope:EP0022] <br>
+ '''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0022]|Barrett's esophagus[GlycoEpitope:EP0022]|bladder cancer[GlycoEpitope:EP0022]|breast cancer[GlycoEpitope:EP0022]|colon cancer[GlycoEpitope:EP0022]|colorectal cancer[GlycoEpitope:EP0022]|erythroblastic leukemia[GlycoEpitope:EP0022]|esophageal cancer[GlycoEpitope:EP0022]|gastric cancer[GlycoEpitope:EP0022]|helicobacter pylori chronic gastritis(HpCG)[GlycoEpitope:EP0022]|liver cancer[GlycoEpitope:EP0022]|iterome cancer[GlycoEpitope:EP0022]|ovary tumor[GlycoEpitope:EP0022]|pancreas cancer[GlycoEpitope:EP0022] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453027 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453027/ Chapter 56]<br>
 ===SLex Core 2 O-glycan===
-'''term (main_entry)''' : SLex Core 2 O-glycan <br>
+ '''term (main_entry)''' : SLex Core 2 O-glycan <br>
-'''glycan_dictionary_accession''' : GD000158 <br>
+ '''glycan_dictionary_accession''' : GSD000158 <br>
-'''glytoucan_accession ''' : G97345NY <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97345NY G97345NY] <br>
-'''term_in_sentence''' : In particular, the sLeX-modified core 2 O-glycan structure C2-O-sLeX has been directly demonstrated to confer significantly higher affinity selectin binding than sLeX.[PMID:15596301] <br>
+ '''term_in_sentence''' : In particular, the sLeX-modified core 2 O-glycan structure C2-O-sLeX has been directly demonstrated to confer significantly higher affinity selectin binding than sLeX.[PMID:[https://pubmed.ncbi.nlm.nih.gov/15596301 15596301]] <br>
-'''publication''' : 15596301 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15596301 15596301] <br>
-'''definition''' :  <br>
+ '''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000053 <br>
+ '''term_xref''' : GlycoMotif:GGM.000053|GTC:G97345NY <br>
-'''best_match''' : GlycoMotif:GGM.000053|GTC:G97345NY <br>
+ '''synonyms''' : SLe^x Core 2 O-glycan <br>
-'''synonymns''' : SLe^x Core 2 O-glycan <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===SSEA-1===
-'''term (main_entry)''' : SSEA-1 <br>
+[[File:G85497PI.png|thumb|G85497PI]]
-'''glycan_dictionary_accession''' : GD000159 <br>
+ '''term (main_entry)''' : SSEA-1 <br>
-'''glytoucan_accession ''' : G85497PI <br>
+ '''glycan_dictionary_accession''' : GSD000159 <br>
-'''term_in_sentence''' : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:27550342] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G85497PI G85497PI] <br>
-'''publication''' : 27550342|25564944|30987116|10778174|19427293|24923741|28092949|16499901|10470652|18787210|2885312|16149609|17003364|27363517|15505339|27990704|2568298|20491542|23572256|1977666|9553168|20458727|2566639|14577357|20960856|15547746|9096265|30639212|1357195|1359630|20181261|20508065|2907526|22624699|22988836|17183690|27188587|7908065|10400391|6137429|1979260|2898921|14736812|30919971 <br>
+ '''term_in_sentence''' : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]|[https://pubmed.ncbi.nlm.nih.gov/25564944 25564944]|[https://pubmed.ncbi.nlm.nih.gov/30987116 30987116]|[https://pubmed.ncbi.nlm.nih.gov/10778174 10778174]|[https://pubmed.ncbi.nlm.nih.gov/19427293 19427293]|[https://pubmed.ncbi.nlm.nih.gov/24923741 24923741]|[https://pubmed.ncbi.nlm.nih.gov/28092949 28092949]|[https://pubmed.ncbi.nlm.nih.gov/16499901 16499901]|[https://pubmed.ncbi.nlm.nih.gov/10470652 10470652]|[https://pubmed.ncbi.nlm.nih.gov/18787210 18787210]|[https://pubmed.ncbi.nlm.nih.gov/2885312 2885312]|[https://pubmed.ncbi.nlm.nih.gov/16149609 16149609]|[https://pubmed.ncbi.nlm.nih.gov/17003364 17003364]|[https://pubmed.ncbi.nlm.nih.gov/27363517 27363517]|[https://pubmed.ncbi.nlm.nih.gov/15505339 15505339]|[https://pubmed.ncbi.nlm.nih.gov/27990704 27990704]|[https://pubmed.ncbi.nlm.nih.gov/2568298 2568298]|[https://pubmed.ncbi.nlm.nih.gov/20491542 20491542]|[https://pubmed.ncbi.nlm.nih.gov/23572256 23572256]|[https://pubmed.ncbi.nlm.nih.gov/1977666 1977666]|[https://pubmed.ncbi.nlm.nih.gov/9553168 9553168]|[https://pubmed.ncbi.nlm.nih.gov/20458727 20458727]|[https://pubmed.ncbi.nlm.nih.gov/2566639 2566639]|[https://pubmed.ncbi.nlm.nih.gov/14577357 14577357]|[https://pubmed.ncbi.nlm.nih.gov/20960856 20960856]|[https://pubmed.ncbi.nlm.nih.gov/15547746 15547746]|[https://pubmed.ncbi.nlm.nih.gov/9096265 9096265]|[https://pubmed.ncbi.nlm.nih.gov/30639212 30639212]|[https://pubmed.ncbi.nlm.nih.gov/1357195 1357195]|[https://pubmed.ncbi.nlm.nih.gov/1359630 1359630]|[https://pubmed.ncbi.nlm.nih.gov/20181261 20181261]|[https://pubmed.ncbi.nlm.nih.gov/20508065 20508065]|[https://pubmed.ncbi.nlm.nih.gov/2907526 2907526]|[https://pubmed.ncbi.nlm.nih.gov/22624699 22624699]|[https://pubmed.ncbi.nlm.nih.gov/22988836 22988836]|[https://pubmed.ncbi.nlm.nih.gov/17183690 17183690]|[https://pubmed.ncbi.nlm.nih.gov/27188587 27188587]|[https://pubmed.ncbi.nlm.nih.gov/7908065 7908065]|[https://pubmed.ncbi.nlm.nih.gov/10400391 10400391]|[https://pubmed.ncbi.nlm.nih.gov/6137429 6137429]|[https://pubmed.ncbi.nlm.nih.gov/1979260 1979260]|[https://pubmed.ncbi.nlm.nih.gov/2898921 2898921]|[https://pubmed.ncbi.nlm.nih.gov/14736812 14736812]|[https://pubmed.ncbi.nlm.nih.gov/30919971 30919971] <br>
-'''term_xref''' : GlycoEpitope:EP0042|CID:91851144|CHEBI:154343 <br>
+ '''definition''' :  <br>
-'''best_match''' : GTC:G85497PI |GlycoEpitope:EP0042|CID:91851144|CHEBI:154343 <br>
+ '''term_xref''' : GTC:G85497PI |GlycoEpitope:EP0042|CID:91851144|CHEBI:154343  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042] <br>
+ '''function''' : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042] <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453030 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
 ===SSEA-3===
-'''term (main_entry)''' : SSEA-3 <br>
+[[File:G25129BT.png|thumb|G25129BT]]
-'''glycan_dictionary_accession''' : GD000160 <br>
+ '''term (main_entry)''' : SSEA-3 <br>
-'''glytoucan_accession ''' : G25129BT <br>
+ '''glycan_dictionary_accession''' : GSD000160 <br>
-'''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:31817926] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25129BT G25129BT] <br>
-'''publication''' : 31817926|30271856|32684574|26677875|23175153|32525407|29227830|18773292|25561682|10837462|2412924|21149348|17008424|2874662|25171543|31304790|31642560|30484221|30525067|21161592|27325407|28170296|29637816|27318475|31346146|7648586|24236059|21964054|27456773|30558911|21559451|29312455|27549315|30599359|6141938|28883415|30733757|26041528|16643871 <br>
+ '''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID: [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]] <br>
-'''definition''' : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]|[https://pubmed.ncbi.nlm.nih.gov/30271856 30271856]|[https://pubmed.ncbi.nlm.nih.gov/32684574 32684574]|[https://pubmed.ncbi.nlm.nih.gov/26677875 26677875]|[https://pubmed.ncbi.nlm.nih.gov/23175153 23175153]|[https://pubmed.ncbi.nlm.nih.gov/32525407 32525407]| [https://pubmed.ncbi.nlm.nih.gov/29227830 29227830]| [https://pubmed.ncbi.nlm.nih.gov/18773292 18773292]|[https://pubmed.ncbi.nlm.nih.gov/25561682 25561682]|[https://pubmed.ncbi.nlm.nih.gov/10837462 10837462]|[https://pubmed.ncbi.nlm.nih.gov/2412924 2412924]|[https://pubmed.ncbi.nlm.nih.gov/21149348 21149348]| [https://pubmed.ncbi.nlm.nih.gov/17008424 17008424]| [https://pubmed.ncbi.nlm.nih.gov/2874662 2874662]|[https://pubmed.ncbi.nlm.nih.gov/25171543 25171543]|[https://pubmed.ncbi.nlm.nih.gov/31304790 31304790]|[https://pubmed.ncbi.nlm.nih.gov/31642560 31642560]|[https://pubmed.ncbi.nlm.nih.gov/30484221 30484221]|[https://pubmed.ncbi.nlm.nih.gov/30525067 30525067]|[https://pubmed.ncbi.nlm.nih.gov/21161592 21161592]|[https://pubmed.ncbi.nlm.nih.gov/27325407 27325407]|[https://pubmed.ncbi.nlm.nih.gov/28170296 28170296]|[https://pubmed.ncbi.nlm.nih.gov/29637816 29637816]| [https://pubmed.ncbi.nlm.nih.gov/27318475 27318475]|[https://pubmed.ncbi.nlm.nih.gov/31346146 31346146]|[https://pubmed.ncbi.nlm.nih.gov/7648586 7648586]|[https://pubmed.ncbi.nlm.nih.gov/24236059 24236059]|[https://pubmed.ncbi.nlm.nih.gov/21964054 21964054]|[https://pubmed.ncbi.nlm.nih.gov/27456773 27456773]|[https://pubmed.ncbi.nlm.nih.gov/30558911 30558911]|[https://pubmed.ncbi.nlm.nih.gov/21559451 21559451]|[https://pubmed.ncbi.nlm.nih.gov/29312455 29312455]|[https://pubmed.ncbi.nlm.nih.gov/27549315 27549315]|[https://pubmed.ncbi.nlm.nih.gov/30599359 30599359]|[https://pubmed.ncbi.nlm.nih.gov/6141938 6141938]|[https://pubmed.ncbi.nlm.nih.gov/28883415 28883415]|[https://pubmed.ncbi.nlm.nih.gov/30733757 30733757]|[https://pubmed.ncbi.nlm.nih.gov/26041528 26041528]|[https://pubmed.ncbi.nlm.nih.gov/16643871 16643871] <br>
-'''term_xref''' : GlycoEpitope:EP0039|CID:91855781|CHEBI:149071|GlycoMotif:GGM.000079 <br>
+ '''definition''' : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071] <br>
-'''best_match''' : GTC:G25129BT|GlycoEpitope:EP0039|CID:91855781|CHEBI:149071|GlycoMotif:GGM.000079 <br>
+ '''term_xref''' : GTC:G25129BT|GlycoEpitope:EP0039|CID:91855781|CHEBI:149071|GlycoMotif:GGM.000079 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : embryonal carcinoma[GlycoEpitope:EP0039]|teratocarcinoma[GlycoEpitope:EP0039]|yolk sac carcinoma[GlycoEpitope:EP0039] <br>
+ '''disease_associations''' : embryonal carcinoma[GlycoEpitope:EP0039]|teratocarcinoma[GlycoEpitope:EP0039]|yolk sac carcinoma[GlycoEpitope:EP0039] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===SSEA-4===
-'''term (main_entry)''' : SSEA-4 <br>
+[[File:G84263XI.png|thumb|G84263XI]]
-'''glycan_dictionary_accession''' : GD000161 <br>
+ '''term (main_entry)''' : SSEA-4 <br>
-'''glytoucan_accession ''' : G84263XI <br>
+ '''glycan_dictionary_accession''' : GSD000161 <br>
-'''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:31817926] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G84263XI G84263XI] <br>
-'''publication''' : 27845370|31817926|26295543|25171543|25978997|30296654|25853231|24862940|31243630|28736232|22895512|24578244|29478902|23574147|23768762|27797400|29227830|18773292|25123923|22924692|22665977|23330736|31831622|31916611|2412924|16033656|24866102|20458727|21149348|26940129|17008424|2874662|23301556|27836003|19118716|24550271|32988880|22743677|20683402|17062733|23570331|30310530|31545316|23509763|24364909|18273440|28985528|22266579 <br>
+ '''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]] <br>
-'''definition''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27845370 27845370]|[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]|[https://pubmed.ncbi.nlm.nih.gov/26295543 26295543]| [https://pubmed.ncbi.nlm.nih.gov/25171543 25171543]|[https://pubmed.ncbi.nlm.nih.gov/25978997 25978997]|[https://pubmed.ncbi.nlm.nih.gov/30296654 30296654]|[https://pubmed.ncbi.nlm.nih.gov/25853231 25853231]|[https://pubmed.ncbi.nlm.nih.gov/24862940 24862940]|[https://pubmed.ncbi.nlm.nih.gov/31243630 31243630]|[https://pubmed.ncbi.nlm.nih.gov/28736232 28736232]|[https://pubmed.ncbi.nlm.nih.gov/22895512 22895512]|[https://pubmed.ncbi.nlm.nih.gov/24578244 24578244]|[https://pubmed.ncbi.nlm.nih.gov/29478902 29478902]|[https://pubmed.ncbi.nlm.nih.gov/23574147 23574147]|[https://pubmed.ncbi.nlm.nih.gov/23768762 23768762]|[https://pubmed.ncbi.nlm.nih.gov/27797400 27797400]|[https://pubmed.ncbi.nlm.nih.gov/29227830 29227830]| [https://pubmed.ncbi.nlm.nih.gov/18773292 18773292]|[https://pubmed.ncbi.nlm.nih.gov/25123923 25123923]|[https://pubmed.ncbi.nlm.nih.gov/22924692 22924692]|[https://pubmed.ncbi.nlm.nih.gov/22665977 22665977]|[https://pubmed.ncbi.nlm.nih.gov/23330736 23330736]|[https://pubmed.ncbi.nlm.nih.gov/31831622 31831622]|[https://pubmed.ncbi.nlm.nih.gov/31916611 31916611]| [https://pubmed.ncbi.nlm.nih.gov/2412924 2412924]|[https://pubmed.ncbi.nlm.nih.gov/16033656 16033656]|[https://pubmed.ncbi.nlm.nih.gov/24866102 24866102]| [https://pubmed.ncbi.nlm.nih.gov/20458727 20458727]| [https://pubmed.ncbi.nlm.nih.gov/21149348 21149348]|[https://pubmed.ncbi.nlm.nih.gov/26940129 26940129]| [https://pubmed.ncbi.nlm.nih.gov/17008424 17008424]| [https://pubmed.ncbi.nlm.nih.gov/2874662 2874662]|[https://pubmed.ncbi.nlm.nih.gov/23301556 23301556]|[https://pubmed.ncbi.nlm.nih.gov/27836003 27836003]|[https://pubmed.ncbi.nlm.nih.gov/19118716 19118716]|[https://pubmed.ncbi.nlm.nih.gov/24550271 24550271]|[https://pubmed.ncbi.nlm.nih.gov/32988880 32988880]|[https://pubmed.ncbi.nlm.nih.gov/22743677 22743677]|[https://pubmed.ncbi.nlm.nih.gov/20683402 20683402]|[https://pubmed.ncbi.nlm.nih.gov/17062733 17062733]|[https://pubmed.ncbi.nlm.nih.gov/23570331 23570331]|[https://pubmed.ncbi.nlm.nih.gov/30310530 30310530]|[https://pubmed.ncbi.nlm.nih.gov/31545316 31545316]|[https://pubmed.ncbi.nlm.nih.gov/23509763 23509763]|[https://pubmed.ncbi.nlm.nih.gov/24364909 24364909]|[https://pubmed.ncbi.nlm.nih.gov/18273440 18273440]|[https://pubmed.ncbi.nlm.nih.gov/28985528 28985528]|[https://pubmed.ncbi.nlm.nih.gov/22266579 22266579] <br>
-'''term_xref''' : GlycoEpitope:EP0044|CID:91845478|CHEBI:154843 <br>
+ '''definition''' :  <br>
-'''best_match''' : GTC:G84263XI|GlycoEpitope:EP0044|CID:91845478|CHEBI:154843 <br>
+ '''term_xref''' : GTC:G84263XI|GlycoEpitope:EP0044|CID: 91845478|CHEBI:154843 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : teratocarcinoma[GlycoEpitope:EP0044] <br>
+ '''disease_associations''' : teratocarcinoma[GlycoEpitope:EP0044] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453023-Chapter 47 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47] <br>
+===Sulfated LacdiNAc===
+[[File:G18464VS.png|thumb|G18464VS]]
+ '''term (main_entry)''' : Sulfated LacdiNAc<br>
+ '''glycan_dictionary_accession''' : GSD000191<br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18464VS G18464VS] <br>
+ '''term_in_sentence''' :  The mRNA expression of the enzymes related to the formation of sulfated LacdiNAc:β(1,4)-N-acetylgalactosaminyltransferases 3 (B4GALNT3) and 4 (B4GALNT4), carbohydrate sulfotransferases 8 (CHST8) and 9 (CHST9); and β(1,4)-galactosyltransferase 1 (B4GALT1) in these cells was confirmed by RT-PCR (Fig. S4).[PMID:31558607]<br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/31558607 31558607]|[https://pubmed.ncbi.nlm.nih.gov/27318476 27318476]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/11279168 11279168]|[https://pubmed.ncbi.nlm.nih.gov/26688390 26688390]<br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000049<br>
+ '''synonyms''' :  4'-O-sulfated LacdiNAc|4'-sulfated LDN|sulfated LDN<br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :
 ===Sulfatide===
-'''term (main_entry)''' : Sulfatide <br>
+ '''term (main_entry)''' : Sulfatide <br>
-'''glycan_dictionary_accession''' : GD000162 <br>
+ '''glycan_dictionary_accession''' : GSD000162 <br>
-'''glytoucan_accession ''' : G72548RZ <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72548RZ G72548RZ] <br>
-'''term_in_sentence''' : In a previous study we found that sulfatide was efficient in lowering HIV-1 viral loads in SCID mice engrafted with human fetal liver/thymus tissues (SCID-hu).[PMID:23550344] <br>
+ '''term_in_sentence''' : In a previous study we found that sulfatide was efficient in lowering HIV-1 viral loads in SCID mice engrafted with human fetal liver/thymus tissues (SCID-hu).[PMID:[https://pubmed.ncbi.nlm.nih.gov/23550344 23550344]] <br>
-'''publication''' : 23550344|18465098|26542149|15158666|10434709|22619219|29676479|30196830|16143863|1052451|30400820|29887538|26981544|17986152|31739035|19941861|24578319|30531843|25645724|31197846|22821828|27861899|31037952|23593400|23604989|17855742|25966258|25989600|9657940|29497057|12838515|25170267|9878314|20554435|1410493|26585924|17257892|17044925|21089387|11445552|22977233|21437360|17179664|6273571|8370675 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23550344 23550344]|[https://pubmed.ncbi.nlm.nih.gov/18465098 18465098]|[https://pubmed.ncbi.nlm.nih.gov/26542149 26542149]|[https://pubmed.ncbi.nlm.nih.gov/15158666 15158666]|[https://pubmed.ncbi.nlm.nih.gov/10434709 10434709]|[https://pubmed.ncbi.nlm.nih.gov/22619219 22619219]|[https://pubmed.ncbi.nlm.nih.gov/29676479 29676479]|[https://pubmed.ncbi.nlm.nih.gov/30196830 30196830]|[https://pubmed.ncbi.nlm.nih.gov/16143863 16143863]|[https://pubmed.ncbi.nlm.nih.gov/1052451 1052451]|[https://pubmed.ncbi.nlm.nih.gov/30400820 30400820]|[https://pubmed.ncbi.nlm.nih.gov/29887538 29887538]|[https://pubmed.ncbi.nlm.nih.gov/26981544 26981544]|[https://pubmed.ncbi.nlm.nih.gov/17986152 17986152]|[https://pubmed.ncbi.nlm.nih.gov/31739035 31739035]|[https://pubmed.ncbi.nlm.nih.gov/19941861 19941861]|[https://pubmed.ncbi.nlm.nih.gov/24578319 24578319]|[https://pubmed.ncbi.nlm.nih.gov/30531843 30531843]|[https://pubmed.ncbi.nlm.nih.gov/25645724 25645724]|[https://pubmed.ncbi.nlm.nih.gov/31197846 31197846]|[https://pubmed.ncbi.nlm.nih.gov/22821828 22821828]|[https://pubmed.ncbi.nlm.nih.gov/27861899 27861899]|[https://pubmed.ncbi.nlm.nih.gov/31037952 31037952]|[https://pubmed.ncbi.nlm.nih.gov/23593400 23593400]|[https://pubmed.ncbi.nlm.nih.gov/23604989 23604989]|[https://pubmed.ncbi.nlm.nih.gov/17855742 17855742]|[https://pubmed.ncbi.nlm.nih.gov/25966258 25966258]|[https://pubmed.ncbi.nlm.nih.gov/25989600 25989600]|[https://pubmed.ncbi.nlm.nih.gov/9657940 9657940]|[https://pubmed.ncbi.nlm.nih.gov/29497057 29497057]|[https://pubmed.ncbi.nlm.nih.gov/12838515 12838515]|[https://pubmed.ncbi.nlm.nih.gov/25170267 25170267]|[https://pubmed.ncbi.nlm.nih.gov/9878314 9878314]|[https://pubmed.ncbi.nlm.nih.gov/20554435 20554435]|[https://pubmed.ncbi.nlm.nih.gov/1410493 1410493]|[https://pubmed.ncbi.nlm.nih.gov/26585924 26585924]|[https://pubmed.ncbi.nlm.nih.gov/17257892 17257892]|[https://pubmed.ncbi.nlm.nih.gov/17044925 17044925]|[https://pubmed.ncbi.nlm.nih.gov/21089387 21089387]|[https://pubmed.ncbi.nlm.nih.gov/11445552 11445552]|[https://pubmed.ncbi.nlm.nih.gov/22977233 22977233]|[https://pubmed.ncbi.nlm.nih.gov/21437360 21437360]|[https://pubmed.ncbi.nlm.nih.gov/17179664 17179664]|[https://pubmed.ncbi.nlm.nih.gov/6273571 6273571]|[https://pubmed.ncbi.nlm.nih.gov/8370675 8370675] <br>
-'''definition''' :  <br>
+ '''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000063 <br>
+ '''term_xref''' : GlycoMotif:GGM.000063|GTC:G72548RZ <br>
-'''best_match''' : GlycoMotif:GGM.000063|GTC:G72548RZ <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
-'''essentials_of_glycobiology''' : NBK453023-Chapter 47 <br>
 ===T antigen===
-'''term (main_entry)''' : T antigen <br>
+[[File:G00031MO.png|thumb|G00031MO]]
-'''glycan_dictionary_accession''' : GD000163 <br>
+ '''term (main_entry)''' : T antigen <br>
-'''glytoucan_accession ''' : G00031MO <br>
+ '''glycan_dictionary_accession''' : GSD000163 <br>
-'''term_in_sentence''' : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00031MO G00031MO] <br>
-'''publication''' : 723127|19505650|31527246|28113048|25868857|26731525|22994493|3849428|25589241|12709866|26615524|26136575|19671663|18551603|11160729|22261839|30758913|25681708|29113555|24998850|1654819|28039910|29206210|32404521|10555041|26517398|2446015|2998768|3026642|18812503|6092664|2153691|8709258|3009889|15109748|12709866|31787742|27433780|26017382|24048785|26735515|9224657|26061652|29343574|25681708|23805194|26751495|22023388|15381338|8249277|3023660|25866902 <br>
+ '''term_in_sentence''' : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] <br>
-'''definition''' : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] <br>
+ '''publication''' :[https://pubmed.ncbi.nlm.nih.gov/723127 723127]|[https://pubmed.ncbi.nlm.nih.gov/19505650 19505650]|[https://pubmed.ncbi.nlm.nih.gov/31527246 31527246]|[https://pubmed.ncbi.nlm.nih.gov/28113048 28113048]|[https://pubmed.ncbi.nlm.nih.gov/25868857 25868857]|[https://pubmed.ncbi.nlm.nih.gov/26731525 26731525]|[https://pubmed.ncbi.nlm.nih.gov/22994493 22994493]|[https://pubmed.ncbi.nlm.nih.gov/3849428 3849428]|[https://pubmed.ncbi.nlm.nih.gov/25589241 25589241]|[https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]|[https://pubmed.ncbi.nlm.nih.gov/26615524 26615524]|[https://pubmed.ncbi.nlm.nih.gov/26136575 26136575]|[https://pubmed.ncbi.nlm.nih.gov/19671663 19671663]|[https://pubmed.ncbi.nlm.nih.gov/18551603 18551603]|[https://pubmed.ncbi.nlm.nih.gov/11160729 11160729]|[https://pubmed.ncbi.nlm.nih.gov/22261839 22261839]|[https://pubmed.ncbi.nlm.nih.gov/30758913 30758913]|[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]|[https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/24998850 24998850]|[https://pubmed.ncbi.nlm.nih.gov/1654819 1654819]|[https://pubmed.ncbi.nlm.nih.gov/28039910 28039910]|[https://pubmed.ncbi.nlm.nih.gov/29206210 29206210]|[https://pubmed.ncbi.nlm.nih.gov/32404521 32404521]|[https://pubmed.ncbi.nlm.nih.gov/10555041 10555041]|[https://pubmed.ncbi.nlm.nih.gov/26517398 26517398]|[https://pubmed.ncbi.nlm.nih.gov/2446015 2446015]|[https://pubmed.ncbi.nlm.nih.gov/2998768 2998768]|[https://pubmed.ncbi.nlm.nih.gov/3026642 3026642]|[https://pubmed.ncbi.nlm.nih.gov/18812503 18812503]|[https://pubmed.ncbi.nlm.nih.gov/6092664 6092664]|[https://pubmed.ncbi.nlm.nih.gov/2153691 2153691]|[https://pubmed.ncbi.nlm.nih.gov/8709258 8709258]|[https://pubmed.ncbi.nlm.nih.gov/3009889 3009889]|[https://pubmed.ncbi.nlm.nih.gov/15109748 15109748]| [https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]|[https://pubmed.ncbi.nlm.nih.gov/31787742 31787742]|[https://pubmed.ncbi.nlm.nih.gov/27433780 27433780]|[https://pubmed.ncbi.nlm.nih.gov/26017382 26017382]|[https://pubmed.ncbi.nlm.nih.gov/24048785 24048785]|[https://pubmed.ncbi.nlm.nih.gov/26735515 26735515]|[https://pubmed.ncbi.nlm.nih.gov/9224657 9224657]|[https://pubmed.ncbi.nlm.nih.gov/26061652 26061652]|[https://pubmed.ncbi.nlm.nih.gov/29343574 29343574]| [https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]|[https://pubmed.ncbi.nlm.nih.gov/23805194 23805194]|[https://pubmed.ncbi.nlm.nih.gov/26751495 26751495]|[https://pubmed.ncbi.nlm.nih.gov/22023388 22023388]|[https://pubmed.ncbi.nlm.nih.gov/15381338 15381338]|[https://pubmed.ncbi.nlm.nih.gov/8249277 8249277]|[https://pubmed.ncbi.nlm.nih.gov/3023660 3023660]|[https://pubmed.ncbi.nlm.nih.gov/25866902 25866902] <br>
-'''term_xref''' : GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009 <br>
+ '''definition''' : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] <br>
-'''best_match''' : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009 <br>
+ '''term_xref''' : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009<br>
-'''synonymns''' : TF antigen <br>
+ '''synonyms''' : TF antigen <br>
-'''function''' : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] <br>
+ '''function''' : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] <br>
-'''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020] <br>
+ '''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453023-Chapter 47 <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
 ===Tetraantennary===
-'''term (main_entry)''' : Tetraantennary <br>
+ '''term (main_entry)''' : Tetraantennary <br>
-'''glycan_dictionary_accession''' : GD000164 <br>
+ '''glycan_dictionary_accession''' : GSD000164 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:24308486] <br>
+ '''term_in_sentence''' : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]] <br>
-'''publication''' : 24308486|17951374|28880909|9177699|9760189|12322961|20129637|2492275|3402460|2361735|6525453|27730440|2551687|25365149|9751793|29875690|29479898|9134426|30943309|3546284|29888905|30624066|30537828|31110965|29311294|12852965|3015940|1907570|29137999|29359131|29858715|30295034|31829566|8381405|26929217|20662591|30612270|3089784|28186213|3427034|26763099|27354006|24991291|7496138|1940447|11114588|29031301|9448855|3979385|27722599|31126011|28002670|28991403|24032650|15316281|25154914|22490318|22430811|1463783|18803208|7881173|7697655|7240157|1768292 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]|[https://pubmed.ncbi.nlm.nih.gov/17951374 17951374]|[https://pubmed.ncbi.nlm.nih.gov/28880909 28880909]|[https://pubmed.ncbi.nlm.nih.gov/9177699 9177699]|[https://pubmed.ncbi.nlm.nih.gov/9760189 9760189]|[https://pubmed.ncbi.nlm.nih.gov/12322961 12322961]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/2492275 2492275]|[https://pubmed.ncbi.nlm.nih.gov/3402460 3402460]|[https://pubmed.ncbi.nlm.nih.gov/2361735 2361735]|[https://pubmed.ncbi.nlm.nih.gov/6525453 6525453]|[https://pubmed.ncbi.nlm.nih.gov/27730440 27730440]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/25365149 25365149]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29875690 29875690]|[https://pubmed.ncbi.nlm.nih.gov/29479898 29479898]|[https://pubmed.ncbi.nlm.nih.gov/9134426 9134426]|[https://pubmed.ncbi.nlm.nih.gov/30943309 30943309]|[https://pubmed.ncbi.nlm.nih.gov/3546284 3546284]|[https://pubmed.ncbi.nlm.nih.gov/29888905 29888905]|[https://pubmed.ncbi.nlm.nih.gov/30624066 30624066]|[https://pubmed.ncbi.nlm.nih.gov/30537828 30537828]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/29311294 29311294]|[https://pubmed.ncbi.nlm.nih.gov/12852965 12852965]|[https://pubmed.ncbi.nlm.nih.gov/3015940 3015940]|[https://pubmed.ncbi.nlm.nih.gov/1907570 1907570]|[https://pubmed.ncbi.nlm.nih.gov/29137999 29137999]|[https://pubmed.ncbi.nlm.nih.gov/29359131 29359131]|[https://pubmed.ncbi.nlm.nih.gov/29858715 29858715]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31829566 31829566]|[https://pubmed.ncbi.nlm.nih.gov/8381405 8381405]|[https://pubmed.ncbi.nlm.nih.gov/26929217 26929217]|[https://pubmed.ncbi.nlm.nih.gov/20662591 20662591]|[https://pubmed.ncbi.nlm.nih.gov/30612270 30612270]|[https://pubmed.ncbi.nlm.nih.gov/3089784 3089784]|[https://pubmed.ncbi.nlm.nih.gov/28186213 28186213]|[https://pubmed.ncbi.nlm.nih.gov/3427034 3427034]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/27354006 27354006]|[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/7496138 7496138]|[https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]|[https://pubmed.ncbi.nlm.nih.gov/29031301 29031301]|[https://pubmed.ncbi.nlm.nih.gov/9448855 9448855]|[https://pubmed.ncbi.nlm.nih.gov/3979385 3979385]|[https://pubmed.ncbi.nlm.nih.gov/27722599 27722599]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28002670 28002670]|[https://pubmed.ncbi.nlm.nih.gov/28991403 28991403]|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]| [https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]|[https://pubmed.ncbi.nlm.nih.gov/25154914 25154914]|[https://pubmed.ncbi.nlm.nih.gov/22490318 22490318]|[https://pubmed.ncbi.nlm.nih.gov/22430811 22430811]|[https://pubmed.ncbi.nlm.nih.gov/1463783 1463783]|[https://pubmed.ncbi.nlm.nih.gov/18803208 18803208]|[https://pubmed.ncbi.nlm.nih.gov/7881173 7881173]|[https://pubmed.ncbi.nlm.nih.gov/7697655 7697655]|[https://pubmed.ncbi.nlm.nih.gov/7240157 7240157]|[https://pubmed.ncbi.nlm.nih.gov/1768292 1768292] <br>
-'''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [NBK453019-Glossary] <br>
+ '''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' : https://www.wikidata.org/wiki/Q[https://pubmed.ncbi.nlm.nih.gov/27104888 27104888] <br>
-'''wikipedia''' : https://www.wikidata.org/wiki/Q27104888 <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Tetraantennary complex-type===
-'''term (main_entry)''' : Tetraantennary complex-type <br>
+ '''term (main_entry)''' : Tetraantennary complex-type <br>
-'''glycan_dictionary_accession''' : GD000165 <br>
+ '''glycan_dictionary_accession''' : GSD000165 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID:1899031] <br>
+ '''term_in_sentence''' : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID: [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]] <br>
-'''publication''' : 1899031|8251489|8274017|1899031| 6317691|23668542| 6088518|21495009|1457971|1783599|10988252|11425798|7522229|2574992|3730425|10200178|2939068|21584695| 7524670|7682847|2930192|1726466|9881746|11068879|6704968|2302846|24032650|15316281|11051207|10220588|2813359|2174368|21755550|3571208|1929437|3681300|6581225|3364983|2902877|2297756|1315684|6830758|1998670 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]|[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8274017 8274017]|[https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]| [https://pubmed.ncbi.nlm.nih.gov/6317691 6317691]|[https://pubmed.ncbi.nlm.nih.gov/23668542 23668542]| [https://pubmed.ncbi.nlm.nih.gov/6088518 6088518]|[https://pubmed.ncbi.nlm.nih.gov/21495009 21495009]|[https://pubmed.ncbi.nlm.nih.gov/1457971 1457971]|[https://pubmed.ncbi.nlm.nih.gov/1783599 1783599]|[https://pubmed.ncbi.nlm.nih.gov/10988252 10988252]|[https://pubmed.ncbi.nlm.nih.gov/11425798 11425798]|[https://pubmed.ncbi.nlm.nih.gov/7522229 7522229]|[https://pubmed.ncbi.nlm.nih.gov/2574992 2574992]|[https://pubmed.ncbi.nlm.nih.gov/3730425 3730425]|[https://pubmed.ncbi.nlm.nih.gov/10200178 10200178]|[https://pubmed.ncbi.nlm.nih.gov/2939068 2939068]|[https://pubmed.ncbi.nlm.nih.gov/21584695 21584695]| [https://pubmed.ncbi.nlm.nih.gov/7524670 7524670]|[https://pubmed.ncbi.nlm.nih.gov/7682847 7682847]|[https://pubmed.ncbi.nlm.nih.gov/2930192 2930192]|[https://pubmed.ncbi.nlm.nih.gov/1726466 1726466]|[https://pubmed.ncbi.nlm.nih.gov/9881746 9881746]|[https://pubmed.ncbi.nlm.nih.gov/11068879 11068879]|[https://pubmed.ncbi.nlm.nih.gov/6704968 6704968]|[https://pubmed.ncbi.nlm.nih.gov/2302846 2302846]| [https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]|[https://pubmed.ncbi.nlm.nih.gov/11051207 11051207]|[https://pubmed.ncbi.nlm.nih.gov/10220588 10220588]|[https://pubmed.ncbi.nlm.nih.gov/2813359 2813359]|[https://pubmed.ncbi.nlm.nih.gov/2174368 2174368]|[https://pubmed.ncbi.nlm.nih.gov/21755550 21755550]|[https://pubmed.ncbi.nlm.nih.gov/3571208 3571208]|[https://pubmed.ncbi.nlm.nih.gov/1929437 1929437]|[https://pubmed.ncbi.nlm.nih.gov/3681300 3681300]|[https://pubmed.ncbi.nlm.nih.gov/6581225 6581225]|[https://pubmed.ncbi.nlm.nih.gov/3364983 3364983]|[https://pubmed.ncbi.nlm.nih.gov/2902877 2902877]|[https://pubmed.ncbi.nlm.nih.gov/2297756 2297756]|[https://pubmed.ncbi.nlm.nih.gov/1315684 1315684]|[https://pubmed.ncbi.nlm.nih.gov/6830758 6830758]|[https://pubmed.ncbi.nlm.nih.gov/1998670 1998670] <br>
-'''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [NBK453019-Glossary] <br>
+ '''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]]  <br>
-'''term_xref''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html <br>
+ '''term_xref''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html<br>
-'''best_match''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
-'''essentials_of_glycobiology''' : NBK453030 <br>
 ===Tetrasialylated diantennary===
-'''term (main_entry)''' : Tetrasialylated diantennary <br>
+ '''term (main_entry)''' : Tetrasialylated diantennary <br>
-'''glycan_dictionary_accession''' : GD000166 <br>
+ '''glycan_dictionary_accession''' : GSD000166 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:1997323] <br>
+ '''term_in_sentence''' : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br>
-'''publication''' : 1997323 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] <br>
-'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Tn antigen===
-'''term (main_entry)''' : Tn antigen <br>
+[[File:G57321FI.png|thumb|G57321FI]]
-'''glycan_dictionary_accession''' : GD000167 <br>
+ '''term (main_entry)''' : Tn antigen <br>
-'''glytoucan_accession ''' : G57321FI <br>
+ '''glycan_dictionary_accession''' : GSD000167 <br>
-'''term_in_sentence''' : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57321FI G57321FI] <br>
-'''publication''' : 27679419|31938254|30637914|24643043|31225574|21259410|31742337|28514044|33014816|28708980|27432485|33050853|26045765|27542280|24411673|27760846|30115016|1410473|29802864|29669308|29251002|32541028|31019509|1582597|2981150|10842187|29638123|22367369|10778170|1510031|19372570|20641477|16149605|15770530|27856425|23814067|28068458|32134186|8174100|10571017|27453399|1727666|23740330 <br>
+ '''term_in_sentence''' : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] <br>
-'''definition''' : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27679419 27679419]|[https://pubmed.ncbi.nlm.nih.gov/31938254 31938254]|[https://pubmed.ncbi.nlm.nih.gov/30637914 30637914]|[https://pubmed.ncbi.nlm.nih.gov/24643043 24643043]|[https://pubmed.ncbi.nlm.nih.gov/31225574 31225574]|[https://pubmed.ncbi.nlm.nih.gov/21259410 21259410]|[https://pubmed.ncbi.nlm.nih.gov/31742337 31742337]|[https://pubmed.ncbi.nlm.nih.gov/28514044 28514044]|[https://pubmed.ncbi.nlm.nih.gov/33014816 33014816]|[https://pubmed.ncbi.nlm.nih.gov/28708980 28708980]|[https://pubmed.ncbi.nlm.nih.gov/27432485 27432485]|[https://pubmed.ncbi.nlm.nih.gov/33050853 33050853]|[https://pubmed.ncbi.nlm.nih.gov/26045765 26045765]|[https://pubmed.ncbi.nlm.nih.gov/27542280 27542280]|[https://pubmed.ncbi.nlm.nih.gov/24411673 24411673]|[https://pubmed.ncbi.nlm.nih.gov/27760846 27760846]|[https://pubmed.ncbi.nlm.nih.gov/30115016 30115016]|[https://pubmed.ncbi.nlm.nih.gov/1410473 1410473]|[https://pubmed.ncbi.nlm.nih.gov/29802864 29802864]|[https://pubmed.ncbi.nlm.nih.gov/29669308 29669308]|[https://pubmed.ncbi.nlm.nih.gov/29251002 29251002]|[https://pubmed.ncbi.nlm.nih.gov/32541028 32541028]|[https://pubmed.ncbi.nlm.nih.gov/31019509 31019509]|[https://pubmed.ncbi.nlm.nih.gov/1582597 1582597]|[https://pubmed.ncbi.nlm.nih.gov/2981150 2981150]|[https://pubmed.ncbi.nlm.nih.gov/10842187 10842187]|[https://pubmed.ncbi.nlm.nih.gov/29638123 29638123]|[https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]|[https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/1510031 1510031]|[https://pubmed.ncbi.nlm.nih.gov/19372570 19372570]|[https://pubmed.ncbi.nlm.nih.gov/20641477 20641477]|[https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/27856425 27856425]|[https://pubmed.ncbi.nlm.nih.gov/23814067 23814067]|[https://pubmed.ncbi.nlm.nih.gov/28068458 28068458]|[https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/8174100 8174100]|[https://pubmed.ncbi.nlm.nih.gov/10571017 10571017]|[https://pubmed.ncbi.nlm.nih.gov/27453399 27453399]|[https://pubmed.ncbi.nlm.nih.gov/1727666 1727666]|[https://pubmed.ncbi.nlm.nih.gov/23740330 23740330] <br>
-'''term_xref''' : GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008 <br>
+ '''definition''' : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212] <br>
-'''best_match''' : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008 <br>
+ '''term_xref''' : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] <br>
+ '''function''' : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] <br>
-'''disease_associations''' : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021]. <br>
+ '''disease_associations''' : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021]. <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Triantennary===
-'''term (main_entry)''' : Triantennary <br>
+ '''term (main_entry)''' : Triantennary <br>
-'''glycan_dictionary_accession''' : GD000168 <br>
+ '''glycan_dictionary_accession''' : GSD000168 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] <br>
+ '''term_in_sentence''' : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] <br>
-'''publication''' : 24992960|27025342|29642865|29456020|26914862|26926155|26299345|28981809|18395704|2211710|23461434|18327885|15264862|22954207|9061362|16581187|26537865|3979568|28129130|7679920|8068017|7783116|3857231|20540518|1706936|2430615|8078981|2211711|6767476|3814128|2597120|7451505|8204583|20619452|10460831|1924399|6643471|31809011|30042045|2477056|7882496|2430614|2551687|2426141|2065052|28988716|31144994|26966183|29809215 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24992960 24992960]|[https://pubmed.ncbi.nlm.nih.gov/27025342 27025342]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/29456020 29456020]|[https://pubmed.ncbi.nlm.nih.gov/26914862 26914862]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26299345 26299345]|[https://pubmed.ncbi.nlm.nih.gov/28981809 28981809]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/2211710 2211710]|[https://pubmed.ncbi.nlm.nih.gov/23461434 23461434]|[https://pubmed.ncbi.nlm.nih.gov/18327885 18327885]|[https://pubmed.ncbi.nlm.nih.gov/15264862 15264862]|[https://pubmed.ncbi.nlm.nih.gov/22954207 22954207]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26537865 26537865]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/28129130 28129130]|[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/8068017 8068017]|[https://pubmed.ncbi.nlm.nih.gov/7783116 7783116]|[https://pubmed.ncbi.nlm.nih.gov/3857231 3857231]|[https://pubmed.ncbi.nlm.nih.gov/20540518 20540518]|[https://pubmed.ncbi.nlm.nih.gov/1706936 1706936]|[https://pubmed.ncbi.nlm.nih.gov/2430615 2430615]|[https://pubmed.ncbi.nlm.nih.gov/8078981 8078981]|[https://pubmed.ncbi.nlm.nih.gov/2211711 2211711]|[https://pubmed.ncbi.nlm.nih.gov/6767476 6767476]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/2597120 2597120]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/20619452 20619452]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/1924399 1924399]|[https://pubmed.ncbi.nlm.nih.gov/6643471 6643471]|[https://pubmed.ncbi.nlm.nih.gov/31809011 31809011]|[https://pubmed.ncbi.nlm.nih.gov/30042045 30042045]|[https://pubmed.ncbi.nlm.nih.gov/2477056 2477056]|[https://pubmed.ncbi.nlm.nih.gov/7882496 7882496]|[https://pubmed.ncbi.nlm.nih.gov/2430614 2430614]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/2426141 2426141]|[https://pubmed.ncbi.nlm.nih.gov/2065052 2065052]|[https://pubmed.ncbi.nlm.nih.gov/28988716 28988716]|[https://pubmed.ncbi.nlm.nih.gov/31144994 31144994]| [https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215] <br>
-'''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [NBK453019-Glossary] <br>
+ '''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Triantennary complex===
-'''term (main_entry)''' : Triantennary complex <br>
+ '''term (main_entry)''' : Triantennary complex <br>
-'''glycan_dictionary_accession''' : GD000169 <br>
+ '''glycan_dictionary_accession''' : GSD000169 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998] <br>
+ '''term_in_sentence''' : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998] <br>
-'''publication''' : 9118998|9061362|18395704|3814128|7451505|10460831|26926155|26966183|16581187|16973123|8204583|29809215|11114588|31322324|15044389|16372382|8251489|8299583|1555586|7509658|1569060|16261636 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/16973123 16973123]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215]|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]|[https://pubmed.ncbi.nlm.nih.gov/31322324 31322324]|[https://pubmed.ncbi.nlm.nih.gov/15044389 15044389]|[https://pubmed.ncbi.nlm.nih.gov/16372382 16372382]|[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8299583 8299583]|[https://pubmed.ncbi.nlm.nih.gov/1555586 1555586]|[https://pubmed.ncbi.nlm.nih.gov/7509658 7509658]|[https://pubmed.ncbi.nlm.nih.gov/1569060 1569060]|[https://pubmed.ncbi.nlm.nih.gov/16261636 16261636] <br>
-'''definition''' : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252]  Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  <br>
+ '''definition''' : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252]  Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  <br>
-'''term_xref''' : CHEBI:156252 <br>
+ '''term_xref''' : CHEBI:156252 <br>
-'''best_match''' : CHEBI:156252 <br>
+ '''synonyms''' : Triantennary complex-type <br>
-'''synonymns''' : Triantennary complex-type <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
-'''essentials_of_glycobiology''' : NBK453030 <br>
 ===Triantennary N-glycans===
-'''term (main_entry)''' : Triantennary N-glycans <br>
+ '''term (main_entry)''' : Triantennary N-glycans <br>
-'''glycan_dictionary_accession''' : GD000170 <br>
+ '''glycan_dictionary_accession''' : GSD000170 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163] <br>
+ '''term_in_sentence''' : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163] <br>
-'''publication''' : 29399163|22325877|18439991|24873509|11454001 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29399163 29399163]|[https://pubmed.ncbi.nlm.nih.gov/22325877 22325877]|[https://pubmed.ncbi.nlm.nih.gov/18439991 18439991]|[https://pubmed.ncbi.nlm.nih.gov/24873509 24873509]|[https://pubmed.ncbi.nlm.nih.gov/11454001 11454001] <br>
-'''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [NBK453019-Glossary] <br>
+ '''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]]  <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Triantennary sialylated===
-'''term (main_entry)''' : Triantennary sialylated <br>
+ '''term (main_entry)''' : Triantennary sialylated <br>
-'''glycan_dictionary_accession''' : GD000171 <br>
+ '''glycan_dictionary_accession''' : GSD000171 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:18642129] <br>
+ '''term_in_sentence''' : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:18642129] <br>
-'''publication''' : 18642129|31964828|3979568|27936604|23681398|21538882|7579793|7613477|2223825|3539023|3674882 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18642129 18642129]|[https://pubmed.ncbi.nlm.nih.gov/31964828 31964828]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/27936604 27936604]|[https://pubmed.ncbi.nlm.nih.gov/23681398 23681398]|[https://pubmed.ncbi.nlm.nih.gov/21538882 21538882]|[https://pubmed.ncbi.nlm.nih.gov/7579793 7579793]|[https://pubmed.ncbi.nlm.nih.gov/7613477 7613477]|[https://pubmed.ncbi.nlm.nih.gov/2223825 2223825]|[https://pubmed.ncbi.nlm.nih.gov/3539023 3539023]|[https://pubmed.ncbi.nlm.nih.gov/3674882 3674882] <br>
-'''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
+ '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' : Appears in human serotransferrin.[PMID: 3979568] <br>
-'''function''' : Appears in human serotransferrin.[PMID: 3979568] <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Triantennary trisialylated fucosylated===
-'''term (main_entry)''' : Triantennary trisialylated fucosylated <br>
+ '''term (main_entry)''' : Triantennary trisialylated fucosylated <br>
-'''glycan_dictionary_accession''' : GD000172 <br>
+ '''glycan_dictionary_accession''' : GSD000172 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:17591618] <br>
+ '''term_in_sentence''' : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]] <br>
-'''publication''' : 17591618 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17591618 17591618] <br>
-'''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added. <br>
+ '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Trifucosyl Lewis b antigen===
-'''term (main_entry)''' : Trifucosyl Lewis b antigen <br>
+[[File:G74578MX.png|thumb|G74578MX]]
-'''glycan_dictionary_accession''' : GD000173 <br>
+ '''term (main_entry)''' : Trifucosyl Lewis b antigen <br>
-'''glytoucan_accession ''' : G74578MX <br>
+ '''glycan_dictionary_accession''' : GSD000173 <br>
-'''term_in_sentence''' : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:1735443] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74578MX G74578MX] <br>
-'''publication''' : 1735443 <br>
+ '''term_in_sentence''' : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:[https://pubmed.ncbi.nlm.nih.gov/1735443 1735443]] <br>
-'''definition''' : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1735443 1735443] <br>
-'''term_xref''' : GlycoEpitope:EP0092|CID:91845957|CHEBI:153783 <br>
+ '''definition''' : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] <br>
-'''best_match''' : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783 <br>
+ '''term_xref''' : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783 <br>
-'''synonymns''' : trifucosyl-Leb antigen <br>
+ '''synonyms''' : trifucosyl-Leb antigen <br>
-'''function''' : cancer-associated antigen[GlycoEpitope: EP0092] <br>
+ '''function''' : cancer-associated antigen[GlycoEpitope: EP0092] <br>
-'''disease_associations''' : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092] <br>
+ '''disease_associations''' : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Trifucosyl lewis y===
-'''term (main_entry)''' : Trifucosyl lewis y <br>
+[[File:G74917JX.png|thumb|G74917JX]]
-'''glycan_dictionary_accession''' : GD000174 <br>
+ '''term (main_entry)''' : Trifucosyl lewis y <br>
-'''glytoucan_accession ''' : G74917JX <br>
+ '''glycan_dictionary_accession''' : GSD000174 <br>
-'''term_in_sentence''' : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:3733752] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74917JX G74917JX] <br>
-'''publication''' : 3733752|2426269 <br>
+ '''term_in_sentence''' : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]] <br>
-'''definition''' : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]|[https://pubmed.ncbi.nlm.nih.gov/2426269 2426269]<br>
-'''term_xref''' : GlycoEpitope:EP0094|CID:50909806|CHEBI:61332 <br>
+ '''definition''' : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] <br>
-'''best_match''' : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332 <br>
+ '''term_xref''' : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332  <br>
-'''synonymns''' : trifucosyl Ley <br>
+ '''synonyms''' : trifucosyl Ley <br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : colonic adenocarcinomia[GlycoEpitope: EP0094] <br>
+ '''disease_associations''' : colonic adenocarcinomia[GlycoEpitope: EP0094] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ===Trimannosyl core===
-'''term (main_entry)''' : Trimannosyl core <br>
+ '''term (main_entry)''' : Trimannosyl core <br>
-'''glycan_dictionary_accession''' : GD000175 <br>
+ '''glycan_dictionary_accession''' : GSD000175 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:18320567] <br>
+ '''term_in_sentence''' : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:18320567] <br>
-'''publication''' : 18320567|27629418|26514868|26821880|2477227|6213618|31747570|29273674|31064325|1291063|28353332|1421754|29666272|11421342|15648688|28179475|28903882|27189951|9455915|22768188|9254048|8721739|2249985|22933239|25629585|24489949|2981047|11067815|1729985|1710649|16672288|2719668|19003000|23025485|22500028|10409642|1325461|23136055|23085445|21656680|22448293|22132163|1425696|20696712|18056652|15084511|18633282|15814299 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18320567 18320567]|[https://pubmed.ncbi.nlm.nih.gov/27629418 27629418]|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]|[https://pubmed.ncbi.nlm.nih.gov/26821880 26821880]|[https://pubmed.ncbi.nlm.nih.gov/2477227 2477227]|[https://pubmed.ncbi.nlm.nih.gov/6213618 6213618]|[https://pubmed.ncbi.nlm.nih.gov/31747570 31747570]|[https://pubmed.ncbi.nlm.nih.gov/29273674 29273674]|[https://pubmed.ncbi.nlm.nih.gov/31064325 31064325]|[https://pubmed.ncbi.nlm.nih.gov/1291063 1291063]|[https://pubmed.ncbi.nlm.nih.gov/28353332 28353332]|[https://pubmed.ncbi.nlm.nih.gov/1421754 1421754]|[https://pubmed.ncbi.nlm.nih.gov/29666272 29666272]|[https://pubmed.ncbi.nlm.nih.gov/11421342 11421342]|[https://pubmed.ncbi.nlm.nih.gov/15648688 15648688]|[https://pubmed.ncbi.nlm.nih.gov/28179475 28179475]|[https://pubmed.ncbi.nlm.nih.gov/28903882 28903882]|[https://pubmed.ncbi.nlm.nih.gov/27189951 27189951]|[https://pubmed.ncbi.nlm.nih.gov/9455915 9455915]|[https://pubmed.ncbi.nlm.nih.gov/22768188 22768188]|[https://pubmed.ncbi.nlm.nih.gov/9254048 9254048]|[https://pubmed.ncbi.nlm.nih.gov/8721739 8721739]|[https://pubmed.ncbi.nlm.nih.gov/2249985 2249985]|[https://pubmed.ncbi.nlm.nih.gov/22933239 22933239]|[https://pubmed.ncbi.nlm.nih.gov/25629585 25629585]|[https://pubmed.ncbi.nlm.nih.gov/24489949 24489949]|[https://pubmed.ncbi.nlm.nih.gov/2981047 2981047]|[https://pubmed.ncbi.nlm.nih.gov/11067815 11067815]|[https://pubmed.ncbi.nlm.nih.gov/1729985 1729985]|[https://pubmed.ncbi.nlm.nih.gov/1710649 1710649]|[https://pubmed.ncbi.nlm.nih.gov/16672288 16672288]|[https://pubmed.ncbi.nlm.nih.gov/2719668 2719668]|[https://pubmed.ncbi.nlm.nih.gov/19003000 19003000]|[https://pubmed.ncbi.nlm.nih.gov/23025485 23025485]|[https://pubmed.ncbi.nlm.nih.gov/22500028 22500028]|[https://pubmed.ncbi.nlm.nih.gov/10409642 10409642]|[https://pubmed.ncbi.nlm.nih.gov/1325461 1325461]|[https://pubmed.ncbi.nlm.nih.gov/23136055 23136055]|[https://pubmed.ncbi.nlm.nih.gov/23085445 23085445]|[https://pubmed.ncbi.nlm.nih.gov/21656680 21656680]|[https://pubmed.ncbi.nlm.nih.gov/22448293 22448293]|[https://pubmed.ncbi.nlm.nih.gov/22132163 22132163]|[https://pubmed.ncbi.nlm.nih.gov/1425696 1425696]|[https://pubmed.ncbi.nlm.nih.gov/20696712 20696712]|[https://pubmed.ncbi.nlm.nih.gov/18056652 18056652]|[https://pubmed.ncbi.nlm.nih.gov/15084511 15084511]|[https://pubmed.ncbi.nlm.nih.gov/18633282 18633282]|[https://pubmed.ncbi.nlm.nih.gov/15814299 15814299] <br>
-'''definition''' : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position. <br>
+ '''definition''' : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Trisialylated===
-'''term (main_entry)''' : Trisialylated <br>
+ '''term (main_entry)''' : Trisialylated <br>
-'''glycan_dictionary_accession''' : GD000176 <br>
+ '''glycan_dictionary_accession''' : GSD000176 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:8477709] <br>
+ '''term_in_sentence''' : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8477709 8477709]] <br>
-'''publication''' : 6469957|18818422|18332077|21138277|9136890|10782293|19841910|20067809|14751029|8797382|16877748|19131698|20578731|24669823|22426998|27501865|2121479|24663386|32209427|32737218|33245334|26927318|30962676|28370937|30194503|26321095|30463578|31455764|31566965|31266306|29782424|31247951|30487799|2049094|1997323|10913832 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6469957 6469957]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/21138277 21138277]|[https://pubmed.ncbi.nlm.nih.gov/9136890 9136890]|[https://pubmed.ncbi.nlm.nih.gov/10782293 10782293]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/20067809 20067809]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/8797382 8797382]|[https://pubmed.ncbi.nlm.nih.gov/16877748 16877748]|[https://pubmed.ncbi.nlm.nih.gov/19131698 19131698]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/24669823 24669823]|[https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/2121479 2121479]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/32209427 32209427]|[https://pubmed.ncbi.nlm.nih.gov/32737218 32737218]|[https://pubmed.ncbi.nlm.nih.gov/33245334 33245334]|[https://pubmed.ncbi.nlm.nih.gov/26927318 26927318]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/26321095 26321095]|[https://pubmed.ncbi.nlm.nih.gov/30463578 30463578]|[https://pubmed.ncbi.nlm.nih.gov/31455764 31455764]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/31266306 31266306]|[https://pubmed.ncbi.nlm.nih.gov/29782424 29782424]|[https://pubmed.ncbi.nlm.nih.gov/31247951 31247951]|[https://pubmed.ncbi.nlm.nih.gov/30487799 30487799]|[https://pubmed.ncbi.nlm.nih.gov/2049094 2049094]| [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832] <br>
-'''definition''' : A glycan with three sialic acid components. <br>
+ '''definition''' : A glycan with three sialic acid components. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Trisialylated complex-type oligosaccharide-alditols===
-'''term (main_entry)''' : Trisialylated complex-type oligosaccharide-alditols <br>
+ '''term (main_entry)''' : Trisialylated complex-type oligosaccharide-alditols <br>
-'''glycan_dictionary_accession''' : GD000177 <br>
+ '''glycan_dictionary_accession''' : GSD000177 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:3571205] <br>
+ '''term_in_sentence''' : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:3571205] <br>
-'''publication''' : 3571205 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3571205 3571205] <br>
-'''definition''' :  <br>
+ '''definition''' :  <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Trisialylated diantennary===
-'''term (main_entry)''' : Trisialylated diantennary <br>
+ '''term (main_entry)''' : Trisialylated diantennary <br>
-'''glycan_dictionary_accession''' : GD000178 <br>
+ '''glycan_dictionary_accession''' : GSD000178 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:1997323] <br>
+ '''term_in_sentence''' : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br>
-'''publication''' : 1997323 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] <br>
-'''definition''' : A diantennary/biantennary glycans with three sialic acid components. <br>
+ '''definition''' : A diantennary/biantennary glycans with three sialic acid components. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===Trisialylated triantennary===
-'''term (main_entry)''' : Trisialylated triantennary <br>
+ '''term (main_entry)''' : Trisialylated triantennary <br>
-'''glycan_dictionary_accession''' : GD000179 <br>
+ '''glycan_dictionary_accession''' : GSD000179 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] <br>
+ '''term_in_sentence''' : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] <br>
-'''publication''' : 30194503|27501865|10998266|20578731|17591618|14751029|18818422|8942648|8900952 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/10998266 10998266]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/8942648 8942648]|[https://pubmed.ncbi.nlm.nih.gov/8900952 8900952] <br>
-'''definition''' : A triantennry glycan with three sialic acid components. <br>
+ '''definition''' : A triantennry glycan with three sialic acid components. <br>
-'''term_xref''' :  <br>
+ '''term_xref''' :  <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
 ===VIM-2===
-'''term (main_entry)''' : VIM-2 <br>
+[[File:G22418PV.png|thumb|G22418PV]]
-'''glycan_dictionary_accession''' : GD000180 <br>
+ '''term (main_entry)''' : VIM-2 <br>
-'''glytoucan_accession ''' : G22418PV <br>
+ '''glycan_dictionary_accession''' : GSD000180 <br>
-'''term_in_sentence''' : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:1690317] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G22418PV G22418PV] <br>
-'''publication''' : 27834790|31523406|29978304|29575185|27326514|29029114|32450200|29432937|31906402|28739428|29298123|30976429|29091730|27770796|31330771|31138570|27154587|31542553|30519059|30590504|25880997|27490501|29981456|28559273|28193652|26638216|25897818|26238337|19553129|29644540|26242685|28487556|32622213|30248413|24762211|11451678|33169865|11897589|31479607 <br>
+ '''term_in_sentence''' : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:1690317] <br>
-'''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27834790 27834790]|[https://pubmed.ncbi.nlm.nih.gov/31523406 31523406]|[https://pubmed.ncbi.nlm.nih.gov/29978304 29978304]|[https://pubmed.ncbi.nlm.nih.gov/29575185 29575185]|[https://pubmed.ncbi.nlm.nih.gov/27326514 27326514]|[https://pubmed.ncbi.nlm.nih.gov/29029114 29029114]|[https://pubmed.ncbi.nlm.nih.gov/32450200 32450200]|[https://pubmed.ncbi.nlm.nih.gov/29432937 29432937]|[https://pubmed.ncbi.nlm.nih.gov/31906402 31906402]|[https://pubmed.ncbi.nlm.nih.gov/28739428 28739428]|[https://pubmed.ncbi.nlm.nih.gov/29298123 29298123]|[https://pubmed.ncbi.nlm.nih.gov/30976429 30976429]|[https://pubmed.ncbi.nlm.nih.gov/29091730 29091730]|[https://pubmed.ncbi.nlm.nih.gov/27770796 27770796]|[https://pubmed.ncbi.nlm.nih.gov/31330771 31330771]|[https://pubmed.ncbi.nlm.nih.gov/31138570 31138570]|[https://pubmed.ncbi.nlm.nih.gov/27154587 27154587]|[https://pubmed.ncbi.nlm.nih.gov/31542553 31542553]|[https://pubmed.ncbi.nlm.nih.gov/30519059 30519059]|[https://pubmed.ncbi.nlm.nih.gov/30590504 30590504]|[https://pubmed.ncbi.nlm.nih.gov/25880997 25880997]|[https://pubmed.ncbi.nlm.nih.gov/27490501 27490501]|[https://pubmed.ncbi.nlm.nih.gov/29981456 29981456]|[https://pubmed.ncbi.nlm.nih.gov/28559273 28559273]|[https://pubmed.ncbi.nlm.nih.gov/28193652 28193652]|[https://pubmed.ncbi.nlm.nih.gov/26638216 26638216]|[https://pubmed.ncbi.nlm.nih.gov/25897818 25897818]|[https://pubmed.ncbi.nlm.nih.gov/26238337 26238337]|[https://pubmed.ncbi.nlm.nih.gov/19553129 19553129]|[https://pubmed.ncbi.nlm.nih.gov/29644540 29644540]|[https://pubmed.ncbi.nlm.nih.gov/26242685 26242685]|[https://pubmed.ncbi.nlm.nih.gov/28487556 28487556]|[https://pubmed.ncbi.nlm.nih.gov/32622213 32622213]|[https://pubmed.ncbi.nlm.nih.gov/30248413 30248413]|[https://pubmed.ncbi.nlm.nih.gov/24762211 24762211]|[https://pubmed.ncbi.nlm.nih.gov/11451678 11451678]|[https://pubmed.ncbi.nlm.nih.gov/33169865 33169865]|[https://pubmed.ncbi.nlm.nih.gov/11897589 11897589]|[https://pubmed.ncbi.nlm.nih.gov/31479607 31479607] <br>
-'''term_xref''' : GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033 <br>
+ '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] <br>
-'''best_match''' : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033 <br>
+ '''term_xref''' : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] <br>
+ '''function''' : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] <br>
-'''disease_associations''' : chronic myelogenous leukemia.[GlycoEpitope:EP0019] <br>
+ '''disease_associations''' : chronic myelogenous leukemia.[GlycoEpitope:EP0019] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
 ==Terms (by Glycan Dictionary Accessions)==
-===GD000001===
+===GSD000001===
-'''term (main_entry)''' : 2,6-Branched O-mannose <br>
+ '''term (main_entry)''' : 2,6-Branched O-mannose <br>
-'''glycan_dictionary_accession''' : GD000001 <br>
+ '''glycan_dictionary_accession''' : GSD000001 <br>
-'''glytoucan_accession ''' : G06953DR <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G06953DR G06953DR] <br>
-'''term_in_sentence''' : Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6-branched structure in the brain O-mannosyl glycan.[PMID:14617637] <br>
+ '''term_in_sentence''' : Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6-branched structure in the brain O-mannosyl glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]] <br>
-'''publication''' : 14617637|10469154 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]|[https://pubmed.ncbi.nlm.nih.gov/10469154 10469154] <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-[[(2R,3S,4S,5S,6S)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:157265] <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-[[(2R,3S,4S,5S,6S)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:157265] <br>
-'''term_xref''' : CHEBI:157265|GlycoMotif:GGM.000056 <br>
+ '''term_xref''' : CHEBI:157265|GlycoMotif:GGM.000056|GTC:G06953DR  <br>
-'''best_match''' : CHEBI:157265|GlycoMotif:GGM.000056|GTC:G06953DR <br>
+ '''synonyms''' : 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→2)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→6)]-alpha-D-manno-hexopyranose|NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)]a-Man <br>
-'''synonymns''' : 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→2)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→6)]-alpha-D-manno-hexopyranose|NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)]a-Man <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000002===
+ '''term (main_entry)''' : 2,6-sialyl-Sulfo-LN <br>
+ '''glycan_dictionary_accession''' : GSD000002 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G41145LF G41145LF] <br>
+ '''term_in_sentence''' : The alpha2-6-sialylated 6-sulfo-LacNAc determinant defined by the antibody was significantly expressed on a majority of normal human peripheral B-lymphocytes as well as follicular B-lymphocytes in peripheral lymph nodes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17728258 17728258]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17728258 17728258] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000026|GTC:G41145LF <br>
+ '''synonyms''' : 6-sialyl-6-sulfo LN <br>
+ '''function''' : B-cell interaction with blood vessels and trafficking[PMID: [https://pubmed.ncbi.nlm.nih.gov/17728258 17728258]] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000003===
+ '''term (main_entry)''' : 2-Fucosyl-GD1b <br>
+ '''glycan_dictionary_accession''' : GSD000003 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67383AR G67383AR] <br>
+ '''term_in_sentence''' : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]] <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] <br>
+ '''term_xref''' : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR<br>
+ '''synonyms''' : 6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose|Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-8)NeuAc(a2-3)]Gal(b1-4)Glc <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000004===
+ '''term (main_entry)''' : 2-Fucosyl-GM1 <br>
+ '''glycan_dictionary_accession''' : GSD000004 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56526JU G56526JU] <br>
+ '''term_in_sentence''' : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]] <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] <br>
+ '''term_xref''' : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101|GTC:G56526JU  <br>
+ '''synonyms''' : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000005===
+ '''term (main_entry)''' : 3-Sialyl-LN (type 2) <br>
+ '''glycan_dictionary_accession''' : GSD000005 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G10203DW G10203DW] <br>
+ '''term_in_sentence''' : Using new crystal structures, we also provide the atomic resolution basis for the differential recognition of 3′ and 6′SiaLacNAc1–4 (with the Galβ1–4 linkage known as Type 2 backbone16; Scheme 1) by TgMIC1-MARR, and make comparisons with the Type 1 chain isomer of 3′SiaLacNAc1–4 (designated 3′SiaLacNAc1–3).[PMID:[https://pubmed.ncbi.nlm.nih.gov/19593815 19593815]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19593815 19593815]|[https://pubmed.ncbi.nlm.nih.gov/15659615 15659615]|[https://pubmed.ncbi.nlm.nih.gov/2414279 2414279]|[https://pubmed.ncbi.nlm.nih.gov/8586620 8586620]|[https://pubmed.ncbi.nlm.nih.gov/2111348 2111348]|[https://pubmed.ncbi.nlm.nih.gov/23747419 23747419] <br>
+ '''definition''' : A linear amino trisaccharide consisting of α-neuraminyl, β-D-galactosyl and N-acetyl-D-glucosamine residues linked in a (2→3) and (1→4) sequence.[CHEBI:52472] <br>
+ '''term_xref''' : GTC:G10203DW|KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 <br>
+ '''synonyms''' : <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Chronic gastritis[SugarBind_Ligand:109]|Toxoplasmosis[SugarBind_Ligand:109]|Peptic ulcers[SugarBind_Ligand:109]|Gastric cancer[SugarBind_Ligand:109] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000006===
+ '''term (main_entry)''' : 3'-Sulfo-Lewis a <br>
+ '''glycan_dictionary_accession''' : GSD000006 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78706CK G78706CK] <br>
+ '''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]|[https://pubmed.ncbi.nlm.nih.gov/17499486 17499486]|[https://pubmed.ncbi.nlm.nih.gov/17691854 17691854]|[https://pubmed.ncbi.nlm.nih.gov/12944557 12944557]|[https://pubmed.ncbi.nlm.nih.gov/19394320 19394320]|[https://pubmed.ncbi.nlm.nih.gov/7534477 7534477]|[https://pubmed.ncbi.nlm.nih.gov/11604107 11604107]|[https://pubmed.ncbi.nlm.nih.gov/28025252 28025252]|[https://pubmed.ncbi.nlm.nih.gov/9061363 9061363]|[https://pubmed.ncbi.nlm.nih.gov/9878545 9878545]|[https://pubmed.ncbi.nlm.nih.gov/11918697 11918697]|[https://pubmed.ncbi.nlm.nih.gov/24239607 24239607]|[https://pubmed.ncbi.nlm.nih.gov/28628803 28628803]|[https://pubmed.ncbi.nlm.nih.gov/25339106 25339106]|[https://pubmed.ncbi.nlm.nih.gov/21400496 21400496]|[https://pubmed.ncbi.nlm.nih.gov/17998215 17998215]|[https://pubmed.ncbi.nlm.nih.gov/12626387 12626387]|[https://pubmed.ncbi.nlm.nih.gov/11425799 11425799]|[https://pubmed.ncbi.nlm.nih.gov/12219077 12219077]|[https://pubmed.ncbi.nlm.nih.gov/10955596 10955596]|[https://pubmed.ncbi.nlm.nih.gov/9453593 9453593] <br>
+ '''definition''' : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] <br>
+ '''term_xref''' : GTC:G78706CK|GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 <br>
+ '''synonyms''' : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a <br>
+ '''function''' : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000007===
+ '''term (main_entry)''' : 3'-Sulfo-Lewis x <br>
+ '''glycan_dictionary_accession''' : GSD000007 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G12295TB G12295TB] <br>
+ '''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]|[https://pubmed.ncbi.nlm.nih.gov/20695481 20695481]|[https://pubmed.ncbi.nlm.nih.gov/8688428 8688428]|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]|[https://pubmed.ncbi.nlm.nih.gov/12770775 12770775]|[https://pubmed.ncbi.nlm.nih.gov/11352731 11352731]|[https://pubmed.ncbi.nlm.nih.gov/9784103 9784103]|[https://pubmed.ncbi.nlm.nih.gov/9022803 9022803] <br>
+ '''definition''' : An amino trisaccharide that consists of ''N''-acetyl-β-<small>D</small>-glucosamine having an α-<small>L</small>-fucosyl residue attached at position 3 and a 3-sulfated β-<small>D</small>-galactosyl residue attached at position 4; β-<small>D</small>-Gal''p''3S-(1→4)-[α-<small>L</small>-Fuc''p''-(1→3)]-<small>D</small>-Glc''p''NAc in which the configuration at the anomeric centre of the reducing-end residue is β. [CHEBI:65171] <br>
+ '''term_xref''' : GTC:G12295TB|GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029  <br>
+ '''synonyms''' : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000008===
+ '''term (main_entry)''' : 6,6'-bisSulfo-Lewis x <br>
+ '''glycan_dictionary_accession''' : GSD000008 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00659GQ G00659GQ] <br>
+ '''term_in_sentence''' : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/15175329 15175329]|[https://pubmed.ncbi.nlm.nih.gov/14568956 14568956]|[https://pubmed.ncbi.nlm.nih.gov/12163379 12163379]|[https://pubmed.ncbi.nlm.nih.gov/11919403 11919403]|[https://pubmed.ncbi.nlm.nih.gov/11520459 11520459]|[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/10200296 10200296]|[https://pubmed.ncbi.nlm.nih.gov/10528213 10528213]|[https://pubmed.ncbi.nlm.nih.gov/9712885 9712885]| [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/9257857 9257857]|[https://pubmed.ncbi.nlm.nih.gov/9164959 9164959]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/8958810 8958810]|[https://pubmed.ncbi.nlm.nih.gov/7560094 7560094]|[https://pubmed.ncbi.nlm.nih.gov/7485559 7485559]|[https://pubmed.ncbi.nlm.nih.gov/7538131 7538131]|[https://pubmed.ncbi.nlm.nih.gov/8161542 8161542]|[https://pubmed.ncbi.nlm.nih.gov/7684905 7684905] <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] <br>
+ '''term_xref''' : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ  <br>
+ '''synonyms''' : 6,6'-DiSulfo Sialyl Lewis x|6,6-bisSulfo-Lewis x (6,60-bissulfo Lewis x )|6,6'- Disulfo Sialyl Lewis x|6,6'-bisSulfo-Lewis x|6,6'-bissulfo Lex|6,6'-Disulfo Sialyl Lewis x|6,6'-bissulfo Le^x <br>
+ '''function''' : lymphocyte homing[GlycoEpitope:EP0016] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000009===
+ '''term (main_entry)''' : 6-Sialyl-GalNAc <br>
+ '''glycan_dictionary_accession''' : GSD000009 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G08371CD G08371CD] <br>
+ '''term_in_sentence''' : mmunohistochemical distributions of carbohydrate antigens based on the type 2 chain in normal as well as fetal and neoplastic tissues of human gastrointestinal tract were investigated with a monoclonal antibody (MAb) H11 (specific for type 2 chain) alone and in combination with the two MAbs MSG15 (for alpha 2----6 sialylated type 2 chain) and IB9 (for the alpha 2----6 sialylated type 2 chain and glycoproteins having NeuAc alpha 2----6Gal-NAc), and 188C1 (for short- and long-chain Lex antigens) and FH2 (for the long-chain Lex antigen). [PMID: [https://pubmed.ncbi.nlm.nih.gov/1618643 1618643]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1618643 1618643]|[https://pubmed.ncbi.nlm.nih.gov/6194157 6194157] <br>
+ '''definition''' : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] <br>
+ '''term_xref''' : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035|GTC:G08371CD <br>
+ '''synonyms''' : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000002===
-'''term (main_entry)''' : 2,6-sialyl-Sulfo-LN <br>
-'''glycan_dictionary_accession''' : GD000002 <br>
-'''glytoucan_accession ''' : G41145LF <br>
-'''term_in_sentence''' : The alpha2-6-sialylated 6-sulfo-LacNAc determinant defined by the antibody was significantly expressed on a majority of normal human peripheral B-lymphocytes as well as follicular B-lymphocytes in peripheral lymph nodes.[PMID:17728258] <br>
-'''publication''' : 17728258 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000026 <br>
-'''best_match''' : GlycoMotif:GGM.000026|GTC:G41145LF <br>
-'''synonymns''' : 6-sialyl-6-sulfo LN <br>
-'''function''' : B-cell interaction with blood vessels and trafficking[PMID: 17728258] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000010===
+ '''term (main_entry)''' : 6-Sulfo LacNac <br>
+ '''glycan_dictionary_accession''' : GSD000010 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G13157WZ G13157WZ] <br>
+ '''term_in_sentence''' : In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31572354 31572354]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31572354 31572354]|[https://pubmed.ncbi.nlm.nih.gov/31191513 31191513]|[https://pubmed.ncbi.nlm.nih.gov/29977237 29977237]|[https://pubmed.ncbi.nlm.nih.gov/29900053 29900053]|[https://pubmed.ncbi.nlm.nih.gov/30984181 30984181]|[https://pubmed.ncbi.nlm.nih.gov/28732748 28732748]|[https://pubmed.ncbi.nlm.nih.gov/26510404 26510404]|[https://pubmed.ncbi.nlm.nih.gov/28769928 28769928]|[https://pubmed.ncbi.nlm.nih.gov/31154896 31154896]|[https://pubmed.ncbi.nlm.nih.gov/27541644 27541644]|[https://pubmed.ncbi.nlm.nih.gov/25262889 25262889]|[https://pubmed.ncbi.nlm.nih.gov/26155414 26155414]|[https://pubmed.ncbi.nlm.nih.gov/28499587 28499587]|[https://pubmed.ncbi.nlm.nih.gov/27086951 27086951]|[https://pubmed.ncbi.nlm.nih.gov/27315572 27315572]|[https://pubmed.ncbi.nlm.nih.gov/26162403 26162403]|[https://pubmed.ncbi.nlm.nih.gov/26391152 26391152]|[https://pubmed.ncbi.nlm.nih.gov/31730025 31730025]|[https://pubmed.ncbi.nlm.nih.gov/12354382 12354382]|[https://pubmed.ncbi.nlm.nih.gov/27318477 27318477]|[https://pubmed.ncbi.nlm.nih.gov/23879812 23879812]|[https://pubmed.ncbi.nlm.nih.gov/25340085 25340085]|[https://pubmed.ncbi.nlm.nih.gov/24682513 24682513]|[https://pubmed.ncbi.nlm.nih.gov/21377044 21377044]|[https://pubmed.ncbi.nlm.nih.gov/21098395 21098395]|[https://pubmed.ncbi.nlm.nih.gov/18942710 18942710]|[https://pubmed.ncbi.nlm.nih.gov/23559493 23559493]|[https://pubmed.ncbi.nlm.nih.gov/23890755 23890755]|[https://pubmed.ncbi.nlm.nih.gov/22643330 22643330]|[https://pubmed.ncbi.nlm.nih.gov/23460612 23460612]|[https://pubmed.ncbi.nlm.nih.gov/23402811 23402811]|[https://pubmed.ncbi.nlm.nih.gov/22890025 22890025]|[https://pubmed.ncbi.nlm.nih.gov/19589615 19589615]|[https://pubmed.ncbi.nlm.nih.gov/32939325 32939325]|[https://pubmed.ncbi.nlm.nih.gov/20210806 20210806]|[https://pubmed.ncbi.nlm.nih.gov/17616642 17616642]|[https://pubmed.ncbi.nlm.nih.gov/22907335 22907335]|[https://pubmed.ncbi.nlm.nih.gov/16782032 16782032]|[https://pubmed.ncbi.nlm.nih.gov/22188261 22188261]|[https://pubmed.ncbi.nlm.nih.gov/21283706 21283706]|[https://pubmed.ncbi.nlm.nih.gov/29875315 29875315]|[https://pubmed.ncbi.nlm.nih.gov/32413173 32413173]|[https://pubmed.ncbi.nlm.nih.gov/19546436 19546436]|[https://pubmed.ncbi.nlm.nih.gov/19384158 19384158]|[https://pubmed.ncbi.nlm.nih.gov/1429720 1429720]|[https://pubmed.ncbi.nlm.nih.gov/30519676 30519676] <br>
+ '''definition''' : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] <br>
+ '''term_xref''' : GlycoEpitope:EP0141|GTC:G13157WZ|CID:10322152|CHEBI:148005<br>
+ '''synonyms''' : 6-Sulfo LacNAc <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000003===
-'''term (main_entry)''' : 2-Fucosyl-GD1b <br>
-'''glycan_dictionary_accession''' : GD000003 <br>
-'''glytoucan_accession ''' : G67383AR <br>
-'''term_in_sentence''' : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:3654655] <br>
-'''publication''' : 3654655 <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] <br>
-'''term_xref''' : CHEBI:156680|GlycoMotif:GGM.000103 <br>
-'''best_match''' : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR <br>
-'''synonymns''' : 6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose|Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-8)NeuAc(a2-3)]Gal(b1-4)Glc <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000011===
+[[File:G00672PE.png|thumb|G00672PE]]
+ '''term (main_entry)''' : 6'-Sulfo Sialyl Lewis x <br>
+ '''glycan_dictionary_accession''' : GSD000011 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00672PE G00672PE] <br>
+ '''term_in_sentence''' : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]|[https://pubmed.ncbi.nlm.nih.gov/26137907 26137907]|[https://pubmed.ncbi.nlm.nih.gov/9400621 9400621]|[https://pubmed.ncbi.nlm.nih.gov/32744401 32744401]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/15972893 15972893]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/22691873 22691873]|[https://pubmed.ncbi.nlm.nih.gov/18652681 18652681]|[https://pubmed.ncbi.nlm.nih.gov/9722682 9722682]|[https://pubmed.ncbi.nlm.nih.gov/10435581 10435581]|[https://pubmed.ncbi.nlm.nih.gov/19458105 19458105]|[https://pubmed.ncbi.nlm.nih.gov/19359410 19359410]|[https://pubmed.ncbi.nlm.nih.gov/15228275 15228275]|[https://pubmed.ncbi.nlm.nih.gov/18250165 18250165]|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]|[https://pubmed.ncbi.nlm.nih.gov/17944600 17944600]|[https://pubmed.ncbi.nlm.nih.gov/10460836 10460836]|[https://pubmed.ncbi.nlm.nih.gov/27993973 27993973]|[https://pubmed.ncbi.nlm.nih.gov/19149511 19149511]|[https://pubmed.ncbi.nlm.nih.gov/19150806 19150806]|[https://pubmed.ncbi.nlm.nih.gov/17172261 17172261]|[https://pubmed.ncbi.nlm.nih.gov/17142960 17142960]|[https://pubmed.ncbi.nlm.nih.gov/27956273 27956273]|[https://pubmed.ncbi.nlm.nih.gov/7578028 7578028]|[https://pubmed.ncbi.nlm.nih.gov/22260995 22260995]|[https://pubmed.ncbi.nlm.nih.gov/24519996 24519996]|[https://pubmed.ncbi.nlm.nih.gov/21596021 21596021]|[https://pubmed.ncbi.nlm.nih.gov/21982762 21982762]|[https://pubmed.ncbi.nlm.nih.gov/21775439 21775439]|[https://pubmed.ncbi.nlm.nih.gov/17334369 17334369]|[https://pubmed.ncbi.nlm.nih.gov/9710564 9710564]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/16227985 16227985]|[https://pubmed.ncbi.nlm.nih.gov/11895802 11895802]|[https://pubmed.ncbi.nlm.nih.gov/22750968 22750968]|[https://pubmed.ncbi.nlm.nih.gov/15157883 15157883]|[https://pubmed.ncbi.nlm.nih.gov/19067429 19067429] <br>
+ '''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] <br>
+ '''term_xref''' : GlycoMotif:GGM.000025|GTC:G00672PE|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128  <br>
+ '''synonyms''' : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x <br>
+ '''function''' : lymphocyte homing[GlycoEpitope:EP0014] <br>
+ '''disease_associations''' : Influenza[SugarBind_Ligand:128] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14] <br>
-===GD000004===
-'''term (main_entry)''' : 2-Fucosyl-GM1 <br>
-'''glycan_dictionary_accession''' : GD000004 <br>
-'''glytoucan_accession ''' : G56526JU <br>
-'''term_in_sentence''' : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:3654655] <br>
-'''publication''' : 3654655 <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] <br>
-'''term_xref''' : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101 <br>
-'''best_match''' : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101|GTC:G56526JU <br>
-'''synonymns''' : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000012===
+ '''term (main_entry)''' : 9-O-Acetyl GD3 <br>
+ '''glycan_dictionary_accession''' : GSD000012 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74121RX G74121RX] <br>
+ '''term_in_sentence''' : To determine whether 9-O-acetyl GD3 (acGD3) has a general antiapoptotic potential, the apoptosis-sensitive Jurkat cell line and an apoptosis-sensitive variant of the cell line Molt-4 were preincubated with micromolar concentrations of acGD3 and then treated with inducers of apoptosis.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16432837 16432837]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16432837 16432837]|[https://pubmed.ncbi.nlm.nih.gov/21507905 21507905]|[https://pubmed.ncbi.nlm.nih.gov/17512674 17512674]|[https://pubmed.ncbi.nlm.nih.gov/21930212 21930212]|[https://pubmed.ncbi.nlm.nih.gov/18194438 18194438]|[https://pubmed.ncbi.nlm.nih.gov/20739294 20739294]|[https://pubmed.ncbi.nlm.nih.gov/3216430 3216430]|[https://pubmed.ncbi.nlm.nih.gov/14724245 14724245]|[https://pubmed.ncbi.nlm.nih.gov/31373393 31373393]|[https://pubmed.ncbi.nlm.nih.gov/7558412 7558412]|[https://pubmed.ncbi.nlm.nih.gov/11273644 11273644]|[https://pubmed.ncbi.nlm.nih.gov/17385751 17385751]|[https://pubmed.ncbi.nlm.nih.gov/30694652 30694652]|[https://pubmed.ncbi.nlm.nih.gov/22894715 22894715]|[https://pubmed.ncbi.nlm.nih.gov/12973826 12973826]|[https://pubmed.ncbi.nlm.nih.gov/7859075 7859075]|[https://pubmed.ncbi.nlm.nih.gov/9749956 9749956]|[https://pubmed.ncbi.nlm.nih.gov/9874495 9874495]|[https://pubmed.ncbi.nlm.nih.gov/12486096 12486096]|[https://pubmed.ncbi.nlm.nih.gov/1989525 1989525]|[https://pubmed.ncbi.nlm.nih.gov/25330147 25330147]|[https://pubmed.ncbi.nlm.nih.gov/23478187 23478187]|[https://pubmed.ncbi.nlm.nih.gov/21807667 21807667]|[https://pubmed.ncbi.nlm.nih.gov/8486686 8486686]|[https://pubmed.ncbi.nlm.nih.gov/11465673 11465673]|[https://pubmed.ncbi.nlm.nih.gov/9511990 9511990]|[https://pubmed.ncbi.nlm.nih.gov/29270199 29270199]|[https://pubmed.ncbi.nlm.nih.gov/9268945 9268945]|[https://pubmed.ncbi.nlm.nih.gov/25045067 25045067]|[https://pubmed.ncbi.nlm.nih.gov/21618115 21618115]|[https://pubmed.ncbi.nlm.nih.gov/16434401 16434401]|[https://pubmed.ncbi.nlm.nih.gov/12493756 12493756]|[https://pubmed.ncbi.nlm.nih.gov/2302705 2302705]|[https://pubmed.ncbi.nlm.nih.gov/2198284 2198284]|[https://pubmed.ncbi.nlm.nih.gov/2685488 2685488]|[https://pubmed.ncbi.nlm.nih.gov/9328574 9328574]|[https://pubmed.ncbi.nlm.nih.gov/4055789 4055789]|[https://pubmed.ncbi.nlm.nih.gov/10096568 10096568]|[https://pubmed.ncbi.nlm.nih.gov/1644805 1644805]|[https://pubmed.ncbi.nlm.nih.gov/2582447 2582447] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GTC:G74121RX|GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 <br>
+ '''synonyms''' : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b <br>
+ '''function''' :  <br>
+ '''disease_associations''' : pancreas cancer[GlycoEpitope:EP0064] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000005===
-'''term (main_entry)''' : 3-Sialyl-LN (type 2) <br>
-'''glycan_dictionary_accession''' : GD000005 <br>
-'''glytoucan_accession ''' : G10203DW <br>
-'''term_in_sentence''' : Using new crystal structures, we also provide the atomic resolution basis for the differential recognition of 3′ and 6′SiaLacNAc1–4 (with the Galβ1–4 linkage known as Type 2 backbone16; Scheme 1) by TgMIC1-MARR, and make comparisons with the Type 1 chain isomer of 3′SiaLacNAc1–4 (designated 3′SiaLacNAc1–3).[PMID:19593815] <br>
-'''publication''' : 19593815|15659615|2414279|8586620|2111348|23747419 <br>
-'''definition''' : A linear amino trisaccharide consisting of α-neuraminyl, β-D-galactosyl and N-acetyl-D-glucosamine residues linked in a (2→3) and (1→4) sequence.[CHEBI:52472] <br>
-'''term_xref''' : KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 <br>
-'''best_match''' : GTC:G10203DW|KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034 <br>
-'''synonymns''' : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444] <br>
-'''function''' :  <br>
-'''disease_associations''' : Chronic gastritis[SugarBind_Ligand:109]|Toxoplasmosis[SugarBind_Ligand:109]|Peptic ulcers[SugarBind_Ligand:109]|Gastric cancer[SugarBind_Ligand:109] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000013===
+ '''term (main_entry)''' : 9-O-Acetyl sialic acid <br>
+ '''glycan_dictionary_accession''' : GSD000013 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G47325QT G47325QT] <br>
+ '''term_in_sentence''' : Levels of 9-O-acetyl sialic acid provide a distinct way to define progenitors and thus facilitate the study of hematopoietic differentiation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31411667 31411667]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31411667 31411667]|[https://pubmed.ncbi.nlm.nih.gov/27936566 27936566]|[https://pubmed.ncbi.nlm.nih.gov/2509478 2509478]|[https://pubmed.ncbi.nlm.nih.gov/10049046 10049046]|[https://pubmed.ncbi.nlm.nih.gov/1826463 1826463] <br>
+ '''definition''' : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] <br>
+ '''term_xref''' : GTC:G47325QT|GlycoEpitope:EP0065|CID:13991612|CHEBI:84941  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453082/ Chapter 15]<br>
-===GD000006===
-'''term (main_entry)''' : 3'-Sulfo-Lewis a <br>
-'''glycan_dictionary_accession''' : GD000006 <br>
-'''glytoucan_accession ''' : G78706CK <br>
-'''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:11504739] <br>
-'''publication''' : 11504739|17499486|17691854|12944557|19394320|7534477|11604107|28025252|9061363|9878545|11918697|24239607|28628803|25339106|21400496|17998215|12626387|11425799|12219077|10955596|9453593 <br>
-'''definition''' : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] <br>
-'''term_xref''' : GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 <br>
-'''best_match''' : GTC:G78706CK|GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 <br>
-'''synonymns''' : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a <br>
-'''function''' : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000014===
+ '''term (main_entry)''' : Blood group A (Type 2) <br>
+ '''glycan_dictionary_accession''' : GSD000014 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74353FF G74353FF] <br>
+ '''term_in_sentence''' : One hybridoma antibody (AH16), obtained on immunization with human gastric cancer cell MKN45, was directed to the blood group A determinant carried by both type 1 and type 2 chains. [PMID:[https://pubmed.ncbi.nlm.nih.gov/6583282 6583282]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27196314 27196314]|[https://pubmed.ncbi.nlm.nih.gov/6583282 6583282]|[https://pubmed.ncbi.nlm.nih.gov/8340255 8340255]|[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]|[https://pubmed.ncbi.nlm.nih.gov/21901093 21901093]|[https://pubmed.ncbi.nlm.nih.gov/2413709 2413709]|[https://pubmed.ncbi.nlm.nih.gov/8036794 8036794]|[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]|[https://pubmed.ncbi.nlm.nih.gov/3285099 3285099] <br>
+ '''definition''' : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] <br>
+ '''term_xref''' : GTC:G74353FF|CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 <br>
+ '''synonyms''' : A Type 2|Blood group A type 2 chain<br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000007===
-'''term (main_entry)''' : 3'-Sulfo-Lewis x <br>
-'''glycan_dictionary_accession''' : GD000007 <br>
-'''glytoucan_accession ''' : G12295TB <br>
-'''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:11504739] <br>
-'''publication''' : 11504739|20695481|8688428|10536036|12770775|11352731|9784103|9022803 <br>
-'''definition''' : A sulphated version of lewis X antigen which is a amino trisaccharide with structure β-D-Galp3S-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc that consists of N-acetyl-beta-D-glucosamine having an alpha-L-fucosyl residue attached at position 3 and a 3-sulfated beta-D-galactosyl residue attached at position 4; beta-D-Galp3S-(1→4)-[alpha-L-Fucp-(1→3)]-D-GlcpNAc in which the configuration at the anomeric centre of the reducing-end residue is beta. [CHEBI:65171] <br>
-'''term_xref''' : GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029 <br>
-'''best_match''' : GTC:G12295TB|GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029 <br>
-'''synonymns''' : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000016===
+ '''term (main_entry)''' : Alpha-gal antigen <br>
+ '''glycan_dictionary_accession''' : GSD000016 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G24432YB G24432YB] <br>
+ '''term_in_sentence''' : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]|[https://pubmed.ncbi.nlm.nih.gov/29319188 29319188]|[https://pubmed.ncbi.nlm.nih.gov/29481481 29481481]|[https://pubmed.ncbi.nlm.nih.gov/26140655 26140655]|[https://pubmed.ncbi.nlm.nih.gov/30337555 30337555]|[https://pubmed.ncbi.nlm.nih.gov/29235434 29235434]|[https://pubmed.ncbi.nlm.nih.gov/22909134 22909134]|[https://pubmed.ncbi.nlm.nih.gov/28280265 28280265]|[https://pubmed.ncbi.nlm.nih.gov/7532618 7532618]|[https://pubmed.ncbi.nlm.nih.gov/23390540 23390540]|[https://pubmed.ncbi.nlm.nih.gov/22808845 22808845]|[https://pubmed.ncbi.nlm.nih.gov/29898796 29898796]|[https://pubmed.ncbi.nlm.nih.gov/22262104 22262104]| [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]|[https://pubmed.ncbi.nlm.nih.gov/25430953 25430953]|[https://pubmed.ncbi.nlm.nih.gov/22993330 22993330]|[https://pubmed.ncbi.nlm.nih.gov/23578170 23578170]|[https://pubmed.ncbi.nlm.nih.gov/21043478 21043478]|[https://pubmed.ncbi.nlm.nih.gov/28294277 28294277]|[https://pubmed.ncbi.nlm.nih.gov/27696820 27696820]|[https://pubmed.ncbi.nlm.nih.gov/15814276 15814276]|[https://pubmed.ncbi.nlm.nih.gov/17991149 17991149]|[https://pubmed.ncbi.nlm.nih.gov/25577211 25577211]|[https://pubmed.ncbi.nlm.nih.gov/30578545 30578545]|[https://pubmed.ncbi.nlm.nih.gov/19895316 19895316]|[https://pubmed.ncbi.nlm.nih.gov/28068870 28068870]|[https://pubmed.ncbi.nlm.nih.gov/18546155 18546155]|[https://pubmed.ncbi.nlm.nih.gov/32907757 32907757]|[https://pubmed.ncbi.nlm.nih.gov/26485996 26485996]|[https://pubmed.ncbi.nlm.nih.gov/9771839 9771839]|[https://pubmed.ncbi.nlm.nih.gov/12042247 12042247]|[https://pubmed.ncbi.nlm.nih.gov/27567275 27567275]|[https://pubmed.ncbi.nlm.nih.gov/12131678 12131678]|[https://pubmed.ncbi.nlm.nih.gov/23114154 23114154]|[https://pubmed.ncbi.nlm.nih.gov/19184002 19184002]|[https://pubmed.ncbi.nlm.nih.gov/29577591 29577591]|[https://pubmed.ncbi.nlm.nih.gov/29806570 29806570]|[https://pubmed.ncbi.nlm.nih.gov/15638815 15638815]|[https://pubmed.ncbi.nlm.nih.gov/21118731 21118731] <br>
+ '''definition''' : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] <br>
+ '''term_xref''' : GTC:G24432YB|GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330  <br>
+ '''synonyms''' : a-Gal antigen <br>
+ '''function''' : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000008===
-'''term (main_entry)''' : 6,6'-bisSulfo-Lewis x <br>
-'''glycan_dictionary_accession''' : GD000008 <br>
-'''glytoucan_accession ''' : G00659GQ <br>
-'''term_in_sentence''' : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:9556613] <br>
-'''publication''' : 19756298|14593101|15175329|14568956|12163379|11919403|11520459|10728707|10200296|10528213|9712885|9556613|9456330|9556613|9257857|9164959|9015359|8958810|7560094|7485559|7538131|8161542|7684905 <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] <br>
-'''term_xref''' : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028 <br>
-'''best_match''' : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ <br>
-'''synonymns''' : 6,6'-DiSulfo Sialyl Lewis x|6,6-bisSulfo-Lewis x (6,60-bissulfo Lewis x )|6,6'- Disulfo Sialyl Lewis x|6,6'-bisSulfo-Lewis x|6,6'-bissulfo Lex|6,6'-Disulfo Sialyl Lewis x|6,6'-bissulfo Le^x <br>
-'''function''' : lymphocyte homing[GlycoEpitope:EP0016] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000017===
+ '''term (main_entry)''' : Alpha-galactosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000017 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : From 24 weeks of age, NZB/NZW F1 mice were injected with alpha-galactosylceramide (α-GalCer) or vehicle once a week for four weeks.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29844470 29844470]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29844470 29844470]|[https://pubmed.ncbi.nlm.nih.gov/30421497 30421497]|[https://pubmed.ncbi.nlm.nih.gov/31575643 31575643]|[https://pubmed.ncbi.nlm.nih.gov/30745361 30745361]|[https://pubmed.ncbi.nlm.nih.gov/30953000 30953000]|[https://pubmed.ncbi.nlm.nih.gov/30556652 30556652]|[https://pubmed.ncbi.nlm.nih.gov/29617191 29617191]|[https://pubmed.ncbi.nlm.nih.gov/31689579 31689579]|[https://pubmed.ncbi.nlm.nih.gov/28872688 28872688]|[https://pubmed.ncbi.nlm.nih.gov/30195979 30195979]|[https://pubmed.ncbi.nlm.nih.gov/29940370 29940370]|[https://pubmed.ncbi.nlm.nih.gov/27004737 27004737]|[https://pubmed.ncbi.nlm.nih.gov/27198610 27198610]|[https://pubmed.ncbi.nlm.nih.gov/28743554 28743554]|[https://pubmed.ncbi.nlm.nih.gov/31649670 31649670]|[https://pubmed.ncbi.nlm.nih.gov/31484693 31484693]|[https://pubmed.ncbi.nlm.nih.gov/25752588 25752588]|[https://pubmed.ncbi.nlm.nih.gov/21383248 21383248]|[https://pubmed.ncbi.nlm.nih.gov/25527277 25527277]|[https://pubmed.ncbi.nlm.nih.gov/30821985 30821985]|[https://pubmed.ncbi.nlm.nih.gov/28947140 28947140]|[https://pubmed.ncbi.nlm.nih.gov/31244823 31244823]|[https://pubmed.ncbi.nlm.nih.gov/29311431 29311431]|[https://pubmed.ncbi.nlm.nih.gov/30803854 30803854]|[https://pubmed.ncbi.nlm.nih.gov/29576533 29576533]|[https://pubmed.ncbi.nlm.nih.gov/26101952 26101952]|[https://pubmed.ncbi.nlm.nih.gov/31213291 31213291]|[https://pubmed.ncbi.nlm.nih.gov/22412194 22412194]|[https://pubmed.ncbi.nlm.nih.gov/28067024 28067024]|[https://pubmed.ncbi.nlm.nih.gov/31199716 31199716]|[https://pubmed.ncbi.nlm.nih.gov/27354638 27354638]|[https://pubmed.ncbi.nlm.nih.gov/24465013 24465013]|[https://pubmed.ncbi.nlm.nih.gov/25445911 25445911]|[https://pubmed.ncbi.nlm.nih.gov/28120096 28120096]|[https://pubmed.ncbi.nlm.nih.gov/15630427 15630427]|[https://pubmed.ncbi.nlm.nih.gov/27803187 27803187]|[https://pubmed.ncbi.nlm.nih.gov/21392534 21392534]|[https://pubmed.ncbi.nlm.nih.gov/31075434 31075434]|[https://pubmed.ncbi.nlm.nih.gov/22683545 22683545]|[https://pubmed.ncbi.nlm.nih.gov/26191196 26191196]|[https://pubmed.ncbi.nlm.nih.gov/26811064 26811064]|[https://pubmed.ncbi.nlm.nih.gov/23935988 23935988]|[https://pubmed.ncbi.nlm.nih.gov/28623127 28623127]|[https://pubmed.ncbi.nlm.nih.gov/24913977 24913977]|[https://pubmed.ncbi.nlm.nih.gov/25434827 25434827]|[https://pubmed.ncbi.nlm.nih.gov/23420533 23420533]|[https://pubmed.ncbi.nlm.nih.gov/21839133 21839133]|[https://pubmed.ncbi.nlm.nih.gov/25314062 25314062]|[https://pubmed.ncbi.nlm.nih.gov/27325450 27325450]|[https://pubmed.ncbi.nlm.nih.gov/23874157 23874157] <br>
+ '''definition''' :  <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' : alpha-GalCer|alpha-GalCers|α-GalCer <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000009===
-'''term (main_entry)''' : 6-Sialyl-GalNAc <br>
-'''glycan_dictionary_accession''' : GD000009 <br>
-'''glytoucan_accession ''' : G08371CD <br>
-'''term_in_sentence''' : mmunohistochemical distributions of carbohydrate antigens based on the type 2 chain in normal as well as fetal and neoplastic tissues of human gastrointestinal tract were investigated with a monoclonal antibody (MAb) H11 (specific for type 2 chain) alone and in combination with the two MAbs MSG15 (for alpha 2----6 sialylated type 2 chain) and IB9 (for the alpha 2----6 sialylated type 2 chain and glycoproteins having NeuAc alpha 2----6Gal-NAc), and 188C1 (for short- and long-chain Lex antigens) and FH2 (for the long-chain Lex antigen). [PMID: 1618643] <br>
-'''publication''' : 1618643|6194157 <br>
-'''definition''' : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] <br>
-'''term_xref''' : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035 <br>
-'''best_match''' : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035|GTC:G08371CD <br>
-'''synonymns''' : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000018===
+ '''term (main_entry)''' : Asialo-biantennary <br>
+ '''glycan_dictionary_accession''' : GSD000018 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:[https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]|[https://pubmed.ncbi.nlm.nih.gov/17645671 17645671]|[https://pubmed.ncbi.nlm.nih.gov/20959391 20959391]|[https://pubmed.ncbi.nlm.nih.gov/18615430 18615430]|[https://pubmed.ncbi.nlm.nih.gov/16945378 16945378]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]|[https://pubmed.ncbi.nlm.nih.gov/3084472 3084472]|[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787] |[https://pubmed.ncbi.nlm.nih.gov/22911097 22911097]|[https://pubmed.ncbi.nlm.nih.gov/24692304 24692304]|[https://pubmed.ncbi.nlm.nih.gov/17013932 17013932]|[https://pubmed.ncbi.nlm.nih.gov/7513972 7513972]| [https://pubmed.ncbi.nlm.nih.gov/6626573 6626573]|[https://pubmed.ncbi.nlm.nih.gov/10835250 10835250]|[https://pubmed.ncbi.nlm.nih.gov/9684342 9684342] <br>
+ '''definition''' :  <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' : asialo diantennary <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000010===
-'''term (main_entry)''' : 6-Sulfo LacNac <br>
-'''glycan_dictionary_accession''' : GD000010 <br>
-'''glytoucan_accession ''' : G13157WZ <br>
-'''term_in_sentence''' : In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan).[PMID:31572354] <br>
-'''publication''' : 31572354|31191513|29977237|29900053|30984181|28732748|26510404|28769928|31154896|27541644|25262889|26155414|28499587|27086951|27315572|26162403|26391152|31730025|12354382|27318477|23879812|25340085|24682513|21377044|21098395|18942710|23559493|23890755|22643330|23460612|23402811|22890025|19589615|32939325|20210806|17616642|22907335|16782032|22188261|21283706|29875315|32413173|19546436|19384158|1429720|30519676 <br>
-'''definition''' : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] <br>
-'''term_xref''' : GlycoEpitope:EP0141|CID:10322152|CHEBI:148005 <br>
-'''best_match''' : GlycoEpitope:EP0141|GTC:G13157WZ|CID:10322152|CHEBI:148005 <br>
-'''synonymns''' : 6-Sulfo LacNAc <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000019===
+[[File:G21856LC.png|thumb|G21856LC]]
+ '''term (main_entry)''' : Asialo-GM1 <br>
+ '''glycan_dictionary_accession''' : GSD000019 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G21856LC G21856LC] <br>
+ '''term_in_sentence''' : We compared the lateral structure of giant unilamellar vesicles (GUVs) composed of three pseudo binary mixtures of different glycosphingolipid (GSL), i.e. sulfatide, asialo-GM1 or GM1, with POPC.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29106974 29106974]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29106974 29106974]|[https://pubmed.ncbi.nlm.nih.gov/3418980 3418980]|[https://pubmed.ncbi.nlm.nih.gov/26975993 26975993]|[https://pubmed.ncbi.nlm.nih.gov/8613364 8613364]|[https://pubmed.ncbi.nlm.nih.gov/9288228 9288228]|[https://pubmed.ncbi.nlm.nih.gov/26710925 26710925]|[https://pubmed.ncbi.nlm.nih.gov/24922516 24922516]|[https://pubmed.ncbi.nlm.nih.gov/6839313 6839313]|[https://pubmed.ncbi.nlm.nih.gov/1828259 1828259]|[https://pubmed.ncbi.nlm.nih.gov/2581667 2581667]|[https://pubmed.ncbi.nlm.nih.gov/8210226 8210226]|[https://pubmed.ncbi.nlm.nih.gov/25062498 25062498]|[https://pubmed.ncbi.nlm.nih.gov/9671150 9671150]|[https://pubmed.ncbi.nlm.nih.gov/10377092 10377092]|[https://pubmed.ncbi.nlm.nih.gov/6171919 6171919]|[https://pubmed.ncbi.nlm.nih.gov/3093429 3093429]|[https://pubmed.ncbi.nlm.nih.gov/6652964 6652964]|[https://pubmed.ncbi.nlm.nih.gov/3124753 3124753]|[https://pubmed.ncbi.nlm.nih.gov/8905612 8905612]|[https://pubmed.ncbi.nlm.nih.gov/18788941 18788941]|[https://pubmed.ncbi.nlm.nih.gov/1467432 1467432]|[https://pubmed.ncbi.nlm.nih.gov/8225593 8225593]|[https://pubmed.ncbi.nlm.nih.gov/2083955 2083955]|[https://pubmed.ncbi.nlm.nih.gov/6171918 6171918]|[https://pubmed.ncbi.nlm.nih.gov/7806377 7806377]|[https://pubmed.ncbi.nlm.nih.gov/1802483 1802483]|[https://pubmed.ncbi.nlm.nih.gov/7927723 7927723]|[https://pubmed.ncbi.nlm.nih.gov/9209156 9209156]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/2584393 2584393]|[https://pubmed.ncbi.nlm.nih.gov/12137200 12137200]|[https://pubmed.ncbi.nlm.nih.gov/6175621 6175621]|[https://pubmed.ncbi.nlm.nih.gov/2936802 2936802]|[https://pubmed.ncbi.nlm.nih.gov/8610366 8610366]|[https://pubmed.ncbi.nlm.nih.gov/21490162 21490162]|[https://pubmed.ncbi.nlm.nih.gov/1548508 1548508]|[https://pubmed.ncbi.nlm.nih.gov/3486908 3486908]|[https://pubmed.ncbi.nlm.nih.gov/26453755 26453755]|[https://pubmed.ncbi.nlm.nih.gov/7910939 7910939]|[https://pubmed.ncbi.nlm.nih.gov/3756909 3756909]|[https://pubmed.ncbi.nlm.nih.gov/1639356 1639356]|[https://pubmed.ncbi.nlm.nih.gov/3259967 3259967]|[https://pubmed.ncbi.nlm.nih.gov/2443562 2443562]|[https://pubmed.ncbi.nlm.nih.gov/3112077 3112077]|[https://pubmed.ncbi.nlm.nih.gov/2572647 2572647]|[https://pubmed.ncbi.nlm.nih.gov/25137483 25137483]|[https://pubmed.ncbi.nlm.nih.gov/2168971 2168971]|[https://pubmed.ncbi.nlm.nih.gov/6950172 6950172] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000099|GTC:G21856LC|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216  <br>
+ '''synonyms''' : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a|ganglio-N-tetraosylceramide <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:2]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:2]|Actinomycosis[SugarBind_Ligand:2]|Lazy leukocyte syndrome[SugarBind_Ligand:2]|Pertussis[SugarBind_Ligand:2]|Cutaneous lesions[SugarBind_Ligand:2]|Melioidosis[SugarBind_Ligand:2]|Candidiasis[SugarBind_Ligand:2]|Taiwan acute respiratory agent[SugarBind_Ligand:2]|Trachoma[SugarBind_Ligand:2]|Cystitis[SugarBind_Ligand:2]|Chronic gastritis[SugarBind_Ligand:2]|Peptic ulcers[SugarBind_Ligand:2]|Gastric cancer[SugarBind_Ligand:2]|Klebsiella pneumonia infection[SugarBind_Ligand:2]|Pneumonia[SugarBind_Ligand:2]|Legionnaires' disease[SugarBind_Ligand:2]|Gonorrhea[SugarBind_Ligand:2]|Gastroenteritis[SugarBind_Ligand:2]|Toxoplasmosis[SugarBind_Ligand:2]|Plague[SugarBind_Ligand:2]|Diarrhea[SugarBind_Ligand:2] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000011===
-'''term (main_entry)''' : 6'-Sulfo Sialyl Lewis x <br>
-'''glycan_dictionary_accession''' : GD000011 <br>
-'''glytoucan_accession ''' : G00672PE <br>
-'''term_in_sentence''' : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:2288521] <br>
-'''publication''' : 2288521|26137907|9400621|32744401|9556613|15972893|9015359|22691873|18652681|9722682|10435581|19458105|19359410|15228275|18250165|10536036|17944600|10460836|27993973|19149511|19150806|17172261|17142960|27956273|7578028|22260995|24519996|21596021|21982762|21775439|17334369|9710564|14593101|16227985|11895802|22750968|15157883|19067429 <br>
-'''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] <br>
-'''term_xref''' : GlycoMotif:GGM.000025|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128 <br>
-'''best_match''' : GlycoMotif:GGM.000025|GTC:G00672PE|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128 <br>
-'''synonymns''' : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x <br>
-'''function''' : lymphocyte homing[GlycoEpitope:EP0014] <br>
-'''disease_associations''' : Influenza[SugarBind_Ligand:128] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===GSD000020===
+ '''term (main_entry)''' : B-GD1B <br>
+ '''glycan_dictionary_accession''' : GSD000020 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72557NR G72557NR] <br>
+ '''term_in_sentence''' : The Molecular Modelling and 10 ns MD simulation of Botulinum Neuro Toxin/B-GD1A and BoNT/B-GD1B complex revealed that this toxin can interact with GD1A in the single binding mode and with GD1B in two binding modes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27956354 27956354]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000104|GTC:G72557NR|CID: 91847819|KEGG:G01803|CHEBI:153361 <br>
+ '''synonyms''' : B-GD1b <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000012===
-'''term (main_entry)''' : 9-O-Acetyl GD3 <br>
-'''glycan_dictionary_accession''' : GD000012 <br>
-'''glytoucan_accession ''' : G74121RX <br>
-'''term_in_sentence''' : To determine whether 9-O-acetyl GD3 (acGD3) has a general antiapoptotic potential, the apoptosis-sensitive Jurkat cell line and an apoptosis-sensitive variant of the cell line Molt-4 were preincubated with micromolar concentrations of acGD3 and then treated with inducers of apoptosis.[PMID:16432837] <br>
-'''publication''' : 16432837|21507905|17512674|21930212|18194438|20739294|3216430|14724245|31373393|7558412|11273644|17385751|30694652|22894715|12973826|7859075|9749956|9874495|12486096|1989525|25330147|23478187|21807667|8486686|11465673|9511990|29270199|9268945|25045067|21618115|16434401|12493756|2302705|2198284|2685488|9328574|4055789|10096568|1644805|2582447 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 <br>
-'''best_match''' : GTC:G74121RX|GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 <br>
-'''synonymns''' : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b <br>
-'''function''' :  <br>
-'''disease_associations''' : pancreas cancer[GlycoEpitope:EP0064] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000021===
+ '''term (main_entry)''' : B-GM1 <br>
+ '''glycan_dictionary_accession''' : GSD000021 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G11485ID G11485ID] <br>
+ '''term_in_sentence''' : The contribution of GM3 and GD3, which accounted for 95% of the ganglioside sialic acid at birth, decreased during the first 3 weeks of life. GM1, fucosyl-GM1, and B-GM1 were not detected at birth. [PMID: [https://pubmed.ncbi.nlm.nih.gov/3680254 3680254]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3680254 3680254] <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] <br>
+ '''term_xref''' : GlycoMotif:GGM.000102|GTC:G11485ID|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Cholera[SugarBind_Ligand:181] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453032/ Chapter 37]<br>
-===GD000013===
-'''term (main_entry)''' : 9-O-Acetyl sialic acid <br>
-'''glycan_dictionary_accession''' : GD000013 <br>
-'''glytoucan_accession ''' : G47325QT <br>
-'''term_in_sentence''' : Levels of 9-O-acetyl sialic acid provide a distinct way to define progenitors and thus facilitate the study of hematopoietic differentiation.[PMID:31411667] <br>
-'''publication''' : 31411667|27936566|2509478|10049046|1826463 <br>
-'''definition''' : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] <br>
-'''term_xref''' : GlycoEpitope:EP0065|CID:13991612|CHEBI:84941 <br>
-'''best_match''' : GTC:G47325QT|GlycoEpitope:EP0065|CID:13991612|CHEBI:84941 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453082-Chapter 77 <br>
+===GSD000022===
+ '''term (main_entry)''' : Biantennary <br>
+ '''glycan_dictionary_accession''' : GSD000022 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID: [https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]] <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]| [https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/29409839 29409839]| [https://pubmed.ncbi.nlm.nih.gov/30325416 30325416]|[https://pubmed.ncbi.nlm.nih.gov/18083109 18083109]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/16715395 16715395]| [https://pubmed.ncbi.nlm.nih.gov/12634321 12634321]|[https://pubmed.ncbi.nlm.nih.gov/24211369 24211369]|[https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]|[https://pubmed.ncbi.nlm.nih.gov/31907993 31907993]| [https://pubmed.ncbi.nlm.nih.gov/23360551 23360551]|[https://pubmed.ncbi.nlm.nih.gov/20861009 20861009]| [https://pubmed.ncbi.nlm.nih.gov/33142198 33142198]|[https://pubmed.ncbi.nlm.nih.gov/11442281 11442281]|[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680]|[https://pubmed.ncbi.nlm.nih.gov/15680603 15680603]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]| [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]]| [https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]| [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754] |[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756]|[https://pubmed.ncbi.nlm.nih.gov/9346821 9346821]|[https://pubmed.ncbi.nlm.nih.gov/19341309 19341309]|[https://pubmed.ncbi.nlm.nih.gov/18529007 18529007]| [https://pubmed.ncbi.nlm.nih.gov/20580347 20580347]|[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152]|[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276]|[https://pubmed.ncbi.nlm.nih.gov/10463590 10463590]|[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657]|[https://pubmed.ncbi.nlm.nih.gov/30525457 30525457]|[https://pubmed.ncbi.nlm.nih.gov/15316280 15316280]|[https://pubmed.ncbi.nlm.nih.gov/8068637 8068637]|[https://pubmed.ncbi.nlm.nih.gov/3881425 3881425]| [https://pubmed.ncbi.nlm.nih.gov/6425277 6425277]|[https://pubmed.ncbi.nlm.nih.gov/8576139 8576139]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]|[https://pubmed.ncbi.nlm.nih.gov/1576211 1576211]|[https://pubmed.ncbi.nlm.nih.gov/11129583 11129583]|[https://pubmed.ncbi.nlm.nih.gov/30421263 30421263]|[https://pubmed.ncbi.nlm.nih.gov/8069634 8069634]|[https://pubmed.ncbi.nlm.nih.gov/30973186 30973186]| [https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]| [https://pubmed.ncbi.nlm.nih.gov/21612260 21612260]|[https://pubmed.ncbi.nlm.nih.gov/29806066 29806066]|[https://pubmed.ncbi.nlm.nih.gov/29443078 29443078] <br>
+ '''definition''' : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' : diantennary <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>
-===GD000014===
-'''term (main_entry)''' : A Type 2 <br>
-'''glycan_dictionary_accession''' : GD000014 <br>
-'''glytoucan_accession ''' : G74353FF <br>
-'''term_in_sentence''' : Herein we report the synthesis of 3-aminopropyl glycosides of A (type 2) and B (type 2) tetrasaccharides via [3 + 1] block scheme.[PMID:27196314] <br>
-'''publication''' : 27196314|6583282|8340255|18701592|21901093|2413709|8036794|1615929|3285099 <br>
-'''definition''' : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] <br>
-'''term_xref''' : CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 <br>
-'''best_match''' : GTC:G74353FF|CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 <br>
-'''synonymns''' : Blood group A (type 2) <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===GSD000023===
+ '''term (main_entry)''' : Biantennary complex <br>
+ '''glycan_dictionary_accession''' : GSD000023 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]|[https://pubmed.ncbi.nlm.nih.gov/3731182 3731182]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]| [https://pubmed.ncbi.nlm.nih.gov/32597008 32597008]|[https://pubmed.ncbi.nlm.nih.gov/6626573 6626573]|[https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]|[https://pubmed.ncbi.nlm.nih.gov/28597152 28597152]|[https://pubmed.ncbi.nlm.nih.gov/25045879 25045879]|[https://pubmed.ncbi.nlm.nih.gov/30325416 30325416]|[https://pubmed.ncbi.nlm.nih.gov/12634321 12634321]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/23360551 23360551]|[https://pubmed.ncbi.nlm.nih.gov/33142198 33142198]|[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]| [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]|[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680]|[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152]|[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775]| [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/20580347 20580347]|[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756]|[https://pubmed.ncbi.nlm.nih.gov/21612260 21612260]|[https://pubmed.ncbi.nlm.nih.gov/6425277 6425277]|[https://pubmed.ncbi.nlm.nih.gov/7691595 7691595]|[https://pubmed.ncbi.nlm.nih.gov/26780731 26780731]|[https://pubmed.ncbi.nlm.nih.gov/16285669 16285669]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/3924097 3924097]|[https://pubmed.ncbi.nlm.nih.gov/30448401 30448401]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276]|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/29408873 29408873] <br>
+ '''definition''' : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] <br>
+ '''term_xref''' : CHEBI:156251 <br>
+ '''synonyms''' : diantennary complex type <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000015===
-'''term (main_entry)''' : A2 <br>
-'''glycan_dictionary_accession''' : GD000015 <br>
-'''glytoucan_accession ''' : G62735WZ <br>
-'''term_in_sentence''' : Landsteiner ABO system of blood groups is most important for transfusion medicine and has subtypes of A Antigen, A1 and A2, upon which further groups of A and AB have been classified.[PMID:28658771] <br>
-'''publication''' : 29000000|28658771 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000041|CID:91852328 <br>
-'''best_match''' : GlycoMotif:GGM.000041|GTC:G62735WZ|CID:91852328 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000024===
+ '''term (main_entry)''' : Bisecting GlcNac <br>
+ '''glycan_dictionary_accession''' : GSD000024 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]|[https://pubmed.ncbi.nlm.nih.gov/29909448 29909448]|[https://pubmed.ncbi.nlm.nih.gov/29274553 29274553]|[https://pubmed.ncbi.nlm.nih.gov/32719771 32719771]|[https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]|[https://pubmed.ncbi.nlm.nih.gov/31375533 31375533]|[https://pubmed.ncbi.nlm.nih.gov/26467158 26467158]|[https://pubmed.ncbi.nlm.nih.gov/27429195 27429195]|[https://pubmed.ncbi.nlm.nih.gov/20816221 20816221]|[https://pubmed.ncbi.nlm.nih.gov/26109616 26109616]|[https://pubmed.ncbi.nlm.nih.gov/30542567 30542567]|[https://pubmed.ncbi.nlm.nih.gov/30144245 30144245]|[https://pubmed.ncbi.nlm.nih.gov/25727145 25727145]|[https://pubmed.ncbi.nlm.nih.gov/29593568 29593568]|[https://pubmed.ncbi.nlm.nih.gov/32612952 32612952]|[https://pubmed.ncbi.nlm.nih.gov/9006930 9006930]|[https://pubmed.ncbi.nlm.nih.gov/19508951 19508951]|[https://pubmed.ncbi.nlm.nih.gov/16000695 16000695]|[https://pubmed.ncbi.nlm.nih.gov/32597008 32597008]|[https://pubmed.ncbi.nlm.nih.gov/19053837 19053837]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/30405631 30405631]|[https://pubmed.ncbi.nlm.nih.gov/19940114 19940114]|[https://pubmed.ncbi.nlm.nih.gov/32719549 32719549]|[https://pubmed.ncbi.nlm.nih.gov/9560299 9560299]|[https://pubmed.ncbi.nlm.nih.gov/29655002 29655002]|[https://pubmed.ncbi.nlm.nih.gov/10589784 10589784]|[https://pubmed.ncbi.nlm.nih.gov/29959030 29959030]|[https://pubmed.ncbi.nlm.nih.gov/20661133 20661133]|[https://pubmed.ncbi.nlm.nih.gov/9061364 9061364]|[https://pubmed.ncbi.nlm.nih.gov/31065629 31065629]|[https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]|[https://pubmed.ncbi.nlm.nih.gov/29549127 29549127]|[https://pubmed.ncbi.nlm.nih.gov/30305426 30305426]|[https://pubmed.ncbi.nlm.nih.gov/29632412 29632412]|[https://pubmed.ncbi.nlm.nih.gov/24108122 24108122]|[https://pubmed.ncbi.nlm.nih.gov/24282611 24282611]|[https://pubmed.ncbi.nlm.nih.gov/27821068 27821068]|[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]|[https://pubmed.ncbi.nlm.nih.gov/10816579 10816579]|[https://pubmed.ncbi.nlm.nih.gov/25032906 25032906]|[https://pubmed.ncbi.nlm.nih.gov/30025558 30025558]|[https://pubmed.ncbi.nlm.nih.gov/9661906 9661906]|[https://pubmed.ncbi.nlm.nih.gov/8542600 8542600]|[https://pubmed.ncbi.nlm.nih.gov/31585439 31585439]|[https://pubmed.ncbi.nlm.nih.gov/29699572 29699572]|[https://pubmed.ncbi.nlm.nih.gov/27443163 27443163]|[https://pubmed.ncbi.nlm.nih.gov/30315103 30315103]|[https://pubmed.ncbi.nlm.nih.gov/23808883 23808883]|[https://pubmed.ncbi.nlm.nih.gov/18812317 18812317]|[https://pubmed.ncbi.nlm.nih.gov/19776078 19776078] <br>
+ '''definition''' : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: [https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]] <br>
+ '''term_xref''' : SID:163312364|KEGG:G13066<br>
+ '''synonyms''' :  <br>
+ '''function''' : The bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression through modulating N-glycan/galectin interactions.[PMID: [https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]]Inhibits growth factor signaling and retards mammary tumor progression[PMID: [https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]]Integrin-mediated cell adhesion [PMID: [https://pubmed.ncbi.nlm.nih.gov/20816221 20816221]]Important in fertilization and fetal development, neuritogenesis, immune tolerance, immunoglobulin G (IgG)[PMID: [https://pubmed.ncbi.nlm.nih.gov/32719771 32719771]] <br>
+ '''disease_associations''' : mammary tumor.[PMID: [https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
-===GD000016===
-'''term (main_entry)''' : Alpha-gal antigen <br>
-'''glycan_dictionary_accession''' : GD000016 <br>
-'''glytoucan_accession ''' : G24432YB <br>
-'''term_in_sentence''' : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:31267683] <br>
-'''publication''' : 31267683|29319188|29481481|26140655|30337555|29235434|22909134|28280265|7532618|23390540|22808845|29898796|22262104|31267683|25430953|22993330|23578170|21043478|28294277|27696820|15814276|17991149|25577211|30578545|19895316|28068870|18546155|32907757|26485996|9771839|12042247|27567275|12131678|23114154|19184002|29577591|29806570|15638815|21118731 <br>
-'''definition''' : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] <br>
-'''term_xref''' : GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330 <br>
-'''best_match''' : GTC:G24432YB|GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330 <br>
-'''synonymns''' : a-Gal antigen <br>
-'''function''' : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===GSD000025===
+ '''term (main_entry)''' : Bisialo-biantennary <br>
+ '''glycan_dictionary_accession''' : GSD000025 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] <br>
+ '''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' : disialo biantennary|disialo diantennary|disialylated biantennary|disialylated diantennary <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000017===
-'''term (main_entry)''' : Alpha-galactosylceramide <br>
-'''glycan_dictionary_accession''' : GD000017 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : From 24 weeks of age, NZB/NZW F1 mice were injected with alpha-galactosylceramide (α-GalCer) or vehicle once a week for four weeks.[PMID:29844470] <br>
-'''publication''' : 29844470|30421497|31575643|30745361|30953000|30556652|29617191|31689579|28872688|30195979|29940370|27004737|27198610|28743554|31649670|31484693|25752588|21383248|25527277|30821985|28947140|31244823|29311431|30803854|29576533|26101952|31213291|22412194|28067024|31199716|27354638|24465013|25445911|28120096|15630427|27803187|21392534|31075434|22683545|26191196|26811064|23935988|28623127|24913977|25434827|23420533|21839133|25314062|27325450|23874157 <br>
-'''definition''' :  <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : alpha-GalCer|alpha-GalCers|α-GalCer <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000026===
+ '''term (main_entry)''' : Bisialo-biantennary complex-type <br>
+ '''glycan_dictionary_accession''' : GSD000026 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID: [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183] <br>
+ '''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae.  <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' : Fully sialylated biantennary N-glycan <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453089/ Chapter 25]<br>
-===GD000018===
-'''term (main_entry)''' : Asialo-biantennary <br>
-'''glycan_dictionary_accession''' : GD000018 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:30990348] <br>
-'''publication''' : 30990348|17645671|20959391|18615430|16945378|2065054|3084472|2386787|22911097|24692304|17013932|7513972|6626573|10835250|9684342 <br>
-'''definition''' : A binantennary glycan lacking sialic acid as non-reducing terminal residues on either antennae [https://en.wiktionary.org/wiki/asialobiantennary] <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : asialo diantennary <br>
-'''function''' : Used as an adjuvant for experimental vaccines [https://www.sciencedirect.com/topics/neuroscience/alpha-galactosylceramide] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000027===
+ '''term (main_entry)''' : Blood group A (Type 2) - Lewis y <br>
+ '''glycan_dictionary_accession''' : GSD000027 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54826OZ G54826OZ] <br>
+ '''term_in_sentence''' : Monoclonal antibodies defining blood group A variants with difucosyl type 1 chain (ALeb) and difucosyl type 2 chain (ALey).[PMID:[https://pubmed.ncbi.nlm.nih.gov/2417620 2417620]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2417620 2417620] <br>
+ '''definition''' : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] <br>
+ '''term_xref''' : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039  <br>
+ '''synonyms''' : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000019===
-'''term (main_entry)''' : Asialo-GM1 <br>
-'''glycan_dictionary_accession''' : GD000019 <br>
-'''glytoucan_accession ''' : G21856LC <br>
-'''term_in_sentence''' : We compared the lateral structure of giant unilamellar vesicles (GUVs) composed of three pseudo binary mixtures of different glycosphingolipid (GSL), i.e. sulfatide, asialo-GM1 or GM1, with POPC.[PMID:29106974] <br>
-'''publication''' : 29106974|3418980|26975993|8613364|9288228|26710925|24922516|6839313|1828259|2581667|8210226|25062498|9671150|10377092|6171919|3093429|6652964|3124753|8905612|18788941|1467432|8225593|2083955|6171918|7806377|1802483|7927723|9209156|21174147|2584393|12137200|6175621|2936802|8610366|21490162|1548508|3486908|26453755|7910939|3756909|1639356|3259967|2443562|3112077|2572647|25137483|2168971 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000099|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216 <br>
-'''best_match''' : GlycoMotif:GGM.000099|GTC:G21856LC|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216 <br>
-'''synonymns''' : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a <br>
-'''function''' :  <br>
-'''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:2]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:2]|Actinomycosis[SugarBind_Ligand:2]|Lazy leukocyte syndrome[SugarBind_Ligand:2]|Pertussis[SugarBind_Ligand:2]|Cutaneous lesions[SugarBind_Ligand:2]|Melioidosis[SugarBind_Ligand:2]|Candidiasis[SugarBind_Ligand:2]|Taiwan acute respiratory agent[SugarBind_Ligand:2]|Trachoma[SugarBind_Ligand:2]|Cystitis[SugarBind_Ligand:2]|Chronic gastritis[SugarBind_Ligand:2]|Peptic ulcers[SugarBind_Ligand:2]|Gastric cancer[SugarBind_Ligand:2]|Klebsiella pneumonia infection[SugarBind_Ligand:2]|Pneumonia[SugarBind_Ligand:2]|Legionnaires' disease[SugarBind_Ligand:2]|Gonorrhea[SugarBind_Ligand:2]|Gastroenteritis[SugarBind_Ligand:2]|Toxoplasmosis[SugarBind_Ligand:2]|Plague[SugarBind_Ligand:2]|Diarrhea[SugarBind_Ligand:2] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000028===
+ '''term (main_entry)''' : Blood group A (Type 4) <br>
+ '''glycan_dictionary_accession''' : GSD000028 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G37830TX G37830TX] <br>
+ '''term_in_sentence''' : Moreover, we have found that αGal, but not αGalNAc, is a weak binder itself for DC-SIGN, which could endow an additional binding mode for the blood group B antigen, but not for blood group A.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31283166 31283166]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7800218 7800218]|[https://pubmed.ncbi.nlm.nih.gov/7521740 7521740]|[https://pubmed.ncbi.nlm.nih.gov/2458640 2458640]|[https://pubmed.ncbi.nlm.nih.gov/31283166 31283166] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000088|GTC:G37830TX|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:48]|Acute cystitis[SugarBind_Ligand:48] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000020===
-'''term (main_entry)''' : B-GD1B <br>
-'''glycan_dictionary_accession''' : GD000020 <br>
-'''glytoucan_accession ''' : G72557NR <br>
-'''term_in_sentence''' : The Molecular Modelling and 10 ns MD simulation of Botulinum Neuro Toxin/B-GD1A and BoNT/B-GD1B complex revealed that this toxin can interact with GD1A in the single binding mode and with GD1B in two binding modes.[PMID:22929125] <br>
-'''publication''' : 27956354|22929125 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000104|CID:91847819|KEGG:G01803|CHEBI:153361 <br>
-'''best_match''' : GlycoMotif:GGM.000104|GTC:G72557NR|CID:91847819|KEGG:G01803|CHEBI:153361 <br>
-'''synonymns''' : B-GD1b <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000029===
+ '''term (main_entry)''' : Blood group A trisaccharide <br>
+ '''glycan_dictionary_accession''' : GSD000029 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00066MO G00066MO] <br>
+ '''term_in_sentence''' : A readily detectable carbohydrate in the urine of two siblings with neuronal ceroid lipofuscinosis was found to be the blood group A trisaccharide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7249368 7249368]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19582848 19582848]|[https://pubmed.ncbi.nlm.nih.gov/7249368 7249368]|[https://pubmed.ncbi.nlm.nih.gov/8774717 8774717]|[https://pubmed.ncbi.nlm.nih.gov/2749874 2749874]|[https://pubmed.ncbi.nlm.nih.gov/28771597 28771597]|[https://pubmed.ncbi.nlm.nih.gov/30619340 30619340]|[https://pubmed.ncbi.nlm.nih.gov/2122121 2122121]|[https://pubmed.ncbi.nlm.nih.gov/11886841 11886841]|[https://pubmed.ncbi.nlm.nih.gov/2991755 2991755]|[https://pubmed.ncbi.nlm.nih.gov/12588002 12588002]|[https://pubmed.ncbi.nlm.nih.gov/3149698 3149698]|[https://pubmed.ncbi.nlm.nih.gov/7048329 7048329]|[https://pubmed.ncbi.nlm.nih.gov/7015594 7015594]|[https://pubmed.ncbi.nlm.nih.gov/10359132 10359132]|[https://pubmed.ncbi.nlm.nih.gov/8724140 8724140]|[https://pubmed.ncbi.nlm.nih.gov/1418679 1418679]|[https://pubmed.ncbi.nlm.nih.gov/1446307 1446307] <br>
+ '''definition''' : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] <br>
+ '''term_xref''' : GlycoEpitope:EP0255|GTC:G00066MO|CID:49852448|KEGG:G10638|CHEBI:61012  <br>
+ '''synonyms''' : blood group A trisaccharide|blood group A type 1 trisaccharide <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000021===
-'''term (main_entry)''' : B-GM1 <br>
-'''glycan_dictionary_accession''' : GD000021 <br>
-'''glytoucan_accession ''' : G11485ID <br>
-'''term_in_sentence''' : The contribution of GM3 and GD3, which accounted for 95% of the ganglioside sialic acid at birth, decreased during the first 3 weeks of life. GM1, fucosyl-GM1, and B-GM1 were not detected at birth. [PMID: 3680254] <br>
-'''publication''' : 3680254 <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] <br>
-'''term_xref''' : GlycoMotif:GGM.000102|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 <br>
-'''best_match''' : GlycoMotif:GGM.000102|GTC:G11485ID|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : Cholera[SugarBind_Ligand:181] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453032 <br>
+===GSD000030===
+ '''term (main_entry)''' : Blood group A (Type 1) <br>
+ '''glycan_dictionary_accession''' : GSD000030 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G66163TI G66163TI] <br>
+ '''term_in_sentence''' : he basis of blood group A(1) and A(2) phenotypes has been debated for many decades, and still the chemical basis is unresolved. [PMID:[https://pubmed.ncbi.nlm.nih.gov/19121199 19121199]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10942408 10942408]|[https://pubmed.ncbi.nlm.nih.gov/19121199 19121199] <br>
+ '''definition''' : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] <br>
+ '''term_xref''' : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 <br>
+ '''synonyms''' : Blood group A(1)|blood group A antigen type 1 <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000022===
-'''term (main_entry)''' : Biantennary <br>
-'''glycan_dictionary_accession''' : GD000022 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID:29249147] <br>
-'''publication''' : 29249147|24991291|29409839|30325416|18083109|26926155|16715395|12634321|24211369|23115267|31907993|23360551|20861009|33142198|11442281|18687680|15680603|31888963|14686925|15819890|22530754|22098756|9346821|19341309|18529007|20580347|11784152|7773775|10913832|8547276|10463590|9404657|30525457|15316280|8068637|3881425|6425277|8576139|29956878|1576211|11129583|30421263|8069634|30973186|16704415|21612260|29806066|29443078 <br>
-'''definition''' : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [NBK453019-Glossary] <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : diantennary <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453020-Chapter 9 <br>
+===GSD000031===
+ '''term (main_entry)''' : Blood group A1 (Type 3) <br>
+ '''glycan_dictionary_accession''' : GSD000031 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G44060QH G44060QH] <br>
+ '''term_in_sentence''' : The structure is essentially a repetitive A epitope attached to type 2 chain and is hereby called type 3 chain A. [PMID:[https://pubmed.ncbi.nlm.nih.gov/2579390 2579390]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2579390 2579390]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298] <br>
+ '''definition''' : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665] <br>
+ '''term_xref''' : GTC:G44060QH|CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040  <br>
+ '''synonyms''' : Blood group A1 (type 3)|Blood Group A1 <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000023===
-'''term (main_entry)''' : Biantennary complex <br>
-'''glycan_dictionary_accession''' : GD000023 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:16704415] <br>
-'''publication''' : 16704415|3731182|26747427|32597008|6626573|29249147|28597152|25045879|30325416|12634321|31888963|26926155|23360551|33142198|9404657|29956878|14686925|18687680|11784152|7773775|22530754|20580347|22098756|21612260|6425277|7691595|26780731|16285669|15819890|3924097|30448401|8547276|17049014|29408873 <br>
-'''definition''' : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] <br>
-'''term_xref''' : CHEBI:156251 <br>
-'''best_match''' : CHEBI:156251 <br>
-'''synonymns''' : diantennary complex type <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000032===
+[[File:G62735WZ.png|thumb|G62735WZ]]
+ '''term (main_entry)''' : Blood group A2 (A-associated H type 3) <br>
+ '''glycan_dictionary_accession''' : GSD000032 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G62735WZ G62735WZ] <br>
+ '''term_in_sentence''' : The H NMR spectrum of the associated H antigen (type 3 chain H) was characterized by the unusual presence of three n-anomeric resonances ('CJ'.~ = 3-4 Hz) in addition to five resonances from @-anomeric protons ("J1:2 = 7-9 Hz).[PMID: [https://pubmed.ncbi.nlm.nih.gov/3944091 3944091]]
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3944091 3944091]|[https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771] <br>
+ '''definition''' : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543] <br>
+ '''term_xref''' : CHEBI:152543|CID: 91852328|GlycoMotif:GGM.000041|GTC:G62735WZ <br>
+ '''synonyms''' : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000024===
-'''term (main_entry)''' : Bisecting GlcNac <br>
-'''glycan_dictionary_accession''' : GD000024 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:1374031] <br>
-'''publication''' : 1374031|29909448|29274553|32719771|22476631|31375533|26467158|27429195|20816221|26109616|30542567|30144245|25727145|29593568|32612952|9006930|19508951|16000695|32597008|19053837|22530754|30405631|19940114|32719549|9560299|29655002|10589784|29959030|20661133|9061364|31065629|20395209|29549127|30305426|29632412|24108122|24282611|27821068|14686925|10816579|25032906|30025558|9661906|8542600|31585439|29699572|27443163|30315103|23808883|18812317|19776078 <br>
-'''definition''' : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: 22476631] <br>
-'''term_xref''' : SID:163312364|KEGG:G13066 <br>
-'''best_match''' : SID:163312364|KEGG:G13066 <br>
-'''synonymns''' :  <br>
-'''function''' : The bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression through modulating N-glycan/galectin interactions.[PMID: 22476631]Inhibits growth factor signaling and retards mammary tumor progression[PMID: 20395209]Integrin-mediated cell adhesion [PMID: 20816221]Important in fertilization and fetal development, neuritogenesis, immune tolerance, immunoglobulin G (IgG)[PMID: 32719771] <br>
-'''disease_associations''' : mammary tumor.[PMID: 20395209] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453020 <br>
+===GSD000033===
+[[File:G31734OS.png|thumb|G31734OS]]
+ '''term (main_entry)''' : Blood group B (Type 1) <br>
+ '''glycan_dictionary_accession''' : GSD000033 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G31734OS G31734OS] <br>
+ '''term_in_sentence''' : The minimal binding epitope was identified as the blood group H type 1 determinant (Fucα2Galβ3GlcNAc), while an optimal binding epitope was created by addition of the terminal α3-linked galactose or N-acetylgalactosamine of the blood group B type 1 determinant (Galα3(Fucα2)Galβ3GlcNAc) and the blood group A type 1 determinant (GalNAcα3(Fucα2)-Galβ3GlcNAc). [PMID: [https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]|[https://pubmed.ncbi.nlm.nih.gov/24749871 24749871]|[https://pubmed.ncbi.nlm.nih.gov/19387828 19387828]|[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]|[https://pubmed.ncbi.nlm.nih.gov/29562255 29562255] <br>
+ '''definition''' : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242] <br>
+ '''term_xref''' : GlycoMotif:GGM.000043|GTC:G31734OS|CID:56927779|CHEBI:63242 <br>
+ '''synonyms''' : blood group B type 1 tetrasaccharide <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000025===
-'''term (main_entry)''' : Bisialo-biantennary <br>
-'''glycan_dictionary_accession''' : GD000025 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. <br>
-'''publication''' : 2386787|2065054 <br>
-'''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : disialo biantennary|disialo diantennary|disialylated biantennary|disialylated diantennary <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000034===
+ '''term (main_entry)''' : Blood group B (Type 2) <br>
+ '''glycan_dictionary_accession''' : GSD000034 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G34881WK G34881WK] <br>
+ '''term_in_sentence''' : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID: [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]|[https://pubmed.ncbi.nlm.nih.gov/27196314 27196314]|[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262  <br>
+ '''synonyms''' : blood group B type 2 <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000026===
-'''term (main_entry)''' : Bisialo-biantennary complex-type <br>
-'''glycan_dictionary_accession''' : GD000026 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID:2386787] <br>
-'''publication''' : 2386787|26966183 <br>
-'''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae.  <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : Fully sialylated biantennary N-glycan <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453089-Chapter 25 <br>
+===GSD000035===
+ '''term (main_entry)''' : Blood group B (Type 4) <br>
+ '''glycan_dictionary_accession''' : GSD000035 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25216QA G25216QA] <br>
+ '''term_in_sentence''' : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1390942 1390942]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1390942 1390942]|[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000087|GTC:G25216QA  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000027===
-'''term (main_entry)''' : Blood group A (type 2) - Lewis y <br>
-'''glycan_dictionary_accession''' : GD000027 <br>
-'''glytoucan_accession ''' : G54826OZ <br>
-'''term_in_sentence''' : Monoclonal antibodies defining blood group A variants with difucosyl type 1 chain (ALeb) and difucosyl type 2 chain (ALey).[PMID:2417620] <br>
-'''publication''' : 2417620 <br>
-'''definition''' : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] <br>
-'''term_xref''' : GlycoEpitope:EP0261|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039 <br>
-'''best_match''' : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039 <br>
-'''synonymns''' : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000036===
+ '''term (main_entry)''' : Blood group H (Type 1) <br>
+ '''glycan_dictionary_accession''' : GSD000036 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00294TN G00294TN] <br>
+ '''term_in_sentence''' : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:[https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]|[https://pubmed.ncbi.nlm.nih.gov/6309836 6309836]|[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]|[https://pubmed.ncbi.nlm.nih.gov/27431816 27431816]| [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]|[https://pubmed.ncbi.nlm.nih.gov/24219248 24219248]|[https://pubmed.ncbi.nlm.nih.gov/6352465 6352465]|[https://pubmed.ncbi.nlm.nih.gov/8499478 8499478]|[https://pubmed.ncbi.nlm.nih.gov/3348768 3348768]|[https://pubmed.ncbi.nlm.nih.gov/3718924 3718924] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153  <br>
+ '''synonyms''' : H type 1 <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:153] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000028===
-'''term (main_entry)''' : Blood group A (Type 4) <br>
-'''glycan_dictionary_accession''' : GD000028 <br>
-'''glytoucan_accession ''' : G37830TX <br>
-'''term_in_sentence''' : Moreover, we have found that αGal, but not αGalNAc, is a weak binder itself for DC-SIGN, which could endow an additional binding mode for the blood group B antigen, but not for blood group A.[PMID:31283166] <br>
-'''publication''' : 7800218|7521740|2458640|31283166 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000088|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48 <br>
-'''best_match''' : GlycoMotif:GGM.000088|GTC:G37830TX|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : Pyelonephritis[SugarBind_Ligand:48]|Acute cystitis[SugarBind_Ligand:48] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000037===
+[[File:G70519XK.png|alt=|thumb|G70519XK]]
+ '''term (main_entry)''' : Blood group H (Type 2) <br>
+ '''glycan_dictionary_accession''' : GSD000037 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G70519XK G70519XK] <br>
+ '''term_in_sentence''' : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID: [https://pubmed.ncbi.nlm.nih.gov/9405495 9405495]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9405495 9405495]|[https://pubmed.ncbi.nlm.nih.gov/8082855 8082855]|[https://pubmed.ncbi.nlm.nih.gov/6177241 6177241]|[https://pubmed.ncbi.nlm.nih.gov/3944092 3944092]|[https://pubmed.ncbi.nlm.nih.gov/21406562 21406562]|[https://pubmed.ncbi.nlm.nih.gov/2410664 2410664]|[https://pubmed.ncbi.nlm.nih.gov/8731502 8731502]|[https://pubmed.ncbi.nlm.nih.gov/6203846 6203846]|[https://pubmed.ncbi.nlm.nih.gov/2238560 2238560]| <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GTC:G70519XK|GlycoMotif:GGM.000036  <br>
+ '''synonyms''' : Blood group H (type 2)|H type 2|H type 2 chain|H type 2 antigen|type 2 chain H|blood group H type II <br>
+ '''function''' : <br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000029===
-'''term (main_entry)''' : Blood group A trisaccharide <br>
-'''glycan_dictionary_accession''' : GD000029 <br>
-'''glytoucan_accession ''' : G00066MO <br>
-'''term_in_sentence''' : A readily detectable carbohydrate in the urine of two siblings with neuronal ceroid lipofuscinosis was found to be the blood group A trisaccharide.[PMID:7249368] <br>
-'''publication''' : 19582848|7249368|8774717|2749874|28771597|30619340|2122121|11886841|2991755|12588002|3149698|7048329|7015594|10359132|8724140|1418679|1446307 <br>
-'''definition''' : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] <br>
-'''term_xref''' : GlycoEpitope:EP0255|CID:49852448|KEGG:G10638|CHEBI:61012 <br>
-'''best_match''' : GlycoEpitope:EP0255|GTC:G00066MO|CID:49852448|KEGG:G10638|CHEBI:61012 <br>
-'''synonymns''' : blood group A trisaccharide|blood group A type 1 trisaccharide <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000038===
+[[File:G00052MO.png|alt=|thumb|G00052MO]]
+ '''term (main_entry)''' : Blood group H (Type 2) - Lewis y <br>
+ '''glycan_dictionary_accession''' : GSD000038 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00052MO G00052MO] <br>
+ '''term_in_sentence''' : The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes.[PMID: [https://pubmed.ncbi.nlm.nih.gov/11479278 11479278]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11479278 11479278] <br>
+ '''definition''' : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] <br>
+ '''term_xref''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045  <br>
+ '''synonyms''' : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y <br>
+ '''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
+ '''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000030===
-'''term (main_entry)''' : Blood group A(1) <br>
-'''glycan_dictionary_accession''' : GD000030 <br>
-'''glytoucan_accession ''' : G66163TI <br>
-'''term_in_sentence''' : he basis of blood group A(1) and A(2) phenotypes has been debated for many decades, and still the chemical basis is unresolved. [PMID:19121199] <br>
-'''publication''' : 10942408|19121199 <br>
-'''definition''' : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] <br>
-'''term_xref''' : GlycoMotif:GGM.000044|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 <br>
-'''best_match''' : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 <br>
-'''synonymns''' : Blood group A (type 1)|blood group A antigen type 1 <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000039===
+ '''term (main_entry)''' : Blood group H (Type 4) <br>
+ '''glycan_dictionary_accession''' : GSD000039 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G98465JN G98465JN] <br>
+ '''term_in_sentence''' : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11261842 11261842]| [https://pubmed.ncbi.nlm.nih.gov/1841684 1841684]|[https://pubmed.ncbi.nlm.nih.gov/11101633 11101633]|[https://pubmed.ncbi.nlm.nih.gov/9405495 9405495] <br>
+ '''definition''' : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245] <br>
+ '''term_xref''' : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245<br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:61] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000031===
-'''term (main_entry)''' : Blood group A1 (type 3) <br>
-'''glycan_dictionary_accession''' : GD000031 <br>
-'''glytoucan_accession ''' : G44060QH <br>
-'''term_in_sentence''' : The structure is essentially a repetitive A epitope attached to type 2 chain and is hereby called type 3 chain A. [PMID:2579390] <br>
-'''publication''' : 2579390|19756298 <br>
-'''definition''' : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665] <br>
-'''term_xref''' : CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040 <br>
-'''best_match''' : GTC:G44060QH|CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040 <br>
-'''synonymns''' : Blood group A1 (type 3)|Blood Group A1 <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000040===
+ '''term (main_entry)''' : C2-O-sLex <br>
+ '''glycan_dictionary_accession''' : GSD000040 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97345NY G97345NY] <br>
+ '''term_in_sentence''' : PSGL-1 lacks 6-sulfo-sLex but contains sulfated tyrosine residues (Tyr-SO3)at positions 46, 48, and 51 and sLex in a core 2-based O-glycan (C2-O-sLex) on Thr at position 57.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12736247 12736247]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12736247 12736247]|[https://pubmed.ncbi.nlm.nih.gov/19267921 19267921]|[https://pubmed.ncbi.nlm.nih.gov/21283832 21283832]|[https://pubmed.ncbi.nlm.nih.gov/15596301 15596301]|[https://pubmed.ncbi.nlm.nih.gov/17072011 17072011] <br>
+ '''definition''' : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192] <br>
+ '''term_xref''' : GlycoMotif:GGM.000053|GTC:G97345NY|CID:91860725|KEGG:G10899|CHEBI:155160  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000032===
-'''term (main_entry)''' : Blood group A2 (A-associated H type 3) <br>
-'''glycan_dictionary_accession''' : GD000032 <br>
-'''glytoucan_accession ''' : G62735WZ <br>
-'''term_in_sentence''' : The 'H NMR spectrum of the Aassociated H antigen (type 3 chain H) was characterized by
- the unusual presence of three n-anomeric resonances ('CJ'.~ =
--4 Hz) in addition to five resonances from @-anomeric protons ("J1:2 = 7-9 Hz).[PMID: 3944091] <br>
-'''publication''' : 3944091 <br>
-'''definition''' : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543] <br>
-'''term_xref''' : CHEBI:152543|CID:91852328|GlycoMotif:GGM.000041 <br>
-'''best_match''' : CHEBI:152543|CID:91852328|GlycoMotif:GGM.000041|GTC:G62735WZ <br>
-'''synonymns''' : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000041===
+[[File:G04416BG.png|thumb|G04416BG]]
+ '''term (main_entry)''' : Ceramide dihexosyl sulfate <br>
+ '''glycan_dictionary_accession''' : GSD000041 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G04416BG G04416BG] <br>
+ '''term_in_sentence''' : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:818074] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/818074 818074] <br>
+ '''definition''' : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides. [http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/<nowiki>] </nowiki><br>
+ '''term_xref''' : GTC:G04416BG|GlycoMotif:GGM.000065 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000033===
-'''term (main_entry)''' : Blood group B (Type 1) <br>
-'''glycan_dictionary_accession''' : GD000033 <br>
-'''glytoucan_accession ''' : G31734OS <br>
-'''term_in_sentence''' : It has been unknown whether NoV distinguishes between the type 1 and type 2 chains of A and B antigens. In this study, we synthesized A type 1, A type 2, B type 1, and B type 2 pentasaccharides in vitro and examined the function of the core structures in the binding between NoV virus-like particles (VLPs) and HBGAs. [PMID: 18701592] <br>
-'''publication''' : 18701592|24749871|19387828|19208633|29562255 <br>
-'''definition''' : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242] <br>
-'''term_xref''' : GlycoMotif:GGM.000043|CID:56927779|CHEBI:63242 <br>
-'''best_match''' : GlycoMotif:GGM.000043|GTC:G31734OS|CID:56927779|CHEBI:63242 <br>
-'''synonymns''' : blood group B type 1 tetrasaccharide <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000043===
+ '''term (main_entry)''' : Chondroitin sulfate <br>
+ '''glycan_dictionary_accession''' : GSD000043 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: [https://pubmed.ncbi.nlm.nih.gov/31013685 31013685]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31013685 31013685]|[https://pubmed.ncbi.nlm.nih.gov/27526113 27526113]|[https://pubmed.ncbi.nlm.nih.gov/27194526 27194526]|[https://pubmed.ncbi.nlm.nih.gov/26980567 26980567]|[https://pubmed.ncbi.nlm.nih.gov/28847361 28847361]|[https://pubmed.ncbi.nlm.nih.gov/24413804 24413804]|[https://pubmed.ncbi.nlm.nih.gov/29891297 29891297]|[https://pubmed.ncbi.nlm.nih.gov/29600622 29600622]|[https://pubmed.ncbi.nlm.nih.gov/25129732 25129732]|[https://pubmed.ncbi.nlm.nih.gov/31317901 31317901]|[https://pubmed.ncbi.nlm.nih.gov/29181550 29181550]|[https://pubmed.ncbi.nlm.nih.gov/31250530 31250530]|[https://pubmed.ncbi.nlm.nih.gov/22265655 22265655]|[https://pubmed.ncbi.nlm.nih.gov/25756648 25756648]|[https://pubmed.ncbi.nlm.nih.gov/29402610 29402610]|[https://pubmed.ncbi.nlm.nih.gov/17928217 17928217]|[https://pubmed.ncbi.nlm.nih.gov/20236040 20236040]|[https://pubmed.ncbi.nlm.nih.gov/28091940 28091940]|[https://pubmed.ncbi.nlm.nih.gov/30824935 30824935]|[https://pubmed.ncbi.nlm.nih.gov/26572336 26572336]|[https://pubmed.ncbi.nlm.nih.gov/31207331 31207331]|[https://pubmed.ncbi.nlm.nih.gov/21110089 21110089]|[https://pubmed.ncbi.nlm.nih.gov/30599999 30599999]|[https://pubmed.ncbi.nlm.nih.gov/20399897 20399897]|[https://pubmed.ncbi.nlm.nih.gov/27226567 27226567]|[https://pubmed.ncbi.nlm.nih.gov/19388612 19388612]|[https://pubmed.ncbi.nlm.nih.gov/23186102 23186102]|[https://pubmed.ncbi.nlm.nih.gov/31494830 31494830]|[https://pubmed.ncbi.nlm.nih.gov/28982096 28982096]|[https://pubmed.ncbi.nlm.nih.gov/30241863 30241863]|[https://pubmed.ncbi.nlm.nih.gov/30295666 30295666]|[https://pubmed.ncbi.nlm.nih.gov/25366475 25366475]|[https://pubmed.ncbi.nlm.nih.gov/20521042 20521042]|[https://pubmed.ncbi.nlm.nih.gov/29456007 29456007]|[https://pubmed.ncbi.nlm.nih.gov/31304829 31304829]|[https://pubmed.ncbi.nlm.nih.gov/18661362 18661362]|[https://pubmed.ncbi.nlm.nih.gov/28576008 28576008]|[https://pubmed.ncbi.nlm.nih.gov/29494632 29494632]|[https://pubmed.ncbi.nlm.nih.gov/30016441 30016441]|[https://pubmed.ncbi.nlm.nih.gov/26906924 26906924]|[https://pubmed.ncbi.nlm.nih.gov/24861964 24861964]|[https://pubmed.ncbi.nlm.nih.gov/23774590 23774590]|[https://pubmed.ncbi.nlm.nih.gov/31887904 31887904]|[https://pubmed.ncbi.nlm.nih.gov/31339761 31339761]| [https://pubmed.ncbi.nlm.nih.gov/12512856 12512856]|[https://pubmed.ncbi.nlm.nih.gov/26957048 26957048]|[https://pubmed.ncbi.nlm.nih.gov/29625000 29625000] <br>
+ '''definition''' : Any of a class of 10‚Äî60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397] <br>
+ '''term_xref''' : CHEBI:37397|CID:24766 <br>
+ '''synonyms''' : chondroitin polysulfate|chondroitin sulfate|chondroitin sulfates|chondroitin sulfuric acid|chondroitin sulphate|Chondroitinsulfate <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000034===
-'''term (main_entry)''' : Blood group B (Type 2) <br>
-'''glycan_dictionary_accession''' : GD000034 <br>
-'''glytoucan_accession ''' : G34881WK <br>
-'''term_in_sentence''' : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID:2432062] <br>
-'''publication''' : 2432062|27196314|18701592 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262|GlycoMotif:GGM.000037 <br>
-'''best_match''' : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262 <br>
-'''synonymns''' : blood group B type 2 <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000044===
+ '''term (main_entry)''' : cisGM1 <br>
+ '''glycan_dictionary_accession''' : GSD000044 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G03277YI G03277YI] <br>
+ '''term_in_sentence''' : Macrophage ganglioside patterns dramatically increase in complexity when murine peritoneal macrophages are stimulated in vivo with the appearance of the sialidase-sensitive monosialoganglioside GM1b (cisGM1) as a major component.[PMID: [https://pubmed.ncbi.nlm.nih.gov/9455923 9455923]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9455923 9455923] <br>
+ '''definition''' : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580] <br>
+ '''term_xref''' : GlycoMotif:GGM.000100|GTC:G03277YI|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 <br>
+ '''synonyms''' : GM1b <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Influenza[SugarBind_Ligand:92] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453054/ Chapter 23]<br>
-===GD000035===
-'''term (main_entry)''' : Blood group B (Type 4) <br>
-'''glycan_dictionary_accession''' : GD000035 <br>
-'''glytoucan_accession ''' : G25216QA <br>
-'''term_in_sentence''' : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:1390942] <br>
-'''publication''' : 1390942|1841684 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000087 <br>
-'''best_match''' : GlycoMotif:GGM.000087|GTC:G25216QA <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000045===
+ '''term (main_entry)''' : Complex-type N-glycans <br>
+ '''glycan_dictionary_accession''' : GSD000045 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10988252 10988252] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29902282 29902282]|[https://pubmed.ncbi.nlm.nih.gov/29212795 29212795]|[https://pubmed.ncbi.nlm.nih.gov/29343819 29343819]|[https://pubmed.ncbi.nlm.nih.gov/27705835 27705835]|[https://pubmed.ncbi.nlm.nih.gov/26745022 26745022]|[https://pubmed.ncbi.nlm.nih.gov/18399796 18399796]|[https://pubmed.ncbi.nlm.nih.gov/16825488 16825488]|[https://pubmed.ncbi.nlm.nih.gov/21964725 21964725]|[https://pubmed.ncbi.nlm.nih.gov/15864431 15864431]|[https://pubmed.ncbi.nlm.nih.gov/22890903 22890903]|[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]|[https://pubmed.ncbi.nlm.nih.gov/28039392 28039392]|[https://pubmed.ncbi.nlm.nih.gov/19426135 19426135]|[https://pubmed.ncbi.nlm.nih.gov/30253927 30253927]|[https://pubmed.ncbi.nlm.nih.gov/16794314 16794314]|[https://pubmed.ncbi.nlm.nih.gov/19806620 19806620]|[https://pubmed.ncbi.nlm.nih.gov/22975979 22975979]|[https://pubmed.ncbi.nlm.nih.gov/25931033 25931033]|[https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]|[https://pubmed.ncbi.nlm.nih.gov/19129634 19129634]|[https://pubmed.ncbi.nlm.nih.gov/19129628 19129628]|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/31021709 31021709]|[https://pubmed.ncbi.nlm.nih.gov/30973186 30973186]|[https://pubmed.ncbi.nlm.nih.gov/28091941 28091941]|[https://pubmed.ncbi.nlm.nih.gov/23115339 23115339]|[https://pubmed.ncbi.nlm.nih.gov/20829342 20829342]|[https://pubmed.ncbi.nlm.nih.gov/27304954 27304954]|[https://pubmed.ncbi.nlm.nih.gov/29090617 29090617]|[https://pubmed.ncbi.nlm.nih.gov/21802690 21802690]|[https://pubmed.ncbi.nlm.nih.gov/29725121 29725121]|[https://pubmed.ncbi.nlm.nih.gov/30471292 30471292]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26098720 26098720]|[https://pubmed.ncbi.nlm.nih.gov/31080188 31080188]|[https://pubmed.ncbi.nlm.nih.gov/1930135 1930135]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/30844485 30844485]|[https://pubmed.ncbi.nlm.nih.gov/24014058 24014058]|[https://pubmed.ncbi.nlm.nih.gov/11129583 11129583] <br>
+ '''definition''' : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' : Involved in protein stability.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17]<br>
-===GD000036===
-'''term (main_entry)''' : Blood group H (Type 1) <br>
-'''glycan_dictionary_accession''' : GD000036 <br>
-'''glytoucan_accession ''' : G00294TN <br>
-'''term_in_sentence''' : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:7718581] <br>
-'''publication''' : 7718581|6309836|19208633|27431816|2432062|24219248|6352465|8499478|3348768|3718924 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000042|SugarBind_Ligand:153 <br>
-'''best_match''' : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153 <br>
-'''synonymns''' : H type 1 <br>
-'''function''' :  <br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:153] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000046===
+ '''term (main_entry)''' : Core 2 <br>
+ '''glycan_dictionary_accession''' : GSD000046 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00033MO G00033MO] <br>
+ '''term_in_sentence''' : To investigate the biological roles of core 2 O-glycans, we produced and characterized mice deficient in one or more of the three known glycosyltransferases that generate core 2 O-glycans (C2GnT1, C2GnT2, and C2GnT3).[PMID: [https://pubmed.ncbi.nlm.nih.gov/19349303 19349303]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19349303 19349303]|[https://pubmed.ncbi.nlm.nih.gov/30315106 30315106]|[https://pubmed.ncbi.nlm.nih.gov/23640779 23640779]|[https://pubmed.ncbi.nlm.nih.gov/26677400 26677400] <br>
+ '''definition''' : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158] <br>
+ '''term_xref''' : GTC:G00033MO|CID: 52921656|CHEBI:62158  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000037===
-'''term (main_entry)''' : Blood group H (type 2) <br>
-'''glycan_dictionary_accession''' : GD000037 <br>
-'''glytoucan_accession ''' : G00052MO <br>
-'''term_in_sentence''' : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID:9405495] <br>
-'''publication''' : 9405495|8082855|6177241|3944092|21406562|2410664|8731502|6203846|2238560| <br>
-'''definition''' : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] <br>
-'''term_xref''' : GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000036 <br>
-'''best_match''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000036 <br>
-'''synonymns''' : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Blood group H (type 2) (Lewis Y)|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|6-deoxy-alpha-L-galactopyranosyl-(1→3)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→4)]-2-acetamido-2-deoxy-beta-D-glucopyranose|alpha-L-Fuc-(1→2)-beta-D-Gal-(1→4)-[alpha-L-Fuc-(1→3)]-beta-D-GlcNAc|alpha-L-Fucp-(1→2)-beta-D-Galp-(1→4)-[alpha-L-Fucp-(1→3)]-beta-D-GlcpNAc|Fucalpha1-2Galbeta1-4(Fucalpha1-3)GlcNAcbeta|Fucalpha1-3(Fucalpha1-2Galbeta1-4)GclNAc|Lewis y Tetrasaccharide <br>
-'''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
-'''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000047===
+ '''term (main_entry)''' : Core 3 <br>
+ '''glycan_dictionary_accession''' : GSD000047 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00035MO G00035MO] <br>
+ '''term_in_sentence''' : Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells.[PMID: [https://pubmed.ncbi.nlm.nih.gov/28745318 28745318]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28745318 28745318]|[https://pubmed.ncbi.nlm.nih.gov/27259834 27259834]|[https://pubmed.ncbi.nlm.nih.gov/27143302 27143302]| <br>
+ '''definition''' : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344] <br>
+ '''term_xref''' : GTC:G00035MO|CID:25061208|CHEBI:71344  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>
-===GD000038===
-'''term (main_entry)''' : Blood group H (type 2) - Lewis y <br>
-'''glycan_dictionary_accession''' : GD000038 <br>
-'''glytoucan_accession ''' : G00052MO <br>
-'''term_in_sentence''' : The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes.[PMID: 11479278] <br>
-'''publication''' : 11479278 <br>
-'''definition''' : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] <br>
-'''term_xref''' : GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045 <br>
-'''best_match''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045 <br>
-'''synonymns''' : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y <br>
-'''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
-'''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===GSD000048===
+ '''term (main_entry)''' : Core 4 <br>
+ '''glycan_dictionary_accession''' : GSD000048 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00037MO G00037MO] <br>
+ '''term_in_sentence''' : The results confirm the predicted existence of a beta1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation.[PMID: [https://pubmed.ncbi.nlm.nih.gov/9988682 9988682]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9988682 9988682]|[https://pubmed.ncbi.nlm.nih.gov/10747980 10747980]| <br>
+ '''definition''' : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341] <br>
+ '''term_xref''' : GTC:G00037MO| CID:25229562|CHEBI:71341 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK20721/ Chapter 8]<br>
-===GD000039===
-'''term (main_entry)''' : Blood group H (Type 4) <br>
-'''glycan_dictionary_accession''' : GD000039 <br>
-'''glytoucan_accession ''' : G98465JN <br>
-'''term_in_sentence''' : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID:1841684] <br>
-'''publication''' : 11261842|1841684|11101633|9405495 <br>
-'''definition''' : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245] <br>
-'''term_xref''' : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245 <br>
-'''best_match''' : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : Pyelonephritis[SugarBind_Ligand:61] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000049===
+[[File:G78059CC.png|thumb|G78059CC]]
+ '''term (main_entry)''' : Core-fucosylated <br>
+ '''glycan_dictionary_accession''' : GSD000049 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
+ '''term_in_sentence''' : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27678371 27678371]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27678371 27678371]|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]|[https://pubmed.ncbi.nlm.nih.gov/15538974 15538974]|[https://pubmed.ncbi.nlm.nih.gov/24914453 24914453]| [https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/32078267 32078267]|[https://pubmed.ncbi.nlm.nih.gov/31268672 31268672]|[https://pubmed.ncbi.nlm.nih.gov/28674882 28674882]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]|[https://pubmed.ncbi.nlm.nih.gov/27798819 27798819]|[https://pubmed.ncbi.nlm.nih.gov/32044029 32044029]|[https://pubmed.ncbi.nlm.nih.gov/30962950 30962950]|[https://pubmed.ncbi.nlm.nih.gov/31548313 31548313]|[https://pubmed.ncbi.nlm.nih.gov/30907281 30907281]|[https://pubmed.ncbi.nlm.nih.gov/29090617 29090617]|[https://pubmed.ncbi.nlm.nih.gov/29571940 29571940]|[https://pubmed.ncbi.nlm.nih.gov/28800497 28800497]|[https://pubmed.ncbi.nlm.nih.gov/27629418 27629418]|[https://pubmed.ncbi.nlm.nih.gov/29733746 29733746]|[https://pubmed.ncbi.nlm.nih.gov/31623829 31623829]|[https://pubmed.ncbi.nlm.nih.gov/28768188 28768188]|[https://pubmed.ncbi.nlm.nih.gov/26897254 26897254]|[https://pubmed.ncbi.nlm.nih.gov/31451706 31451706]|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]]|[https://pubmed.ncbi.nlm.nih.gov/29427759 29427759]|[https://pubmed.ncbi.nlm.nih.gov/28982386 28982386]|[https://pubmed.ncbi.nlm.nih.gov/26587313 26587313]|[https://pubmed.ncbi.nlm.nih.gov/30940702 30940702]| [https://pubmed.ncbi.nlm.nih.gov/15538974 15538974]|[https://pubmed.ncbi.nlm.nih.gov/31249452 31249452]|[https://pubmed.ncbi.nlm.nih.gov/27282921 27282921]|[https://pubmed.ncbi.nlm.nih.gov/31229844 31229844]|[https://pubmed.ncbi.nlm.nih.gov/30445455 30445455]|[https://pubmed.ncbi.nlm.nih.gov/31325506 31325506]|[https://pubmed.ncbi.nlm.nih.gov/24732908 24732908]|[https://pubmed.ncbi.nlm.nih.gov/29209018 29209018]|[https://pubmed.ncbi.nlm.nih.gov/26965517 26965517]|[https://pubmed.ncbi.nlm.nih.gov/28609658 28609658]| [https://pubmed.ncbi.nlm.nih.gov/24914453 24914453]|[https://pubmed.ncbi.nlm.nih.gov/25573275 25573275]|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/19218400 19218400]|[https://pubmed.ncbi.nlm.nih.gov/27012207 27012207]|[https://pubmed.ncbi.nlm.nih.gov/27139574 27139574]| [https://pubmed.ncbi.nlm.nih.gov/32078267 32078267]|[https://pubmed.ncbi.nlm.nih.gov/25861849 25861849]|[https://pubmed.ncbi.nlm.nih.gov/32561391 32561391]|[https://pubmed.ncbi.nlm.nih.gov/21374780 21374780]|[https://pubmed.ncbi.nlm.nih.gov/31669139 31669139]|[https://pubmed.ncbi.nlm.nih.gov/25732060 25732060]|[https://pubmed.ncbi.nlm.nih.gov/29408166 29408166]|[https://pubmed.ncbi.nlm.nih.gov/31268672 31268672]|[https://pubmed.ncbi.nlm.nih.gov/30472795 30472795]|[https://pubmed.ncbi.nlm.nih.gov/30614075 30614075]|[https://pubmed.ncbi.nlm.nih.gov/19003000 19003000]|[https://pubmed.ncbi.nlm.nih.gov/25664929 25664929] <br>
+ '''definition''' : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006<nowiki>]. </nowiki><br>
+ '''term_xref''' : GTC:G78059CC|CID: 70679232|CHEBI:70967|CHEBI:156499 <br>
+ '''synonyms''' : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc <br>
+ '''function''' : Required for signaling through TCR [PMID: 29434598]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:17132494]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:29062024] <br>
+ '''disease_associations''' : Emphysema|systemic lupus erythematosuslung cancer|autoimmunity|tumor metastasis <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK20721/ Chapter 8] <br>
-===GD000040===
-'''term (main_entry)''' : C2-O-sLex <br>
-'''glycan_dictionary_accession''' : GD000040 <br>
-'''glytoucan_accession ''' : G97345NY <br>
-'''term_in_sentence''' : PSGL-1 lacks 6-sulfo-sLex but contains sulfated tyrosine residues (Tyr-SO3)at positions 46, 48, and 51 and sLex in a core 2-based O-glycan (C2-O-sLex) on Thr at position 57.[PMID:12736247] <br>
-'''publication''' : 12736247|19267921|21283832|15596301|17072011 <br>
-'''definition''' : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192] <br>
-'''term_xref''' : GlycoMotif:GGM.000053|CID:91860725|KEGG:G10899|CHEBI:155160 <br>
-'''best_match''' : GlycoMotif:GGM.000053|GTC:G97345NY|CID:91860725|KEGG:G10899|CHEBI:155160 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000050===
+ '''term (main_entry)''' : Core-fucosylated biantennary <br>
+ '''glycan_dictionary_accession''' : GSD000050 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
+ '''term_in_sentence''' : The IFN-alpha14c N-glycans were shown to exhibit core-fucosylated biantennary glycans , with about 10% carrying an additional alpha1,3-linked fucose unit at the antennae.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9654101 9654101]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9654101 9654101]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/28263871 28263871]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/22256781 22256781]|[https://pubmed.ncbi.nlm.nih.gov/23681398 23681398]|[https://pubmed.ncbi.nlm.nih.gov/25855029 25855029]|[https://pubmed.ncbi.nlm.nih.gov/10529240 10529240]|[https://pubmed.ncbi.nlm.nih.gov/26544759 26544759]|[https://pubmed.ncbi.nlm.nih.gov/8206921 8206921]|[https://pubmed.ncbi.nlm.nih.gov/33149259 33149259]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276] <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br>
+ '''term_xref''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br>
+ '''synonyms''' : core-fucosylated diantennary <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK20721/ Chapter 8] <br>
-===GD000041===
-'''term (main_entry)''' : Ceramide dihexosyl sulfate <br>
-'''glycan_dictionary_accession''' : GD000041 <br>
-'''glytoucan_accession ''' : G04416BG <br>
-'''term_in_sentence''' : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:818074] <br>
-'''publication''' : 818074 <br>
-'''definition''' : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides.[http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/] <br>
-'''term_xref''' : GlycoMotif:GGM.000065 <br>
-'''best_match''' : GTC:G04416BG|GlycoMotif:GGM.000065 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000051===
+ '''term (main_entry)''' : Core-fucosylated biantennary complex-type <br>
+ '''glycan_dictionary_accession''' : GSD000051 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
+ '''term_in_sentence''' : The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10731668 10731668]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10731668 10731668] <br>
+ '''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br>
+ '''term_xref''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499  <br>
+ '''synonyms''' : core fucosylated diantennary complex-type <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000042===
-'''term (main_entry)''' : Chitin <br>
-'''glycan_dictionary_accession''' : GD000042 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241] <br>
-'''publication''' : 25738328|31102247|26982439|31685194|29197571|29182521|25725011|27787767|21736263|25300540|30840869|25081074|28250359|29763421|29910219|20161969|32019265|30879650|12587986|29773374|31376451|10906950|26096004|25595947|21673932|29452181|24083454|10856926|22732132|18657571|29175166|28842199|27592817|27302593|27339323|12705640|31635752|31063786|31151236|25940531|26093316|28962761|28093332|30875044|27723949|28119189|30600008|25081085|21673932 <br>
-'''definition''' : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029] <br>
-'''term_xref''' : CHEBI:17029 <br>
-'''best_match''' : CHEBI:17029 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000052===
+[[File:G11148DZ.png|thumb|G11148DZ]]
+ '''term (main_entry)''' : Cyclic sialyl 6-sulfo Lewis x <br>
+ '''glycan_dictionary_accession''' : GSD000052 <br>
+ '''glytoucan_accession ''' :  [https://www.glygen.org/glycan/G11148DZ G11148DZ]<br>
+ '''term_in_sentence''' : Stimulation of the sialyl 6-sulfo Lewis X-positive colon cancer cell line with a calcium ionophore ionomycin markedly reduced sialyl 6-sulfo Lewis X and induced cyclic sialyl 6-sulfo Lewis X expression.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/31222115 31222115]|[https://pubmed.ncbi.nlm.nih.gov/9990070 9990070]|[https://pubmed.ncbi.nlm.nih.gov/23088960 23088960] <br>
+ '''definition''' :  <br>
+ '''term_xref''' :  GlycoEpitope:EP0017|CID: 91858084|CHEBI:147484<br>
+ '''synonyms''' :  <br>
+ '''function''' : The accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000043===
-'''term (main_entry)''' : Chondroitin sulfate <br>
-'''glycan_dictionary_accession''' : GD000043 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: 31013685] <br>
-'''publication''' : 31013685|27526113|27194526|26980567|28847361|24413804|29891297|29600622|25129732|31317901|29181550|31250530|22265655|25756648|29402610|17928217|20236040|28091940|30824935|26572336|31207331|21110089|30599999|20399897|27226567|19388612|23186102|31494830|28982096|30241863|30295666|25366475|20521042|29456007|31304829|18661362|28576008|29494632|30016441|26906924|24861964|23774590|31887904|31339761|12512856|26957048|29625000 <br>
-'''definition''' : Any of a class of 10‚Äî60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397] <br>
-'''term_xref''' : CHEBI:37397|CID:24766 <br>
-'''best_match''' : CHEBI:37397| CID: 24766 <br>
-'''synonymns''' : chondroitin polysulfate|chondroitin sulfate|chondroitin sulfates|chondroitin sulfuric acid|chondroitin sulphate|Chondroitinsulfate <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000053===
+ '''term (main_entry)''' : Cytolipin R <br>
+ '''glycan_dictionary_accession''' : GSD000053 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57710SU G57710SU] <br>
+ '''term_in_sentence''' : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:[https://pubmed.ncbi.nlm.nih.gov/4110375 4110375]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/893368 893368]|[https://pubmed.ncbi.nlm.nih.gov/4375678 4375678]|[https://pubmed.ncbi.nlm.nih.gov/51702 51702]|[https://pubmed.ncbi.nlm.nih.gov/186204 186204]|[https://pubmed.ncbi.nlm.nih.gov/4110375 4110375]|[https://pubmed.ncbi.nlm.nih.gov/5068000 5068000]|[https://pubmed.ncbi.nlm.nih.gov/24174198 24174198]|[https://pubmed.ncbi.nlm.nih.gov/6072378 6072378]|[https://pubmed.ncbi.nlm.nih.gov/389925 389925]|[https://pubmed.ncbi.nlm.nih.gov/7054174 7054174] <br>
+ '''definition''' : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/5068000 5068000]] <br>
+ '''term_xref''' : GlycoMotif:GGM.000083|GTC:G57710SU|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Actinomycosis[SugarBind_Ligand:17] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000044===
-'''term (main_entry)''' : cisGM1 <br>
-'''glycan_dictionary_accession''' : GD000044 <br>
-'''glytoucan_accession ''' : G03277YI <br>
-'''term_in_sentence''' : Macrophage ganglioside patterns dramatically increase in complexity when murine peritoneal macrophages are stimulated in vivo with the appearance of the sialidase-sensitive monosialoganglioside GM1b (cisGM1) as a major component.[PMID: 9455923] <br>
-'''publication''' : 9455923 <br>
-'''definition''' : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580] <br>
-'''term_xref''' : GlycoMotif:GGM.000100|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 <br>
-'''best_match''' : GlycoMotif:GGM.000100|GTC:G03277YI|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 <br>
-'''synonymns''' : GM1b <br>
-'''function''' :  <br>
-'''disease_associations''' : Influenza[SugarBind_Ligand:92] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453054-Chapter 23 <br>
+===GSD000054===
+ '''term (main_entry)''' : Dermatan sulfate <br>
+ '''glycan_dictionary_accession''' : GSD000054 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29111696 29111696]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27526113 27526113]|[https://pubmed.ncbi.nlm.nih.gov/29111696 29111696]|[https://pubmed.ncbi.nlm.nih.gov/29891297 29891297]|[https://pubmed.ncbi.nlm.nih.gov/26164146 26164146]|[https://pubmed.ncbi.nlm.nih.gov/30869126 30869126]|[https://pubmed.ncbi.nlm.nih.gov/7789716 7789716]|[https://pubmed.ncbi.nlm.nih.gov/8597249 8597249]|[https://pubmed.ncbi.nlm.nih.gov/12512856 12512856]| [https://pubmed.ncbi.nlm.nih.gov/31250530 31250530]| [https://pubmed.ncbi.nlm.nih.gov/17928217 17928217]|[https://pubmed.ncbi.nlm.nih.gov/12213784 12213784]|[https://pubmed.ncbi.nlm.nih.gov/27226567 27226567]|[https://pubmed.ncbi.nlm.nih.gov/31455633 31455633]|[https://pubmed.ncbi.nlm.nih.gov/28091940 28091940]|[https://pubmed.ncbi.nlm.nih.gov/19075609 19075609]|[https://pubmed.ncbi.nlm.nih.gov/31071403 31071403]|[https://pubmed.ncbi.nlm.nih.gov/15078125 15078125]|[https://pubmed.ncbi.nlm.nih.gov/18661328 18661328]|[https://pubmed.ncbi.nlm.nih.gov/20581662 20581662]|[https://pubmed.ncbi.nlm.nih.gov/17239765 17239765]|[https://pubmed.ncbi.nlm.nih.gov/15749837 15749837]|[https://pubmed.ncbi.nlm.nih.gov/2777747 2777747]|[https://pubmed.ncbi.nlm.nih.gov/20632047 20632047]|[https://pubmed.ncbi.nlm.nih.gov/8930750 8930750]|[https://pubmed.ncbi.nlm.nih.gov/7762784 7762784]|[https://pubmed.ncbi.nlm.nih.gov/31006321 31006321]|[https://pubmed.ncbi.nlm.nih.gov/26876822 26876822]|[https://pubmed.ncbi.nlm.nih.gov/1522290 1522290]|[https://pubmed.ncbi.nlm.nih.gov/131009 131009]|[https://pubmed.ncbi.nlm.nih.gov/26986023 26986023]|[https://pubmed.ncbi.nlm.nih.gov/8161353 8161353]|[https://pubmed.ncbi.nlm.nih.gov/15315969 15315969]|[https://pubmed.ncbi.nlm.nih.gov/12543559 12543559]|[https://pubmed.ncbi.nlm.nih.gov/30637950 30637950]|[https://pubmed.ncbi.nlm.nih.gov/2525357 2525357]|[https://pubmed.ncbi.nlm.nih.gov/18156656 18156656]|[https://pubmed.ncbi.nlm.nih.gov/9692613 9692613]|[https://pubmed.ncbi.nlm.nih.gov/9200333 9200333]|[https://pubmed.ncbi.nlm.nih.gov/19661164 19661164]|[https://pubmed.ncbi.nlm.nih.gov/2299256 2299256]|[https://pubmed.ncbi.nlm.nih.gov/16075147 16075147]|[https://pubmed.ncbi.nlm.nih.gov/1126924 1126924]|[https://pubmed.ncbi.nlm.nih.gov/9774430 9774430]|[https://pubmed.ncbi.nlm.nih.gov/8537360 8537360]|[https://pubmed.ncbi.nlm.nih.gov/15563459 15563459]|[https://pubmed.ncbi.nlm.nih.gov/21077227 21077227]|[https://pubmed.ncbi.nlm.nih.gov/23275130 23275130]|[https://pubmed.ncbi.nlm.nih.gov/17137817 17137817]|[https://pubmed.ncbi.nlm.nih.gov/6447930 6447930]|[https://pubmed.ncbi.nlm.nih.gov/6209270 6209270] <br>
+ '''definition''' : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.[CHEBI:18376] <br>
+ '''term_xref''' : CHEBI:18376|CID:32756 <br>
+ '''synonyms''' : beta-Heparin|Chondroitin sulfate B|Dermatan L-iduronate <br>
+ '''function''' : Wound healing[Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453034/ Chapter 7]]|maintain the structure of the dermis.[Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453056/ Chapter 41]] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000045===
-'''term (main_entry)''' : Complex-type N-glycans <br>
-'''glycan_dictionary_accession''' : GD000045 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:10988252] <br>
-'''publication''' : 29902282|29212795|29343819|27705835|26745022|18399796|16825488|21964725|15864431|22890903|12417032|28039392|19426135|30253927|16794314|19806620|22975979|25931033|15201278|19129634|19129628|24032650|22530754|31021709|30973186|28091941|23115339|20829342|27304954|29090617|21802690|29725121|30471292|16581187|26098720|31080188|1930135|31888963|30844485|24014058|11129583 <br>
-'''definition''' : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' : Involved in protein stability.[PMID:12417032] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453033-Chapter 17 <br>
+===GSD000055===
+ '''term (main_entry)''' : Desialylated <br>
+ '''glycan_dictionary_accession''' : GSD000055 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Furthermore, we found no evidence for "desialylated" apoB100 glycans in any of the samples analyzed.[PMID:11588155] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30015642 30015642]|[https://pubmed.ncbi.nlm.nih.gov/26168491 26168491]|[https://pubmed.ncbi.nlm.nih.gov/29492899 29492899]|[https://pubmed.ncbi.nlm.nih.gov/31774586 31774586]|[https://pubmed.ncbi.nlm.nih.gov/32321401 32321401]|[https://pubmed.ncbi.nlm.nih.gov/23780974 23780974]|[https://pubmed.ncbi.nlm.nih.gov/7600681 7600681]|[https://pubmed.ncbi.nlm.nih.gov/18045697 18045697]|[https://pubmed.ncbi.nlm.nih.gov/1450583 1450583]|[https://pubmed.ncbi.nlm.nih.gov/4137057 4137057]|[https://pubmed.ncbi.nlm.nih.gov/28911304 28911304]|[https://pubmed.ncbi.nlm.nih.gov/27562992 27562992]|[https://pubmed.ncbi.nlm.nih.gov/29950245 29950245]|[https://pubmed.ncbi.nlm.nih.gov/31978220 31978220]|[https://pubmed.ncbi.nlm.nih.gov/2408573 2408573]|[https://pubmed.ncbi.nlm.nih.gov/8612720 8612720]|[https://pubmed.ncbi.nlm.nih.gov/10910970 10910970]|[https://pubmed.ncbi.nlm.nih.gov/27195066 27195066]|[https://pubmed.ncbi.nlm.nih.gov/1434544 1434544]|[https://pubmed.ncbi.nlm.nih.gov/22175031 22175031]|[https://pubmed.ncbi.nlm.nih.gov/24517196 24517196]|[https://pubmed.ncbi.nlm.nih.gov/29794068 29794068]|[https://pubmed.ncbi.nlm.nih.gov/30101537 30101537]|[https://pubmed.ncbi.nlm.nih.gov/18972200 18972200]|[https://pubmed.ncbi.nlm.nih.gov/1478792 1478792]|[https://pubmed.ncbi.nlm.nih.gov/4440781 4440781]|[https://pubmed.ncbi.nlm.nih.gov/21229239 21229239]|[https://pubmed.ncbi.nlm.nih.gov/30844664 30844664]|[https://pubmed.ncbi.nlm.nih.gov/31351722 31351722]|[https://pubmed.ncbi.nlm.nih.gov/31330845 31330845]|[https://pubmed.ncbi.nlm.nih.gov/1872910 1872910] <br>
+ '''definition''' : A glycan from which sialyl groups have been removed. [https://en.wiktionary.org/wiki/desialylated<nowiki>] </nowiki><br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000046===
-'''term (main_entry)''' : Core 2 <br>
-'''glycan_dictionary_accession''' : GD000046 <br>
-'''glytoucan_accession ''' : G00033MO <br>
-'''term_in_sentence''' : To investigate the biological roles of core 2 O-glycans, we produced and characterized mice deficient in one or more of the three known glycosyltransferases that generate core 2 O-glycans (C2GnT1, C2GnT2, and C2GnT3).[PMID: 19349303] <br>
-'''publication''' : 19349303|30315106|23640779|26677400 <br>
-'''definition''' : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158] <br>
-'''term_xref''' : CID:52921656|CHEBI:62158 <br>
-'''best_match''' : GTC:G00033MO|CID:52921656|CHEBI:62158 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000056===
+ '''term (main_entry)''' : Desialylated tetrasaccharide <br>
+ '''glycan_dictionary_accession''' : GSD000056 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The structures of a desialylated tetrasaccharide , two monosialylated trisaccharides , and five other minor products were defined.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8384526 8384526]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/8384526 8384526] <br>
+ '''definition''' : A tetrasachharide (four branches) glycan from which sialyl groups have been removed.  <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17]<br>
-===GD000047===
-'''term (main_entry)''' : Core 3 <br>
-'''glycan_dictionary_accession''' : GD000047 <br>
-'''glytoucan_accession ''' : G00035MO <br>
-'''term_in_sentence''' : Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells.[PMID: 28745318] <br>
-'''publication''' : 28745318|27259834|27143302| <br>
-'''definition''' : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344] <br>
-'''term_xref''' : CID:25061208|CHEBI:71344 <br>
-'''best_match''' : GTC:G00035MO|CID:25061208|CHEBI:71344 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453020-Chapter 9 <br>
+===GSD000057===
+ '''term (main_entry)''' : Difucosylated tetra-antennary N-glycans <br>
+ '''glycan_dictionary_accession''' : GSD000057 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID: [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] <br>
+ '''definition''' : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : pancreatic cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000048===
-'''term (main_entry)''' : Core 4 <br>
-'''glycan_dictionary_accession''' : GD000048 <br>
-'''glytoucan_accession ''' : G00037MO <br>
-'''term_in_sentence''' : The results confirm the predicted existence of a beta1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation.[PMID: 9988682] <br>
-'''publication''' : 9988682|10747980| <br>
-'''definition''' : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341] <br>
-'''term_xref''' : CID:25229562|CHEBI:71341 <br>
-'''best_match''' : GTC:G00037MO| CID:25229562|CHEBI:71341 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK20721-Chapter 8 <br>
+===GSD000058===
+ '''term (main_entry)''' : Dimeric Lewis x <br>
+ '''glycan_dictionary_accession''' : GSD000058 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79535HZ G79535HZ] <br>
+ '''term_in_sentence''' : The carbohydrate antigen dimeric Lewis X (DimLex), which accumulates in colonic and liver adenocarcinomas, is a valuable target to develop anti-cancer therapeutics.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32957489 32957489]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32957489 32957489]|[https://pubmed.ncbi.nlm.nih.gov/31276881 31276881]|[https://pubmed.ncbi.nlm.nih.gov/12062524 12062524]|[https://pubmed.ncbi.nlm.nih.gov/15488731 15488731]|[https://pubmed.ncbi.nlm.nih.gov/1979361 1979361]|[https://pubmed.ncbi.nlm.nih.gov/8737237 8737237]|[https://pubmed.ncbi.nlm.nih.gov/17939723 17939723]|[https://pubmed.ncbi.nlm.nih.gov/7683631 7683631]|[https://pubmed.ncbi.nlm.nih.gov/11384108 11384108]|[https://pubmed.ncbi.nlm.nih.gov/11133015 11133015]|[https://pubmed.ncbi.nlm.nih.gov/17388629 17388629]|[https://pubmed.ncbi.nlm.nih.gov/15483381 15483381]|[https://pubmed.ncbi.nlm.nih.gov/12662048 12662048]|[https://pubmed.ncbi.nlm.nih.gov/3233598 3233598]|[https://pubmed.ncbi.nlm.nih.gov/18618154 18618154]|[https://pubmed.ncbi.nlm.nih.gov/21892456 21892456] <br>
+ '''definition''' : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325] <br>
+ '''term_xref''' : GTC:G79535HZ|GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031 <br>
+ '''synonyms''' : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx <br>
+ '''function''' : cancer-associated antigen[GlycoEpitope:EP0093] <br>
+ '''disease_associations''' : colonic cancer[GlycoEpitope:EP0093]|liver cancer[GlycoEpitope:EP0093] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000049===
-'''term (main_entry)''' : Core-fucosylated <br>
-'''glycan_dictionary_accession''' : GD000049 <br>
-'''glytoucan_accession ''' : G78059CC <br>
-'''term_in_sentence''' : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:27678371] <br>
-'''publication''' : 27678371|26514868|15538974|24914453|17049014|32078267|31268672|28674882|29956878|27798819|32044029|30962950|31548313|30907281|29090617|29571940|28800497|27629418|29733746|31623829|28768188|26897254|31451706|26514868|29427759|28982386|26587313|30940702|15538974|31249452|27282921|31229844|30445455|31325506|24732908|29209018|26965517|28609658|24914453|25573275|17049014|19218400|27012207|27139574|32078267|25861849|32561391|21374780|31669139|25732060|29408166|31268672|30472795|30614075|19003000|25664929 <br>
-'''definition''' : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006]. <br>
-'''term_xref''' : CID:70679232|CHEBI:70967|CHEBI:156499 <br>
-'''best_match''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br>
-'''synonymns''' : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc <br>
-'''function''' : Required for signaling through TCR [PMID: 29434598]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:17132494]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:29062024] <br>
-'''disease_associations''' : Emphysema|systemic lupus erythematosuslung cancer|autoimmunity|tumor metastasis <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK20721-Chapter 8 <br>
+===GSD000059===
+ '''term (main_entry)''' : Diphosphorylated Man6 <br>
+ '''glycan_dictionary_accession''' : GSD000059 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54792LL G54792LL] <br>
+ '''term_in_sentence''' : Here we report that the single-chain variable domain (scFv) M6P-1 is a unique antibody fragment with specificity for Man6P monosaccharide that, through an array-screening approach against a number of phosphorylated N-glycans, is shown to bind mono- and diphosphorylated Man6 and Man7 glycans that contain terminal αMan6P(1 → 2)αMan(1 → 3)αMan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26503547 26503547]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/26503547 26503547] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GTC:G54792LL|GlycoMotif:GGM.000054<br>
+ '''synonyms''' : Diphosphorylated Man_6 <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000050===
-'''term (main_entry)''' : Core-fucosylated biantennary <br>
-'''glycan_dictionary_accession''' : GD000050 <br>
-'''glytoucan_accession ''' : G78059CC <br>
-'''term_in_sentence''' : The IFN-alpha14c N-glycans were shown to exhibit core-fucosylated biantennary glycans , with about 10% carrying an additional alpha1,3-linked fucose unit at the antennae.[PMID:9654101] <br>
-'''publication''' : 9654101|15819890|28263871|26763099|22256781|23681398|25855029|10529240|26544759|8206921|33149259|8547276 <br>
-'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br>
-'''term_xref''' : CID:70679232|CHEBI:70967|CHEBI:156499 <br>
-'''best_match''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br>
-'''synonymns''' : core-fucosylated diantennary <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK20721-Chapter 8 <br>
+===GSD000060===
+ '''term (main_entry)''' : Disialosyl globopentaosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000060 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97932OH G97932OH] <br>
+ '''term_in_sentence''' : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]|[https://pubmed.ncbi.nlm.nih.gov/24637536 24637536]|[https://pubmed.ncbi.nlm.nih.gov/25864532 25864532]|[https://pubmed.ncbi.nlm.nih.gov/27344728 27344728]| [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]| [https://pubmed.ncbi.nlm.nih.gov/32567311 32567311]|[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]|[https://pubmed.ncbi.nlm.nih.gov/20663960 20663960]|[https://pubmed.ncbi.nlm.nih.gov/18214042 18214042] <br>
+ '''definition''' : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]] <br>
+ '''term_xref''' : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID:91860287|KEGG:G00181|SugarBind_Ligand:57  <br>
+ '''synonyms''' : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside <br>
+ '''function''' : promotes metastasis[PMID:[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]] <br>
+ '''disease_associations''' : prostate cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/24637536 24637536]]|renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000051===
-'''term (main_entry)''' : Core-fucosylated biantennary complex-type <br>
-'''glycan_dictionary_accession''' : GD000051 <br>
-'''glytoucan_accession ''' : G78059CC <br>
-'''term_in_sentence''' : The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.[PMID:10731668] <br>
-'''publication''' : 10731668 <br>
-'''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br>
-'''term_xref''' : CID:70679232|CHEBI:70967|CHEBI:156499 <br>
-'''best_match''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br>
-'''synonymns''' : core fucosylated diantennary complex-type <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000061===
+ '''term (main_entry)''' : Disialyl Gb5 <br>
+ '''glycan_dictionary_accession''' : GSD000061 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97932OH G97932OH] <br>
+ '''term_in_sentence''' : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]  <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoEpitope:EP0098|GTC:G97932OH|CID:  91860287|SugarBind_Ligand:57|KEGG:G00181  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000052===
-'''term (main_entry)''' : Cyclic sialyl 6-sulfo Lewis x <br>
-'''glycan_dictionary_accession''' : GD000052 <br>
-'''glytoucan_accession ''' : G80722US <br>
-'''term_in_sentence''' : Stimulation of the sialyl 6-sulfo Lewis X-positive colon cancer cell line with a calcium ionophore ionomycin markedly reduced sialyl 6-sulfo Lewis X and induced cyclic sialyl 6-sulfo Lewis X expression.[PMID:10728707] <br>
-'''publication''' : 10728707|31222115|9990070|23088960 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000023|GlycoEpitope:EP0015|CID:70698321|CHEBI:71628 <br>
-'''best_match''' : GlycoMotif:GGM.000023|GTC:G80722US|GlycoEpitope:EP0015|CID:70698321|CHEBI:71628 <br>
-'''synonymns''' :  <br>
-'''function''' : the accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000062===
+ '''term (main_entry)''' : Disialyl I <br>
+ '''glycan_dictionary_accession''' : GSD000062 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54937EM G54937EM] <br>
+ '''term_in_sentence''' : Here we present an example of promotion of binding of soluble-form FN from placenta or from hepatoma cells, having a specific carbohydrate epitope termed "disialyl-I," to K562 or VA13 cell surface in the presence of glycosphingolipid Gg3, which interacts specifically with disialyl-I[PMID:[https://pubmed.ncbi.nlm.nih.gov/10640401 10640401]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10640401 10640401] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoEpitope:EP0095|GTC:G54937EM|CID:91849523  <br>
+ '''synonyms''' : disialyl-I <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000053===
-'''term (main_entry)''' : Cytolipin R <br>
-'''glycan_dictionary_accession''' : GD000053 <br>
-'''glytoucan_accession ''' : G57710SU <br>
-'''term_in_sentence''' : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:4110375] <br>
-'''publication''' : 893368|4375678|51702|186204|4110375|5068000|24174198|6072378|389925|7054174 <br>
-'''definition''' : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:5068000] <br>
-'''term_xref''' : GlycoMotif:GGM.000083|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17 <br>
-'''best_match''' : GlycoMotif:GGM.000083|GTC:G57710SU|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : Actinomycosis[SugarBind_Ligand:17] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000063===
+ '''term (main_entry)''' : Disialyl Lewis a <br>
+ '''glycan_dictionary_accession''' : GSD000063 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93400AK G93400AK] <br>
+ '''term_in_sentence''' : Biosynthesis of disialyl Lewis a (Lea) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12668675 12668675]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12668675 12668675]|[https://pubmed.ncbi.nlm.nih.gov/17760270 17760270]|[https://pubmed.ncbi.nlm.nih.gov/15231659 15231659]|[https://pubmed.ncbi.nlm.nih.gov/12668106 12668106]|[https://pubmed.ncbi.nlm.nih.gov/30716533 30716533]|[https://pubmed.ncbi.nlm.nih.gov/32050430 32050430]|[https://pubmed.ncbi.nlm.nih.gov/22467657 22467657] <br>
+ '''definition''' : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:[https://pubmed.ncbi.nlm.nih.gov/15231659 15231659]] <br>
+ '''term_xref''' : GTC:G93400AK |GlycoEpitope:EP0040|CID:91854138|CHEBI:155549 <br>
+ '''synonyms''' : disialyl Lea <br>
+ '''function''' : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040] <br>
+ '''disease_associations''' : Mucin antigen carrying 2-3 sialylated Le a antigen or 2-3, 2-6 disialylated Lc4 antigen in cancer patients had the lowest carbohydrate/protein ratio. Thus, the carbohydrate/protein ratio in the type 1 chain mucin antigens in sera of normal subjects is higher than that in sera of cancer patients.[GlycoEpitope:EP0040] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000054===
-'''term (main_entry)''' : Dermatan sulfate <br>
-'''glycan_dictionary_accession''' : GD000054 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:29111696] <br>
-'''publication''' : 27526113|29111696|29891297|26164146|30869126|7789716|8597249|12512856|31250530|17928217|12213784|27226567|31455633|28091940|19075609|31071403|15078125|18661328|20581662|17239765|15749837|2777747|20632047|8930750|7762784|31006321|26876822|1522290|131009|26986023|8161353|15315969|12543559|30637950|2525357|18156656|9692613|9200333|19661164|2299256|16075147|1126924|9774430|8537360|15563459|21077227|23275130|17137817|6447930|6209270 <br>
-'''definition''' : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.
-[CHEBI:18376] <br>
-'''term_xref''' : CHEBI:18376|CID:32756 <br>
-'''best_match''' : CHEBI:18376| CID: 32756 <br>
-'''synonymns''' : beta-Heparin|Chondroitin sulfate B|Dermatan L-iduronate <br>
-'''function''' : Wound healing[NBK453034-Chapter 7]|maintain the structure of the dermis.[NBK453056-Chapter 41] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000064===
+ '''term (main_entry)''' : Disialyl T antigen <br>
+ '''glycan_dictionary_accession''' : GSD000064 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G01614ZM G01614ZM] <br>
+ '''term_in_sentence''' : The most potent glycoside was disialyl T antigen (NeuAcalpha2-3Galbeta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides.[PMID: [https://pubmed.ncbi.nlm.nih.gov/15701648 15701648]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/17974963 17974963]|[https://pubmed.ncbi.nlm.nih.gov/33242079 33242079]|[https://pubmed.ncbi.nlm.nih.gov/12645620 12645620]|[https://pubmed.ncbi.nlm.nih.gov/15701648 15701648]|[https://pubmed.ncbi.nlm.nih.gov/26598643 26598643] <br>
+ '''definition''' : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602] <br>
+ '''term_xref''' : GlycoMotif:GGM.000014|GTC:G01614ZM|CID: 70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027  <br>
+ '''synonyms''' : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen <br>
+ '''function''' : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000055===
-'''term (main_entry)''' : Desialylated <br>
-'''glycan_dictionary_accession''' : GD000055 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Furthermore, we found no evidence for "desialylated" apoB100 glycans in any of the samples analyzed.[PMID:11588155] <br>
-'''publication''' : 30015642|26168491|29492899|31774586|32321401|23780974|7600681|18045697|1450583|4137057|28911304|27562992|29950245|31978220|2408573|8612720|10910970|27195066|1434544|22175031|24517196|29794068|30101537|18972200|1478792|4440781|21229239|30844664|31351722|31330845|1872910 <br>
-'''definition''' : A glycan from which sialyl groups have been removed. [https://en.wiktionary.org/wiki/desialylated] <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000065===
+ '''term (main_entry)''' : Disialylated biantennary <br>
+ '''glycan_dictionary_accession''' : GSD000065 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8486673 8486673]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/17171781 17171781]|[https://pubmed.ncbi.nlm.nih.gov/25022802 25022802]|[https://pubmed.ncbi.nlm.nih.gov/24812685 24812685]|[https://pubmed.ncbi.nlm.nih.gov/24780636 24780636]|[https://pubmed.ncbi.nlm.nih.gov/26582205 26582205]|[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]|[https://pubmed.ncbi.nlm.nih.gov/22978794 22978794]|[https://pubmed.ncbi.nlm.nih.gov/22594947 22594947]|[https://pubmed.ncbi.nlm.nih.gov/8486673 8486673]|[https://pubmed.ncbi.nlm.nih.gov/20356825 20356825]|[https://pubmed.ncbi.nlm.nih.gov/1634621 1634621]|[https://pubmed.ncbi.nlm.nih.gov/9244386 9244386]|[https://pubmed.ncbi.nlm.nih.gov/12966096 12966096]|[https://pubmed.ncbi.nlm.nih.gov/1472054 1472054]| [https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]|[https://pubmed.ncbi.nlm.nih.gov/19579232 19579232]|[https://pubmed.ncbi.nlm.nih.gov/27943633 27943633] <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' : disialylated diantennary <br>
+ '''function''' : appears in human transferrin[PMID:  [https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] <br>
+ '''disease_associations''' : galactosemia.[PMID: [https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000056===
-'''term (main_entry)''' : Desialylated tetrasaccharide <br>
-'''glycan_dictionary_accession''' : GD000056 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The structures of a desialylated tetrasaccharide , two monosialylated trisaccharides , and five other minor products were defined.[PMID:8384526] <br>
-'''publication''' : 8384526 <br>
-'''definition''' : A tetrasachharide (four branches) glycan from which sialyl groups have been removed.  <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453033-Chapter 17 <br>
+===GSD000066===
+ '''term (main_entry)''' : Disialylated biantennary complex-type <br>
+ '''glycan_dictionary_accession''' : GSD000066 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11738084 11738084]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11738084 11738084]|[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]|[https://pubmed.ncbi.nlm.nih.gov/9244386 9244386]|[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]|[https://pubmed.ncbi.nlm.nih.gov/12966096 12966096]|[https://pubmed.ncbi.nlm.nih.gov/25124522 25124522]|[https://pubmed.ncbi.nlm.nih.gov/19371135 19371135] <br>
+ '''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' : appears in human transferrin[PMID:[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] <br>
+ '''disease_associations''' : galactosemia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000057===
-'''term (main_entry)''' : Difucosylated tetra-antennary N-glycans <br>
-'''glycan_dictionary_accession''' : GD000057 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID:18214858] <br>
-'''publication''' : 18214858 <br>
-'''definition''' : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : pancreatic cancer[PMID:18214858] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000067===
+ '''term (main_entry)''' : Disialylated fucosylated <br>
+ '''glycan_dictionary_accession''' : GSD000067 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17591618 17591618] <br>
+ '''definition''' : A fucosylated glycan with two sialic acid components. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45]<br>
-===GD000058===
-'''term (main_entry)''' : Dimeric Lewis x <br>
-'''glycan_dictionary_accession''' : GD000058 <br>
-'''glytoucan_accession ''' : G79535HZ <br>
-'''term_in_sentence''' : The carbohydrate antigen dimeric Lewis X (DimLex), which accumulates in colonic and liver adenocarcinomas, is a valuable target to develop anti-cancer therapeutics.[PMID:32957489] <br>
-'''publication''' : 32957489|31276881|12062524|15488731|1979361|8737237|17939723|7683631|11384108|11133015|17388629|15483381|12662048|3233598|18618154|21892456 <br>
-'''definition''' : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325] <br>
-'''term_xref''' : GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031 <br>
-'''best_match''' : GTC:G79535HZ|GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031 <br>
-'''synonymns''' : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx <br>
-'''function''' : cancer-associated antigen[GlycoEpitope:EP0093] <br>
-'''disease_associations''' : colonic cancer[GlycoEpitope:EP0093]|liver cancer[GlycoEpitope:EP0093] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042-Chapter 14 <br>
+===GSD000068===
+ '''term (main_entry)''' : Forssman antigen <br>
+ '''glycan_dictionary_accession''' : GSD000068 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80062GG G80062GG] <br>
+ '''term_in_sentence''' : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution).[PMID:[https://pubmed.ncbi.nlm.nih.gov/28510705 28510705]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28510705 28510705]|[https://pubmed.ncbi.nlm.nih.gov/31933576 31933576]| [https://pubmed.ncbi.nlm.nih.gov/28134301 28134301]|[https://pubmed.ncbi.nlm.nih.gov/7021748 7021748]|[https://pubmed.ncbi.nlm.nih.gov/1802714 1802714]|[https://pubmed.ncbi.nlm.nih.gov/7512587 7512587]|[https://pubmed.ncbi.nlm.nih.gov/7747818 7747818]|[https://pubmed.ncbi.nlm.nih.gov/23325748 23325748]|[https://pubmed.ncbi.nlm.nih.gov/268649 268649]|[https://pubmed.ncbi.nlm.nih.gov/31816281 31816281]|[https://pubmed.ncbi.nlm.nih.gov/22015168 22015168]|[https://pubmed.ncbi.nlm.nih.gov/4147161 4147161]|[https://pubmed.ncbi.nlm.nih.gov/2857159 2857159]|[https://pubmed.ncbi.nlm.nih.gov/6267170 6267170]|[https://pubmed.ncbi.nlm.nih.gov/7293775 7293775]|[https://pubmed.ncbi.nlm.nih.gov/13367419 13367419]|[https://pubmed.ncbi.nlm.nih.gov/20636540 20636540]| [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]  [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]|[https://pubmed.ncbi.nlm.nih.gov/23255552 23255552]|[https://pubmed.ncbi.nlm.nih.gov/2675268 2675268]|[https://pubmed.ncbi.nlm.nih.gov/18955372 18955372]|[https://pubmed.ncbi.nlm.nih.gov/7020692 7020692]|[https://pubmed.ncbi.nlm.nih.gov/31784953 31784953]|[https://pubmed.ncbi.nlm.nih.gov/4114942 4114942]|[https://pubmed.ncbi.nlm.nih.gov/31273262 31273262]|[https://pubmed.ncbi.nlm.nih.gov/6257673 6257673]|[https://pubmed.ncbi.nlm.nih.gov/7696847 7696847]|[https://pubmed.ncbi.nlm.nih.gov/1916901 1916901]|[https://pubmed.ncbi.nlm.nih.gov/11169215 11169215]|[https://pubmed.ncbi.nlm.nih.gov/48262 48262]|[https://pubmed.ncbi.nlm.nih.gov/26022515 26022515]|[https://pubmed.ncbi.nlm.nih.gov/6175621 6175621]|[https://pubmed.ncbi.nlm.nih.gov/31404475 31404475]|[https://pubmed.ncbi.nlm.nih.gov/6983878 6983878]|[https://pubmed.ncbi.nlm.nih.gov/8381954 8381954]| [https://pubmed.ncbi.nlm.nih.gov/10431785 10431785]|[https://pubmed.ncbi.nlm.nih.gov/3257757 3257757]|[https://pubmed.ncbi.nlm.nih.gov/6792413 6792413]|[https://pubmed.ncbi.nlm.nih.gov/25039359 25039359] <br>
+ '''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789 <br>
+ '''term_xref''' : GTC:G80062GG |GlycoEpitope:EP0037|CID 91825690|CHEBI:85789 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45]<br>
-===GD000059===
-'''term (main_entry)''' : Diphosphorylated Man6 <br>
-'''glycan_dictionary_accession''' : GD000059 <br>
-'''glytoucan_accession ''' : G54792LL <br>
-'''term_in_sentence''' : Here we report that the single-chain variable domain (scFv) M6P-1 is a unique antibody fragment with specificity for Man6P monosaccharide that, through an array-screening approach against a number of phosphorylated N-glycans, is shown to bind mono- and diphosphorylated Man6 and Man7 glycans that contain terminal αMan6P(1 → 2)αMan(1 → 3)αMan.[PMID:26503547] <br>
-'''publication''' : 26503547 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000054 <br>
-'''best_match''' : GTC:G54792LL|GlycoMotif:GGM.000054 <br>
-'''synonymns''' : Diphosphorylated Man_6 <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000069===
+ '''term (main_entry)''' : Forssman glycolipid <br>
+ '''glycan_dictionary_accession''' : GSD000069 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80062GG G80062GG] <br>
+ '''term_in_sentence''' : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3040119 3040119]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3040119 3040119]|268649|[https://pubmed.ncbi.nlm.nih.gov/23240079 23240079]|[https://pubmed.ncbi.nlm.nih.gov/28134301 28134301]|[https://pubmed.ncbi.nlm.nih.gov/3495590 3495590]|[https://pubmed.ncbi.nlm.nih.gov/1138893 1138893]| [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]|[https://pubmed.ncbi.nlm.nih.gov/10506200 10506200]|[https://pubmed.ncbi.nlm.nih.gov/8855242 8855242]|[https://pubmed.ncbi.nlm.nih.gov/1955453 1955453]|[https://pubmed.ncbi.nlm.nih.gov/1933935 1933935]|[https://pubmed.ncbi.nlm.nih.gov/3355161 3355161]|[https://pubmed.ncbi.nlm.nih.gov/6773959 6773959]|[https://pubmed.ncbi.nlm.nih.gov/14573676 14573676]|[https://pubmed.ncbi.nlm.nih.gov/29898878 29898878]|[https://pubmed.ncbi.nlm.nih.gov/10431785 10431785]|[https://pubmed.ncbi.nlm.nih.gov/1747956 1747956]|[https://pubmed.ncbi.nlm.nih.gov/11214737 11214737]|[https://pubmed.ncbi.nlm.nih.gov/7423202 7423202]|[https://pubmed.ncbi.nlm.nih.gov/389939 389939]|[https://pubmed.ncbi.nlm.nih.gov/3871816 3871816]|[https://pubmed.ncbi.nlm.nih.gov/6187373 6187373]|[https://pubmed.ncbi.nlm.nih.gov/16133832 16133832]|[https://pubmed.ncbi.nlm.nih.gov/469271 469271]|[https://pubmed.ncbi.nlm.nih.gov/3753492 3753492]|[https://pubmed.ncbi.nlm.nih.gov/2695680 2695680]|[https://pubmed.ncbi.nlm.nih.gov/7037611 7037611]|[https://pubmed.ncbi.nlm.nih.gov/25703376 25703376]|[https://pubmed.ncbi.nlm.nih.gov/23798992 23798992]|[https://pubmed.ncbi.nlm.nih.gov/414913 414913]|[https://pubmed.ncbi.nlm.nih.gov/1868069 1868069]| [https://pubmed.ncbi.nlm.nih.gov/7960243 7960243] <br>
+ '''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789] <br>
+ '''term_xref''' : GlycoMotif:GGM.000084|GTC:G80062GG|CID:91825690|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86 <br>
+ '''synonyms''' : Forssman antigen|Globopentosylceramide <br>
+ '''function''' : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:[https://pubmed.ncbi.nlm.nih.gov/3495590 3495590]] <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:86]|Acute cystitis[SugarBind_Ligand:86] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45]<br>
-===GD000060===
-'''term (main_entry)''' : Disialosyl globopentaosylceramide <br>
-'''glycan_dictionary_accession''' : GD000060 <br>
-'''glytoucan_accession ''' : G97932OH <br>
-'''term_in_sentence''' : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID:31339142] <br>
-'''publication''' : 31339142|24637536|25864532|27344728|12084983|32567311|28205070|20663960|18214042 <br>
-'''definition''' : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:28205070] <br>
-'''term_xref''' : GlycoMotif:GGM.000082|GlycoEpitope:EP0098|CID:91860287|KEGG:G00181|SugarBind_Ligand:57 <br>
-'''best_match''' : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID:91860287|KEGG:G00181|SugarBind_Ligand:57 <br>
-'''synonymns''' : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside <br>
-'''function''' : promotes metastasis[PMID:28205070] <br>
-'''disease_associations''' : prostate cancer[PMID:24637536]|renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000070===
+ '''term (main_entry)''' : Fucose-containing tetraantennary <br>
+ '''glycan_dictionary_accession''' : GSD000070 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The two major N-linked oligosaccharides of Namalwa EPO were fucose-containing tetraantennary and fucose-containing triantennary structures.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2550193 2550193]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2550193 2550193] <br>
+ '''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of fucose. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/Forssman_antigen <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000061===
-'''term (main_entry)''' : Disialyl Gb5 <br>
-'''glycan_dictionary_accession''' : GD000061 <br>
-'''glytoucan_accession ''' : G97932OH <br>
-'''term_in_sentence''' : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: 12084983] <br>
-'''publication''' : 12084983 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoEpitope:EP0098|CID:91860287|SugarBind_Ligand:57|KEGG:G00181 <br>
-'''best_match''' : GlycoEpitope:EP0098|GTC:G97932OH|CID:91860287|SugarBind_Ligand:57|KEGG:G00181 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000071===
+ '''term (main_entry)''' : Fucosyl GM1 <br>
+ '''glycan_dictionary_accession''' : GSD000071 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G91532KA G91532KA] <br>
+ '''term_in_sentence''' : Unique localization of fucosyl GM1 implicates its possible role in cell adhesion and recognition in the nervous system.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8068725 8068725]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6619101 6619101]|[https://pubmed.ncbi.nlm.nih.gov/16880505 16880505]|[https://pubmed.ncbi.nlm.nih.gov/9089399 9089399]|[https://pubmed.ncbi.nlm.nih.gov/29789847 29789847]|[https://pubmed.ncbi.nlm.nih.gov/8068725 8068725]|[https://pubmed.ncbi.nlm.nih.gov/19556222 19556222]|[https://pubmed.ncbi.nlm.nih.gov/1660040 1660040]|[https://pubmed.ncbi.nlm.nih.gov/2420639 2420639]|[https://pubmed.ncbi.nlm.nih.gov/9076515 9076515]|[https://pubmed.ncbi.nlm.nih.gov/15926079 15926079]|[https://pubmed.ncbi.nlm.nih.gov/19555091 19555091]|[https://pubmed.ncbi.nlm.nih.gov/2541996 2541996]|[https://pubmed.ncbi.nlm.nih.gov/16211870 16211870]|[https://pubmed.ncbi.nlm.nih.gov/1336587 1336587]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/14967068 14967068]|[https://pubmed.ncbi.nlm.nih.gov/18923900 18923900]|[https://pubmed.ncbi.nlm.nih.gov/30021910 30021910]|[https://pubmed.ncbi.nlm.nih.gov/16941490 16941490]|[https://pubmed.ncbi.nlm.nih.gov/27070150 27070150]|[https://pubmed.ncbi.nlm.nih.gov/8305235 8305235]|[https://pubmed.ncbi.nlm.nih.gov/10602885 10602885]|[https://pubmed.ncbi.nlm.nih.gov/2645049 2645049]|[https://pubmed.ncbi.nlm.nih.gov/7993838 7993838]|[https://pubmed.ncbi.nlm.nih.gov/10537341 10537341]|[https://pubmed.ncbi.nlm.nih.gov/3002616 3002616]|[https://pubmed.ncbi.nlm.nih.gov/8336147 8336147]|[https://pubmed.ncbi.nlm.nih.gov/15447995 15447995]|[https://pubmed.ncbi.nlm.nih.gov/8905401 8905401]|[https://pubmed.ncbi.nlm.nih.gov/11714535 11714535]|[https://pubmed.ncbi.nlm.nih.gov/9260862 9260862]|[https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]|[https://pubmed.ncbi.nlm.nih.gov/3315641 3315641]|[https://pubmed.ncbi.nlm.nih.gov/8076384 8076384]|[https://pubmed.ncbi.nlm.nih.gov/2317201 2317201]|[https://pubmed.ncbi.nlm.nih.gov/3680254 3680254]|[https://pubmed.ncbi.nlm.nih.gov/6403518 6403518] <br>
+ '''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686] <br>
+ '''term_xref''' : GTC:G91532KA |GlycoEpitope:EP0049|CID: 53356699|CHEBI:62686 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : small-cell lung cancer(SCLC)[GlycoEpitope:EP0049]|hepatoma[GlycoEpitope:EP0049] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000062===
-'''term (main_entry)''' : Disialyl I <br>
-'''glycan_dictionary_accession''' : GD000062 <br>
-'''glytoucan_accession ''' : G54937EM <br>
-'''term_in_sentence''' : Here we present an example of promotion of binding of soluble-form FN from placenta or from hepatoma cells, having a specific carbohydrate epitope termed "disialyl-I," to K562 or VA13 cell surface in the presence of glycosphingolipid Gg3, which interacts specifically with disialyl-I[PMID:10640401] <br>
-'''publication''' : 10640401 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoEpitope:EP0095|CID:91849523 <br>
-'''best_match''' : GlycoEpitope:EP0095|GTC:G54937EM|CID:91849523 <br>
-'''synonymns''' : disialyl-I <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000072===
+ '''term (main_entry)''' : Fucosylated asialo-biantennary <br>
+ '''glycan_dictionary_accession''' : GSD000072 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]|[https://pubmed.ncbi.nlm.nih.gov/17013932 17013932] <br>
+ '''definition''' : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' : fucosylated asialo-diantennary <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000063===
-'''term (main_entry)''' : Disialyl Lewis a <br>
-'''glycan_dictionary_accession''' : GD000063 <br>
-'''glytoucan_accession ''' : G93400AK <br>
-'''term_in_sentence''' : Biosynthesis of disialyl Lewis a (Lea) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides.[PMID:12668675] <br>
-'''publication''' : 12668675|17760270|15231659|12668106|30716533|32050430|22467657 <br>
-'''definition''' : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:15231659] <br>
-'''term_xref''' : GlycoEpitope:EP0040|CID:91854138|CHEBI:155549 <br>
-'''best_match''' : GTC:G93400AK |GlycoEpitope:EP0040|CID:91854138|CHEBI:155549 <br>
-'''synonymns''' : disialyl Lea <br>
-'''function''' : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040] <br>
-'''disease_associations''' : Mucin antigen carrying 2-3 sialylated Le a antigen or 2-3, 2-6 disialylated Lc4 antigen in cancer patients had the lowest carbohydrate/protein ratio. Thus, the carbohydrate/protein ratio in the type 1 chain mucin antigens in sera of normal subjects is higher than that in sera of cancer patients.[GlycoEpitope:EP0040] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000073===
+ '''term (main_entry)''' : Fucosylated biantennary <br>
+ '''glycan_dictionary_accession''' : GSD000073 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17956937 17956937]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17956937 17956937]|[https://pubmed.ncbi.nlm.nih.gov/30525457 30525457]|[https://pubmed.ncbi.nlm.nih.gov/1933856 1933856] <br>
+ '''definition''' : a biantennary glycan with two GlcNAc branches linked to the core and the addition of fucose. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' : fucosylated bisialo-diantennary <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000064===
-'''term (main_entry)''' : Disialyl T antigen <br>
-'''glycan_dictionary_accession''' : GD000064 <br>
-'''glytoucan_accession ''' : G01614ZM <br>
-'''term_in_sentence''' : The most potent glycoside was disialyl T antigen (NeuAcalpha2-3Galbeta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides.[PMID: 15701648] <br>
-'''publication''' : 29113555|17974963|33242079|12645620|15701648|26598643 <br>
-'''definition''' : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602] <br>
-'''term_xref''' : GlycoMotif:GGM.000014|CID:70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027 <br>
-'''best_match''' : GlycoMotif:GGM.000014|GTC:G01614ZM|CID:70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027 <br>
-'''synonymns''' : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen <br>
-'''function''' : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000074===
+ '''term (main_entry)''' : Fucosylated bisialo-biantennary <br>
+ '''glycan_dictionary_accession''' : GSD000074 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] <br>
+ '''definition''' : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' : Fucosylated biantennary <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000065===
-'''term (main_entry)''' : Disialylated biantennary <br>
-'''glycan_dictionary_accession''' : GD000065 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:8486673] <br>
-'''publication''' : 22426998|17171781|25022802|24812685|24780636|26582205|9499382|22978794|22594947|8486673|20356825|1634621|9244386|12966096|1472054|24243045|19579232|27943633 <br>
-'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : disialylated diantennary <br>
-'''function''' : appears in human transferrin[PMID: 24243045]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] <br>
-'''disease_associations''' : galactosemia.[PMID:9499382] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000075===
+ '''term (main_entry)''' : Fucosylated LDN <br>
+ '''glycan_dictionary_accession''' : GSD000075 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02240AO G02240AO] <br>
+ '''term_in_sentence''' : To date, oligomeric LDN and oligomeric fucosylated LDN (LDNF) have been found only on N-glycans from mammalian cells engineered to express Caenorhabditis elegansbeta4-GalNAc transferase and human alpha3-fucosyltransferase IX [Z. S. Kawar et al. (2005) J Biol Chem280, 12810-12819]. [PMID:[https://pubmed.ncbi.nlm.nih.gov/16403022 16403022]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16403022 16403022]|[https://pubmed.ncbi.nlm.nih.gov/28151933 28151933]|[https://pubmed.ncbi.nlm.nih.gov/19545571 19545571]|[https://pubmed.ncbi.nlm.nih.gov/22448293 22448293] <br>
+ '''definition''' : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864] <br>
+ '''term_xref''' : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID: 52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594 <br>
+ '''synonyms''' : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1 <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000066===
-'''term (main_entry)''' : Disialylated biantennary complex-type <br>
-'''glycan_dictionary_accession''' : GD000066 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:11738084] <br>
-'''publication''' : 11738084|9499382|9244386|24243045|12966096|25124522|19371135 <br>
-'''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' : appears in human transferrin[PMID:24243045]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] <br>
-'''disease_associations''' : galactosemia.[PMID:9499382] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000076===
+ '''term (main_entry)''' : Fucosylated N-glycans <br>
+ '''glycan_dictionary_accession''' : GSD000076 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]|[https://pubmed.ncbi.nlm.nih.gov/31141660 31141660]|[https://pubmed.ncbi.nlm.nih.gov/26869352 26869352]|[https://pubmed.ncbi.nlm.nih.gov/29790113 29790113]|[https://pubmed.ncbi.nlm.nih.gov/31931062 31931062] <br>
+ '''definition''' : The fucose from GDP-fucose is transferred to N-linked glycans. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : pancreatic cancer.[PMID: [https://pubmed.ncbi.nlm.nih.gov/26869352 26869352]] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000067===
-'''term (main_entry)''' : Disialylated fucosylated <br>
-'''glycan_dictionary_accession''' : GD000067 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.[PMID:17591618] <br>
-'''publication''' : 17591618 <br>
-'''definition''' : A fucosylated glycan with two sialic acid components. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453041 <br>
+===GSD000077===
+ '''term (main_entry)''' : Fucosylated triantennary <br>
+ '''glycan_dictionary_accession''' : GSD000077 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2513186 2513186]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2513186 2513186]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/15051952 15051952]|[https://pubmed.ncbi.nlm.nih.gov/12943224 12943224] <br>
+ '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' : appears in human alpha-fetoprotein (AFP).[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br>
+ '''disease_associations''' : neoplastic diseases of the liver[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] |hepatocellular carcinoma[PMID:  [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]]. <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453068/ Chapter 43]<br>
-===GD000068===
-'''term (main_entry)''' : Forssman antigen <br>
-'''glycan_dictionary_accession''' : GD000068 <br>
-'''glytoucan_accession ''' : G80062GG <br>
-'''term_in_sentence''' : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution.[PMID:28510705] <br>
-'''publication''' : 28510705|31933576|28134301|7021748|1802714|7512587|7747818|23325748|268649|31816281|22015168|4147161|2857159|6267170|7293775|13367419|20636540|10460829|23255552|2675268|18955372|7020692|31784953|4114942|31273262|6257673|7696847|1916901|11169215|48262|26022515|6175621|31404475|6983878|8381954|10431785|3257757|6792413|25039359 <br>
-'''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789] <br>
-'''term_xref''' : GlycoEpitope:EP0037|CID91825690|CHEBI:85789 <br>
-'''best_match''' : GTC:G80062GG |GlycoEpitope:EP0037|CID91825690|CHEBI:85789 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453041 <br>
+===GSD000078===
+ '''term (main_entry)''' : Galabiosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000078 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67988RO G67988RO] <br>
+ '''term_in_sentence''' : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:[https://pubmed.ncbi.nlm.nih.gov/33360824 33360824]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/33360824 33360824]|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]|[https://pubmed.ncbi.nlm.nih.gov/25582508 25582508]|[https://pubmed.ncbi.nlm.nih.gov/2824515 2824515]|[https://pubmed.ncbi.nlm.nih.gov/4027258 4027258]|[https://pubmed.ncbi.nlm.nih.gov/32854306 32854306]|[https://pubmed.ncbi.nlm.nih.gov/32868283 32868283]|[https://pubmed.ncbi.nlm.nih.gov/31319156 31319156]|[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250]|[https://pubmed.ncbi.nlm.nih.gov/27367163 27367163]|[https://pubmed.ncbi.nlm.nih.gov/2564247 2564247]|[https://pubmed.ncbi.nlm.nih.gov/27727434 27727434]|[https://pubmed.ncbi.nlm.nih.gov/10216186 10216186]| [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]|[https://pubmed.ncbi.nlm.nih.gov/24992926 24992926]|[https://pubmed.ncbi.nlm.nih.gov/23590301 23590301]|[https://pubmed.ncbi.nlm.nih.gov/15702404 15702404]|[https://pubmed.ncbi.nlm.nih.gov/1854798 1854798]|[https://pubmed.ncbi.nlm.nih.gov/14761135 14761135]|[https://pubmed.ncbi.nlm.nih.gov/3600200 3600200]|[https://pubmed.ncbi.nlm.nih.gov/8603914 8603914]|[https://pubmed.ncbi.nlm.nih.gov/8601603 8601603]|[https://pubmed.ncbi.nlm.nih.gov/1965141 1965141]|[https://pubmed.ncbi.nlm.nih.gov/17400502 17400502]|[https://pubmed.ncbi.nlm.nih.gov/3840690 3840690]|[https://pubmed.ncbi.nlm.nih.gov/15959771 15959771]|[https://pubmed.ncbi.nlm.nih.gov/7930586 7930586]|[https://pubmed.ncbi.nlm.nih.gov/7721812 7721812]|[https://pubmed.ncbi.nlm.nih.gov/17095952 17095952]|[https://pubmed.ncbi.nlm.nih.gov/2500499 2500499]|[https://pubmed.ncbi.nlm.nih.gov/3815386 3815386]|[https://pubmed.ncbi.nlm.nih.gov/8842706 8842706]|[https://pubmed.ncbi.nlm.nih.gov/10746023 10746023]|[https://pubmed.ncbi.nlm.nih.gov/3928791 3928791]|[https://pubmed.ncbi.nlm.nih.gov/3782065 3782065]|[https://pubmed.ncbi.nlm.nih.gov/6440894 6440894] <br>
+ '''definition''' : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314] <br>
+ '''term_xref''' : GlycoEpitope:EP0113|GTC:G67988RO|CID: 5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : tumor/lung[GlycoEpitope:EP0113]|tumor/gallbladder[GlycoEpitope:EP0113]|tumor/kidney[GlycoEpitope:EP0113]|tumor/pancreas[GlycoEpitope:EP0113] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000069===
-'''term (main_entry)''' : Forssman glycolipid <br>
-'''glycan_dictionary_accession''' : GD000069 <br>
-'''glytoucan_accession ''' : G80062GG <br>
-'''term_in_sentence''' : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:3040119] <br>
-'''publication''' : 3040119|268649|23240079|28134301|3495590|1138893|10460829|10506200|8855242|1955453|1933935|3355161|6773959|14573676|29898878|10431785|1747956|11214737|7423202|389939|3871816|6187373|16133832|469271|3753492|2695680|7037611|25703376|23798992|414913|1868069|7960243 <br>
-'''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789] <br>
-'''term_xref''' : GlycoMotif:GGM.000084|CID:91825690|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86 <br>
-'''best_match''' : GlycoMotif:GGM.000084|GTC:G80062GG|CID:91825690|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86 <br>
-'''synonymns''' : Forssman antigen|Globopentosylceramide <br>
-'''function''' : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:3495590] <br>
-'''disease_associations''' : Pyelonephritis[SugarBind_Ligand:86]|Acute cystitis[SugarBind_Ligand:86] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453041 <br>
+===GSD000079===
+ '''term (main_entry)''' : Galactosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000079 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G65889KE G65889KE] <br>
+ '''term_in_sentence''' : Galactosylceramide improved behavioral, neuropathological, and biochemical parameters in Cln3 Cln3 Δex7/8 mice, paving the way for effective therapy for CLN3 disease and use of serum ceramide as a potential biomarker to track impact of therapies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31393621 31393621]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31393621 31393621]|[https://pubmed.ncbi.nlm.nih.gov/19941861 19941861]|[https://pubmed.ncbi.nlm.nih.gov/9883654 9883654]|[https://pubmed.ncbi.nlm.nih.gov/33006978 33006978]|[https://pubmed.ncbi.nlm.nih.gov/26735924 26735924]|[https://pubmed.ncbi.nlm.nih.gov/22032265 22032265]|[https://pubmed.ncbi.nlm.nih.gov/18035062 18035062]|[https://pubmed.ncbi.nlm.nih.gov/25129050 25129050]|[https://pubmed.ncbi.nlm.nih.gov/2802541 2802541]|[https://pubmed.ncbi.nlm.nih.gov/1761517 1761517]|[https://pubmed.ncbi.nlm.nih.gov/28660574 28660574]|[https://pubmed.ncbi.nlm.nih.gov/475780 475780]|[https://pubmed.ncbi.nlm.nih.gov/2302222 2302222] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GTC:G65889KE|GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061<br>
+ '''synonyms''' : GalCer|Galactocerebroside|LC <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:1]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:1]|Lyme disease[SugarBind_Ligand:1]|Plague[SugarBind_Ligand:1]|Acquired immune deficiency syndrome[SugarBind_Ligand:1] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000070===
-'''term (main_entry)''' : Fucose-containing tetraantennary <br>
-'''glycan_dictionary_accession''' : GD000070 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The two major N-linked oligosaccharides of Namalwa EPO were fucose-containing tetraantennary and fucose-containing triantennary structures.[PMID:2550193] <br>
-'''publication''' : 2550193 <br>
-'''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of fucose. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' : https://en.wikipedia.org/wiki/Forssman_antigen <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===GSD000080===
+ '''term (main_entry)''' : Galnac disialyl Lc4 (Hexasaccharide) <br>
+ '''glycan_dictionary_accession''' : GSD000080 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G33532XU G33532XU] <br>
+ '''term_in_sentence''' : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15704108 15704108]|[https://pubmed.ncbi.nlm.nih.gov/11278988 11278988]|[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]|[https://pubmed.ncbi.nlm.nih.gov/7509790 7509790] <br>
+ '''definition''' : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID: 91857945] <br>
+ '''term_xref''' : GlycoEpitope:EP0097|GTC:G33532XU|CID: 91857945|CHEBI:149360 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : prostate cancer[GlycoEpitope:EP0097]|renal cell carcinoma/RCC[GlycoEpitope:EP0097] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000071===
-'''term (main_entry)''' : Fucosyl GM1 <br>
-'''glycan_dictionary_accession''' : GD000071 <br>
-'''glytoucan_accession ''' : G91532KA <br>
-'''term_in_sentence''' : Unique localization of fucosyl GM1 implicates its possible role in cell adhesion and recognition in the nervous system.[PMID:8068725] <br>
-'''publication''' : 6619101|16880505|9089399|29789847|8068725|19556222|1660040|2420639|9076515|15926079|19555091|2541996|16211870|1336587|21174147|14967068|18923900|30021910|16941490|27070150|8305235|10602885|2645049|7993838|10537341|3002616|8336147|15447995|8905401|11714535|9260862|32228455|3315641|8076384|2317201|3680254|6403518 <br>
-'''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686] <br>
-'''term_xref''' : GlycoEpitope:EP0049|CID:53356699|CHEBI:62686 <br>
-'''best_match''' : GTC:G91532KA |GlycoEpitope:EP0049|CID:53356699|CHEBI:62686 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : small-cell lung cancer(SCLC)[GlycoEpitope:EP0049]|hepatoma[GlycoEpitope:EP0049] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000081===
+ '''term (main_entry)''' : Gb5 <br>
+ '''glycan_dictionary_accession''' : GSD000081 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99053DY G99053DY] <br>
+ '''term_in_sentence''' : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25839135 25839135]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]|[https://pubmed.ncbi.nlm.nih.gov/25839135 25839135]|[https://pubmed.ncbi.nlm.nih.gov/31540393 31540393]|[https://pubmed.ncbi.nlm.nih.gov/31140679 31140679]|[https://pubmed.ncbi.nlm.nih.gov/3028540 3028540]|[https://pubmed.ncbi.nlm.nih.gov/3674263 3674263]|[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]|[https://pubmed.ncbi.nlm.nih.gov/30026902 30026902]|[https://pubmed.ncbi.nlm.nih.gov/10721708 10721708]|[https://pubmed.ncbi.nlm.nih.gov/30671362 30671362]|[https://pubmed.ncbi.nlm.nih.gov/26176557 26176557]|[https://pubmed.ncbi.nlm.nih.gov/25039255 25039255]|[https://pubmed.ncbi.nlm.nih.gov/24044869 24044869]|[https://pubmed.ncbi.nlm.nih.gov/32567311 32567311]|[https://pubmed.ncbi.nlm.nih.gov/27857717 27857717]|[https://pubmed.ncbi.nlm.nih.gov/21491978 21491978]|[https://pubmed.ncbi.nlm.nih.gov/24910250 24910250]|[https://pubmed.ncbi.nlm.nih.gov/29077212 29077212]|[https://pubmed.ncbi.nlm.nih.gov/8014006 8014006]|[https://pubmed.ncbi.nlm.nih.gov/27107335 27107335]|[https://pubmed.ncbi.nlm.nih.gov/32679486 32679486]|[https://pubmed.ncbi.nlm.nih.gov/1747956 1747956]|[https://pubmed.ncbi.nlm.nih.gov/8679447 8679447]|[https://pubmed.ncbi.nlm.nih.gov/28352526 28352526]|[https://pubmed.ncbi.nlm.nih.gov/11341836 11341836]|[https://pubmed.ncbi.nlm.nih.gov/10837462 10837462]| [https://pubmed.ncbi.nlm.nih.gov/7960243 7960243]|[https://pubmed.ncbi.nlm.nih.gov/16158941 16158941]|[https://pubmed.ncbi.nlm.nih.gov/3297853 3297853]|[https://pubmed.ncbi.nlm.nih.gov/2431136 2431136]|[https://pubmed.ncbi.nlm.nih.gov/21734356 21734356]|[https://pubmed.ncbi.nlm.nih.gov/8625206 8625206]|[https://pubmed.ncbi.nlm.nih.gov/30732055 30732055]|[https://pubmed.ncbi.nlm.nih.gov/12716912 12716912]|[https://pubmed.ncbi.nlm.nih.gov/20128040 20128040]|[https://pubmed.ncbi.nlm.nih.gov/2582447 2582447]|[https://pubmed.ncbi.nlm.nih.gov/14659673 14659673] <br>
+ '''definition''' : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842] <br>
+ '''term_xref''' : GlycoMotif:GGM.000076|GTC:G99053DY|CID:53239691|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12<br>
+ '''synonyms''' : Globopentaosylceramide <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:12]|Actinomycosis[SugarBind_Ligand:12|Influenza[SugarBind_Ligand:12] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GD000072===
-'''term (main_entry)''' : Fucosylated asialo-biantennary <br>
-'''glycan_dictionary_accession''' : GD000072 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:2065054] <br>
-'''publication''' : 2065054|17013932 <br>
-'''definition''' : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : fucosylated asialo-diantennary <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000082===
+ '''term (main_entry)''' : GD1 <br>
+ '''glycan_dictionary_accession''' : GSD000082 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G81983KG G81983KG] <br>
+ '''term_in_sentence''' : Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31791361 31791361]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/5652802 5652802]|[https://pubmed.ncbi.nlm.nih.gov/25345088 25345088]|[https://pubmed.ncbi.nlm.nih.gov/31791361 31791361]|[https://pubmed.ncbi.nlm.nih.gov/29361370 29361370]|[https://pubmed.ncbi.nlm.nih.gov/31234327 31234327]|[https://pubmed.ncbi.nlm.nih.gov/30264864 30264864]|[https://pubmed.ncbi.nlm.nih.gov/25250137 25250137]|[https://pubmed.ncbi.nlm.nih.gov/7528216 7528216]|[https://pubmed.ncbi.nlm.nih.gov/31669751 31669751]|[https://pubmed.ncbi.nlm.nih.gov/20684311 20684311]|[https://pubmed.ncbi.nlm.nih.gov/16306603 16306603]|[https://pubmed.ncbi.nlm.nih.gov/10420586 10420586]|[https://pubmed.ncbi.nlm.nih.gov/7766692 7766692]|[https://pubmed.ncbi.nlm.nih.gov/31614613 31614613]|[https://pubmed.ncbi.nlm.nih.gov/26384672 26384672]|[https://pubmed.ncbi.nlm.nih.gov/31613991 31613991]|[https://pubmed.ncbi.nlm.nih.gov/19210136 19210136]|[https://pubmed.ncbi.nlm.nih.gov/8926633 8926633]|[https://pubmed.ncbi.nlm.nih.gov/29696051 29696051]|[https://pubmed.ncbi.nlm.nih.gov/32300455 32300455]|[https://pubmed.ncbi.nlm.nih.gov/7513313 7513313]|[https://pubmed.ncbi.nlm.nih.gov/26674302 26674302]|[https://pubmed.ncbi.nlm.nih.gov/20336376 20336376]|[https://pubmed.ncbi.nlm.nih.gov/24259734 24259734]|[https://pubmed.ncbi.nlm.nih.gov/31704237 31704237]|[https://pubmed.ncbi.nlm.nih.gov/21067946 21067946]|[https://pubmed.ncbi.nlm.nih.gov/30516933 30516933]|[https://pubmed.ncbi.nlm.nih.gov/27979707 27979707]|[https://pubmed.ncbi.nlm.nih.gov/26345314 26345314]|[https://pubmed.ncbi.nlm.nih.gov/30516941 30516941]|[https://pubmed.ncbi.nlm.nih.gov/31849452 31849452]|[https://pubmed.ncbi.nlm.nih.gov/27789132 27789132]|[https://pubmed.ncbi.nlm.nih.gov/30218706 30218706]|[https://pubmed.ncbi.nlm.nih.gov/29388611 29388611]|[https://pubmed.ncbi.nlm.nih.gov/20177787 20177787] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000105|GTC:G81983KG|CID: 91859783|KEGG:G00126  <br>
+ '''synonyms''' : GD1c <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000073===
-'''term (main_entry)''' : Fucosylated biantennary <br>
-'''glycan_dictionary_accession''' : GD000073 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class.[PMID:17956937] <br>
-'''publication''' : 17956937|30525457|1933856 <br>
-'''definition''' : a biantennary glycan with two GlcNAc branches linked to the core and the addition of fucose. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : fucosylated bisialo-diantennary <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000083===
+ '''term (main_entry)''' : GD1a <br>
+ '''glycan_dictionary_accession''' : GSD000083 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G46677TE G46677TE] | [https://glygen.org/glycan/G45714BQ G45714BQ]<br>
+ '''term_in_sentence''' : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: [https://pubmed.ncbi.nlm.nih.gov/28899916 28899916]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28899916 28899916]|[https://pubmed.ncbi.nlm.nih.gov/26860251 26860251]|[https://pubmed.ncbi.nlm.nih.gov/21930390 21930390]|[https://pubmed.ncbi.nlm.nih.gov/32906699 32906699]|[https://pubmed.ncbi.nlm.nih.gov/26054879 26054879]|[https://pubmed.ncbi.nlm.nih.gov/29951721 29951721]|[https://pubmed.ncbi.nlm.nih.gov/11745410 11745410]|[https://pubmed.ncbi.nlm.nih.gov/17653976 17653976]|[https://pubmed.ncbi.nlm.nih.gov/26119566 26119566]|[https://pubmed.ncbi.nlm.nih.gov/21554929 21554929]|[https://pubmed.ncbi.nlm.nih.gov/18435913 18435913]|[https://pubmed.ncbi.nlm.nih.gov/15342262 15342262]|[https://pubmed.ncbi.nlm.nih.gov/26865725 26865725]|[https://pubmed.ncbi.nlm.nih.gov/21151139 21151139]|[https://pubmed.ncbi.nlm.nih.gov/15716397 15716397]|[https://pubmed.ncbi.nlm.nih.gov/21492147 21492147]|[https://pubmed.ncbi.nlm.nih.gov/16942752 16942752]|[https://pubmed.ncbi.nlm.nih.gov/26973195 26973195]|[https://pubmed.ncbi.nlm.nih.gov/24449473 24449473]|[https://pubmed.ncbi.nlm.nih.gov/14999485 14999485]|[https://pubmed.ncbi.nlm.nih.gov/22735313 22735313]|[https://pubmed.ncbi.nlm.nih.gov/20589721 20589721]|[https://pubmed.ncbi.nlm.nih.gov/10521808 10521808]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]|[https://pubmed.ncbi.nlm.nih.gov/7827024 7827024]|[https://pubmed.ncbi.nlm.nih.gov/16897174 16897174]|[https://pubmed.ncbi.nlm.nih.gov/25062498 25062498]|[https://pubmed.ncbi.nlm.nih.gov/17227759 17227759] <br>
+ '''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209] <br>
+ '''term_xref''' : GlycoMotif:GGM.000106|GlycoMotif:GGM.000107|GTC:G46677TE|GTC:G45714BQ|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111  <br>
+ '''synonyms''' : GD1alpha <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:22]|Actinomycosis[SugarBind_Ligand:22]|Lazy leukocyte syndrome[SugarBind_Ligand:22]|Toxoplasmosis[SugarBind_Ligand:22]|Lyme disease[SugarBind_Ligand:22]|Botulism[SugarBind_Ligand:22]|Keratoconjunctivitis[SugarBind_Ligand:22]|Influenza[SugarBind_Ligand:22] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000074===
-'''term (main_entry)''' : Fucosylated bisialo-biantennary <br>
-'''glycan_dictionary_accession''' : GD000074 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:2065054] <br>
-'''publication''' : 2065054 <br>
-'''definition''' : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : Fucosylated biantennary <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000084===
+[[File:G37184KW.png|thumb|G37184KW]]
+ '''term (main_entry)''' : GD1b <br>
+ '''glycan_dictionary_accession''' : GSD000084 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G37184KW G37184KW] <br>
+ '''term_in_sentence''' : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27144558 27144558]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27144558 27144558]|[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332]|[https://pubmed.ncbi.nlm.nih.gov/18625966 18625966]|[https://pubmed.ncbi.nlm.nih.gov/7945223 7945223]|[https://pubmed.ncbi.nlm.nih.gov/32518172 32518172]|[https://pubmed.ncbi.nlm.nih.gov/26710925 26710925]|[https://pubmed.ncbi.nlm.nih.gov/31837178 31837178]|[https://pubmed.ncbi.nlm.nih.gov/20594196 20594196]|[https://pubmed.ncbi.nlm.nih.gov/30985655 30985655]|[https://pubmed.ncbi.nlm.nih.gov/11511306 11511306]|[https://pubmed.ncbi.nlm.nih.gov/1742806 1742806]|[https://pubmed.ncbi.nlm.nih.gov/11123278 11123278]|[https://pubmed.ncbi.nlm.nih.gov/7685064 7685064]|[https://pubmed.ncbi.nlm.nih.gov/2709011 2709011]|[https://pubmed.ncbi.nlm.nih.gov/33279873 33279873]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]|[https://pubmed.ncbi.nlm.nih.gov/9179156 9179156]|[https://pubmed.ncbi.nlm.nih.gov/17964572 17964572]|[https://pubmed.ncbi.nlm.nih.gov/8821498 8821498]|[https://pubmed.ncbi.nlm.nih.gov/32726962 32726962]|[https://pubmed.ncbi.nlm.nih.gov/26560950 26560950]|[https://pubmed.ncbi.nlm.nih.gov/2611779 2611779]|[https://pubmed.ncbi.nlm.nih.gov/10072058 10072058]|[https://pubmed.ncbi.nlm.nih.gov/20030259 20030259]|[https://pubmed.ncbi.nlm.nih.gov/16415013 16415013]|[https://pubmed.ncbi.nlm.nih.gov/10797556 10797556]|[https://pubmed.ncbi.nlm.nih.gov/11342695 11342695]|[https://pubmed.ncbi.nlm.nih.gov/8619520 8619520]|[https://pubmed.ncbi.nlm.nih.gov/21519903 21519903]|[https://pubmed.ncbi.nlm.nih.gov/16199892 16199892]|[https://pubmed.ncbi.nlm.nih.gov/23777091 23777091]|[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056]|[https://pubmed.ncbi.nlm.nih.gov/10481046 10481046] <br>
+ '''definition''' : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222] <br>
+ '''term_xref''' : GlycoMotif:GGM.000108|GTC:G37184KW|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
-===GD000075===
-'''term (main_entry)''' : Fucosylated LDN <br>
-'''glycan_dictionary_accession''' : GD000075 <br>
-'''glytoucan_accession ''' : G02240AO <br>
-'''term_in_sentence''' : To date, oligomeric LDN and oligomeric fucosylated LDN (LDNF) have been found only on N-glycans from mammalian cells engineered to express Caenorhabditis elegansbeta4-GalNAc transferase and human alpha3-fucosyltransferase IX [Z. S. Kawar et al. (2005) J Biol Chem280, 12810-12819]. [PMID:16403022] <br>
-'''publication''' : 16403022|28151933|19545571|22448293 <br>
-'''definition''' : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864] <br>
-'''term_xref''' : GlycoMotif:GGM.000017|GlycoEpitope:EP0151|CID:52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594 <br>
-'''best_match''' : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID:52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594 <br>
-'''synonymns''' : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1 <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000085===
+ '''term (main_entry)''' : GD2 <br>
+ '''glycan_dictionary_accession''' : GSD000085 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02657AK G02657AK] <br>
+ '''term_in_sentence''' : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: [https://pubmed.ncbi.nlm.nih.gov/25440605 25440605]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28154831 28154831]|[https://pubmed.ncbi.nlm.nih.gov/32002293 32002293]|[https://pubmed.ncbi.nlm.nih.gov/32733795 32733795]|[https://pubmed.ncbi.nlm.nih.gov/28145567 28145567]|[https://pubmed.ncbi.nlm.nih.gov/31500597 31500597]|[https://pubmed.ncbi.nlm.nih.gov/31903906 31903906]|[https://pubmed.ncbi.nlm.nih.gov/29180536 29180536]|[https://pubmed.ncbi.nlm.nih.gov/28415563 28415563]|[https://pubmed.ncbi.nlm.nih.gov/25440605 25440605]|[https://pubmed.ncbi.nlm.nih.gov/30617136 30617136]|[https://pubmed.ncbi.nlm.nih.gov/25604432 25604432]|[https://pubmed.ncbi.nlm.nih.gov/30198960 30198960]|[https://pubmed.ncbi.nlm.nih.gov/31075227 31075227]|[https://pubmed.ncbi.nlm.nih.gov/31721713 31721713]|[https://pubmed.ncbi.nlm.nih.gov/30955398 30955398]|[https://pubmed.ncbi.nlm.nih.gov/32195035 32195035]|[https://pubmed.ncbi.nlm.nih.gov/27304202 27304202]|[https://pubmed.ncbi.nlm.nih.gov/31015228 31015228]|[https://pubmed.ncbi.nlm.nih.gov/31653037 31653037]|[https://pubmed.ncbi.nlm.nih.gov/31016728 31016728]|[https://pubmed.ncbi.nlm.nih.gov/30670592 30670592]|[https://pubmed.ncbi.nlm.nih.gov/30613134 30613134]|[https://pubmed.ncbi.nlm.nih.gov/29221154 29221154]|[https://pubmed.ncbi.nlm.nih.gov/30027525 30027525]|[https://pubmed.ncbi.nlm.nih.gov/29442009 29442009]|[https://pubmed.ncbi.nlm.nih.gov/31762628 31762628]|[https://pubmed.ncbi.nlm.nih.gov/30485077 30485077]|[https://pubmed.ncbi.nlm.nih.gov/25642322 25642322]| [https://pubmed.ncbi.nlm.nih.gov/29436609 29436609]|[https://pubmed.ncbi.nlm.nih.gov/29151270 29151270]|[https://pubmed.ncbi.nlm.nih.gov/24773917 24773917]|[https://pubmed.ncbi.nlm.nih.gov/30612272 30612272]|[https://pubmed.ncbi.nlm.nih.gov/27654028 27654028]|[https://pubmed.ncbi.nlm.nih.gov/26298772 26298772] <br>
+ '''definition''' : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218] <br>
+ '''term_xref''' : GlycoMotif:GGM.000094|GTC:G02657AK|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : breast cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/28415563 28415563]] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]|[https://www.ncbi.nlm.nih.gov/books/NBK453073/ Chatper 35]<br>
-===GD000076===
-'''term (main_entry)''' : Fucosylated N-glycans <br>
-'''glycan_dictionary_accession''' : GD000076 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:18214858] <br>
-'''publication''' : 18214858|31141660|26869352|29790113|31931062 <br>
-'''definition''' : The fucose from GDP-fucose is transferred to N-linked glycans. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : pancreatic cancer.[PMID: 26869352] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000086===
+ '''term (main_entry)''' : GD3 <br>
+ '''glycan_dictionary_accession''' : GSD000086 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G98544DH G98544DH] <br>
+ '''term_in_sentence''' : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: [https://pubmed.ncbi.nlm.nih.gov/12531552 12531552]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30245960 30245960]|[https://pubmed.ncbi.nlm.nih.gov/27591028 27591028]|[https://pubmed.ncbi.nlm.nih.gov/12531552 12531552]|[https://pubmed.ncbi.nlm.nih.gov/29069780 29069780]|[https://pubmed.ncbi.nlm.nih.gov/12470841 12470841]|[https://pubmed.ncbi.nlm.nih.gov/29436609 29436609]|[https://pubmed.ncbi.nlm.nih.gov/28295752 28295752]|[https://pubmed.ncbi.nlm.nih.gov/27304202 27304202]]|[https://pubmed.ncbi.nlm.nih.gov/31138648 31138648]|[https://pubmed.ncbi.nlm.nih.gov/27288875 27288875]|[https://pubmed.ncbi.nlm.nih.gov/30446565 30446565]|[https://pubmed.ncbi.nlm.nih.gov/8721669 8721669]|[https://pubmed.ncbi.nlm.nih.gov/3903474 3903474]|[https://pubmed.ncbi.nlm.nih.gov/16081368 16081368]|[https://pubmed.ncbi.nlm.nih.gov/32743804 32743804]|[https://pubmed.ncbi.nlm.nih.gov/24372645 24372645]|[https://pubmed.ncbi.nlm.nih.gov/26792897 26792897]|[https://pubmed.ncbi.nlm.nih.gov/20890432 20890432]|[https://pubmed.ncbi.nlm.nih.gov/25330147 25330147]|[https://pubmed.ncbi.nlm.nih.gov/20581115 20581115]|[https://pubmed.ncbi.nlm.nih.gov/11174200 11174200]|[https://pubmed.ncbi.nlm.nih.gov/16040804 16040804]|[https://pubmed.ncbi.nlm.nih.gov/23783008 23783008]|[https://pubmed.ncbi.nlm.nih.gov/17368571 17368571]|[https://pubmed.ncbi.nlm.nih.gov/11023989 11023989]|[https://pubmed.ncbi.nlm.nih.gov/12901230 12901230]|[https://pubmed.ncbi.nlm.nih.gov/21807667 21807667]|[https://pubmed.ncbi.nlm.nih.gov/7061953 7061953]|[https://pubmed.ncbi.nlm.nih.gov/2231782 2231782]|[https://pubmed.ncbi.nlm.nih.gov/19423750 19423750]|[https://pubmed.ncbi.nlm.nih.gov/22632091 22632091]|[https://pubmed.ncbi.nlm.nih.gov/18202973 18202973]|[https://pubmed.ncbi.nlm.nih.gov/6392333 6392333]|[https://pubmed.ncbi.nlm.nih.gov/15896784 15896784]|[https://pubmed.ncbi.nlm.nih.gov/8261439 8261439]|[https://pubmed.ncbi.nlm.nih.gov/20052288 20052288]|[https://pubmed.ncbi.nlm.nih.gov/12847141 12847141]|[https://pubmed.ncbi.nlm.nih.gov/12486096 12486096]|[https://pubmed.ncbi.nlm.nih.gov/12118012 12118012]|[https://pubmed.ncbi.nlm.nih.gov/19912988 19912988]|[https://pubmed.ncbi.nlm.nih.gov/22795094 22795094]|[https://pubmed.ncbi.nlm.nih.gov/18655184 18655184]|[https://pubmed.ncbi.nlm.nih.gov/17043769 17043769]|[https://pubmed.ncbi.nlm.nih.gov/21395555 21395555]|[https://pubmed.ncbi.nlm.nih.gov/2472199 2472199]|[https://pubmed.ncbi.nlm.nih.gov/19776077 19776077] <br>
+ '''definition''' : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210] <br>
+ '''term_xref''' : GlycoMotif:GGM.000091|GTC:G98544DH|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Cholera[SugarBind_Ligand:89]|Influenza[SugarBind_Ligand:89] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GD000077===
-'''term (main_entry)''' : Fucosylated triantennary <br>
-'''glycan_dictionary_accession''' : GD000077 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:2513186] <br>
-'''publication''' : 2513186|29642865|7679920|31110965|2551687|15051952|12943224 <br>
-'''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' : appears in human alpha-fetoprotein (AFP).[PMID: 7679920] <br>
-'''disease_associations''' : neoplastic diseases of the liver[PMID: 7679920 ]|hepatocellular carcinoma[PMID: 7679920]. <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453068 <br>
+===GSD000087===
+ '''term (main_entry)''' : Globoside <br>
+ '''glycan_dictionary_accession''' : GSD000087 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br>
+ '''term_in_sentence''' : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:[https://pubmed.ncbi.nlm.nih.gov/10993897 10993897]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10993897 10993897] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000070|GTC:G00061MO  <br>
+ '''synonyms''' : Cytolipin K|Gb4|Globoside I|Globotetraosylceramide|P antigen <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
-===GD000078===
-'''term (main_entry)''' : Galabiosylceramide <br>
-'''glycan_dictionary_accession''' : GD000078 <br>
-'''glytoucan_accession ''' : G67988RO <br>
-'''term_in_sentence''' : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:33360824] <br>
-'''publication''' : 33360824|29099167|25582508|2824515|4027258|32854306|32868283|31319156|29530250|27367163|2564247|27727434|10216186|10460829|24992926|23590301|15702404|1854798|14761135|3600200|8603914|8601603|1965141|17400502|3840690|15959771|7930586|7721812|17095952|2500499|3815386|8842706|10746023|3928791|3782065|6440894 <br>
-'''definition''' : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314] <br>
-'''term_xref''' : GlycoEpitope:EP0113|CID:5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314 <br>
-'''best_match''' : GlycoEpitope:EP0113|GTC:G67988RO|CID:5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : tumor/lung[GlycoEpitope:EP0113]|tumor/gallbladder[GlycoEpitope:EP0113]|tumor/kidney[GlycoEpitope:EP0113]|tumor/pancreas[GlycoEpitope:EP0113] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000088===
+ '''term (main_entry)''' : Globotetraosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000088 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br>
+ '''term_in_sentence''' : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:[https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]|[https://pubmed.ncbi.nlm.nih.gov/25787850 25787850]|[https://pubmed.ncbi.nlm.nih.gov/23471986 23471986]|[https://pubmed.ncbi.nlm.nih.gov/2559078 2559078]|[https://pubmed.ncbi.nlm.nih.gov/32455599 32455599]|[https://pubmed.ncbi.nlm.nih.gov/2663859 2663859]|[https://pubmed.ncbi.nlm.nih.gov/32796033 32796033]|[https://pubmed.ncbi.nlm.nih.gov/3517161 3517161]|[https://pubmed.ncbi.nlm.nih.gov/20082214 20082214]|[https://pubmed.ncbi.nlm.nih.gov/30853699 30853699]|[https://pubmed.ncbi.nlm.nih.gov/15279935 15279935]|[https://pubmed.ncbi.nlm.nih.gov/26104834 26104834]|[https://pubmed.ncbi.nlm.nih.gov/20732996 20732996]|[https://pubmed.ncbi.nlm.nih.gov/30224239 30224239]|[https://pubmed.ncbi.nlm.nih.gov/31142708 31142708]|[https://pubmed.ncbi.nlm.nih.gov/30338271 30338271]|[https://pubmed.ncbi.nlm.nih.gov/25033755 25033755]|[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389]|[https://pubmed.ncbi.nlm.nih.gov/7104376 7104376]|[https://pubmed.ncbi.nlm.nih.gov/29866658 29866658]|[https://pubmed.ncbi.nlm.nih.gov/24983355 24983355]|[https://pubmed.ncbi.nlm.nih.gov/6794884 6794884]|[https://pubmed.ncbi.nlm.nih.gov/31361021 31361021]|[https://pubmed.ncbi.nlm.nih.gov/21740983 21740983]|[https://pubmed.ncbi.nlm.nih.gov/33168837 33168837]|[https://pubmed.ncbi.nlm.nih.gov/31752441 31752441]|[https://pubmed.ncbi.nlm.nih.gov/28123520 28123520]|[https://pubmed.ncbi.nlm.nih.gov/29068380 29068380]|[https://pubmed.ncbi.nlm.nih.gov/24841197 24841197]|[https://pubmed.ncbi.nlm.nih.gov/27932383 27932383]|[https://pubmed.ncbi.nlm.nih.gov/28535204 28535204]|[https://pubmed.ncbi.nlm.nih.gov/31691795 31691795]|[https://pubmed.ncbi.nlm.nih.gov/27916888 27916888]|[https://pubmed.ncbi.nlm.nih.gov/27558838 27558838]|[https://pubmed.ncbi.nlm.nih.gov/10227680 10227680]|[https://pubmed.ncbi.nlm.nih.gov/26464281 26464281]|[https://pubmed.ncbi.nlm.nih.gov/22348006 22348006]|[https://pubmed.ncbi.nlm.nih.gov/22279060 22279060]|[https://pubmed.ncbi.nlm.nih.gov/25156739 25156739]|[https://pubmed.ncbi.nlm.nih.gov/32314902 32314902]|[https://pubmed.ncbi.nlm.nih.gov/22718629 22718629]|[https://pubmed.ncbi.nlm.nih.gov/23701631 23701631]|[https://pubmed.ncbi.nlm.nih.gov/23906628 23906628]|[https://pubmed.ncbi.nlm.nih.gov/8613382 8613382]|[https://pubmed.ncbi.nlm.nih.gov/23555772 23555772]|[https://pubmed.ncbi.nlm.nih.gov/20059899 20059899]|[https://pubmed.ncbi.nlm.nih.gov/7868240 7868240] <br>
+ '''definition''' : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] <br>
+ '''term_xref''' : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID: 5288889|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032<br>
+ '''synonyms''' : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Actinomycosis[SugarBind_Ligand:18]|Pyelonephritis[SugarBind_Ligand:18]|Acute cystitis[SugarBind_Ligand:18]|Shigellosis[SugarBind_Ligand:18]|Lazy leukocyte syndrome[SugarBind_Ligand:18]|Influenza[SugarBind_Ligand:18] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GD000079===
-'''term (main_entry)''' : Galactosylceramide <br>
-'''glycan_dictionary_accession''' : GD000079 <br>
-'''glytoucan_accession ''' : G65889KE <br>
-'''term_in_sentence''' : Galactosylceramide improved behavioral, neuropathological, and biochemical parameters in Cln3 Cln3 Δex7/8 mice, paving the way for effective therapy for CLN3 disease and use of serum ceramide as a potential biomarker to track impact of therapies.[PMID:31393621] <br>
-'''publication''' : 31393621|19941861|9883654|33006978|26735924|22032265|18035062|25129050|2802541|1761517|28660574|475780|2302222 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061 <br>
-'''best_match''' : GTC:G65889KE|GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061 <br>
-'''synonymns''' : GalCer|Galactocerebroside|LC <br>
-'''function''' :  <br>
-'''disease_associations''' : Pleuropneumonia[SugarBind_Ligand:1]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:1]|Lyme disease[SugarBind_Ligand:1]|Plague[SugarBind_Ligand:1]|Acquired immune deficiency syndrome[SugarBind_Ligand:1] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000089===
+[[File:G00061MO.png|thumb|G00061MO]]
+ '''term (main_entry)''' : Globotriaosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000089 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00059MO G00059MO] <br>
+ '''term_in_sentence''' : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]|[https://pubmed.ncbi.nlm.nih.gov/28674962 28674962]|[https://pubmed.ncbi.nlm.nih.gov/30875019 30875019]|[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389]|[https://pubmed.ncbi.nlm.nih.gov/31778662 31778662]|[https://pubmed.ncbi.nlm.nih.gov/31101366 31101366]|[https://pubmed.ncbi.nlm.nih.gov/24335674 24335674]|[https://pubmed.ncbi.nlm.nih.gov/31241709 31241709]|[https://pubmed.ncbi.nlm.nih.gov/24158513 24158513]|[https://pubmed.ncbi.nlm.nih.gov/28947349 28947349]|[https://pubmed.ncbi.nlm.nih.gov/31566927 31566927]|[https://pubmed.ncbi.nlm.nih.gov/28672034 28672034]|[https://pubmed.ncbi.nlm.nih.gov/31939530 31939530]|[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250]|[https://pubmed.ncbi.nlm.nih.gov/27851774 27851774]|[https://pubmed.ncbi.nlm.nih.gov/26426881 26426881]|[https://pubmed.ncbi.nlm.nih.gov/25031264 25031264]|[https://pubmed.ncbi.nlm.nih.gov/29982630 29982630]|[https://pubmed.ncbi.nlm.nih.gov/24496231 24496231]|[https://pubmed.ncbi.nlm.nih.gov/29983334 29983334]|[https://pubmed.ncbi.nlm.nih.gov/28756410 28756410]|[https://pubmed.ncbi.nlm.nih.gov/27190352 27190352]|[https://pubmed.ncbi.nlm.nih.gov/29274327 29274327]|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]|[https://pubmed.ncbi.nlm.nih.gov/28402705 28402705]|[https://pubmed.ncbi.nlm.nih.gov/23680766 23680766]|[https://pubmed.ncbi.nlm.nih.gov/28625968 28625968]|[https://pubmed.ncbi.nlm.nih.gov/26960552 26960552]|[https://pubmed.ncbi.nlm.nih.gov/26797827 26797827]|[https://pubmed.ncbi.nlm.nih.gov/22742555 22742555]|[https://pubmed.ncbi.nlm.nih.gov/27756537 27756537]|[https://pubmed.ncbi.nlm.nih.gov/31630715 31630715]|[https://pubmed.ncbi.nlm.nih.gov/3827883 3827883]|[https://pubmed.ncbi.nlm.nih.gov/28384397 28384397]|[https://pubmed.ncbi.nlm.nih.gov/29523338 29523338]|[https://pubmed.ncbi.nlm.nih.gov/31010832 31010832]|[https://pubmed.ncbi.nlm.nih.gov/27195818 27195818]|[https://pubmed.ncbi.nlm.nih.gov/26661087 26661087]|[https://pubmed.ncbi.nlm.nih.gov/23093409 23093409]|[https://pubmed.ncbi.nlm.nih.gov/30879639 30879639]|[https://pubmed.ncbi.nlm.nih.gov/27081853 27081853]|[https://pubmed.ncbi.nlm.nih.gov/17409683 17409683]|[https://pubmed.ncbi.nlm.nih.gov/29921669 29921669]|[https://pubmed.ncbi.nlm.nih.gov/25575293 25575293]|[https://pubmed.ncbi.nlm.nih.gov/26291612 26291612]|[https://pubmed.ncbi.nlm.nih.gov/23146289 23146289]|[https://pubmed.ncbi.nlm.nih.gov/25857295 25857295]|[https://pubmed.ncbi.nlm.nih.gov/26070511 26070511] <br>
+ '''definition''' : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] <br>
+ '''term_xref''' : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID: 5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27  <br>
+ '''synonyms''' : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Pyelonephritis[SugarBind_Ligand:27]|Acute cystitis[SugarBind_Ligand:27]|Shigellosis[SugarBind_Ligand:27]|Lyme disease[SugarBind_Ligand:27]|Cutaneous lesions[SugarBind_Ligand:27]|Diarrhea[SugarBind_Ligand:27] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000080===
-'''term (main_entry)''' : Galnac disialyl Lc4 (Hexasaccharide) <br>
-'''glycan_dictionary_accession''' : GD000080 <br>
-'''glytoucan_accession ''' : G33532XU <br>
-'''term_in_sentence''' : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: 12084983] <br>
-'''publication''' : 15704108|11278988|12084983|7509790 <br>
-'''definition''' : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID:91857945] <br>
-'''term_xref''' : GlycoEpitope:EP0097|CID:91857945|CHEBI:149360 <br>
-'''best_match''' : GlycoEpitope:EP0097|GTC:G33532XU|CID:91857945|CHEBI:149360 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : prostate cancer[GlycoEpitope:EP0097]|renal cell carcinoma/RCC[GlycoEpitope:EP0097] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000090===
+ '''term (main_entry)''' : Glucosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000090 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G71142DF G71142DF] <br>
+ '''term_in_sentence''' : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]|[https://pubmed.ncbi.nlm.nih.gov/29290548 29290548]|[https://pubmed.ncbi.nlm.nih.gov/29627573 29627573]|[https://pubmed.ncbi.nlm.nih.gov/20919653 20919653]|[https://pubmed.ncbi.nlm.nih.gov/28427052 28427052]|[https://pubmed.ncbi.nlm.nih.gov/30550553 30550553]|[https://pubmed.ncbi.nlm.nih.gov/24415933 24415933]|[https://pubmed.ncbi.nlm.nih.gov/31914593 31914593]|[https://pubmed.ncbi.nlm.nih.gov/31051284 31051284]|[https://pubmed.ncbi.nlm.nih.gov/23073611 23073611]|[https://pubmed.ncbi.nlm.nih.gov/30146946 30146946]|[https://pubmed.ncbi.nlm.nih.gov/31619618 31619618]|[https://pubmed.ncbi.nlm.nih.gov/26840726 26840726]|[https://pubmed.ncbi.nlm.nih.gov/29750412 29750412]|[https://pubmed.ncbi.nlm.nih.gov/8065509 8065509]|[https://pubmed.ncbi.nlm.nih.gov/27412675 27412675]|[https://pubmed.ncbi.nlm.nih.gov/27840079 27840079]|[https://pubmed.ncbi.nlm.nih.gov/30611744 30611744]|[https://pubmed.ncbi.nlm.nih.gov/31353719 31353719]|[https://pubmed.ncbi.nlm.nih.gov/25661072 25661072]|[https://pubmed.ncbi.nlm.nih.gov/28686011 28686011]|[https://pubmed.ncbi.nlm.nih.gov/25803043 25803043]|[https://pubmed.ncbi.nlm.nih.gov/28865794 28865794]|[https://pubmed.ncbi.nlm.nih.gov/28154347 28154347]|[https://pubmed.ncbi.nlm.nih.gov/31466334 31466334]|[https://pubmed.ncbi.nlm.nih.gov/30242129 30242129]|[https://pubmed.ncbi.nlm.nih.gov/12531551 12531551]|[https://pubmed.ncbi.nlm.nih.gov/30639288 30639288]|[https://pubmed.ncbi.nlm.nih.gov/30864417 30864417]|[https://pubmed.ncbi.nlm.nih.gov/27711049 27711049]|[https://pubmed.ncbi.nlm.nih.gov/22764777 22764777]|[https://pubmed.ncbi.nlm.nih.gov/27905603 27905603]|[https://pubmed.ncbi.nlm.nih.gov/29077010 29077010]|[https://pubmed.ncbi.nlm.nih.gov/28744000 28744000]|[https://pubmed.ncbi.nlm.nih.gov/23555901 23555901]|[https://pubmed.ncbi.nlm.nih.gov/24115322 24115322]|[https://pubmed.ncbi.nlm.nih.gov/12803919 12803919]|[https://pubmed.ncbi.nlm.nih.gov/29204666 29204666]|[https://pubmed.ncbi.nlm.nih.gov/23628459 23628459]|[https://pubmed.ncbi.nlm.nih.gov/28851512 28851512]|[https://pubmed.ncbi.nlm.nih.gov/26136173 26136173]|[https://pubmed.ncbi.nlm.nih.gov/23563543 23563543]|[https://pubmed.ncbi.nlm.nih.gov/30110701 30110701]|[https://pubmed.ncbi.nlm.nih.gov/26572681 26572681]|[https://pubmed.ncbi.nlm.nih.gov/2193825 2193825]|[https://pubmed.ncbi.nlm.nih.gov/29926415 29926415]|[https://pubmed.ncbi.nlm.nih.gov/31727994 31727994]|[https://pubmed.ncbi.nlm.nih.gov/27479571 27479571] <br>
+ '''definition''' : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963] <br>
+ '''term_xref''' : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF<br>
+ '''synonyms''' : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH <br>
+ '''function''' : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30611744 30611744]]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]] <br>
+ '''disease_associations''' : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453065/ Chapter 31]<br>
-===GD000081===
-'''term (main_entry)''' : Gb5 <br>
-'''glycan_dictionary_accession''' : GD000081 <br>
-'''glytoucan_accession ''' : G99053DY <br>
-'''term_in_sentence''' : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:25839135] <br>
-'''publication''' : 12401210|25839135|31540393|31140679|3028540|3674263|31339142|30026902|10721708|30671362|26176557|25039255|24044869|32567311|27857717|21491978|24910250|29077212|8014006|27107335|32679486|1747956|8679447|28352526|11341836|10837462|7960243|16158941|3297853|2431136|21734356|8625206|30732055|12716912|20128040|2582447|14659673 <br>
-'''definition''' : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842] <br>
-'''term_xref''' : GlycoMotif:GGM.000076|CID:53239691|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12 <br>
-'''best_match''' : GlycoMotif:GGM.000076|GTC:G99053DY|CID:53239691|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12 <br>
-'''synonymns''' : Globopentaosylceramide <br>
-'''function''' :  <br>
-'''disease_associations''' : Pyelonephritis[SugarBind_Ligand:12]|Actinomycosis[SugarBind_Ligand:12|Influenza[SugarBind_Ligand:12] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+===GSD000091===
+[[File:G48558GR.png|thumb|G48558GR]]
+ '''term (main_entry)''' : GM1 <br>
+ '''glycan_dictionary_accession''' : GSD000091 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G48558GR G48558GR] <br>
+ '''term_in_sentence''' : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18524657 18524657]|[https://pubmed.ncbi.nlm.nih.gov/31761138 31761138]|[https://pubmed.ncbi.nlm.nih.gov/36180805 36180805]|[https://pubmed.ncbi.nlm.nih.gov/29920238 29920238]|[https://pubmed.ncbi.nlm.nih.gov/33859490 33859490]|[https://pubmed.ncbi.nlm.nih.gov/31937438 31937438]|[https://pubmed.ncbi.nlm.nih.gov/25762012 25762012]|[https://pubmed.ncbi.nlm.nih.gov/25931034 25931034]|[https://pubmed.ncbi.nlm.nih.gov/31776384 31776384]|[https://pubmed.ncbi.nlm.nih.gov/32013258 32013258]|[https://pubmed.ncbi.nlm.nih.gov/30776097 30776097]|[https://pubmed.ncbi.nlm.nih.gov/31048748 31048748]|[https://pubmed.ncbi.nlm.nih.gov/31447771 31447771]|[https://pubmed.ncbi.nlm.nih.gov/30292198 30292198]|[https://pubmed.ncbi.nlm.nih.gov/28796418 28796418]|[https://pubmed.ncbi.nlm.nih.gov/27806275 27806275]|[https://pubmed.ncbi.nlm.nih.gov/21076871 21076871]|[https://pubmed.ncbi.nlm.nih.gov/27552916 27552916]|[https://pubmed.ncbi.nlm.nih.gov/17986147 17986147]|[https://pubmed.ncbi.nlm.nih.gov/26960162 26960162]|[https://pubmed.ncbi.nlm.nih.gov/27815022 27815022]|[https://pubmed.ncbi.nlm.nih.gov/25851126 25851126]|[https://pubmed.ncbi.nlm.nih.gov/32916822 32916822]|[https://pubmed.ncbi.nlm.nih.gov/11462671 11462671]|[https://pubmed.ncbi.nlm.nih.gov/28236574 28236574]|[https://pubmed.ncbi.nlm.nih.gov/15911874 15911874]|[https://pubmed.ncbi.nlm.nih.gov/28577204 28577204]|[https://pubmed.ncbi.nlm.nih.gov/28497346 28497346]|[https://pubmed.ncbi.nlm.nih.gov/1794005 1794005]|[https://pubmed.ncbi.nlm.nih.gov/31934908 31934908]|[https://pubmed.ncbi.nlm.nih.gov/30267299 30267299]|[https://pubmed.ncbi.nlm.nih.gov/16902585 16902585]|[https://pubmed.ncbi.nlm.nih.gov/29439846 29439846]|[https://pubmed.ncbi.nlm.nih.gov/32325905 32325905]|[https://pubmed.ncbi.nlm.nih.gov/29747823 29747823]|[https://pubmed.ncbi.nlm.nih.gov/27576485 27576485]|[https://pubmed.ncbi.nlm.nih.gov/26338710 26338710]|[https://pubmed.ncbi.nlm.nih.gov/27858734 27858734]|[https://pubmed.ncbi.nlm.nih.gov/24501414 24501414]|[https://pubmed.ncbi.nlm.nih.gov/26818965 26818965]|[https://pubmed.ncbi.nlm.nih.gov/26629687 26629687]|[https://pubmed.ncbi.nlm.nih.gov/26958633 26958633]|[https://pubmed.ncbi.nlm.nih.gov/1854596 1854596]|[https://pubmed.ncbi.nlm.nih.gov/32134593 32134593]|[https://pubmed.ncbi.nlm.nih.gov/32198666 32198666]|[https://pubmed.ncbi.nlm.nih.gov/6619101 6619101] <br>
+ '''definition''' : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] <br>
+ '''term_xref''' : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br>
+ '''synonyms''' :  GM1 ganglioside|GM1-ganglioside<br>
+ '''function''' :  The branched pentasaccharide chain of ganglioside GM1 is a prominent cell surface ligand, for example, for cholera toxin or tumor growth-regulatory homodimeric galectins.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16267866/ 16267866]]<br>
+ '''disease_associations''' : GM1 gangliosidosis (GM1) [PMID: [https://pubmed.ncbi.nlm.nih.gov/33859490/ 33859490]]|Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13] <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/GM1 <br>
+ '''essentials_of_glycobiology''' :  [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]| [https://www.ncbi.nlm.nih.gov/books/NBK579929/ Chapter 14] <br>
-===GD000082===
-'''term (main_entry)''' : GD1 <br>
-'''glycan_dictionary_accession''' : GD000082 <br>
-'''glytoucan_accession ''' : G81983KG <br>
-'''term_in_sentence''' : Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1.[PMID:31791361] <br>
-'''publication''' : 5652802|25345088|31791361|29361370|31234327|30264864|25250137|7528216|31669751|20684311|16306603|10420586|7766692|31614613|26384672|31613991|19210136|8926633|29696051|32300455|7513313|26674302|20336376|24259734|31704237|21067946|30516933|27979707|26345314|30516941|31849452|27789132|30218706|29388611|20177787 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000105|CID:91859783|KEGG:G00126 <br>
-'''best_match''' : GlycoMotif:GGM.000105|GTC:G81983KG|CID:91859783|KEGG:G00126 <br>
-'''synonymns''' : GD1c <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000092===
+ '''term (main_entry)''' : GM2 <br>
+ '''glycan_dictionary_accession''' : GSD000092 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79389NT G79389NT] <br>
+ '''term_in_sentence''' : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27491214 27491214]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29618308 29618308]|[https://pubmed.ncbi.nlm.nih.gov/27491214 27491214]|[https://pubmed.ncbi.nlm.nih.gov/32867370 32867370]|[https://pubmed.ncbi.nlm.nih.gov/30030044 30030044]|[https://pubmed.ncbi.nlm.nih.gov/27499644 27499644]|[https://pubmed.ncbi.nlm.nih.gov/31097363 31097363]|[https://pubmed.ncbi.nlm.nih.gov/29100724 29100724]|[https://pubmed.ncbi.nlm.nih.gov/27402091 27402091]|[https://pubmed.ncbi.nlm.nih.gov/31852956 31852956]|[https://pubmed.ncbi.nlm.nih.gov/30389374 30389374]|[https://pubmed.ncbi.nlm.nih.gov/30988135 30988135]|[https://pubmed.ncbi.nlm.nih.gov/8786814 8786814]|[https://pubmed.ncbi.nlm.nih.gov/14533808 14533808]|[https://pubmed.ncbi.nlm.nih.gov/23370522 23370522]|[https://pubmed.ncbi.nlm.nih.gov/28192816 28192816]|[https://pubmed.ncbi.nlm.nih.gov/32692591 32692591]|[https://pubmed.ncbi.nlm.nih.gov/29106755 29106755]|[https://pubmed.ncbi.nlm.nih.gov/28833537 28833537]|[https://pubmed.ncbi.nlm.nih.gov/11339652 11339652]|[https://pubmed.ncbi.nlm.nih.gov/9728335 9728335]|[https://pubmed.ncbi.nlm.nih.gov/27270764 27270764]|[https://pubmed.ncbi.nlm.nih.gov/9714704 9714704]|[https://pubmed.ncbi.nlm.nih.gov/26175473 26175473]|[https://pubmed.ncbi.nlm.nih.gov/27018595 27018595]|[https://pubmed.ncbi.nlm.nih.gov/28615102 28615102]|[https://pubmed.ncbi.nlm.nih.gov/28974375 28974375]|[https://pubmed.ncbi.nlm.nih.gov/32951593 32951593]|[https://pubmed.ncbi.nlm.nih.gov/11462672 11462672]|[https://pubmed.ncbi.nlm.nih.gov/28955902 28955902]|[https://pubmed.ncbi.nlm.nih.gov/17192692 17192692]|[https://pubmed.ncbi.nlm.nih.gov/26538065 26538065]|[https://pubmed.ncbi.nlm.nih.gov/25421609 25421609]|[https://pubmed.ncbi.nlm.nih.gov/9572057 9572057]|[https://pubmed.ncbi.nlm.nih.gov/11596983 11596983]|[https://pubmed.ncbi.nlm.nih.gov/15264019 15264019]|[https://pubmed.ncbi.nlm.nih.gov/23236285 23236285]|[https://pubmed.ncbi.nlm.nih.gov/11596984 11596984]|[https://pubmed.ncbi.nlm.nih.gov/31261761 31261761]|[https://pubmed.ncbi.nlm.nih.gov/30113798 30113798]|[https://pubmed.ncbi.nlm.nih.gov/24391178 24391178]|[https://pubmed.ncbi.nlm.nih.gov/24309906 24309906]|[https://pubmed.ncbi.nlm.nih.gov/22224667 22224667]|[https://pubmed.ncbi.nlm.nih.gov/7980537 7980537]|[https://pubmed.ncbi.nlm.nih.gov/18272501 18272501]|[https://pubmed.ncbi.nlm.nih.gov/9006924 9006924]| <br>
+ '''definition''' : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
+ '''term_xref''' : GlycoMotif:GGM.000095|GTC:G79389NT|CID: 45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]|Gastroenteritis[SugarBind_Ligand:39]|Cholera[SugarBind_Ligand:39]|Clostridial myonecrosis[SugarBind_Ligand:39]|Tetanus[SugarBind_Ligand:39] <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/GM1_gangliosidoses <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GD000083===
-'''term (main_entry)''' : GD1a <br>
-'''glycan_dictionary_accession''' : GD000083 <br>
-'''glytoucan_accession ''' : G46677TE <br>
-'''term_in_sentence''' : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: 28899916] <br>
-'''publication''' : 28899916|26860251|21930390|32906699|26054879|29951721|11745410|17653976|26119566|21554929|18435913|15342262|26865725|21151139|15716397|21492147|16942752|26973195|24449473|14999485|22735313|20589721|10521808|22929125|7827024|16897174|25062498|17227759 <br>
-'''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209] <br>
-'''term_xref''' : GlycoMotif:GGM.000107|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111 <br>
-'''best_match''' : GlycoMotif:GGM.000107|GTC:G46677TE|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111 <br>
-'''synonymns''' : GD1alpha <br>
-'''function''' :  <br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:22]|Actinomycosis[SugarBind_Ligand:22]|Lazy leukocyte syndrome[SugarBind_Ligand:22]|Toxoplasmosis[SugarBind_Ligand:22]|Lyme disease[SugarBind_Ligand:22]|Botulism[SugarBind_Ligand:22]|Keratoconjunctivitis[SugarBind_Ligand:22]|Influenza[SugarBind_Ligand:22] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000093===
+ '''term (main_entry)''' : GM3 <br>
+ '''glycan_dictionary_accession''' : GSD000093 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G91237TK G91237TK] <br>
+ '''term_in_sentence''' : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: [https://pubmed.ncbi.nlm.nih.gov/29747813 29747813]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29376491 29376491]|[https://pubmed.ncbi.nlm.nih.gov/29747813 29747813]|[https://pubmed.ncbi.nlm.nih.gov/25613425 25613425]|[https://pubmed.ncbi.nlm.nih.gov/30318083 30318083]|[https://pubmed.ncbi.nlm.nih.gov/31526872 31526872]|[https://pubmed.ncbi.nlm.nih.gov/31004109 31004109]|[https://pubmed.ncbi.nlm.nih.gov/28019668 28019668]|[https://pubmed.ncbi.nlm.nih.gov/26434718 26434718]|[https://pubmed.ncbi.nlm.nih.gov/27313500 27313500]|[https://pubmed.ncbi.nlm.nih.gov/27539856 27539856]|[https://pubmed.ncbi.nlm.nih.gov/30111401 30111401]|[https://pubmed.ncbi.nlm.nih.gov/28544772 28544772]|[https://pubmed.ncbi.nlm.nih.gov/29407985 29407985]|[https://pubmed.ncbi.nlm.nih.gov/19364317 19364317]|[https://pubmed.ncbi.nlm.nih.gov/30190430 30190430]|[https://pubmed.ncbi.nlm.nih.gov/31297734 31297734]|[https://pubmed.ncbi.nlm.nih.gov/30091781 30091781]|[https://pubmed.ncbi.nlm.nih.gov/26043887 26043887]|[https://pubmed.ncbi.nlm.nih.gov/32183071 32183071]|[https://pubmed.ncbi.nlm.nih.gov/30665141 30665141]|[https://pubmed.ncbi.nlm.nih.gov/27873002 27873002]|[https://pubmed.ncbi.nlm.nih.gov/25801320 25801320]|[https://pubmed.ncbi.nlm.nih.gov/30209782 30209782]|[https://pubmed.ncbi.nlm.nih.gov/32378734 32378734]|[https://pubmed.ncbi.nlm.nih.gov/23050851 23050851]|[https://pubmed.ncbi.nlm.nih.gov/22768242 22768242]|[https://pubmed.ncbi.nlm.nih.gov/14993837 14993837]|[https://pubmed.ncbi.nlm.nih.gov/24934090 24934090]|[https://pubmed.ncbi.nlm.nih.gov/17638075 17638075]|[https://pubmed.ncbi.nlm.nih.gov/21518140 21518140]|[https://pubmed.ncbi.nlm.nih.gov/26102277 26102277]|[https://pubmed.ncbi.nlm.nih.gov/19759399 19759399]|[https://pubmed.ncbi.nlm.nih.gov/24502144 24502144]|[https://pubmed.ncbi.nlm.nih.gov/25303960 25303960]|[https://pubmed.ncbi.nlm.nih.gov/23564406 23564406]|[https://pubmed.ncbi.nlm.nih.gov/16636105 16636105]|[https://pubmed.ncbi.nlm.nih.gov/16491123 16491123]|[https://pubmed.ncbi.nlm.nih.gov/11259118 11259118]|[https://pubmed.ncbi.nlm.nih.gov/15102521 15102521]|[https://pubmed.ncbi.nlm.nih.gov/12724312 12724312]|[https://pubmed.ncbi.nlm.nih.gov/24985965 24985965]|[https://pubmed.ncbi.nlm.nih.gov/8496625 8496625]|[https://pubmed.ncbi.nlm.nih.gov/25403557 25403557]|[https://pubmed.ncbi.nlm.nih.gov/15690123 15690123]|[https://pubmed.ncbi.nlm.nih.gov/15939439 15939439]|[https://pubmed.ncbi.nlm.nih.gov/25893133 25893133]|[https://pubmed.ncbi.nlm.nih.gov/23591593 23591593]|[https://pubmed.ncbi.nlm.nih.gov/20634908 20634908]|[https://pubmed.ncbi.nlm.nih.gov/2004380 2004380]|[https://pubmed.ncbi.nlm.nih.gov/739008 739008]| <br>
+ '''definition''' : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] <br>
+ '''term_xref''' : GlycoMotif:GGM.000090|GTC:G91237TK|CID: 5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 <br>
+ '''synonyms''' :  <br>
+ '''function''' : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844] <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453032/ Chapter 37]<br>
-===GD000084===
-'''term (main_entry)''' : GD1b <br>
-'''glycan_dictionary_accession''' : GD000084 <br>
-'''glytoucan_accession ''' : G37184KW <br>
-'''term_in_sentence''' : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: 27144558] <br>
-'''publication''' : 27144558|24859332|18625966|7945223|32518172|26710925|31837178|20594196|30985655|11511306|1742806|11123278|7685064|2709011|33279873|22929125|9179156|17964572|8821498|32726962|26560950|2611779|10072058|20030259|16415013|10797556|11342695|8619520|21519903|16199892|23777091|30246056|10481046 <br>
-'''definition''' : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222] <br>
-'''term_xref''' : GlycoMotif:GGM.000108|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14 <br>
-'''best_match''' : GlycoMotif:0GGM.00108|GTC:G37184KW|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453023 <br>
+===GSD000094===
+[[File:G30207PZ.png|thumb|G30207PZ]]
+ '''term (main_entry)''' : GM4 <br>
+ '''glycan_dictionary_accession''' : GSD000094 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G30207PZ G30207PZ] <br>
+ '''term_in_sentence''' : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:[https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]|[https://pubmed.ncbi.nlm.nih.gov/2332419 2332419]|[https://pubmed.ncbi.nlm.nih.gov/12091485 12091485]|[https://pubmed.ncbi.nlm.nih.gov/19542236 19542236]|[https://pubmed.ncbi.nlm.nih.gov/8407875 8407875]|[https://pubmed.ncbi.nlm.nih.gov/23320941 23320941]|[https://pubmed.ncbi.nlm.nih.gov/28808804 28808804]|[https://pubmed.ncbi.nlm.nih.gov/3621237 3621237]|[https://pubmed.ncbi.nlm.nih.gov/23203271 23203271]|[https://pubmed.ncbi.nlm.nih.gov/7057115 7057115]|[https://pubmed.ncbi.nlm.nih.gov/26362868 26362868]|[https://pubmed.ncbi.nlm.nih.gov/6170387 6170387]|[https://pubmed.ncbi.nlm.nih.gov/18034482 18034482]|[https://pubmed.ncbi.nlm.nih.gov/7076644 7076644]|[https://pubmed.ncbi.nlm.nih.gov/2391348 2391348]|[https://pubmed.ncbi.nlm.nih.gov/25464080 25464080]|[https://pubmed.ncbi.nlm.nih.gov/3701369 3701369]|[https://pubmed.ncbi.nlm.nih.gov/11217952 11217952]|[https://pubmed.ncbi.nlm.nih.gov/6201236 6201236]|[https://pubmed.ncbi.nlm.nih.gov/30744426 30744426]|[https://pubmed.ncbi.nlm.nih.gov/9388026 9388026]|[https://pubmed.ncbi.nlm.nih.gov/27177620 27177620]|[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056]|[https://pubmed.ncbi.nlm.nih.gov/15979459 15979459]|[https://pubmed.ncbi.nlm.nih.gov/7586078 7586078]|[https://pubmed.ncbi.nlm.nih.gov/6779816 6779816]|[https://pubmed.ncbi.nlm.nih.gov/29402905 29402905]|[https://pubmed.ncbi.nlm.nih.gov/7335153 7335153]|[https://pubmed.ncbi.nlm.nih.gov/3306476 3306476]|[https://pubmed.ncbi.nlm.nih.gov/17499534 17499534]|[https://pubmed.ncbi.nlm.nih.gov/7074082 7074082]|[https://pubmed.ncbi.nlm.nih.gov/9668345 9668345]|[https://pubmed.ncbi.nlm.nih.gov/3701884 3701884]|[https://pubmed.ncbi.nlm.nih.gov/26862430 26862430]|[https://pubmed.ncbi.nlm.nih.gov/6831238 6831238]|[https://pubmed.ncbi.nlm.nih.gov/27311552 27311552]|[https://pubmed.ncbi.nlm.nih.gov/26831445 26831445]|[https://pubmed.ncbi.nlm.nih.gov/24417799 24417799]|[https://pubmed.ncbi.nlm.nih.gov/7097284 7097284]|[https://pubmed.ncbi.nlm.nih.gov/4169231 4169231]|[https://pubmed.ncbi.nlm.nih.gov/16854400 16854400]|[https://pubmed.ncbi.nlm.nih.gov/26483798 26483798] <br>
+ '''definition''' : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position
+ [CHEBI:63155] <br>
+ '''term_xref''' : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 <br>
+ '''synonyms''' :  Sialylated GalCer<br>
+ '''function''' :  <br>
+ '''disease_associations''' : Chronic gastritis[SugarBind_Ligand:110]|Peptic ulcers[SugarBind_Ligand:110]|Gastric cancer[SugarBind_Ligand:110] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]|[https://www.ncbi.nlm.nih.gov/books/NBK453082/ Chapter 15]|[https://www.ncbi.nlm.nih.gov/books/NBK453095/ Chapter 44]|[https://www.ncbi.nlm.nih.gov/books/NBK453018/ Appendix 45A] <br>
-===GD000085===
-'''term (main_entry)''' : GD2 <br>
-'''glycan_dictionary_accession''' : GD000085 <br>
-'''glytoucan_accession ''' : G02657AK <br>
-'''term_in_sentence''' : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: 25440605] <br>
-'''publication''' : 28154831|32002293|32733795|28145567|31500597|31903906|29180536|28415563|25440605|30617136|25604432|30198960|31075227|31721713|30955398|32195035|27304202|31015228|31653037|31016728|30670592|30613134|29221154|30027525|29442009|31762628|30485077|25642322|29436609|29151270|24773917|30612272|27654028|26298772 <br>
-'''definition''' : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218] <br>
-'''term_xref''' : GlycoMotif:GGM.000094|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88 <br>
-'''best_match''' : GlycoMotif:GGM.000094|GTC:G02657AK|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : breast cancer[PMID:28415563] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016|NBK453073 <br>
+===GSD000095===
+ '''term (main_entry)''' : GP1c <br>
+ '''glycan_dictionary_accession''' : GSD000095 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93805MV G93805MV] <br>
+ '''term_in_sentence''' : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]|[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]|[https://pubmed.ncbi.nlm.nih.gov/4091974 4091974]|[https://pubmed.ncbi.nlm.nih.gov/10775425 10775425]|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350]|[https://pubmed.ncbi.nlm.nih.gov/3064875 3064875]|[https://pubmed.ncbi.nlm.nih.gov/11432974 11432974]| [https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]|[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845]|[https://pubmed.ncbi.nlm.nih.gov/1879553 1879553]| [https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]|[https://pubmed.ncbi.nlm.nih.gov/8969459 8969459]|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]|[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286]|[https://pubmed.ncbi.nlm.nih.gov/1304332 1304332]|[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001]|[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000118|GTC:G93805MV<br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]|[https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]|[https://www.ncbi.nlm.nih.gov/books/NBK453076/ Chapter 27]|[https://www.ncbi.nlm.nih.gov/books/NBK453073/ Chapter 35]|[https://www.ncbi.nlm.nih.gov/books/NBK453041/ Chapter 45] |[https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]|[https://www.ncbi.nlm.nih.gov/books/NBK453088/ Chapter 49] <br>
-===GD000086===
-'''term (main_entry)''' : GD3 <br>
-'''glycan_dictionary_accession''' : GD000086 <br>
-'''glytoucan_accession ''' : G98544DH <br>
-'''term_in_sentence''' : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: 12531552] <br>
-'''publication''' : 30245960|27591028|12531552|29069780|12470841|29436609|28295752|27304202|31138648|27288875|30446565|8721669|3903474|16081368|32743804|24372645|26792897|20890432|25330147|20581115|11174200|16040804|23783008|17368571|11023989|12901230|21807667|7061953|2231782|19423750|22632091|18202973|6392333|15896784|8261439|20052288|12847141|12486096|12118012|19912988|22795094|18655184|17043769|21395555|2472199|19776077 <br>
-'''definition''' : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210] <br>
-'''term_xref''' : GlycoMotif:GGM.000091|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062 <br>
-'''best_match''' : GlycoMotif:GGM.000091|GTC:G98544DH|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : Cholera[SugarBind_Ligand:89]|Influenza[SugarBind_Ligand:89] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+===GSD000096===
+ '''term (main_entry)''' : GQ1b <br>
+ '''glycan_dictionary_accession''' : GSD000096 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18625KA G18625KA] <br>
+ '''term_in_sentence''' : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30798387 30798387]|[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]|[https://pubmed.ncbi.nlm.nih.gov/26704905 26704905]|[https://pubmed.ncbi.nlm.nih.gov/23677659 23677659]|[https://pubmed.ncbi.nlm.nih.gov/26984947 26984947]|[https://pubmed.ncbi.nlm.nih.gov/24184316 24184316]|[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237]|[https://pubmed.ncbi.nlm.nih.gov/9819299 9819299]|[https://pubmed.ncbi.nlm.nih.gov/18514410 18514410]|[https://pubmed.ncbi.nlm.nih.gov/22189683 22189683]|[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332] <br>
+ '''definition''' : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] <br>
+ '''term_xref''' : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GD000087===
-'''term (main_entry)''' : Globoside <br>
-'''glycan_dictionary_accession''' : GD000087 <br>
-'''glytoucan_accession ''' : G00061MO <br>
-'''term_in_sentence''' : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:10993897] <br>
-'''publication''' : 10993897 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000070 <br>
-'''best_match''' : GlycoMotif:GGM.000070|GTC:G00061MO <br>
-'''synonymns''' : Cytolipin K|Gb4|Globoside I|Globotetraosylceramide|P antigen <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453023 <br>
+===GSD000097===
+ '''term (main_entry)''' : GQ1ba <br>
+ '''glycan_dictionary_accession''' : GSD000097 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54733XO G54733XO] <br>
+ '''term_in_sentence''' : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25024341 25024341]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/25024341 25024341]|[https://pubmed.ncbi.nlm.nih.gov/23717411 23717411]|[https://pubmed.ncbi.nlm.nih.gov/17870542 17870542]|[https://pubmed.ncbi.nlm.nih.gov/10702226 10702226]|[https://pubmed.ncbi.nlm.nih.gov/21137678 21137678]|[https://pubmed.ncbi.nlm.nih.gov/26748510 26748510]|[https://pubmed.ncbi.nlm.nih.gov/8662799 8662799]|[https://pubmed.ncbi.nlm.nih.gov/21274438 21274438]|[https://pubmed.ncbi.nlm.nih.gov/24649890 24649890]|[https://pubmed.ncbi.nlm.nih.gov/16580208 16580208]|[https://pubmed.ncbi.nlm.nih.gov/28124591 28124591]|[https://pubmed.ncbi.nlm.nih.gov/20095613 20095613]|[https://pubmed.ncbi.nlm.nih.gov/17507233 17507233]|[https://pubmed.ncbi.nlm.nih.gov/23565921 23565921]|[https://pubmed.ncbi.nlm.nih.gov/14505645 14505645]|[https://pubmed.ncbi.nlm.nih.gov/20930939 20930939]|[https://pubmed.ncbi.nlm.nih.gov/9201997 9201997] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000116|GTC:G54733XO  <br>
+ '''synonyms''' : GQ1balpha <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000088===
-'''term (main_entry)''' : Globotetraosylceramide <br>
-'''glycan_dictionary_accession''' : GD000088 <br>
-'''glytoucan_accession ''' : G00061MO <br>
-'''term_in_sentence''' : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:28392398] <br>
-'''publication''' : 28392398|25787850|23471986|2559078|32455599|2663859|32796033|3517161|20082214|30853699|15279935|26104834|20732996|30224239|31142708|30338271|25033755|30413389|7104376|29866658|24983355|6794884|31361021|21740983|33168837|31752441|28123520|29068380|24841197|27932383|28535204|31691795|27916888|27558838|10227680|26464281|22348006|22279060|25156739|32314902|22718629|23701631|23906628|8613382|23555772|20059899|7868240 <br>
-'''definition''' : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] <br>
-'''term_xref''' : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID:5288889|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032 <br>
-'''best_match''' :  l;' <br>
-'''synonymns''' : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K <br>
-'''function''' :  <br>
-'''disease_associations''' : Actinomycosis[SugarBind_Ligand:18]|Pyelonephritis[SugarBind_Ligand:18]|Acute cystitis[SugarBind_Ligand:18]|Shigellosis[SugarBind_Ligand:18]|Lazy leukocyte syndrome[SugarBind_Ligand:18]|Influenza[SugarBind_Ligand:18] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+===GSD000098===
+ '''term (main_entry)''' : GQ1c <br>
+ '''glycan_dictionary_accession''' : GSD000098 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99524KA G99524KA] <br>
+ '''term_in_sentence''' : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]| [https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]|[https://pubmed.ncbi.nlm.nih.gov/7798936 7798936]|[https://pubmed.ncbi.nlm.nih.gov/1729139 1729139]|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/20368669 20368669]|[https://pubmed.ncbi.nlm.nih.gov/2723647 2723647]|[https://pubmed.ncbi.nlm.nih.gov/1814411 1814411]| [https://pubmed.ncbi.nlm.nih.gov/3064875 3064875]|[https://pubmed.ncbi.nlm.nih.gov/6085330 6085330]|[https://pubmed.ncbi.nlm.nih.gov/1613492 1613492]|[https://pubmed.ncbi.nlm.nih.gov/17883393 17883393]|[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845]| [https://pubmed.ncbi.nlm.nih.gov/10775425 10775425]|[https://pubmed.ncbi.nlm.nih.gov/8219015 8219015]|[https://pubmed.ncbi.nlm.nih.gov/8804704 8804704]|[https://pubmed.ncbi.nlm.nih.gov/1384262 1384262]|[https://pubmed.ncbi.nlm.nih.gov/7066685 7066685]|[https://pubmed.ncbi.nlm.nih.gov/2299192 2299192]|[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]|[https://pubmed.ncbi.nlm.nih.gov/10350354 10350354]|[https://pubmed.ncbi.nlm.nih.gov/1304337 1304337]|[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001]|[https://pubmed.ncbi.nlm.nih.gov/11959025 11959025]|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]|[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350]| [https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]|[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]|[https://pubmed.ncbi.nlm.nih.gov/3942818 3942818]|[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286]|[https://pubmed.ncbi.nlm.nih.gov/7361620 7361620] <br>
+ '''definition''' : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID: 91860352] <br>
+ '''term_xref''' : GlycoMotif:GGM.000117|GTC:G99524KA|CID: 91860352|CHEBI:145645|KEGG:G00121 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453044/ Chapter 46]<br>
-===GD000089===
-'''term (main_entry)''' : Globotriaosylceramide <br>
-'''glycan_dictionary_accession''' : GD000089 <br>
-'''glytoucan_accession ''' : G00059MO <br>
-'''term_in_sentence''' : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:32127409] <br>
-'''publication''' : 32127409|28674962|30875019|30413389|31778662|31101366|24335674|31241709|24158513|28947349|31566927|28672034|31939530|29530250|27851774|26426881|25031264|29982630|24496231|29983334|28756410|27190352|29274327|29099167|28402705|23680766|28625968|26960552|26797827|22742555|27756537|31630715|3827883|28384397|29523338|31010832|27195818|26661087|23093409|30879639|27081853|17409683|29921669|25575293|26291612|23146289|25857295|26070511 <br>
-'''definition''' : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] <br>
-'''term_xref''' : GlycoMotif:GGM.000068|GlycoEpitope:EP0071|CID:5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27 <br>
-'''best_match''' : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID:5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27 <br>
-'''synonymns''' : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide <br>
-'''function''' :  <br>
-'''disease_associations''' : Pyelonephritis[SugarBind_Ligand:27]|Acute cystitis[SugarBind_Ligand:27]|Shigellosis[SugarBind_Ligand:27]|Lyme disease[SugarBind_Ligand:27]|Cutaneous lesions[SugarBind_Ligand:27]|Diarrhea[SugarBind_Ligand:27] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000099===
+ '''term (main_entry)''' : GT1a <br>
+ '''glycan_dictionary_accession''' : GSD000099 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G68110IF G68110IF] <br>
+ '''term_in_sentence''' : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12023422 12023422]|[https://pubmed.ncbi.nlm.nih.gov/32623212 32623212]|[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]|[https://pubmed.ncbi.nlm.nih.gov/9585812 9585812]|[https://pubmed.ncbi.nlm.nih.gov/29747820 29747820]|[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237]|[https://pubmed.ncbi.nlm.nih.gov/11993188 11993188]|[https://pubmed.ncbi.nlm.nih.gov/31683059 31683059]|[https://pubmed.ncbi.nlm.nih.gov/19631994 19631994]|[https://pubmed.ncbi.nlm.nih.gov/9742882 9742882]|[https://pubmed.ncbi.nlm.nih.gov/29709941 29709941]|[https://pubmed.ncbi.nlm.nih.gov/8971119 8971119]|[https://pubmed.ncbi.nlm.nih.gov/8706663 8706663]|893404|[https://pubmed.ncbi.nlm.nih.gov/31829433 31829433]|[https://pubmed.ncbi.nlm.nih.gov/8910600 8910600]|[https://pubmed.ncbi.nlm.nih.gov/30600291 30600291]|[https://pubmed.ncbi.nlm.nih.gov/29319803 29319803]|[https://pubmed.ncbi.nlm.nih.gov/26176883 26176883]|[https://pubmed.ncbi.nlm.nih.gov/29063860 29063860]|[https://pubmed.ncbi.nlm.nih.gov/6766128 6766128]|[https://pubmed.ncbi.nlm.nih.gov/31602715 31602715]|[https://pubmed.ncbi.nlm.nih.gov/29808463 29808463]|[https://pubmed.ncbi.nlm.nih.gov/30711390 30711390]|[https://pubmed.ncbi.nlm.nih.gov/29847988 29847988]|[https://pubmed.ncbi.nlm.nih.gov/30116054 30116054]|[https://pubmed.ncbi.nlm.nih.gov/28187751 28187751] <br>
+ '''definition''' : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] <br>
+ '''term_xref''' : CID:45266863|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000090===
-'''term (main_entry)''' : Glucosylceramide <br>
-'''glycan_dictionary_accession''' : GD000090 <br>
-'''glytoucan_accession ''' : G71142DF <br>
-'''term_in_sentence''' : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321] <br>
-'''publication''' : 31265321|29290548|29627573|20919653|28427052|30550553|24415933|31914593|31051284|23073611|30146946|31619618|26840726|29750412|8065509|27412675|27840079|30611744|31353719|25661072|28686011|25803043|28865794|28154347|31466334|30242129|12531551|30639288|30864417|27711049|22764777|27905603|29077010|28744000|23555901|24115322|12803919|29204666|23628459|28851512|26136173|23563543|30110701|26572681|2193825|29926415|31727994|27479571 <br>
-'''definition''' : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963] <br>
-'''term_xref''' : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264 <br>
-'''best_match''' : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF <br>
-'''synonymns''' : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH <br>
-'''function''' : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:30611744]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321] <br>
-'''disease_associations''' : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453065 <br>
+===GSD000100===
+ '''term (main_entry)''' : GT1a alpha <br>
+ '''glycan_dictionary_accession''' : GSD000100 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02149VR G02149VR] <br>
+ '''term_in_sentence''' : A new class of gangliosides, GT1a alpha and GQ1b alpha, were initially identified as cholinergic neuron-specific antigens in bovine brain. [PMID:[https://pubmed.ncbi.nlm.nih.gov/8082783 8082783]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7710562 7710562]|[https://pubmed.ncbi.nlm.nih.gov/8082783 8082783]|[https://pubmed.ncbi.nlm.nih.gov/10972137 10972137]|[https://pubmed.ncbi.nlm.nih.gov/9468624 9468624]|[https://pubmed.ncbi.nlm.nih.gov/9143254 9143254]|[https://pubmed.ncbi.nlm.nih.gov/8221098 8221098]|[https://pubmed.ncbi.nlm.nih.gov/9679279 9679279]|[https://pubmed.ncbi.nlm.nih.gov/11368158 11368158]|[https://pubmed.ncbi.nlm.nih.gov/11878808 11878808] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID: 91851751|CHEBI:156678|KEGG:G00128  <br>
+ '''synonyms''' : GT1aa <br>
+ '''function''' : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000091===
-'''term (main_entry)''' : GM1 <br>
-'''glycan_dictionary_accession''' : GD000091 <br>
-'''glytoucan_accession ''' : G48558GR <br>
-'''term_in_sentence''' : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238] <br>
-'''publication''' : 18524657|31761138|29920238|31937438|25762012|25931034|31776384|32013258|30776097|31048748|31447771|30292198|28796418|27806275|21076871|27552916|17986147|26960162|27815022|25851126|32916822|11462671|28236574|15911874|28577204|28497346|1794005|31934908|30267299|16902585|29439846|32325905|29747823|27576485|26338710|27858734|24501414|26818965|26629687|26958633|1854596|32134593|32198666|6619101 <br>
-'''definition''' : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] <br>
-'''term_xref''' : GlycoMotif:GGM.000098|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br>
-'''best_match''' : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000101===
+ '''term (main_entry)''' : GT1b <br>
+ '''glycan_dictionary_accession''' : GSD000101 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G40183QN G40183QN] <br>
+ '''term_in_sentence''' : GT1b ganglioside is axonally transported to the spinal cord dorsal horn and contributes to characteristics of neuropathic pain such as mechanical and thermal hypersensitivity.[PMID: [https://pubmed.ncbi.nlm.nih.gov/32030804 32030804]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32030804 32030804]|[https://pubmed.ncbi.nlm.nih.gov/26370787 26370787]|[https://pubmed.ncbi.nlm.nih.gov/32046393 32046393]|[https://pubmed.ncbi.nlm.nih.gov/9712688 9712688]|[https://pubmed.ncbi.nlm.nih.gov/7636307 7636307]|[https://pubmed.ncbi.nlm.nih.gov/9931455 9931455]|[https://pubmed.ncbi.nlm.nih.gov/25520869 25520869]|[https://pubmed.ncbi.nlm.nih.gov/19605473 19605473]|[https://pubmed.ncbi.nlm.nih.gov/17188834 17188834]|[https://pubmed.ncbi.nlm.nih.gov/10233751 10233751]|[https://pubmed.ncbi.nlm.nih.gov/22735313 22735313]|[https://pubmed.ncbi.nlm.nih.gov/20540782 20540782]|[https://pubmed.ncbi.nlm.nih.gov/22746533 22746533]|[https://pubmed.ncbi.nlm.nih.gov/1861141 1861141]|[https://pubmed.ncbi.nlm.nih.gov/19490186 19490186]|[https://pubmed.ncbi.nlm.nih.gov/9521848 9521848]|[https://pubmed.ncbi.nlm.nih.gov/11921200 11921200]|[https://pubmed.ncbi.nlm.nih.gov/10731661 10731661]|[https://pubmed.ncbi.nlm.nih.gov/31431523 31431523]|[https://pubmed.ncbi.nlm.nih.gov/15274627 15274627]|[https://pubmed.ncbi.nlm.nih.gov/32726962 32726962]|[https://pubmed.ncbi.nlm.nih.gov/12573517 12573517]|[https://pubmed.ncbi.nlm.nih.gov/18277613 18277613]|[https://pubmed.ncbi.nlm.nih.gov/11370834 11370834]|[https://pubmed.ncbi.nlm.nih.gov/11234774 11234774]|[https://pubmed.ncbi.nlm.nih.gov/11123278 11123278]|[https://pubmed.ncbi.nlm.nih.gov/18704164 18704164]|[https://pubmed.ncbi.nlm.nih.gov/16291967 16291967]|[https://pubmed.ncbi.nlm.nih.gov/11411041 11411041]|[https://pubmed.ncbi.nlm.nih.gov/27549393 27549393]|[https://pubmed.ncbi.nlm.nih.gov/25253868 25253868]|[https://pubmed.ncbi.nlm.nih.gov/22720883 22720883]|[https://pubmed.ncbi.nlm.nih.gov/10686582 10686582]|[https://pubmed.ncbi.nlm.nih.gov/11511306 11511306]|[https://pubmed.ncbi.nlm.nih.gov/29904724 29904724]|[https://pubmed.ncbi.nlm.nih.gov/31472390 31472390]|[https://pubmed.ncbi.nlm.nih.gov/19156870 19156870] <br>
+ '''definition''' : A branched amino heptasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries an N-acetyl-α-neuraminyl-(2→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl trisaccharide unit and an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide unit through (2→4) and (2→3) linkages respectively. It corresponds to the carbohydrate portion of ganglioside GT1b.[CHEBI:59225] <br>
+ '''term_xref''' : GlycoMotif:GGM.000112|GTC:G40183QN|GlycoEpitopeEP0067|CID:45266781|CHEBI:59225| GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Toxoplasmosis[SugarBind_Ligand:26]|Lyme disease[SugarBind_Ligand:26]|Cholera[SugarBind_Ligand:26]|Botulism[SugarBind_Ligand:26]|Tetanus[SugarBind_Ligand:26]|Influenza[SugarBind_Ligand:26] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000092===
-'''term (main_entry)''' : GM2 <br>
-'''glycan_dictionary_accession''' : GD000092 <br>
-'''glytoucan_accession ''' : G79389NT <br>
-'''term_in_sentence''' : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: 27491214] <br>
-'''publication''' : 29618308|27491214|32867370|30030044|27499644|31097363|29100724|27402091|31852956|30389374|30988135|8786814|14533808|23370522|28192816|32692591|29106755|28833537|11339652|9728335|27270764|9714704|26175473|27018595|28615102|28974375|32951593|11462672|28955902|17192692|26538065|25421609|9572057|11596983|15264019|23236285|11596984|31261761|30113798|24391178|24309906|22224667|7980537|18272501|9006924| <br>
-'''definition''' : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
-'''term_xref''' : GlycoMotif:GGM.000095|CID:45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351 <br>
-'''best_match''' : GlycoMotif:GGM.000095|GTC:G79389NT|CID:45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]|Gastroenteritis[SugarBind_Ligand:39]|Cholera[SugarBind_Ligand:39]|Clostridial myonecrosis[SugarBind_Ligand:39]|Tetanus[SugarBind_Ligand:39] <br>
-'''wikipedia''' : https://en.wikipedia.org/wiki/GM1_gangliosidoses <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+===GSD000102===
+[[File:G78818SP.png|thumb|G78818SP]]
+ '''term (main_entry)''' : GT1c <br>
+ '''glycan_dictionary_accession''' : GSD000102 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78818SP G78818SP] <br>
+ '''term_in_sentence''' : We show here that VVH associates with ganglioside GM1a, Fucosyl-GM1, GD1a, GT1c, and GD1b by glycan array.[PMID: [https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28088450 28088450]|[https://pubmed.ncbi.nlm.nih.gov/30085356 30085356]|[https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/23877172 23877172]|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]|[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]|[https://pubmed.ncbi.nlm.nih.gov/1613492 1613492]|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]|[https://pubmed.ncbi.nlm.nih.gov/7798936 7798936]|[https://pubmed.ncbi.nlm.nih.gov/11180643 11180643]|[https://pubmed.ncbi.nlm.nih.gov/2723647 2723647]|[https://pubmed.ncbi.nlm.nih.gov/7066685 7066685]|[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]|[https://pubmed.ncbi.nlm.nih.gov/7361620 7361620]|[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494] <br>
+ '''definition''' : A branched amino heptasaccharide consisting of a linear tetrasaccharide of β-D-galactose, N-acetyl-β-D-galactosamine, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→4) and (1→4), to the galactose residue proximal to the reducing end is also linked (2→3) an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl trisaccharide side-chain. The carbohydrate moiety of ganglioside GT1c.[CHEBI:90509] <br>
+ '''term_xref''' : GlycoMotif:GGM.000113|GTC:G78818SP|CID:91846734|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000093===
-'''term (main_entry)''' : GM3 <br>
-'''glycan_dictionary_accession''' : GD000093 <br>
-'''glytoucan_accession ''' : G91237TK <br>
-'''term_in_sentence''' : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: 29747813] <br>
-'''publication''' : 29376491|29747813|25613425|30318083|31526872|31004109|28019668|26434718|27313500|27539856|30111401|28544772|29407985|19364317|30190430|31297734|30091781|26043887|32183071|30665141|27873002|25801320|30209782|32378734|23050851|22768242|14993837|24934090|17638075|21518140|26102277|19759399|24502144|25303960|23564406|16636105|16491123|11259118|15102521|12724312|24985965|8496625|25403557|15690123|15939439|25893133|23591593|20634908|2004380|739008| <br>
-'''definition''' : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] <br>
-'''term_xref''' : GlycoMotif:GGM.000090|CID:5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 <br>
-'''best_match''' : GlycoMotif:GGM.000090|GTC:G91237TK|CID:5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 <br>
-'''synonymns''' :  <br>
-'''function''' : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844] <br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35]|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453032 <br>
+===GSD000103===
+ '''term (main_entry)''' : GT2 <br>
+ '''glycan_dictionary_accession''' : GSD000103 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G36476BA G36476BA] <br>
+ '''term_in_sentence''' : Biosynthesis of the c-series gangliosides GT3, GT2 and GP1c was studied in Golgi derived from rat liver.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]|[https://pubmed.ncbi.nlm.nih.gov/15498585 15498585]|[https://pubmed.ncbi.nlm.nih.gov/16005859 16005859]|[https://pubmed.ncbi.nlm.nih.gov/27540730 27540730]|[https://pubmed.ncbi.nlm.nih.gov/31533196 31533196]|[https://pubmed.ncbi.nlm.nih.gov/31201844 31201844] <br>
+ '''definition''' : A branched amino hexasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-galactosaminyl residue. The carbohydrate moiety of ganglioside GT2.[CHEBI:72446] <br>
+ '''term_xref''' : GlycoMotif:GGM.000109|GTC:G36476BA|CID: 70788971|CHEBI:72446|KEGG:G00119  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GD000094===
-'''term (main_entry)''' : GM4 <br>
-'''glycan_dictionary_accession''' : GD000094 <br>
-'''glytoucan_accession ''' : G30207PZ <br>
-'''term_in_sentence''' : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:23999868] <br>
-'''publication''' : 23999868|2332419|12091485|19542236|8407875|23320941|28808804|3621237|23203271|7057115|26362868|6170387|18034482|7076644|2391348|25464080|3701369|11217952|6201236|30744426|9388026|27177620|30246056|15979459|7586078|6779816|29402905|7335153|3306476|17499534|7074082|9668345|3701884|26862430|6831238|27311552|26831445|24417799|7097284|4169231|16854400|26483798 <br>
-'''definition''' : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position
-[CHEBI:63155] <br>
-'''term_xref''' : GlycoMotif:GGM.000089|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 <br>
-'''best_match''' : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : Chronic gastritis[SugarBind_Ligand:110]|Peptic ulcers[SugarBind_Ligand:110]|Gastric cancer[SugarBind_Ligand:110] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016|NBK453095|NBK453018|NBK453082| <br>
+===GSD000104===
+ '''term (main_entry)''' : GT3 <br>
+ '''glycan_dictionary_accession''' : GSD000104 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93899SO G93899SO] <br>
+ '''term_in_sentence''' : The purpose of this study was two-fold: (1) to formulate γ-tocotrienol (GT3) in a nanoemulsion formulation as a prophylactic orally administered radioprotective agent; and (2) to optimize the storage conditions to preserve the structural integrity of both the formulation and the compound.[PMID: [https://pubmed.ncbi.nlm.nih.gov/28029115 28029115]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28029115 28029115]|[https://pubmed.ncbi.nlm.nih.gov/31355968 31355968]|[https://pubmed.ncbi.nlm.nih.gov/30987413 30987413]|[https://pubmed.ncbi.nlm.nih.gov/27869747 27869747]|[https://pubmed.ncbi.nlm.nih.gov/27216753 27216753]|[https://pubmed.ncbi.nlm.nih.gov/8631981 8631981]|[https://pubmed.ncbi.nlm.nih.gov/29672891 29672891]|[https://pubmed.ncbi.nlm.nih.gov/10385047 10385047]|[https://pubmed.ncbi.nlm.nih.gov/29642403 29642403]|[https://pubmed.ncbi.nlm.nih.gov/10412028 10412028]|[https://pubmed.ncbi.nlm.nih.gov/27193023 27193023]|[https://pubmed.ncbi.nlm.nih.gov/30068561 30068561]|[https://pubmed.ncbi.nlm.nih.gov/23415908 23415908]|[https://pubmed.ncbi.nlm.nih.gov/8858920 8858920]|[https://pubmed.ncbi.nlm.nih.gov/2303428 2303428]|[https://pubmed.ncbi.nlm.nih.gov/27153057 27153057]|[https://pubmed.ncbi.nlm.nih.gov/27128741 27128741]|[https://pubmed.ncbi.nlm.nih.gov/2654294 2654294]|[https://pubmed.ncbi.nlm.nih.gov/26930378 26930378]|[https://pubmed.ncbi.nlm.nih.gov/7561885 7561885]|[https://pubmed.ncbi.nlm.nih.gov/25860286 25860286]|[https://pubmed.ncbi.nlm.nih.gov/30845647 30845647]|[https://pubmed.ncbi.nlm.nih.gov/24712339 24712339]|[https://pubmed.ncbi.nlm.nih.gov/30070965 30070965]|[https://pubmed.ncbi.nlm.nih.gov/8910600 8910600]|[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]|[https://pubmed.ncbi.nlm.nih.gov/27356050 27356050]|[https://pubmed.ncbi.nlm.nih.gov/8514740 8514740]|[https://pubmed.ncbi.nlm.nih.gov/18509108 18509108]|[https://pubmed.ncbi.nlm.nih.gov/23000517 23000517]|[https://pubmed.ncbi.nlm.nih.gov/29769046 29769046]|[https://pubmed.ncbi.nlm.nih.gov/29566611 29566611] <br>
+ '''definition''' : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444] <br>
+ '''term_xref''' : GlycoEpitope:EP0070|KEGG:G00118|CID:70788970|GlycoMotif:GGM.000092|GTC:G93899SO|CHEBI:72444  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GD000095===
-'''term (main_entry)''' : GP1c <br>
-'''glycan_dictionary_accession''' : GD000095 <br>
-'''glytoucan_accession ''' : G93805MV <br>
-'''term_in_sentence''' : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:19053458] <br>
-'''publication''' : 1606358|19053458|1695858|4091974|10775425|2468656|2299350|3064875|11432974|9613831|11831845|1879553|10699494|8969459|8474578|12031286|1304332|9153001|10564776 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000118 <br>
-'''best_match''' : GlycoMotif:GGM.000118|GTC:G93805MV <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016|NBK453023|NBK453042|NBK453088|/NBK453073|NBK453076|NBK453041 <br>
+===GSD000105===
+[[File:G94435QH.png|thumb|G94435QH]]
+ '''term (main_entry)''' : Blood group H (Type 3) <br>
+ '''glycan_dictionary_accession''' : GSD000105 <br>
+ '''glytoucan_accession ''' :  [https://glygen.org/glycan/G94435QH G94435QH]<br>
+ '''term_in_sentence''' : One particular lambody, VLRB.aGPA.23, was shown by glycan array analysis to be selective for the blood group H type 3 trisaccharide (BG-H3, Fucα1-2Galβ1-3GalNAcα), aGPA, and TFα (Galβ1-3GalNAcα), with affinity constants of 0.2, 1, and 8 nM, respectively.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23030719 23030719]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23030719 23030719]|[https://pubmed.ncbi.nlm.nih.gov/20466654 20466654]|[https://pubmed.ncbi.nlm.nih.gov/1563908 1563908]|[https://pubmed.ncbi.nlm.nih.gov/3944092 3944092]|[https://pubmed.ncbi.nlm.nih.gov/11218748 11218748]|[https://pubmed.ncbi.nlm.nih.gov/11101633 11101633]|[https://pubmed.ncbi.nlm.nih.gov/18842005 18842005]|[https://pubmed.ncbi.nlm.nih.gov/27550195 27550195]|[https://pubmed.ncbi.nlm.nih.gov/2469783 2469783]|[https://pubmed.ncbi.nlm.nih.gov/2433836 2433836]|[https://pubmed.ncbi.nlm.nih.gov/23118206 23118206]|[https://pubmed.ncbi.nlm.nih.gov/8445257 8445257]|[https://pubmed.ncbi.nlm.nih.gov/2664192 2664192]|[https://pubmed.ncbi.nlm.nih.gov/3063304 3063304] <br>
+ '''definition''' :  <br>
+ '''term_xref''' :  GlycoMotif:GGM.000010|GTC:G94435QH<br>
+ '''synonyms''' : H type 3|H antigen (type 3)|Type 3 chain H <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]<br>
-===GD000096===
-'''term (main_entry)''' : GQ1b <br>
-'''glycan_dictionary_accession''' : GD000096 <br>
-'''glytoucan_accession ''' : G18625KA <br>
-'''term_in_sentence''' : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:31186474] <br>
-'''publication''' : 30798387|31186474|26704905|23677659|26984947|24184316|23804237|9819299|18514410|22189683|24859332 <br>
-'''definition''' : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] <br>
-'''term_xref''' : GlycoMotif:GGM.000115|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212 <br>
-'''best_match''' : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+===GSD000106===
+ '''term (main_entry)''' : Heparan sulfate <br>
+ '''glycan_dictionary_accession''' : GSD000106 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : In Niemann-Pick C-1 fibroblasts, where deaminative degradation of heparan sulfate is defective, carbonylated proteins were abundant.[PMID: 17540770] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32266657 32266657]|[https://pubmed.ncbi.nlm.nih.gov/29554552 29554552]|[https://pubmed.ncbi.nlm.nih.gov/29032302 29032302]|[https://pubmed.ncbi.nlm.nih.gov/30003471 30003471]|[https://pubmed.ncbi.nlm.nih.gov/25197032 25197032]|[https://pubmed.ncbi.nlm.nih.gov/28538085 28538085]|[https://pubmed.ncbi.nlm.nih.gov/26236728 26236728]|[https://pubmed.ncbi.nlm.nih.gov/16917509 16917509]|[https://pubmed.ncbi.nlm.nih.gov/22899865 22899865]|[https://pubmed.ncbi.nlm.nih.gov/17080204 17080204]|[https://pubmed.ncbi.nlm.nih.gov/23042481 23042481]|[https://pubmed.ncbi.nlm.nih.gov/28982096 28982096]|[https://pubmed.ncbi.nlm.nih.gov/24146040 24146040]|[https://pubmed.ncbi.nlm.nih.gov/25081076 25081076]|[https://pubmed.ncbi.nlm.nih.gov/15719168 15719168]|[https://pubmed.ncbi.nlm.nih.gov/17453622 17453622]|[https://pubmed.ncbi.nlm.nih.gov/25325954 25325954]|[https://pubmed.ncbi.nlm.nih.gov/21110089 21110089]|[https://pubmed.ncbi.nlm.nih.gov/29797526 29797526]|[https://pubmed.ncbi.nlm.nih.gov/21967329 21967329]|[https://pubmed.ncbi.nlm.nih.gov/23313092 23313092]|[https://pubmed.ncbi.nlm.nih.gov/11212344 11212344]|[https://pubmed.ncbi.nlm.nih.gov/28465034 28465034]|[https://pubmed.ncbi.nlm.nih.gov/11746174 11746174]|[https://pubmed.ncbi.nlm.nih.gov/12512855 12512855]|[https://pubmed.ncbi.nlm.nih.gov/8836040 8836040]|[https://pubmed.ncbi.nlm.nih.gov/28394734 28394734]|[https://pubmed.ncbi.nlm.nih.gov/24182748 24182748]|[https://pubmed.ncbi.nlm.nih.gov/28264929 28264929]|[https://pubmed.ncbi.nlm.nih.gov/28745308 28745308]|[https://pubmed.ncbi.nlm.nih.gov/26555370 26555370]|[https://pubmed.ncbi.nlm.nih.gov/14718374 14718374]|[https://pubmed.ncbi.nlm.nih.gov/16767693 16767693]|[https://pubmed.ncbi.nlm.nih.gov/25246018 25246018]|[https://pubmed.ncbi.nlm.nih.gov/19584012 19584012]|[https://pubmed.ncbi.nlm.nih.gov/8274190 8274190]|[https://pubmed.ncbi.nlm.nih.gov/25034023 25034023]|[https://pubmed.ncbi.nlm.nih.gov/8370471 8370471]|[https://pubmed.ncbi.nlm.nih.gov/26571620 26571620]|[https://pubmed.ncbi.nlm.nih.gov/29920400 29920400]|[https://pubmed.ncbi.nlm.nih.gov/31731076 31731076]|[https://pubmed.ncbi.nlm.nih.gov/20816205 20816205]|[https://pubmed.ncbi.nlm.nih.gov/16880267 16880267]|[https://pubmed.ncbi.nlm.nih.gov/31547957 31547957]|[https://pubmed.ncbi.nlm.nih.gov/11457867 11457867]|[https://pubmed.ncbi.nlm.nih.gov/27241222 27241222]|[https://pubmed.ncbi.nlm.nih.gov/28718936 28718936]|[https://pubmed.ncbi.nlm.nih.gov/21204109 21204109]|[https://pubmed.ncbi.nlm.nih.gov/31016560 31016560]|[https://pubmed.ncbi.nlm.nih.gov/11166215 11166215]|[https://pubmed.ncbi.nlm.nih.gov/11457866 11457866] <br>
+ '''definition''' : A linear polysaccharide in which the backbone consists of a variably sulfated repeating disaccharide unit.[CHEBI:28815] <br>
+ '''term_xref''' : CHEBI:28815|CID: 53477715|GlycoEpitope: EP0086 <br>
+ '''synonyms''' : Heparan N-sulfate|Heparan sulfate|Heparan sulphate|Heparatan sulfate|Heparin monosulfate| Heparin sulfate|Heparitin monosulfate|Heparitin sulfate|N-Acetylheparan sulfate <br>
+ '''function''' : Heparan sulfate proteoglycans (HSPGs) play crucial roles regulating key developmental signaling pathways, such as the Wnt, Hedgehog, transforming growth factor-beta, and fibroblast growth factor pathways.[GlycoEpitope: EP0086] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000097===
-'''term (main_entry)''' : GQ1ba <br>
-'''glycan_dictionary_accession''' : GD000097 <br>
-'''glytoucan_accession ''' : G54733XO <br>
-'''term_in_sentence''' : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:25024341] <br>
-'''publication''' : 25024341|23717411|17870542|10702226|21137678|26748510|8662799|21274438|24649890|16580208|28124591|20095613|17507233|23565921|14505645|20930939|9201997 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000116 <br>
-'''best_match''' : GlycoMotif:GGM.000116|GTC:G54733XO <br>
-'''synonymns''' : GQ1balpha <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000107===
+ '''term (main_entry)''' : Heparin <br>
+ '''glycan_dictionary_accession''' : GSD000107 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Two cellulose-based membranes, containing 5 and 20% N, N-diethyl-aminoethyl cellulose (DEAE) respectively, were investigated for ionic attachment of heparin and heparin release.[PMID:[https://pubmed.ncbi.nlm.nih.gov/6416324 6416324]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27100512 27100512]|[https://pubmed.ncbi.nlm.nih.gov/22566218 22566218]|[https://pubmed.ncbi.nlm.nih.gov/27264866 27264866]|[https://pubmed.ncbi.nlm.nih.gov/30094590 30094590]|[https://pubmed.ncbi.nlm.nih.gov/31077659 31077659]|[https://pubmed.ncbi.nlm.nih.gov/26975675 26975675]|[https://pubmed.ncbi.nlm.nih.gov/2083874 2083874]|[https://pubmed.ncbi.nlm.nih.gov/25088334 25088334]|[https://pubmed.ncbi.nlm.nih.gov/3333067 3333067]|[https://pubmed.ncbi.nlm.nih.gov/2191809 2191809]|[https://pubmed.ncbi.nlm.nih.gov/28118750 28118750]|[https://pubmed.ncbi.nlm.nih.gov/28224913 28224913]|[https://pubmed.ncbi.nlm.nih.gov/22495506 22495506]|[https://pubmed.ncbi.nlm.nih.gov/29385025 29385025]|[https://pubmed.ncbi.nlm.nih.gov/10332503 10332503]|[https://pubmed.ncbi.nlm.nih.gov/22393937 22393937]|[https://pubmed.ncbi.nlm.nih.gov/19947315 19947315]|[https://pubmed.ncbi.nlm.nih.gov/27655335 27655335]|[https://pubmed.ncbi.nlm.nih.gov/14529394 14529394]|[https://pubmed.ncbi.nlm.nih.gov/2419035 2419035]|[https://pubmed.ncbi.nlm.nih.gov/22048616 22048616]|[https://pubmed.ncbi.nlm.nih.gov/23849978 23849978]|[https://pubmed.ncbi.nlm.nih.gov/10204652 10204652]|[https://pubmed.ncbi.nlm.nih.gov/28958760 28958760]|[https://pubmed.ncbi.nlm.nih.gov/12627673 12627673]|[https://pubmed.ncbi.nlm.nih.gov/9042555 9042555]|[https://pubmed.ncbi.nlm.nih.gov/15639107 15639107]|[https://pubmed.ncbi.nlm.nih.gov/28880550 28880550]|[https://pubmed.ncbi.nlm.nih.gov/27238483 27238483]|[https://pubmed.ncbi.nlm.nih.gov/1964668 1964668]|[https://pubmed.ncbi.nlm.nih.gov/16716101 16716101]|[https://pubmed.ncbi.nlm.nih.gov/10796377 10796377]|[https://pubmed.ncbi.nlm.nih.gov/25981976 25981976]|[https://pubmed.ncbi.nlm.nih.gov/24680753 24680753]|[https://pubmed.ncbi.nlm.nih.gov/2191118 2191118]|[https://pubmed.ncbi.nlm.nih.gov/21166465 21166465]|[https://pubmed.ncbi.nlm.nih.gov/30582884 30582884]|[https://pubmed.ncbi.nlm.nih.gov/1322434 1322434]|[https://pubmed.ncbi.nlm.nih.gov/15330727 15330727]|[https://pubmed.ncbi.nlm.nih.gov/9752370 9752370]|[https://pubmed.ncbi.nlm.nih.gov/6416324 6416324]|[https://pubmed.ncbi.nlm.nih.gov/14996629 14996629]|[https://pubmed.ncbi.nlm.nih.gov/20452241 20452241]|[https://pubmed.ncbi.nlm.nih.gov/1340407 1340407]|[https://pubmed.ncbi.nlm.nih.gov/29050610 29050610]|[https://pubmed.ncbi.nlm.nih.gov/345399 345399]|[https://pubmed.ncbi.nlm.nih.gov/6916469 6916469]|[https://pubmed.ncbi.nlm.nih.gov/6565376 6565376]|[https://pubmed.ncbi.nlm.nih.gov/26714061 26714061] <br>
+ '''definition''' : A highly sulfated linear glycosaminoglycan comprising complex patterns of uronic acid-(1→4)-D-glucosamine repeating subunits. Used as an injectable anticoagulant, it has the highest negative charge density of any known biological molecule.[CHEBI:28304] <br>
+ '''term_xref''' : CID:772|CHEBI:28304  <br>
+ '''synonyms''' : bemiparin|bemiparin|certoparin|Cy 222|enoxaparin|fluxum|Heparin|Heparinic acid|parnaparin|reviparin|sandoparin <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000098===
-'''term (main_entry)''' : GQ1c <br>
-'''glycan_dictionary_accession''' : GD000098 <br>
-'''glytoucan_accession ''' : G99524KA <br>
-'''term_in_sentence''' : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: 6640289] <br>
-'''publication''' : 6640289|1695858|7798936|1729139|2468656|20368669|2723647|1814411|3064875|6085330|1613492|17883393|11831845|10775425|8219015|8804704|1384262|7066685|2299192|9613831|10350354|1304337|9153001|11959025|8474578|2299350|10564776|10699494|3942818|12031286|7361620 <br>
-'''definition''' : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID:91860352] <br>
-'''term_xref''' : GlycoMotif:GGM.000117|CID:91860352|CHEBI:145645|KEGG:G00121 <br>
-'''best_match''' : GlycoMotif:GGM.000117|GTC:G99524KA|CID:91860352|CHEBI:145645|KEGG:G00121 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453044 <br>
+===GSD000108===
+ '''term (main_entry)''' : High mannose <br>
+ '''glycan_dictionary_accession''' : GSD000108 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G55220VL G55220VL] <br>
+ '''term_in_sentence''' : Each glycoform contained a number of peaks differing by 162 Da indicating heterogeneity and suggesting the presence of high-mannose sugars.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11258925 11258925]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11258925 11258925]|[https://pubmed.ncbi.nlm.nih.gov/17956937 17956937]|[https://pubmed.ncbi.nlm.nih.gov/2059624 2059624]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]|[https://pubmed.ncbi.nlm.nih.gov/26791533 26791533]|[https://pubmed.ncbi.nlm.nih.gov/4077844 4077844]|[https://pubmed.ncbi.nlm.nih.gov/7780197 7780197]|[https://pubmed.ncbi.nlm.nih.gov/9136890 9136890]|[https://pubmed.ncbi.nlm.nih.gov/30659065 30659065]|[https://pubmed.ncbi.nlm.nih.gov/30075362 30075362]|[https://pubmed.ncbi.nlm.nih.gov/21421994 21421994]|[https://pubmed.ncbi.nlm.nih.gov/31076349 31076349]|[https://pubmed.ncbi.nlm.nih.gov/29738673 29738673]|[https://pubmed.ncbi.nlm.nih.gov/29508223 29508223]| [https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]|[https://pubmed.ncbi.nlm.nih.gov/30634645 30634645]|[https://pubmed.ncbi.nlm.nih.gov/23007868 23007868]|[https://pubmed.ncbi.nlm.nih.gov/29051951 29051951]|[https://pubmed.ncbi.nlm.nih.gov/24549150 24549150]|[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]|[https://pubmed.ncbi.nlm.nih.gov/26724786 26724786]|[https://pubmed.ncbi.nlm.nih.gov/26956389 26956389]|[https://pubmed.ncbi.nlm.nih.gov/26493153 26493153]|[https://pubmed.ncbi.nlm.nih.gov/31102532 31102532]|[https://pubmed.ncbi.nlm.nih.gov/29673624 29673624]|[https://pubmed.ncbi.nlm.nih.gov/8348230 8348230]|[https://pubmed.ncbi.nlm.nih.gov/25586968 25586968]|[https://pubmed.ncbi.nlm.nih.gov/24975601 24975601]| [https://pubmed.ncbi.nlm.nih.gov/29803109 29803109]|[https://pubmed.ncbi.nlm.nih.gov/28465212 28465212]|[https://pubmed.ncbi.nlm.nih.gov/25776945 25776945]|[https://pubmed.ncbi.nlm.nih.gov/30151520 30151520]|[https://pubmed.ncbi.nlm.nih.gov/21097542 21097542]|[https://pubmed.ncbi.nlm.nih.gov/24326091 24326091]|[https://pubmed.ncbi.nlm.nih.gov/27995699 27995699]|[https://pubmed.ncbi.nlm.nih.gov/26003537 26003537]|[https://pubmed.ncbi.nlm.nih.gov/6722291 6722291]|[https://pubmed.ncbi.nlm.nih.gov/2925680 2925680]|[https://pubmed.ncbi.nlm.nih.gov/25565276 25565276]|[https://pubmed.ncbi.nlm.nih.gov/21460211 21460211]|[https://pubmed.ncbi.nlm.nih.gov/25196214 25196214]|[https://pubmed.ncbi.nlm.nih.gov/27387600 27387600]|[https://pubmed.ncbi.nlm.nih.gov/22373601 22373601]|[https://pubmed.ncbi.nlm.nih.gov/3729933 3729933]|[https://pubmed.ncbi.nlm.nih.gov/16423983 16423983]|[https://pubmed.ncbi.nlm.nih.gov/24174266 24174266]|[https://pubmed.ncbi.nlm.nih.gov/30605318 30605318] <br>
+ '''definition''' : An N-linked oligosaccharide that possesses between five and nine mannose residues attached to the chitobiose [(GlcNAc)2] core. [CHEBI:5717] None of the Man residues are substituted with any monosaccharide other than Man . <br>
+ '''term_xref''' : GTC:G55220VL|CID:70698382|CHEBI:71514  <br>
+ '''synonyms''' : oligomannose <br>
+ '''function''' : Involved in promotion of protein folding in ER. [PMID:[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]].|High Man glycans are enriched at cell surface during apoptosis.[PMID: 17516205] <br>
+ '''disease_associations''' : Relative abundance changes in multiple CDGs [PMID: 30770376][PMID: 28484880] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17]<br>
-===GD000099===
-'''term (main_entry)''' : GT1a <br>
-'''glycan_dictionary_accession''' : GD000099 <br>
-'''glytoucan_accession ''' : G68110IF <br>
-'''term_in_sentence''' : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:26197476] <br>
-'''publication''' : 12023422|32623212|26197476|9585812|29747820|23804237|11993188|31683059|19631994|9742882|29709941|8971119|8706663|893404|31829433|8910600|30600291|29319803|26176883|29063860|6766128|31602715|29808463|30711390|29847988|30116054|28187751 <br>
-'''definition''' : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] <br>
-'''term_xref''' : CID:45266863|GlycoMotif:GGM.000110|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215 <br>
-'''best_match''' : CID:45266863|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000109===
+ '''term (main_entry)''' : HNK-1 <br>
+ '''glycan_dictionary_accession''' : GSD000109 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54406UD G54406UD] <br>
+ '''term_in_sentence''' : The human natural killer-1 (HNK-1) carbohydrate, a unique trisaccharide possessing sulfated glucuronic acid in a non-reducing terminus (HSO3-3GlcAß1-3Galß1-4GlcNAc-), is highly expressed in the nervous system and its spatiotemporal expression is strictly regulated.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28709864 28709864]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28709864 28709864]|[https://pubmed.ncbi.nlm.nih.gov/31738061 31738061]|[https://pubmed.ncbi.nlm.nih.gov/26738850 26738850]|[https://pubmed.ncbi.nlm.nih.gov/30306736 30306736]|[https://pubmed.ncbi.nlm.nih.gov/11070366 11070366]|[https://pubmed.ncbi.nlm.nih.gov/20855890 20855890]|[https://pubmed.ncbi.nlm.nih.gov/18024472 18024472]|[https://pubmed.ncbi.nlm.nih.gov/22669261 22669261]|[https://pubmed.ncbi.nlm.nih.gov/19729452 19729452]|[https://pubmed.ncbi.nlm.nih.gov/19796667 19796667]|[https://pubmed.ncbi.nlm.nih.gov/26850637 26850637]|[https://pubmed.ncbi.nlm.nih.gov/11769463 11769463]|[https://pubmed.ncbi.nlm.nih.gov/18263654 18263654]|[https://pubmed.ncbi.nlm.nih.gov/15843379 15843379]|[https://pubmed.ncbi.nlm.nih.gov/26659409 26659409]|[https://pubmed.ncbi.nlm.nih.gov/9003039 9003039]|[https://pubmed.ncbi.nlm.nih.gov/22087768 22087768]|[https://pubmed.ncbi.nlm.nih.gov/21771787 21771787]|[https://pubmed.ncbi.nlm.nih.gov/15173636 15173636]|[https://pubmed.ncbi.nlm.nih.gov/9210489 9210489]|[https://pubmed.ncbi.nlm.nih.gov/15258996 15258996]|[https://pubmed.ncbi.nlm.nih.gov/17924534 17924534]|[https://pubmed.ncbi.nlm.nih.gov/26382082 26382082]|[https://pubmed.ncbi.nlm.nih.gov/16171882 16171882]|[https://pubmed.ncbi.nlm.nih.gov/18802400 18802400]|[https://pubmed.ncbi.nlm.nih.gov/9800516 9800516]|[https://pubmed.ncbi.nlm.nih.gov/7504418 7504418]| [https://pubmed.ncbi.nlm.nih.gov/11891229 11891229]|[https://pubmed.ncbi.nlm.nih.gov/15232286 15232286]|[https://pubmed.ncbi.nlm.nih.gov/9013478 9013478]|[https://pubmed.ncbi.nlm.nih.gov/21621858 21621858]|[https://pubmed.ncbi.nlm.nih.gov/11677051 11677051]|[https://pubmed.ncbi.nlm.nih.gov/18668221 18668221]|[https://pubmed.ncbi.nlm.nih.gov/11414798 11414798]|[https://pubmed.ncbi.nlm.nih.gov/19265195 19265195]|[https://pubmed.ncbi.nlm.nih.gov/8982638 8982638]|[https://pubmed.ncbi.nlm.nih.gov/8798480 8798480]|[https://pubmed.ncbi.nlm.nih.gov/28403522 28403522]|[https://pubmed.ncbi.nlm.nih.gov/17935701 17935701]|[https://pubmed.ncbi.nlm.nih.gov/1691305 1691305]|[https://pubmed.ncbi.nlm.nih.gov/10998116 10998116]|[https://pubmed.ncbi.nlm.nih.gov/9364602 9364602]|[https://pubmed.ncbi.nlm.nih.gov/7528651 7528651]|[https://pubmed.ncbi.nlm.nih.gov/12472892 12472892]|[https://pubmed.ncbi.nlm.nih.gov/21176892 21176892]|[https://pubmed.ncbi.nlm.nih.gov/28416698 28416698]|[https://pubmed.ncbi.nlm.nih.gov/19389918 19389918]| [https://pubmed.ncbi.nlm.nih.gov/28427937 28427937]|[https://pubmed.ncbi.nlm.nih.gov/25450311 25450311] <br>
+ '''definition''' : An amino trisaccharide consisting of a 3-O-sulfo-β-D-glucuronic acid residue, a D-galactosyl residue and an N-acetyl-D-glucosamine residue (at the reducing end) in a linear sequence.[CHEBI:60322] <br>
+ '''term_xref''' : GTC:G54406UD|GlycoEpitope:EP0001|CID: 46906103|CHEBI:60322|GlycoMotif:GGM.000058 <br>
+ '''synonyms''' : HNK-1 carbohydrate epitope| CD57|HNK-1 antigen <br>
+ '''function''' : learning and memory[GlycoEpitope:EP0001]|neural crest cell migration[GlycoEpitope:EP0001]|neurite extension[GlycoEpitope:EP0001]|neuron-astrocyte adhesion[GlycoEpitope:EP0001] <br>
+ '''disease_associations''' : schizophrenia-like psychosis[GlycoEpitope:EP0001]|neuropathy[GlycoEpitope:EP0001]|exfoliation syndrome[GlycoEpitope:EP0001]|secondary cataract[GlycoEpitope:EP0001] <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/N-linked_glycosylation <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17]<br>
-===GD000100===
-'''term (main_entry)''' : GT1a alpha <br>
-'''glycan_dictionary_accession''' : GD000100 <br>
-'''glytoucan_accession ''' : G02149VR <br>
-'''term_in_sentence''' : A new class of gangliosides, GT1a alpha and GQ1b alpha, were initially identified as cholinergic neuron-specific antigens in bovine brain. [PMID:8082783] <br>
-'''publication''' : 7710562|8082783|10972137|9468624|9143254|8221098|9679279|11368158|11878808 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000111|GlycoEpitope:EP0111|CID:91851751|CHEBI:156678|KEGG:G00128 <br>
-'''best_match''' : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID:91851751|CHEBI:156678|KEGG:G00128 <br>
-'''synonymns''' : GT1aa <br>
-'''function''' : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000110===
+ '''term (main_entry)''' : Hybrid <br>
+ '''glycan_dictionary_accession''' : GSD000110 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G16828VN G16828VN] <br>
+ '''term_in_sentence''' : A hybrid-type N-glycan was accessed by total synthesis, converted to an oxazoline, and used as a donor substrate with both wild type Endo M and an N175Q glycosynthase Endo M mutant allowing the convergent synthesis of a glycosylated amino acid bearing a hybrid N-glycan structure. [PMID:[https://pubmed.ncbi.nlm.nih.gov/27058295 27058295]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27058295 27058295]|[https://pubmed.ncbi.nlm.nih.gov/15044398 15044398]|[https://pubmed.ncbi.nlm.nih.gov/28714086 28714086]|[https://pubmed.ncbi.nlm.nih.gov/29578688 29578688]|[https://pubmed.ncbi.nlm.nih.gov/26999365 26999365] <br>
+ '''definition''' : An N-linked glycan in which the Manα1-6 arm of the trimannosyl core Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1–4GlcNAcβ1–Asn-X-Ser/Thr is substituted by one or more additional Man residues and the Manα1-3 arm is substituted by a GlcNAc residue added by GlcNAcT1. The GlcNAc linked to the a3 Man can be extended in the same manner as any complex glycan antenna. The trimannosyl core can also be core fucosylated and/or bisected by the addition of a GlcNAc to the 3 position of the α-linked Man residue.[Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]] <br>
+ '''term_xref''' : GTC:G16828VN|CID:91847108|CHEBI:147471 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
-===GD000101===
-'''term (main_entry)''' : GT1b <br>
-'''glycan_dictionary_accession''' : GD000101 <br>
-'''glytoucan_accession ''' : G40183QN <br>
-'''term_in_sentence''' : GT1b ganglioside is axonally transported to the spinal cord dorsal horn and contributes to characteristics of neuropathic pain such as mechanical and thermal hypersensitivity.[PMID: 32030804] <br>
-'''publication''' : 32030804|26370787|32046393|9712688|7636307|9931455|25520869|19605473|17188834|10233751|22735313|20540782|22746533|1861141|19490186|9521848|11921200|10731661|31431523|15274627|32726962|12573517|18277613|11370834|11234774|11123278|18704164|16291967|11411041|27549393|25253868|22720883|10686582|11511306|29904724|31472390|19156870 <br>
-'''definition''' : A branched amino heptasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries an N-acetyl-α-neuraminyl-(2→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl trisaccharide unit and an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide unit through (2→4) and (2→3) linkages respectively. It corresponds to the carbohydrate portion of ganglioside GT1b.[CHEBI:59225] <br>
-'''term_xref''' : GlycoMotif:GGM.000112|GlycoEpitopeEP0067|CID:45266781|CHEBI:59225|GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116 <br>
-'''best_match''' : GlycoMotif:GGM.000112|GTC:G40183QN|GlycoEpitopeEP0067|CID:45266781|CHEBI:59225| GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : Toxoplasmosis[SugarBind_Ligand:26]|Lyme disease[SugarBind_Ligand:26]|Cholera[SugarBind_Ligand:26]|Botulism[SugarBind_Ligand:26]|Tetanus[SugarBind_Ligand:26]|Influenza[SugarBind_Ligand:26] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000111===
+ '''term (main_entry)''' : i antigen <br>
+ '''glycan_dictionary_accession''' : GSD000111 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00058MO G00058MO]|[https://www.glygen.org/glycan/G46055MA G46055MA] <br>
+ '''term_in_sentence''' : Inasmuch as the hybridoma was established by hybridization of lymphocytes derived from regional lymph nodes of lung cancer, and the antigen was found in the patient's lung cancer tissue, the i antigen in lung cancer is probably recognized as a tumor-associated antigen by the host's immune cell system.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2422274 2422274]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2422274 2422274]|[https://pubmed.ncbi.nlm.nih.gov/15679458 15679458]|[https://pubmed.ncbi.nlm.nih.gov/21912254 21912254]|[https://pubmed.ncbi.nlm.nih.gov/12468428 12468428]|[https://pubmed.ncbi.nlm.nih.gov/28508465 28508465]|[https://pubmed.ncbi.nlm.nih.gov/6203982 6203982]|[https://pubmed.ncbi.nlm.nih.gov/30728302 30728302]|[https://pubmed.ncbi.nlm.nih.gov/8449405 8449405]|[https://pubmed.ncbi.nlm.nih.gov/9122902 9122902]|[https://pubmed.ncbi.nlm.nih.gov/10360315 10360315]|[https://pubmed.ncbi.nlm.nih.gov/6159787 6159787]|[https://pubmed.ncbi.nlm.nih.gov/6183759 6183759]|[https://pubmed.ncbi.nlm.nih.gov/518539 518539]| [https://pubmed.ncbi.nlm.nih.gov/6715951 6715951]|[https://pubmed.ncbi.nlm.nih.gov/21933024 21933024] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000004|GlycoMotif:GGM.000002|GTC:G46055MA|GTC:G00058MO <br>
+ '''synonyms''' : Type 2 LN2 <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000102===
-'''term (main_entry)''' : GT1c <br>
-'''glycan_dictionary_accession''' : GD000102 <br>
-'''glytoucan_accession ''' : G78818SP <br>
-'''term_in_sentence''' : We show here that VVH associates with ganglioside GM1a, Fucosyl-GM1, GD1a, GT1c, and GD1b by glycan array.[PMID: 32228455] <br>
-'''publication''' : 28088450|30085356|32228455|2468656|19841910|23877172|1695858|10564776|1613492|8474578|7798936|11180643|2723647|7066685|9613831|7361620|10699494 <br>
-'''definition''' : A branched amino heptasaccharide consisting of a linear tetrasaccharide of β-D-galactose, N-acetyl-β-D-galactosamine, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→4) and (1→4), to the galactose residue proximal to the reducing end is also linked (2→3) an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl trisaccharide side-chain. The carbohydrate moiety of ganglioside GT1c.[CHEBI:90509] <br>
-'''term_xref''' : GlycoMotif:GGM.000113|CID:91846734|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120 <br>
-'''best_match''' : GlycoMotif:GGM.000113|GTC:G78818SP|CID:91846734|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000112===
+ '''term (main_entry)''' : I antigen <br>
+ '''glycan_dictionary_accession''' : GSD000112 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56045WU G56045WU] <br>
+ '''term_in_sentence''' : The I antigen is formed by the action of an enzyme (a glycosyltransferase), which adds branches onto the i antigen.[PMID: [https://pubmed.ncbi.nlm.nih.gov/15679458 15679458]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15679458 15679458]|[https://pubmed.ncbi.nlm.nih.gov/21912254 21912254]|[https://pubmed.ncbi.nlm.nih.gov/30705292 30705292]|[https://pubmed.ncbi.nlm.nih.gov/33403394 33403394]|[https://pubmed.ncbi.nlm.nih.gov/6715951 6715951]|[https://pubmed.ncbi.nlm.nih.gov/12468428 12468428]|[https://pubmed.ncbi.nlm.nih.gov/6088627 6088627]|[https://pubmed.ncbi.nlm.nih.gov/6159787 6159787] <br>
+ '''definition''' : N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S,6R)-4-[(2R,3R,4R,5S,6R)-3-Acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[[(2R,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide (CHEBI:151390) is a amino sugar.[CHEBI:151390] <br>
+ '''term_xref''' : GlycoMotif:GGM.000003|GlycoEpitope:EP0138|GTC:G56045WU|CID: 91852915|CHEBI:151390 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
-===GD000103===
-'''term (main_entry)''' : GT2 <br>
-'''glycan_dictionary_accession''' : GD000103 <br>
-'''glytoucan_accession ''' : G36476BA <br>
-'''term_in_sentence''' : Biosynthesis of the c-series gangliosides GT3, GT2 and GP1c was studied in Golgi derived from rat liver.[PMID:1606358] <br>
-'''publication''' : 1606358|15498585|16005859|27540730|31533196|31201844 <br>
-'''definition''' : A branched amino hexasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-galactosaminyl residue. The carbohydrate moiety of ganglioside GT2.[CHEBI:72446] <br>
-'''term_xref''' : GlycoMotif:GGM.000109|CID:70788971|CHEBI:72446|KEGG:G00119 <br>
-'''best_match''' : GlycoMotif:GGM.000109|GTC:G36476BA|CID:70788971|CHEBI:72446|KEGG:G00119 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+===GSD000113===
+ '''term (main_entry)''' : Isoglobotetraosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000113 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57710SU G57710SU] <br>
+ '''term_in_sentence''' : Furthermore, isoglobotetraosylceramide seems to play a direct role in the metastatic process since the blocking of exposed antigen with monoclonal antibodies, or their Fab fragments, results in a highly significant decrease in lung colony formation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8504431 8504431]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1396705 1396705]|[https://pubmed.ncbi.nlm.nih.gov/8504431 8504431]|[https://pubmed.ncbi.nlm.nih.gov/2713378 2713378]|[https://pubmed.ncbi.nlm.nih.gov/3489485 3489485]|[https://pubmed.ncbi.nlm.nih.gov/18997175 18997175]|[https://pubmed.ncbi.nlm.nih.gov/7053385 7053385]|[https://pubmed.ncbi.nlm.nih.gov/3379797 3379797]|[https://pubmed.ncbi.nlm.nih.gov/2465279 2465279]|[https://pubmed.ncbi.nlm.nih.gov/3743633 3743633]|[https://pubmed.ncbi.nlm.nih.gov/11479210 11479210] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000071|GTC:G57710SU|CID:91849719|KEGG:G03211|CHEBI:148232|SugarBind_Ligand:17  <br>
+ '''synonyms''' :  <br>
+ '''function''' : a marker for highly metastatic cells in rat mammary adenocarcinomas[PMID:[https://pubmed.ncbi.nlm.nih.gov/8504431 8504431]] <br>
+ '''disease_associations''' : Actinomycosis[SugarBind_Ligand:17] <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/Ii_antigen_system <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000104===
-'''term (main_entry)''' : GT3 <br>
-'''glycan_dictionary_accession''' : GD000104 <br>
-'''glytoucan_accession ''' : G93899SO <br>
-'''term_in_sentence''' : The purpose of this study was two-fold: (1) to formulate γ-tocotrienol (GT3) in a nanoemulsion formulation as a prophylactic orally administered radioprotective agent; and (2) to optimize the storage conditions to preserve the structural integrity of both the formulation and the compound.[PMID: 28029115] <br>
-'''publication''' : 28029115|31355968|30987413|27869747|27216753|8631981|29672891|10385047|29642403|10412028|27193023|30068561|23415908|8858920|2303428|27153057|27128741|2654294|26930378|7561885|25860286|30845647|24712339|30070965|8910600|1606358|27356050|8514740|18509108|23000517|29769046|29566611 <br>
-'''definition''' : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444] <br>
-'''term_xref''' : GlycoEpitope:EP0070|KEGG:G00118|CID:70788970|GlycoMotif:GGM.000092|CHEBI:72444 <br>
-'''best_match''' : GlycoEpitope:EP0070|KEGG:G00118|CID:70788970|GlycoMotif:GGM.000092|GTC:G93899SO|CHEBI:72444 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+===GSD000114===
+ '''term (main_entry)''' : Keratan sulfate <br>
+ '''glycan_dictionary_accession''' : GSD000114 <br>
+ '''glytoucan_accession ''' :  [https://www.glygen.org/glycan/G82109MW G82109MW] <br>
+ '''term_in_sentence''' : Compared to the other classes of glycosaminoglycans (GAGs), that is, chondroitin/dermatan sulfate, heparin/heparan sulfate and hyaluronan, keratan sulfate (KS), have the least known of its interactive properties.[PMID: [https://pubmed.ncbi.nlm.nih.gov/30578672 30578672]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29340594 29340594]|[https://pubmed.ncbi.nlm.nih.gov/30578672 30578672]|[https://pubmed.ncbi.nlm.nih.gov/12512857 12512857]|[https://pubmed.ncbi.nlm.nih.gov/29625490 29625490]|[https://pubmed.ncbi.nlm.nih.gov/25325967 25325967]|[https://pubmed.ncbi.nlm.nih.gov/30025865 30025865]|[https://pubmed.ncbi.nlm.nih.gov/29924315 29924315]|[https://pubmed.ncbi.nlm.nih.gov/9549787 9549787]|[https://pubmed.ncbi.nlm.nih.gov/11030741 11030741]|[https://pubmed.ncbi.nlm.nih.gov/28078490 28078490]|[https://pubmed.ncbi.nlm.nih.gov/8298243 8298243]|[https://pubmed.ncbi.nlm.nih.gov/29096187 29096187]|[https://pubmed.ncbi.nlm.nih.gov/30059256 30059256]|[https://pubmed.ncbi.nlm.nih.gov/26958998 26958998]|[https://pubmed.ncbi.nlm.nih.gov/26773479 26773479]|[https://pubmed.ncbi.nlm.nih.gov/22840010 22840010]|[https://pubmed.ncbi.nlm.nih.gov/15597951 15597951]|[https://pubmed.ncbi.nlm.nih.gov/28110685 28110685]|[https://pubmed.ncbi.nlm.nih.gov/28535934 28535934]|[https://pubmed.ncbi.nlm.nih.gov/2942429 2942429]|[https://pubmed.ncbi.nlm.nih.gov/18234072 18234072]|[https://pubmed.ncbi.nlm.nih.gov/8641829 8641829]|[https://pubmed.ncbi.nlm.nih.gov/8940154 8940154]|[https://pubmed.ncbi.nlm.nih.gov/2027120 2027120]|[https://pubmed.ncbi.nlm.nih.gov/30849116 30849116]|41589|[https://pubmed.ncbi.nlm.nih.gov/6238957 6238957]|[https://pubmed.ncbi.nlm.nih.gov/1907283 1907283]|[https://pubmed.ncbi.nlm.nih.gov/7722002 7722002]|[https://pubmed.ncbi.nlm.nih.gov/29275050 29275050]|[https://pubmed.ncbi.nlm.nih.gov/24274541 24274541]|[https://pubmed.ncbi.nlm.nih.gov/2527236 2527236]|[https://pubmed.ncbi.nlm.nih.gov/1731862 1731862]|[https://pubmed.ncbi.nlm.nih.gov/8991509 8991509]|[https://pubmed.ncbi.nlm.nih.gov/24291704 24291704]|[https://pubmed.ncbi.nlm.nih.gov/10517185 10517185]|[https://pubmed.ncbi.nlm.nih.gov/6451953 6451953]|[https://pubmed.ncbi.nlm.nih.gov/7688312 7688312]|[https://pubmed.ncbi.nlm.nih.gov/8663590 8663590]|139406|[https://pubmed.ncbi.nlm.nih.gov/25770829 25770829]|[https://pubmed.ncbi.nlm.nih.gov/25036480 25036480]|[https://pubmed.ncbi.nlm.nih.gov/9275006 9275006]|[https://pubmed.ncbi.nlm.nih.gov/25179279 25179279]|[https://pubmed.ncbi.nlm.nih.gov/32627425 32627425]|[https://pubmed.ncbi.nlm.nih.gov/26903438 26903438]|[https://pubmed.ncbi.nlm.nih.gov/27941632 27941632]|[https://pubmed.ncbi.nlm.nih.gov/12807022 12807022]|[https://pubmed.ncbi.nlm.nih.gov/32266652 32266652]|[https://pubmed.ncbi.nlm.nih.gov/21624346 21624346] <br>
+ '''definition''' : A sulfated glycosaminoglycan, a linear polymer that consists of the repeating disaccharide [3)-β-Gal-(1→4)-β-GlcNAc-(1→] and containing sulfo groups located at random positions.[CHEBI:60924] <br>
+ '''term_xref''' : CHEBI:60924|CID:446715|GlycoEpitope: EP0085|GTC: G82109MW  <br>
+ '''synonyms''' : keratan| Kerato sulphate|Kerato sulfate|Keratan sulphate|kerato 6'-sulfate|keratan 6'-sulfate|Kerato 6'-sulphate|Keratan 6'-sulphate <br>
+ '''function''' : Tissue hydration.[PMID: [https://pubmed.ncbi.nlm.nih.gov/11030741 11030741]] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000105===
-'''term (main_entry)''' : H type 3 <br>
-'''glycan_dictionary_accession''' : GD000105 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The expression of type 3 chain H and A antigens was always compatible with the ABO blood type of the individual and seems to be regulated by the secretor genes, as secretors [Lewis (a-b+)] expressed more A and H type 3 chains than nonsecretors [Lewis (a+b-)].[PMID:1563908] <br>
-'''publication''' : 1563908|3944092|11218748|11101633|18842005|27550195|2469783|2433836|23118206|8445257|2664192|3063304 <br>
-'''definition''' :  <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : H antigen (type 3)|Type 3 chain H <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453016 <br>
+===GSD000115===
+ '''term (main_entry)''' : LacdiNac <br>
+ '''glycan_dictionary_accession''' : GSD000115 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G31736BK G31736BK] <br>
+ '''term_in_sentence''' : We previously showed that the expression level of the LacdiNAc group in N-glycans decreases dramatically during the progression of human breast cancer.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25003135 25003135]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/25003135 25003135]|[https://pubmed.ncbi.nlm.nih.gov/31711843 31711843]|[https://pubmed.ncbi.nlm.nih.gov/31145522 31145522]|[https://pubmed.ncbi.nlm.nih.gov/27601469 27601469]|[https://pubmed.ncbi.nlm.nih.gov/30669833 30669833]|[https://pubmed.ncbi.nlm.nih.gov/25210040 25210040]|[https://pubmed.ncbi.nlm.nih.gov/24633693 24633693]|[https://pubmed.ncbi.nlm.nih.gov/24755437 24755437]|[https://pubmed.ncbi.nlm.nih.gov/22653491 22653491]|[https://pubmed.ncbi.nlm.nih.gov/30898876 30898876]|[https://pubmed.ncbi.nlm.nih.gov/7758724 7758724]| [https://pubmed.ncbi.nlm.nih.gov/22474328 22474328]|[https://pubmed.ncbi.nlm.nih.gov/21305673 21305673]|[https://pubmed.ncbi.nlm.nih.gov/31558607 31558607]|[https://pubmed.ncbi.nlm.nih.gov/31271862 31271862]|[https://pubmed.ncbi.nlm.nih.gov/28549117 28549117]|[https://pubmed.ncbi.nlm.nih.gov/26213980 26213980]|[https://pubmed.ncbi.nlm.nih.gov/9134425 9134425]|[https://pubmed.ncbi.nlm.nih.gov/25561735 25561735]|[https://pubmed.ncbi.nlm.nih.gov/31756927 31756927]|[https://pubmed.ncbi.nlm.nih.gov/31170332 31170332]|[https://pubmed.ncbi.nlm.nih.gov/16282603 16282603]|[https://pubmed.ncbi.nlm.nih.gov/15265923 15265923]|[https://pubmed.ncbi.nlm.nih.gov/32267274 32267274]|[https://pubmed.ncbi.nlm.nih.gov/23015818 23015818]|[https://pubmed.ncbi.nlm.nih.gov/32676595 32676595]|[https://pubmed.ncbi.nlm.nih.gov/16728562 16728562]|[https://pubmed.ncbi.nlm.nih.gov/10814702 10814702]|[https://pubmed.ncbi.nlm.nih.gov/9591048 9591048]|[https://pubmed.ncbi.nlm.nih.gov/22245701 22245701]| [https://pubmed.ncbi.nlm.nih.gov/29751628 29751628]|[https://pubmed.ncbi.nlm.nih.gov/22997242 22997242]|[https://pubmed.ncbi.nlm.nih.gov/15535969 15535969]|[https://pubmed.ncbi.nlm.nih.gov/31911241 31911241]|[https://pubmed.ncbi.nlm.nih.gov/30622255 30622255]|[https://pubmed.ncbi.nlm.nih.gov/29888905 29888905]|[https://pubmed.ncbi.nlm.nih.gov/30236114 30236114]| [https://pubmed.ncbi.nlm.nih.gov/30298790 30298790]|[https://pubmed.ncbi.nlm.nih.gov/29373511 29373511]|[https://pubmed.ncbi.nlm.nih.gov/22298779 22298779]|[https://pubmed.ncbi.nlm.nih.gov/19179461 19179461]|[https://pubmed.ncbi.nlm.nih.gov/31606752 31606752]|[https://pubmed.ncbi.nlm.nih.gov/15653684 15653684]|[https://pubmed.ncbi.nlm.nih.gov/16403022 16403022]|[https://pubmed.ncbi.nlm.nih.gov/11162373 11162373]|[https://pubmed.ncbi.nlm.nih.gov/32005658 32005658]|[https://pubmed.ncbi.nlm.nih.gov/30529570 30529570] <br>
+ '''definition''' : An amino disaccharide consisting of N-acetylglucosamine having an N-acetylgalactosaminyl resiude attached at the 4-position via a β-linkage.[CHEBI:61190] <br>
+ '''term_xref''' : GTC:G31736BK|GlycoEpitope:P0150|CID:25257164|CHEBI:61190|GlycoMotif:GGM.000016 <br>
+ '''synonyms''' : LDN <br>
+ '''function''' : Has a role of epitope.[CHEBI:61190] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000106===
-'''term (main_entry)''' : Heparan sulfate <br>
-'''glycan_dictionary_accession''' : GD000106 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In Niemann-Pick C-1 fibroblasts, where deaminative degradation of heparan sulfate is defective, carbonylated proteins were abundant.[PMID: 17540770] <br>
-'''publication''' : 32266657|29554552|29032302|30003471|25197032|28538085|26236728|22899865|17080204|23042481|28982096|24146040|25081076|15719168|17453622|25325954|21110089|29797526|21967329|23313092|11212344|28465034|11746174|12512855|8836040|28394734|24182748|28264929|28745308|26555370|14718374|16767693|25246018|19584012|8274190|25034023|8370471|26571620|29920400|31731076|20816205|16880267|31547957|11457867|27241222|28718936|21204109|31016560|11166215|11457866 <br>
-'''definition''' : A linear polysaccharide in which the backbone consists of a variably sulfated repeating disaccharide unit.[CHEBI:28815] <br>
-'''term_xref''' : CHEBI:28815|CID:53477715|GlycoEpitope:EP0086 <br>
-'''best_match''' : CHEBI:28815|CID: 53477715|GlycoEpitope: EP0086 <br>
-'''synonymns''' : Heparan N-sulfate|Heparan sulfate|Heparan sulphate|Heparatan sulfate|Heparin monosulfate| Heparin sulfate|Heparitin monosulfate|Heparitin sulfate|N-Acetylheparan sulfate <br>
-'''function''' : Heparan sulfate proteoglycans (HSPGs) play crucial roles regulating key developmental signaling pathways, such as the Wnt, Hedgehog, transforming growth factor-beta, and fibroblast growth factor pathways.[GlycoEpitope: EP0086] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===GSD000116===
+ '''term (main_entry)''' : Lactosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000116 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G84224TW G84224TW] <br>
+ '''term_in_sentence''' : In the 1970s, a neutral glycosphingolipid lactosylceramide (LacCer) was found to bind specifically to several kinds of microorganisms.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30175814 30175814]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30175814 30175814]|[https://pubmed.ncbi.nlm.nih.gov/26900161 26900161]|[https://pubmed.ncbi.nlm.nih.gov/30502090 30502090]|[https://pubmed.ncbi.nlm.nih.gov/29624959 29624959]|[https://pubmed.ncbi.nlm.nih.gov/28444900 28444900]|[https://pubmed.ncbi.nlm.nih.gov/25408340 25408340]|[https://pubmed.ncbi.nlm.nih.gov/31801289 31801289]|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]|[https://pubmed.ncbi.nlm.nih.gov/25595946 25595946]|[https://pubmed.ncbi.nlm.nih.gov/32592089 32592089]|[https://pubmed.ncbi.nlm.nih.gov/27729551 27729551]|[https://pubmed.ncbi.nlm.nih.gov/24658420 24658420]|[https://pubmed.ncbi.nlm.nih.gov/25216636 25216636]|[https://pubmed.ncbi.nlm.nih.gov/25638276 25638276]|[https://pubmed.ncbi.nlm.nih.gov/9499377 9499377]|[https://pubmed.ncbi.nlm.nih.gov/17986153 17986153]|[https://pubmed.ncbi.nlm.nih.gov/8143857 8143857]|[https://pubmed.ncbi.nlm.nih.gov/23801329 23801329]|[https://pubmed.ncbi.nlm.nih.gov/18077097 18077097]|[https://pubmed.ncbi.nlm.nih.gov/32708181 32708181]|[https://pubmed.ncbi.nlm.nih.gov/15346887 15346887]|[https://pubmed.ncbi.nlm.nih.gov/19015977 19015977]|[https://pubmed.ncbi.nlm.nih.gov/18393821 18393821]|[https://pubmed.ncbi.nlm.nih.gov/25279740 25279740]|[https://pubmed.ncbi.nlm.nih.gov/21057870 21057870]|[https://pubmed.ncbi.nlm.nih.gov/11915327 11915327]|[https://pubmed.ncbi.nlm.nih.gov/25212460 25212460]|[https://pubmed.ncbi.nlm.nih.gov/23882130 23882130]|[https://pubmed.ncbi.nlm.nih.gov/11915329 11915329]|[https://pubmed.ncbi.nlm.nih.gov/8195125 8195125]|[https://pubmed.ncbi.nlm.nih.gov/8808768 8808768]|[https://pubmed.ncbi.nlm.nih.gov/3396945 3396945]|[https://pubmed.ncbi.nlm.nih.gov/22128256 22128256]|[https://pubmed.ncbi.nlm.nih.gov/6733104 6733104]|[https://pubmed.ncbi.nlm.nih.gov/24968752 24968752]|[https://pubmed.ncbi.nlm.nih.gov/32518749 32518749]|[https://pubmed.ncbi.nlm.nih.gov/30688114 30688114]|[https://pubmed.ncbi.nlm.nih.gov/7666005 7666005]|[https://pubmed.ncbi.nlm.nih.gov/8200356 8200356]|[https://pubmed.ncbi.nlm.nih.gov/24718572 24718572]|[https://pubmed.ncbi.nlm.nih.gov/6193809 6193809]|[https://pubmed.ncbi.nlm.nih.gov/25781947 25781947]|[https://pubmed.ncbi.nlm.nih.gov/12383912 12383912]|[https://pubmed.ncbi.nlm.nih.gov/26086247 26086247]|[https://pubmed.ncbi.nlm.nih.gov/30606995 30606995]|[https://pubmed.ncbi.nlm.nih.gov/12419803 12419803] <br>
+ '''definition''' : Glycosphingolipids which contain as their polar head group a lactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in lactosylceramide beta-galactosidase, is the cause of lactosylceramidosis.[MeSH:D007790] <br>
+ '''term_xref''' : GTC:G84224TW|MeSH:D007790|GlycoMotif:GGM.000064|GlycoEpitope:EP0078|SugarBind_Ligand:3 <br>
+ '''synonyms''' : LacCer|Lc2|CDH <br>
+ '''function''' : mammalian cell receptors for Neisseria gonorrhoeae recognized by Helicobacter pylori[GlycoEpitope:EP0078] <br>
+ '''disease_associations''' : chronic gastritis[GlycoEpitope:EP0078,SugarBind_Ligand:3]|duodenal ulcers[GlycoEpitope:EP0078]|gastric adenocarcinoma[GlycoEpitope:EP0078,SugarBind_Ligand:3]|gastric ulcers[GlycoEpitope:EP0078]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Actinomycosis[SugarBind_Ligand:3]|Pertussis[SugarBind_Ligand:3]|Candidiasis[SugarBind_Ligand:3]|Cryptococcosis[SugarBind_Ligand:3]|Hemorrhagic colitis[SugarBind_Ligand:3]|Peptic ulcers[SugarBind_Ligand:3]|Histoplasmosis[SugarBind_Ligand:3]|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Gonorrhea[SugarBind_Ligand:3]|Sporotrichosis[SugarBind_Ligand:3]|Plague[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453033/ Chapter 17]<br>
-===GD000107===
-'''term (main_entry)''' : Heparin <br>
-'''glycan_dictionary_accession''' : GD000107 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Two cellulose-based membranes, containing 5 and 20% N, N-diethyl-aminoethyl cellulose (DEAE) respectively, were investigated for ionic attachment of heparin and heparin release.[PMID:6416324] <br>
-'''publication''' : 27100512|22566218|27264866|30094590|31077659|26975675|2083874|25088334|3333067|2191809|28118750|28224913|22495506|29385025|10332503|22393937|19947315|27655335|14529394|2419035|22048616|23849978|10204652|28958760|12627673|9042555|15639107|28880550|27238483|1964668|16716101|10796377|25981976|24680753|2191118|21166465|30582884|1322434|15330727|9752370|6416324|14996629|20452241|1340407|29050610|345399|6916469|6565376|26714061 <br>
-'''definition''' : A highly sulfated linear glycosaminoglycan comprising complex patterns of uronic acid-(1→4)-D-glucosamine repeating subunits. Used as an injectable anticoagulant, it has the highest negative charge density of any known biological molecule.[CHEBI:28304] <br>
-'''term_xref''' : CID:772|CHEBI:28304 <br>
-'''best_match''' : CID:772|CHEBI:28304 <br>
-'''synonymns''' : bemiparin|bemiparin|certoparin|Cy 222|enoxaparin|fluxum|Heparin|Heparinic acid|parnaparin|reviparin|sandoparin <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000117===
+ '''term (main_entry)''' : Lactotriaosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000117 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G06239NA G06239NA] <br>
+ '''term_in_sentence''' : The results showed that AML patients had higher expression of the GSL lactotriaosylceramide (Lc3), GM3 and neolactotetraosylceramide (nLc4) in their bone marrow than did the healthy donors (P < 0.05), especially the M1 subtype of AML.[PMID:[https://pubmed.ncbi.nlm.nih.gov/22411838 22411838]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/22411838 22411838]|[https://pubmed.ncbi.nlm.nih.gov/20693232 20693232]|[https://pubmed.ncbi.nlm.nih.gov/26104834 26104834]|[https://pubmed.ncbi.nlm.nih.gov/27435676 27435676]|[https://pubmed.ncbi.nlm.nih.gov/26405105 26405105]|[https://pubmed.ncbi.nlm.nih.gov/32340400 32340400]|[https://pubmed.ncbi.nlm.nih.gov/25241919 25241919]|[https://pubmed.ncbi.nlm.nih.gov/23404501 23404501]|[https://pubmed.ncbi.nlm.nih.gov/32452379 32452379]|[https://pubmed.ncbi.nlm.nih.gov/2960671 2960671]|[https://pubmed.ncbi.nlm.nih.gov/272643 272643]|[https://pubmed.ncbi.nlm.nih.gov/27711049 27711049]|[https://pubmed.ncbi.nlm.nih.gov/33202844 33202844]|[https://pubmed.ncbi.nlm.nih.gov/4060695 4060695]|[https://pubmed.ncbi.nlm.nih.gov/27638607 27638607]|[https://pubmed.ncbi.nlm.nih.gov/20547865 20547865]|[https://pubmed.ncbi.nlm.nih.gov/2277039 2277039]|[https://pubmed.ncbi.nlm.nih.gov/6238026 6238026]|[https://pubmed.ncbi.nlm.nih.gov/8448388 8448388]|[https://pubmed.ncbi.nlm.nih.gov/8489255 8489255]|[https://pubmed.ncbi.nlm.nih.gov/9363437 9363437]|[https://pubmed.ncbi.nlm.nih.gov/11836161 11836161]|[https://pubmed.ncbi.nlm.nih.gov/6892925 6892925]|[https://pubmed.ncbi.nlm.nih.gov/1551117 1551117]|[https://pubmed.ncbi.nlm.nih.gov/6811267 6811267]|[https://pubmed.ncbi.nlm.nih.gov/8059935 8059935]|[https://pubmed.ncbi.nlm.nih.gov/7861954 7861954]|[https://pubmed.ncbi.nlm.nih.gov/11283017 11283017]|[https://pubmed.ncbi.nlm.nih.gov/8514762 8514762]|[https://pubmed.ncbi.nlm.nih.gov/1291049 1291049]|[https://pubmed.ncbi.nlm.nih.gov/3805024 3805024]|[https://pubmed.ncbi.nlm.nih.gov/10816509 10816509]|[https://pubmed.ncbi.nlm.nih.gov/12393713 12393713]|[https://pubmed.ncbi.nlm.nih.gov/6417117 6417117]|[https://pubmed.ncbi.nlm.nih.gov/11054095 11054095]|[https://pubmed.ncbi.nlm.nih.gov/8781973 8781973]|[https://pubmed.ncbi.nlm.nih.gov/1692829 1692829] <br>
+ '''definition''' : A linear amino trisaccharide consisting of β-D-glucose at the reducing end having an N-acetyl-β-D-glucosaminyl-(1→3)-β-D-galactosyl group attached at the 4-position.[CHEBI:61758] <br>
+ '''term_xref''' : GTC:G06239NA|GlycoMotif:GGM.000067|MeSH:C025575|CID: 10230777|CHEBI:61758|SugarBind_Ligand:20<br>
+ '''synonyms''' : Lc3|Lc(3)Cer|Lc_3 <br>
+ '''function''' : acute myeloid leukemia-associated glycosphingolipids lactotriaosylceramide, GM3 and neolactotetraosylceramide are possibly involved in initiation and differentiation of acute myeloid leukemia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/22411838 22411838]] <br>
+ '''disease_associations''' : Pharyngitis[SugarBind_Ligand:20]|Tracheobronchitis[SugarBind_Ligand:20]|Gonorrhea[SugarBind_Ligand:20]|Actinomycosis[SugarBind_Ligand:20]|Diarrhea[SugarBind_Ligand:20] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000108===
-'''term (main_entry)''' : High mannose <br>
-'''glycan_dictionary_accession''' : GD000108 <br>
-'''glytoucan_accession ''' : G55220VL <br>
-'''term_in_sentence''' : Each glycoform contained a number of peaks differing by 162 Da indicating heterogeneity and suggesting the presence of high-mannose sugars.[PMID:11258925] <br>
-'''publication''' : 11258925|17956937|2059624|2065054|26791533|4077844|7780197|9136890|30659065|30075362|21421994|31076349|29738673|29508223|26747427|30634645|23007868|29051951|24549150|12417032|26724786|26956389|26493153|31102532|29673624|8348230|25586968|24975601|29803109|28465212|25776945|30151520|21097542|24326091|27995699|26003537|6722291|2925680|25565276|21460211|25196214|27387600|22373601|3729933|16423983|24174266|30605318 <br>
-'''definition''' : An N-linked oligosaccharide that possesses between five and nine mannose residues attached to the chitobiose [(GlcNAc)2] core. [CHEBI:5717] None of the Man residues are substituted with any monosaccharide other than Man . <br>
-'''term_xref''' : CID:70698382|CHEBI:71514 <br>
-'''best_match''' : GTC:G55220VL|CID:70698382|CHEBI:71514 <br>
-'''synonymns''' : oligomannose <br>
-'''function''' : Involved in promotion of protein folding in ER. [PMID:12417032].|High Man glycans are enriched at cell surface during apoptosis.[PMID: 17516205] <br>
-'''disease_associations''' : Relative abundance changes in multiple CDGs [PMID: 30770376][PMID: 28484880] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453033-Chapter 17 <br>
+===GSD000118===
+ '''term (main_entry)''' : LcGg4 <br>
+ '''glycan_dictionary_accession''' : GSD000118 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G62554JH G62554JH] <br>
+ '''term_in_sentence''' : Murine leukemia cells (M1), in their undifferentiated state, have been characterized by the presence of cancer-associated lactoganglio-series glycolipids, one of which was identified as lactogangliotetraosylceramide (LcGg4) having a novel branching at the II-Gal of lactosylceramide through GlcNAc beta 1----3 and GalNAc beta 1----4 linkage, as shown below (Kannagi, R., Levery, S.B., and Hakomori, S. (1984) J. Biol. Chem., 259, 8444-8451): GalNAc beta 1----4 Gal beta 1----4Glc beta 1----1Cer GlcNac beta 1----3 [PMID: [https://pubmed.ncbi.nlm.nih.gov/3805024 3805024]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3805024 3805024]|[https://pubmed.ncbi.nlm.nih.gov/33395290 33395290] <br>
+ '''definition''' : N-[(2S,3R,4R,5R,6R)-2-[(2R,3S,4R,5R,6S)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide is an oligosaccharide.[CHEBI:152521] <br>
+ '''term_xref''' : GlycoMotif:GGM.000075|GTC:G62554JH|CID:91850076|CHEBI:152521|GlycoEpitope:EP0035  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000109===
-'''term (main_entry)''' : HNK-1 <br>
-'''glycan_dictionary_accession''' : GD000109 <br>
-'''glytoucan_accession ''' : G54406UD <br>
-'''term_in_sentence''' : The human natural killer-1 (HNK-1) carbohydrate, a unique trisaccharide possessing sulfated glucuronic acid in a non-reducing terminus (HSO3-3GlcAß1-3Galß1-4GlcNAc-), is highly expressed in the nervous system and its spatiotemporal expression is strictly regulated.[PMID:28709864] <br>
-'''publication''' : 28709864|31738061|26738850|30306736|11070366|20855890|18024472|22669261|19729452|19796667|26850637|11769463|18263654|15843379|26659409|9003039|22087768|21771787|15173636|9210489|15258996|17924534|26382082|16171882|18802400|9800516|7504418|11891229|15232286|9013478|21621858|11677051|18668221|11414798|19265195|8982638|8798480|28403522|17935701|1691305|10998116|9364602|7528651|12472892|21176892|28416698|19389918|28427937|25450311 <br>
-'''definition''' : An amino trisaccharide consisting of a 3-O-sulfo-β-D-glucuronic acid residue, a D-galactosyl residue and an N-acetyl-D-glucosamine residue (at the reducing end) in a linear sequence.[CHEBI:60322] <br>
-'''term_xref''' : GlycoEpitope:EP0001|CID:46906103|CHEBI:60322|GGM.00058 <br>
-'''best_match''' : GTC:G54406UD |GlycoEpitope:EP0001|CID:46906103|CHEBI:60322 <br>
-'''synonymns''' : HNK-1 carbohydrate epitope| CD57|HNK-1 antigen <br>
-'''function''' : learning and memory[GlycoEpitope:EP0001]|neural crest cell migration[GlycoEpitope:EP0001]|neurite extension[GlycoEpitope:EP0001]|neuron-astrocyte adhesion[GlycoEpitope:EP0001] <br>
-'''disease_associations''' : schizophrenia-like psychosis[GlycoEpitope:EP0001]|neuropathy[GlycoEpitope:EP0001]|exfoliation syndrome[GlycoEpitope:EP0001]|secondary cataract[GlycoEpitope:EP0001] <br>
-'''wikipedia''' : https://en.wikipedia.org/wiki/N-linked_glycosylation <br>
-'''essentials_of_glycobiology''' : NBK453033-Chapter 17 <br>
+===GSD000119===
+ '''term (main_entry)''' : Lewis a <br>
+ '''glycan_dictionary_accession''' : GSD000119 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00047MO G00047MO] <br>
+ '''term_in_sentence''' : Regardless of the vaccine administered, significantly fewer of the children with Lewis A phenotype (0/14) seroconverted after receiving the first vaccine dose compared to 26% (45/175) of those with the Lewis B phenotype and 32% (15/47) of the Lewis negative individuals (P < 0.01). [PMID:[https://pubmed.ncbi.nlm.nih.gov/29367698 29367698]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29367698 29367698]|[https://pubmed.ncbi.nlm.nih.gov/27187324 27187324]|[https://pubmed.ncbi.nlm.nih.gov/30562693 30562693]|[https://pubmed.ncbi.nlm.nih.gov/27646625 27646625]| [https://pubmed.ncbi.nlm.nih.gov/26911286 26911286]|[https://pubmed.ncbi.nlm.nih.gov/30225822 30225822]|[https://pubmed.ncbi.nlm.nih.gov/28600306 28600306]|[https://pubmed.ncbi.nlm.nih.gov/32527016 32527016]| [https://pubmed.ncbi.nlm.nih.gov/2385097 2385097]|[https://pubmed.ncbi.nlm.nih.gov/11064310 11064310]|[https://pubmed.ncbi.nlm.nih.gov/23809433 23809433]|[https://pubmed.ncbi.nlm.nih.gov/30050155 30050155]|[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]| [https://pubmed.ncbi.nlm.nih.gov/29527514 29527514]| [https://pubmed.ncbi.nlm.nih.gov/9207264 9207264]|[https://pubmed.ncbi.nlm.nih.gov/1675497 1675497]| [https://pubmed.ncbi.nlm.nih.gov/3677023 3677023]|[https://pubmed.ncbi.nlm.nih.gov/27705835 27705835]|[https://pubmed.ncbi.nlm.nih.gov/7593252 7593252]| [https://pubmed.ncbi.nlm.nih.gov/2579997 2579997]|[https://pubmed.ncbi.nlm.nih.gov/17630273 17630273]|[https://pubmed.ncbi.nlm.nih.gov/9350993 9350993]| [https://pubmed.ncbi.nlm.nih.gov/9098001 9098001] <br>
+ '''definition''' : A lewis blood group antigen with structure beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an alpha-linkage and a galactosyl residue attached at the 3-position via a beta-linkage. It has a role as an epitope and an antigen. It is an amino trisaccharide and a glucosamine oligosaccharide.[CHEBI:62265] <br>
+ '''term_xref''' : GTC:G00047MO|CID: 22806751|CHEBI:62265|GlycoMotif:GGM.000020|SugarBind_Ligand:155  <br>
+ '''synonyms''' : Le(a)|Lea-3|Lea|Le^a <br>
+ '''function''' :  <br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:155] <br>
+ '''wikipedia''' : https://www.wikidata.org/wiki/Q50687009 <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000110===
-'''term (main_entry)''' : Hybrid <br>
-'''glycan_dictionary_accession''' : GD000110 <br>
-'''glytoucan_accession ''' : G16828VN <br>
-'''term_in_sentence''' : A hybrid-type N-glycan was accessed by total synthesis, converted to an oxazoline, and used as a donor substrate with both wild type Endo M and an N175Q glycosynthase Endo M mutant allowing the convergent synthesis of a glycosylated amino acid bearing a hybrid N-glycan structure. [PMID:27058295] <br>
-'''publication''' : 27058295|15044398|28714086|29578688|26999365 <br>
-'''definition''' : An N-linked glycan in which the Manα1-6 arm of the trimannosyl core Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1–4GlcNAcβ1–Asn-X-Ser/Thr is substituted by one or more additional Man residues and the Manα1-3 arm is substituted by a GlcNAc residue added by GlcNAcT1. The GlcNAc linked to the a3 Man can be extended in the same manner as any complex glycan antenna. The trimannosyl core can also be core fucosylated and/or bisected by the addition of a GlcNAc to the 3 position of the α-linked Man residue.[NBK453020-Chapter 9] <br>
-'''term_xref''' : CID:91847108|CHEBI:147471 <br>
-'''best_match''' : GTC:G16828VN|CID:91847108|CHEBI:147471 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453020 <br>
+===GSD000120===
+[[File:G39211DH.png|thumb|G39211DH]]
+ '''term (main_entry)''' : Lewis b <br>
+ '''glycan_dictionary_accession''' : GSD000120 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G39211DH G39211DH] <br>
+ '''term_in_sentence''' : Human mannose-binding lectin preferentially binds to human colon adenocarcinoma cell lines expressing high amount of Lewis A and Lewis B antigens.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10328552 10328552]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10328552 10328552]|[https://pubmed.ncbi.nlm.nih.gov/23408949 23408949]|[https://pubmed.ncbi.nlm.nih.gov/31927399 31927399]|[https://pubmed.ncbi.nlm.nih.gov/26601230 26601230]|[https://pubmed.ncbi.nlm.nih.gov/28279343 28279343]|[https://pubmed.ncbi.nlm.nih.gov/32527016 32527016]|[https://pubmed.ncbi.nlm.nih.gov/30831115 30831115]|[https://pubmed.ncbi.nlm.nih.gov/27318698 27318698]|[https://pubmed.ncbi.nlm.nih.gov/9207264 9207264]|[https://pubmed.ncbi.nlm.nih.gov/23828675 23828675]|[https://pubmed.ncbi.nlm.nih.gov/29527514 29527514]|[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]| [https://pubmed.ncbi.nlm.nih.gov/2385097 2385097]|[https://pubmed.ncbi.nlm.nih.gov/2579997 2579997]|[https://pubmed.ncbi.nlm.nih.gov/25516619 25516619]| [https://pubmed.ncbi.nlm.nih.gov/3677023 3677023]|[https://pubmed.ncbi.nlm.nih.gov/8509439 8509439]|[https://pubmed.ncbi.nlm.nih.gov/19832116 19832116]|[https://pubmed.ncbi.nlm.nih.gov/15270746 15270746]|[https://pubmed.ncbi.nlm.nih.gov/3166398 3166398]|[https://pubmed.ncbi.nlm.nih.gov/30909206 30909206]|[https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]|[https://pubmed.ncbi.nlm.nih.gov/18400963 18400963]| [https://pubmed.ncbi.nlm.nih.gov/29751628 29751628]|[https://pubmed.ncbi.nlm.nih.gov/8982241 8982241]|[https://pubmed.ncbi.nlm.nih.gov/30284922 30284922]|[https://pubmed.ncbi.nlm.nih.gov/24576035 24576035]|[https://pubmed.ncbi.nlm.nih.gov/30974776 30974776]| [https://pubmed.ncbi.nlm.nih.gov/9098001 9098001]|[https://pubmed.ncbi.nlm.nih.gov/31768613 31768613]|[https://pubmed.ncbi.nlm.nih.gov/1651804 1651804]|[https://pubmed.ncbi.nlm.nih.gov/25428879 25428879]|[https://pubmed.ncbi.nlm.nih.gov/15946883 15946883]| [https://pubmed.ncbi.nlm.nih.gov/30298790 30298790]|[https://pubmed.ncbi.nlm.nih.gov/30544260 30544260]|[https://pubmed.ncbi.nlm.nih.gov/29197783 29197783]|[https://pubmed.ncbi.nlm.nih.gov/8632739 8632739]|[https://pubmed.ncbi.nlm.nih.gov/7679772 7679772]|[https://pubmed.ncbi.nlm.nih.gov/18666312 18666312]|[https://pubmed.ncbi.nlm.nih.gov/20231766 20231766]|[https://pubmed.ncbi.nlm.nih.gov/29922666 29922666]|95124|[https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]|[https://pubmed.ncbi.nlm.nih.gov/21519121 21519121]|[https://pubmed.ncbi.nlm.nih.gov/25153235 25153235]|[https://pubmed.ncbi.nlm.nih.gov/28751211 28751211] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000021|SugarBind_Ligand:146|GTC:G39211DH|CID:45480568|CHEBI:59440 <br>
+ '''synonyms''' : Le(b)|Lewis(b)|Le^b <br>
+ '''function''' : possible receptor for Helicobacter pylori[https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/blood-group-lewis-system<nowiki>] </nowiki><br>
+ '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:146] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000111===
-'''term (main_entry)''' : i antigen <br>
-'''glycan_dictionary_accession''' : GD000111 <br>
-'''glytoucan_accession ''' : G00058MO|G46055MA <br>
-'''term_in_sentence''' : Inasmuch as the hybridoma was established by hybridization of lymphocytes derived from regional lymph nodes of lung cancer, and the antigen was found in the patient's lung cancer tissue, the i antigen in lung cancer is probably recognized as a tumor-associated antigen by the host's immune cell system.[PMID:2422274] <br>
-'''publication''' : 2422274|15679458|21912254|12468428|28508465|6203982|30728302|8449405|9122902|10360315|6159787|6183759|518539|6715951|21933024 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000004|GlycoMotif:GGM.000002 <br>
-'''best_match''' : GlycoMotif:GGM.000004|GlycoMotif:GGM.000002|GTC:G46055MA|GTC:G00058MO <br>
-'''synonymns''' : Type 2 LN2 <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000121===
+ '''term (main_entry)''' : Lewis x <br>
+ '''glycan_dictionary_accession''' : GSD000121 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00051MO G00051MO] <br>
+ '''term_in_sentence''' : In particular, the observation of oxonium ions at m/z 512.2 and 803.2 is useful for probing outer non-reducing terminal fucosylation, which represented carbohydrate structures consisting of Hex Hex , dHex Hex , and HexNAc , and NeuNAc , Hex Hex , dHex Hex , and HexNAc , respectively, from which the Lewis X structure (Galbeta1-4(Fucalpha1-3)GlcNAc) was readily deduced.[PMID:[https://pubmed.ncbi.nlm.nih.gov/15536627 15536627]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15536627 15536627]|[https://pubmed.ncbi.nlm.nih.gov/31666308 31666308]|[https://pubmed.ncbi.nlm.nih.gov/29019053 29019053]|[https://pubmed.ncbi.nlm.nih.gov/28296340 28296340]|[https://pubmed.ncbi.nlm.nih.gov/29593094 29593094]|[https://pubmed.ncbi.nlm.nih.gov/17607374 17607374]|[https://pubmed.ncbi.nlm.nih.gov/16581086 16581086]|[https://pubmed.ncbi.nlm.nih.gov/20858014 20858014]|[https://pubmed.ncbi.nlm.nih.gov/19962782 19962782]|[https://pubmed.ncbi.nlm.nih.gov/7912739 7912739]|[https://pubmed.ncbi.nlm.nih.gov/25121780 25121780]|[https://pubmed.ncbi.nlm.nih.gov/24059473 24059473]|[https://pubmed.ncbi.nlm.nih.gov/29210428 29210428]|[https://pubmed.ncbi.nlm.nih.gov/31276881 31276881]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/7628844 7628844]|[https://pubmed.ncbi.nlm.nih.gov/7499837 7499837]|[https://pubmed.ncbi.nlm.nih.gov/16850248 16850248]|[https://pubmed.ncbi.nlm.nih.gov/28425129 28425129]|[https://pubmed.ncbi.nlm.nih.gov/28869691 28869691]|[https://pubmed.ncbi.nlm.nih.gov/19576189 19576189]| [https://pubmed.ncbi.nlm.nih.gov/10223649 10223649]|[https://pubmed.ncbi.nlm.nih.gov/22593503 22593503]|[https://pubmed.ncbi.nlm.nih.gov/15632313 15632313]|[https://pubmed.ncbi.nlm.nih.gov/27198630 27198630]|[https://pubmed.ncbi.nlm.nih.gov/26582608 26582608]|[https://pubmed.ncbi.nlm.nih.gov/11500392 11500392]|[https://pubmed.ncbi.nlm.nih.gov/31256373 31256373]|[https://pubmed.ncbi.nlm.nih.gov/23399157 23399157]|[https://pubmed.ncbi.nlm.nih.gov/21984435 21984435]|[https://pubmed.ncbi.nlm.nih.gov/26244810 26244810]|[https://pubmed.ncbi.nlm.nih.gov/26162743 26162743]|[https://pubmed.ncbi.nlm.nih.gov/17335083 17335083]|[https://pubmed.ncbi.nlm.nih.gov/15388363 15388363]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/10760152 10760152]|[https://pubmed.ncbi.nlm.nih.gov/11267844 11267844]|[https://pubmed.ncbi.nlm.nih.gov/20876654 20876654]|[https://pubmed.ncbi.nlm.nih.gov/12131290 12131290] <br>
+ '''definition''' : A Lewis blood group antigen with structure α-L-Fucp-(1→3)-[β-D-Galp-(1→4)]-D-GlcpNAc where the glucosamine at the reducing end has β-configuration at its anomeric centre. Commonly known as Lewis x trisaccharide or Lex.[CHEBI:59294] <br>
+ '''term_xref''' : GTC:G00051MO |GlycoEpitope:EP0011|CID:44611539|CHEBI:59294|GlycoMotif:GGM.000018 <br>
+ '''synonyms''' : Lex|Galbeta1-4(Fucalpha1-3)GlcNAc|Lewis x trisaccharide|Le(X)|Le^x|SSEA-1 <br>
+ '''function''' : Involved in carbohydrate-carbohydrate interaction[Glycoepitope:EP0011].|Also implicated in apoptosis.[Glycoepitope:EP0011]|influence antigenic presentation and interfere with pathogen transfer in breastfed infants.[Glycoepitope:EP0011] <br>
+ '''disease_associations''' : acute leukemia[GlycoEpitope:EP0011]|lymphoma[GlycoEpitope:EP0011] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000112===
-'''term (main_entry)''' : I antigen <br>
-'''glycan_dictionary_accession''' : GD000112 <br>
-'''glytoucan_accession ''' : G56045WU <br>
-'''term_in_sentence''' : The I antigen is formed by the action of an enzyme (a glycosyltransferase), which adds branches onto the i antigen.[PMID:15679458] <br>
-'''publication''' : 15679458|21912254|30705292|33403394|6715951|12468428|6088627|6159787 <br>
-'''definition''' : N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S,6R)-4-[(2R,3R,4R,5S,6R)-3-Acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[[(2R,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide (CHEBI:151390) is a amino sugar.[CHEBI:151390] <br>
-'''term_xref''' : GlycoMotif:GGM.000003|GlycoEpitope:EP0138|CID:91852915|CHEBI:151390 <br>
-'''best_match''' : GlycoMotif:GGM.000003|GlycoEpitope:EP0138|GTC:G56045WU|CID:91852915|CHEBI:151390 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453020-Chapter 9 <br>
+===GSD000122===
+[[File:G00052MO.png|alt=|thumb|G00052MO]]
+ '''term (main_entry)''' : Lewis y <br>
+ '''glycan_dictionary_accession''' : GSD000122 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00052MO G00052MO] <br>
+ '''term_in_sentence''' : In conclusion, Lewis y antigen and CD147 were significantly upregulated in ovarian tumors, and the altered expression of Lewis y may cause changes in CD147.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30816446 30816446]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30816446 30816446]|[https://pubmed.ncbi.nlm.nih.gov/20003467 20003467]|[https://pubmed.ncbi.nlm.nih.gov/24692145 24692145]| [https://pubmed.ncbi.nlm.nih.gov/24998328 24998328]| [https://pubmed.ncbi.nlm.nih.gov/25726913 25726913]|[https://pubmed.ncbi.nlm.nih.gov/29299130 29299130]|[https://pubmed.ncbi.nlm.nih.gov/30816446 30816446]|[https://pubmed.ncbi.nlm.nih.gov/20003467 20003467]| [https://pubmed.ncbi.nlm.nih.gov/24692145 24692145]| [https://pubmed.ncbi.nlm.nih.gov/24998328 24998328]|[https://pubmed.ncbi.nlm.nih.gov/20127027 20127027]|[https://pubmed.ncbi.nlm.nih.gov/22138668 22138668]|[https://pubmed.ncbi.nlm.nih.gov/23894390 23894390]|[https://pubmed.ncbi.nlm.nih.gov/25726913 25726913]|[https://pubmed.ncbi.nlm.nih.gov/25416440 25416440]|[https://pubmed.ncbi.nlm.nih.gov/27646625 27646625]|[https://pubmed.ncbi.nlm.nih.gov/23725446 23725446]|[https://pubmed.ncbi.nlm.nih.gov/21294926 21294926]|[https://pubmed.ncbi.nlm.nih.gov/22312289 22312289]|[https://pubmed.ncbi.nlm.nih.gov/25973320 25973320]|[https://pubmed.ncbi.nlm.nih.gov/23242548 23242548]|[https://pubmed.ncbi.nlm.nih.gov/30328452 30328452]|[https://pubmed.ncbi.nlm.nih.gov/21119363 21119363]|[https://pubmed.ncbi.nlm.nih.gov/29130097 29130097]|[https://pubmed.ncbi.nlm.nih.gov/23443083 23443083]|[https://pubmed.ncbi.nlm.nih.gov/23708102 23708102]|[https://pubmed.ncbi.nlm.nih.gov/28671040 28671040]|[https://pubmed.ncbi.nlm.nih.gov/19715603 19715603]|[https://pubmed.ncbi.nlm.nih.gov/23468946 23468946]|[https://pubmed.ncbi.nlm.nih.gov/27723168 27723168]|[https://pubmed.ncbi.nlm.nih.gov/21747684 21747684]|[https://pubmed.ncbi.nlm.nih.gov/19771739 19771739] <br>
+ '''definition''' : A Lewis blood group antigen which is a branched amino tetrasaccharide with structure alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc, consisting of consisting of N-acetyl-beta-D-glucosamine at the reducing end having an alpha-L-fucosyl residue attached at the 3-position and an alpha-L-fucosyl-(1→2)-beta-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure. It has a role as an antigen and an epitope. [CHEBI:59045] <br>
+ '''term_xref''' : GTC:G00052MO|GlycoEpitope:EP0018|CID: 45266908|CHEBI:59045|GlycoMotif:GGM.000019  <br>
+ '''synonyms''' : LeY|Le(y)|Ley|Le^y <br>
+ '''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
+ '''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000113===
-'''term (main_entry)''' : Isoglobotetraosylceramide <br>
-'''glycan_dictionary_accession''' : GD000113 <br>
-'''glytoucan_accession ''' : G57710SU <br>
-'''term_in_sentence''' : Furthermore, isoglobotetraosylceramide seems to play a direct role in the metastatic process since the blocking of exposed antigen with monoclonal antibodies, or their Fab fragments, results in a highly significant decrease in lung colony formation.[PMID:8504431] <br>
-'''publication''' : 1396705|8504431|2713378|3489485|18997175|7053385|3379797|2465279|3743633|11479210 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000071|CID:91849719|KEGG:G03211|CHEBI:148232|SugarBind_Ligand:17 <br>
-'''best_match''' : GlycoMotif:GGM.000071|GTC:G57710SU|CID:91849719|KEGG:G03211|CHEBI:148232|SugarBind_Ligand:17 <br>
-'''synonymns''' :  <br>
-'''function''' : a marker for highly metastatic cells in rat mammary adenocarcinomas[PMID:8504431] <br>
-'''disease_associations''' : Actinomycosis[SugarBind_Ligand:17] <br>
-'''wikipedia''' : https://en.wikipedia.org/wiki/Ii_antigen_system <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000123===
+ '''term (main_entry)''' : Monosialylated <br>
+ '''glycan_dictionary_accession''' : GSD000123 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The structures of the asparagine-linked sugar chains of U- CD59 were biantennary complex type , only 4.2% of which are monosialylated.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7514386 7514386]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7514386 7514386]|[https://pubmed.ncbi.nlm.nih.gov/8477709 8477709]|[https://pubmed.ncbi.nlm.nih.gov/8942648 8942648]|[https://pubmed.ncbi.nlm.nih.gov/29752599 29752599]|[https://pubmed.ncbi.nlm.nih.gov/31669586 31669586]|[https://pubmed.ncbi.nlm.nih.gov/29747818 29747818]|[https://pubmed.ncbi.nlm.nih.gov/16425369 16425369]|[https://pubmed.ncbi.nlm.nih.gov/12089170 12089170]|[https://pubmed.ncbi.nlm.nih.gov/31390883 31390883]|[https://pubmed.ncbi.nlm.nih.gov/1632647 1632647]|[https://pubmed.ncbi.nlm.nih.gov/29733234 29733234]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/30555678 30555678]|[https://pubmed.ncbi.nlm.nih.gov/28263871 28263871]|[https://pubmed.ncbi.nlm.nih.gov/29652662 29652662]|[https://pubmed.ncbi.nlm.nih.gov/25915761 25915761]|[https://pubmed.ncbi.nlm.nih.gov/16381065 16381065]|[https://pubmed.ncbi.nlm.nih.gov/29247593 29247593]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/23896595 23896595]|[https://pubmed.ncbi.nlm.nih.gov/26633899 26633899]|[https://pubmed.ncbi.nlm.nih.gov/32155999 32155999]|[https://pubmed.ncbi.nlm.nih.gov/25261856 25261856]|[https://pubmed.ncbi.nlm.nih.gov/2737211 2737211]|[https://pubmed.ncbi.nlm.nih.gov/26945091 26945091]|[https://pubmed.ncbi.nlm.nih.gov/27065039 27065039]|[https://pubmed.ncbi.nlm.nih.gov/26784838 26784838]|[https://pubmed.ncbi.nlm.nih.gov/26582205 26582205] <br>
+ '''definition''' : A glycan that have the addition of one sialic acid residues. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' : appears in bovine brain gangliosides.[PMID: [https://pubmed.ncbi.nlm.nih.gov/29752599 29752599]] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000114===
-'''term (main_entry)''' : Keratan sulfate <br>
-'''glycan_dictionary_accession''' : GD000114 <br>
-'''glytoucan_accession ''' :  G82109MW <br>
-'''term_in_sentence''' : Compared to the other classes of glycosaminoglycans (GAGs), that is, chondroitin/dermatan sulfate, heparin/heparan sulfate and hyaluronan, keratan sulfate (KS), have the least known of its interactive properties.[PMID: 30578672] <br>
-'''publication''' : 29340594|30578672|12512857|29625490|25325967|30025865|29924315|9549787|11030741|28078490|8298243|29096187|30059256|26958998|26773479|22840010|15597951|28110685|28535934|2942429|18234072|8641829|8940154|2027120|30849116|41589|6238957|1907283|7722002|29275050|24274541|2527236|1731862|8991509|24291704|10517185|6451953|7688312|8663590|139406|25770829|25036480|9275006|25179279|32627425|26903438|27941632|12807022|32266652|21624346 <br>
-'''definition''' : A sulfated glycosaminoglycan, a linear polymer that consists of the repeating disaccharide [3)-β-Gal-(1→4)-β-GlcNAc-(1→] and containing sulfo groups located at random positions.[CHEBI:60924] <br>
-'''term_xref''' : CHEBI:60924|CID:446715|GlycoEpitope:EP0085 <br>
-'''best_match''' : CHEBI:60924|CID:446715|GlycoEpitope: EP0085|GTC: G82109MW <br>
-'''synonymns''' : keratan| Kerato sulphate|Kerato sulfate|Keratan sulphate|kerato 6'-sulfate|keratan 6'-sulfate|Kerato 6'-sulphate|Keratan 6'-sulphate <br>
-'''function''' : Tissue hydration.[PMID: 11030741] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000124===
+ '''term (main_entry)''' : Monosialyl-biantennary <br>
+ '''glycan_dictionary_accession''' : GSD000124 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : In contrast, the sugar chain structure of HCC highly specific AFP isoform was found to comprise a monosialyl-biantennary sugar chain with additional fucosylation of the proximal N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7686446 7686446]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7686446 7686446]|[https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]|[https://pubmed.ncbi.nlm.nih.gov/9648261 9648261]|[https://pubmed.ncbi.nlm.nih.gov/10460833 10460833]|[https://pubmed.ncbi.nlm.nih.gov/19524219 19524219]|[https://pubmed.ncbi.nlm.nih.gov/10207016 10207016]|[https://pubmed.ncbi.nlm.nih.gov/15797573 15797573]|[https://pubmed.ncbi.nlm.nih.gov/15218190 15218190] <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' : monosialyl biantennary|sialylated diantennary|sialylated biantennary <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000115===
-'''term (main_entry)''' : LacdiNac <br>
-'''glycan_dictionary_accession''' : GD000115 <br>
-'''glytoucan_accession ''' : G31736BK <br>
-'''term_in_sentence''' : We previously showed that the expression level of the LacdiNAc group in N-glycans decreases dramatically during the progression of human breast cancer.[PMID:25003135] <br>
-'''publication''' : 25003135|31711843|31145522|27601469|30669833|25210040|24633693|24755437|22653491|30898876|7758724|22474328|21305673|31558607|31271862|28549117|26213980|9134425|25561735|31756927|31170332|16282603|15265923|32267274|23015818|32676595|16728562|10814702|9591048|22245701|29751628|22997242|15535969|31911241|30622255|29888905|30236114|30298790|29373511|22298779|19179461|31606752|15653684|16403022|11162373|32005658|30529570 <br>
-'''definition''' : An amino disaccharide consisting of N-acetylglucosamine having an N-acetylgalactosaminyl resiude attached at the 4-position via a β-linkage.[CHEBI:61190] <br>
-'''term_xref''' : GlycoEpitope:P0150|CID:25257164|CHEBI:61190|GlycoMotif:GGM.000016 <br>
-'''best_match''' : GTC:G31736BK|GlycoEpitope:P0150|CID:25257164|CHEBI:61190|GlycoMotif:GGM.000016 <br>
-'''synonymns''' : LDN <br>
-'''function''' : Has a role of epitope.[CHEBI:61190] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000125===
+ '''term (main_entry)''' : Monosialyl-Gb5 <br>
+ '''glycan_dictionary_accession''' : GSD000125 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G32254QI G32254QI] <br>
+ '''term_in_sentence''' : Thus, malignancy of MCF-7 is highly dependent on monosialyl-Gb5, and its activation of cSrc and FAK in GEM.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]|[https://pubmed.ncbi.nlm.nih.gov/16995838 16995838]|[https://pubmed.ncbi.nlm.nih.gov/27318475 27318475] <br>
+ '''definition''' : alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp is a linear amino hexasaccharide comprising β-D-glucose at the reducing end with at the 4-position a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety, α(2→3)-sialylated at the terminal galactosyl residue.[CHEBI:62313] <br>
+ '''term_xref''' : GTC:G32254QI|GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID: 73427363|CHEBI:62313  <br>
+ '''synonyms''' : GL-7 globoseries ganglioside (SSEA-4)|Monosialyl Gb5|Sialosyl galactosyl globoside|GL-7 globoseries ganglioside|SSEA-4 <br>
+ '''function''' :  <br>
+ '''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0099] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000116===
-'''term (main_entry)''' : Lactosylceramide <br>
-'''glycan_dictionary_accession''' : GD000116 <br>
-'''glytoucan_accession ''' : G84224TW <br>
-'''term_in_sentence''' : In the 1970s, a neutral glycosphingolipid lactosylceramide (LacCer) was found to bind specifically to several kinds of microorganisms.[PMID:30175814] <br>
-'''publication''' : 30175814|26900161|30502090|29624959|28444900|25408340|31801289|29099167|25595946|32592089|27729551|24658420|25216636|25638276|9499377|17986153|8143857|23801329|18077097|32708181|15346887|19015977|18393821|25279740|21057870|11915327|25212460|23882130|11915329|8195125|8808768|3396945|22128256|6733104|24968752|32518749|30688114|7666005|8200356|24718572|6193809|25781947|12383912|26086247|30606995|12419803 <br>
-'''definition''' : Glycosphingolipids which contain as their polar head group a lactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in lactosylceramide beta-galactosidase, is the cause of lactosylceramidosis.[MeSH:D007790] <br>
-'''term_xref''' : MeSH:D007790|GlycoMotif:GGM.000064|GlycoEpitope:EP0078|SugarBind_Ligand:3 <br>
-'''best_match''' : GTC:G84224TW|MeSH:D007790|GlycoMotif:GGM.000064|GlycoEpitope:EP0078|SugarBind_Ligand:3 <br>
-'''synonymns''' : LacCer|Lc2|CDH <br>
-'''function''' : mammalian cell receptors for Neisseria gonorrhoeae recognized by Helicobacter pylori[GlycoEpitope:EP0078] <br>
-'''disease_associations''' : chronic gastritis[GlycoEpitope:EP0078,SugarBind_Ligand:3]|duodenal ulcers[GlycoEpitope:EP0078]|gastric adenocarcinoma[GlycoEpitope:EP0078,SugarBind_Ligand:3]|gastric ulcers[GlycoEpitope:EP0078]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Actinomycosis[SugarBind_Ligand:3]|Pertussis[SugarBind_Ligand:3]|Candidiasis[SugarBind_Ligand:3]|Cryptococcosis[SugarBind_Ligand:3]|Hemorrhagic colitis[SugarBind_Ligand:3]|Peptic ulcers[SugarBind_Ligand:3]|Histoplasmosis[SugarBind_Ligand:3]|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Gonorrhea[SugarBind_Ligand:3]|Sporotrichosis[SugarBind_Ligand:3]|Plague[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453033-Chapter 17 <br>
+===GSD000126===
+[[File:G80193TN.png|thumb|G80193TN]]
+ '''term (main_entry)''' : Mono-sulfated globopentaosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000126 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80193TN G80193TN] <br>
+ '''term_in_sentence''' : Mono-sulfated globopentaosylceramide from human kidney.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2777788 2777788]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2777788 2777788] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000072|GTC:G80193TN <br>
+ '''synonyms''' : Monosulfated globopentaosylceramide <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000117===
-'''term (main_entry)''' : Lactotriaosylceramide <br>
-'''glycan_dictionary_accession''' : GD000117 <br>
-'''glytoucan_accession ''' : G06239NA <br>
-'''term_in_sentence''' : The results showed that AML patients had higher expression of the GSL lactotriaosylceramide (Lc3), GM3 and neolactotetraosylceramide (nLc4) in their bone marrow than did the healthy donors (P < 0.05), especially the M1 subtype of AML.[PMID:22411838] <br>
-'''publication''' : 22411838|20693232|26104834|27435676|26405105|32340400|25241919|23404501|32452379|2960671|272643|27711049|33202844|4060695|27638607|20547865|2277039|6238026|8448388|8489255|9363437|11836161|6892925|1551117|6811267|8059935|7861954|11283017|8514762|1291049|3805024|10816509|12393713|6417117|11054095|8781973|1692829 <br>
-'''definition''' : A linear amino trisaccharide consisting of β-D-glucose at the reducing end having an N-acetyl-β-D-glucosaminyl-(1→3)-β-D-galactosyl group attached at the 4-position.[CHEBI:61758] <br>
-'''term_xref''' : GlycoMotif:GGM.000067|MeSH:C025575|CID:10230777|CHEBI:61758|SugarBind_Ligand:20 <br>
-'''best_match''' : GTC:G06239NA|GlycoMotif:GGM.000067|MeSH:C025575|CID:10230777|CHEBI:61758|SugarBind_Ligand:20 <br>
-'''synonymns''' : Lc3|Lc(3)Cer|Lc_3 <br>
-'''function''' : acute myeloid leukemia-associated glycosphingolipids lactotriaosylceramide, GM3 and neolactotetraosylceramide are possibly involved in initiation and differentiation of acute myeloid leukemia.[PMID:22411838] <br>
-'''disease_associations''' : Pharyngitis[SugarBind_Ligand:20]|Tracheobronchitis[SugarBind_Ligand:20]|Gonorrhea[SugarBind_Ligand:20]|Actinomycosis[SugarBind_Ligand:20]|Diarrhea[SugarBind_Ligand:20] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===GSD000127===
+ '''term (main_entry)''' : Mono-sulfated globotetraosylceramide <br>
+ '''glycan_dictionary_accession''' : GSD000127 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G05297EK G05297EK] <br>
+ '''term_in_sentence''' : Mono-sulfated globotetraosylceramide from human kidney.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2559078 2559078]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2559078 2559078] <br>
+ '''definition''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000073|GTC:G05297EK<br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000118===
-'''term (main_entry)''' : LcGg4 <br>
-'''glycan_dictionary_accession''' : GD000118 <br>
-'''glytoucan_accession ''' : G62554JH <br>
-'''term_in_sentence''' : Murine leukemia cells (M1), in their undifferentiated state, have been characterized by the presence of cancer-associated lactoganglio-series glycolipids, one of which was identified as lactogangliotetraosylceramide (LcGg4) having a novel branching at the II-Gal of lactosylceramide through GlcNAc beta 1----3 and GalNAc beta 1----4 linkage, as shown below (Kannagi, R., Levery, S.B., and Hakomori, S. (1984) J. Biol. Chem., 259, 8444-8451): GalNAc beta 1----4 Gal beta 1----4Glc beta 1----1Cer GlcNac beta 1----3 [PMID: 3805024] <br>
-'''publication''' : 3805024|33395290 <br>
-'''definition''' : N-[(2S,3R,4R,5R,6R)-2-[(2R,3S,4R,5R,6S)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide is an oligosaccharide.[CHEBI:152521] <br>
-'''term_xref''' : GlycoMotif:GGM.000075|CID:91850076|CHEBI:152521|GlycoEpitope:EP0035 <br>
-'''best_match''' : GlycoMotif:GGM.000075|GTC:G62554JH|CID:91850076|CHEBI:152521|GlycoEpitope:EP0035 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===GSD000128===
+ '''term (main_entry)''' : N-acetyl GM2 <br>
+ '''glycan_dictionary_accession''' : GSD000128 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79389NT G79389NT] <br>
+ '''term_in_sentence''' : The appearance of the N-acetyl GM2 antigen correlated well with the degree of differentiation of the cancer cells in patients with squamous cell carcinoma and adenocarcinoma of the lung.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]|[https://pubmed.ncbi.nlm.nih.gov/2153431 2153431]| [https://pubmed.ncbi.nlm.nih.gov/25673107 25673107] <br>
+ '''definition''' : beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp is a branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
+ '''term_xref''' : GTC:G79389NT|GlycoEpitope:EP0051|CID: 45266845|CHEBI:59220 <br>
+ '''synonyms''' :  <br>
+ '''function''' : The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.[CHEBI:59220] <br>
+ '''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000119===
-'''term (main_entry)''' : Lewis a <br>
-'''glycan_dictionary_accession''' : GD000119 <br>
-'''glytoucan_accession ''' : G00047MO <br>
-'''term_in_sentence''' : Regardless of the vaccine administered, significantly fewer of the children with Lewis A phenotype (0/14) seroconverted after receiving the first vaccine dose compared to 26% (45/175) of those with the Lewis B phenotype and 32% (15/47) of the Lewis negative individuals (P < 0.01). [PMID:29367698] <br>
-'''publication''' : 29367698|27187324|30562693|27646625|26911286|30225822|28600306|32527016|2385097|11064310|23809433|30050155|1615929|29527514|9207264|1675497|3677023|27705835|7593252|2579997|17630273|9350993|9098001 <br>
-'''definition''' : A lewis blood group antigen with structure beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an alpha-linkage and a galactosyl residue attached at the 3-position via a beta-linkage. It has a role as an epitope and an antigen. It is an amino trisaccharide and a glucosamine oligosaccharide.[CHEBI:62265] <br>
-'''term_xref''' : CID:22806751|CHEBI:62265|GlycoMotif:GGM.000020|SugarBind_Ligand:155 <br>
-'''best_match''' : GTC:G00047MO|CID:22806751|CHEBI:62265|GlycoMotif:GGM.000020|SugarBind_Ligand:155 <br>
-'''synonymns''' : Le(a)|Lea-3|Lea|Le^a <br>
-'''function''' :  <br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:155] <br>
-'''wikipedia''' : https://www.wikidata.org/wiki/Q50687009 <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000129===
+ '''term (main_entry)''' : N-acetyllactosamine (Type 2)<br>
+ '''glycan_dictionary_accession''' : GSD000129 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00055MO G00055MO] <br>
+ '''term_in_sentence''' : Utilising a fast and sensitive screening method based on imidazolium-tagged probes, we report unprecedented reversible activity of bacterial beta1,4-galactosyltransferases to catalyse the transgalactosylation from lactose to N-acetylglucosamine to form N-acetyllactosamine in the presence of UDP.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31165848 31165848]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31165848 31165848]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]|[https://pubmed.ncbi.nlm.nih.gov/6236210 6236210]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29740087 29740087]|[https://pubmed.ncbi.nlm.nih.gov/9151975 9151975]|[https://pubmed.ncbi.nlm.nih.gov/10567443 10567443]|[https://pubmed.ncbi.nlm.nih.gov/21472942 21472942]|[https://pubmed.ncbi.nlm.nih.gov/26477523 26477523]|[https://pubmed.ncbi.nlm.nih.gov/6548353 6548353]|[https://pubmed.ncbi.nlm.nih.gov/28167527 28167527]|[https://pubmed.ncbi.nlm.nih.gov/20056550 20056550]|[https://pubmed.ncbi.nlm.nih.gov/7737204 7737204]|[https://pubmed.ncbi.nlm.nih.gov/22052010 22052010]| [https://pubmed.ncbi.nlm.nih.gov/10223649 10223649]|[https://pubmed.ncbi.nlm.nih.gov/11323440 11323440]|[https://pubmed.ncbi.nlm.nih.gov/10420596 10420596]|[https://pubmed.ncbi.nlm.nih.gov/7766648 7766648]|[https://pubmed.ncbi.nlm.nih.gov/25257940 25257940]|[https://pubmed.ncbi.nlm.nih.gov/17977857 17977857]|[https://pubmed.ncbi.nlm.nih.gov/15556936 15556936]|[https://pubmed.ncbi.nlm.nih.gov/26541999 26541999]|[https://pubmed.ncbi.nlm.nih.gov/23650594 23650594]|[https://pubmed.ncbi.nlm.nih.gov/9692202 9692202]|[https://pubmed.ncbi.nlm.nih.gov/29429899 29429899]|[https://pubmed.ncbi.nlm.nih.gov/21062783 21062783]|[https://pubmed.ncbi.nlm.nih.gov/25034434 25034434]|[https://pubmed.ncbi.nlm.nih.gov/8985145 8985145]|[https://pubmed.ncbi.nlm.nih.gov/28503789 28503789]|[https://pubmed.ncbi.nlm.nih.gov/8720464 8720464]/ <br>
+ '''definition''' : N-acetyllactosamine is a beta-D-galactopyranosyl-(1→4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. It is also known as galb1-4glcnacb or lacnac, belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group. N-Acetyllactosamine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Acetyllactosamine exists in all living organisms, ranging from bacteria to humans.[CHEBI:16153,HMDB0001542] <br>
+ '''term_xref''' : GTC:G00055MO|CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001  <br>
+ '''synonyms''' : LacNAc|Type 2 LN <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000120===
-'''term (main_entry)''' : Lewis b <br>
-'''glycan_dictionary_accession''' : GD000120 <br>
-'''glytoucan_accession ''' : G39211DH <br>
-'''term_in_sentence''' : Human mannose-binding lectin preferentially binds to human colon adenocarcinoma cell lines expressing high amount of Lewis A and Lewis B antigens.[PMID:10328552] <br>
-'''publication''' : 10328552|23408949|31927399|26601230|28279343|32527016|30831115|27318698|9207264|23828675|29527514|1615929|2385097|2579997|25516619|3677023|8509439|19832116|15270746|3166398|30909206|7718581|18400963|29751628|8982241|30284922|24576035|30974776|9098001|31768613|1651804|25428879|15946883|30298790|30544260|29197783|8632739|7679772|18666312|20231766|29922666|95124|2247887|21519121|25153235|28751211 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000021|SugarBind_Ligand:146|CID:45480568|CHEBI:59440 <br>
-'''best_match''' : GlycoMotif:GGM.000021|SugarBind_Ligand:146|GTC:G39211DH|CID:45480568|CHEBI:59440 <br>
-'''synonymns''' : Le(b)|Lewis(b)|Le^b <br>
-'''function''' : possible receptor for Helicobacter pylori[https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/blood-group-lewis-system] <br>
-'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:146] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000130===
+ '''term (main_entry)''' : N-Glycolyl-GM2 <br>
+ '''glycan_dictionary_accession''' : GSD000130 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56478LD G56478LD] <br>
+ '''term_in_sentence''' : The monoclonal antibodies MK2-34 and MK1-16 (both IgM), which specifically detect N-glycolyl GM2 and N-acetyl GM2, respectively, were generated by immunizing mice with liposomes containing monophosphoryl lipid A, trehalose dimycolate, and the antigenic ganglioside.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]|[https://pubmed.ncbi.nlm.nih.gov/11861662 11861662]|[https://pubmed.ncbi.nlm.nih.gov/17980710 17980710]|[https://pubmed.ncbi.nlm.nih.gov/3731079 3731079]|[https://pubmed.ncbi.nlm.nih.gov/25673107 25673107] <br>
+ '''definition''' : (2S,4S,5R,6R)-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of carbohydrates and carbohydrate derivatives.[CHEBI:151464] <br>
+ '''term_xref''' : GTC:G56478LD |GlycoEpitope:EP0052|CID: 91845742|CHEBI:151464|GlycoEpitope:GGM.000096  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' : choriocarcinoma[GlycoEpitope:EP0052]|teratocarcinoma|[GlycoEpitope:EP0052]yolk sac tumor[GlycoEpitope:EP0052] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000121===
-'''term (main_entry)''' : Lewis x <br>
-'''glycan_dictionary_accession''' : GD000121 <br>
-'''glytoucan_accession ''' : G00051MO <br>
-'''term_in_sentence''' : In particular, the observation of oxonium ions at m/z 512.2 and 803.2 is useful for probing outer non-reducing terminal fucosylation, which represented carbohydrate structures consisting of Hex Hex , dHex Hex , and HexNAc , and NeuNAc , Hex Hex , dHex Hex , and HexNAc , respectively, from which the Lewis X structure (Galbeta1-4(Fucalpha1-3)GlcNAc) was readily deduced.[PMID:15536627] <br>
-'''publication''' : 15536627|31666308|29019053|28296340|29593094|17607374|16581086|20858014|19962782|7912739|25121780|24059473|29210428|31276881|9015359|7628844|7499837|16850248|28425129|28869691|19576189|10223649|22593503|15632313|27198630|26582608|11500392|31256373|23399157|21984435|26244810|26162743|17335083|15388363|9556613|10760152|11267844|20876654|12131290 <br>
-'''definition''' : A Lewis blood group antigen with structure α-L-Fucp-(1→3)-[β-D-Galp-(1→4)]-D-GlcpNAc where the glucosamine at the reducing end has β-configuration at its anomeric centre. Commonly known as Lewis x trisaccharide or Lex.[CHEBI:59294] <br>
-'''term_xref''' : GlycoEpitope:EP0011|CID:44611539|CHEBI:59294|GlycoMotif:GGM.000018 <br>
-'''best_match''' : GTC:G00051MO |GlycoEpitope:EP0011|CID:44611539|CHEBI:59294|GlycoMotif:GGM.000018 <br>
-'''synonymns''' : Lex|Galbeta1-4(Fucalpha1-3)GlcNAc|Lewis x trisaccharide|Le(X)|Le^x|SSEA-1 <br>
-'''function''' : Involved in carbohydrate-carbohydrate interaction[Glycoepitope:EP0011].|Also implicated in apoptosis.[Glycoepitope:EP0011]|influence antigenic presentation and interfere with pathogen transfer in breastfed infants.[Glycoepitope:EP0011] <br>
-'''disease_associations''' : acute leukemia[GlycoEpitope:EP0011]|lymphoma[GlycoEpitope:EP0011] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===GSD000131===
+ '''term (main_entry)''' : N-linked glycans <br>
+ '''glycan_dictionary_accession''' : GSD000131 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
+ '''term_in_sentence''' : Our study identifies extracellular N-linked glycans-and the glycoprotein neurexin 1β specifically-as key modulators of neuronal uptake of αSacetyl, drawing attention to the potential therapeutic value of αSacetyl-glycan interactions.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]|[https://pubmed.ncbi.nlm.nih.gov/28384382 28384382]|[https://pubmed.ncbi.nlm.nih.gov/30305477 30305477]|[https://pubmed.ncbi.nlm.nih.gov/31364612 31364612]|[https://pubmed.ncbi.nlm.nih.gov/26899268 26899268]|[https://pubmed.ncbi.nlm.nih.gov/29945790 29945790]|[https://pubmed.ncbi.nlm.nih.gov/29652253 29652253]|[https://pubmed.ncbi.nlm.nih.gov/29723274 29723274]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/29778448 29778448]|[https://pubmed.ncbi.nlm.nih.gov/25325701 25325701]|[https://pubmed.ncbi.nlm.nih.gov/31100702 31100702]|[https://pubmed.ncbi.nlm.nih.gov/28898525 28898525]|[https://pubmed.ncbi.nlm.nih.gov/22944671 22944671]|[https://pubmed.ncbi.nlm.nih.gov/19277537 19277537]|[https://pubmed.ncbi.nlm.nih.gov/24473128 24473128]|[https://pubmed.ncbi.nlm.nih.gov/17957771 17957771]|[https://pubmed.ncbi.nlm.nih.gov/27554083 27554083]|[https://pubmed.ncbi.nlm.nih.gov/15189166 15189166]|[https://pubmed.ncbi.nlm.nih.gov/11269317 11269317]|[https://pubmed.ncbi.nlm.nih.gov/19577919 19577919]|[https://pubmed.ncbi.nlm.nih.gov/24303005 24303005]|[https://pubmed.ncbi.nlm.nih.gov/12042249 12042249]|[https://pubmed.ncbi.nlm.nih.gov/22191536 22191536]|[https://pubmed.ncbi.nlm.nih.gov/28324664 28324664]|[https://pubmed.ncbi.nlm.nih.gov/25965797 25965797]|[https://pubmed.ncbi.nlm.nih.gov/25434632 25434632]|[https://pubmed.ncbi.nlm.nih.gov/30484244 30484244]|[https://pubmed.ncbi.nlm.nih.gov/28110657 28110657]|[https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/27346875 27346875]|[https://pubmed.ncbi.nlm.nih.gov/30280442 30280442]|[https://pubmed.ncbi.nlm.nih.gov/26911286 26911286]|[https://pubmed.ncbi.nlm.nih.gov/22491358 22491358]|[https://pubmed.ncbi.nlm.nih.gov/26582281 26582281]|[https://pubmed.ncbi.nlm.nih.gov/26398792 26398792]|[https://pubmed.ncbi.nlm.nih.gov/31548313 31548313]|[https://pubmed.ncbi.nlm.nih.gov/31066275 31066275]|[https://pubmed.ncbi.nlm.nih.gov/28331984 28331984]|[https://pubmed.ncbi.nlm.nih.gov/25482090 25482090]|[https://pubmed.ncbi.nlm.nih.gov/28518173 28518173]|[https://pubmed.ncbi.nlm.nih.gov/30733536 30733536]|[https://pubmed.ncbi.nlm.nih.gov/22326428 22326428]|[https://pubmed.ncbi.nlm.nih.gov/30063825 30063825]|[https://pubmed.ncbi.nlm.nih.gov/30315103 30315103]|[https://pubmed.ncbi.nlm.nih.gov/21558494 21558494]|[https://pubmed.ncbi.nlm.nih.gov/31676555 31676555]|[https://pubmed.ncbi.nlm.nih.gov/31256374 31256374] <br>
+ '''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the nitrogen of an asparagine side-chain.[CHEBI:59520] <br>
+ '''term_xref''' : GTC:G78059CC|CID:70679232|CHEBI:70967 <br>
+ '''synonyms''' :  <br>
+ '''function''' : N-glycans modulate the function of several cell surface proteins which involved in migration, adhesion and which are responsible for regulating myelination.[PMID: 25151374]|Affect transportation of the glycosylated proteins in the Golgi.[PMID: 25151374]|Affects cell-cell interaction, adhesion, expression, proper folding.[PMID: 25151374]|extracellular N-glycans act as key modulators of neuronal uptake of αacetyl [PMID: [https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]]. <br>
+ '''disease_associations''' : Rheumatoid arthritis[PMID:17392038]|Type 1 Diabetes[PMID:29146600]|Lung Cancer[PMID: 23766031] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-===GD000122===
-'''term (main_entry)''' : Lewis y <br>
-'''glycan_dictionary_accession''' : GD000122 <br>
-'''glytoucan_accession ''' : G00052MO <br>
-'''term_in_sentence''' : In conclusion, Lewis y antigen and CD147 were significantly upregulated in ovarian tumors, and the altered expression of Lewis y may cause changes in CD147.[PMID:30816446] <br>
-'''publication''' : 30816446|20003467|24692145|24998328|25726913|29299130|30816446|20003467|24692145|24998328|20127027|22138668|23894390|25726913|25416440|27646625|23725446|21294926|22312289|25973320|23242548|30328452|21119363|29130097|23443083|23708102|28671040|19715603|23468946|27723168|21747684|19771739 <br>
-'''definition''' : A Lewis blood group antigen which is a branched amino tetrasaccharide with structure alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc, consisting of consisting of N-acetyl-beta-D-glucosamine at the reducing end having an alpha-L-fucosyl residue attached at the 3-position and an alpha-L-fucosyl-(1→2)-beta-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure. It has a role as an antigen and an epitope. [CHEBI:59045]] <br>
-'''term_xref''' : GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000019 <br>
-'''best_match''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000019 <br>
-'''synonymns''' : LeY|Le(y)|Ley|Le^y <br>
-'''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br>
-'''disease_associations''' : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
+===GSD000132===
+ '''term (main_entry)''' : Nonfucosylated <br>
+ '''glycan_dictionary_accession''' : GSD000132 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : In the carbohydrate moiety , alpha-subunit from normal pregnancy hCG contained nonfucosylated , mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).[PMID: [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]|[https://pubmed.ncbi.nlm.nih.gov/30258536 30258536]|[https://pubmed.ncbi.nlm.nih.gov/23554380 23554380]|[https://pubmed.ncbi.nlm.nih.gov/16675584 16675584]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]|[https://pubmed.ncbi.nlm.nih.gov/22457527 22457527]|[https://pubmed.ncbi.nlm.nih.gov/24362443 24362443]|[https://pubmed.ncbi.nlm.nih.gov/19657637 19657637]|[https://pubmed.ncbi.nlm.nih.gov/8811881 8811881]|[https://pubmed.ncbi.nlm.nih.gov/19218011 19218011]|[https://pubmed.ncbi.nlm.nih.gov/20022111 20022111]|[https://pubmed.ncbi.nlm.nih.gov/17363544 17363544]|[https://pubmed.ncbi.nlm.nih.gov/17368483 17368483]|[https://pubmed.ncbi.nlm.nih.gov/20564614 20564614]|[https://pubmed.ncbi.nlm.nih.gov/27054024 27054024]|[https://pubmed.ncbi.nlm.nih.gov/28397880 28397880]|[https://pubmed.ncbi.nlm.nih.gov/31490688 31490688]|[https://pubmed.ncbi.nlm.nih.gov/31860772 31860772]|[https://pubmed.ncbi.nlm.nih.gov/17012310 17012310]|[https://pubmed.ncbi.nlm.nih.gov/29633346 29633346]|[https://pubmed.ncbi.nlm.nih.gov/9442021 9442021]|[https://pubmed.ncbi.nlm.nih.gov/30350565 30350565]|[https://pubmed.ncbi.nlm.nih.gov/30296068 30296068]|[https://pubmed.ncbi.nlm.nih.gov/31800250 31800250]|[https://pubmed.ncbi.nlm.nih.gov/30021910 30021910]|[https://pubmed.ncbi.nlm.nih.gov/31133022 31133022]|[https://pubmed.ncbi.nlm.nih.gov/29224385 29224385]|[https://pubmed.ncbi.nlm.nih.gov/28630087 28630087]|[https://pubmed.ncbi.nlm.nih.gov/26444434 26444434]|[https://pubmed.ncbi.nlm.nih.gov/31697975 31697975]|[https://pubmed.ncbi.nlm.nih.gov/30991260 30991260] <br>
+ '''definition''' : glycans without a fucose component/monosaccharide residue. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000123===
-'''term (main_entry)''' : Monosialylated <br>
-'''glycan_dictionary_accession''' : GD000123 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The structures of the asparagine-linked sugar chains of U- CD59 were biantennary complex type , only 4.2% of which are monosialylated.[PMID:7514386] <br>
-'''publication''' : 7514386|8477709|8942648|29752599|31669586|29747818|16425369|12089170|31390883|1632647|29733234|31110965|31566965|30555678|28263871|29652662|25915761|16381065|29247593|28370937|23896595|26633899|32155999|25261856|2737211|26945091|27065039|26784838|26582205 <br>
-'''definition''' : A glycan that have the addition of one sialic acid residues. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' : appears in bovine brain gangliosides.[PMID: 29752599] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000133===
+ '''term (main_entry)''' : Nonfucosylated biantennary <br>
+ '''glycan_dictionary_accession''' : GSD000133 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Structural analysis combining methylation-mass spectrometry and 400 MHz 1H-n.m.r. spectrometry of oligosaccharide alditols released from human leucocyte lactotransferrin shows the presence of two disialylated and non-fucosylated biantennary glycans of the N-acetyl-lactosaminic type.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2390069 2390069]] <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/2390069 2390069]| [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]|[https://pubmed.ncbi.nlm.nih.gov/1375510 1375510]|[https://pubmed.ncbi.nlm.nih.gov/9101715 9101715]|[https://pubmed.ncbi.nlm.nih.gov/2390069 2390069]|[https://pubmed.ncbi.nlm.nih.gov/2332109 2332109] <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
-===GD000124===
-'''term (main_entry)''' : Monosialyl-biantennary <br>
-'''glycan_dictionary_accession''' : GD000124 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In contrast, the sugar chain structure of HCC highly specific AFP isoform was found to comprise a monosialyl-biantennary sugar chain with additional fucosylation of the proximal N-acetylglucosamine.[PMID:7686446] <br>
-'''publication''' : 7686446|1374031|9648261|10460833|19524219|10207016|15797573|15218190 <br>
-'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' : monosialyl biantennary|sialylated diantennary|sialylated biantennary <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000134===
+ '''term (main_entry)''' : Nonfucosylated biantennary N-Linked structures <br>
+ '''glycan_dictionary_accession''' : GSD000134 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] <br>
+ '''definition''' : A biantennary N-linked glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000125===
-'''term (main_entry)''' : Monosialyl-Gb5 <br>
-'''glycan_dictionary_accession''' : GD000125 <br>
-'''glytoucan_accession ''' : G32254QI <br>
-'''term_in_sentence''' : Thus, malignancy of MCF-7 is highly dependent on monosialyl-Gb5, and its activation of cSrc and FAK in GEM.[PMID:12401210] <br>
-'''publication''' : 12401210|16995838|27318475 <br>
-'''definition''' : alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp is a linear amino hexasaccharide comprising β-D-glucose at the reducing end with at the 4-position a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety, α(2→3)-sialylated at the terminal galactosyl residue.[CHEBI:62313] <br>
-'''term_xref''' : GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID:73427363|CHEBI:62313 <br>
-'''best_match''' : GTC:G32254QI|GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID:73427363|CHEBI:62313 <br>
-'''synonymns''' : GL-7 globoseries ganglioside (SSEA-4)|Monosialyl Gb5|Sialosyl galactosyl globoside|GL-7 globoseries ganglioside|SSEA-4 <br>
-'''function''' :  <br>
-'''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0099] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000135===
+ '''term (main_entry)''' : Nonfucosylated triantennary <br>
+ '''glycan_dictionary_accession''' : GSD000135 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/23274891 23274891] <br>
+ '''definition''' : A triantennary N-linked glycan with three GlcNAc branches linked to the core and no fucose appears. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' : Appears in human alpha-fetoprotein (AFP).[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br>
+ '''disease_associations''' : hepatocellular carcinoma[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]]. <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000126===
-'''term (main_entry)''' : Mono-sulfated globopentaosylceramide <br>
-'''glycan_dictionary_accession''' : GD000126 <br>
-'''glytoucan_accession ''' : G80193TN <br>
-'''term_in_sentence''' : Mono-sulfated Globopentaosylceramide from HumanKidney.[PMID:2777788] <br>
-'''publication''' : 2777788 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000072 <br>
-'''best_match''' : GTC:G80193TN <br>
-'''synonymns''' : Monosulfated globopentaosylceramide <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000136===
+ '''term (main_entry)''' : Nonsialylated <br>
+ '''glycan_dictionary_accession''' : GSD000136 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The pattern of nonsialylated oligosaccharides was used for interpretation of the fully sialylated species using bioinformatics tools. From pooled human plasma, we find 90, 101, and 64 different glycan compositions for genetic variants ORM1*F1, ORM1*S, and ORM2, respectively. Glycan structures carry dominantly between 15 and 16 sialic acids indicating an almost complete termination of all antenae with sialic acid.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/14533820 14533820]|[https://pubmed.ncbi.nlm.nih.gov/1377689 1377689]|[https://pubmed.ncbi.nlm.nih.gov/9705949 9705949]|[https://pubmed.ncbi.nlm.nih.gov/30788437 30788437]|[https://pubmed.ncbi.nlm.nih.gov/28090561 28090561]|[https://pubmed.ncbi.nlm.nih.gov/12498371 12498371]|[https://pubmed.ncbi.nlm.nih.gov/26839900 26839900]|[https://pubmed.ncbi.nlm.nih.gov/31490688 31490688]|[https://pubmed.ncbi.nlm.nih.gov/2656426 2656426]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31545048 31545048]|[https://pubmed.ncbi.nlm.nih.gov/12381155 12381155]|[https://pubmed.ncbi.nlm.nih.gov/25730103 25730103]|[https://pubmed.ncbi.nlm.nih.gov/26787879 26787879]|[https://pubmed.ncbi.nlm.nih.gov/25646460 25646460]| [https://pubmed.ncbi.nlm.nih.gov/29224385 29224385]|[https://pubmed.ncbi.nlm.nih.gov/26063435 26063435]|[https://pubmed.ncbi.nlm.nih.gov/26954852 26954852]|[https://pubmed.ncbi.nlm.nih.gov/32889432 32889432]|[https://pubmed.ncbi.nlm.nih.gov/2825412 2825412]|[https://pubmed.ncbi.nlm.nih.gov/27504786 27504786]|[https://pubmed.ncbi.nlm.nih.gov/22431161 22431161] <br>
+ '''definition''' : A glycan which is not sialylated. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000127===
-'''term (main_entry)''' : Mono-sulfated globotetraosylceramide <br>
-'''glycan_dictionary_accession''' : GD000127 <br>
-'''glytoucan_accession ''' : G05297EK <br>
-'''term_in_sentence''' : Mono-sulfated globotetraosylceramide from human kidney.[PMID:2559078] <br>
-'''publication''' : 2559078 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000073 <br>
-'''best_match''' : GTC:G05297EK <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000137===
+ '''term (main_entry)''' : O-fucose glycans <br>
+ '''glycan_dictionary_accession''' : GSD000137 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G39294YF G39294YF] <br>
+ '''term_in_sentence''' : Recently, a number of laboratories have shown that O-fucose glycans on the epidermal growth factor (EGF)-like repeats of the Notch extracellular domain modulate Notch signaling.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12417415 12417415]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19594638 19594638]|[https://pubmed.ncbi.nlm.nih.gov/30690220 30690220]|[https://pubmed.ncbi.nlm.nih.gov/18952191 18952191]|[https://pubmed.ncbi.nlm.nih.gov/22415200 22415200]|[https://pubmed.ncbi.nlm.nih.gov/12417415 12417415]|[https://pubmed.ncbi.nlm.nih.gov/16400812 16400812]|[https://pubmed.ncbi.nlm.nih.gov/18948267 18948267]|[https://pubmed.ncbi.nlm.nih.gov/21464368 21464368]|[https://pubmed.ncbi.nlm.nih.gov/20816394 20816394]|[https://pubmed.ncbi.nlm.nih.gov/30207383 30207383]|[https://pubmed.ncbi.nlm.nih.gov/20301232 20301232]|[https://pubmed.ncbi.nlm.nih.gov/27129198 27129198]|[https://pubmed.ncbi.nlm.nih.gov/17132502 17132502]|[https://pubmed.ncbi.nlm.nih.gov/22492969 22492969]|[https://pubmed.ncbi.nlm.nih.gov/30030822 30030822]|[https://pubmed.ncbi.nlm.nih.gov/30214079 30214079]|[https://pubmed.ncbi.nlm.nih.gov/26175457 26175457]|[https://pubmed.ncbi.nlm.nih.gov/25378397 25378397]|[https://pubmed.ncbi.nlm.nih.gov/18272537 18272537]|[https://pubmed.ncbi.nlm.nih.gov/28729422 28729422]|[https://pubmed.ncbi.nlm.nih.gov/11524432 11524432]|[https://pubmed.ncbi.nlm.nih.gov/31722217 31722217]|[https://pubmed.ncbi.nlm.nih.gov/23045360 23045360]|[https://pubmed.ncbi.nlm.nih.gov/24803430 24803430]|[https://pubmed.ncbi.nlm.nih.gov/28876865 28876865]|[https://pubmed.ncbi.nlm.nih.gov/25700513 25700513]|[https://pubmed.ncbi.nlm.nih.gov/32518939 32518939]|[https://pubmed.ncbi.nlm.nih.gov/30523691 30523691]|[https://pubmed.ncbi.nlm.nih.gov/18227520 18227520]|[https://pubmed.ncbi.nlm.nih.gov/20816217 20816217]|[https://pubmed.ncbi.nlm.nih.gov/24909690 24909690]|[https://pubmed.ncbi.nlm.nih.gov/17964136 17964136]|[https://pubmed.ncbi.nlm.nih.gov/12036964 12036964]|[https://pubmed.ncbi.nlm.nih.gov/27268051 27268051]|[https://pubmed.ncbi.nlm.nih.gov/15653671 15653671]|[https://pubmed.ncbi.nlm.nih.gov/19948734 19948734]|[https://pubmed.ncbi.nlm.nih.gov/31590629 31590629]|[https://pubmed.ncbi.nlm.nih.gov/32201074 32201074]|[https://pubmed.ncbi.nlm.nih.gov/15189151 15189151]|[https://pubmed.ncbi.nlm.nih.gov/17263732 17263732]|[https://pubmed.ncbi.nlm.nih.gov/32913123 32913123]|[https://pubmed.ncbi.nlm.nih.gov/12909620 12909620]|[https://pubmed.ncbi.nlm.nih.gov/28785176 28785176]|[https://pubmed.ncbi.nlm.nih.gov/17132500 17132500]|[https://pubmed.ncbi.nlm.nih.gov/22949680 22949680]|[https://pubmed.ncbi.nlm.nih.gov/25053492 25053492]|[https://pubmed.ncbi.nlm.nih.gov/28939751 28939751] <br>
+ '''definition''' : Form of glycosylation where the protein is modified by a fucose residue and can be extended futher to form a tetrasaccharide in certain cases. alpha-linked o-fucose have a consensus motif of C2X4(s/T)C3 where C2 and C3 are conserved cysteines number 2 and 3 respectively of the EGFR like repeats. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453017/ Chapter13]]<br>
+ '''term_xref''' : GTC:G39294YF|GlycoEpitope:EP0005  <br>
+ '''synonyms''' :  <br>
+ '''function''' : modification of Notch signaling.[GlycoEpitope:EP0005] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000128===
-'''term (main_entry)''' : N-acetyl GM2 <br>
-'''glycan_dictionary_accession''' : GD000128 <br>
-'''glytoucan_accession ''' : G79389NT <br>
-'''term_in_sentence''' : The appearance of the N-acetyl GM2 antigen correlated well with the degree of differentiation of the cancer cells in patients with squamous cell carcinoma and adenocarcinoma of the lung.[PMID:3167861] <br>
-'''publication''' : 3167861|2153431|25673107 <br>
-'''definition''' : beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp is a branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
-'''term_xref''' : GlycoEpitope:EP0051|CID:45266845|CHEBI:59220 <br>
-'''best_match''' : GTC:G79389NT|GlycoEpitope:EP0051|CID:45266845|CHEBI:59220 <br>
-'''synonymns''' :  <br>
-'''function''' : The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.[CHEBI:59220] <br>
-'''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000138===
+ '''term (main_entry)''' : O-GlcNAc <br>
+ '''glycan_dictionary_accession''' : GSD000138 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G49108TO G49108TO] <br>
+ '''term_in_sentence''' : A better understanding of the mechanisms of OGT/OGA action would enable us to derive therapeutic benefits of resetting cellular O-GlcNAc levels within an optimal range.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30464755 30464755]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30464755 30464755]|[https://pubmed.ncbi.nlm.nih.gov/29049853 29049853]|[https://pubmed.ncbi.nlm.nih.gov/29594839 29594839]|[https://pubmed.ncbi.nlm.nih.gov/31654859 31654859]|[https://pubmed.ncbi.nlm.nih.gov/29404877 29404877]|[https://pubmed.ncbi.nlm.nih.gov/30105004 30105004]|[https://pubmed.ncbi.nlm.nih.gov/30669087 30669087]|[https://pubmed.ncbi.nlm.nih.gov/29790000 29790000]|[https://pubmed.ncbi.nlm.nih.gov/28408483 28408483]|[https://pubmed.ncbi.nlm.nih.gov/26862193 26862193]|[https://pubmed.ncbi.nlm.nih.gov/30523150 30523150]|[https://pubmed.ncbi.nlm.nih.gov/30037904 30037904]|[https://pubmed.ncbi.nlm.nih.gov/28408480 28408480]|[https://pubmed.ncbi.nlm.nih.gov/29352075 29352075]|[https://pubmed.ncbi.nlm.nih.gov/29456783 29456783]|[https://pubmed.ncbi.nlm.nih.gov/29577901 29577901]|[https://pubmed.ncbi.nlm.nih.gov/29223644 29223644]|[https://pubmed.ncbi.nlm.nih.gov/28638491 28638491]|[https://pubmed.ncbi.nlm.nih.gov/30221662 30221662]|[https://pubmed.ncbi.nlm.nih.gov/29904918 29904918]|[https://pubmed.ncbi.nlm.nih.gov/32155042 32155042]|[https://pubmed.ncbi.nlm.nih.gov/30298013 30298013]|[https://pubmed.ncbi.nlm.nih.gov/31630803 31630803]|[https://pubmed.ncbi.nlm.nih.gov/31847126 31847126]|[https://pubmed.ncbi.nlm.nih.gov/29784830 29784830]|[https://pubmed.ncbi.nlm.nih.gov/30181664 30181664]|[https://pubmed.ncbi.nlm.nih.gov/28768194 28768194]|[https://pubmed.ncbi.nlm.nih.gov/30134155 30134155]|[https://pubmed.ncbi.nlm.nih.gov/25336654 25336654]|[https://pubmed.ncbi.nlm.nih.gov/30356792 30356792]|[https://pubmed.ncbi.nlm.nih.gov/30199580 30199580]|[https://pubmed.ncbi.nlm.nih.gov/32329777 32329777]|[https://pubmed.ncbi.nlm.nih.gov/28408494 28408494]|[https://pubmed.ncbi.nlm.nih.gov/29774032 29774032]|[https://pubmed.ncbi.nlm.nih.gov/29044951 29044951]|[https://pubmed.ncbi.nlm.nih.gov/23836420 23836420]|[https://pubmed.ncbi.nlm.nih.gov/20301273 20301273]|[https://pubmed.ncbi.nlm.nih.gov/29772801 29772801]|[https://pubmed.ncbi.nlm.nih.gov/28922739 28922739]|[https://pubmed.ncbi.nlm.nih.gov/30100348 30100348]|[https://pubmed.ncbi.nlm.nih.gov/30793403 30793403]|[https://pubmed.ncbi.nlm.nih.gov/30657688 30657688]|[https://pubmed.ncbi.nlm.nih.gov/31237748 31237748]|[https://pubmed.ncbi.nlm.nih.gov/29756380 29756380]|[https://pubmed.ncbi.nlm.nih.gov/29954943 29954943]|[https://pubmed.ncbi.nlm.nih.gov/30018219 30018219]|[https://pubmed.ncbi.nlm.nih.gov/32207184 32207184]|[https://pubmed.ncbi.nlm.nih.gov/25566193 25566193]|[https://pubmed.ncbi.nlm.nih.gov/30626734 30626734]|[https://pubmed.ncbi.nlm.nih.gov/24759912 24759912]| <br>
+ '''definition''' : Form of glycosylation which exclusively occurs in the mitochondrial, cytoplasmic or nuclear compartments of the cell where the protein is modified by a GlcNAc monosaccharide on the serine or threonine residues and is generally not modified or elongated further to form more complex structures. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453063/ Chapter19]] <br>
+ '''term_xref''' : GTC:G49108TO|GlycoEpitope:EP0004|CID:24139|HMDB:HMDB0000803 <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000129===
-'''term (main_entry)''' : N-acetyllactosamine <br>
-'''glycan_dictionary_accession''' : GD000129 <br>
-'''glytoucan_accession ''' : G00055MO <br>
-'''term_in_sentence''' : Utilising a fast and sensitive screening method based on imidazolium-tagged probes, we report unprecedented reversible activity of bacterial beta1,4-galactosyltransferases to catalyse the transgalactosylation from lactose to N-acetylglucosamine to form N-acetyllactosamine in the presence of UDP.[PMID:31165848] <br>
-'''publication''' : 31165848|31126011|28796164|6236210|9751793|29740087|9151975|10567443|21472942|26477523|6548353|28167527|20056550|7737204|22052010|10223649|11323440|10420596|7766648|25257940|17977857|15556936|26541999|23650594|9692202|29429899|21062783|25034434|8985145|28503789|8720464/ <br>
-'''definition''' : N-acetyllactosamine is a beta-D-galactopyranosyl-(1→4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. It is also known as galb1-4glcnacb or lacnac, belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group. N-Acetyllactosamine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Acetyllactosamine exists in all living organisms, ranging from bacteria to humans.[CHEBI:16153,HMDB0001542] <br>
-'''term_xref''' : CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001 <br>
-'''best_match''' : GTC:G00055MO|CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001 <br>
-'''synonymns''' : LacNAc|Type 2 LN <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000139===
+ '''term (main_entry)''' : O-linked glycans <br>
+ '''glycan_dictionary_accession''' : GSD000139 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]|[https://pubmed.ncbi.nlm.nih.gov/30952424 30952424]|[https://pubmed.ncbi.nlm.nih.gov/31611643 31611643]|[https://pubmed.ncbi.nlm.nih.gov/19577919 19577919]|[https://pubmed.ncbi.nlm.nih.gov/32019882 32019882]|[https://pubmed.ncbi.nlm.nih.gov/19139197 19139197]|[https://pubmed.ncbi.nlm.nih.gov/26184710 26184710]|[https://pubmed.ncbi.nlm.nih.gov/11159917 11159917]|[https://pubmed.ncbi.nlm.nih.gov/21536259 21536259]|[https://pubmed.ncbi.nlm.nih.gov/25186198 25186198]|[https://pubmed.ncbi.nlm.nih.gov/19277556 19277556]|[https://pubmed.ncbi.nlm.nih.gov/22261557 22261557]|[https://pubmed.ncbi.nlm.nih.gov/24115046 24115046]|[https://pubmed.ncbi.nlm.nih.gov/18725413 18725413]| [https://pubmed.ncbi.nlm.nih.gov/15966855 15966855]|[https://pubmed.ncbi.nlm.nih.gov/24256304 24256304]|[https://pubmed.ncbi.nlm.nih.gov/25477510 25477510]|[https://pubmed.ncbi.nlm.nih.gov/10359703 10359703]|[https://pubmed.ncbi.nlm.nih.gov/24406064 24406064]|[https://pubmed.ncbi.nlm.nih.gov/22259135 22259135]|[https://pubmed.ncbi.nlm.nih.gov/29279989 29279989]| [https://pubmed.ncbi.nlm.nih.gov/15966855 15966855]|[https://pubmed.ncbi.nlm.nih.gov/30619255 30619255]|[https://pubmed.ncbi.nlm.nih.gov/9673446 9673446]| [https://pubmed.ncbi.nlm.nih.gov/31676555 31676555]|[https://pubmed.ncbi.nlm.nih.gov/28745859 28745859]|[https://pubmed.ncbi.nlm.nih.gov/28196325 28196325]|[https://pubmed.ncbi.nlm.nih.gov/27975143 27975143]|[https://pubmed.ncbi.nlm.nih.gov/30591584 30591584]| [https://pubmed.ncbi.nlm.nih.gov/28518173 28518173]|[https://pubmed.ncbi.nlm.nih.gov/17522109 17522109]| [https://pubmed.ncbi.nlm.nih.gov/26328495 26328495]|[https://pubmed.ncbi.nlm.nih.gov/32178593 32178593]|[https://pubmed.ncbi.nlm.nih.gov/27529638 27529638]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/22474328 22474328]|[https://pubmed.ncbi.nlm.nih.gov/28096352 28096352]|[https://pubmed.ncbi.nlm.nih.gov/27496768 27496768]| [https://pubmed.ncbi.nlm.nih.gov/18952191 18952191]|[https://pubmed.ncbi.nlm.nih.gov/11135308 11135308]|[https://pubmed.ncbi.nlm.nih.gov/24917611 24917611]|[https://pubmed.ncbi.nlm.nih.gov/11532966 11532966]|[https://pubmed.ncbi.nlm.nih.gov/22786570 22786570]| [https://pubmed.ncbi.nlm.nih.gov/11891229 11891229]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/26867212 26867212]|[https://pubmed.ncbi.nlm.nih.gov/26925665 26925665]|[https://pubmed.ncbi.nlm.nih.gov/16769205 16769205]|[https://pubmed.ncbi.nlm.nih.gov/23475718 23475718]|[https://pubmed.ncbi.nlm.nih.gov/16005634 16005634]|[https://pubmed.ncbi.nlm.nih.gov/28785176 28785176] <br>
+ '''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the hydroxyl oxygen of serine, threonine, hydroxylysine or hydroxyproline side-chains.[CHEBI:59521] <br>
+ '''term_xref''' : CHEBI:59521 <br>
+ '''synonyms''' :  <br>
+ '''function''' : Affects several important activities like protein stability, modulation of signaling molecules and enzyme activity.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9673446 9673446]] <br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000130===
+===GSD000140===
-'''term (main_entry)''' : N-Glycolyl-GM2 <br>
+ '''term (main_entry)''' : O-linked mannose <br>
-'''glycan_dictionary_accession''' : GD000130 <br>
+ '''glycan_dictionary_accession''' : GSD000140 <br>
-'''glytoucan_accession ''' : G56478LD <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G59126YU G59126YU] <br>
-'''term_in_sentence''' : The monoclonal antibodies MK2-34 and MK1-16 (both IgM), which specifically detect N-glycolyl GM2 and N-acetyl GM2, respectively, were generated by immunizing mice with liposomes containing monophosphoryl lipid A, trehalose dimycolate, and the antigenic ganglioside.[PMID:3167861] <br>
+ '''term_in_sentence''' : Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2) catalyzes the first step toward the functional matriglycan structure on alpha-dystroglycan that is responsible for binding extracellular matrix proteins and certain arenaviruses.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27932460 27932460]] <br>
-'''publication''' : 3167861|11861662|17980710|3731079|25673107 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27932460 27932460]|[https://pubmed.ncbi.nlm.nih.gov/24526361 24526361]|[https://pubmed.ncbi.nlm.nih.gov/25381909 25381909]|[https://pubmed.ncbi.nlm.nih.gov/26644575 26644575]|[https://pubmed.ncbi.nlm.nih.gov/23851827 23851827]|[https://pubmed.ncbi.nlm.nih.gov/28810660 28810660]|[https://pubmed.ncbi.nlm.nih.gov/19054127 19054127]|[https://pubmed.ncbi.nlm.nih.gov/23929950 23929950]|[https://pubmed.ncbi.nlm.nih.gov/21684258 21684258]|[https://pubmed.ncbi.nlm.nih.gov/22608994 22608994]|[https://pubmed.ncbi.nlm.nih.gov/28973932 28973932]|[https://pubmed.ncbi.nlm.nih.gov/24733390 24733390]|[https://pubmed.ncbi.nlm.nih.gov/31851597 31851597]|[https://pubmed.ncbi.nlm.nih.gov/29884773 29884773]|[https://pubmed.ncbi.nlm.nih.gov/28711406 28711406]|[https://pubmed.ncbi.nlm.nih.gov/14577328 14577328]|[https://pubmed.ncbi.nlm.nih.gov/21089343 21089343]|[https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]|[https://pubmed.ncbi.nlm.nih.gov/9838223 9838223]|[https://pubmed.ncbi.nlm.nih.gov/17072003 17072003]| [https://pubmed.ncbi.nlm.nih.gov/26328495 26328495]|[https://pubmed.ncbi.nlm.nih.gov/11181560 11181560]|[https://pubmed.ncbi.nlm.nih.gov/31949166 31949166]|[https://pubmed.ncbi.nlm.nih.gov/31988979 31988979]|[https://pubmed.ncbi.nlm.nih.gov/20362685 20362685]|[https://pubmed.ncbi.nlm.nih.gov/27733679 27733679]|[https://pubmed.ncbi.nlm.nih.gov/27493216 27493216]|[https://pubmed.ncbi.nlm.nih.gov/20044576 20044576]|[https://pubmed.ncbi.nlm.nih.gov/30643095 30643095]|[https://pubmed.ncbi.nlm.nih.gov/29732660 29732660]|[https://pubmed.ncbi.nlm.nih.gov/10580142 10580142]|[https://pubmed.ncbi.nlm.nih.gov/14568618 14568618]|[https://pubmed.ncbi.nlm.nih.gov/28079948 28079948]|[https://pubmed.ncbi.nlm.nih.gov/15467391 15467391]|[https://pubmed.ncbi.nlm.nih.gov/27812179 27812179]|[https://pubmed.ncbi.nlm.nih.gov/23761899 23761899]|[https://pubmed.ncbi.nlm.nih.gov/25737452 25737452]|[https://pubmed.ncbi.nlm.nih.gov/32930586 32930586]|[https://pubmed.ncbi.nlm.nih.gov/25381372 25381372]|[https://pubmed.ncbi.nlm.nih.gov/23434682 23434682]|[https://pubmed.ncbi.nlm.nih.gov/16857188 16857188]|[https://pubmed.ncbi.nlm.nih.gov/21452199 21452199]|[https://pubmed.ncbi.nlm.nih.gov/19429925 19429925]|[https://pubmed.ncbi.nlm.nih.gov/25361541 25361541]|[https://pubmed.ncbi.nlm.nih.gov/24297939 24297939]|[https://pubmed.ncbi.nlm.nih.gov/30322079 30322079]|[https://pubmed.ncbi.nlm.nih.gov/23428289 23428289]| [https://pubmed.ncbi.nlm.nih.gov/28427937 28427937]|[https://pubmed.ncbi.nlm.nih.gov/22746206 22746206]|[https://pubmed.ncbi.nlm.nih.gov/27533452 27533452]|[https://pubmed.ncbi.nlm.nih.gov/17502374 17502374]|[https://pubmed.ncbi.nlm.nih.gov/20816174 20816174]|[https://pubmed.ncbi.nlm.nih.gov/27496765 27496765] <br>
-'''definition''' : (2S,4S,5R,6R)-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of carbohydrates and carbohydrate derivatives.[CHEBI:151464] <br>
+ '''definition''' : O-linked glycans that are initiated by the addtion of a Man residue to Ser or Thr. Subsequent extension of the Man defines the O-Man core type, either M1, M2, or M3. The M1 type is initated by addition of a GlcNAc in β-linkage to the 2 position of the Man residue. M2 is initiated by addition of another GlcNAc to the 6 position of the M1 core. M3 is initiated by the addition of a GlcNAc in β-linkage to the 4 position of the Man residue. M1 and M2 type core glycans can be extended and branched with Gal, Fuc, Sialic Acid, and GlcA. The M3 core is uniquely extended by a multienzyme system to generate the matriglycan polysaccharide, a protein-specific modification found only on alpha-dystroglycan. [CHEBI:87761] <br>
-'''term_xref''' : GlycoEpitope:EP0052|CID:91845742|CHEBI:151464|GlycoEpitope:GGM.000096 <br>
+ '''term_xref''' : GlycoMotif:GGM.000055|GTC:G59126YU|CHEBI:87761|GlycoEpitope:EP0002|CID: 91859038 <br>
-'''best_match''' : GTC:G56478LD |GlycoEpitope:EP0052|CID:91845742|CHEBI:151464|GlycoEpitope:GGM.000096 <br>
+ '''synonyms''' : O-mannosyl glycan <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' : MEB/muscle-eye-brain disease[GlycoEpitope:EP0002]|WWS/walker-warburg syndrome |muscular dystrophy[GlycoEpitope:EP0002]|neuronal migration disorder[GlycoEpitope:EP0002]|Muscle-Eye-Brain disease (MEB) and Walker-Warburg Syndrome (WWS) have mutations in genes encoding glycosyltransferases needed for O -mannosyl oligosaccharide synthesis[GlycoEpitope:EP0002]|Muscular dystrophy and neuronal migration disorder are caused by mutations in a glycosyltransferase, POMGnT1.[GlycoEpitope:EP0002] <br>
-'''disease_associations''' : choriocarcinoma[GlycoEpitope:EP0052]|teratocarcinoma|[GlycoEpitope:EP0052]yolk sac tumor[GlycoEpitope:EP0052] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000131===
+===GSD000141===
-'''term (main_entry)''' : N-linked glycans <br>
+ '''term (main_entry)''' : P1 antigen <br>
-'''glycan_dictionary_accession''' : GD000131 <br>
+ '''glycan_dictionary_accession''' : GSD000141 <br>
-'''glytoucan_accession ''' : G78059CC <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G12460DL G12460DL] <br>
-'''term_in_sentence''' : Our study identifies extracellular N-linked glycans-and the glycoprotein neurexin 1β specifically-as key modulators of neuronal uptake of αSacetyl, drawing attention to the potential therapeutic value of αSacetyl-glycan interactions.[PMID:31211781] <br>
+ '''term_in_sentence''' : The P1 antigen was disovered in 1927 by Landsteiner and Levine, and Pk and NOR were described in 1951 and 1982, respectively.[PMID: [https://pubmed.ncbi.nlm.nih.gov/24046920 24046920]] <br>
-'''publication''' : 31211781|28384382|30305477|31364612|26899268|29945790|29652253|29723274|30962676|29778448|25325701|31100702|28898525|22944671|19277537|24473128|17957771|27554083|15189166|11269317|19577919|24303005|12042249|22191536|28324664|25965797|25434632|30484244|28110657|29865036|20129637|27346875|30280442|26911286|22491358|26582281|26398792|31548313|31066275|28331984|25482090|28518173|30733536|22326428|30063825|30315103|21558494|31676555|31256374 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29622537 29622537]|[https://pubmed.ncbi.nlm.nih.gov/26773500 26773500]|[https://pubmed.ncbi.nlm.nih.gov/24046920 24046920]|[https://pubmed.ncbi.nlm.nih.gov/6207232 6207232]|[https://pubmed.ncbi.nlm.nih.gov/8550516 8550516]|[https://pubmed.ncbi.nlm.nih.gov/6609976 6609976]|[https://pubmed.ncbi.nlm.nih.gov/6375319 6375319]|817855|[https://pubmed.ncbi.nlm.nih.gov/2428855 2428855]|[https://pubmed.ncbi.nlm.nih.gov/3312011 3312011]|[https://pubmed.ncbi.nlm.nih.gov/15364312 15364312]|[https://pubmed.ncbi.nlm.nih.gov/1937801 1937801]|[https://pubmed.ncbi.nlm.nih.gov/7729906 7729906] <br>
-'''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the nitrogen of an asparagine side-chain.[CHEBI:59520] <br>
+ '''definition''' : An amino pentasaccharide consisting of α-D-galactose, β-D-galactose N-acetyl-α-D-glucosamine, β-D-galactose, and β-D-glucose residues joined in sequence with ((1→4)-, (1→4)-, (1→3)- and (1→4)-linkages, respectively.[CHEBI:68484] <br>
-'''term_xref''' : CID:70679232|CHEBI:70967 <br>
+ '''term_xref''' : GlycoMotif:GGM.000069|GTC:G12460DL|CID:71296137|CHEBI:68484|SugarBind_Ligand:160  <br>
-'''best_match''' : GTC:G78059CC|CID:70679232|CHEBI:70967 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' : N-glycans modulate the function of several cell surface proteins which involved in migration, adhesion and which are responsible for regulating myelination.[PMID: 25151374]|Affect transportation of the glycosylated proteins in the Golgi.[PMID: 25151374]|Affects cell-cell interaction, adhesion, expression, proper folding.[PMID: 25151374]|extracellular N-glycans act as key modulators of neuronal uptake of αacetyl [PMID: 31211781]. <br>
+ '''disease_associations''' : Shigellosis[SugarBind_Ligand:160] <br>
-'''disease_associations''' : Rheumatoid arthritis[PMID:17392038]|Type 1 Diabetes[PMID:29146600]|Lung Cancer[PMID: 23766031] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453054/ Chapter 23]<br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
-===GD000132===
+===GSD000142===
-'''term (main_entry)''' : Nonfucosylated <br>
+[[File:G51699SI.png|thumb|G51699SI]]
-'''glycan_dictionary_accession''' : GD000132 <br>
+ '''term (main_entry)''' : Para-Forssman glycolipid <br>
-'''glytoucan_accession ''' :  <br>
+ '''glycan_dictionary_accession''' : GSD000142 <br>
-'''term_in_sentence''' : In the carbohydrate moiety , alpha-subunit from normal pregnancy hCG contained nonfucosylated , mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).[PMID:9449027] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G51699SI G51699SI] <br>
-'''publication''' : 9449027|30258536|23554380|16675584|26747427|22457527|24362443|19657637|8811881|19218011|20022111|17363544|17368483|20564614|27054024|28397880|31490688|31860772|17012310|29633346|9442021|30350565|30296068|31800250|30021910|31133022|29224385|28630087|26444434|31697975|30991260 <br>
+ '''term_in_sentence''' : A novel pentaglycosyl ceramide containing di-beta-N-acetylgalactos-aminyl residue (Para-Forssman glycolipid) isolated from human erythrocyte membrane. [PMID:[https://pubmed.ncbi.nlm.nih.gov/6814203 6814203]] <br>
-'''definition''' : glycans without a fucose component/monosaccharide residue. <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6814203 6814203] <br>
-'''term_xref''' :  <br>
+ '''definition''' : GalNAcβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1Cer [https://doi.org/10.1016/S0040-4039(01)93814-6<nowiki>] </nowiki><br>
-'''best_match''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000085|GTC:G51699SI|CID:56836111|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565 <br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  <br>
-'''function''' :  <br>
+  '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' : Actinomycosis[SugarBind_Ligand:19] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' : https://en.wikipedia.org/wiki/P1PK_blood_group_system <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000133===
+===GSD000143===
-'''term (main_entry)''' : Nonfucosylated biantennary <br>
+ '''term (main_entry)''' : Paragloboside <br>
-'''glycan_dictionary_accession''' : GD000133 <br>
+ '''glycan_dictionary_accession''' : GSD000143 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G58896AZ G58896AZ] <br>
-'''term_in_sentence''' : Structural analysis combining methylation-mass spectrometry and 400 MHz 1H-n.m.r. spectrometry of oligosaccharide alditols released from human leucocyte lactotransferrin shows the presence of two disialylated and non-fucosylated biantennary glycans of the N-acetyl-lactosaminic type.[PMID:2390069] <br>
+ '''term_in_sentence''' : Galactosyltransferase activities in sera of cancer patients were determined by assaying the formation of paragloboside from UDP-galactose and lactotriaosylceramide immobilized on microtiter plates by means of the enzyme-linked immunosorbent assay using a monoclonal antibody, H-11, directed to paragloboside. [PMID:  [https://pubmed.ncbi.nlm.nih.gov/1551117 1551117]] <br>
-'''publication''' : 2390069|9449027|1375510|9101715|2390069|2332109 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3345524 3345524]|[https://pubmed.ncbi.nlm.nih.gov/850070 850070]|[https://pubmed.ncbi.nlm.nih.gov/10569746 10569746]|[https://pubmed.ncbi.nlm.nih.gov/30624951 30624951]|[https://pubmed.ncbi.nlm.nih.gov/29438961 29438961]|[https://pubmed.ncbi.nlm.nih.gov/6816790 6816790]| [https://pubmed.ncbi.nlm.nih.gov/1551117 1551117]|[https://pubmed.ncbi.nlm.nih.gov/6865961 6865961]|[https://pubmed.ncbi.nlm.nih.gov/25039255 25039255] <br>
-'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
+ '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is α.[CHEBI:65257] <br>
-'''term_xref''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000077|GTC:G58896AZ|CID: 21670519|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15 <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' : Pharyngitis[SugarBind_Ligand:15]|Tracheobronchitis[SugarBind_Ligand:15]|Gonorrhea[SugarBind_Ligand:15]|Actinomycosis[SugarBind_Ligand:15]|Diarrhea[SugarBind_Ligand:15]|Hemorrhagic colitis[SugarBind_Ligand:15]|Chronic gastritis[SugarBind_Ligand:15]|Peptic ulcers[SugarBind_Ligand:15]|Gastric cancer[SugarBind_Ligand:15]|Influenza[SugarBind_Ligand:15] <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-'''essentials_of_glycobiology''' : NBK453020 <br>
-===GD000134===
+===GSD000144===
-'''term (main_entry)''' : Nonfucosylated biantennary N-Linked structures <br>
+ '''term (main_entry)''' : Paucimannose <br>
-'''glycan_dictionary_accession''' : GD000134 <br>
+ '''glycan_dictionary_accession''' : GSD000144 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).[PMID:9449027] <br>
+ '''term_in_sentence''' : The galactosylation of core fucose (GalFuc epitope) in paucimannose and complex-type N-glycans is characteristic of protostome organisms, including flatworms (planarians).[PMID:[https://pubmed.ncbi.nlm.nih.gov/29475940 29475940]] <br>
-'''publication''' : 9449027 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29475940 29475940]| [https://pubmed.ncbi.nlm.nih.gov/29803109 29803109]|[https://pubmed.ncbi.nlm.nih.gov/12603202 12603202]|[https://pubmed.ncbi.nlm.nih.gov/31817246 31817246]|[https://pubmed.ncbi.nlm.nih.gov/31719144 31719144]|[https://pubmed.ncbi.nlm.nih.gov/21057214 21057214]|[https://pubmed.ncbi.nlm.nih.gov/31932305 31932305]|[https://pubmed.ncbi.nlm.nih.gov/17132514 17132514]|[https://pubmed.ncbi.nlm.nih.gov/30382146 30382146]|[https://pubmed.ncbi.nlm.nih.gov/27731363 27731363]|[https://pubmed.ncbi.nlm.nih.gov/31325506 31325506]|[https://pubmed.ncbi.nlm.nih.gov/25746926 25746926]|[https://pubmed.ncbi.nlm.nih.gov/26513758 26513758]|[https://pubmed.ncbi.nlm.nih.gov/16522637 16522637]|[https://pubmed.ncbi.nlm.nih.gov/21169367 21169367]|[https://pubmed.ncbi.nlm.nih.gov/25190359 25190359]|[https://pubmed.ncbi.nlm.nih.gov/27928741 27928741]|[https://pubmed.ncbi.nlm.nih.gov/22496646 22496646]|[https://pubmed.ncbi.nlm.nih.gov/27384337 27384337]|[https://pubmed.ncbi.nlm.nih.gov/16897177 16897177]|[https://pubmed.ncbi.nlm.nih.gov/15228383 15228383]|[https://pubmed.ncbi.nlm.nih.gov/27379103 27379103]|[https://pubmed.ncbi.nlm.nih.gov/27189951 27189951]|[https://pubmed.ncbi.nlm.nih.gov/23475714 23475714]|[https://pubmed.ncbi.nlm.nih.gov/24907509 24907509]|[https://pubmed.ncbi.nlm.nih.gov/20558211 20558211]|[https://pubmed.ncbi.nlm.nih.gov/28060516 28060516]|[https://pubmed.ncbi.nlm.nih.gov/20441997 20441997]|[https://pubmed.ncbi.nlm.nih.gov/27720757 27720757]|[https://pubmed.ncbi.nlm.nih.gov/28817611 28817611]|[https://pubmed.ncbi.nlm.nih.gov/24550396 24550396]|[https://pubmed.ncbi.nlm.nih.gov/19494052 19494052]|[https://pubmed.ncbi.nlm.nih.gov/19515361 19515361]| [https://pubmed.ncbi.nlm.nih.gov/28630087 28630087]|[https://pubmed.ncbi.nlm.nih.gov/31320997 31320997]|[https://pubmed.ncbi.nlm.nih.gov/30651366 30651366]|[https://pubmed.ncbi.nlm.nih.gov/30253927 30253927]|[https://pubmed.ncbi.nlm.nih.gov/25922361 25922361]|[https://pubmed.ncbi.nlm.nih.gov/31655162 31655162]|[https://pubmed.ncbi.nlm.nih.gov/18056652 18056652]|[https://pubmed.ncbi.nlm.nih.gov/24467287 24467287]|[https://pubmed.ncbi.nlm.nih.gov/32367383 32367383] <br>
-'''definition''' : A biantennary N-linked glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
+ '''definition''' : Any N-linked glycan derivative with composition Man1-4Fuc0-1 GlcNAc2, in which the chitobiose core (GlcNAc2) is intact. Found in relatively large amounts in invertebrates and plants, they are formed by removal of the non-reducing terminal GlcNAc (\added by GlcNAcT1) from GlcNAcMan3-5GlcNAc2 by a Golgi hexosaminidase and subsequent removal of Man residues by Golgi mannosidases. Pauscimannose glycans have also been detected in vertebrates.[CHEBI:144386] <br>
-'''term_xref''' :  <br>
+ '''term_xref''' : CHEBI:144386 <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000135===
+===GSD000145===
-'''term (main_entry)''' : Nonfucosylated triantennary <br>
+ '''term (main_entry)''' : Sd(A)/Cad <br>
-'''glycan_dictionary_accession''' : GD000135 <br>
+ '''glycan_dictionary_accession''' : GSD000145 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G41052GC G41052GC] <br>
-'''term_in_sentence''' : Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans.[PMID:7679920] <br>
+ '''term_in_sentence''' : The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24112972 24112972]] <br>
-'''publication''' : 7679920|23274891 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24112972 24112972]|[https://pubmed.ncbi.nlm.nih.gov/11577689 11577689]|[https://pubmed.ncbi.nlm.nih.gov/30067891 30067891]|[https://pubmed.ncbi.nlm.nih.gov/15361072 15361072] <br>
-'''definition''' : A triantennary N-linked glycan with three GlcNAc branches linked to the core and no fucose appears. <br>
+ '''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, β-D-galactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the galactose residue of which is also linked (1→4) an N-acetyl-β-L-galactosamine residue.
-'''term_xref''' :  <br>
+ [CHEBI:71561] <br>
-'''best_match''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000051|GTC:G41052GC|CID:70698375|CHEBI:71561  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' : Sd^a /Cad <br>
-'''function''' : Appears in human alpha-fetoprotein (AFP).[PMID:7679920] <br>
+  '''function''' :  <br>
-'''disease_associations''' : hepatocellular carcinoma[PMID:7679920]. <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>
-===GD000136===
+===GSD000146===
-'''term (main_entry)''' : Nonsialylated <br>
+ '''term (main_entry)''' : SDlex <br>
-'''glycan_dictionary_accession''' : GD000136 <br>
+ '''glycan_dictionary_accession''' : GSD000146 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G19619KS G19619KS] <br>
-'''term_in_sentence''' : The pattern of nonsialylated oligosaccharides was used for interpretation of the fully sialylated species using bioinformatics tools. From pooled human plasma, we find 90, 101, and 64 different glycan compositions for genetic variants ORM1*F1, ORM1*S, and ORM2, respectively. Glycan structures carry dominantly between 15 and 16 sialic acids indicating an almost complete termination of all antenae with sialic acid.[PMID:30295034] <br>
+ '''term_in_sentence''' : Hepatic expression of sialylated difucosyl Lex antigen (SDLex, NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-) was studied with monoclonal antibody FH6, which defines this structure.[PMID: [https://pubmed.ncbi.nlm.nih.gov/3341453 3341453]] <br>
-'''publication''' : 14533820|1377689|9705949|30788437|28090561|12498371|26839900|31490688|2656426|30295034|31545048|12381155|25730103|26787879|25646460|29224385|26063435|26954852|32889432|2825412|27504786|22431161 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30226570 30226570]|[https://pubmed.ncbi.nlm.nih.gov/3341453 3341453]|[https://pubmed.ncbi.nlm.nih.gov/12725333 12725333] <br>
-'''definition''' : A glycan which is not sialylated. <br>
+ '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:148203] <br>
-'''term_xref''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000032|GTC:G19619KS|CID:91856705|CHEBI:148203  <br>
-'''best_match''' :  <br>
+ '''synonyms''' : Sdlex|SDLe^x|SDLex <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000137===
+===GSD000147===
-'''term (main_entry)''' : O-fucose glycans <br>
+ '''term (main_entry)''' : Seminolipid <br>
-'''glycan_dictionary_accession''' : GD000137 <br>
+ '''glycan_dictionary_accession''' : GSD000147 <br>
-'''glytoucan_accession ''' : G39294YF <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72548RZ G72548RZ] <br>
-'''term_in_sentence''' : Recently, a number of laboratories have shown that O-fucose glycans on the epidermal growth factor (EGF)-like repeats of the Notch extracellular domain modulate Notch signaling.[PMID:12417415] <br>
+ '''term_in_sentence''' : A concise total synthesis of seminolipid, a sulfoglycolipid, has been achieved; key features include regioselective, tin-free sulfation of allyl β-d-galactopyranoside using 2,6-bis(trifluoromethyl)phenylboronic acid as protective reagent, stereoselective epoxidation, and site-selective acylation. [PMID: [https://pubmed.ncbi.nlm.nih.gov/31353379 31353379]] <br>
-'''publication''' : 19594638|30690220|18952191|22415200|12417415|16400812|18948267|21464368|20816394|30207383|20301232|27129198|17132502|22492969|30030822|30214079|26175457|25378397|18272537|28729422|11524432|31722217|23045360|24803430|28876865|25700513|32518939|30523691|18227520|20816217|24909690|17964136|12036964|27268051|15653671|19948734|31590629|32201074|15189151|17263732|32913123|12909620|28785176|17132500|22949680|25053492|28939751 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31353379 31353379]|[https://pubmed.ncbi.nlm.nih.gov/31736776 31736776]|[https://pubmed.ncbi.nlm.nih.gov/12810822 12810822]|[https://pubmed.ncbi.nlm.nih.gov/19582571 19582571]|[https://pubmed.ncbi.nlm.nih.gov/19542524 19542524]|[https://pubmed.ncbi.nlm.nih.gov/20670037 20670037]|[https://pubmed.ncbi.nlm.nih.gov/15659616 15659616]|[https://pubmed.ncbi.nlm.nih.gov/20817833 20817833]|[https://pubmed.ncbi.nlm.nih.gov/870059 870059]|[https://pubmed.ncbi.nlm.nih.gov/10801776 10801776]|[https://pubmed.ncbi.nlm.nih.gov/21965315 21965315]|[https://pubmed.ncbi.nlm.nih.gov/8095813 8095813]|[https://pubmed.ncbi.nlm.nih.gov/1280685 1280685]|[https://pubmed.ncbi.nlm.nih.gov/4690236 4690236]|[https://pubmed.ncbi.nlm.nih.gov/34199863 34199863]|[https://pubmed.ncbi.nlm.nih.gov/4207869 4207869]|[https://pubmed.ncbi.nlm.nih.gov/2373957 2373957]|[https://pubmed.ncbi.nlm.nih.gov/845131 845131]<br>
-'''definition''' : Form of glycosylation where the protein is modified by a fucose residue and can be extended futher to form a tetrasaccharide in certain cases. alpha-linked o-fucose have a consensus motif of C2X4(s/T)C3 where C2 and C3 are conserved cysteines number 2 and 3 respectively of the EGFR like repeats. [NBK453017-Chapter13] <br>
+ '''definition''' :  <br>
-'''term_xref''' : GlycoEpitope:EP0005 <br>
+ '''term_xref''' : GlycoMotif:GGM.000062|GTC:G72548RZ  <br>
-'''best_match''' : GTC:G39294YF|GlycoEpitope:EP0005 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' : modification of Notch signaling.[GlycoEpitope:EP0005] <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000138===
+===GSD000148===
-'''term (main_entry)''' : O-GlcNAc <br>
+ '''term (main_entry)''' : Sialopentaosylceramide <br>
-'''glycan_dictionary_accession''' : GD000138 <br>
+ '''glycan_dictionary_accession''' : GSD000148 <br>
-'''glytoucan_accession ''' : G49108TO <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G13224CR G13224CR] <br>
-'''term_in_sentence''' : A better understanding of the mechanisms of OGT/OGA action would enable us to derive therapeutic benefits of resetting cellular O-GlcNAc levels within an optimal range.[PMID:30464755] <br>
+ '''term_in_sentence''' : Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosap[PMID: [https://pubmed.ncbi.nlm.nih.gov/2139874 2139874]] <br>
-'''publication''' : 30464755|29049853|29594839|31654859|29404877|30105004|30669087|29790000|28408483|26862193|30523150|30037904|28408480|29352075|29456783|29577901|29223644|28638491|30221662|29904918|32155042|30298013|31630803|31847126|29784830|30181664|28768194|30134155|25336654|30356792|30199580|32329777|28408494|29774032|29044951|23836420|20301273|29772801|28922739|30100348|30793403|30657688|31237748|29756380|29954943|30018219|32207184|25566193|30626734|24759912| <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2139874 2139874] <br>
-'''definition''' : Form of glycosylation which exclusively occurs in the mitochondrial, cytoplasmic or nuclear compartments of the cell where the protein is modified by a GlcNAc monosaccharide on the serine or threonine residues and is generally not modified or elongated further to form more complex structures. [NBK453063-Chapter19] <br>
+ '''definition''' : A ganglioside in which the oligosaccharide portion is composed of a pentasaccharide containing one or more sialic acid residues.[CHEBI:36542] <br>
-'''term_xref''' : GlycoEpitope:EP0004|CID:24139|HMDB:HMDB0000803 <br>
+ '''term_xref''' : GlycoMotif:GGM.000097|GTC:G13224CR|CID:91859576|CHEBI:148045|KEGG:G00883|CHEBI:36542 <br>
-'''best_match''' : GTC:G49108TO|GlycoEpitope:EP0004|CID:24139|HMDB:HMDB0000803 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000139===
+===GSD000149===
-'''term (main_entry)''' : O-linked glycans <br>
+ '''term (main_entry)''' : Sialosyl paragloboside <br>
-'''glycan_dictionary_accession''' : GD000139 <br>
+ '''glycan_dictionary_accession''' : GSD000149 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G50123ZO G50123ZO] <br>
-'''term_in_sentence''' : Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.[PMID:29865036] <br>
+ '''term_in_sentence''' : Unlike CNS myelin, human peripheral nerve myelin has the acidic glycosphingolipids sialosyl paragloboside (SPG), sialosyl lactosaminyl paragloboside (SLPG), and sulfated glucuronyl paragloboside (SGPG).[PMID:[https://pubmed.ncbi.nlm.nih.gov/8862128 8862128]] <br>
-'''publication''' : 29865036|30952424|31611643|19577919|32019882|19139197|26184710|11159917|21536259|25186198|19277556|22261557|24115046|18725413|15966855|24256304|25477510|10359703|24406064|22259135|29279989|15966855|30619255|9673446|31676555|28745859|28196325|27975143|30591584|28518173|17522109|26328495|32178593|27529638|24663386|22474328|28096352|27496768|18952191|11135308|24917611|11532966|22786570|11891229|18332077|26867212|26925665|16769205|23475718|16005634|28785176 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/8862128 8862128]|[https://pubmed.ncbi.nlm.nih.gov/7236652 7236652]|[https://pubmed.ncbi.nlm.nih.gov/2370108 2370108]|[https://pubmed.ncbi.nlm.nih.gov/3133978 3133978]|[https://pubmed.ncbi.nlm.nih.gov/2905604 2905604]|[https://pubmed.ncbi.nlm.nih.gov/1749114 1749114]|[https://pubmed.ncbi.nlm.nih.gov/1573418 1573418] <br>
-'''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the hydroxyl oxygen of serine, threonine, hydroxylysine or hydroxyproline side-chains.[CHEBI:59521] <br>
+ '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-D-GlcpNAc with β configuration at the anomeric position of the reducing-end N-acetyl-D-glucosamine residue.[CHEBI:71612] <br>
-'''term_xref''' : CHEBI:59521 <br>
+ '''term_xref''' : GlycoMotif:GGM.000081|GTC:G50123ZO|CID:91845504|KEGG:G01429|CHEBI:151914  <br>
-'''best_match''' : CHEBI:59521 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' : Affects several important activities like protein stability, modulation of signaling molecules and enzyme activity.[PMID:9673446] <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' : Cancers[https://doi.org/10.1016/bs.acr.2014.11.002] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000140===
+===GSD000150===
-'''term (main_entry)''' : O-linked mannose <br>
+ '''term (main_entry)''' : Sialyl Lewis a <br>
-'''glycan_dictionary_accession''' : GD000140 <br>
+ '''glycan_dictionary_accession''' : GSD000150 <br>
-'''glytoucan_accession ''' : G59126YU <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00053MO G00053MO] <br>
-'''term_in_sentence''' : Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2) catalyzes the first step toward the functional matriglycan structure on alpha-dystroglycan that is responsible for binding extracellular matrix proteins and certain arenaviruses.[PMID: 27932460] <br>
+ '''term_in_sentence''' : By comparing the serum O-glycan profiles from healthy controls with those of cancer patients, we identified a marker candidate, core 1 sialyl Lewis A (NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal) (abbreviated C1SLA), whose concentration appeared to be weakly correlated with CA19-9 values.[PMID: [https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]] <br>
-'''publication''' : 27932460|24526361|25381909|26644575|23851827|28810660|19054127|23929950|21684258|22608994|28973932|24733390|31851597|29884773|28711406|14577328|21089343|14617637|9838223|17072003|26328495|11181560|31949166|31988979|20362685|27733679|27493216|20044576|30643095|29732660|10580142|14568618|28079948|15467391|27812179|23761899|25737452|32930586|25381372|23434682|16857188|21452199|19429925|25361541|24297939|30322079|23428289|28427937|22746206|27533452|17502374|20816174|27496765 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]|[https://pubmed.ncbi.nlm.nih.gov/31424423 31424423]|[https://pubmed.ncbi.nlm.nih.gov/26530370 26530370]|[https://pubmed.ncbi.nlm.nih.gov/17760270 17760270]|[https://pubmed.ncbi.nlm.nih.gov/18343410 18343410]|[https://pubmed.ncbi.nlm.nih.gov/16033091 16033091]|[https://pubmed.ncbi.nlm.nih.gov/8829184 8829184]|[https://pubmed.ncbi.nlm.nih.gov/11907351 11907351]|[https://pubmed.ncbi.nlm.nih.gov/20592391 20592391]|[https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]|[https://pubmed.ncbi.nlm.nih.gov/24128856 24128856]|[https://pubmed.ncbi.nlm.nih.gov/30249386 30249386]|[https://pubmed.ncbi.nlm.nih.gov/10773785 10773785]|[https://pubmed.ncbi.nlm.nih.gov/16149606 16149606]|[https://pubmed.ncbi.nlm.nih.gov/10996727 10996727]|[https://pubmed.ncbi.nlm.nih.gov/10436809 10436809]|[https://pubmed.ncbi.nlm.nih.gov/10667238 10667238]|[https://pubmed.ncbi.nlm.nih.gov/7720892 7720892]|[https://pubmed.ncbi.nlm.nih.gov/7630017 7630017]|[https://pubmed.ncbi.nlm.nih.gov/10612415 10612415]|[https://pubmed.ncbi.nlm.nih.gov/9836451 9836451]|[https://pubmed.ncbi.nlm.nih.gov/12511721 12511721]|[https://pubmed.ncbi.nlm.nih.gov/22623153 22623153] <br>
-'''definition''' : O-linked glycans that are initiated by the addtion of a Man residue to Ser or Thr. Subsequent extension of the Man defines the O-Man core type, either M1, M2, or M3. The M1 type is initated by addition of a GlcNAc in β-linkage to the 2 position of the Man residue. M2 is initiated by addition of another GlcNAc to the 6 position of the M1 core. M3 is initiated by the addition of a GlcNAc in β-linkage to the 4 position of the Man residue. M1 and M2 type core glycans can be extended and branched with Gal, Fuc, Sialic Acid, and GlcA. The M3 core is uniquely extended by a multienzyme system to generate the matriglycan polysaccharide, a protein-specific modification found only on alpha-dystroglycan. [CHEBI:87761] <br>
+ '''definition''' : A sialyated version of Lewis A with a branched structure of amino tetrasaccharide consisting of a sialyl residue, linked (2→3) to a galactosyl residue that in turn is linked (1→3) to a glucosaminyl residue at the reducing end, which is also carrying a fucosyl residue at the 4-position.[CHEBI:62681] <br>
-'''term_xref''' : GlycoMotif:GGM.000055|CHEBI:87761|GlycoEpitope:EP0002|CID:91859038 <br>
+ '''term_xref''' : GTC:G00053MO|GlycoEpitope:EP0008|CID:53356732|CHEBI:62681|GlycoMotif:GGM.000024 <br>
-'''best_match''' : GlycoMotif:000055|GTC:G59126YU|CHEBI:87761|GlycoEpitope:EP0002|CID:91859038 <br>
+ '''synonyms''' : SLea|CA19-9|CA19-9 antigen|SLe^a|Slea <br>
-'''synonymns''' : O-mannosyl glycan <br>
+ '''function''' : The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0008] <br>
-'''function''' :  <br>
+ '''disease_associations''' : pancreatic adenocarcinoma[GlycoEpitope:EP0008]|hepatocellular cancer[GlycoEpitope:EP0008]|cholangiocellular cancer[GlycoEpitope:EP0008]|gastric cancer|[GlycoEpitope:EP0008]colorectal cancer[GlycoEpitope:EP0008]|ovarian cancer[GlycoEpitope:EP0008]|lung cancer[GlycoEpitope:EP0008]|breast cancer[GlycoEpitope:EP0008]|uterine cancer[GlycoEpitope:EP0008] <br>
-'''disease_associations''' : MEB/muscle-eye-brain disease[GlycoEpitope:EP0002]|WWS/walker-warburg syndrome |muscular dystrophy[GlycoEpitope:EP0002]|neuronal migration disorder[GlycoEpitope:EP0002]|Muscle-Eye-Brain disease (MEB) and Walker-Warburg Syndrome (WWS) have mutations in genes encoding glycosyltransferases needed for O -mannosyl oligosaccharide synthesis[GlycoEpitope:EP0002]|Muscular dystrophy and neuronal migration disorder are caused by mutations in a glycosyltransferase, POMGnT1.[GlycoEpitope:EP0002] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000141===
+===GSD000151===
-'''term (main_entry)''' : P1 antigen <br>
+[[File:G00054MO.png|thumb|G00054MO]]
-'''glycan_dictionary_accession''' : GD000141 <br>
+ '''term (main_entry)''' : Sialyl Lewis x <br>
-'''glytoucan_accession ''' : G12460DL <br>
+ '''glycan_dictionary_accession''' : GSD000151 <br>
-'''term_in_sentence''' : The P1 antigen was disovered in 1927 by Landsteiner and Levine, and Pk and NOR were described in 1951 and 1982, respectively.[PMID: 24046920] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00054MO G00054MO] <br>
-'''publication''' : 29622537|26773500|24046920|6207232|8550516|6609976|6375319|817855|2428855|3312011|15364312|1937801|7729906 <br>
+ '''term_in_sentence''' : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]] <br>
-'''definition''' : An amino pentasaccharide consisting of α-D-galactose, β-D-galactose N-acetyl-α-D-glucosamine, β-D-galactose, and β-D-glucose residues joined in sequence with ((1→4)-, (1→4)-, (1→3)- and (1→4)-linkages, respectively.[CHEBI:68484] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]|[https://pubmed.ncbi.nlm.nih.gov/8940172 8940172]|[https://pubmed.ncbi.nlm.nih.gov/10075923 10075923]|[https://pubmed.ncbi.nlm.nih.gov/19054801 19054801]|[https://pubmed.ncbi.nlm.nih.gov/9642161 9642161]|[https://pubmed.ncbi.nlm.nih.gov/31054033 31054033]|[https://pubmed.ncbi.nlm.nih.gov/15229399 15229399]|[https://pubmed.ncbi.nlm.nih.gov/29061785 29061785]|[https://pubmed.ncbi.nlm.nih.gov/16033070 16033070]|[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]| [https://pubmed.ncbi.nlm.nih.gov/8940172 8940172]|[https://pubmed.ncbi.nlm.nih.gov/9298692 9298692]|[https://pubmed.ncbi.nlm.nih.gov/18607721 18607721]|[https://pubmed.ncbi.nlm.nih.gov/22593503 22593503]|[https://pubmed.ncbi.nlm.nih.gov/25944902 25944902]| [https://pubmed.ncbi.nlm.nih.gov/9642161 9642161]|[https://pubmed.ncbi.nlm.nih.gov/15780091 15780091]|[https://pubmed.ncbi.nlm.nih.gov/20401888 20401888] <br>
-'''term_xref''' : GlycoMotif:GGM.000069|CID:71296137|CHEBI:68484|SugarBind_Ligand:160 <br>
+ '''definition''' : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH: 2030970],CHEI:71622 <br>
-'''best_match''' : GlycoMotif:GGM.000069|GTC:G12460DL|CID:71296137|CHEBI:68484|SugarBind_Ligand:160 <br>
+ '''term_xref''' : GTC:G00054MO |GlycoEpitope:EP0012|CID: 44456859|CHEBI:71622|MESH: 2030970|GlycoMotif:GGM.000022  <br>
-'''synonymns''' :  <br>
+ '''synonyms''' : SLe(x)|SLe^x|SLex|Slex <br>
-'''function''' :  <br>
+  '''function''' : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012] <br>
-'''disease_associations''' : Shigellosis[SugarBind_Ligand:160] <br>
+ '''disease_associations''' : colon cancer[GlycoEpitope:EP0012]|colorectal cancer[GlycoEpitope:EP0012] <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453054 <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000142===
+===GSD000152===
-'''term (main_entry)''' : Para-Forssman glycolipid <br>
+ '''term (main_entry)''' : Sialyl Lewis x-i <br>
-'''glycan_dictionary_accession''' : GD000142 <br>
+ '''glycan_dictionary_accession''' : GSD000152 <br>
-'''glytoucan_accession ''' : G51699SI <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G06597DS G06597DS] <br>
-'''term_in_sentence''' : A novel pentaglycosyl ceramide containing di-beta-N-acetylgalactos-aminyl residue (Para-Forssman glycolipid) isolated from human erythrocyte membrane. [PMID:6814203] <br>
+ '''term_in_sentence''' : Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9815711 9815711]] <br>
-'''publication''' : 6814203 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9815711 9815711]|[https://pubmed.ncbi.nlm.nih.gov/9730796 9730796]|[https://pubmed.ncbi.nlm.nih.gov/11867833 11867833]|[https://pubmed.ncbi.nlm.nih.gov/9713476 9713476]|[https://pubmed.ncbi.nlm.nih.gov/2819663 2819663]|[https://pubmed.ncbi.nlm.nih.gov/9372327 9372327]|[https://pubmed.ncbi.nlm.nih.gov/9615762 9615762]|[https://pubmed.ncbi.nlm.nih.gov/1352835 1352835]|[https://pubmed.ncbi.nlm.nih.gov/2575680 2575680]|[https://pubmed.ncbi.nlm.nih.gov/9330526 9330526]|[https://pubmed.ncbi.nlm.nih.gov/8753037 8753037]|[https://pubmed.ncbi.nlm.nih.gov/2210805 2210805]|[https://pubmed.ncbi.nlm.nih.gov/12680155 12680155]|[https://pubmed.ncbi.nlm.nih.gov/11974864 11974864]|[https://pubmed.ncbi.nlm.nih.gov/10453898 10453898]|[https://pubmed.ncbi.nlm.nih.gov/2565704 2565704]|[https://pubmed.ncbi.nlm.nih.gov/17144590 17144590] <br>
-'''definition''' : GalNAcβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1Cer [https://doi.org/10.1016/S0040-4039(01)93814-6] <br>
+ '''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000085|CID:56836111|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565 <br>
+ '''term_xref''' : GTC:G06597DS|GlycoEpitope:EP0043|CID: 91855346|CHEBI:147019 <br>
-'''best_match''' : GlycoMotif:GGM.000085|GTC:G51699SI|CID:56836111|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043] <br>
-'''function''' :  <br>
+ '''disease_associations''' : lung cancer[GlycoEpitope:EP0043]|ovarian cancer[GlycoEpitope:EP0043]|pancreatic adenocarcinoma[GlycoEpitope:EP0043] <br>
-'''disease_associations''' : Actinomycosis[SugarBind_Ligand:19] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' : https://en.wikipedia.org/wiki/P1PK_blood_group_system <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000143===
+===GSD000153===
-'''term (main_entry)''' : Paragloboside <br>
+ '''term (main_entry)''' : Sialyl T antigen <br>
-'''glycan_dictionary_accession''' : GD000143 <br>
+ '''glycan_dictionary_accession''' : GSD000153 <br>
-'''glytoucan_accession ''' : G58896AZ <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G65562ZE G65562ZE] <br>
-'''term_in_sentence''' : Galactosyltransferase activities in sera of cancer patients were determined by assaying the formation of paragloboside from UDP-galactose and lactotriaosylceramide immobilized on microtiter plates by means of the enzyme-linked immunosorbent assay using a monoclonal antibody, H-11, directed to paragloboside. [PMID: 1551117] <br>
+ '''term_in_sentence''' : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]] <br>
-'''publication''' : 3345524|850070|10569746|30624951|29438961|6816790|1551117|6865961|25039255 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]|[https://pubmed.ncbi.nlm.nih.gov/31897478 31897478]|[https://pubmed.ncbi.nlm.nih.gov/31719620 31719620]|[https://pubmed.ncbi.nlm.nih.gov/10365852 10365852]|[https://pubmed.ncbi.nlm.nih.gov/25727149 25727149]|[https://pubmed.ncbi.nlm.nih.gov/11523928 11523928]|[https://pubmed.ncbi.nlm.nih.gov/20407596 20407596]|[https://pubmed.ncbi.nlm.nih.gov/25464017 25464017]|[https://pubmed.ncbi.nlm.nih.gov/30864133 30864133]|[https://pubmed.ncbi.nlm.nih.gov/26391208 26391208]|[https://pubmed.ncbi.nlm.nih.gov/19811634 19811634]|[https://pubmed.ncbi.nlm.nih.gov/29796594 29796594]|[https://pubmed.ncbi.nlm.nih.gov/23725156 23725156]|[https://pubmed.ncbi.nlm.nih.gov/8905873 8905873]|[https://pubmed.ncbi.nlm.nih.gov/11192238 11192238]|[https://pubmed.ncbi.nlm.nih.gov/18275089 18275089]|[https://pubmed.ncbi.nlm.nih.gov/27037304 27037304]|[https://pubmed.ncbi.nlm.nih.gov/11949946 11949946]|[https://pubmed.ncbi.nlm.nih.gov/15604091 15604091]|[https://pubmed.ncbi.nlm.nih.gov/24118321 24118321] <br>
-'''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is α.[CHEBI:65257] <br>
+ '''definition''' : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257] <br>
-'''term_xref''' : GlycoMotif:GGM.000077|CID:21670519|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15 <br>
+ '''term_xref''' : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:44611726|CHEBI:65257<br>
-'''best_match''' : GlycoMotif:GGM.000077|GTC:G58896AZ|CID:21670519|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' : Pharyngitis[SugarBind_Ligand:15]|Tracheobronchitis[SugarBind_Ligand:15]|Gonorrhea[SugarBind_Ligand:15]|Actinomycosis[SugarBind_Ligand:15]|Diarrhea[SugarBind_Ligand:15]|Hemorrhagic colitis[SugarBind_Ligand:15]|Chronic gastritis[SugarBind_Ligand:15]|Peptic ulcers[SugarBind_Ligand:15]|Gastric cancer[SugarBind_Ligand:15]|Influenza[SugarBind_Ligand:15] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
-===GD000144===
+===GSD000154===
-'''term (main_entry)''' : Paucimannose <br>
+ '''term (main_entry)''' : Sialylated biantennary <br>
-'''glycan_dictionary_accession''' : GD000144 <br>
+ '''glycan_dictionary_accession''' : GSD000154 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The galactosylation of core fucose (GalFuc epitope) in paucimannose and complex-type N-glycans is characteristic of protostome organisms, including flatworms (planarians).[PMID:29475940] <br>
+ '''term_in_sentence''' : Simbucus nigra agglutinin or an antibody specific to sialylated lactosamine with a preference for Neu5Acalpha2-6Gal rather than Neu5Acalpha2-3Gal reduced sperm binding to oviduct isthmic cells, as did occupying putative receptors on sperm with sialylated biantennary glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]] <br>
-'''publication''' : 29475940|29803109|12603202|31817246|31719144|21057214|31932305|17132514|30382146|27731363|31325506|25746926|26513758|16522637|21169367|25190359|27928741|22496646|27384337|16897177|15228383|27379103|27189951|23475714|24907509|20558211|28060516|20441997|27720757|28817611|24550396|19494052|19515361|28630087|31320997|30651366|30253927|25922361|31655162|18056652|24467287|32367383 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]|[https://pubmed.ncbi.nlm.nih.gov/31510952 31510952]|[https://pubmed.ncbi.nlm.nih.gov/29265394 29265394]|[https://pubmed.ncbi.nlm.nih.gov/31589880 31589880]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/26045275 26045275]|[https://pubmed.ncbi.nlm.nih.gov/29029079 29029079]|[https://pubmed.ncbi.nlm.nih.gov/30252064 30252064] <br>
-'''definition''' : Any N-linked glycan derivative with composition Man1-4Fuc0-1 GlcNAc2, in which the chitobiose core (GlcNAc2) is intact. Found in relatively large amounts in invertebrates and plants, they are formed by removal of the non-reducing terminal GlcNAc (\added by GlcNAcT1) from GlcNAcMan3-5GlcNAc2 by a Golgi hexosaminidase and subsequent removal of Man residues by Golgi mannosidases. Pauscimannose glycans have also been detected in vertebrates.[CHEBI:144386] <br>
+ '''definition''' : A binantennary glycan with one or two sialic acid residues as non-reducing terminal residues on one or both antennae. [RN] <br>
-'''term_xref''' : CHEBI:144386 <br>
+ '''term_xref''' :  <br>
-'''best_match''' : CHEBI:144386 <br>
+ '''synonyms''' : sialyl biantennary <br>
-'''synonymns''' :  <br>
+  '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000145===
+===GSD000155===
-'''term (main_entry)''' : Sd(A)/Cad <br>
+ '''term (main_entry)''' : Sialylated complex-type <br>
-'''glycan_dictionary_accession''' : GD000145 <br>
+ '''glycan_dictionary_accession''' : GSD000155 <br>
-'''glytoucan_accession ''' : G41052GC <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2.[PMID:24112972] <br>
+ '''term_in_sentence''' : By using 1H-NMR spectroscopy we were able to establish that our product contains a single N-linked biantennary , fully sialylated complex-type oligosaccharide , typical of human hepatomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1694115 1694115]] <br>
-'''publication''' : 24112972|11577689|30067891|15361072 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1694115 1694115]|[https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]|[https://pubmed.ncbi.nlm.nih.gov/30471292 30471292]|[https://pubmed.ncbi.nlm.nih.gov/30969765 30969765]|[https://pubmed.ncbi.nlm.nih.gov/11058758 11058758]|[https://pubmed.ncbi.nlm.nih.gov/28342150 28342150] <br>
-'''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, β-D-galactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the galactose residue of which is also linked (1→4) an N-acetyl-β-L-galactosamine residue.
+ '''definition''' : Complex N-linked glycan that have added GlcNAc residues at both the α-3 and α-6 mannose sites and do not contain mannose residues apart from the core structure but with sialic acid residues. <br>
-[CHEBI:71561] <br>
+ '''term_xref''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000051|CID:70698375|CHEBI:71561 <br>
+ '''synonyms''' : sialo-complex type <br>
-'''best_match''' : GlycoMotif:GGM.000051|GTC:G41052GC|CID:70698375|CHEBI:71561 <br>
+ '''function''' : enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes [PMID: [https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]] Appears in IgG-Fc.[PMID:[https://pubmed.ncbi.nlm.nih.gov/20647032 20647032] ] <br>
-'''synonymns''' : Sd^a /Cad <br>
+  '''disease_associations''' :  <br>
-'''function''' :  <br>
+ '''wikipedia''' :  <br>
-'''disease_associations''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453020-Chapter 9 <br>
-===GD000146===
+===GSD000156===
-'''term (main_entry)''' : SDlex <br>
+ '''term (main_entry)''' : Sialylated tetraantennary <br>
-'''glycan_dictionary_accession''' : GD000146 <br>
+ '''glycan_dictionary_accession''' : GSD000156 <br>
-'''glytoucan_accession ''' : G19619KS <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Hepatic expression of sialylated difucosyl Lex antigen (SDLex, NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-) was studied with monoclonal antibody FH6, which defines this structure.[PMID: 3341453] <br>
+ '''term_in_sentence''' : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]] <br>
-'''publication''' : 30226570|3341453|12725333 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]| [https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]| [https://pubmed.ncbi.nlm.nih.gov/27501865 27501865] <br>
-'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:148203] <br>
+ '''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
-'''term_xref''' : GlycoMotif:GGM.000032|CID:91856705|CHEBI:148203 <br>
+ '''term_xref''' :  <br>
-'''best_match''' : GlycoMotif:GGM.000032|GTC:G19619KS|CID:91856705|CHEBI:148203 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' : Sdlex|SDLe^x|SDLex <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
-===GD000147===
+===GSD000157===
-'''term (main_entry)''' : Seminolipid <br>
+ '''term (main_entry)''' : Sialyl-Tn antigen <br>
-'''glycan_dictionary_accession''' : GD000147 <br>
+ '''glycan_dictionary_accession''' : GSD000157 <br>
-'''glytoucan_accession ''' : G72548RZ <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G36123IU G36123IU] <br>
-'''term_in_sentence''' : A concise total synthesis of seminolipid, a sulfoglycolipid, has been achieved; key features include regioselective, tin-free sulfation of allyl β-d-galactopyranoside using 2,6-bis(trifluoromethyl)phenylboronic acid as protective reagent, stereoselective epoxidation, and site-selective acylation. [PMID: 31353379] <br>
+ '''term_in_sentence''' : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]] <br>
-'''publication''' : 31353379|31736776|12810822|19582571|19542524|20670037|15659616|20817833|870059|10801776|21965315|8095813|1280685|4690236|34199863|4207869|2373957|845131 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]|[https://pubmed.ncbi.nlm.nih.gov/29273237 29273237]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/31595388 31595388]|[https://pubmed.ncbi.nlm.nih.gov/26617889 26617889]|[https://pubmed.ncbi.nlm.nih.gov/1720922 1720922]|[https://pubmed.ncbi.nlm.nih.gov/15466199 15466199]|[https://pubmed.ncbi.nlm.nih.gov/10971172 10971172]|[https://pubmed.ncbi.nlm.nih.gov/14652017 14652017]|[https://pubmed.ncbi.nlm.nih.gov/8616877 8616877]|[https://pubmed.ncbi.nlm.nih.gov/1543361 1543361]|[https://pubmed.ncbi.nlm.nih.gov/16965854 16965854]|[https://pubmed.ncbi.nlm.nih.gov/21566901 21566901]|[https://pubmed.ncbi.nlm.nih.gov/9269833 9269833]|[https://pubmed.ncbi.nlm.nih.gov/9834267 9834267]|[https://pubmed.ncbi.nlm.nih.gov/24970145 24970145]| [https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]| [https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/30018351 30018351]|[https://pubmed.ncbi.nlm.nih.gov/28628803 28628803]| [https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/28632300 28632300]|[https://pubmed.ncbi.nlm.nih.gov/11308020 11308020]| [https://pubmed.ncbi.nlm.nih.gov/10365852 10365852]|[https://pubmed.ncbi.nlm.nih.gov/17195456 17195456]|[https://pubmed.ncbi.nlm.nih.gov/23567325 23567325]|[https://pubmed.ncbi.nlm.nih.gov/11014575 11014575]|[https://pubmed.ncbi.nlm.nih.gov/2342728 2342728]|[https://pubmed.ncbi.nlm.nih.gov/8575847 8575847]|[https://pubmed.ncbi.nlm.nih.gov/1851822 1851822]|[https://pubmed.ncbi.nlm.nih.gov/11735169 11735169]|[https://pubmed.ncbi.nlm.nih.gov/20960853 20960853]|[https://pubmed.ncbi.nlm.nih.gov/7846011 7846011] <br>
-'''definition''' :  <br>
+ '''definition''' : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818] <br>
-'''term_xref''' : GlycoMotif:GGM.000062 <br>
+ '''term_xref''' : GTC:G36123IU|GlycoEpitope:EP0022|CID: 51351800|CHEBI:61818  <br>
-'''best_match''' : GlycoMotif:GGM.000062|GTC:G72548RZ <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022] <br>
-'''function''' :  <br>
+ '''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0022]|Barrett's esophagus[GlycoEpitope:EP0022]|bladder cancer[GlycoEpitope:EP0022]|breast cancer[GlycoEpitope:EP0022]|colon cancer[GlycoEpitope:EP0022]|colorectal cancer[GlycoEpitope:EP0022]|erythroblastic leukemia[GlycoEpitope:EP0022]|esophageal cancer[GlycoEpitope:EP0022]|gastric cancer[GlycoEpitope:EP0022]|helicobacter pylori chronic gastritis(HpCG)[GlycoEpitope:EP0022]|liver cancer[GlycoEpitope:EP0022]|iterome cancer[GlycoEpitope:EP0022]|ovary tumor[GlycoEpitope:EP0022]|pancreas cancer[GlycoEpitope:EP0022] <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453027/ Chapter 56]<br>
-'''essentials_of_glycobiology''' : NBK453042 <br>
-===GD000148===
+===GSD000158===
-'''term (main_entry)''' : Sialopentaosylceramide <br>
+ '''term (main_entry)''' : SLex Core 2 O-glycan <br>
-'''glycan_dictionary_accession''' : GD000148 <br>
+ '''glycan_dictionary_accession''' : GSD000158 <br>
-'''glytoucan_accession ''' : G13224CR <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97345NY G97345NY] <br>
-'''term_in_sentence''' : Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosap[PMID: 2139874] <br>
+ '''term_in_sentence''' : In particular, the sLeX-modified core 2 O-glycan structure C2-O-sLeX has been directly demonstrated to confer significantly higher affinity selectin binding than sLeX.[PMID:[https://pubmed.ncbi.nlm.nih.gov/15596301 15596301]] <br>
-'''publication''' : 2139874 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15596301 15596301] <br>
-'''definition''' : A ganglioside in which the oligosaccharide portion is composed of a pentasaccharide containing one or more sialic acid residues.[CHEBI:36542] <br>
+ '''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000097|CID:91859576|CHEBI:148045|KEGG:G00883|CHEBI:36542 <br>
+ '''term_xref''' : GlycoMotif:GGM.000053|GTC:G97345NY  <br>
-'''best_match''' : GlycoMotif:GGM.000097|GTC:G13224CR|CID:91859576|CHEBI:148045|KEGG:G00883|CHEBI:36542 <br>
+ '''synonyms''' : SLe^x Core 2 O-glycan <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000149===
+===GSD000159===
-'''term (main_entry)''' : Sialosyl paragloboside <br>
+ '''term (main_entry)''' : SSEA-1 <br>
-'''glycan_dictionary_accession''' : GD000149 <br>
+ '''glycan_dictionary_accession''' : GSD000159 <br>
-'''glytoucan_accession ''' : G50123ZO <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G85497PI G85497PI] <br>
-'''term_in_sentence''' : Unlike CNS myelin, human peripheral nerve myelin has the acidic glycosphingolipids sialosyl paragloboside (SPG), sialosyl lactosaminyl paragloboside (SLPG), and sulfated glucuronyl paragloboside (SGPG).[PMID:8862128] <br>
+ '''term_in_sentence''' : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]] <br>
-'''publication''' : 8862128|7236652|2370108|3133978|2905604|1749114|1573418 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]|[https://pubmed.ncbi.nlm.nih.gov/25564944 25564944]|[https://pubmed.ncbi.nlm.nih.gov/30987116 30987116]|[https://pubmed.ncbi.nlm.nih.gov/10778174 10778174]|[https://pubmed.ncbi.nlm.nih.gov/19427293 19427293]|[https://pubmed.ncbi.nlm.nih.gov/24923741 24923741]|[https://pubmed.ncbi.nlm.nih.gov/28092949 28092949]|[https://pubmed.ncbi.nlm.nih.gov/16499901 16499901]|[https://pubmed.ncbi.nlm.nih.gov/10470652 10470652]|[https://pubmed.ncbi.nlm.nih.gov/18787210 18787210]|[https://pubmed.ncbi.nlm.nih.gov/2885312 2885312]|[https://pubmed.ncbi.nlm.nih.gov/16149609 16149609]|[https://pubmed.ncbi.nlm.nih.gov/17003364 17003364]|[https://pubmed.ncbi.nlm.nih.gov/27363517 27363517]|[https://pubmed.ncbi.nlm.nih.gov/15505339 15505339]|[https://pubmed.ncbi.nlm.nih.gov/27990704 27990704]|[https://pubmed.ncbi.nlm.nih.gov/2568298 2568298]|[https://pubmed.ncbi.nlm.nih.gov/20491542 20491542]|[https://pubmed.ncbi.nlm.nih.gov/23572256 23572256]|[https://pubmed.ncbi.nlm.nih.gov/1977666 1977666]|[https://pubmed.ncbi.nlm.nih.gov/9553168 9553168]| [https://pubmed.ncbi.nlm.nih.gov/20458727 20458727]|[https://pubmed.ncbi.nlm.nih.gov/2566639 2566639]|[https://pubmed.ncbi.nlm.nih.gov/14577357 14577357]|[https://pubmed.ncbi.nlm.nih.gov/20960856 20960856]|[https://pubmed.ncbi.nlm.nih.gov/15547746 15547746]|[https://pubmed.ncbi.nlm.nih.gov/9096265 9096265]|[https://pubmed.ncbi.nlm.nih.gov/30639212 30639212]|[https://pubmed.ncbi.nlm.nih.gov/1357195 1357195]|[https://pubmed.ncbi.nlm.nih.gov/1359630 1359630]|[https://pubmed.ncbi.nlm.nih.gov/20181261 20181261]|[https://pubmed.ncbi.nlm.nih.gov/20508065 20508065]|[https://pubmed.ncbi.nlm.nih.gov/2907526 2907526]|[https://pubmed.ncbi.nlm.nih.gov/22624699 22624699]|[https://pubmed.ncbi.nlm.nih.gov/22988836 22988836]|[https://pubmed.ncbi.nlm.nih.gov/17183690 17183690]|[https://pubmed.ncbi.nlm.nih.gov/27188587 27188587]|[https://pubmed.ncbi.nlm.nih.gov/7908065 7908065]|[https://pubmed.ncbi.nlm.nih.gov/10400391 10400391]|[https://pubmed.ncbi.nlm.nih.gov/6137429 6137429]|[https://pubmed.ncbi.nlm.nih.gov/1979260 1979260]|[https://pubmed.ncbi.nlm.nih.gov/2898921 2898921]|[https://pubmed.ncbi.nlm.nih.gov/14736812 14736812]|[https://pubmed.ncbi.nlm.nih.gov/30919971 30919971] <br>
-'''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-D-GlcpNAc with β configuration at the anomeric position of the reducing-end N-acetyl-D-glucosamine residue.[CHEBI:71612] <br>
+ '''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000081|CID:91845504|KEGG:G01429|CHEBI:151914 <br>
+ '''term_xref''' : GTC:G85497PI |GlycoEpitope:EP0042|CID:91851144|CHEBI:154343  <br>
-'''best_match''' : GlycoMotif:GGM.000081|GTC:G50123ZO|CID:91845504|KEGG:G01429|CHEBI:151914 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042] <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000150===
+===GSD000160===
-'''term (main_entry)''' : Sialyl Lewis a <br>
+ '''term (main_entry)''' : SSEA-3 <br>
-'''glycan_dictionary_accession''' : GD000150 <br>
+ '''glycan_dictionary_accession''' : GSD000160 <br>
-'''glytoucan_accession ''' : G00053MO <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25129BT G25129BT] <br>
-'''term_in_sentence''' : By comparing the serum O-glycan profiles from healthy controls with those of cancer patients, we identified a marker candidate, core 1 sialyl Lewis A (NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal) (abbreviated C1SLA), whose concentration appeared to be weakly correlated with CA19-9 values.[PMID:26641888] <br>
+ '''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]] <br>
-'''publication''' : 26641888|31424423|26530370|17760270|18343410|16033091|8829184|11907351|20592391|26641888|24128856|30249386|10773785|16149606|10996727|10436809|10667238|7720892|7630017|10612415|9836451|12511721|22623153 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]|[https://pubmed.ncbi.nlm.nih.gov/30271856 30271856]|[https://pubmed.ncbi.nlm.nih.gov/32684574 32684574]|[https://pubmed.ncbi.nlm.nih.gov/26677875 26677875]|[https://pubmed.ncbi.nlm.nih.gov/23175153 23175153]|[https://pubmed.ncbi.nlm.nih.gov/32525407 32525407]|[https://pubmed.ncbi.nlm.nih.gov/29227830 29227830]|[https://pubmed.ncbi.nlm.nih.gov/18773292 18773292]|[https://pubmed.ncbi.nlm.nih.gov/25561682 25561682]|[https://pubmed.ncbi.nlm.nih.gov/10837462 10837462]| [https://pubmed.ncbi.nlm.nih.gov/2412924 2412924]|[https://pubmed.ncbi.nlm.nih.gov/21149348 21149348]|[https://pubmed.ncbi.nlm.nih.gov/17008424 17008424]| [https://pubmed.ncbi.nlm.nih.gov/2874662 2874662]|[https://pubmed.ncbi.nlm.nih.gov/25171543 25171543]|[https://pubmed.ncbi.nlm.nih.gov/31304790 31304790]|[https://pubmed.ncbi.nlm.nih.gov/31642560 31642560]|[https://pubmed.ncbi.nlm.nih.gov/30484221 30484221]|[https://pubmed.ncbi.nlm.nih.gov/30525067 30525067]|[https://pubmed.ncbi.nlm.nih.gov/21161592 21161592]|[https://pubmed.ncbi.nlm.nih.gov/27325407 27325407]|[https://pubmed.ncbi.nlm.nih.gov/28170296 28170296]|[https://pubmed.ncbi.nlm.nih.gov/29637816 29637816]|[https://pubmed.ncbi.nlm.nih.gov/27318475 27318475]|[https://pubmed.ncbi.nlm.nih.gov/31346146 31346146]|[https://pubmed.ncbi.nlm.nih.gov/7648586 7648586]|[https://pubmed.ncbi.nlm.nih.gov/24236059 24236059]|[https://pubmed.ncbi.nlm.nih.gov/21964054 21964054]|[https://pubmed.ncbi.nlm.nih.gov/27456773 27456773]|[https://pubmed.ncbi.nlm.nih.gov/30558911 30558911]|[https://pubmed.ncbi.nlm.nih.gov/21559451 21559451]|[https://pubmed.ncbi.nlm.nih.gov/29312455 29312455]|[https://pubmed.ncbi.nlm.nih.gov/27549315 27549315]|[https://pubmed.ncbi.nlm.nih.gov/30599359 30599359]|[https://pubmed.ncbi.nlm.nih.gov/6141938 6141938]|[https://pubmed.ncbi.nlm.nih.gov/28883415 28883415]|[https://pubmed.ncbi.nlm.nih.gov/30733757 30733757]|[https://pubmed.ncbi.nlm.nih.gov/26041528 26041528]|[https://pubmed.ncbi.nlm.nih.gov/16643871 16643871] <br>
-'''definition''' : A sialyated version of Lewis A with a branched structure of amino tetrasaccharide consisting of a sialyl residue, linked (2→3) to a galactosyl residue that in turn is linked (1→3) to a glucosaminyl residue at the reducing end, which is also carrying a fucosyl residue at the 4-position.[CHEBI:62681] <br>
+ '''definition''' : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071] <br>
-'''term_xref''' : GlycoEpitope:EP0008|CID:53356732|CHEBI:62681|GlycoMotif:GGM.000024 <br>
+ '''term_xref''' : GTC:G25129BT|GlycoEpitope:EP0039|CID: 91855781|CHEBI:149071|GlycoMotif:GGM.000079  <br>
-'''best_match''' : GTC:G00053MO|GlycoEpitope:EP0008|CID:53356732|CHEBI:62681|GlycoMotif:GGM.000024 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' : SLea|CA19-9|CA19-9 antigen|SLe^a|Slea <br>
+ '''function''' :  <br>
-'''function''' : The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0008] <br>
+ '''disease_associations''' : embryonal carcinoma[GlycoEpitope:EP0039]|teratocarcinoma[GlycoEpitope:EP0039]|yolk sac carcinoma[GlycoEpitope:EP0039] <br>
-'''disease_associations''' : pancreatic adenocarcinoma[GlycoEpitope:EP0008]|hepatocellular cancer[GlycoEpitope:EP0008]|cholangiocellular cancer[GlycoEpitope:EP0008]|gastric cancer|[GlycoEpitope:EP0008]colorectal cancer[GlycoEpitope:EP0008]|ovarian cancer[GlycoEpitope:EP0008]|lung cancer[GlycoEpitope:EP0008]|breast cancer[GlycoEpitope:EP0008]|uterine cancer[GlycoEpitope:EP0008] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000151===
+===GSD000161===
-'''term (main_entry)''' : Sialyl Lewis x <br>
+ '''term (main_entry)''' : SSEA-4 <br>
-'''glycan_dictionary_accession''' : GD000151 <br>
+ '''glycan_dictionary_accession''' : GSD000161 <br>
-'''glytoucan_accession ''' : G00054MO <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G84263XI G84263XI] <br>
-'''term_in_sentence''' : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:12828079] <br>
+ '''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]] <br>
-'''publication''' : 12828079|8940172|10075923|19054801|9642161|31054033|15229399|29061785|16033070|10728707|9556613|8940172|9298692|18607721|22593503|25944902|9642161|15780091|20401888 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27845370 27845370]|[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]|[https://pubmed.ncbi.nlm.nih.gov/26295543 26295543]|[https://pubmed.ncbi.nlm.nih.gov/25171543 25171543]|[https://pubmed.ncbi.nlm.nih.gov/25978997 25978997]|[https://pubmed.ncbi.nlm.nih.gov/30296654 30296654]|[https://pubmed.ncbi.nlm.nih.gov/25853231 25853231]|[https://pubmed.ncbi.nlm.nih.gov/24862940 24862940]|[https://pubmed.ncbi.nlm.nih.gov/31243630 31243630]|[https://pubmed.ncbi.nlm.nih.gov/28736232 28736232]|[https://pubmed.ncbi.nlm.nih.gov/22895512 22895512]|[https://pubmed.ncbi.nlm.nih.gov/24578244 24578244]|[https://pubmed.ncbi.nlm.nih.gov/29478902 29478902]|[https://pubmed.ncbi.nlm.nih.gov/23574147 23574147]|[https://pubmed.ncbi.nlm.nih.gov/23768762 23768762]|[https://pubmed.ncbi.nlm.nih.gov/27797400 27797400]| [https://pubmed.ncbi.nlm.nih.gov/29227830 29227830]|[https://pubmed.ncbi.nlm.nih.gov/18773292 18773292]|[https://pubmed.ncbi.nlm.nih.gov/25123923 25123923]|[https://pubmed.ncbi.nlm.nih.gov/22924692 22924692]|[https://pubmed.ncbi.nlm.nih.gov/22665977 22665977]|[https://pubmed.ncbi.nlm.nih.gov/23330736 23330736]|[https://pubmed.ncbi.nlm.nih.gov/31831622 31831622]|[https://pubmed.ncbi.nlm.nih.gov/31916611 31916611]| [https://pubmed.ncbi.nlm.nih.gov/2412924 2412924]|[https://pubmed.ncbi.nlm.nih.gov/16033656 16033656]|[https://pubmed.ncbi.nlm.nih.gov/24866102 24866102]| [https://pubmed.ncbi.nlm.nih.gov/20458727 20458727]| [https://pubmed.ncbi.nlm.nih.gov/21149348 21149348]|[https://pubmed.ncbi.nlm.nih.gov/26940129 26940129]| [https://pubmed.ncbi.nlm.nih.gov/17008424 17008424]|[https://pubmed.ncbi.nlm.nih.gov/2874662 2874662]|[https://pubmed.ncbi.nlm.nih.gov/23301556 23301556]|[https://pubmed.ncbi.nlm.nih.gov/27836003 27836003]|[https://pubmed.ncbi.nlm.nih.gov/19118716 19118716]|[https://pubmed.ncbi.nlm.nih.gov/24550271 24550271]|[https://pubmed.ncbi.nlm.nih.gov/32988880 32988880]|[https://pubmed.ncbi.nlm.nih.gov/22743677 22743677]|[https://pubmed.ncbi.nlm.nih.gov/20683402 20683402]|[https://pubmed.ncbi.nlm.nih.gov/17062733 17062733]|[https://pubmed.ncbi.nlm.nih.gov/23570331 23570331]|[https://pubmed.ncbi.nlm.nih.gov/30310530 30310530]|[https://pubmed.ncbi.nlm.nih.gov/31545316 31545316]|[https://pubmed.ncbi.nlm.nih.gov/23509763 23509763]|[https://pubmed.ncbi.nlm.nih.gov/24364909 24364909]|[https://pubmed.ncbi.nlm.nih.gov/18273440 18273440]|[https://pubmed.ncbi.nlm.nih.gov/28985528 28985528]|[https://pubmed.ncbi.nlm.nih.gov/22266579 22266579] <br>
-'''definition''' : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH:2030970,CHEI:71622] <br>
+ '''definition''' :  <br>
-'''term_xref''' : GlycoEpitope:EP0012|CID:44456859|CHEBI:71622|MESH:2030970|GlycoMotif:GGM.000022 <br>
+ '''term_xref''' : GTC:G84263XI|GlycoEpitope:EP0044|CID:91845478|CHEBI:154843  <br>
-'''best_match''' : GTC:G00054MO |GlycoEpitope:EP0012|CID:44456859|CHEBI:71622|MESH:2030970|GlycoMotif:GGM.000022 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' : SLe(x)|SLe^x|SLex|Slex <br>
+ '''function''' :  <br>
-'''function''' : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012] <br>
+ '''disease_associations''' : teratocarcinoma[GlycoEpitope:EP0044] <br>
-'''disease_associations''' : colon cancer[GlycoEpitope:EP0012]|colorectal cancer[GlycoEpitope:EP0012] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000152===
+===GSD000162===
-'''term (main_entry)''' : Sialyl Lewis x-i <br>
+ '''term (main_entry)''' : Sulfatide <br>
-'''glycan_dictionary_accession''' : GD000152 <br>
+ '''glycan_dictionary_accession''' : GSD000162 <br>
-'''glytoucan_accession ''' : G06597DS <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72548RZ G72548RZ] <br>
-'''term_in_sentence''' : Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001).[PMID:9815711] <br>
+ '''term_in_sentence''' : In a previous study we found that sulfatide was efficient in lowering HIV-1 viral loads in SCID mice engrafted with human fetal liver/thymus tissues (SCID-hu).[PMID:[https://pubmed.ncbi.nlm.nih.gov/23550344 23550344]] <br>
-'''publication''' : 9815711|9730796|11867833|9713476|2819663|9372327|9615762|1352835|2575680|9330526|8753037|2210805|12680155|11974864|10453898|2565704|17144590 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23550344 23550344]|[https://pubmed.ncbi.nlm.nih.gov/18465098 18465098]|[https://pubmed.ncbi.nlm.nih.gov/26542149 26542149]|[https://pubmed.ncbi.nlm.nih.gov/15158666 15158666]|[https://pubmed.ncbi.nlm.nih.gov/10434709 10434709]|[https://pubmed.ncbi.nlm.nih.gov/22619219 22619219]|[https://pubmed.ncbi.nlm.nih.gov/29676479 29676479]|[https://pubmed.ncbi.nlm.nih.gov/30196830 30196830]|[https://pubmed.ncbi.nlm.nih.gov/16143863 16143863]|[https://pubmed.ncbi.nlm.nih.gov/1052451 1052451]|[https://pubmed.ncbi.nlm.nih.gov/30400820 30400820]|[https://pubmed.ncbi.nlm.nih.gov/29887538 29887538]|[https://pubmed.ncbi.nlm.nih.gov/26981544 26981544]|[https://pubmed.ncbi.nlm.nih.gov/17986152 17986152]|[https://pubmed.ncbi.nlm.nih.gov/31739035 31739035]|[https://pubmed.ncbi.nlm.nih.gov/19941861 19941861]|[https://pubmed.ncbi.nlm.nih.gov/24578319 24578319]|[https://pubmed.ncbi.nlm.nih.gov/30531843 30531843]|[https://pubmed.ncbi.nlm.nih.gov/25645724 25645724]|[https://pubmed.ncbi.nlm.nih.gov/31197846 31197846]|[https://pubmed.ncbi.nlm.nih.gov/22821828 22821828]|[https://pubmed.ncbi.nlm.nih.gov/27861899 27861899]|[https://pubmed.ncbi.nlm.nih.gov/31037952 31037952]|[https://pubmed.ncbi.nlm.nih.gov/23593400 23593400]|[https://pubmed.ncbi.nlm.nih.gov/23604989 23604989]|[https://pubmed.ncbi.nlm.nih.gov/17855742 17855742]|[https://pubmed.ncbi.nlm.nih.gov/25966258 25966258]|[https://pubmed.ncbi.nlm.nih.gov/25989600 25989600]|[https://pubmed.ncbi.nlm.nih.gov/9657940 9657940]|[https://pubmed.ncbi.nlm.nih.gov/29497057 29497057]|[https://pubmed.ncbi.nlm.nih.gov/12838515 12838515]|[https://pubmed.ncbi.nlm.nih.gov/25170267 25170267]|[https://pubmed.ncbi.nlm.nih.gov/9878314 9878314]|[https://pubmed.ncbi.nlm.nih.gov/20554435 20554435]|[https://pubmed.ncbi.nlm.nih.gov/1410493 1410493]|[https://pubmed.ncbi.nlm.nih.gov/26585924 26585924]|[https://pubmed.ncbi.nlm.nih.gov/17257892 17257892]|[https://pubmed.ncbi.nlm.nih.gov/17044925 17044925]|[https://pubmed.ncbi.nlm.nih.gov/21089387 21089387]|[https://pubmed.ncbi.nlm.nih.gov/11445552 11445552]|[https://pubmed.ncbi.nlm.nih.gov/22977233 22977233]|[https://pubmed.ncbi.nlm.nih.gov/21437360 21437360]|[https://pubmed.ncbi.nlm.nih.gov/17179664 17179664]|[https://pubmed.ncbi.nlm.nih.gov/6273571 6273571]|[https://pubmed.ncbi.nlm.nih.gov/8370675 8370675] <br>
-'''definition''' :  <br>
+ '''definition''' :  <br>
-'''term_xref''' : GlycoEpitope:EP0043|CID:91855346|CHEBI:147019 <br>
+ '''term_xref''' : GlycoMotif:GGM.000063|GTC:G72548RZ  <br>
-'''best_match''' : GTC:G06597DS|GlycoEpitope:EP0043|CID:91855346|CHEBI:147019 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043] <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' : lung cancer[GlycoEpitope:EP0043]|ovarian cancer[GlycoEpitope:EP0043]|pancreatic adenocarcinoma[GlycoEpitope:EP0043] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47] <br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000153===
+===GSD000163===
-'''term (main_entry)''' : Sialyl T antigen <br>
+ '''term (main_entry)''' : T antigen <br>
-'''glycan_dictionary_accession''' : GD000153 <br>
+ '''glycan_dictionary_accession''' : GSD000163 <br>
-'''glytoucan_accession ''' : G65562ZE <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00031MO G00031MO] <br>
-'''term_in_sentence''' : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:32583304] <br>
+ '''term_in_sentence''' : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] <br>
-'''publication''' : 32583304|31897478|31719620|10365852|25727149|11523928|20407596|25464017|30864133|26391208|19811634|29796594|23725156|8905873|11192238|18275089|27037304|11949946|15604091|24118321 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/723127 723127]|[https://pubmed.ncbi.nlm.nih.gov/19505650 19505650]|[https://pubmed.ncbi.nlm.nih.gov/31527246 31527246]|[https://pubmed.ncbi.nlm.nih.gov/28113048 28113048]|[https://pubmed.ncbi.nlm.nih.gov/25868857 25868857]|[https://pubmed.ncbi.nlm.nih.gov/26731525 26731525]|[https://pubmed.ncbi.nlm.nih.gov/22994493 22994493]|[https://pubmed.ncbi.nlm.nih.gov/3849428 3849428]|[https://pubmed.ncbi.nlm.nih.gov/25589241 25589241]|[https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]|[https://pubmed.ncbi.nlm.nih.gov/26615524 26615524]|[https://pubmed.ncbi.nlm.nih.gov/26136575 26136575]|[https://pubmed.ncbi.nlm.nih.gov/19671663 19671663]|[https://pubmed.ncbi.nlm.nih.gov/18551603 18551603]|[https://pubmed.ncbi.nlm.nih.gov/11160729 11160729]|[https://pubmed.ncbi.nlm.nih.gov/22261839 22261839]|[https://pubmed.ncbi.nlm.nih.gov/30758913 30758913]|[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]|[https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/24998850 24998850]|[https://pubmed.ncbi.nlm.nih.gov/1654819 1654819]|[https://pubmed.ncbi.nlm.nih.gov/28039910 28039910]|[https://pubmed.ncbi.nlm.nih.gov/29206210 29206210]|[https://pubmed.ncbi.nlm.nih.gov/32404521 32404521]|[https://pubmed.ncbi.nlm.nih.gov/10555041 10555041]|[https://pubmed.ncbi.nlm.nih.gov/26517398 26517398]|[https://pubmed.ncbi.nlm.nih.gov/2446015 2446015]|[https://pubmed.ncbi.nlm.nih.gov/2998768 2998768]|[https://pubmed.ncbi.nlm.nih.gov/3026642 3026642]|[https://pubmed.ncbi.nlm.nih.gov/18812503 18812503]|[https://pubmed.ncbi.nlm.nih.gov/6092664 6092664]|[https://pubmed.ncbi.nlm.nih.gov/2153691 2153691]|[https://pubmed.ncbi.nlm.nih.gov/8709258 8709258]|[https://pubmed.ncbi.nlm.nih.gov/3009889 3009889]|[https://pubmed.ncbi.nlm.nih.gov/15109748 15109748]| [https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]|[https://pubmed.ncbi.nlm.nih.gov/31787742 31787742]|[https://pubmed.ncbi.nlm.nih.gov/27433780 27433780]|[https://pubmed.ncbi.nlm.nih.gov/26017382 26017382]|[https://pubmed.ncbi.nlm.nih.gov/24048785 24048785]|[https://pubmed.ncbi.nlm.nih.gov/26735515 26735515]|[https://pubmed.ncbi.nlm.nih.gov/9224657 9224657]|[https://pubmed.ncbi.nlm.nih.gov/26061652 26061652]|[https://pubmed.ncbi.nlm.nih.gov/29343574 29343574]| [https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]|[https://pubmed.ncbi.nlm.nih.gov/23805194 23805194]|[https://pubmed.ncbi.nlm.nih.gov/26751495 26751495]|[https://pubmed.ncbi.nlm.nih.gov/22023388 22023388]|[https://pubmed.ncbi.nlm.nih.gov/15381338 15381338]|[https://pubmed.ncbi.nlm.nih.gov/8249277 8249277]|[https://pubmed.ncbi.nlm.nih.gov/3023660 3023660]|[https://pubmed.ncbi.nlm.nih.gov/25866902 25866902] <br>
-'''definition''' : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257] <br>
+ '''definition''' : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] <br>
-'''term_xref''' : GlycoMotif:GGM.000013|CID:44611726|CHEBI:65257 <br>
+ '''term_xref''' : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009 <br>
-'''best_match''' : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:44611726|CHEBI:65257 <br>
+ '''synonyms''' : TF antigen <br>
-'''synonymns''' :  <br>
+ '''function''' : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] <br>
-'''function''' :  <br>
+ '''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020] <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>
-'''essentials_of_glycobiology''' :  <br>
-===GD000154===
+===GSD000164===
-'''term (main_entry)''' : Sialylated biantennary <br>
+'''term (main_entry)''' : Tetraantennary <br>
-'''glycan_dictionary_accession''' : GD000154 <br>
+'''glycan_dictionary_accession''' : GSD000164 <br>
 '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Simbucus nigra agglutinin or an antibody specific to sialylated lactosamine with a preference for Neu5Acalpha2-6Gal rather than Neu5Acalpha2-3Gal reduced sperm binding to oviduct isthmic cells, as did occupying putative receptors on sperm with sialylated biantennary glycans.[PMID:23115267] <br>
+'''term_in_sentence''' : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]] <br>
-'''publication''' : 23115267|31510952|29265394|31589880|3979568|26045275|29029079|30252064 <br>
+'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]|[https://pubmed.ncbi.nlm.nih.gov/17951374 17951374]|[https://pubmed.ncbi.nlm.nih.gov/28880909 28880909]|[https://pubmed.ncbi.nlm.nih.gov/9177699 9177699]|[https://pubmed.ncbi.nlm.nih.gov/9760189 9760189]|[https://pubmed.ncbi.nlm.nih.gov/12322961 12322961]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/2492275 2492275]|[https://pubmed.ncbi.nlm.nih.gov/3402460 3402460]|[https://pubmed.ncbi.nlm.nih.gov/2361735 2361735]|[https://pubmed.ncbi.nlm.nih.gov/6525453 6525453]|[https://pubmed.ncbi.nlm.nih.gov/27730440 27730440]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/25365149 25365149]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29875690 29875690]|[https://pubmed.ncbi.nlm.nih.gov/29479898 29479898]|[https://pubmed.ncbi.nlm.nih.gov/9134426 9134426]|[https://pubmed.ncbi.nlm.nih.gov/30943309 30943309]|[https://pubmed.ncbi.nlm.nih.gov/3546284 3546284]|[https://pubmed.ncbi.nlm.nih.gov/29888905 29888905]|[https://pubmed.ncbi.nlm.nih.gov/30624066 30624066]|[https://pubmed.ncbi.nlm.nih.gov/30537828 30537828]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/29311294 29311294]|[https://pubmed.ncbi.nlm.nih.gov/12852965 12852965]|[https://pubmed.ncbi.nlm.nih.gov/3015940 3015940]|[https://pubmed.ncbi.nlm.nih.gov/1907570 1907570]|[https://pubmed.ncbi.nlm.nih.gov/29137999 29137999]|[https://pubmed.ncbi.nlm.nih.gov/29359131 29359131]|[https://pubmed.ncbi.nlm.nih.gov/29858715 29858715]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31829566 31829566]|[https://pubmed.ncbi.nlm.nih.gov/8381405 8381405]|[https://pubmed.ncbi.nlm.nih.gov/26929217 26929217]|[https://pubmed.ncbi.nlm.nih.gov/20662591 20662591]|[https://pubmed.ncbi.nlm.nih.gov/30612270 30612270]|[https://pubmed.ncbi.nlm.nih.gov/3089784 3089784]|[https://pubmed.ncbi.nlm.nih.gov/28186213 28186213]|[https://pubmed.ncbi.nlm.nih.gov/3427034 3427034]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/27354006 27354006]|[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/7496138 7496138]|[https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]|[https://pubmed.ncbi.nlm.nih.gov/29031301 29031301]|[https://pubmed.ncbi.nlm.nih.gov/9448855 9448855]|[https://pubmed.ncbi.nlm.nih.gov/3979385 3979385]|[https://pubmed.ncbi.nlm.nih.gov/27722599 27722599]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28002670 28002670]|[https://pubmed.ncbi.nlm.nih.gov/28991403 28991403]|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]|[https://pubmed.ncbi.nlm.nih.gov/25154914 25154914]|[https://pubmed.ncbi.nlm.nih.gov/22490318 22490318]|[https://pubmed.ncbi.nlm.nih.gov/22430811 22430811]|[https://pubmed.ncbi.nlm.nih.gov/1463783 1463783]|[https://pubmed.ncbi.nlm.nih.gov/18803208 18803208]|[https://pubmed.ncbi.nlm.nih.gov/7881173 7881173]|[https://pubmed.ncbi.nlm.nih.gov/7697655 7697655]|[https://pubmed.ncbi.nlm.nih.gov/7240157 7240157]|[https://pubmed.ncbi.nlm.nih.gov/1768292 1768292] <br>
-'''definition''' : A binantennary glycan with one or two sialic acid residues as non-reducing terminal residues on one or both antennae. [RN] <br>
+'''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
 '''term_xref''' :  <br>
-'''best_match''' :  <br>
+'''synonyms''' :  <br>
-'''synonymns''' : sialyl biantennary <br>
 '''function''' :  <br>
 '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+'''wikipedia''' : https://www.wikidata.org/wiki/Q[https://pubmed.ncbi.nlm.nih.gov/27104888 27104888] <br>
 '''essentials_of_glycobiology''' :  <br>
-===GD000155===
+===GSD000165===
-'''term (main_entry)''' : Sialylated complex-type <br>
+ '''term (main_entry)''' : Tetraantennary complex-type <br>
-'''glycan_dictionary_accession''' : GD000155 <br>
+ '''glycan_dictionary_accession''' : GSD000165 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : By using 1H-NMR spectroscopy we were able to establish that our product contains a single N-linked biantennary , fully sialylated complex-type oligosaccharide , typical of human hepatomas.[PMID:1694115] <br>
+ '''term_in_sentence''' : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]] <br>
-'''publication''' : 1694115|15201278|30471292|30969765|11058758|28342150 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]|[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8274017 8274017]| [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]| [https://pubmed.ncbi.nlm.nih.gov/6317691 6317691]|[https://pubmed.ncbi.nlm.nih.gov/23668542 23668542]| [https://pubmed.ncbi.nlm.nih.gov/6088518 6088518]|[https://pubmed.ncbi.nlm.nih.gov/21495009 21495009]|[https://pubmed.ncbi.nlm.nih.gov/1457971 1457971]|[https://pubmed.ncbi.nlm.nih.gov/1783599 1783599]|[https://pubmed.ncbi.nlm.nih.gov/10988252 10988252]|[https://pubmed.ncbi.nlm.nih.gov/11425798 11425798]|[https://pubmed.ncbi.nlm.nih.gov/7522229 7522229]|[https://pubmed.ncbi.nlm.nih.gov/2574992 2574992]|[https://pubmed.ncbi.nlm.nih.gov/3730425 3730425]|[https://pubmed.ncbi.nlm.nih.gov/10200178 10200178]|[https://pubmed.ncbi.nlm.nih.gov/2939068 2939068]|[https://pubmed.ncbi.nlm.nih.gov/21584695 21584695]| [https://pubmed.ncbi.nlm.nih.gov/7524670 7524670]|[https://pubmed.ncbi.nlm.nih.gov/7682847 7682847]|[https://pubmed.ncbi.nlm.nih.gov/2930192 2930192]|[https://pubmed.ncbi.nlm.nih.gov/1726466 1726466]|[https://pubmed.ncbi.nlm.nih.gov/9881746 9881746]|[https://pubmed.ncbi.nlm.nih.gov/11068879 11068879]|[https://pubmed.ncbi.nlm.nih.gov/6704968 6704968]|[https://pubmed.ncbi.nlm.nih.gov/2302846 2302846]| [https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]| [https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]|[https://pubmed.ncbi.nlm.nih.gov/11051207 11051207]|[https://pubmed.ncbi.nlm.nih.gov/10220588 10220588]|[https://pubmed.ncbi.nlm.nih.gov/2813359 2813359]|[https://pubmed.ncbi.nlm.nih.gov/2174368 2174368]|[https://pubmed.ncbi.nlm.nih.gov/21755550 21755550]|[https://pubmed.ncbi.nlm.nih.gov/3571208 3571208]|[https://pubmed.ncbi.nlm.nih.gov/1929437 1929437]|[https://pubmed.ncbi.nlm.nih.gov/3681300 3681300]|[https://pubmed.ncbi.nlm.nih.gov/6581225 6581225]|[https://pubmed.ncbi.nlm.nih.gov/3364983 3364983]|[https://pubmed.ncbi.nlm.nih.gov/2902877 2902877]|[https://pubmed.ncbi.nlm.nih.gov/2297756 2297756]|[https://pubmed.ncbi.nlm.nih.gov/1315684 1315684]|[https://pubmed.ncbi.nlm.nih.gov/6830758 6830758]|[https://pubmed.ncbi.nlm.nih.gov/1998670 1998670] <br>
-'''definition''' : Complex N-linked glycan that have added GlcNAc residues at both the α-3 and α-6 mannose sites and do not contain mannose residues apart from the core structure but with sialic acid residues. <br>
+ '''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]]  <br>
-'''term_xref''' :  <br>
+ '''term_xref''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html <br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' : sialo-complex type <br>
+ '''function''' :  <br>
-'''function''' : enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes [PMID: 15201278] Appears in IgG-Fc.[PMID:20647032 ] <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
-'''essentials_of_glycobiology''' : NBK453030 <br>
+===GSD000166===
+ '''term (main_entry)''' : Tetrasialylated diantennary <br>
+ '''glycan_dictionary_accession''' : GSD000166 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] <br>
+ '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000167===
+ '''term (main_entry)''' : Tn antigen <br>
+ '''glycan_dictionary_accession''' : GSD000167 <br>
+  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57321FI G57321FI] <br>
+ '''term_in_sentence''' : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27679419 27679419]|[https://pubmed.ncbi.nlm.nih.gov/31938254 31938254]|[https://pubmed.ncbi.nlm.nih.gov/30637914 30637914]|[https://pubmed.ncbi.nlm.nih.gov/24643043 24643043]|[https://pubmed.ncbi.nlm.nih.gov/31225574 31225574]|[https://pubmed.ncbi.nlm.nih.gov/21259410 21259410]|[https://pubmed.ncbi.nlm.nih.gov/31742337 31742337]|[https://pubmed.ncbi.nlm.nih.gov/28514044 28514044]|[https://pubmed.ncbi.nlm.nih.gov/33014816 33014816]|[https://pubmed.ncbi.nlm.nih.gov/28708980 28708980]|[https://pubmed.ncbi.nlm.nih.gov/27432485 27432485]|[https://pubmed.ncbi.nlm.nih.gov/33050853 33050853]|[https://pubmed.ncbi.nlm.nih.gov/26045765 26045765]|[https://pubmed.ncbi.nlm.nih.gov/27542280 27542280]|[https://pubmed.ncbi.nlm.nih.gov/24411673 24411673]|[https://pubmed.ncbi.nlm.nih.gov/27760846 27760846]|[https://pubmed.ncbi.nlm.nih.gov/30115016 30115016]|[https://pubmed.ncbi.nlm.nih.gov/1410473 1410473]|[https://pubmed.ncbi.nlm.nih.gov/29802864 29802864]|[https://pubmed.ncbi.nlm.nih.gov/29669308 29669308]|[https://pubmed.ncbi.nlm.nih.gov/29251002 29251002]|[https://pubmed.ncbi.nlm.nih.gov/32541028 32541028]|[https://pubmed.ncbi.nlm.nih.gov/31019509 31019509]|[https://pubmed.ncbi.nlm.nih.gov/1582597 1582597]|[https://pubmed.ncbi.nlm.nih.gov/2981150 2981150]|[https://pubmed.ncbi.nlm.nih.gov/10842187 10842187]|[https://pubmed.ncbi.nlm.nih.gov/29638123 29638123]| [https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]|[https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/1510031 1510031]|[https://pubmed.ncbi.nlm.nih.gov/19372570 19372570]|[https://pubmed.ncbi.nlm.nih.gov/20641477 20641477]| [https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/27856425 27856425]|[https://pubmed.ncbi.nlm.nih.gov/23814067 23814067]|[https://pubmed.ncbi.nlm.nih.gov/28068458 28068458]| [https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/8174100 8174100]|[https://pubmed.ncbi.nlm.nih.gov/10571017 10571017]|[https://pubmed.ncbi.nlm.nih.gov/27453399 27453399]|[https://pubmed.ncbi.nlm.nih.gov/1727666 1727666]|[https://pubmed.ncbi.nlm.nih.gov/23740330 23740330] <br>
+ '''definition''' : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212] <br>
+ '''term_xref''' : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008  <br>
+ '''synonyms''' :  <br>
+ '''function''' : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] <br>
+ '''disease_associations''' : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021]. <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000168===
+ '''term (main_entry)''' : Triantennary <br>
+ '''glycan_dictionary_accession''' : GSD000168 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24992960 24992960]|[https://pubmed.ncbi.nlm.nih.gov/27025342 27025342]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/29456020 29456020]|[https://pubmed.ncbi.nlm.nih.gov/26914862 26914862]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26299345 26299345]|[https://pubmed.ncbi.nlm.nih.gov/28981809 28981809]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/2211710 2211710]|[https://pubmed.ncbi.nlm.nih.gov/23461434 23461434]|[https://pubmed.ncbi.nlm.nih.gov/18327885 18327885]|[https://pubmed.ncbi.nlm.nih.gov/15264862 15264862]|[https://pubmed.ncbi.nlm.nih.gov/22954207 22954207]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26537865 26537865]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/28129130 28129130]|[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/8068017 8068017]|[https://pubmed.ncbi.nlm.nih.gov/7783116 7783116]|[https://pubmed.ncbi.nlm.nih.gov/3857231 3857231]|[https://pubmed.ncbi.nlm.nih.gov/20540518 20540518]|[https://pubmed.ncbi.nlm.nih.gov/1706936 1706936]|[https://pubmed.ncbi.nlm.nih.gov/2430615 2430615]|[https://pubmed.ncbi.nlm.nih.gov/8078981 8078981]|[https://pubmed.ncbi.nlm.nih.gov/2211711 2211711]|[https://pubmed.ncbi.nlm.nih.gov/6767476 6767476]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/2597120 2597120]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/20619452 20619452]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/1924399 1924399]|[https://pubmed.ncbi.nlm.nih.gov/6643471 6643471]|[https://pubmed.ncbi.nlm.nih.gov/31809011 31809011]|[https://pubmed.ncbi.nlm.nih.gov/30042045 30042045]|[https://pubmed.ncbi.nlm.nih.gov/2477056 2477056]|[https://pubmed.ncbi.nlm.nih.gov/7882496 7882496]|[https://pubmed.ncbi.nlm.nih.gov/2430614 2430614]| [https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/2426141 2426141]|[https://pubmed.ncbi.nlm.nih.gov/2065052 2065052]|[https://pubmed.ncbi.nlm.nih.gov/28988716 28988716]|[https://pubmed.ncbi.nlm.nih.gov/31144994 31144994]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215] <br>
+ '''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+===GSD000169===
+ '''term (main_entry)''' : Triantennary complex <br>
+ '''glycan_dictionary_accession''' : GSD000169 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/16973123 16973123]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215]|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]|[https://pubmed.ncbi.nlm.nih.gov/31322324 31322324]|[https://pubmed.ncbi.nlm.nih.gov/15044389 15044389]|[https://pubmed.ncbi.nlm.nih.gov/16372382 16372382]| [https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8299583 8299583]|[https://pubmed.ncbi.nlm.nih.gov/1555586 1555586]|[https://pubmed.ncbi.nlm.nih.gov/7509658 7509658]|[https://pubmed.ncbi.nlm.nih.gov/1569060 1569060]|[https://pubmed.ncbi.nlm.nih.gov/16261636 16261636] <br>
+ '''definition''' : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252]  Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  <br>
+ '''term_xref''' : CHEBI:156252 <br>
+ '''synonyms''' : Triantennary complex-type <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
+===GSD000170===
+ '''term (main_entry)''' : Triantennary N-glycans <br>
+ '''glycan_dictionary_accession''' : GSD000170 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29399163 29399163]|[https://pubmed.ncbi.nlm.nih.gov/22325877 22325877]|[https://pubmed.ncbi.nlm.nih.gov/18439991 18439991]|[https://pubmed.ncbi.nlm.nih.gov/24873509 24873509]|[https://pubmed.ncbi.nlm.nih.gov/11454001 11454001] <br>
+ '''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]]  <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000156===
-'''term (main_entry)''' : Sialylated tetraantennary <br>
-'''glycan_dictionary_accession''' : GD000156 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:16321355] <br>
-'''publication''' : 16321355|1940447|27501865 <br>
-'''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000171===
+ '''term (main_entry)''' : Triantennary sialylated <br>
+ '''glycan_dictionary_accession''' : GSD000171 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/18642129 18642129]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18642129 18642129]|[https://pubmed.ncbi.nlm.nih.gov/31964828 31964828]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/27936604 27936604]|[https://pubmed.ncbi.nlm.nih.gov/23681398 23681398]|[https://pubmed.ncbi.nlm.nih.gov/21538882 21538882]|[https://pubmed.ncbi.nlm.nih.gov/7579793 7579793]|[https://pubmed.ncbi.nlm.nih.gov/7613477 7613477]|[https://pubmed.ncbi.nlm.nih.gov/2223825 2223825]|[https://pubmed.ncbi.nlm.nih.gov/3539023 3539023]|[https://pubmed.ncbi.nlm.nih.gov/3674882 3674882] <br>
+ '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' : Appears in human serotransferrin.[PMID: [https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]] <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000157===
-'''term (main_entry)''' : Sialyl-Tn antigen <br>
-'''glycan_dictionary_accession''' : GD000157 <br>
-'''glytoucan_accession ''' : G36123IU <br>
-'''term_in_sentence''' : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:23035012] <br>
-'''publication''' : 23035012|29273237|15770530|31595388|26617889|1720922|15466199|10971172|14652017|8616877|1543361|16965854|21566901|9269833|9834267|24970145|22367369|10778170|30018351|28628803|16149605|32134186|28632300|11308020|10365852|17195456|23567325|11014575|2342728|8575847|1851822|11735169|20960853|7846011 <br>
-'''definition''' : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818] <br>
-'''term_xref''' : GlycoEpitope:EP0022|CID:51351800|CHEBI:61818 <br>
-'''best_match''' : GTC:G36123IU|GlycoEpitope:EP0022|CID:51351800|CHEBI:61818 <br>
-'''synonymns''' :  <br>
-'''function''' : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022] <br>
-'''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0022]|Barrett's esophagus[GlycoEpitope:EP0022]|bladder cancer[GlycoEpitope:EP0022]|breast cancer[GlycoEpitope:EP0022]|colon cancer[GlycoEpitope:EP0022]|colorectal cancer[GlycoEpitope:EP0022]|erythroblastic leukemia[GlycoEpitope:EP0022]|esophageal cancer[GlycoEpitope:EP0022]|gastric cancer[GlycoEpitope:EP0022]|helicobacter pylori chronic gastritis(HpCG)[GlycoEpitope:EP0022]|liver cancer[GlycoEpitope:EP0022]|iterome cancer[GlycoEpitope:EP0022]|ovary tumor[GlycoEpitope:EP0022]|pancreas cancer[GlycoEpitope:EP0022] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453027 <br>
+===GSD000172===
+ '''term (main_entry)''' : Triantennary trisialylated fucosylated <br>
+ '''glycan_dictionary_accession''' : GSD000172 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/17591618 17591618] <br>
+ '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000158===
-'''term (main_entry)''' : SLex Core 2 O-glycan <br>
-'''glycan_dictionary_accession''' : GD000158 <br>
-'''glytoucan_accession ''' : G97345NY <br>
-'''term_in_sentence''' : In particular, the sLeX-modified core 2 O-glycan structure C2-O-sLeX has been directly demonstrated to confer significantly higher affinity selectin binding than sLeX.[PMID:15596301] <br>
-'''publication''' : 15596301 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000053 <br>
-'''best_match''' : GlycoMotif:GGM.000053|GTC:G97345NY <br>
-'''synonymns''' : SLe^x Core 2 O-glycan <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000173===
+ '''term (main_entry)''' : Trifucosyl Lewis b antigen <br>
+ '''glycan_dictionary_accession''' : GSD000173 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74578MX G74578MX] <br>
+ '''term_in_sentence''' : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:[https://pubmed.ncbi.nlm.nih.gov/1735443 1735443]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1735443 1735443] <br>
+ '''definition''' : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] <br>
+ '''term_xref''' : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783 <br>
+ '''synonyms''' : trifucosyl-Leb antigen <br>
+ '''function''' : cancer-associated antigen[GlycoEpitope: EP0092] <br>
+ '''disease_associations''' : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000159===
-'''term (main_entry)''' : SSEA-1 <br>
-'''glycan_dictionary_accession''' : GD000159 <br>
-'''glytoucan_accession ''' : G85497PI <br>
-'''term_in_sentence''' : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:27550342] <br>
-'''publication''' : 27550342|25564944|30987116|10778174|19427293|24923741|28092949|16499901|10470652|18787210|2885312|16149609|17003364|27363517|15505339|27990704|2568298|20491542|23572256|1977666|9553168|20458727|2566639|14577357|20960856|15547746|9096265|30639212|1357195|1359630|20181261|20508065|2907526|22624699|22988836|17183690|27188587|7908065|10400391|6137429|1979260|2898921|14736812|30919971 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoEpitope:EP0042|CID:91851144|CHEBI:154343 <br>
-'''best_match''' : GTC:G85497PI |GlycoEpitope:EP0042|CID:91851144|CHEBI:154343 <br>
-'''synonymns''' :  <br>
-'''function''' : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042] <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453030 <br>
+===GSD000174===
+ '''term (main_entry)''' : Trifucosyl lewis y <br>
+ '''glycan_dictionary_accession''' : GSD000174 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74917JX G74917JX] <br>
+ '''term_in_sentence''' : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]|[https://pubmed.ncbi.nlm.nih.gov/2426269 2426269] <br>
+ '''definition''' : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] <br>
+ '''term_xref''' : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332  <br>
+ '''synonyms''' : trifucosyl Ley <br>
+ '''function''' :  <br>
+ '''disease_associations''' : colonic adenocarcinomia[GlycoEpitope: EP0094] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000160===
-'''term (main_entry)''' : SSEA-3 <br>
-'''glycan_dictionary_accession''' : GD000160 <br>
-'''glytoucan_accession ''' : G25129BT <br>
-'''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:31817926] <br>
-'''publication''' : 31817926|30271856|32684574|26677875|23175153|32525407|29227830|18773292|25561682|10837462|2412924|21149348|17008424|2874662|25171543|31304790|31642560|30484221|30525067|21161592|27325407|28170296|29637816|27318475|31346146|7648586|24236059|21964054|27456773|30558911|21559451|29312455|27549315|30599359|6141938|28883415|30733757|26041528|16643871 <br>
-'''definition''' : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071] <br>
-'''term_xref''' : GlycoEpitope:EP0039|CID:91855781|CHEBI:149071|GlycoMotif:GGM.000079 <br>
-'''best_match''' : GTC:G25129BT|GlycoEpitope:EP0039|CID:91855781|CHEBI:149071|GlycoMotif:GGM.000079 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : embryonal carcinoma[GlycoEpitope:EP0039]|teratocarcinoma[GlycoEpitope:EP0039]|yolk sac carcinoma[GlycoEpitope:EP0039] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000175===
+ '''term (main_entry)''' : Trimannosyl core <br>
+ '''glycan_dictionary_accession''' : GSD000175 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/18320567 18320567]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18320567 18320567]|[https://pubmed.ncbi.nlm.nih.gov/27629418 27629418]|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]|[https://pubmed.ncbi.nlm.nih.gov/26821880 26821880]|[https://pubmed.ncbi.nlm.nih.gov/2477227 2477227]|[https://pubmed.ncbi.nlm.nih.gov/6213618 6213618]|[https://pubmed.ncbi.nlm.nih.gov/31747570 31747570]|[https://pubmed.ncbi.nlm.nih.gov/29273674 29273674]|[https://pubmed.ncbi.nlm.nih.gov/31064325 31064325]|[https://pubmed.ncbi.nlm.nih.gov/1291063 1291063]|[https://pubmed.ncbi.nlm.nih.gov/28353332 28353332]|[https://pubmed.ncbi.nlm.nih.gov/1421754 1421754]|[https://pubmed.ncbi.nlm.nih.gov/29666272 29666272]|[https://pubmed.ncbi.nlm.nih.gov/11421342 11421342]|[https://pubmed.ncbi.nlm.nih.gov/15648688 15648688]|[https://pubmed.ncbi.nlm.nih.gov/28179475 28179475]|[https://pubmed.ncbi.nlm.nih.gov/28903882 28903882]|[https://pubmed.ncbi.nlm.nih.gov/27189951 27189951]|[https://pubmed.ncbi.nlm.nih.gov/9455915 9455915]|[https://pubmed.ncbi.nlm.nih.gov/22768188 22768188]|[https://pubmed.ncbi.nlm.nih.gov/9254048 9254048]|[https://pubmed.ncbi.nlm.nih.gov/8721739 8721739]|[https://pubmed.ncbi.nlm.nih.gov/2249985 2249985]|[https://pubmed.ncbi.nlm.nih.gov/22933239 22933239]|[https://pubmed.ncbi.nlm.nih.gov/25629585 25629585]|[https://pubmed.ncbi.nlm.nih.gov/24489949 24489949]|[https://pubmed.ncbi.nlm.nih.gov/2981047 2981047]|[https://pubmed.ncbi.nlm.nih.gov/11067815 11067815]|[https://pubmed.ncbi.nlm.nih.gov/1729985 1729985]|[https://pubmed.ncbi.nlm.nih.gov/1710649 1710649]|[https://pubmed.ncbi.nlm.nih.gov/16672288 16672288]|[https://pubmed.ncbi.nlm.nih.gov/2719668 2719668]|[https://pubmed.ncbi.nlm.nih.gov/19003000 19003000]|[https://pubmed.ncbi.nlm.nih.gov/23025485 23025485]|[https://pubmed.ncbi.nlm.nih.gov/22500028 22500028]|[https://pubmed.ncbi.nlm.nih.gov/10409642 10409642]|[https://pubmed.ncbi.nlm.nih.gov/1325461 1325461]|[https://pubmed.ncbi.nlm.nih.gov/23136055 23136055]|[https://pubmed.ncbi.nlm.nih.gov/23085445 23085445]|[https://pubmed.ncbi.nlm.nih.gov/21656680 21656680]|[https://pubmed.ncbi.nlm.nih.gov/22448293 22448293]|[https://pubmed.ncbi.nlm.nih.gov/22132163 22132163]|[https://pubmed.ncbi.nlm.nih.gov/1425696 1425696]|[https://pubmed.ncbi.nlm.nih.gov/20696712 20696712]|[https://pubmed.ncbi.nlm.nih.gov/18056652 18056652]|[https://pubmed.ncbi.nlm.nih.gov/15084511 15084511]|[https://pubmed.ncbi.nlm.nih.gov/18633282 18633282]|[https://pubmed.ncbi.nlm.nih.gov/15814299 15814299] <br>
+ '''definition''' : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000161===
-'''term (main_entry)''' : SSEA-4 <br>
-'''glycan_dictionary_accession''' : GD000161 <br>
-'''glytoucan_accession ''' : G84263XI <br>
-'''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:31817926] <br>
-'''publication''' : 27845370|31817926|26295543|25171543|25978997|30296654|25853231|24862940|31243630|28736232|22895512|24578244|29478902|23574147|23768762|27797400|29227830|18773292|25123923|22924692|22665977|23330736|31831622|31916611|2412924|16033656|24866102|20458727|21149348|26940129|17008424|2874662|23301556|27836003|19118716|24550271|32988880|22743677|20683402|17062733|23570331|30310530|31545316|23509763|24364909|18273440|28985528|22266579 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoEpitope:EP0044|CID:91845478|CHEBI:154843 <br>
-'''best_match''' : GTC:G84263XI|GlycoEpitope:EP0044|CID:91845478|CHEBI:154843 <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' : teratocarcinoma[GlycoEpitope:EP0044] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453023-Chapter 47 <br>
+===GSD000176===
+ '''term (main_entry)''' : Trisialylated <br>
+ '''glycan_dictionary_accession''' : GSD000176 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:8477709] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6469957 6469957]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/21138277 21138277]|[https://pubmed.ncbi.nlm.nih.gov/9136890 9136890]|[https://pubmed.ncbi.nlm.nih.gov/10782293 10782293]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/20067809 20067809]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/8797382 8797382]|[https://pubmed.ncbi.nlm.nih.gov/16877748 16877748]|[https://pubmed.ncbi.nlm.nih.gov/19131698 19131698]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/24669823 24669823]|[https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/2121479 2121479]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/32209427 32209427]|[https://pubmed.ncbi.nlm.nih.gov/32737218 32737218]|[https://pubmed.ncbi.nlm.nih.gov/33245334 33245334]|[https://pubmed.ncbi.nlm.nih.gov/26927318 26927318]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/26321095 26321095]|[https://pubmed.ncbi.nlm.nih.gov/30463578 30463578]|[https://pubmed.ncbi.nlm.nih.gov/31455764 31455764]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/31266306 31266306]|[https://pubmed.ncbi.nlm.nih.gov/29782424 29782424]|[https://pubmed.ncbi.nlm.nih.gov/31247951 31247951]|[https://pubmed.ncbi.nlm.nih.gov/30487799 30487799]|[https://pubmed.ncbi.nlm.nih.gov/2049094 2049094]|[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832] <br>
+ '''definition''' : A glycan with three sialic acid components. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000162===
-'''term (main_entry)''' : Sulfatide <br>
-'''glycan_dictionary_accession''' : GD000162 <br>
-'''glytoucan_accession ''' : G72548RZ <br>
-'''term_in_sentence''' : In a previous study we found that sulfatide was efficient in lowering HIV-1 viral loads in SCID mice engrafted with human fetal liver/thymus tissues (SCID-hu).[PMID:23550344] <br>
-'''publication''' : 23550344|18465098|26542149|15158666|10434709|22619219|29676479|30196830|16143863|1052451|30400820|29887538|26981544|17986152|31739035|19941861|24578319|30531843|25645724|31197846|22821828|27861899|31037952|23593400|23604989|17855742|25966258|25989600|9657940|29497057|12838515|25170267|9878314|20554435|1410493|26585924|17257892|17044925|21089387|11445552|22977233|21437360|17179664|6273571|8370675 <br>
-'''definition''' :  <br>
-'''term_xref''' : GlycoMotif:GGM.000063 <br>
-'''best_match''' : GlycoMotif:GGM.000063|GTC:G72548RZ <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453023-Chapter 47 <br>
+===GSD000177===
+ '''term (main_entry)''' : Trisialylated complex-type oligosaccharide-alditols <br>
+ '''glycan_dictionary_accession''' : GSD000177 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3571205 3571205]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3571205 3571205] <br>
+ '''definition''' :  <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000163===
-'''term (main_entry)''' : T antigen <br>
-'''glycan_dictionary_accession''' : GD000163 <br>
-'''glytoucan_accession ''' : G00031MO <br>
-'''term_in_sentence''' : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] <br>
-'''publication''' : 723127|19505650|31527246|28113048|25868857|26731525|22994493|3849428|25589241|12709866|26615524|26136575|19671663|18551603|11160729|22261839|30758913|25681708|29113555|24998850|1654819|28039910|29206210|32404521|10555041|26517398|2446015|2998768|3026642|18812503|6092664|2153691|8709258|3009889|15109748|12709866|31787742|27433780|26017382|24048785|26735515|9224657|26061652|29343574|25681708|23805194|26751495|22023388|15381338|8249277|3023660|25866902 <br>
-'''definition''' : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] <br>
-'''term_xref''' : GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009 <br>
-'''best_match''' : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009 <br>
-'''synonymns''' : TF antigen <br>
-'''function''' : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] <br>
-'''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020] <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453023-Chapter 47 <br>
+===GSD000178===
+ '''term (main_entry)''' : Trisialylated diantennary <br>
+ '''glycan_dictionary_accession''' : GSD000178 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] <br>
+ '''definition''' : A diantennary/biantennary glycans with three sialic acid components. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000164===
-'''term (main_entry)''' : Tetraantennary <br>
-'''glycan_dictionary_accession''' : GD000164 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:24308486] <br>
-'''publication''' : 24308486|17951374|28880909|9177699|9760189|12322961|20129637|2492275|3402460|2361735|6525453|27730440|2551687|25365149|9751793|29875690|29479898|9134426|30943309|3546284|29888905|30624066|30537828|31110965|29311294|12852965|3015940|1907570|29137999|29359131|29858715|30295034|31829566|8381405|26929217|20662591|30612270|3089784|28186213|3427034|26763099|27354006|24991291|7496138|1940447|11114588|29031301|9448855|3979385|27722599|31126011|28002670|28991403|24032650|15316281|25154914|22490318|22430811|1463783|18803208|7881173|7697655|7240157|1768292 <br>
-'''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [NBK453019-Glossary] <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' : https://www.wikidata.org/wiki/Q27104888 <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000179===
+ '''term (main_entry)''' : Trisialylated triantennary <br>
+ '''glycan_dictionary_accession''' : GSD000179 <br>
+ '''glytoucan_accession ''' :  <br>
+ '''term_in_sentence''' : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]| [https://pubmed.ncbi.nlm.nih.gov/27501865 27501865] |[https://pubmed.ncbi.nlm.nih.gov/10998266 10998266]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/8942648 8942648]|[https://pubmed.ncbi.nlm.nih.gov/8900952 8900952] <br>
+ '''definition''' : A triantennry glycan with three sialic acid components. <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  <br>
+ '''function''' :  <br>
+ '''disease_associations''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000165===
-'''term (main_entry)''' : Tetraantennary complex-type <br>
-'''glycan_dictionary_accession''' : GD000165 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID:1899031] <br>
-'''publication''' : 1899031|8251489|8274017|1899031| 6317691|23668542| 6088518|21495009|1457971|1783599|10988252|11425798|7522229|2574992|3730425|10200178|2939068|21584695| 7524670|7682847|2930192|1726466|9881746|11068879|6704968|2302846|24032650|15316281|11051207|10220588|2813359|2174368|21755550|3571208|1929437|3681300|6581225|3364983|2902877|2297756|1315684|6830758|1998670 <br>
-'''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [NBK453019-Glossary] <br>
-'''term_xref''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html <br>
-'''best_match''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' : NBK453030 <br>
+===GSD000180===
+ '''term (main_entry)''' : VIM-2 <br>
+ '''glycan_dictionary_accession''' : GSD000180 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G22418PV G22418PV] <br>
+ '''term_in_sentence''' : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1690317 1690317]] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27834790 27834790]|[https://pubmed.ncbi.nlm.nih.gov/31523406 31523406]|[https://pubmed.ncbi.nlm.nih.gov/29978304 29978304]|[https://pubmed.ncbi.nlm.nih.gov/29575185 29575185]|[https://pubmed.ncbi.nlm.nih.gov/27326514 27326514]|[https://pubmed.ncbi.nlm.nih.gov/29029114 29029114]|[https://pubmed.ncbi.nlm.nih.gov/32450200 32450200]|[https://pubmed.ncbi.nlm.nih.gov/29432937 29432937]|[https://pubmed.ncbi.nlm.nih.gov/31906402 31906402]|[https://pubmed.ncbi.nlm.nih.gov/28739428 28739428]|[https://pubmed.ncbi.nlm.nih.gov/29298123 29298123]|[https://pubmed.ncbi.nlm.nih.gov/30976429 30976429]|[https://pubmed.ncbi.nlm.nih.gov/29091730 29091730]|[https://pubmed.ncbi.nlm.nih.gov/27770796 27770796]|[https://pubmed.ncbi.nlm.nih.gov/31330771 31330771]|[https://pubmed.ncbi.nlm.nih.gov/31138570 31138570]|[https://pubmed.ncbi.nlm.nih.gov/27154587 27154587]|[https://pubmed.ncbi.nlm.nih.gov/31542553 31542553]|[https://pubmed.ncbi.nlm.nih.gov/30519059 30519059]|[https://pubmed.ncbi.nlm.nih.gov/30590504 30590504]|[https://pubmed.ncbi.nlm.nih.gov/25880997 25880997]|[https://pubmed.ncbi.nlm.nih.gov/27490501 27490501]|[https://pubmed.ncbi.nlm.nih.gov/29981456 29981456]|[https://pubmed.ncbi.nlm.nih.gov/28559273 28559273]|[https://pubmed.ncbi.nlm.nih.gov/28193652 28193652]|[https://pubmed.ncbi.nlm.nih.gov/26638216 26638216]|[https://pubmed.ncbi.nlm.nih.gov/25897818 25897818]|[https://pubmed.ncbi.nlm.nih.gov/26238337 26238337]|[https://pubmed.ncbi.nlm.nih.gov/19553129 19553129]|[https://pubmed.ncbi.nlm.nih.gov/29644540 29644540]|[https://pubmed.ncbi.nlm.nih.gov/26242685 26242685]|[https://pubmed.ncbi.nlm.nih.gov/28487556 28487556]|[https://pubmed.ncbi.nlm.nih.gov/32622213 32622213]|[https://pubmed.ncbi.nlm.nih.gov/30248413 30248413]|[https://pubmed.ncbi.nlm.nih.gov/24762211 24762211]|[https://pubmed.ncbi.nlm.nih.gov/11451678 11451678]|[https://pubmed.ncbi.nlm.nih.gov/33169865 33169865]|[https://pubmed.ncbi.nlm.nih.gov/11897589 11897589]|[https://pubmed.ncbi.nlm.nih.gov/31479607 31479607] <br>
+ '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] <br>
+ '''term_xref''' : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033 <br>
+ '''synonyms''' :  <br>
+ '''function''' : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] <br>
+ '''disease_associations''' : chronic myelogenous leukemia.[GlycoEpitope:EP0019] <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000166===
-'''term (main_entry)''' : Tetrasialylated diantennary <br>
-'''glycan_dictionary_accession''' : GD000166 <br>
-'''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:1997323] <br>
-'''publication''' : 1997323 <br>
-'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. <br>
-'''term_xref''' :  <br>
-'''best_match''' :  <br>
-'''synonymns''' :  <br>
-'''function''' :  <br>
-'''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000181===
+ '''term (main_entry)''' : N-acetyllactosamine (Type 1)<br>
+ '''glycan_dictionary_accession''' : GSD000181<br>
+ '''glytoucan_accession ''' : [https://glygen.org/glycan/G00056MO G00056MO]<br>
+ '''term_in_sentence''' : The N-acetyllactosamine type 1 (LacNAc type 1, Galβ1,3GlcNAc) is a well-known precursor of several important blood group epitopes, such as Lewis A, Lewis B, or sialyl Lewis A [1], which are involved in many biological processes, e.g., fertilization [2] and pathogen adhesion [3]. [PMID:[https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]]<br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]|[https://pubmed.ncbi.nlm.nih.gov/28167527 28167527]<br>
+ '''definition''' : <br>
+ '''term_xref''' : GTC:G00056MO|GlycoMotif:GGM.000005<br>
+ '''synonyms''' :  LacNAc type 1|Type 1 LN|Type-1 lactosamine<br>
+ '''function''' : <br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000167===
-'''term (main_entry)''' : Tn antigen <br>
-'''glycan_dictionary_accession''' : GD000167 <br>
-'''glytoucan_accession ''' : G57321FI <br>
-'''term_in_sentence''' : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] <br>
-'''publication''' : 27679419|31938254|30637914|24643043|31225574|21259410|31742337|28514044|33014816|28708980|27432485|33050853|26045765|27542280|24411673|27760846|30115016|1410473|29802864|29669308|29251002|32541028|31019509|1582597|2981150|10842187|29638123|22367369|10778170|1510031|19372570|20641477|16149605|15770530|27856425|23814067|28068458|32134186|8174100|10571017|27453399|1727666|23740330 <br>
-'''definition''' : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212] <br>
-'''term_xref''' : GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008 <br>
-'''best_match''' : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008 <br>
-'''synonymns''' :  <br>
-'''function''' : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] <br>
-'''disease_associations''' : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021]. <br>
-'''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+===GSD000182===
+ '''term (main_entry)''' : Polysialic acid<br>
+ '''glycan_dictionary_accession''' : GSD000182<br>
+ '''glytoucan_accession ''' : <br>
+ '''term_in_sentence''' : Polysialic acid (PSA) is a carbohydrate composed of a linear polymer of α2,8-linked sialic acids, primarily attached to the Neural Cell Adhesion Molecule (NCAM). [PMID:[https://pubmed.ncbi.nlm.nih.gov/36076963 36076963]]<br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/36076963 36076963]|[https://pubmed.ncbi.nlm.nih.gov/35222358 35222358]<br>
+ '''definition''' : <br>
+ '''term_xref''' : GlycoMotif:GGM.000252 <br>
+ '''synonyms''' :  polySia|PSA<br>
+ '''function''' : <br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000168===
-'''term (main_entry)''' : Triantennary <br>
+===GSD000183===
-'''glycan_dictionary_accession''' : GD000168 <br>
+ '''term (main_entry)''' : Hyaluronan<br>
-'''glytoucan_accession ''' :  <br>
+ '''glycan_dictionary_accession''' : GSD000183<br>
-'''term_in_sentence''' : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] <br>
+ '''glytoucan_accession ''' : [https://glygen.org/glycan/G29086KO G29086KO]<br>
-'''publication''' : 24992960|27025342|29642865|29456020|26914862|26926155|26299345|28981809|18395704|2211710|23461434|18327885|15264862|22954207|9061362|16581187|26537865|3979568|28129130|7679920|8068017|7783116|3857231|20540518|1706936|2430615|8078981|2211711|6767476|3814128|2597120|7451505|8204583|20619452|10460831|1924399|6643471|31809011|30042045|2477056|7882496|2430614|2551687|2426141|2065052|28988716|31144994|26966183|29809215 <br>
+ '''term_in_sentence''' : Hyaluronan (HA) comprises a major component of the extracellular matrix (ECM) in vertebrate connective tissues and is abundant in the cartilage, skin, brain, vitreous body, umbilical cord, and synovial fluid. [PMID:[https://pubmed.ncbi.nlm.nih.gov/33171800 33171800]]<br>
-'''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [NBK453019-Glossary] <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/33171800 33171800]|[https://pubmed.ncbi.nlm.nih.gov/34209222 34209222]<br>
-'''term_xref''' :  <br>
+ '''definition''' : <br>
-'''best_match''' :  <br>
+ '''term_xref''' : GTC:[https://glygen.org/glycan/G29086KO G29086KO]<br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  HA<br>
-'''function''' :  <br>
+ '''function''' : <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' : <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000169===
+===GSD000184===
-'''term (main_entry)''' : Triantennary complex <br>
+ '''term (main_entry)''' : Chondroitin sulfate/dermatan sulfate<br>
-'''glycan_dictionary_accession''' : GD000169 <br>
+ '''glycan_dictionary_accession''' : GSD000184<br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' : <br>
-'''term_in_sentence''' : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998] <br>
+ '''term_in_sentence''' : Heparan sulfate (HS) and chondroitin sulfate/dermatan sulfate (CS/DS) proteoglycans are heavily glycosylated proteins, crucial for animal development and homeostasis. [PMID:[https://pubmed.ncbi.nlm.nih.gov/35192612 35192612]]<br>
-'''publication''' : 9118998|9061362|18395704|3814128|7451505|10460831|26926155|26966183|16581187|16973123|8204583|29809215|11114588|31322324|15044389|16372382|8251489|8299583|1555586|7509658|1569060|16261636 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/35192612 35192612]|[https://pubmed.ncbi.nlm.nih.gov/35425970 35425970]<br>
-'''definition''' : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252]  Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.  <br>
+ '''definition''' : <br>
-'''term_xref''' : CHEBI:156252 <br>
+ '''term_xref''' : <br>
-'''best_match''' : CHEBI:156252 <br>
+ '''synonyms''' :  CS/DS|chondroitin/dermatan sulfate<br>
-'''synonymns''' : Triantennary complex-type <br>
+ '''function''' : <br>
-'''function''' :  <br>
+ '''disease_associations''' : <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-'''essentials_of_glycobiology''' : NBK453030 <br>
+===GSD000185===
+ '''term (main_entry)''' : Heparan sulfate/heparin<br>
+ '''glycan_dictionary_accession''' : GSD000185<br>
+ '''glytoucan_accession ''' : <br>
+ '''term_in_sentence''' : Heparan sulfate (HS)/heparin is a structurally complex class of glycosaminoglycans (GAGs) that have been implicated in a wide range of biological activities. [PMID:[https://pubmed.ncbi.nlm.nih.gov/31016560 31016560]]<br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23313092 23313092]|[https://pubmed.ncbi.nlm.nih.gov/31016560 31016560]|[https://pubmed.ncbi.nlm.nih.gov/23152789 23152789]<br>
+ '''definition''' : <br>
+ '''term_xref''' :  <br>
+ '''synonyms''' :  HS/heparin|heparan sufate (HS)/heparin|H/HS<br>
+ '''function''' : <br>
+ '''disease_associations''' : <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000170===
-'''term (main_entry)''' : Triantennary N-glycans <br>
+===GSD000186===
-'''glycan_dictionary_accession''' : GD000170 <br>
+[[File:G00031MO.png|thumb|G00031MO]]
-'''glytoucan_accession ''' :  <br>
+ '''term (main_entry)''' : Core 1<br>
-'''term_in_sentence''' : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163] <br>
+ '''glycan_dictionary_accession''' : GSD000186<br>
-'''publication''' : 29399163|22325877|18439991|24873509|11454001 <br>
+ '''glytoucan_accession ''' : [https://glygen.org/glycan/G00031MO G00031MO]<br>
-'''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [NBK453019-Glossary] <br>
+ '''term_in_sentence''' : O-glycans are initiated by the addition of GalNAc to serine or threonine (via the ppGalNAcT family of glycosyltransferases), forming the Tn antigen (GalNAcα-O-Ser/Thr), which is used to generate the core 1 structure (Galβ1,3GalNAcα-O-Ser/Thr) on which most complex and branched O-glycans are derived. [PMID:31645367]<br>
-'''term_xref''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31645367 31645367]|[https://pubmed.ncbi.nlm.nih.gov/32297877 32297877]<br>
-'''best_match''' :  <br>
+ '''definition''' : <br>
-'''synonymns''' :  <br>
+ '''term_xref''' : GTC:[https://glygen.org/glycan/G00031MO G00031MO]|GlycoMotif:GGM.001005 <br>
-'''function''' :  <br>
+ '''synonyms''' :  C1G<br>
-'''disease_associations''' :  <br>
+ '''function''' : <br>
-'''wikipedia''' :  <br>
+ '''disease_associations''' : <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000171===
+===GSD000187===
-'''term (main_entry)''' : Triantennary sialylated <br>
+[[File:G99315PE.png|thumb|G99315PE]]
-'''glycan_dictionary_accession''' : GD000171 <br>
+ '''term (main_entry)''' : Blood group A (Type 3)<br>
-'''glytoucan_accession ''' :  <br>
+ '''glycan_dictionary_accession''' : GSD000187<br>
-'''term_in_sentence''' : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:18642129] <br>
+ '''glytoucan_accession ''' : [https://glygen.org/glycan/G99315PE G99315PE]<br>
-'''publication''' : 18642129|31964828|3979568|27936604|23681398|21538882|7579793|7613477|2223825|3539023|3674882 <br>
+ '''term_in_sentence''' : <br>
-'''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7800218 7800218]|[https://pubmed.ncbi.nlm.nih.gov/17998569 17998569]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/3191504 3191504]<br>
-'''term_xref''' :  <br>
+ '''definition''' : <br>
-'''best_match''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000011|GTC:[https://glygen.org/glycan/G99315PE G99315PE]<br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  A type 3 antigen|blood group A type 3|A antigen (type 3)<br>
-'''function''' : Appears in human serotransferrin.[PMID: 3979568] <br>
+  '''function''' : <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' : <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  [https://www.ncbi.nlm.nih.gov/books/NBK579929/ Chapter 14]<br>
-===GD000172===
+===GSD000188===
-'''term (main_entry)''' : Triantennary trisialylated fucosylated <br>
+[[File:G80722US.png|thumb|G80722US]]
-'''glycan_dictionary_accession''' : GD000172 <br>
+ '''term (main_entry)''' : 6-Sulfo Sialyl Lewis x <br>
-'''glytoucan_accession ''' :  <br>
+ '''glycan_dictionary_accession''' : GSD000188<br>
-'''term_in_sentence''' : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:17591618] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80722US G80722US] <br>
-'''publication''' : 17591618 <br>
+ '''term_in_sentence''' : The cognate ligands for L-selectin possess the unusual sulfated tetrasaccharide epitope 6-sulfo sialyl Lewis x (Siaalpha2-->3Galbeta1-->4[Fucalpha1-->3][SO(3)-->6]GlcNAc).[PMID:[https://pubmed.ncbi.nlm.nih.gov/11331001 11331001]] <br>
-'''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added. <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11331001 11331001]|[https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]|[https://pubmed.ncbi.nlm.nih.gov/26137907 26137907]|[https://pubmed.ncbi.nlm.nih.gov/9400621 9400621]| [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/15972893 15972893]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/22691873 22691873]|[https://pubmed.ncbi.nlm.nih.gov/18652681 18652681]|[https://pubmed.ncbi.nlm.nih.gov/9722682 9722682]|[https://pubmed.ncbi.nlm.nih.gov/10435581 10435581]|[https://pubmed.ncbi.nlm.nih.gov/19359410 19359410]|[https://pubmed.ncbi.nlm.nih.gov/15228275 15228275]|[https://pubmed.ncbi.nlm.nih.gov/18250165 18250165]|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]|[https://pubmed.ncbi.nlm.nih.gov/17944600 17944600]|[https://pubmed.ncbi.nlm.nih.gov/10460836 10460836]|[https://pubmed.ncbi.nlm.nih.gov/27993973 27993973]|[https://pubmed.ncbi.nlm.nih.gov/19149511 19149511]|[https://pubmed.ncbi.nlm.nih.gov/19150806 19150806]|[https://pubmed.ncbi.nlm.nih.gov/17172261 17172261]|[https://pubmed.ncbi.nlm.nih.gov/17142960 17142960]|[https://pubmed.ncbi.nlm.nih.gov/27956273 27956273]|[https://pubmed.ncbi.nlm.nih.gov/7578028 7578028]|[https://pubmed.ncbi.nlm.nih.gov/22260995 22260995]|[https://pubmed.ncbi.nlm.nih.gov/24519996 24519996]|[https://pubmed.ncbi.nlm.nih.gov/21596021 21596021]|[https://pubmed.ncbi.nlm.nih.gov/21982762 21982762]|[https://pubmed.ncbi.nlm.nih.gov/21775439 21775439]|[https://pubmed.ncbi.nlm.nih.gov/17334369 17334369]|[https://pubmed.ncbi.nlm.nih.gov/9710564 9710564]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/16227985 16227985]|[https://pubmed.ncbi.nlm.nih.gov/11895802 11895802]|[https://pubmed.ncbi.nlm.nih.gov/22750968 22750968]|[https://pubmed.ncbi.nlm.nih.gov/15157883 15157883]|[https://pubmed.ncbi.nlm.nih.gov/19067429 19067429] <br>
-'''term_xref''' :  <br>
+ '''definition''' : <br>
-'''best_match''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000027|GlycoEpitope:EP0015|CID:70698321|CHEBI:71628<br>
-'''synonymns''' :  <br>
+ '''synonyms''' : 6-sulfo SLex|6-Sulfo-sialyl Lewis x|6-sulfo SLe^x <br>
-'''function''' :  <br>
+  '''function''' : lymphocyte homing[GlycoEpitope:EP0015]<br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' : <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK579916/ Chapter 34]|[https://www.ncbi.nlm.nih.gov/books/NBK579966/ Chapter 35]<br>
-===GD000173===
+===GSD000189===
-'''term (main_entry)''' : Trifucosyl Lewis b antigen <br>
+[[File:G89208KM.png|thumb|G89208KM]]
-'''glycan_dictionary_accession''' : GD000173 <br>
+ '''term (main_entry)''' : Blood group B (Type 1) - Lewis b<br>
-'''glytoucan_accession ''' : G74578MX <br>
+ '''glycan_dictionary_accession''' : GSD000189<br>
-'''term_in_sentence''' : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:1735443] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G89208KM G89208KM] <br>
-'''publication''' : 1735443 <br>
+ '''term_in_sentence''' :  Ten monoclonal antibodies and one lectin were used to study the localization and distribution of Blood Group ABH, type 1 chain (Lewis a, Lewis b) and type 2 chain (H-2, Y) antigens in 22 cases of normal uterine cervix, with known ABO and Lewis phenotype and secretor status. [PMID:[https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]]<br>
-'''definition''' : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/30831115 30831115]<br>
-'''term_xref''' : GlycoEpitope:EP0092|CID:91845957|CHEBI:153783 <br>
+ '''definition''' :  <br>
-'''best_match''' : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783 <br>
+ '''term_xref''' : GlycoMotif:GGM.000046<br>
-'''synonymns''' : trifucosyl-Leb antigen <br>
+ '''synonyms''' :  Blood Group B, type 1 chain (Lewis b)|B-Leb|B-Le^b<br>
-'''function''' : cancer-associated antigen[GlycoEpitope: EP0092] <br>
+ '''function''' :  <br>
-'''disease_associations''' : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092] <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000174===
+===GSD000190===
-'''term (main_entry)''' : Trifucosyl lewis y <br>
+[[File:G97501MA.png|thumb|G97501MA]]
-'''glycan_dictionary_accession''' : GD000174 <br>
+ '''term (main_entry)''' : Blood group A (Type 1) - Lewis b<br>
-'''glytoucan_accession ''' : G74917JX <br>
+ '''glycan_dictionary_accession''' : GSD000190<br>
-'''term_in_sentence''' : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:3733752] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97501MA G97501MA] <br>
-'''publication''' : 3733752|2426269 <br>
+ '''term_in_sentence''' :  Ten monoclonal antibodies and one lectin were used to study the localization and distribution of Blood Group ABH, type 1 chain (Lewis a, Lewis b) and type 2 chain (H-2, Y) antigens in 22 cases of normal uterine cervix, with known ABO and Lewis phenotype and secretor status.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]]<br>
-'''definition''' : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/4041428 4041428]|[https://pubmed.ncbi.nlm.nih.gov/5686860 5686860]<br>
-'''term_xref''' : GlycoEpitope:EP0094|CID:50909806|CHEBI:61332 <br>
+ '''definition''' :  A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 4 of the glucosamine. Corresponds to a partial structure of blood group A type 1 oligosaccharide.[CHEBI:62988]<br>
-'''best_match''' : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332 <br>
+ '''term_xref''' : GlycoMotif:GGM.000047|CID:53477630|CHEBI:62988|GlycoEpitope:EP0260<br>
-'''synonymns''' : trifucosyl Ley <br>
+ '''synonyms''' :  Blood Group A Type 1 (difucosyl)|ALe^b|A-Leb|A-Le^b|A Lewis b<br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' : colonic adenocarcinomia[GlycoEpitope: EP0094] <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000175===
+===GSD000191===
-'''term (main_entry)''' : Trimannosyl core <br>
+[[File:G18464VS.png|thumb|G18464VS]]
-'''glycan_dictionary_accession''' : GD000175 <br>
+ '''term (main_entry)''' : Sulfated LacdiNAc<br>
-'''glytoucan_accession ''' :  <br>
+ '''glycan_dictionary_accession''' : GSD000191<br>
-'''term_in_sentence''' : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:18320567] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18464VS G18464VS] <br>
-'''publication''' : 18320567|27629418|26514868|26821880|2477227|6213618|31747570|29273674|31064325|1291063|28353332|1421754|29666272|11421342|15648688|28179475|28903882|27189951|9455915|22768188|9254048|8721739|2249985|22933239|25629585|24489949|2981047|11067815|1729985|1710649|16672288|2719668|19003000|23025485|22500028|10409642|1325461|23136055|23085445|21656680|22448293|22132163|1425696|20696712|18056652|15084511|18633282|15814299 <br>
+ '''term_in_sentence''' :  The mRNA expression of the enzymes related to the formation of sulfated LacdiNAc:β(1,4)-N-acetylgalactosaminyltransferases 3 (B4GALNT3) and 4 (B4GALNT4), carbohydrate sulfotransferases 8 (CHST8) and 9 (CHST9); and β(1,4)-galactosyltransferase 1 (B4GALT1) in these cells was confirmed by RT-PCR (Fig. S4).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31558607 31558607]]<br>
-'''definition''' : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position. <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/31558607 31558607]|[https://pubmed.ncbi.nlm.nih.gov/27318476 27318476]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/11279168 11279168]|[https://pubmed.ncbi.nlm.nih.gov/26688390 26688390]<br>
-'''term_xref''' :  <br>
+ '''definition''' :  <br>
-'''best_match''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000049<br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  4'-O-sulfated LacdiNAc|4'-sulfated LDN|sulfated LDN<br>
-'''function''' :  <br>
+ '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000176===
+===GSD000192===
-'''term (main_entry)''' : Trisialylated <br>
+[[File:G55583HW.png|thumb|G55583HW]]
-'''glycan_dictionary_accession''' : GD000176 <br>
+ '''term (main_entry)''' : Sialylated LacdiNAc<br>
-'''glytoucan_accession ''' :  <br>
+ '''glycan_dictionary_accession''' : GSD000192<br>
-'''term_in_sentence''' : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:8477709] <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G55583HW G55583HW] <br>
-'''publication''' : 6469957|18818422|18332077|21138277|9136890|10782293|19841910|20067809|14751029|8797382|16877748|19131698|20578731|24669823|22426998|27501865|2121479|24663386|32209427|32737218|33245334|26927318|30962676|28370937|30194503|26321095|30463578|31455764|31566965|31266306|29782424|31247951|30487799|2049094|1997323|10913832 <br>
+ '''term_in_sentence''' :  The major non-reducing epitopes in the complex-type glycans are: Gal beta 1-4GlcNAc (lacNAc), GalNAc beta 1-4GlcNAc (lacdiNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacdiNAc), Gal beta 1-4(Fuc alpha 1-3)GlcNAc (Lewisx), and GalNAc beta 1-4(Fuc alpha 1-3)GlcNAc (lacdiNAc analogue of Lewisx).[PMID:[https://pubmed.ncbi.nlm.nih.gov/7592613 7592613]]<br>
-'''definition''' : A glycan with three sialic acid components. <br>
+ '''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/7592613 7592613]|[https://pubmed.ncbi.nlm.nih.gov/34192302 34192302]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/16286643 16286643]<br>
-'''term_xref''' :  <br>
+ '''definition''' :  <br>
-'''best_match''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000050<br>
-'''synonymns''' :  <br>
+ '''synonyms''' :  sialylated-LacdiNAc|Sialylated LDN<br>
-'''function''' :  <br>
+  '''function''' :  <br>
-'''disease_associations''' :  <br>
+ '''disease_associations''' :  <br>
-'''wikipedia''' :  <br>
+ '''wikipedia''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
-===GD000177===
+==Retired Terms (by Term Name)==
-'''term (main_entry)''' : Trisialylated complex-type oligosaccharide-alditols <br>
+===A2===
-'''glycan_dictionary_accession''' : GD000177 <br>
+[[File:G62735WZ.png|thumb|G62735WZ]]
-'''glytoucan_accession ''' :  <br>
+ '''term (main_entry)''' : A2 <br>
-'''term_in_sentence''' : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:3571205] <br>
+ '''glycan_dictionary_accession''' : GSD000015 <br>
-'''publication''' : 3571205 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G62735WZ G62735WZ] <br>
-'''definition''' :  <br>
+ '''term_in_sentence''' : Landsteiner ABO system of blood groups is most important for transfusion medicine and has subtypes of A Antigen, A1 and A2, upon which further groups of A and AB have been classified.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771]] <br>
-'''term_xref''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771] <br>
-'''best_match''' :  <br>
+ '''definition''' :  <br>
-'''synonymns''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000041|GTC:G62735WZ|CID:91852328 <br>
-'''function''' :  <br>
+ '''synonyms''' :  <br>
-'''disease_associations''' :  <br>
+ '''function''' :  <br>
-'''wikipedia''' :  <br>
+ '''disease_associations''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+ '''date retired''' : 01/27/2023 <br>
+  '''reason for retirement''' : Duplicated entry. See [https://wiki.glygen.org/index.php/Glycan_structure_dictionary#GD000032 GSD000032]. <br>
-===GD000178===
+===Chitin===
-'''term (main_entry)''' : Trisialylated diantennary <br>
+ '''term (main_entry)''' : Chitin (This term has been retired.)<br>
-'''glycan_dictionary_accession''' : GD000178 <br>
+ '''glycan_dictionary_accession''' : GSD000042 <br>
-'''glytoucan_accession ''' :  <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:1997323] <br>
+ '''term_in_sentence''' : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241] <br>
-'''publication''' : 1997323 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/25738328 25738328]|[https://pubmed.ncbi.nlm.nih.gov/31102247 31102247]|[https://pubmed.ncbi.nlm.nih.gov/26982439 26982439]|[https://pubmed.ncbi.nlm.nih.gov/31685194 31685194]|[https://pubmed.ncbi.nlm.nih.gov/29197571 29197571]|[https://pubmed.ncbi.nlm.nih.gov/29182521 29182521]|[https://pubmed.ncbi.nlm.nih.gov/25725011 25725011]| [https://pubmed.ncbi.nlm.nih.gov/27787767 27787767]|[https://pubmed.ncbi.nlm.nih.gov/21736263 21736263]|[https://pubmed.ncbi.nlm.nih.gov/25300540 25300540]|[https://pubmed.ncbi.nlm.nih.gov/30840869 30840869]|[https://pubmed.ncbi.nlm.nih.gov/25081074 25081074]|[https://pubmed.ncbi.nlm.nih.gov/28250359 28250359]| [https://pubmed.ncbi.nlm.nih.gov/29763421 29763421]|[https://pubmed.ncbi.nlm.nih.gov/29910219 29910219]|[https://pubmed.ncbi.nlm.nih.gov/20161969 20161969]|[https://pubmed.ncbi.nlm.nih.gov/32019265 32019265]| [https://pubmed.ncbi.nlm.nih.gov/30879650 30879650]| [https://pubmed.ncbi.nlm.nih.gov/12587986 12587986]|[https://pubmed.ncbi.nlm.nih.gov/29773374 29773374]|[https://pubmed.ncbi.nlm.nih.gov/31376451 31376451]| [https://pubmed.ncbi.nlm.nih.gov/10906950 10906950]|[https://pubmed.ncbi.nlm.nih.gov/26096004 26096004]|[https://pubmed.ncbi.nlm.nih.gov/25595947 25595947]| [https://pubmed.ncbi.nlm.nih.gov/21673932 21673932]|[https://pubmed.ncbi.nlm.nih.gov/29452181 29452181]|[https://pubmed.ncbi.nlm.nih.gov/24083454 24083454]|[https://pubmed.ncbi.nlm.nih.gov/10856926 10856926]|[https://pubmed.ncbi.nlm.nih.gov/22732132 22732132]| [https://pubmed.ncbi.nlm.nih.gov/18657571 18657571]|[https://pubmed.ncbi.nlm.nih.gov/29175166 29175166]|[https://pubmed.ncbi.nlm.nih.gov/28842199 28842199]|[https://pubmed.ncbi.nlm.nih.gov/27592817 27592817]| [https://pubmed.ncbi.nlm.nih.gov/27302593 27302593]| [https://pubmed.ncbi.nlm.nih.gov/27339323 27339323]| [https://pubmed.ncbi.nlm.nih.gov/12705640 12705640]|[https://pubmed.ncbi.nlm.nih.gov/31635752 31635752]| [https://pubmed.ncbi.nlm.nih.gov/31063786 31063786]|[https://pubmed.ncbi.nlm.nih.gov/31151236 31151236]|[https://pubmed.ncbi.nlm.nih.gov/25940531 25940531]|[https://pubmed.ncbi.nlm.nih.gov/26093316 26093316]|[https://pubmed.ncbi.nlm.nih.gov/28962761 28962761]|[https://pubmed.ncbi.nlm.nih.gov/28093332 28093332]| [https://pubmed.ncbi.nlm.nih.gov/30875044 30875044]|[https://pubmed.ncbi.nlm.nih.gov/27723949 27723949]|[https://pubmed.ncbi.nlm.nih.gov/28119189 28119189]|[https://pubmed.ncbi.nlm.nih.gov/30600008 30600008]|[https://pubmed.ncbi.nlm.nih.gov/25081085 25081085]|[https://pubmed.ncbi.nlm.nih.gov/21673932 21673932] <br>
-'''definition''' : A diantennary/biantennary glycans with three sialic acid components. <br>
+ '''definition''' : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029] <br>
-'''term_xref''' :  <br>
+ '''term_xref''' : CHEBI:17029<br>
-'''best_match''' :  <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' :  <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' :  <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  [https://www.ncbi.nlm.nih.gov/books/NBK579931/ Chapter 26]<br>
-'''essentials_of_glycobiology''' :  <br>
+ '''date retired''' : 01/27/2023 <br>
+  '''reason for retirement''' : Not including linear polysaccharides to glycan structure dictionary. <br>
-===GD000179===
+==Retired Terms (by Glycan Dictionary Accessions)==
-'''term (main_entry)''' : Trisialylated triantennary <br>
+===GSD000015===
-'''glycan_dictionary_accession''' : GD000179 <br>
+[[File:G62735WZ.png|thumb|G62735WZ]]
-'''glytoucan_accession ''' :  <br>
+ '''term (main_entry)''' : A2 <br>
-'''term_in_sentence''' : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] <br>
+ '''glycan_dictionary_accession''' : GSD000015 <br>
-'''publication''' : 30194503|27501865|10998266|20578731|17591618|14751029|18818422|8942648|8900952 <br>
+ '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G62735WZ G62735WZ] <br>
-'''definition''' : A triantennry glycan with three sialic acid components. <br>
+ '''term_in_sentence''' : Landsteiner ABO system of blood groups is most important for transfusion medicine and has subtypes of A Antigen, A1 and A2, upon which further groups of A and AB have been classified.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771]] <br>
-'''term_xref''' :  <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771] <br>
-'''best_match''' :  <br>
+ '''definition''' :  <br>
-'''synonymns''' :  <br>
+ '''term_xref''' : GlycoMotif:GGM.000041|GTC:G62735WZ|CID:91852328 <br>
-'''function''' :  <br>
+ '''synonyms''' :  <br>
-'''disease_associations''' :  <br>
+ '''function''' :  <br>
-'''wikipedia''' :  <br>
+ '''disease_associations''' :  <br>
-'''essentials_of_glycobiology''' :  <br>
+ '''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  <br>
+ '''date retired''' : 01/27/2023 <br>
+  '''reason for retirement''' : Duplicated entry. See [https://wiki.glygen.org/index.php/Glycan_structure_dictionary#GD000032 GSD000032]. <br>
-===GD000180===
+===GSD000042===
-'''term (main_entry)''' : VIM-2 <br>
+ '''term (main_entry)''' : Chitin <br>
-'''glycan_dictionary_accession''' : GD000180 <br>
+ '''glycan_dictionary_accession''' : GSD000042 <br>
-'''glytoucan_accession ''' : G22418PV <br>
+ '''glytoucan_accession ''' :  <br>
-'''term_in_sentence''' : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:1690317] <br>
+ '''term_in_sentence''' : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241] <br>
-'''publication''' : 27834790|31523406|29978304|29575185|27326514|29029114|32450200|29432937|31906402|28739428|29298123|30976429|29091730|27770796|31330771|31138570|27154587|31542553|30519059|30590504|25880997|27490501|29981456|28559273|28193652|26638216|25897818|26238337|19553129|29644540|26242685|28487556|32622213|30248413|24762211|11451678|33169865|11897589|31479607 <br>
+ '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/25738328 25738328]|[https://pubmed.ncbi.nlm.nih.gov/31102247 31102247]|[https://pubmed.ncbi.nlm.nih.gov/26982439 26982439]|[https://pubmed.ncbi.nlm.nih.gov/31685194 31685194]|[https://pubmed.ncbi.nlm.nih.gov/29197571 29197571]|[https://pubmed.ncbi.nlm.nih.gov/29182521 29182521]|[https://pubmed.ncbi.nlm.nih.gov/25725011 25725011]|[https://pubmed.ncbi.nlm.nih.gov/27787767 27787767]|[https://pubmed.ncbi.nlm.nih.gov/21736263 21736263]|[https://pubmed.ncbi.nlm.nih.gov/25300540 25300540]|[https://pubmed.ncbi.nlm.nih.gov/30840869 30840869]|[https://pubmed.ncbi.nlm.nih.gov/25081074 25081074]|[https://pubmed.ncbi.nlm.nih.gov/28250359 28250359]| [https://pubmed.ncbi.nlm.nih.gov/29763421 29763421]|[https://pubmed.ncbi.nlm.nih.gov/29910219 29910219]|[https://pubmed.ncbi.nlm.nih.gov/20161969 20161969]|[https://pubmed.ncbi.nlm.nih.gov/32019265 32019265]|[https://pubmed.ncbi.nlm.nih.gov/30879650 30879650]|[https://pubmed.ncbi.nlm.nih.gov/12587986 12587986]|[https://pubmed.ncbi.nlm.nih.gov/29773374 29773374]|[https://pubmed.ncbi.nlm.nih.gov/31376451 31376451]| [https://pubmed.ncbi.nlm.nih.gov/10906950 10906950]| [https://pubmed.ncbi.nlm.nih.gov/26096004 26096004]|[https://pubmed.ncbi.nlm.nih.gov/25595947 25595947]|[https://pubmed.ncbi.nlm.nih.gov/21673932 21673932]|[https://pubmed.ncbi.nlm.nih.gov/29452181 29452181]| [https://pubmed.ncbi.nlm.nih.gov/24083454 24083454]|[https://pubmed.ncbi.nlm.nih.gov/10856926 10856926]|[https://pubmed.ncbi.nlm.nih.gov/22732132 22732132]|[https://pubmed.ncbi.nlm.nih.gov/18657571 18657571]|[https://pubmed.ncbi.nlm.nih.gov/29175166 29175166]|[https://pubmed.ncbi.nlm.nih.gov/28842199 28842199]| [https://pubmed.ncbi.nlm.nih.gov/27592817 27592817]|[https://pubmed.ncbi.nlm.nih.gov/27302593 27302593]|[https://pubmed.ncbi.nlm.nih.gov/27339323 27339323]|[https://pubmed.ncbi.nlm.nih.gov/12705640 12705640]| [https://pubmed.ncbi.nlm.nih.gov/31635752 31635752]| [https://pubmed.ncbi.nlm.nih.gov/31063786 31063786]|[https://pubmed.ncbi.nlm.nih.gov/31151236 31151236]|[https://pubmed.ncbi.nlm.nih.gov/25940531 25940531]|[https://pubmed.ncbi.nlm.nih.gov/26093316 26093316]|[https://pubmed.ncbi.nlm.nih.gov/28962761 28962761]|[https://pubmed.ncbi.nlm.nih.gov/28093332 28093332]|[https://pubmed.ncbi.nlm.nih.gov/30875044 30875044]|[https://pubmed.ncbi.nlm.nih.gov/27723949 27723949]|[https://pubmed.ncbi.nlm.nih.gov/28119189 28119189]|[https://pubmed.ncbi.nlm.nih.gov/30600008 30600008]|[https://pubmed.ncbi.nlm.nih.gov/25081085 25081085]| [https://pubmed.ncbi.nlm.nih.gov/21673932 21673932]<br>
-'''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] <br>
+ '''definition''' : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029] <br>
-'''term_xref''' : GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033 <br>
+ '''term_xref''' : CHEBI:17029 <br>
-'''best_match''' : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033 <br>
+ '''synonyms''' :  <br>
-'''synonymns''' :  <br>
+ '''function''' :  <br>
-'''function''' : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] <br>
+ '''disease_associations''' :  <br>
-'''disease_associations''' : chronic myelogenous leukemia.[GlycoEpitope:EP0019] <br>
+ '''wikipedia''' :  <br>
-'''wikipedia''' :  <br>
+ '''essentials_of_glycobiology''' :  [https://www.ncbi.nlm.nih.gov/books/NBK579931/ Chapter 26]<br>
-'''essentials_of_glycobiology''' :  <br>
+ '''date retired''' : 01/27/2023 <br>
+ '''reason for retirement''' : Not including linear polysaccharides to glycan structure dictionary. <br>
 ==Submit new terms==
-If you feel that a term is missing, you can submit a single term using the online form found at https://data.glygen.org/gsd/ . To submit multiple terms you can use GlyGen file upload https://data.glygen.org/upload. Template for submitting terms can be found [https://docs.google.com/spreadsheets/d/19ZCAJk_LyLjXT4W-hNWCCwcyndQlGooFLoJ5qCDdxDI/edit?usp=sharing here]. Contact https://www.glygen.org/contact-us/ for any questions.
+If you feel that a term is missing, you can submit a single term using the online form found at https://data.glygen.org/gsd/ . To submit multiple terms you can use GlyGen file upload https://data.glygen.org/uploads. Template for submitting terms can be found [https://docs.google.com/spreadsheets/d/19ZCAJk_LyLjXT4W-hNWCCwcyndQlGooFLoJ5qCDdxDI/edit#gid=0 here]. Contact https://www.glygen.org/contact-us/ for any questions.